<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24923909</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.</ArticleTitle><Pagination><StartPage>4159</StartPage><MedlinePgn>4159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms5159</ELocationID><Abstract><AbstractText>Amyloid plaques and tau tangles are common pathological hallmarks for Alzheimer's disease (AD); however, reducing A&#x3b2; production failed to relieve the symptoms of AD patients. Here we report a high GABA (&#x3b3;-aminobutyric acid) content in reactive astrocytes in the dentate gyrus (DG) of a mouse model for AD (5xFAD) that results in increased tonic inhibition and memory deficit. We also confirm in human AD patient brains that dentate astrocytes have a high GABA content, suggesting that high astrocytic GABA level may be a novel biomarker and a potential diagnostic tool for AD. The excessive GABA in 5xFAD astrocytes is released through an astrocyte-specific GABA transporter GAT3/4, and significantly enhances tonic GABA inhibition in dentate granule cells. Importantly, reducing tonic inhibition in 5xFAD mice rescues the impairment of long-term potentiation (LTP) and memory deficit. Thus, reducing tonic GABA inhibition in the DG may lead to a novel therapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biology, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ziyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biology, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Gong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biology, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG045656</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH083911</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH083911</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG045656</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Commun. 2014;5:4810</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="Y">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing financial interests: The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24923909</ArticleId><ArticleId IdType="mid">NIHMS597307</ArticleId><ArticleId IdType="pmc">PMC4159602</ArticleId><ArticleId IdType="doi">10.1038/ncomms5159</ArticleId><ArticleId IdType="pii">ncomms5159</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tomiyama T, et al. A new amyloid beta variant favoring oligomerization in Alzheimer&#x2019;s-type dementia. Ann Neurol. 2008;63:377&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer&#x2019;s disease. Science. 2006;314:781&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer&#x2019;s disease: clinical trials and drug development. Lancet Neurol. 2010;9:702&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610346</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer&#x2019;s disease: disappointments and hopes. Curr Top Med Chem. 2011;11:1555&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510832</ArticleId></ArticleIdList></Reference><Reference><Citation>Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011;69:237&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21387368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, et al. gamma-Aminobutyric Acid Type A (GABAA) Receptor alpha Subunits Play a Direct Role in Synaptic Versus Extrasynaptic Targeting. J Biol Chem. 2012;287:27417&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431651</ArticleId><ArticleId IdType="pubmed">22711532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, et al. Homeostatic Competition between phasic and tonic inhibition. J Biol Chem. 2013;288:25053&#x2013;25065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757170</ArticleId><ArticleId IdType="pubmed">23839941</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3399243</ArticleId><ArticleId IdType="pubmed">22243744</ArticleId></ArticleIdList></Reference><Reference><Citation>Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci. 2008;28:1421&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671570</ArticleId><ArticleId IdType="pubmed">18256262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Yu S, Wong W, McGeer EG, McGeer PL. GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer&#x2019;s disease. Journal of Alzheimer&#x2019;s disease: JAD. 2013;33:1073&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">23114513</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele ML, Robinson SR. Reactive astrocytes give neurons less support: implications for Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;33:423 e1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21051108</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer&#x2019;s disease. Neurotherapeutics. 2010;7:399&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084302</ArticleId><ArticleId IdType="pubmed">20880504</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen KK, White HS, Schousboe A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacology &amp; therapeutics. 2010;125:394&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">20026354</ArticleId></ArticleIdList></Reference><Reference><Citation>Heja L, et al. Glutamate uptake triggers transporter-mediated GABA release from astrocytes. PLoS ONE. 2009;4:e7153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744931</ArticleId><ArticleId IdType="pubmed">19777062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. European journal of pharmacology. 2013;698:6&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23123057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperk G, Schwarzer C, Tsunashima K, Fuchs K, Sieghart W. GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience. 1997;80:987&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">9284055</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol. 2002;136:965&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1573424</ArticleId><ArticleId IdType="pubmed">12145096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutcheon B, Fritschy JM, Poulter MO. Organization of GABA receptor alpha-subunit clustering in the developing rat neocortex and hippocampus. Eur J Neurosci. 2004;19:2475&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128401</ArticleId></ArticleIdList></Reference><Reference><Citation>Semyanov A, Walker MC, Kullmann DM. GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat Neurosci. 2003;6:484&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679782</ArticleId></ArticleIdList></Reference><Reference><Citation>Glessner JT, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009;459:569&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925224</ArticleId><ArticleId IdType="pubmed">19404257</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Barres BA. Emerging roles of astrocytes in neural circuit development. Nature reviews Neuroscience. 2013;14:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431630</ArticleId><ArticleId IdType="pubmed">23595014</ArticleId></ArticleIdList></Reference><Reference><Citation>Stobart JL, Anderson CM. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Frontiers in cellular neuroscience. 2013;7:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622037</ArticleId><ArticleId IdType="pubmed">23596393</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, et al. Astrocytes and disease: a neurodevelopmental perspective. Genes Dev. 2012;26:891&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347787</ArticleId><ArticleId IdType="pubmed">22549954</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends in molecular medicine. 2007;13:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17207662</ArticleId></ArticleIdList></Reference><Reference><Citation>Danbolt NC. Glutamate uptake. Progress in neurobiology. 2001;65:1&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochi S, et al. Transient presence of GABA in astrocytes of the developing optic nerve. Glia. 1993;9:188&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">8294149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Channel-mediated tonic GABA release from glia. Science. 2010;330:790&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20929730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, McGeer EG, McGeer PL. Mechanisms of GABA release from human astrocytes. Glia. 2011;59:1600&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21748804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Schwab C, McGeer PL. Astrocytes are GABAergic cells that modulate microglial activity. Glia. 2011;59:152&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">21046567</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo MC, Le Meur K, Kozlov AS, Charpak S, Audinat E. GABA, a forgotten gliotransmitter. Progress in neurobiology. 2008;86:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin RC, Polsky K, Matesic DF. Expression of gamma-aminobutyric acid immunoreactivity in reactive astrocytes after ischemia-induced injury in the adult forebrain. Brain research. 1993;600:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422577</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F, Minelli A, Melone M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain research Brain research reviews. 2004;45:196&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer&#x2019;s disease and AD model mice. Neurobiology of aging. 2013;34:2341&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23643146</ArticleId></ArticleIdList></Reference><Reference><Citation>Richerson GB, Wu Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J Neurophysiol. 2003;90:1363&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersante F, et al. A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. The Journal of physiology. 2013;591:2429&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678035</ArticleId><ArticleId IdType="pubmed">23381899</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci. 1992;12:4151&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576006</ArticleId><ArticleId IdType="pubmed">1331359</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinson N, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 2002;22:5572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758233</ArticleId><ArticleId IdType="pubmed">12097508</ArticleId></ArticleIdList></Reference><Reference><Citation>Crestani F, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 2002;99:8980&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124409</ArticleId><ArticleId IdType="pubmed">12084936</ArticleId></ArticleIdList></Reference><Reference><Citation>Braudeau J, et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol. 2011;25:1030&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160204</ArticleId><ArticleId IdType="pubmed">21693554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigstrom H, Gustafsson B. Facilitated induction of hippocampal long-lasting potentiation during blockade of inhibition. Nature. 1983;301:603&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">6298626</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Aimone JB, Xu X, Callaway EM, Gage FH. Development of GABAergic inputs controls the contribution of maturing neurons to the adult hippocampal network. Proc Natl Acad Sci U S A. 2012;109:4290&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306704</ArticleId><ArticleId IdType="pubmed">22371596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Sailor KA, Ming GL, Song H. Synaptic integration and plasticity of new neurons in the adult hippocampus. J Physiol. 2008;586:3759&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538931</ArticleId><ArticleId IdType="pubmed">18499723</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, et al. Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J Neurosci. 2010;30:5269&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632746</ArticleId><ArticleId IdType="pubmed">20392949</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature. 2010;468:305&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058798</ArticleId><ArticleId IdType="pubmed">21048709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DS, et al. Memory deficits induced by inflammation are regulated by alpha5-subunit-containing GABAA receptors. Cell Rep. 2012;2:488&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4391624</ArticleId><ArticleId IdType="pubmed">22999935</ArticleId></ArticleIdList></Reference><Reference><Citation>Atack JR. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacology &amp; therapeutics. 2010;125:11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770002</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C, Bonvento G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol. 2008;38:231&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931960</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron. 2008;60:430&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18995817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institute on Aging, a.R.I.W.G.o.D.C.f.t.N.A.o.A.s.D. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:S1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24928124</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>260</EndPage><MedlinePgn>253-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000596</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p &lt; 10(-16), r2 &gt; 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryman</LastName><ForeName>Davis C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston. rymand@neuro.wustl.edu batemanr@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frommelt</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universit&#xe4;t Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medell&#xed;n, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM 46255</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 21544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 11762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="Y">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025063" MajorTopicYN="N">Chromosome Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24928124</ArticleId><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000596</ArticleId><ArticleId IdType="pii">WNL.0000000000000596</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>M&#xfc;ller U, Winter P, Graeber MB. A presenilin 1 mutation in the first case of Alzheimer's disease. Lancet Neurol 2013;12:129&#x2013;130</Citation><ArticleIdList><ArticleId IdType="pubmed">23246540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001;158:2165&#x2013;2175</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891993</ArticleId><ArticleId IdType="pubmed">11395394</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006;253:139&#x2013;158</Citation><ArticleIdList><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Daw EW, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 2005;132B:14&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">15389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. Apolipoprotein epsilon4 modifies Alzheimer&#x2019;s disease onset in an E280A PS1 kindred. Ann Neurol 2003;54:163&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Brinton RD, Katz R, et al. Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci 2012;67:766&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391068</ArticleId><ArticleId IdType="pubmed">22573913</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Preventing Alzheimer's disease. Science 2012;337:1488&#x2013;1492</Citation><ArticleIdList><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig 2012;2:975&#x2013;984</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321&#x2013;329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012;33:1340&#x2013;1344</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen M, Mullin K, Blacker DTR.
The AlzGene database [online]. Available at: http://alzforum.org/mutations. Accessed January 6, 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org. Accessed January 11, 2013</Citation></Reference><Reference><Citation>Lopera F, Ardilla A, Mart&#xed;nez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277:793&#x2013;799</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Lampe TH, Nemens EJ, Miner GW, Sumi SM, Schellenberg GD. Familial Alzheimer's disease in American descendants of the Volga Germans: probable genetic founder effect. Ann Neurol 1988;23:25&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">3345066</ArticleId></ArticleIdList></Reference><Reference><Citation>Frommelt P, Schnabel R, K&#xfc;hne W, Nee LE, Polinsky RJ. Familial Alzheimer disease: a large, multigeneration German kindred. Alzheimer Dis Assoc Disord 1991;5:36&#x2013;43</Citation><ArticleIdList><ArticleId IdType="pubmed">2025423</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliese P. Within-group agreement, non-independence, and reliability: implications for data aggregation and analysis. In: Klein K, Kozlowski S, editors. Multilevel Theory, Research and Methods in Organizations. San Francisco: Jossey-Bass; 2000:349&#x2013;381</Citation></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349&#x2013;1356</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011;16:903&#x2013;907</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi K. What is &#x201c;early onset dementia&#x201d;? Psychogeriatrics 2009;9:67&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">19604328</ArticleId></ArticleIdList></Reference><Reference><Citation>Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 2005;19:178&#x2013;183</Citation><ArticleIdList><ArticleId IdType="pubmed">16327343</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Gajdusek DC, Gibbs CJ. The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease. Brain 1981;104:535&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pubmed">7023604</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer&#x2019;s disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2010;31:725&#x2013;731</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850052</ArticleId><ArticleId IdType="pubmed">18667258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU Trial. Rev Neurol 2013;169:737&#x2013;743</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880800</ArticleId><ArticleId IdType="pubmed">24016464</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010;133:1143&#x2013;1154</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850581</ArticleId><ArticleId IdType="pubmed">20375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Dunn JK, Huang E, Azher S, Kataki M. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:1&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">14560058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24931606</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>&#x391;-synuclein immunotherapy blocks uptake and templated propagation of misfolded &#x3b1;-synuclein and neurodegeneration.</ArticleTitle><Pagination><StartPage>2054</StartPage><EndPage>2065</EndPage><MedlinePgn>2054-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.05.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)00427-6</ELocationID><Abstract><AbstractText>Accumulation of misfolded alpha-synuclein (&#x3b1;-syn) into Lewy bodies (LBs) and Lewy neurites (LNs) is a major hallmark of Parkinson's disease (PD) and dementia with LBs (DLB). Recent studies showed that synthetic preformed fibrils (pffs) recruit endogenous &#x3b1;-syn and induce LB/LN pathology in vitro and in vivo, thereby implicating propagation and cell-to-cell transmission of pathological &#x3b1;-syn as mechanisms for the progressive spread of LBs/LNs. Here, we demonstrate that &#x3b1;-syn monoclonal antibodies (mAbs) reduce &#x3b1;-syn pff-induced LB/LN formation and rescue synapse/neuron loss in primary neuronal cultures by preventing both pff uptake and subsequent cell-to-cell transmission of pathology. Moreover, intraperitoneal (i.p.) administration of mAb specific for misfolded &#x3b1;-syn into nontransgenic mice injected intrastriatally with &#x3b1;-syn pffs reduces LB/LN pathology, ameliorates substantia nigra dopaminergic neuron loss, and improves motor impairments. We conclude that &#x3b1;-syn antibodies could exert therapeutic effects in PD/DLB by blocking entry of pathological &#x3b1;-syn and/or its propagation in neurons.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Hien T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Charlotte Hiu-Yan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Kelvin C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute of Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Electronic address: vmylee@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Aug;10(8):426. doi: 10.1038/nrneurol.2014.119.</RefSource><PMID Version="1">25002110</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24931606</ArticleId><ArticleId IdType="mid">NIHMS678016</ArticleId><ArticleId IdType="pmc">PMC4410967</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.05.033</ArticleId><ArticleId IdType="pii">S2211-1247(14)00427-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular &#x3b1;-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 2012;32:13454&#x2013;13469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752153</ArticleId><ArticleId IdType="pubmed">23015436</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011;118:658&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, R&#xfc;b U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol. Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo M, Zurzolo C. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem. J. 2013;452:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23614720</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE. 2013;8:e62402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639259</ArticleId><ArticleId IdType="pubmed">23638068</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, et al. A plaque-specific antibody clears existing &#x3b2;-amyloid plaques in Alzheimer&#x2019;s disease mice. Neuron. 2012;76:908&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 2002;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VM. A panel of epitope-specific antibodies detects protein domains distributed throughout human &#x3b1;-synuclein in Lewy bodies of Parkinson&#x2019;s disease. J. Neurosci. Res. 2000a;59:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective &#x3b1;-synuclein nitration in synucleinopathy lesions. Science. 2000b;290:985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Soucy G, Larivi&#xe8;re R, Julien JP. Intracerebro-ventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 2010;113:1188&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014;20:130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 2012;72:587&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Gan M, Yen SH. Dopamine prevents lipid peroxidation-induced accumulation of toxic &#x3b1;-synuclein oligomers by preserving autophagy-lysosomal function. Front. Cell. Neurosci. 2013;7:81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668273</ArticleId><ArticleId IdType="pubmed">23754979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012;287:19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat. Med. 2008;14:504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-&#x3b2; immunotherapy? Nat. Rev. Neurol. 2010;6:108&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864089</ArticleId><ArticleId IdType="pubmed">20140000</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bj&#xf6;rklund A, et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat. Med. 2008;14:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, Lee VM. &#x3b1;-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 2011;31:10076&#x2013;10087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144489</ArticleId><ArticleId IdType="pubmed">21734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O&#x2019;Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous &#x3b1;-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA. 2009;106:20051&#x2013;20056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012a;338:949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J. Exp. Med. 2012b;209:975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of &#x3b1;-synuclein immunization in a mouse model of Parkinson&#x2019;s disease. Neuron. 2005;46:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an &#x3b1;-synuclein transgenic model of Lewy body disease. PLoS ONE. 2011;6:e19338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012;336:1511&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 2003;163:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868149</ArticleId><ArticleId IdType="pubmed">12819014</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Blurton-Jones M, Rhee SW, Cribbs DH, Cotman CW, Jeon NL. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat. Methods. 2005;2:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. Exogenous &#x3b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Jucker M. Seeds of dementia. Sci. Am. 2013;308:52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10699165</ArticleId><ArticleId IdType="pubmed">23627220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008;84:548&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784655</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of &#x3b1;-synuclein. J. Neuropathol. Exp. Neurol. 2008;67:402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930078</ArticleId><ArticleId IdType="pubmed">18451726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington&#x2019;s disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. USA. 2005;102:11563&#x2013;11568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183604</ArticleId><ArticleId IdType="pubmed">16061794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24934289</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><Issue>Pt 8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.</ArticleTitle><Pagination><StartPage>2329</StartPage><EndPage>2345</EndPage><MedlinePgn>2329-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awu138</ELocationID><Abstract><AbstractText>Mitochondrial DNA instability disorders are responsible for a large clinical spectrum, among which amyotrophic lateral sclerosis-like symptoms and frontotemporal dementia are extremely rare. We report a large family with a late-onset phenotype including motor neuron disease, cognitive decline resembling frontotemporal dementia, cerebellar ataxia and myopathy. In all patients, muscle biopsy showed ragged-red and cytochrome c oxidase-negative fibres with combined respiratory chain deficiency and abnormal assembly of complex V. The multiple mitochondrial DNA deletions found in skeletal muscle revealed a mitochondrial DNA instability disorder. Patient fibroblasts present with respiratory chain deficiency, mitochondrial ultrastructural alterations and fragmentation of the mitochondrial network. Interestingly, expression of matrix-targeted photoactivatable GFP showed that mitochondrial fusion was not inhibited in patient fibroblasts. Using whole-exome sequencing we identified a missense mutation (c.176C&gt;T; p.Ser59Leu) in the CHCHD10 gene that encodes a coiled-coil helix coiled-coil helix protein, whose function is unknown. We show that CHCHD10 is a mitochondrial protein located in the intermembrane space and enriched at cristae junctions. Overexpression of a CHCHD10 mutant allele in HeLa cells led to fragmentation of the mitochondrial network and ultrastructural major abnormalities including loss, disorganization and dilatation of cristae. The observation of a frontotemporal dementia-amyotrophic lateral sclerosis phenotype in a mitochondrial disease led us to analyse CHCHD10 in a cohort of 21 families with pathologically proven frontotemporal dementia-amyotrophic lateral sclerosis. We identified the same missense p.Ser59Leu mutation in one of these families. This work opens a novel field to explore the pathogenesis of the frontotemporal dementia-amyotrophic lateral sclerosis clinical spectrum by showing that mitochondrial disease may be at the origin of some of these phenotypes.</AbstractText><CopyrightInformation>&#xa9; The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bannwarth</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ait-El-Mkadem</LastName><ForeName>Samira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaussenot</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genin</LastName><ForeName>Emmanuelle C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacas-Gervais</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>3 Joint Centre for Applied Electron Microscopy, Nice Sophia-Antipolis University, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragaki</LastName><ForeName>Konstantina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg-Alonso</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kageyama</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>4 Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serre</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>5 UMR7592 CNRS, Jacques Monod Institute, Paris Diderot University, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>6 Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschueren</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>7 Department of Neurology, Timone Hospital, Marseille Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouzier</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>8 Sorbonne Universit&#xe9;, UPMC Univ Paris 06, UM75, Inserm U1127, Cnrs UMR7225, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM), F-75013 Paris, France9 National Reference Centre on Rare Dementias, AP-HP, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aug&#xe9;</LastName><ForeName>Ga&#xeb;lle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochaud</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lespinasse</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N'Guyen</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>10 Department of Medical Genetics, Timone Hospital, Marseille Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Septenville</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>8 Sorbonne Universit&#xe9;, UPMC Univ Paris 06, UM75, Inserm U1127, Cnrs UMR7225, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM), F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>8 Sorbonne Universit&#xe9;, UPMC Univ Paris 06, UM75, Inserm U1127, Cnrs UMR7225, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM), F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu-Wai-Man</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>6 Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sesaki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>4 Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pouget</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>7 Department of Neurology, Timone Hospital, Marseille Teaching Hospital, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquis-Flucklinger</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1 IRCAN, UMR CNRS 7284/INSERM U1081/UNS, School of Medicine, Nice Sophia-Antipolis University, France 2 Department of Medical Genetics, National Centre for Mitochondrial Diseases, Nice Teaching Hospital, France paquis@hermes.unice.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0701386</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1002570</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GM089853</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C554426">CHCHD10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e309. doi: 10.1093/brain/awu227.</RefSource><PMID Version="1">25113787</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e310. doi: 10.1093/brain/awu228.</RefSource><PMID Version="1">25113788</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e312. doi: 10.1093/brain/awu267.</RefSource><PMID Version="1">25261971</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e311. doi: 10.1093/brain/awu265.</RefSource><PMID Version="1">25261972</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e313. doi: 10.1093/brain/awu299.</RefSource><PMID Version="1">25348631</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Dec;137(Pt 12):e314. doi: 10.1093/brain/awu300.</RefSource><PMID Version="1">25348633</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Aug;138(Pt 8):e372. doi: 10.1093/brain/awu384.</RefSource><PMID Version="1">25576308</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Aug;138(Pt 8):e373. doi: 10.1093/brain/awu385.</RefSource><PMID Version="1">25576309</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Sep;138(Pt 9):e377. doi: 10.1093/brain/awv015.</RefSource><PMID Version="1">25681413</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Sep;138(Pt 9):e376. doi: 10.1093/brain/awv014.</RefSource><PMID Version="1">25681414</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Sep;138(Pt 9):e380. doi: 10.1093/brain/awv082.</RefSource><PMID Version="1">25833818</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Oct;138(Pt 10):e386. doi: 10.1093/brain/awv116.</RefSource><PMID Version="1">25953779</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Oct;138(Pt 10):e385. doi: 10.1093/brain/awv115.</RefSource><PMID Version="1">25953780</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2016 Feb;139(Pt 2):e8. doi: 10.1093/brain/awv218.</RefSource><PMID Version="1">26362909</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2016 Apr;139(Pt 4):e22. doi: 10.1093/brain/awv368.</RefSource><PMID Version="1">26719380</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2016 Apr;139(Pt 4):e21. doi: 10.1093/brain/awv367.</RefSource><PMID Version="1">26719383</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHCHD10</Keyword><Keyword MajorTopicYN="N">FTD-ALS</Keyword><Keyword MajorTopicYN="N">mitochondrial DNA instability</Keyword><Keyword MajorTopicYN="N">mitochondrial disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24934289</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pii">awu138</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amati-Bonneau P, Valentino M, Reynier P, Gallardo M, Bornstein B, Boissi&#xe8;re A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy &#x2018;plus' phenotype. Brain. 2008;131:338&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18158317</ArticleId></ArticleIdList></Reference><Reference><Citation>An J, Shi J, He Q, Lui K, Liu Y, Huang Y, et al. CHM1/CHCHD6, a novel mitochondrial protein linked to regulation of mitofilin and mitochondrial cristae morphology. J Biol Chem. 2012;287:7411&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293568</ArticleId><ArticleId IdType="pubmed">22228767</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, Bertini I, Ciofi-Baffoni S, Tokatlidis K. The coiled coil-helix coil-helix proteins may be redox proteins. FEBS Lett. 2009;583:1699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">19345215</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, Bertini I, Coffi-Baffoni S, Jaiswal D, Peruzzini R, Winkelman J. Structural characterization of CHCHD5 and CHCHD7: two atypical twin CX9C proteins. J Struct Biol. 2012;180:190&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S, Figueroa A, Fragaki K, Destroismaisons L, Lacas-Gervais S, Lespinasse F, et al. The human MSH5 (MutS Homolog 5) gene localizes to mitochondria and protects the mitochondrial genome from oxidative damage. Mitochondrion. 2012;12:654&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22917773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford M. A rapid and sensitive method for the quantitation of micrograms quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;251:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TA, Tkachuk AN, Shtengel G, Kopek BG, Bogenhagen BF, Hess HF, et al. Superresolution fluorescence imaging of mitochondrial nucleoids reveals their spatial range, limits and membrane interaction. Mol Cell Biol. 2011;31:4494&#x2013;5010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233019</ArticleId><ArticleId IdType="pubmed">22006021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallo G. Genome-wide analysis of eukaryotic twin CX9C proteins. Mol Biosyst. 2010;6:2459&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">20922212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Chan D. Physiological functions of mitochondrial fusion. Ann N Y Acad Sci. 2010;1201:21&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20649534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogliati S, Frezza C, Soriano M, Varanita T, Quintana-Cabrera R, Corrado M, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes and respiratory efficiency. Cell. 2013;155:160&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790458</ArticleId><ArticleId IdType="pubmed">24055366</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland W. Defects in mitochondrial DNA replication and human disease. Crit Rev Biochem Mol Biol. 2012;47:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244805</ArticleId><ArticleId IdType="pubmed">22176657</ArticleId></ArticleIdList></Reference><Reference><Citation>Darshi M, Mendiola V, Mackey M, Murphy A, Koller A, Perkins G, et al. ChChd3, an inner mitochondrial membrane protein, is essential for maintening crista integrity and mitochondrial function. J Biol Chem. 2011;286:2918&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024787</ArticleId><ArticleId IdType="pubmed">21081504</ArticleId></ArticleIdList></Reference><Reference><Citation>Darshi M, Trinh K, Murphy A, Taylor S. Targeting and import mechanism of coiled-coil helix coiled-coil helix domain-containing protein 3 (ChChd3) into the mitochondrial intermembrane space. J Biol Chem. 2012;287:39480&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501047</ArticleId><ArticleId IdType="pubmed">23019327</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Delettre C, Laeners G, Griffoin J, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017079</ArticleId></ArticleIdList></Reference><Reference><Citation>Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko G, Rudka T, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006;126:177&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakonen A, Isohanni P, Paetau A, Herva R, Suomalainen A, Lonngvist T. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain. 2007;130:3032&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17921179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson G, Amati-Bonneau P, Blakely E, Stewart J, He L, Schaefer A, et al. Mutation of OPA1 causes dominant optic atrophy with external ophtalmoplegia, ataxia, deafness, and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain. 2008;131:329&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18065439</ArticleId></ArticleIdList></Reference><Reference><Citation>Jans D, Wurm C, Riedel D, Wenzel D, Stagge F, Deckers M, et al. STED super-resolution microscopy reveals an array of MINOS clusters along human mitochondria. PNAS. 2013;110:8936&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670330</ArticleId><ArticleId IdType="pubmed">23676277</ArticleId></ArticleIdList></Reference><Reference><Citation>Karbowski M, Arnoult D, Chen H, Chan DC, Smith CL, Youle RJ. Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis. J Cell Biol. 2004;164:493&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172000</ArticleId><ArticleId IdType="pubmed">14769861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley L, Sternberg M. Protein structure prediction on the web: a case study using the Phyre server. Nat Protoc. 2009;4:363&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">19247286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, et al. Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol. 2011;31:2756&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3133370</ArticleId><ArticleId IdType="pubmed">21536651</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshiba T, Detmer S, Kaiser J, Chen H, McCaffery M, Chan D. Structural basis of mitochondrial tethering by mitofusin complexes. Science. 2004;305:858&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297672</ArticleId></ArticleIdList></Reference><Reference><Citation>Longen S, Bien M, Bihlmaier K, Kloeppel C, Kauff F, Hammermeister M, et al. Systematic analysis of the twin cx(9)c protein family. J Mol Biol. 2009;393:356&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703468</ArticleId></ArticleIdList></Reference><Reference><Citation>Martherus RS, Sluiter W, Timmer ED, VanHerle SJ, Smeets HJ, Ayoubi TA. Functional annotation of heart enriched mitochondrial genes GBAS and CHCHD10 through guilt by association. Biochem Biophys Res Com. 2010;402:203&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20888800</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeusen S, McCaffery M, Nunnari J. Mitochondrial fusion intermediates revealed in vitro. Science. 2004;305:1747&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297626</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraes C, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda A, et al. Mitochondrial DNA deletions in progressive external ophtalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;18:1293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2541333</ArticleId></ArticleIdList></Reference><Reference><Citation>Naimi M, Bannwarth S, Procaccio V, Pouget J, Desnuelle C, Pellissier J, et al. Molecular analysis of ANT1, TWINKLE and POLG in patients with multiple deletions or depletion of mitochondrial DNA by dHPLC-based assay. Eur J Hum Genet. 2006;14:917&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639411</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul R, Santucci S, Sauni&#xe8;res S, Desnuelle C, Paquis-Flucklinger V. Rapid mapping of mitochondrial DNA deletions by large-fragment PCR. Trends Genet. 1996;12:131&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901416</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchi D, Garone C, Bordoni A, Rios PG, Calvo SE, Ripolone M, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mtDNA deletions. Brain. 2012;135:3404&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501975</ArticleId><ArticleId IdType="pubmed">23043144</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzier C, Bannwarth S, Chaussenot A, Chevrollier A, Verschueren A, Bonello-Palot N, et al. The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy &#x2018;plus' phenotype. Brain. 2012;135:23&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22189565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzier C, Le Gu&#xe9;dard-M&#xe9;reuze S, Fragaki K, Serre V, Miro J, Tuffery-Giraud S, et al. The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein. J Med Genet. 2010;47:670&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20693550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray J. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chem Acta. 1994;228:31&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7955428</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;gger H, Pfeiffer K. The ratio of oxidative phosphorylation complexes I-IV in bovine heart mitochondria and the composition of respiratory chain supercomplexes. J Biol Chem. 2001;276:37861&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483615</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira A. Mitochondrial diseases. Lancet. 2012;379:1825&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482939</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z, Ghochani M, McCaffery M, Frey T, Chan D. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell. 2009;20:3525&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719570</ArticleId><ArticleId IdType="pubmed">19477917</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovski D, Bragozewski P, Chacinska A. The MIA pathway: a tight bond between protein transport and oxidative folding in mitochondria. Biochim Biophys Acta. 2012;1823:1142&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">22579494</ArticleId></ArticleIdList></Reference><Reference><Citation>Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscul Disord. 2010;20:429&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">20444604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuyasu T A. A technique for ultracryotomy of cell suspensions and tissues. J Cell Biol. 1973;57:551&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108989</ArticleId><ArticleId IdType="pubmed">4121290</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan M, Bohnert M, Wiedemann N, Pfanner N. Role of MINOS in mitochondrial membrane architecture and biogenesis. Trends Cell Biol. 2012;22:185&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22386790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi J, Zhang Z, Wakabayashi N, Tamura Y, Fukaya M, Kensler TW, et al. The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J Cell Biol. 2009;186:805&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753156</ArticleId><ArticleId IdType="pubmed">19752021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylikallio E, Suomalainen A. Mechanisms of mitochondrial disease. Ann Med. 2012;44:41&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">21806499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanna C, Ghelli A, Porcelli A, Karbowski M, Youle R, Schimpf S, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008;131:352&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18222991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zick M, Rabl R, Reichert A. Cristae formation-linking ultrastructure and function of mitochondria. Biochim Biophys Acta. 2009;1793:5&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18620004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuchner S, Mersiyanova I, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali E, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36:459&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064763</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24945775</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Amyloid inhibits E-S potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition.</ArticleTitle><Pagination><StartPage>1334</StartPage><EndPage>1345</EndPage><MedlinePgn>1334-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.04.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00354-7</ELocationID><Abstract><AbstractText>It has been widely reported that &#x3b2;-amyloid peptide (A&#x3b2;) blocks long-term potentiation (LTP) of hippocampal synapses. Here, we show evidence that A&#x3b2; more potently blocks the potentiation of excitatory postsynaptic potential (EPSP)-spike coupling (E-S potentiation). This occurs, not by direct effect on excitatory synapses or postsynaptic neurons, but rather through an indirect mechanism: reduction of endocannabinoid-mediated peritetanic disinhibition. During high-frequency (tetanic) stimulation, somatic synaptic inhibition is suppressed by endocannabinoids. We find that A&#x3b2; prevents this endocannabinoid-mediated disinhibition, thus leaving synaptic inhibition more intact during tetanic stimulation. This intact inhibition opposes the normal depolarization of hippocampal pyramidal neurons that occurs during tetanus, thus opposing the induction of synaptic plasticity. Thus, a pathway through which A&#x3b2; can act to modulate neural activity is identified, relevant to learning and memory and how it may mediate aspects of the cognitive decline seen in Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Adrienne L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Jesse E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klotz</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Dale</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seubert</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>Daniel V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: madison@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH065541</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH065541</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043884" MajorTopicYN="N">Receptor, Cannabinoid, CB1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24945775</ArticleId><ArticleId IdType="mid">NIHMS605582</ArticleId><ArticleId IdType="pmc">PMC4114400</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.04.039</ArticleId><ArticleId IdType="pii">S0896-6273(14)00354-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abraham WC, Bliss TV, Goddard GV. Heterosynaptic changes accompany long-term but not short-term potentiation of the perforant path in the anaesthetized rat. J Physiol. 1985;363:335&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1192933</ArticleId><ArticleId IdType="pubmed">2991506</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WC, Gustafsson B, Wigstrom H. Long-term potentiation involves enhanced synaptic excitation relative to synaptic inhibition in guinea-pig hippocampus. J Physiol. 1987;394:367&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1191966</ArticleId><ArticleId IdType="pubmed">3443970</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci. 2009;12:1567&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">19935655</ArticleId></ArticleIdList></Reference><Reference><Citation>Alger BE, Nicoll RA. Pharmacological evidence for two kinds of GABA receptor on rat hippocampal pyramidal cells studied in vitro. J Physiol. 1982;328:125&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225650</ArticleId><ArticleId IdType="pubmed">7131310</ArticleId></ArticleIdList></Reference><Reference><Citation>Alger BE, Pitler TA, Wagner JJ, Martin LA, Morishita W, Kirov SA, Lenz RA. Retrograde signalling in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells. J Physiol. 1996;496(Pt 1):197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160836</ArticleId><ArticleId IdType="pubmed">8910208</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P, Bliss TV, Lomo T, Olsen LI, Skrede KK. Lamellar organization of hippocampal excitatory pathways. Acta physiologica Scandinavica. 1969;76:4A&#x2013;5A.</Citation><ArticleIdList><ArticleId IdType="pubmed">5823402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso E, Palomer E, Juves S, Maldonado R, Munoz FJ, Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. Journal of Alzheimer's disease : JAD. 2012;30:439&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">22451318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard C, Wheal HV. Expression of EPSP/spike potentiation following low frequency and tetanic stimulation in the CA1 area of the rat hippocampus. J Neurosci. 1995a;15:6542&#x2013;6551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578003</ArticleId><ArticleId IdType="pubmed">7472416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard CL, Wheal HV. Simultaneous expression of long-term depression of NMDA and long-term potentiation of AMPA receptor-mediated synaptic responses in the CA1 area of the kainic acid-lesioned hippocampus. Eur J Neurosci. 1995b;7:1651&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">7551191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350458</ArticleId><ArticleId IdType="pubmed">4727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Breakwell NA, Rowan MJ, Anwyl R. Metabotropic glutamate receptor dependent EPSP and EPSP-spike potentiation in area CA1 of the submerged rat hippocampal slice. J Neurophysiol. 1996;76:3126&#x2013;3135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8930260</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci. 2002;5:723&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">12080342</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517813</ArticleId><ArticleId IdType="pubmed">23040807</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Noriega LE, Bliss TV, Halliwell JV. The EPSP-spike (E-S) component of long-term potentiation in the rat hippocampal slice is modulated by GABAergic but not cholinergic mechanisms. Neurosci Lett. 1989;104:58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">2554222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Noriega LE, Halliwell JV, Bliss TV. A decrease in firing threshold observed after induction of the EPSP-spike (E-S) component of long-term potentiation in rat hippocampal slices. Exp Brain Res. 1990;79:633&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">2340880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Kagan BL, Hirakura Y, Xie CW. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res. 2000;60:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10723069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevaleyre V, Castillo PE. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron. 2003;38:461&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">12741992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevaleyre V, Castillo PE. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron. 2004;43:871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevaleyre V, Heifets BD, Kaeser PS, Sudhof TC, Castillo PE. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron. 2007;54:801&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001295</ArticleId><ArticleId IdType="pubmed">17553427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen GA, Doze VA, Madison DV. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron. 1992;9:325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">1497896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 1997;8:3213&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoudal G, Debanne D. Long-term plasticity of intrinsic excitability: learning rules and mechanisms. Learn Mem. 2003;10:456&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">14657257</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoudal G, Hanada Y, Debanne D. Bidirectional plasticity of excitatory postsynaptic potential (EPSP)-spike coupling in CA1 hippocampal pyramidal neurons. Proc Natl Acad Sci U S A. 2002;99:14512&#x2013;14517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137914</ArticleId><ArticleId IdType="pubmed">12391303</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies SN, Pertwee RG, Riedel G. Functions of cannabinoid receptors in the hippocampus. Neuropharmacology. 2002;42:993&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">12128000</ArticleId></ArticleIdList></Reference><Reference><Citation>Doze VA, Cohen GA, Madison DV. Synaptic localization of adrenergic disinhibition in the rat hippocampus. Neuron. 1991;6:889&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">1675862</ArticleId></ArticleIdList></Reference><Reference><Citation>Doze VA, Cohen GA, Madison DV. Calcium channel involvement in GABAB receptor-mediated inhibition of GABA release in area CA1 of the rat hippocampus. J Neurophysiol. 1995;74:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7472344</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrens DL, Dunham TD, Fay JF, Dews IC, Caldwell J, Nauert B. Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/ G-protein fusion protein. The journal of peptide research : official journal of the American Peptide Society. 2002;60:336&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464112</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Holscher C, Herron CE. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol. 2001;85:708&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gengler S, Gault VA, Harriott P, Holscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25&#x2013;35) are dependent on stimulation-protocol and genetic background. Exp Brain Res. 2007;179:621&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17171334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS neuroscience &amp; therapeutics. 2011;17:637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493861</ArticleId><ArticleId IdType="pubmed">20875047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson B, Wigstrom H, Abraham WC, Huang YY. Long-term potentiation in the hippocampus using depolarizing current pulses as the conditioning stimulus to single volley synaptic potentials. J Neurosci. 1987;7:774&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569059</ArticleId><ArticleId IdType="pubmed">2881989</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghani M, Janahmadi M, Shabani M. Protective effect of cannabinoid CB1 receptor activation against altered intrinsic repetitive firing properties induced by Abeta neurotoxicity. Neurosci Lett. 2012a;507:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">22172925</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghani M, Shabani M, Javan M, Motamedi F, Janahmadi M. CB1 cannabinoid receptor activation rescues amyloid beta-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2012b;29:391&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">22508047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanse E. Associating synaptic and intrinsic plasticity. J Physiol. 2008;586:691&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375624</ArticleId><ArticleId IdType="pubmed">18245206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee HK, Pak DT. The upside of APP at synapses. CNS neuroscience &amp; therapeutics. 2012;18:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116065</ArticleId><ArticleId IdType="pubmed">21199446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jester JM, Campbell LW, Sejnowski TJ. Associative EPSP--spike potentiation induced by pairing orthodromic and antidromic stimulation in rat hippocampal slices. J Physiol. 1995;484(Pt 3):689&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157953</ArticleId><ArticleId IdType="pubmed">7623285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kairiss EW, Abraham WC, Bilkey DK, Goddard GV. Field potential evidence for long-term potentiation of feed-forward inhibition in the rat dentate gyrus. Brain Res. 1987;401:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">3028573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science. 2013;341:1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci. 2004;19:2839&#x2013;2846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroker KS, Moreth J, Kussmaul L, Rast G, Rosenbrock H. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain Res Bull. 2013;96:28&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">23639920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison DV, Nicoll RA. Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol. 1986;372:221&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1192760</ArticleId><ArticleId IdType="pubmed">2873241</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R, Miller JP. Postsynaptic hyperpolarization during conditioning reversibly blocks induction of long-term potentiation. Nature. 1986;320:529&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">3008000</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishita W, Alger BE. Direct depolarization and antidromic action potentials transiently suppress dendritic IPSPs in hippocampal CA1 pyramidal cells. J Neurophysiol. 2001;85:480&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura I, Kato N, Kita T, Takechi H. Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci Lett. 2005;391:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura I, Takechi H, Kato N. Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices. J Neurophysiol. 2012;107:2526&#x2013;2531.</Citation><ArticleIdList><ArticleId IdType="pubmed">22338026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitler TA, Alger BE. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron. 1994;13:1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">7993636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology. 2011;60:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">21310164</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 2003;968:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronicke R, Klemm A, Meinhardt J, Schroder UH, Fandrich M, Reymann KG. Abeta mediated diminution of MTT reduction--an artefact of single cell culture? PLoS One. 2008;3:e3236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2529401</ArticleId><ArticleId IdType="pubmed">18800168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol. 2004;39:1661&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Wang Q, Anwyl R. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem Soc Trans. 2005;33:563&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042545</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff NP, Spruston N. Intracellular correlate of EPSP-spike potentiation in CA1 pyramidal neurons is controlled by GABAergic modulation. Hippocampus. 2003;13:801&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">14620875</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, Lutz B, Behl C, Clement AB. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiology of aging. 2013;34:2574&#x2013;2584.</Citation><ArticleIdList><ArticleId IdType="pubmed">23838176</ArticleId></ArticleIdList></Reference><Reference><Citation>Taube JS, Schwartzkroin PA. Mechanisms of long-term potentiation: a current-source density analysis. J Neurosci. 1988;8:1645&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569210</ArticleId><ArticleId IdType="pubmed">3367214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasulo RA, Levy WB, Steward O. LTP-associated EPSP/spike dissociation in the dentate gyrus: GABAergic and non-GABAergic components. Brain Res. 1991;561:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">1797347</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. The Journal of physiology. 2006a;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006b;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A. 2002;99:13217&#x2013;13221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002a;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain research. 2002b;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Klyubin I, Wright S, Griswold-Prenner I, Rowan MJ, Anwyl R. Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation. Neurobiol Aging. 2008;29:1485&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci. 2004a;24:6049&#x2013;6056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729673</ArticleId><ArticleId IdType="pubmed">15240796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004b;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigstrom H, Gustafsson B. Facilitated induction of hippocampal long-lasting potentiation during blockade of inhibition. Nature. 1983;301:603&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">6298626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigstrom H, Gustafsson B. Facilitation of hippocampal long-lasting potentiation by GABA antagonists. Acta physiologica Scandinavica. 1985;125:159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">2996303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RC. Changes in translation of synaptic excitation to dentate granule cell discharge accompanying long-term potentiation. I. Differences between normal and reinnervated dentate gyrus. J Neurophysiol. 1981;46:324&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">6267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RC, Levy WB, Steward O. Changes in translation of synaptic excitation to dentate granule cell discharge accompanying long-term potentiation. II. An evaluation of mechanisms utilizing dentate gyrus dually innervated by surviving ipsilateral and sprouted crossed temporodentate inputs. J Neurophysiol. 1981;46:339&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">6267217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410:588&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R, Lu B. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet. 2012;21:1384&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284124</ArticleId><ArticleId IdType="pubmed">22156579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24948815</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>25</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gene-environment interactions: lifetime cognitive activity, APOE genotype, and &#x3b2;-amyloid burden.</ArticleTitle><Pagination><StartPage>8612</StartPage><EndPage>8617</EndPage><MedlinePgn>8612-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4612-13.2014</ELocationID><Abstract><AbstractText>Carriers of the apolipoprotein E (APOE) &#x3b5;4 allele, the major genetic risk for Alzheimer's disease (AD), harbor an increased load of &#x3b2;-amyloid (A&#x3b2;) plaque burden that is felt to be a major instigator of AD development. Data has suggested that lifestyle factors may reduce AD risk by directly mitigating A&#x3b2; pathology, which could be particularly beneficial in APOE &#x3b5;4 carriers. We therefore examined the interaction between lifetime cognitive activity and the APOE &#x3b5;4 allele in relation to brain A&#x3b2; burden. We obtained measures of lifetime cognitive activity in 118 cognitively normal human individuals (mean age: 76.13 &#xb1; 5.56 years, 70 women) using a validated questionnaire that included measures over early, middle, and current age epochs. Hierarchical regression models (adjusted for age, gender, and years of education) were conducted to examine effects of APOE &#x3b5;4 carrier status, lifetime cognitive activity, and the interaction of the two factors with cortical A&#x3b2; deposition, quantified using [11C] Pittsburgh-compound-B (PIB)-PET. As expected, the &#x3b5;4 carriers exhibited higher PIB retention compared with noncarriers. Lifetime cognitive activity moderated the APOE genotype effect such that cortical PIB retention was diminished in &#x3b5;4 carriers that reported higher cognitive activity over the life course. The findings suggest that greater lifetime cognitive activity may forestall AD pathology, specifically in genetically susceptible individuals. The effect could imply that cognitive training promotes increased neural efficiency that might retard the lifelong neurally mediated deposition of A&#x3b2;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/348612-06$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wirth</LastName><ForeName>Miranka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and miranka.wirth@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeneuve</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2581-8100</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Shawn M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and School of Public Health, University of California, Berkeley, California 94720, and Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="Y">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">PIB-PET</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">lifestyle activity</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24948815</ArticleId><ArticleId IdType="pmc">PMC4061397</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4612-13.2014</ArticleId><ArticleId IdType="pii">34/25/8612</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aiken LS, West SG. Multiple regression: testing and interpreting interactions. Newbury Park, CA: Sage Publications; 1991.</Citation></Reference><Reference><Citation>Anguera JA, Boccanfuso J, Rintoul JL, Al-Hashimi O, Faraji F, Janowich J, Kong E, Larraburo Y, Rolle C, Johnston E, Gazzaley A. Video game training enhances cognitive control in older adults. Nature. 2013;501:97&#x2013;101. doi: 10.1038/nature12486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12486</ArticleId><ArticleId IdType="pmc">PMC3983066</ArticleId><ArticleId IdType="pubmed">24005416</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819&#x2013;828. doi: 10.1016/S1474-4422(11)70072-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70072-2</ArticleId><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224. doi: 10.1126/science.1161591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1161591</ArticleId><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush A, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, Martins RN. Physical activity and amyloid-beta plasma and brain levels: results from the Australian imaging, biomarkers and lifestyle study of ageing. Mol Psychiatry. 2013;18:875&#x2013;881. doi: 10.1038/mp.2012.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.107</ArticleId><ArticleId IdType="pubmed">22889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson MC, Helms MJ, Steffens DC, Burke JR, Potter GG, Plassman BL. Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement. 2008;4:324&#x2013;331. doi: 10.1016/j.jalz.2008.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.07.002</ArticleId><ArticleId IdType="pmc">PMC3673771</ArticleId><ArticleId IdType="pubmed">18790459</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, Cohen P, West SG, Aiken LS. Applied multiple regression/correlation analysis for the behavioral sciences. Ed 3. Mahwah, NJ: L. Erlbaum Associates; 2003.</Citation></Reference><Reference><Citation>Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, Mervis RF, Arendash GW, Potter H. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging. 2007;28:831&#x2013;844. doi: 10.1016/j.neurobiolaging.2006.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.04.009</ArticleId><ArticleId IdType="pubmed">16730391</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980. doi: 10.1016/j.neuroimage.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278:1349&#x2013;1356. doi: 10.1001/jama.1997.03550160069041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214. doi: 10.1073/pnas.0811879106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811879106</ArticleId><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355. doi: 10.1016/S0896-6273(02)00569-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00569-X</ArticleId><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153:242&#x2013;250. doi: 10.1093/aje/153.3.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/153.3.242</ArticleId><ArticleId IdType="pubmed">11157411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold BT, Kim C, Johnson NF, Kryscio RJ, Smith CD. Lifelong bilingualism maintains neural efficiency for cognitive control in aging. J Neurosci. 2013;33:387&#x2013;396. doi: 10.1523/JNEUROSCI.3837-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3837-12.2013</ArticleId><ArticleId IdType="pmc">PMC3710134</ArticleId><ArticleId IdType="pubmed">23303919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser RM, Warren JR. Socioeconomic indexes for occupations: a review, update, and critique. Soc Methodol. 1997;27:177&#x2013;298. doi: 10.1111/1467-9531.271028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-9531.271028</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol. 2012;69:636&#x2013;643. doi: 10.1001/archneurol.2011.845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.845</ArticleId><ArticleId IdType="pmc">PMC3583203</ArticleId><ArticleId IdType="pubmed">22232206</ArticleId></ArticleIdList></Reference><Reference><Citation>Herring A, Lewejohann L, Panzer AL, Donath A, Kr&#xf6;ll O, Sachser N, Paulus W, Keyvani K. Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiol Dis. 2011;42:530&#x2013;538. doi: 10.1016/j.nbd.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.03.007</ArticleId><ArticleId IdType="pubmed">21406231</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128. doi: 10.1016/S1474-4422(09)70299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520&#x2013;526. doi: 10.1016/j.tics.2011.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2011.09.004</ArticleId><ArticleId IdType="pmc">PMC3206968</ArticleId><ArticleId IdType="pubmed">21983147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Rovio S, Ngandu T, K&#xe5;reholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med. 2008;12:2762&#x2013;2771. doi: 10.1111/j.1582-4934.2008.00296.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00296.x</ArticleId><ArticleId IdType="pmc">PMC3828889</ArticleId><ArticleId IdType="pubmed">18318693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65:650&#x2013;657. doi: 10.1002/ana.21696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21696</ArticleId><ArticleId IdType="pubmed">19557866</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, Wilson RS, Jagust WJ. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol. 2012a;69:623&#x2013;629. doi: 10.1001/archneurol.2011.2748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.2748</ArticleId><ArticleId IdType="pmc">PMC3747737</ArticleId><ArticleId IdType="pubmed">22271235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713. doi: 10.1016/j.cell.2005.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.01.015</ArticleId><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, Morris JC, Head D. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68:311&#x2013;318. doi: 10.1002/ana.22096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22096</ArticleId><ArticleId IdType="pmc">PMC2936720</ArticleId><ArticleId IdType="pubmed">20818789</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron. 2013;77:929&#x2013;941. doi: 10.1016/j.neuron.2012.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.040</ArticleId><ArticleId IdType="pmc">PMC3596823</ArticleId><ArticleId IdType="pubmed">23473322</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840. doi: 10.1097/00004647-199609000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-199609000-00008</ArticleId><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vd&#xe9;n M, Bodammer NC, K&#xfc;hn S, Kaufmann J, Sch&#xfc;tze H, Tempelmann C, Heinze HJ, D&#xfc;zel E, Schmiedek F, Lindenberger U. Experience-dependent plasticity of white-matter microstructure extends into old age. Neuropsychologia. 2010;48:3878&#x2013;3883. doi: 10.1016/j.neuropsychologia.2010.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2010.08.026</ArticleId><ArticleId IdType="pubmed">20816877</ArticleId></ArticleIdList></Reference><Reference><Citation>Niti M, Yap KB, Kua EH, Tan CH, Ng TP. Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int Psychogeriatr. 2008;20:237&#x2013;251. doi: 10.1017/S1041610207006655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610207006655</ArticleId><ArticleId IdType="pubmed">18190728</ArticleId></ArticleIdList></Reference><Reference><Citation>Packard CJ, Westendorp RG, Stott DJ, Caslake MJ, Murray HM, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Jolles J, Perry IJ, Sweeney BJ, Twomey C, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc. 2007;55:1777&#x2013;1785. doi: 10.1111/j.1532-5415.2007.01415.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2007.01415.x</ArticleId><ArticleId IdType="pubmed">17979899</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012;69:223&#x2013;229. doi: 10.1001/archneurol.2011.666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.666</ArticleId><ArticleId IdType="pmc">PMC4004919</ArticleId><ArticleId IdType="pubmed">22332189</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289. doi: 10.1073/pnas.2635903100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2635903100</ArticleId><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825. doi: 10.1073/pnas.0900345106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Sr, Diaz-Arrastia R, Park DC. Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70:600&#x2013;606. doi: 10.1001/jamaneurol.2013.1342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.1342</ArticleId><ArticleId IdType="pmc">PMC3968915</ArticleId><ArticleId IdType="pubmed">23553344</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor HL, Jacobs DR, Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31:741&#x2013;755. doi: 10.1016/0021-9681(78)90058-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(78)90058-9</ArticleId><ArticleId IdType="pubmed">748370</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR., Jr Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67:308&#x2013;316. doi: 10.1002/ana.21953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21953</ArticleId><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Roberts RO, Lowe VJ, Kantarci K, Senjem ML, Gunter JL, Boeve BF, Petersen RC, Jack CR., Jr Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol. 2012;72:730&#x2013;738. doi: 10.1002/ana.23665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23665</ArticleId><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002a;287:742&#x2013;748. doi: 10.1001/jama.287.6.742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.6.742</ArticleId><ArticleId IdType="pubmed">11851541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bennett DA, Bienias JL, Aggarwal NT, Mendes De Leon CF, Morris MC, Schneider JA, Evans DA. Cognitive activity and incident AD in a population-based sample of older persons. Neurology. 2002b;59:1910&#x2013;1914. doi: 10.1212/01.WNL.0000036905.59156.A1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000036905.59156.A1</ArticleId><ArticleId IdType="pubmed">12499482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Segawa E, Boyle PA, Bennett DA. Influence of late-life cognitive activity on cognitive health. Neurology. 2012;78:1123&#x2013;1129. doi: 10.1212/WNL.0b013e31824f8c03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31824f8c03</ArticleId><ArticleId IdType="pmc">PMC3320053</ArticleId><ArticleId IdType="pubmed">22491864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson R, Barnes L, Bennett D. Assessment of lifetime participation in cognitively stimulating activities. J Clin Exp Neuropsychol. 2003;25:634&#x2013;642. doi: 10.1076/jcen.25.5.634.14572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/jcen.25.5.634.14572</ArticleId><ArticleId IdType="pubmed">12815501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci. 2013;33:5553&#x2013;5563. doi: 10.1523/JNEUROSCI.4409-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4409-12.2013</ArticleId><ArticleId IdType="pmc">PMC3687777</ArticleId><ArticleId IdType="pubmed">23536070</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodard JL, Sugarman MA, Nielson KA, Smith JC, Seidenberg M, Durgerian S, Butts A, Hantke N, Lancaster M, Matthews MA, Rao SM. Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. Curr Alzheimer Res. 2012;9:436&#x2013;446. doi: 10.2174/156720512800492477.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512800492477</ArticleId><ArticleId IdType="pmc">PMC3584642</ArticleId><ArticleId IdType="pubmed">22272622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37&#x2013;49. doi: 10.1016/0022-3956(82)90033-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(82)90033-4</ArticleId><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24951474</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.</ArticleTitle><Pagination><StartPage>434</StartPage><EndPage>440</EndPage><MedlinePgn>434-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000650</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether asymptomatic persons with Alzheimer disease (AD) neuropathologic change differ in the trajectory of their cognitive performance compared to asymptomatic persons without AD neuropathologic change.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Longitudinal performance on standard neuropsychological tests was examined in participants who died within 2 years of their last cognitive assessment and who were never diagnosed with mild cognitive impairment or dementia (Clinical Dementia Rating global score of 0 at all assessments). Using cognitive and neuropathologic data collected between 2005 and 2013 from the 34 National Institute on Aging-sponsored Alzheimer's Disease Centers, cognitive trajectories were compared for persons with and without evidence of AD neuropathologic change. We evaluated rates of decline in 4 domains (episodic memory, language, attention/working memory, executive function). The significance of the differences (&#x3b2;) in rates of decline was tested using linear regression, adjusting for age, education, sex, and other neuropathologic lesions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants who had low to high levels of AD neuropathologic change (n = 131) showed a greater rate of decline on the attention/working memory domain score (&#x3b2; = -0.11; 95% confidence interval = -0.19, -0.02; p = 0.02) when compared to 80 participants who died without evidence of AD neuropathologic change.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinically normal individuals who come to autopsy with AD neuropathologic change exhibit subtle evidence of declining cognitive trajectories for attention/working memory.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monsell</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO. smonsell@u.washington.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mock</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the National Alzheimer's Coordinating Center (S.E.M., C.M., W.K.), University of Washington, Seattle; and Knight Alzheimer's Disease Research Center (J.H., C.M.R., N.J.C., J.C.M.), Department of Neurology, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK094982</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24951474</ArticleId><ArticleId IdType="pmc">PMC4132573</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000650</ArticleId><ArticleId IdType="pii">WNL.0000000000000650</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;18:1732&#x2013;1740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>NIA and Reagan Institute Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1&#x2013;S2</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 1991;41:479&#x2013;486</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 2007;21:249&#x2013;258</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389&#x2013;404</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791&#x2013;1800</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsell SE, Mock C, Roe CM, et al. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology 2013;80:2121&#x2013;2129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716351</ArticleId><ArticleId IdType="pubmed">23645594</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychological Test Battery. Alzheimer Dis Assoc Disord 2009;23:91&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised Manual. Cleveland, OH: Psychological Corp., Harcourt Brace Jovanovich; 1987</Citation></Reference><Reference><Citation>Kaplan E. Boston Naming Test. Philadelphia, PA: Lea &amp; Febiger; 1983</Citation></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159&#x2013;1165</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WAIS-R: Manual: Wechsler Adult Intelligence Scale&#x2013;Revised. Cleveland, OH: Harcourt Brace Jovanovich [for] Psychological Corp; 1981</Citation></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd ed. Tucson, AZ: Neuropsychology Press; 1993</Citation></Reference><Reference><Citation>Hayden KM, Jones RN, Zimmer C, et al. Factor structure of the National Alzheimer's Coordinating Centers uniform dataset neuropsychological battery: an evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord 2011;25:128&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101374</ArticleId><ArticleId IdType="pubmed">21606904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13&#x2013;22</Citation></Reference><Reference><Citation>Dodge HH, Wang C-N, Chang C-CH, Ganguli M. Terminal decline and practice effects in older adults without dementia: the MoVIES project. Neurology 2011;77:722&#x2013;730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164394</ArticleId><ArticleId IdType="pubmed">21832224</ArticleId></ArticleIdList></Reference><Reference><Citation>Balota DA, Tse C-S, Hutchison KA, Spieler DH, Duchek JM, Morris JC. Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming. Psychol Aging 2010;25:208&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886285</ArticleId><ArticleId IdType="pubmed">20230140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse C-S, Balota DA, Moynan SC, Duchek JM, Jacoby LL. The utility of placing recollection in opposition to familiarity in early discrimination of healthy aging and very mild dementia of the Alzheimer's type. Neuropsychology 2010;24:49&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807137</ArticleId><ArticleId IdType="pubmed">20063946</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476&#x2013;1481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Ropacki SAL, Bondi MW. Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc JINS 2006;12:707&#x2013;735</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621044</ArticleId><ArticleId IdType="pubmed">16961952</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Caselli RJ. Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegener Dis Manag 2012;2:183&#x2013;195</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395065</ArticleId><ArticleId IdType="pubmed">22798965</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Jicha GA, Davis D, et al. Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis JAD 2011;25:707&#x2013;717</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353267</ArticleId><ArticleId IdType="pubmed">21498903</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001;56:361&#x2013;367</Citation><ArticleIdList><ArticleId IdType="pubmed">11171902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168&#x2013;1174</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. &#x201c;Preclinical&#x201d; AD revisited: neuropathology of cognitively normal older adults. Neurology 2000;55:370&#x2013;376</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol 2006;60:688&#x2013;695</Citation><ArticleIdList><ArticleId IdType="pubmed">17192929</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026&#x2013;1036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012;72:599&#x2013;609</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576&#x2013;1582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, Aisen PS, Sampaio C, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011;95:594&#x2013;600</Citation><ArticleIdList><ArticleId IdType="pubmed">21925234</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957&#x2013;965</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Monsell SE. Choosing Alzheimer's disease prevention clinical trial populations. Neurobiol Aging 2014;35:466&#x2013;471</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864603</ArticleId><ArticleId IdType="pubmed">24119546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels RPC, van den Berg E, Ruis C, Brands AMA. The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment 2008;15:426&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pubmed">18483192</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulsky DS, Price LR. The joint WAIS-III and WMS-III factor structure: development and cross-validation of a six-factor model of cognitive functioning. Psychol Assess 2003;15:149&#x2013;162</Citation><ArticleIdList><ArticleId IdType="pubmed">12847775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24966406</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Traumatic brain injury and risk of dementia in older veterans.</ArticleTitle><Pagination><StartPage>312</StartPage><EndPage>319</EndPage><MedlinePgn>312-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000616</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Traumatic brain injury (TBI) is common in military personnel, and there is growing concern about the long-term effects of TBI on the brain; however, few studies have examined the association between TBI and risk of dementia in veterans.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study of 188,764 US veterans aged 55 years or older who had at least one inpatient or outpatient visit during both the baseline (2000-2003) and follow-up (2003-2012) periods and did not have a dementia diagnosis at baseline. TBI and dementia diagnoses were determined using ICD-9 codes in electronic medical records. Fine-Gray proportional hazards models were used to determine whether TBI was associated with greater risk of incident dementia, accounting for the competing risk of death and adjusting for demographics, medical comorbidities, and psychiatric disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Veterans were a mean age of 68 years at baseline. During the 9-year follow-up period, 16% of those with TBI developed dementia compared with 10% of those without TBI (adjusted hazard ratio, 1.57; 95% confidence interval: 1.35-1.83). There was evidence of an additive association between TBI and other conditions on risk of dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TBI in older veterans was associated with a 60% increase in the risk of developing dementia over 9 years after accounting for competing risks and potential confounders. Our results suggest that TBI in older veterans may predispose toward development of symptomatic dementia and raise concern about the potential long-term consequences of TBI in younger veterans and civilians.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Deborah E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD. Deborah.barnes@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaup</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Katharine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byers</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the University of California, San Francisco (D.E.B., A.K., K.A.K., A.L.B., K.Y.); San Francisco Veterans Affairs Medical Center (D.E.B., A.K., K.A.K., A.L.B., K.Y.); and Uniformed Services University of the Health Sciences and Center for Neuroscience and Regenerative Medicine (R.D.-A.), Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Jul 22;83(4):298-9. doi: 10.1212/WNL.0000000000000630.</RefSource><PMID Version="1">24966404</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008889" MajorTopicYN="N">Military Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24966406</ArticleId><ArticleId IdType="pmc">PMC4115602</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000616</ArticleId><ArticleId IdType="pii">WNL.0000000000000616</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Institute of Medicine of the National Academies. Gulf War and Health: Volume 7: Long-Term Consequences of Traumatic Brain Injury. Washington, DC: National Academies Press; 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">25009909</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM, de Groot RR, van Romunde LK, Hofman A. Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol 1995;142:1300&#x2013;1305</Citation><ArticleIdList><ArticleId IdType="pubmed">7503050</ArticleId></ArticleIdList></Reference><Reference><Citation>Dams-O'Connor K, Gibbons LE, Bowen JD, McCurry SM, Larson EB, Crane PK. Risk for late-life re-injury, dementia and death among individuals with traumatic brain injury: a population-based study. J Neurol Neurosurg Psychiatry 2013;84:177&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752841</ArticleId><ArticleId IdType="pubmed">23172868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003;74:857&#x2013;862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738550</ArticleId><ArticleId IdType="pubmed">12810767</ArticleId></ArticleIdList></Reference><Reference><Citation>Guskiewicz KM, Marshall SW, Bailes J, et al. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 2005;57:719&#x2013;726</Citation><ArticleIdList><ArticleId IdType="pubmed">16239884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YK, Hou SW, Lee CC, Hsu CY, Huang YS, Su YC. Increased risk of dementia in patients with mild traumatic brain injury: a nationwide cohort study. PloS One 2013;8:e62422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641064</ArticleId><ArticleId IdType="pubmed">23658727</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555&#x2013;557</Citation><ArticleIdList><ArticleId IdType="pubmed">7898715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta KM, Ott A, Kalmijn S, et al. Head trauma and risk of dementia and Alzheimer's disease: the Rotterdam Study. Neurology 1999;53:1959&#x2013;1962</Citation><ArticleIdList><ArticleId IdType="pubmed">10599765</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(suppl 2):S28&#x2013;S35</Citation><ArticleIdList><ArticleId IdType="pubmed">1833351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemetz PN, Leibson C, Naessens JM, et al. Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 1999;149:32&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">9883791</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55:1158&#x2013;1166</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield PW, Tang M, Marder K, et al. Alzheimer's disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry 1997;62:119&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486721</ArticleId><ArticleId IdType="pubmed">9048710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundstrom A, Nilsson LG, Cruts M, Adolfsson R, Van Broeckhoven C, Nyberg L. Increased risk of dementia following mild head injury for carriers but not for non-carriers of the APOE epsilon4 allele. Int Psychogeriatr 2007;19:159&#x2013;165</Citation><ArticleIdList><ArticleId IdType="pubmed">16684399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HK, Lin SH, Sung PS, et al. Population based study on patients with traumatic brain injury suggests increased risk of dementia. J Neurol Neurosurg Psychiatry 2012;83:1080&#x2013;1085</Citation><ArticleIdList><ArticleId IdType="pubmed">22842203</ArticleId></ArticleIdList></Reference><Reference><Citation>Byers AL, Covinsky KE, Barnes DE, Yaffe K. Dysthymia and depression increase risk of dementia and mortality among older veterans. Am J Geriatric Psychiatry 2012;20:664&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229643</ArticleId><ArticleId IdType="pubmed">21597358</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Vittinghoff E, Lindquist K, et al. Posttraumatic stress disorder and risk of dementia among US veterans. Arch General Psychiatry 2010;67:608&#x2013;613</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933793</ArticleId><ArticleId IdType="pubmed">20530010</ArticleId></ArticleIdList></Reference><Reference><Citation>Selassie AW, Zaloshnja E, Langlois JA, Miller T, Jones P, Steiner C. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil 2008;23:123&#x2013;131</Citation><ArticleIdList><ArticleId IdType="pubmed">18362766</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan LL, Petersen NJ, Snow AL, et al. Prevalence of dementia among Veterans Affairs medical care system users. Dement Geriatr Cogn Disord 2005;20:245&#x2013;253</Citation><ArticleIdList><ArticleId IdType="pubmed">16088141</ArticleId></ArticleIdList></Reference><Reference><Citation>VA Dementia Registry Task Force. VA Dementia Registry Methods Report: Summary Data Tables on Demographics, Service Use and Costs. 2006. 
Available to researchers with VA network access at: http://vaww.arc.med.va.gov/gec/dementia/fy04/dementia2_reg_methods_report_2nov06.doc. Accessed June 3, 2014</Citation></Reference><Reference><Citation>(VIReC) VIRC. VHA Vital Status File [online]. Available to researchers with VA network access at: http://vaww.virec.research.va.gov/VSF/Overview.htm. Accessed June 3, 2014</Citation></Reference><Reference><Citation>Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006;4:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458356</ArticleId><ArticleId IdType="pubmed">16606453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496&#x2013;509</Citation></Reference><Reference><Citation>Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13:559&#x2013;565</Citation><ArticleIdList><ArticleId IdType="pubmed">17255278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay S, De Beaumont L, Henry LC, et al. Sports concussions and aging: a neuroimaging investigation. Cereb Cortex 2013;23:1159&#x2013;1166</Citation><ArticleIdList><ArticleId IdType="pubmed">22581847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology 2012;79:1970&#x2013;1974</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098841</ArticleId><ArticleId IdType="pubmed">22955124</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymont V, Greathouse A, Reding K, Lipsky R, Salazar A, Grafman J. Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury. Brain 2008;131:543&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pubmed">18094019</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkonde YV, Jawaid A, Qureshi SU, et al. Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population. Alzheimers Dement 2012;8:204&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">22465176</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hardy J, Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. Neuron 2012;76:886&#x2013;899</Citation><ArticleIdList><ArticleId IdType="pubmed">23217738</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol 2013;9:211&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513655</ArticleId><ArticleId IdType="pubmed">23458973</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Blennow K, Ikonomovic MD, Gandy S. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 2013;9:192&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006940</ArticleId><ArticleId IdType="pubmed">23558985</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti L, Cristofori I, Weaver SM, Chau A, Portelli JN, Grafman J. Cognitive decline in older adults with a history of traumatic brain injury. Lancet Neurol 2012;11:1103&#x2013;1112</Citation><ArticleIdList><ArticleId IdType="pubmed">23153408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed N, Culver C, Dams-O'Connor K, Hammond F, Diaz-Arrastia R. Clinical phenotype of dementia after traumatic brain injury. J Neurotrauma 2013;30:1117&#x2013;1122</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3705947</ArticleId><ArticleId IdType="pubmed">23374007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? Arch Neurol 2012;69:1245&#x2013;1251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716376</ArticleId><ArticleId IdType="pubmed">22776913</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein L, Fisher AM, Tagge CA, et al. Chronic traumatic encephalopathy in blast-exposed military veterans. Sci Transl Med 2012;4:1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739428</ArticleId><ArticleId IdType="pubmed">22593173</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Rademakers R, Kass JS, Kalkonde Y, Schulz PE. Traumatic brain injury may increase the risk for frontotemporal dementia through reduced progranulin. Neurodegener Dis 2010;6:219&#x2013;220</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837889</ArticleId><ArticleId IdType="pubmed">20145419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordts PR, Brosch LA, Holcomb JB. Now and then: combat casualty care policies for Operation Iraqi Freedom and Operation Enduring Freedom compared with those of Vietnam. J Trauma 2008;64:S14&#x2013;S20</Citation><ArticleIdList><ArticleId IdType="pubmed">18376157</ArticleId></ArticleIdList></Reference><Reference><Citation>DePalma RG, Burris DG, Champion HR, Hodgson MJ. Blast injuries. N Engl J Med 2005;352:1335&#x2013;1342</Citation><ArticleIdList><ArticleId IdType="pubmed">15800229</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronado VG, McGuire LC, Sarmiento K, et al. Trends in traumatic brain injury in the U.S. and the public health response: 1995&#x2013;2009. J Saf Res 2012;43:299&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pubmed">23127680</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul M, Xu L, Wald MM, Coronado V. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths, 2002&#x2013;2006. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25054282</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of lifetime intellectual enrichment with cognitive decline in the older population.</ArticleTitle><Pagination><StartPage>1017</StartPage><EndPage>1024</EndPage><MedlinePgn>1017-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.963</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Intellectual lifestyle enrichment throughout life is increasingly viewed as a protective strategy against commonly observed cognitive decline in the older population.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the association of lifetime intellectual enrichment with baseline cognitive performance and rate of cognitive decline in an older population without dementia and to estimate the years of protection provided against cognitive impairment by these factors.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Prospective analysis of individuals enrolled from October 1, 2004, and in 2008 and 2009 in the Mayo Clinic Study of Aging, a longitudinal, population-based study of cognitive aging in Olmsted County, Minnesota. We studied 1995 individuals without dementia (1718 cognitively normal individuals and 277 individuals with mild cognitive impairment) who completed intellectual lifestyle enrichment measures at baseline and underwent at least 1 follow-up visit.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">We studied the effect of lifetime intellectual enrichment by separating the variables into 2 nonoverlapping principal components: education/occupation score and mid/late-life cognitive activity based on self-report questionnaires. A global cognitive z score served as the summary cognition measure. Linear mixed-effects models were used to investigate the associations of demographic and intellectual enrichment measures with global cognitive z score trajectories.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline cognitive performance was lower in older individuals; individuals with lower education/occupation score, lower mid/late-life cognitive activity, and APOE genotype; and men (P&#x2009;&lt;&#x2009;.001). The interaction between the 2 intellectual enrichment measures was significant (P&#x2009;&lt;&#x2009;.03) such that the beneficial effect of mid/late-life cognitive activity on baseline cognitive performance was reduced with increasing education/occupation score. Only baseline age, mid/late-life cognitive activity, and APOE4 genotype were significantly associated with longitudinal change in cognitive performance from baseline (P&#x2009;&lt;&#x2009;.05). For APOE4 carriers with high lifetime intellectual enrichment (75th percentile of education/occupation score and midlife to late-life cognitive activity), the onset of cognitive impairment was approximately 8.7 years later compared with low lifetime intellectual enrichment (25th percentile of education/occupation score and mid/late-life cognitive activity).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Higher education/occupation scores were associated with higher levels of cognition. Higher levels of mid/late-life cognitive activity were also associated with higher levels of cognition, but the slope of this association slightly increased over time. Lifetime intellectual enrichment might delay the onset of cognitive impairment and be used as a successful preventive intervention to reduce the impending dementia epidemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesnick</LastName><ForeName>Timothy G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przybelski</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota4Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Psychology, Mayo Clinic, Rochester, Minnesota5Department of Psychiatry, Mayo Clinic, Scottsdale, Arizona6Department of Neurology, Mayo Clinic, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota4Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06-RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000135</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG037573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018898</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99/R00-AG37573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG037573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008910" MajorTopicYN="N" Type="Geographic">Minnesota</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: The authors report no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25054282</ArticleId><ArticleId IdType="mid">NIHMS646893</ArticleId><ArticleId IdType="pmc">PMC4266551</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.963</ArticleId><ArticleId IdType="pii">1883334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aging Ao.  [Accessed 06/14/2013];Projected Future Growth of the Older Population. 2010   http://www.aoa.gov/Aging_Statistics/future_growth/future_growth.aspx.</Citation></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer&#x2019;s disease. Jama. 1994 Apr 6;271(13):1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb JL, Wolf PA, Au R, White R, D&#x2019;Agostino RB. The effect of education on the incidence of dementia and Alzheimer&#x2019;s disease in the Framingham Study. Neurology. 1995 Sep;45(9):1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">7675231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer&#x2019;s disease and vascular dementia: association with education. The Rotterdam study. BMJ. 1995 Apr 15;310(6985):970&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2549358</ArticleId><ArticleId IdType="pubmed">7728032</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Karp A, von Strauss E, Winblad B, Fratiglioni L, Bellander T. Lifetime principal occupation and risk of Alzheimer&#x2019;s disease in the Kungsholmen project. Am J Ind Med. 2003 Feb;43(2):204&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12541276</ArticleId></ArticleIdList></Reference><Reference><Citation>Karp A, Kareholt I, Qiu C, Bellander T, Winblad B, Fratiglioni L. Relation of education and occupation-based socioeconomic status to incident Alzheimer&#x2019;s disease. Am J Epidemiol. 2004 Jan 15;159(2):175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718220</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer&#x2019;s disease. Neurology. 2001 Dec 26;57(12):2236&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025284</ArticleId><ArticleId IdType="pubmed">11756603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrigoule C. Do leisure activities protect against Alzheimer&#x2019;s disease? Lancet neurology. 2002 May;1(1):11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849540</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe M, Andel R, Pedersen NL, Johansson B, Gatz M. Does participation in leisure activities lead to reduced risk of Alzheimer&#x2019;s disease? A prospective study of Swedish twins. J Gerontol B Psychol Sci Soc Sci. 2003 Sep;58(5):249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler C, Toro P, Schonknecht P, Schroder J. Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer&#x2019;s disease. Psychiatry Res. 2012 Mar 30;196(1):90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22390831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ., 3rd History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012 Dec;87(12):1202&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541925</ArticleId><ArticleId IdType="pubmed">23199802</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, 3rd, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol. 2011 May 1;173(9):1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105274</ArticleId><ArticleId IdType="pubmed">21430193</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010 Sep 7;75(10):889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology. 2012 Jan 31;78(5):342&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Topazian HM, Roberts LA, et al. Engaging in cognitive activities, aging, and mild cognitive impairment: a population-based study. J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):149&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204924</ArticleId><ArticleId IdType="pubmed">21677242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on alzheimer disease biomarkers and cognition. Ann Neurol. 2012 Nov;72(5):730&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Beglinger LJ, Moser DJ, Paulsen JS, Schultz SK, Arndt S. Predicting cognitive change in older adults: the relative contribution of practice effects. Arch Clin Neuropsychol. 2010 Mar;25(2):81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819829</ArticleId><ArticleId IdType="pubmed">20064816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge HH, Wang CN, Chang CC, Ganguli M. Terminal decline and practice effects in older adults without dementia: the MoVIES project. Neurology. 2011 Aug 23;77(8):722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164394</ArticleId><ArticleId IdType="pubmed">21832224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to NIA-AA crtiteria for preclinical Alzheimer&#x2019;s disease. Ann Neurol. 2012 Apr; Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider AL, Sharrett AR, Patel MD, et al. Education and cognitive change over 15 years: the atherosclerosis risk in communities study. J Am Geriatr Soc. 2012 Oct;60(10):1847&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662980</ArticleId><ArticleId IdType="pubmed">23013064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bennett DA, Bienias JL, Mendes de Leon CF, Morris MC, Evans DA. Cognitive activity and cognitive decline in a biracial community population. Neurology. 2003 Sep 23;61(6):812&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504326</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Barnes LL, Bennett DA. Late-life social activity and cognitive decline in old age. J Int Neuropsychol Soc. 2011 Nov;17(6):998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206295</ArticleId><ArticleId IdType="pubmed">22040898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell MB, Cimino CR, Benitez A, et al. Cognitively Stimulating Activities: Effects on Cognition across Four Studies with up to 21 Years of Longitudinal Data. J Aging Res. 2012;2012:461592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3449118</ArticleId><ArticleId IdType="pubmed">23024862</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer&#x2019;s disease in a community population of older persons. Higher than previously reported. Jama. 1989 Nov 10;262(18):2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993 Aug 13;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993 Aug;43(8):1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon DP, Ferris SH, Thomas RG, et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul;27(4):391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831285</ArticleId><ArticleId IdType="pubmed">23876113</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. Changing the Trajectory of Alzheimer&#x2019;s Disease. 2010  http://www.alz.org/alzheimers_disease_trajectory.asp.</Citation></Reference><Reference><Citation>Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer&#x2019;s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011 Jan;7(1):80&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026476</ArticleId><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24952504</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.</ArticleTitle><Pagination><StartPage>738</StartPage><EndPage>748</EndPage><MedlinePgn>738-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ni.2919</ELocationID><Abstract><AbstractText>Assembly of the NLRP3 inflammasome activates caspase-1 and mediates the processing and release of the leaderless cytokine IL-1&#x3b2; and thereby serves a central role in the inflammatory response and in diverse human diseases. Here we found that upon activation of caspase-1, oligomeric NLRP3 inflammasome particles were released from macrophages. Recombinant oligomeric protein particles composed of the adaptor ASC or the p.D303N mutant form of NLRP3 associated with cryopyrin-associated periodic syndromes (CAPS) stimulated further activation of caspase-1 extracellularly, as well as intracellularly after phagocytosis by surrounding macrophages. We found oligomeric ASC particles in the serum of patients with active CAPS but not in that of patients with other inherited autoinflammatory diseases. Our findings support a model whereby the NLRP3 inflammasome, acting as an extracellular oligomeric complex, amplifies the inflammatory response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baroja-Mazo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-S&#xe1;nchez</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1] Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Ana I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Carlos M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amores-Iniesta</LastName><ForeName>Joaqu&#xed;n</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compan</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Faculty of Life Sciences, University of Manchester, Manchester, UK. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber&#xe0;-Cremades</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yag&#xfc;e</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology-CDB, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Ortiz</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology-CDB, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ant&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Reumathology Pediatric Unit, Hospital Sant Joan de Deu, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buj&#xe1;n</LastName><ForeName>Segundo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couillin</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Experimental and Molecular Immunology and Neurogenetics, CNRS UMR 7355, University of Orleans, Orleans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brough</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arostegui</LastName><ForeName>Juan I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Immunology-CDB, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelegr&#xed;n</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000000296881804</Identifier><AffiliationInfo><Affiliation>1] Inflammation and Experimental Surgery Unit, CIBERehd, Institute for Bio-Health Research of Murcia, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain. [2] Faculty of Life Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053468">CARD Signaling Adaptor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498534">Pycard protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C101136">Casp4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053471">Caspases, Initiator</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053468" MajorTopicYN="N">CARD Signaling Adaptor Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053471" MajorTopicYN="N">Caspases, Initiator</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056587" MajorTopicYN="N">Cryopyrin-Associated Periodic Syndromes</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24952504</ArticleId><ArticleId IdType="doi">10.1038/ni.2919</ArticleId><ArticleId IdType="pii">ni.2919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Death Differ. 1999 Apr;6(4):362-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10381624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Sep 4;284(36):24035-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19605353</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2011 Nov;63(11):3625-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21702021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosurg. 2012 Dec;117(6):1119-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23061392</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2013 Jun 27;38(6):1142-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23809161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Jun 19;453(7198):1122-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18496530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Apr 29;464(7293):1357-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20428172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2010 Oct 1;185(7):4385-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20802146</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2012 Mar 23;36(3):401-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22342844</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2011 Sep;243(1):206-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21884178</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2011 Nov 08;30(23):4701-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22068051</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2010 Oct;11(10):897-904</Citation><ArticleIdList><ArticleId IdType="pubmed">20835230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2008 Aug;9(8):847-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18604214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2013 Feb 1;190(3):1217-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23267025</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2008 Aug;58(8):2443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18668535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2010 Dec;11(12):1136-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21057511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Dec 1;175(11):7611-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16301671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2015 Mar;74(3):603-10</Citation><ArticleIdList><ArticleId IdType="pubmed">24326009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 9;440(7081):237-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16407889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Mar 19;140(6):821-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20303873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2011 Mar;12(3):222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21151103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2011 Aug;22(4):189-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22019906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2013 May 10;288(19):13410-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23530046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 9;440(7081):228-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16407890</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2008;442:251-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18662574</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2008 Aug;9(8):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11282-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22733741</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):314-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20588114</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19449-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20974980</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Apr 1;103(7):2809-15</Citation><ArticleIdList><ArticleId IdType="pubmed">14630794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2007 Sep;14(9):1590-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17599095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Jul 8;430(6996):213-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15190255</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jun 4;360(23):2416-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19494217</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 5;303(5663):1532-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2010 Feb;11(2):136-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20023662</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Biol Med (Maywood). 2008 Nov;233(11):1324-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18791131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2008 Mar 7;132(5):818-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18329368</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2012 Sep 21;37(3):487-500</Citation><ArticleIdList><ArticleId IdType="pubmed">22981536</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2012 Mar 23;36(3):388-400</Citation><ArticleIdList><ArticleId IdType="pubmed">22444631</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1995 Mar 31;267(5206):2000-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7535475</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2009;27:621-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Mar 13;156(6):1193-1206</Citation><ArticleIdList><ArticleId IdType="pubmed">24630722</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry (Mosc). 2009 May;74(5):469-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19538120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Nov 13-19;364(9447):1779-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15541451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2007 Sep;14(9):1583-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17599094</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2012 Jan 29;13(3):255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22286270</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2009;27:519-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19302047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Mar 13;156(6):1207-1222</Citation><ArticleIdList><ArticleId IdType="pubmed">24630723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2013 Jan 25;288(4):2721-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23209292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24952505</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.</ArticleTitle><Pagination><StartPage>727</StartPage><EndPage>737</EndPage><MedlinePgn>727-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ni.2913</ELocationID><Abstract><AbstractText>Microbes or danger signals trigger inflammasome sensors, which induce polymerization of the adaptor ASC and the assembly of ASC specks. ASC specks recruit and activate caspase-1, which induces maturation of the cytokine interleukin 1&#x3b2; (IL-1&#x3b2;) and pyroptotic cell death. Here we found that after pyroptosis, ASC specks accumulated in the extracellular space, where they promoted further maturation of IL-1&#x3b2;. In addition, phagocytosis of ASC specks by macrophages induced lysosomal damage and nucleation of soluble ASC, as well as activation of IL-1&#x3b2; in recipient cells. ASC specks appeared in bodily fluids from inflamed tissues, and autoantibodies to ASC specks developed in patients and mice with autoimmune pathologies. Together these findings reveal extracellular functions of ASC specks and a previously unknown form of cell-to-cell communication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Bernardo S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossaller</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany. [2] Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Nardo</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratter</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stutz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engels</LastName><ForeName>Gudrun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenker</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordhoff</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirandola</LastName><ForeName>Sandra R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Amoudi</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangan</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>1] Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany. [2] German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine/Cardiology, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monks</LastName><ForeName>Brian G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>1] Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany. [2] Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fricke</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espevik</LastName><ForeName>Terje</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarnicki</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansbro</LastName><ForeName>Philip M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busto</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshak-Rothstein</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornemann</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Hospital Z&#xfc;rich, Institute of Neuropathology, Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguzzi</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Hospital Z&#xfc;rich, Institute of Neuropathology, Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastenm&#xfc;ller</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine and Experimental Immunology, University Hospitals, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Institute of Innate Immunity, University Hospitals, University of Bonn, Bonn, Germany. [2] Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. [3] German Center for Neurodegenerative Diseases, Bonn, Germany. [4] Center of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-HL112661</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HL093262</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AI083713</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL112661</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL093262</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000590">Amino Acid Chloromethyl Ketones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053468">CARD Signaling Adaptor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498534">Pycard protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C460579">benzyloxycarbonyltyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000590" MajorTopicYN="N">Amino Acid Chloromethyl Ketones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053468" MajorTopicYN="N">CARD Signaling Adaptor Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="N">Caspase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011552" MajorTopicYN="N">Pseudomonas Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24952505</ArticleId><ArticleId IdType="mid">NIHMS592129</ArticleId><ArticleId IdType="pmc">PMC4116676</ArticleId><ArticleId IdType="doi">10.1038/ni.2913</ArticleId><ArticleId IdType="pii">ni.2913</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12524386</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz E, et al. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807999</ArticleId><ArticleId IdType="pubmed">23702978</ArticleId></ArticleIdList></Reference><Reference><Citation>Masumoto J, et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem. 1999;274:33835&#x2013;33838.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567338</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Alnemri T, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14:1590&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345951</ArticleId><ArticleId IdType="pubmed">17599095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu A, et al. Unified PolymerizationMechanism for the Assemblyof ASC-Dependent Inflammasomes. Cell. 2014;156:1193&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000066</ArticleId><ArticleId IdType="pubmed">24630722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, et al. Prion-like Polymerization Underlies Signal Transduction in Antiviral Immune Defense and Inflammasome Activation. Cell. 2014;156:1207&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034535</ArticleId><ArticleId IdType="pubmed">24630723</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K, et al. A splice variant of ASC regulates IL-1beta release and aggregates differently from intact ASC. Mediators of Inflammation. 2009;2009:287387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744265</ArticleId><ArticleId IdType="pubmed">19759850</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H. Higher-order assemblies in a new paradigm of signal transduction. Cell. 2013;153:287&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687143</ArticleId><ArticleId IdType="pubmed">23582320</ArticleId></ArticleIdList></Reference><Reference><Citation>Proell M, Gerlic M, Mace PD, Reed JC, Riedl SJ. The CARD plays a critical role in ASC foci formation and inflammasome signalling. J Biol Chem. 2009;284:32932&#x2013;32941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966062</ArticleId><ArticleId IdType="pubmed">23110696</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustin B, et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell. 2007;25:713&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">17349957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergsbaken T, et al. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910423</ArticleId><ArticleId IdType="pubmed">19148178</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M, Ruegg A, Werner S, Beer H-D. Active Caspase-1 Is a Regulator of Unconventional Protein Secretion. Cell. 2008;132:14&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329368</ArticleId></ArticleIdList></Reference><Reference><Citation>Balci-Peynircioglu B, et al. Expression of ASC in renal tissues of familial mediterranean fever patients with amyloidosis: postulating a role for ASC in AA type amyloid deposition. Exp Biol Med (Maywood) 2008;233:1324&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">18791131</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutz A, Horvath GL, Monks BG, Latz E. ASC Speck Formation as a Readout for Inflammasome Activation. Methods Mol Biol. 2013;1040:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobs C, Bartok E, Kubarenko A, Bauernfeind F, Hornung V. Immunoblotting for active caspase-1. Methods Mol Biol. 2012;1040:103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima-Junior DS, et al. Inflammasome-derived IL-1. Nat Med. 2013:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23749230</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-&#x3b2;. Nat. Immunol. 2008;9:857&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheedy FJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 2013:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720827</ArticleId><ArticleId IdType="pubmed">23812099</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwell-Roper C, Dunne A, Kim ML, Verchere CB, Masters SL. Activating the NLRP3 inflammasome using the amyloidogenic peptide IAPP. Methods Mol Biol. 2013;1040:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852593</ArticleId></ArticleIdList></Reference><Reference><Citation>Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946640</ArticleId><ArticleId IdType="pubmed">20428172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008;9:847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834784</ArticleId><ArticleId IdType="pubmed">18604214</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nat Cell Biol. 2006;440:237&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407889</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostert C, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396588</ArticleId><ArticleId IdType="pubmed">18403674</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1&#x3b2; in type 2 diabetes. Nat. Immunol. 2010;11:897&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103663</ArticleId><ArticleId IdType="pubmed">20835230</ArticleId></ArticleIdList></Reference><Reference><Citation>Duewell P, Duewell P, Latz E, Latz E. Assessment and Quantification of Crystal-Induced Lysosomal Damage. Methods Mol Biol. 2013;1040:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852594</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A. Cell biology: Beyond the prion principle. Nature. 2009;459:924&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">19536253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann JP, et al. Cell-to-cell propagation of infectious cytosolic protein aggregates. Proc. Natl. Acad. Sci. U.S.A. 2013;110:5951&#x2013;5956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625284</ArticleId><ArticleId IdType="pubmed">23509289</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Nuvolone M, Zhu C. The immunobiology of prion diseases. Nature Publishing Group. 2013:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24189576</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Falsig J. Prion propagation, toxicity and degradation. Nature Neuroscience. 2012;15:936&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">22735515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. The molecular basis of functional bacterial amyloid polymerization and nucleation. J Biol Chem. 2008;283:21530&#x2013;21539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2490784</ArticleId><ArticleId IdType="pubmed">18508760</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI. Cellular mechanisms of protein aggregate propagation. Current Opinion in Neurology. 2012;25:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564233</ArticleId><ArticleId IdType="pubmed">23108252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala FS, et al. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med. 2007;204:3235&#x2013;3245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150987</ArticleId><ArticleId IdType="pubmed">18070936</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nardo D, De Nardo CM, Latz E. New Insights into Mechanisms Controlling the NLRP3 Inflammasome and Its Role in Lung Disease. The American Journal of Pathology. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873477</ArticleId><ArticleId IdType="pubmed">24183846</ArticleId></ArticleIdList></Reference><Reference><Citation>Botelho FM, et al. IL-1&#x3b1;/IL-1R1 Expression in Chronic Obstructive Pulmonary Disease and Mechanistic Relevance to Smoke-Induced Neutrophilia in Mice. PLoS ONE. 2011;6:e28457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232226</ArticleId><ArticleId IdType="pubmed">22163019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci E, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. Journal of Allergy and Clinical Immunology. 2013;131:752&#x2013;762. e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060894</ArticleId><ArticleId IdType="pubmed">23380220</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097510</ArticleId><ArticleId IdType="pubmed">17063184</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiss H, et al. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. CORD Conference Proceedings. 2012;22:778&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">23817510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou F, et al. MAVS Forms Functional Prion-like Aggregates to Activate and Propagate Antiviral Innate Immune Response. Cell. 2011;146:448&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179916</ArticleId><ArticleId IdType="pubmed">21782231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, et al. The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis. Cell. 2012;150:339&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664196</ArticleId><ArticleId IdType="pubmed">22817896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Bin, et al. Structural Basis for dsRNA Recognition, Filament Formation, and Antiviral Signal Activation by MDA5. Cell. 2012;152:276&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">23273991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakele M, et al. Localization and functionality of the inflammasome in neutrophils. J Biol Chem. 2014;289:5320&#x2013;5329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931087</ArticleId><ArticleId IdType="pubmed">24398679</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczak S, et al. Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome. Journal of Neurosurgery. 2012:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576729</ArticleId><ArticleId IdType="pubmed">23061392</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F, Molawi K, Zychlinsky A. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat. Immunol. 2008;9:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18604212</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rivero Vaccari JP, et al. A Molecular Platform in Neurons Regulates Inflammation after Spinal Cord Injury. Journal of Neuroscience. 2008;28:3404&#x2013;3414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670583</ArticleId><ArticleId IdType="pubmed">18367607</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rivero Vaccari JP, et al. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab. 2009;29:1251&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846547</ArticleId><ArticleId IdType="pubmed">19401709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CR, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2009:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809046</ArticleId><ArticleId IdType="pubmed">20037584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Alnemri T, Fernandes-Alnemri T, Alnemri ES, Alnemri ES. Assembly, purification, and assay of the activity of the ASC pyroptosome. Meth Enzymol. 2008;442:251&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">18662574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenm&#xfc;ller W, Torabi-Parizi P, Subramanian N, L&#xe4;mmermann T, Germain RN. A Spatially-Organized Multicellular Innate Immune Response in Lymph Nodes Limits Systemic Pathogen Spread. Cell. 2012;150:1235&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514884</ArticleId><ArticleId IdType="pubmed">22980983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24973918</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>886</StartPage><EndPage>896</EndPage><MedlinePgn>886-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3639</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), memory impairment is the most prominent feature that afflicts patients and their families. Although reactive astrocytes have been observed around amyloid plaques since the disease was first described, their role in memory impairment has been poorly understood. Here, we show that reactive astrocytes aberrantly and abundantly produce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA through the bestrophin 1 channel. In the dentate gyrus of mouse models of AD, the released GABA reduces spike probability of granule cells by acting on presynaptic GABA receptors. Suppressing GABA production or release from reactive astrocytes fully restores the impaired spike probability, synaptic plasticity, and learning and memory in the mice. In the postmortem brain of individuals with AD, astrocytic GABA and MAOB are significantly upregulated. We propose that selective inhibition of astrocytic GABA synthesis or release may serve as an effective therapeutic strategy for treating memory impairment in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Seonmi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. [2] WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarishkin</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>1] WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Yu Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Center for Neuro-Medicine, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Ye Eun</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>1] WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. [2] Neuroscience Program, Korea University of Science and Technology, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Mijeong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Neuroscience Program, Korea University of Science and Technology, Daejeon, Republic of Korea. [2] Center for Neuroscience, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Dong Ho</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Jin Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, School of Dentistry, Kyungpook National University, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Taekeun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jaekwang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Heejung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Da Yong</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Jinpyo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Yun</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Center for Neuro-Medicine, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Soo-Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seung Ju</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Bo-Eun</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>YoungSoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000000150297082</Identifier><AffiliationInfo><Affiliation>Center for Neuro-Medicine, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Insop</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Yong Chul</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, School of Dentistry, Kyungpook National University, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jeiwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Neuroscience Program, Korea University of Science and Technology, Daejeon, Republic of Korea. [2] Center for Neuroscience, Brain Science Institute, KIST, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>1] Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts, USA. [2] Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. [3] VA Boston Healthcare System, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hoon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] Center for Neuro-Medicine, Brain Science Institute, KIST, Seoul, Republic of Korea. [2] Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts, USA. [3] Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. [4] VA Boston Healthcare System, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Eunmi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daesoo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Justin</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>1] WCI Center for Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. [2] Neuroscience Program, Korea University of Science and Technology, Daejeon, Republic of Korea. [3] Center for Neuroscience, Brain Science Institute, KIST, Seoul, Republic of Korea. [4] KU-KIST Graduate School of Converging Science of Technology, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491856">Best1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075002">Bestrophins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018756">GABA Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>V10TVZ52E4</RegistryNumber><NameOfSubstance UI="D011700">Putrescine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075002" MajorTopicYN="N">Bestrophins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005136" MajorTopicYN="N">Eye Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018756" MajorTopicYN="N">GABA Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011700" MajorTopicYN="N">Putrescine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING FINANCIAL INTERESTS. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24973918</ArticleId><ArticleId IdType="mid">NIHMS1728614</ArticleId><ArticleId IdType="pmc">PMC8385452</ArticleId><ArticleId IdType="doi">10.1038/nm.3639</ArticleId><ArticleId IdType="pii">nm.3639</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. 2012 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement 8, 131&#x2013;168 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22404854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature 430, 631&#x2013;639 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L &amp; Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM-Y &amp; Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci 8, 663&#x2013;672 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddleston M &amp; Mucke L. Molecular profile of reactive astrocytes&#x2014;implications for their role in neurologic disease. Neuroscience 54, 15&#x2013;36 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130906</ArticleId><ArticleId IdType="pubmed">8515840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM &amp; Wegiel J. Spatial relationships between astrocytes and classical plaque components. Neurobiol. Aging 12, 593&#x2013;600 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1770990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32, 638&#x2013;647 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787735</ArticleId><ArticleId IdType="pubmed">19782411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT &amp; Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211&#x2013;1215 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo DH et al.TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation. Cell 151, 25&#x2013;40 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23021213</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneberger C, Papouin T, Oliet SH &amp; Rusakov DA. Long-term potentiation depends on release of d-serine from astrocytes. Nature 463, 232&#x2013;236 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807667</ArticleId><ArticleId IdType="pubmed">20075918</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum AE, Joseph SM, Przybylski RJ &amp; Dubyak GR. Rho-family GTPases modulate Ca2+-dependent ATP release from astrocytes. Am. J. Physiol. Cell Physiol 295, C231&#x2013;C241 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493544</ArticleId><ArticleId IdType="pubmed">18495810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S et al.Channel-mediated tonic GABA release from glia. Science 330, 790&#x2013;796 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20929730</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrant M &amp; Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci 6, 215&#x2013;229 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15738957</ArticleId></ArticleIdList></Reference><Reference><Citation>Samakashvili S et al.Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease. Electrophoresis 32, 2757&#x2013;2764 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21983823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y et al.GABAA Receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 3, e3029 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515633</ArticleId><ArticleId IdType="pubmed">18716656</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon BE et al.The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum. Mol. Brain 4, 42 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253681</ArticleId><ArticleId IdType="pubmed">22107761</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR et al.Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939&#x2013;945 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W et al.GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE 7, e42823 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418292</ArticleId><ArticleId IdType="pubmed">22912745</ArticleId></ArticleIdList></Reference><Reference><Citation>Volianskis A, K&#xf8;stner R, M&#xf8;lgaard M, Hass S &amp; Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1&#x394;E9-deleted transgenic mice model of &#x3b2;-amyloidosis. Neurobiol. Aging 31, 1173&#x2013;1187 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">18790549</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC et al.A&#x3b2; deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci 17, 7053&#x2013;7059 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Matousek SB et al.Chronic IL-1&#x3b2;&#x2013;mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer&#x2019;s disease without inducing overt neurodegeneration. J. Neuroimmune Pharmacol 7, 156&#x2013;164 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302720</ArticleId><ArticleId IdType="pubmed">22173340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-R&#xfc;bsamen M et al.Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-A&#x3b2; deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol 121, 705&#x2013;719 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098988</ArticleId><ArticleId IdType="pubmed">21301857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesner RP. A behavioral analysis of dentate gyrus function. Prog. Brain Res 163, 567&#x2013;576 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17765738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashiba T et al.Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell 149, 188&#x2013;201 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319279</ArticleId><ArticleId IdType="pubmed">22365813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Lu H, Lewis TL &amp; Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem 282, 36275&#x2013;36282 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17942401</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K-S et al.Channel-mediated astrocytic glutamate release via Bestrophin-1 targets synaptic NMDARs. Mol. Brain 6, 4 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577500</ArticleId><ArticleId IdType="pubmed">23324492</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H et al.High glutamate permeability and distal localization of Best1 channel in CA1 hippocampal astrocyte. Mol. Brain 6, 54 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029177</ArticleId><ArticleId IdType="pubmed">24321245</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiler N, Sshmidt-Glenewinkel T &amp; Sarhan S. On the formation of &#x3b3;-aminobutyric acid from putrescine in brain. J. Biochem 86, 277&#x2013;279 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">479128</ArticleId></ArticleIdList></Reference><Reference><Citation>Laschet J, Grisar T, Bureau M &amp; Guillaume D. Characteristics of putrescine uptake and subsequent GABA formation in primary cultured astrocytes from normal C57BL/6J and epileptic DBA/2J mouse brain cortices. Neuroscience 48, 151&#x2013;157 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1584419</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspi R et al.The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res 40, D742&#x2013;D753 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245006</ArticleId><ArticleId IdType="pubmed">22102576</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiler N &amp; Al-Therib M. Putrescine catabolism in mammalian brain. Biochem. J 144, 29&#x2013;35 (1974).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1168460</ArticleId><ArticleId IdType="pubmed">4156831</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J et al.Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62, 15&#x2013;30 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7816197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S et al.Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80, 419&#x2013;425 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2239154</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Kettler R, Da Prada M &amp; Richards J. Quantitative enzyme radioautography with 3H-Ro 41&#x2013;1049 and 3H-Ro 19&#x2013;6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci 12, 1977&#x2013;1999 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575899</ArticleId><ArticleId IdType="pubmed">1578281</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitt P, Pintar JE &amp; Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. USA 79, 6385&#x2013;6389 (1982).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC347126</ArticleId><ArticleId IdType="pubmed">6755469</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkmayer W, Riederer P, Youdim M &amp; Linauer W. The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil. J. Neural Transm 36, 303&#x2013;326 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1172524</ArticleId></ArticleIdList></Reference><Reference><Citation>Youdim MB et al.Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res 79, 172&#x2013;179 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15573406</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gga K, Bogdanovic N &amp; Marcusson J. GABA transporters (GAT-1) in Alzheimer&#x2019;s disease. J. Neural Transm 106, 1141&#x2013;1149 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10651110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Kannagi M, Ferrante RJ, Kowall NW &amp; Ryu H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB J 23, 1739&#x2013;1749 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698657</ArticleId><ArticleId IdType="pubmed">19179380</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG. The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 135, 422&#x2013;435 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834419</ArticleId><ArticleId IdType="pubmed">18984155</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen C &amp; Stevens CF. An evaluation of causes for unreliability of synaptic transmission. Proc. Natl. Acad. Sci. USA 91, 10380&#x2013;10383 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45023</ArticleId><ArticleId IdType="pubmed">7937958</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA et al.Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci 30, 6367&#x2013;6374 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis L &amp; Furlan C. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. Pharmacol. Biochem. Behav 65, 649&#x2013;653 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10764917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Birks J, Whitehead A &amp; Evans SJ. The effect of selegiline in the treatment of people with Alzheimer&#x2019;s disease: a meta&#x2010;analysis of published trials. Int. J. Geriatr. Psychiatry 17, 175&#x2013;183 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11813282</ArticleId></ArticleIdList></Reference><Reference><Citation>Engberg G, Elebring T &amp; Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J. Pharmacol. Exp. Ther 259, 841&#x2013;847 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1658311</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzo A et al.Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res 50, 77&#x2013;85 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15082032</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Stark CE &amp; Clark RE. The medial temporal lobe*. Annu. Rev. Neurosci 27, 279&#x2013;306 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15217334</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J &amp; Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768&#x2013;773 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Cummings B, Monzavi R &amp; Cotman CW. &#x3b2;-amyloid&#x2013;induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer&#x2019;s disease. Neuroscience 63, 517&#x2013;531 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7891862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G et al.A learning deficit related to age and &#x3b2;-amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Nature 408, 975&#x2013;979 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H et al.AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron 52, 831&#x2013;843 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW &amp; Price DA. Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J. Neuropathol. Exp. Neurol 57, 1146&#x2013;1153 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9862637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs K, Kharazia VN &amp; Prince DA. Mechanisms underlying epileptogenesis in cortical malformations. Epilepsy Res 36, 165&#x2013;188 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10515164</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L et al.Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccinin GL, Finali G &amp; Piccirilli M. Neuropsychological effects of l-deprenyl in Alzheimer&#x2019;s type dementia. Clin. Neuropharmacol 13, 147&#x2013;163 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2109658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN et al.l-deprenyl in Alzheimer&#x2019;s disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry 44, 427&#x2013;433 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3107514</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteverde A, Gnemmi P, Rossi F &amp; Finali G. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin. Ther 12, 315&#x2013;322 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2121360</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J &amp; Flicker L. Selegiline for Alzheimer&#x2019;s disease. Cochrane Database Syst. Rev CD000442 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12535396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach M, Youdim M &amp; Riederer P. Pharmacology of selegiline. Neurology 47, S137&#x2013;S145 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8959982</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430&#x2013;440 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18995817</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G &amp; Franklin K The Mouse Brain in Stereotaxic Coordinates: Compact Second Edition (Academic Press, San Diego, 2003).</Citation></Reference><Reference><Citation>Kutl&#xe1;n D &amp; Molnar-Perl I. New aspects of the simultaneous analysis of amino acids and amines as their o-phthaldialdehyde derivatives by high-performance liquid chromatography. Analysis of wine, beer and vinegar. J. Chromatogr. A 987, 311&#x2013;322 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12613825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengerink Y, Kutlan D, Toth F, Csampai A &amp; Molnar-Perl I. Advances in the evaluation of the stability and characteristics of the amino acid and amine derivatives obtained with the o-phthaldialdehyde/3-mercaptopropionic acid and o-phthaldialdehyde/N-acetyl-l-cysteine reagents. High-performance liquid chromatography-mass spectrometry study. J. Chromatogr. A 949, 99&#x2013;124 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11999763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, Moss JA &amp; Janda KD. Biological tuning of synthetic tactics in solid-phase synthesis: Application to A&#x3b2; (1&#x2013;42). J. Org. Chem 69, 7776&#x2013;7778 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15498016</ArticleId></ArticleIdList></Reference><Reference><Citation>Unal Cevik I &amp; Dalkara T. Intravenously administered propidium iodide labels necrotic cells in the intact mouse brain after injury. Cell Death Differ 10, 928&#x2013;929 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12868000</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H et al.Bestrophin-1 encodes for the Ca2+-activated anion channel in hippocampal astrocytes. J. Neurosci 29, 13063&#x2013;13073 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825675</ArticleId><ArticleId IdType="pubmed">19828819</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara K, Tanabe T, Yabuuchi M, Ueoka R &amp; Tsuru D. A monoclonal antibody against the glutaraldehyde-conjugated polyamine, putrescine: application to immunocytochemistry. Histochem. Cell Biol 115, 471&#x2013;477 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11455447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal N et al.Withania somnifera reverses Alzheimer&#x2019;s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA 109, 3510&#x2013;3515 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295277</ArticleId><ArticleId IdType="pubmed">22308347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J et al.Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death. J. Biol. Chem 285, 39447&#x2013;39457 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998094</ArticleId><ArticleId IdType="pubmed">20923777</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ &amp; Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-&#x394;&#x394;CT method. Methods 25, 402&#x2013;408 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24979790</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>26</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Transcellular degradation of axonal mitochondria.</ArticleTitle><Pagination><StartPage>9633</StartPage><EndPage>9638</EndPage><MedlinePgn>9633-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1404651111</ELocationID><Abstract><AbstractText>It is generally accepted that healthy cells degrade their own mitochondria. Here, we report that retinal ganglion cell axons of WT mice shed mitochondria at the optic nerve head (ONH), and that these mitochondria are internalized and degraded by adjacent astrocytes. EM demonstrates that mitochondria are shed through formation of large protrusions that originate from otherwise healthy axons. A virally introduced tandem fluorophore protein reporter of acidified mitochondria reveals that acidified axonal mitochondria originating from the retinal ganglion cell are associated with lysosomes within columns of astrocytes in the ONH. According to this reporter, a greater proportion of retinal ganglion cell mitochondria are degraded at the ONH than in the ganglion cell soma. Consistently, analyses of degrading DNA reveal extensive mtDNA degradation within the optic nerve astrocytes, some of which comes from retinal ganglion cell axons. Together, these results demonstrate that surprisingly large proportions of retinal ganglion cell axonal mitochondria are normally degraded by the astrocytes of the ONH. This transcellular degradation of mitochondria, or transmitophagy, likely occurs elsewhere in the CNS, because structurally similar accumulations of degrading mitochondria are also found along neurites in superficial layers of the cerebral cortex. Thus, the general assumption that neurons or other cells necessarily degrade their own mitochondria should be reconsidered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Chung-ha O</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Keun-Young</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bushong</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boassa</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinebuchi</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bihlmeyer</LastName><ForeName>Nathan A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Judy V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yunju</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellisman</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Center for Microscopy and Imaging Research, Center for Research in Biological Systems, Department of Neurosciences, University of California at San Diego, La Jolla, CA 92093.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh-Armstrong</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD 21205; and marsh-armstrong@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 GM103412</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P41RR004050</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32GM07814</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY022680</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01GM82949</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR004050</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM082949</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA016602</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY019960</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P41GM103412-25</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS050274</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007814</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA016602</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2014 Jul 25;345(6195):385-6. doi: 10.1126/science.1258295.</RefSource><PMID Version="1">25061193</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Autophagy. 2014;10(12):2383-4. doi: 10.4161/15548627.2014.981920.</RefSource><PMID Version="1">25484086</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055032" MajorTopicYN="N">Electron Microscope Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009898" MajorTopicYN="N">Optic Disk</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097573" MajorTopicYN="N">Red Fluorescent Protein</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mitophagy</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24979790</ArticleId><ArticleId IdType="pmc">PMC4084443</ArticleId><ArticleId IdType="doi">10.1073/pnas.1404651111</ArticleId><ArticleId IdType="pii">1404651111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab. 2012;23(9):459&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580164</ArticleId><ArticleId IdType="pubmed">22817841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013;20(1):31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524633</ArticleId><ArticleId IdType="pubmed">22743996</ArticleId></ArticleIdList></Reference><Reference><Citation>Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762028</ArticleId><ArticleId IdType="pubmed">22936770</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen JV, et al. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci USA. 2011;108(3):1176&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024691</ArticleId><ArticleId IdType="pubmed">21199938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankiv S, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131&#x2013;24145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17580304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshenker S. The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J Mol Neurosci. 2009;39(1-2):99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19253007</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan MR, et al. Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci. 2007;27(25):6607&#x2013;6619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672708</ArticleId><ArticleId IdType="pubmed">17581948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato KI, Gon&#xe7;alves JM, Houts GE, Bollum FJ. Deoxynucleotide-polymerizing enzymes of calf thymus gland. II. Properties of the terminal deoxynucleotidyltransferase. J Biol Chem. 1967;242(11):2780&#x2013;2789.</Citation><ArticleIdList><ArticleId IdType="pubmed">6027247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Jones D, Gonzalez-Lima F. Mouse model of optic neuropathy caused by mitochondrial complex I dysfunction. Neurosci Lett. 2002;326(2):97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057837</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell GR, et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol. 2007;179(7):1523&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373494</ArticleId><ArticleId IdType="pubmed">18158332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504(7480):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Sato K. Degradation of paternal mitochondria by fertilization-triggered autophagy in C. elegans embryos. Science. 2011;334(6059):1141&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21998252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, et al. Noncanonical autophagy promotes the visual cycle. Cell. 2013;154(2):365&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744125</ArticleId><ArticleId IdType="pubmed">23870125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843437</ArticleId><ArticleId IdType="pubmed">20203610</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485(7397):251&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378041</ArticleId><ArticleId IdType="pubmed">22535248</ArticleId></ArticleIdList></Reference><Reference><Citation>Court FA, Coleman MP. Mitochondria as a central sensor for axonal degenerative stimuli. Trends Neurosci. 2012;35(6):364&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">22578891</ArticleId></ArticleIdList></Reference><Reference><Citation>Schon EA, Przedborski S. Mitochondria: The next (neurode)generation. Neuron. 2011;70(6):1033&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407575</ArticleId><ArticleId IdType="pubmed">21689593</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintz N. Gene expression nervous system atlas (GENSAT) Nat Neurosci. 2004;7(5):483.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke SA, et al. Deconstructing complexity: Serial block-face electron microscopic analysis of the hippocampal mossy fiber synapse. J Neurosci. 2013;33(2):507&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756657</ArticleId><ArticleId IdType="pubmed">23303931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer JR, Mastronarde DN, McIntosh JR. Computer visualization of three-dimensional image data using IMOD. J Struct Biol. 1996;116(1):71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence A, Bouwer JC, Perkins G, Ellisman MH. Transform-based backprojection for volume reconstruction of large format electron microscope tilt series. J Struct Biol. 2006;154(2):144&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">16542854</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermulst M, Bielas JH, Loeb LA. Quantification of random mutations in the mitochondrial genome. Methods. 2008;46(4):263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615251</ArticleId><ArticleId IdType="pubmed">18948200</ArticleId></ArticleIdList></Reference><Reference><Citation>Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods. 2008;44(3):250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2295206</ArticleId><ArticleId IdType="pubmed">18314056</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Corput MP, et al. Detection of mitochondrial DNA deletions in human skin fibroblasts of patients with Pearson&#x2019;s syndrome by two-color fluorescence in situ hybridization. J Histochem Cytochem. 1997;45(1):55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010469</ArticleId></ArticleIdList></Reference><Reference><Citation>Janes MS, et al. Rapid analysis of mitochondrial DNA depletion by fluorescence in situ hybridization and immunocytochemistry: Potential strategies for HIV therapeutic monitoring. J Histochem Cytochem. 2004;52(8):1011&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">15258176</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto I, et al. Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J Neurosci. 2008;28(2):548&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670511</ArticleId><ArticleId IdType="pubmed">18184797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24982139</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>28</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>10323</StartPage><EndPage>10328</EndPage><MedlinePgn>10323-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1408900111</ELocationID><Abstract><AbstractText>An increasing number of studies argues that self-propagating protein conformations (i.e., prions) feature in the pathogenesis of several common neurodegenerative diseases. Mounting evidence contends that aggregates of the amyloid-&#x3b2; (A&#x3b2;) peptide become self-propagating in Alzheimer's disease (AD) patients. An important characteristic of prions is their ability to replicate distinct strains, the biological information for which is enciphered within different conformations of protein aggregates. To investigate whether distinct strains of A&#x3b2; prions can be discerned in AD patients, we performed transmission studies in susceptible transgenic mice using brain homogenates from sporadic or heritable (Arctic and Swedish) AD cases. Mice inoculated with the Arctic AD sample exhibited a pathology that could be distinguished from mice inoculated with the Swedish or sporadic AD samples, which was judged by differential accumulation of A&#x3b2; isoforms and the morphology of cerebrovascular A&#x3b2; deposition. Unlike Swedish AD- or sporadic AD-inoculated animals, Arctic AD-inoculated mice, like Arctic AD patients, displayed a prominent A&#x3b2;38-containing cerebral amyloid angiopathy. The divergent transmission behavior of the Arctic AD sample compared with the Swedish and sporadic AD samples was maintained during second passage in mice, showing that A&#x3b2; strains are serially transmissible. We conclude that at least two distinct strains of A&#x3b2; prions can be discerned in the brains of AD patients and that strain fidelity was preserved on serial passage in mice. Our results provide a potential explanation for the clinical and pathological heterogeneity observed in AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Joel C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases andDepartments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;hr</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases andDepartments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oehler</LastName><ForeName>Abby</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology, University of California, San Francisco, CA 94143; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeArmond</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases andPathology, University of California, San Francisco, CA 94143; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases andDepartments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases andDepartments of Neurology and stanley@ind.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG042453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG042453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioluminescence imaging</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteinopathies</Keyword><Keyword MajorTopicYN="N">seeding</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24982139</ArticleId><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="doi">10.1073/pnas.1408900111</ArticleId><ArticleId IdType="pii">1408900111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501(7465):45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014;20(2):130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner RB. [URE3] as an altered URE2 protein: Evidence for a prion analog in Saccharomyces cerevisiae. Science. 1994;264(5158):566&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909170</ArticleId></ArticleIdList></Reference><Reference><Citation>Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell. 2003;115(7):879&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697205</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012;336(6088):1511&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion. 2013;7(1):55&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609051</ArticleId><ArticleId IdType="pubmed">23208281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Revesz T. The spread of neurodegenerative disease. N Engl J Med. 2012;366(22):2126&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22646635</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330(6006):980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2011;108(6):2528&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038719</ArticleId><ArticleId IdType="pubmed">21262831</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-&#x3b2; deposition in vivo. Mol Psychiatry. 2012;17(12):1347&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968933</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proc Natl Acad Sci USA. 2012;109(27):11025&#x2013;11030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, et al. Exogenous seeding of cerebral &#x3b2;-amyloid deposition in &#x3b2;APP-transgenic rats. J Neurochem. 2012;120(5):660&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293176</ArticleId><ArticleId IdType="pubmed">22017494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessen RA, et al. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 1995;375(6533):698&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">7791905</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science. 1996;274(5295):2079&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Conformational variations in an infectious protein determine prion strain differences. Nature. 2004;428(6980):323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15029196</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Science. 2005;307(5707):262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Williams AD, Chemuru S, Wetzel R. Abeta(1-40) forms five distinct amyloid structures whose &#x3b2;-sheet contents and fibril stabilities are correlated. J Mol Biol. 2010;401(3):503&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919579</ArticleId><ArticleId IdType="pubmed">20600131</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson KP, et al. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer&#x2019;s disease using novel luminescent probes. ACS Chem Biol. 2007;2(8):553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">17672509</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. Seeded growth of beta-amyloid fibrils from Alzheimer&#x2019;s brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA. 2009;106(18):7443&#x2013;7448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="pubmed">19376973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154(6):1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: Evidence of subgroups. Neurology. 1985;35(4):453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982631</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, et al. The &#x2018;Arctic&#x2019; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, et al. Mixtures of wild-type and a pathogenic (E22G) form of A&#x3b2;40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol. 2003;332(4):795&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972252</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipson O, et al. The Arctic amyloid-&#x3b2; precursor protein (A&#x3b2;PP) mutation results in distinct plaques and accumulation of N- and C-truncated A&#x3b2;. Neurobiol Aging. 2012;33:1010.e1&#x2013;1010.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalimo H, et al. The Arctic A&#x3b2;PP mutation leads to Alzheimer&#x2019;s disease pathology with highly variable topographic deposition of differentially truncated A&#x3b2;. Acta Neuropathol Commun. 2013;1(1):60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226306</ArticleId><ArticleId IdType="pubmed">24252272</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, et al. Mutation of the &#x3b2;-amyloid precursor protein in familial Alzheimer&#x2019;s disease increases &#x3b2;-protein production. Nature. 1992;360(6405):672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, et al. Amyloid precursor protein mutation causes Alzheimer&#x2019;s disease in a Swedish family. Neurosci Lett. 1994;168(1-2):254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8028788</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretz D, et al. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci. 2001;10(4):854&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373967</ArticleId><ArticleId IdType="pubmed">11274476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94(24):13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, et al. Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett. 2004;367(2):210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331155</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med. 2010;16(11):1210&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052075</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner G, et al. Seeded strain-like transmission of &#x3b2;-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013;14(11):1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818077</ArticleId><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnb&#xe4;ck A, et al. Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol Aging. 2011;32(2):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">19329229</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro ML, et al. APP mutations in the A&#x3b2; coding region are associated with abundant cerebral deposition of A&#x3b2;38. Acta Neuropathol. 2012;124(6):809&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">23143229</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabizon R, et al. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Nat Med. 1996;2(1):59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8564843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SG, et al. Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nat Med. 1997;3(9):1009&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288728</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchi P, et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Str&#xe4;ussler-Scheinker disease. Proc Natl Acad Sci USA. 1998;95(14):8322&#x2013;8327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20974</ArticleId><ArticleId IdType="pubmed">9653185</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: An emperor in need of clothes. Nat Neurosci. 2012;15(3):349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr, et al. Distinct synthetic A&#x3b2; prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci USA. 2014;111:10329&#x2013;10334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104853</ArticleId><ArticleId IdType="pubmed">24982137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks L, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the &#x3b2;-amyloid precursor protein gene. Nat Genet. 1992;1(3):218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, et al. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">21911694</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, et al. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA. 2013;110(48):19555&#x2013;19560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110(23):9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry DB, et al. Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA. 2013;110(44):E4160&#x2013;E4169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816483</ArticleId><ArticleId IdType="pubmed">24128760</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-&#x3b2; in Alzheimer&#x2019;s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Delrieu J, Ousset PJ, Caillaud C, Vellas B. &#x2018;Clinical trials in Alzheimer&#x2019;s disease&#x2019;: Immunotherapy approaches. J Neurochem. 2012;120(Suppl 1):186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">21883222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24982137</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>28</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Distinct synthetic A&#x3b2; prion strains producing different amyloid deposits in bigenic mice.</ArticleTitle><Pagination><StartPage>10329</StartPage><EndPage>10334</EndPage><MedlinePgn>10329-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1408968111</ELocationID><Abstract><AbstractText>An increasing number of studies continue to show that the amyloid &#x3b2; (A&#x3b2;) peptide adopts an alternative conformation and acquires transmissibility; hence, it becomes a prion. Here, we report on the attributes of two strains of A&#x3b2; prions formed from synthetic A&#x3b2; peptides composed of either 40 or 42 residues. Modifying the conditions for A&#x3b2; polymerization increased both the protease resistance and prion infectivity compared with an earlier study. Approximately 150 d after intracerebral inoculation, both synthetic A&#x3b2;40 and A&#x3b2;42 prions produced a sustained rise in the bioluminescence imaging signal in the brains of bigenic Tg(APP23:Gfap-luc) mice, indicative of astrocytic gliosis. Pathological investigations showed that synthetic A&#x3b2;40 prions produced amyloid plaques containing both A&#x3b2;40 and A&#x3b2;42 in the brains of inoculated bigenic mice, whereas synthetic A&#x3b2;42 prions stimulated the formation of smaller, more numerous plaques composed predominantly of A&#x3b2;42. Synthetic A&#x3b2;40 preparations consisted of long straight fibrils; in contrast, the A&#x3b2;42 fibrils were much shorter. Addition of 3.47 mM (0.1%) SDS to the polymerization reaction produced A&#x3b2;42 fibrils that were indistinguishable from A&#x3b2;40 fibrils produced in the absence or presence of SDS. Moreover, the A&#x3b2; amyloid plaques in the brains of bigenic mice inoculated with A&#x3b2;42 prions prepared in the presence of SDS were similar to those found in mice that received A&#x3b2;40 prions. From these results, we conclude that the composition of A&#x3b2; plaques depends on the conformation of the inoculated A&#x3b2; polymers, and thus, these inocula represent distinct synthetic A&#x3b2; prion strains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>St&#xf6;hr</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases,Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Joel C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases,Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Lillian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oehler</LastName><ForeName>Abby</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nick</LastName><ForeName>Mimi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Chemistry, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeArmond</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases,Pathology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases,Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeGrado</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Pharmaceutical Chemistry, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases,Departments of Neurology and stanley@ind.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041997</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007731</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS041997</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG042453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG042453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">in vitro</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24982137</ArticleId><ArticleId IdType="pmc">PMC4104853</ArticleId><ArticleId IdType="doi">10.1073/pnas.1408968111</ArticleId><ArticleId IdType="pii">1408968111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer&#x2019;s disease. Acta Neuropathol. 2012;124(3):305&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708460</ArticleId><ArticleId IdType="pubmed">22618995</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012;336(6088):1511&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8):423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudsmit J, et al. Evidence for and against the transmissibility of Alzheimer disease. Neurology. 1980;30(9):945&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">6775247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm. 2006;113(9):1243&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362635</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94(24):13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330(6006):980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2011;108(6):2528&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038719</ArticleId><ArticleId IdType="pubmed">21262831</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proc Natl Acad Sci USA. 2012;109(27):11025&#x2013;11030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic A&#x3b2; in different aggregation states. Methods Mol Biol. 2011;670:13&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott M, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell. 1989;59(5):847&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">2574076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Staufenbiel M. Pathogenic mechanisms of Alzheimer&#x2019;s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci. 2000;920:134&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193142</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels K, et al. Structural basis for increased toxicity of pathological a&#x3b2;42:a&#x3b2;40 ratios in Alzheimer disease. J Biol Chem. 2012;287(8):5650&#x2013;5660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285338</ArticleId><ArticleId IdType="pubmed">22157754</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell. 1990;63(4):673&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce ME. Scrapie strain variation and mutation. Br Med Bull. 1993;49(4):822&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137131</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">1675487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol. 1994;68(12):7859&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237248</ArticleId><ArticleId IdType="pubmed">7966576</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science. 1996;274(5295):2079&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI, et al. The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog. 2011;7(3):e1001317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060105</ArticleId><ArticleId IdType="pubmed">21437239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner RB. [URE3] as an altered URE2 protein: Evidence for a prion analog in Saccharomyces cerevisiae. Science. 1994;264(5158):566&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Collins SR, Toyama BH, Weissman JS. The physical basis of how prion conformations determine strain phenotypes. Nature. 2006;442(7102):585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810177</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby DW, et al. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci USA. 2009;106(48):20417&#x2013;20422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787151</ArticleId><ArticleId IdType="pubmed">19915150</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen F, Poulter M, Collinge J, Crow TJ. Codon 129 changes in the prion protein gene in Caucasians. Am J Hum Genet. 1990;46(6):1215&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683817</ArticleId><ArticleId IdType="pubmed">2378641</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchi P, et al. Agent strain variation in human prion disease: Insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain. 2010;133(10):3030&#x2013;3042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947429</ArticleId><ArticleId IdType="pubmed">20823086</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, et al. Linkage of prion protein and scrapie incubation time genes. Cell. 1986;46(4):503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">3015416</ArticleId></ArticleIdList></Reference><Reference><Citation>Westaway D, et al. Distinct prion proteins in short and long scrapie incubation period mice. Cell. 1987;51(4):651&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">2890436</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner G, et al. Seeded strain-like transmission of &#x3b2;-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013;14(11):1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818077</ArticleId><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen K, et al. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form. Biol Chem. 2001;382(4):683&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405232</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong L-W, Raymond LD, Hayes SF, Raymond GJ, Caughey B. Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem. 2001;79(3):669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701770</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, et al. Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA. 2008;105(7):2409&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268150</ArticleId><ArticleId IdType="pubmed">18268326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangachari V, et al. Amyloid-&#x3b2;(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry. 2007;46(43):12451&#x2013;12462.</Citation><ArticleIdList><ArticleId IdType="pubmed">17910477</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, et al. Globular amyloid &#x3b2;-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer&#x2019;s disease. J Neurochem. 2005;95(3):834&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135089</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelein A, et al. Formation of dynamic soluble surfactant-induced amyloid &#x3b2; peptide aggregation intermediates. J Biol Chem. 2013;288(32):23518&#x2013;23528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395029</ArticleId><ArticleId IdType="pubmed">23775077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer's disease brain tissue. Cell. 2013;154(6):1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer's disease patients. Proc Natl Acad Sci USA. 2014;111:10323&#x2013;10328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2010;120(2):185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro ML, et al. APP mutations in the A&#x3b2; coding region are associated with abundant cerebral deposition of A&#x3b2;38. Acta Neuropathol. 2012;124(6):809&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">23143229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemmaghami S, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog. 2009;5(11):e1000673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777304</ArticleId><ArticleId IdType="pubmed">19956709</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry DB, et al. Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA. 2013;110(44):E4160&#x2013;E4169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816483</ArticleId><ArticleId IdType="pubmed">24128760</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelschlegel AM, Weissmann C. Acquisition of drug resistance and dependence by prions. PLoS Pathog. 2013;9(2):e1003158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567182</ArticleId><ArticleId IdType="pubmed">23408888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25009180</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>29</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Allosteric regulation of &#x3b3;-secretase activity by a phenylimidazole-type &#x3b3;-secretase modulator.</ArticleTitle><Pagination><StartPage>10544</StartPage><EndPage>10549</EndPage><MedlinePgn>10544-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1402171111</ELocationID><Abstract><AbstractText>&#x3b3;-Secretase is an intramembrane-cleaving protease responsible for the generation of amyloid-&#x3b2; (A&#x3b2;) peptides. Recently, a series of compounds called &#x3b3;-secretase modulators (GSMs) has been shown to decrease the levels of long toxic A&#x3b2; species (i.e., A&#x3b2;42), with a concomitant elevation of the production of shorter A&#x3b2; species. In this study, we show that a phenylimidazole-type GSM allosterically induces conformational changes in the catalytic site of &#x3b3;-secretase to augment the proteolytic activity. Analyses using the photoaffinity labeling technique and systematic mutational studies revealed that the phenylimidazole-type GSM targets a previously unidentified extracellular binding pocket within the N-terminal fragment of presenilin (PS). Collectively, we provide a model for the mechanism of action of the phenylimidazole-type GSM in which binding at the luminal side of PS induces a conformational change in the catalytic center of &#x3b3;-secretase to modulate A&#x3b2; production.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeo</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanimura</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Synthetic Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinoda</LastName><ForeName>Takehiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osawa</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahariev</LastName><ForeName>Ivan Krasmirov</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Synthetic Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takegami</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience andFaculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan;Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishizuka-Katsura</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinya</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi-Niidome</LastName><ForeName>Shizuka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tominaga</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohsawa</LastName><ForeName>Noboru</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura-Someya</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirouzu</LastName><ForeName>Mikako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andDivision of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoshima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Synthetic Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Shigeyuki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>RIKEN Systems and Structural Biology Center andRIKEN Structural Biology Laboratory, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuyama</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Synthetic Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience andCore Research for Evolutional Science and Technology, Japan Science and Technology Agency, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan taisuke@mol.f.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Neuropathology and Neuroscience andFaculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan;Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005453" MajorTopicYN="N">Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040681" MajorTopicYN="N">Structural Homology, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">allosteric modulator</Keyword><Keyword MajorTopicYN="N">amyloid-&#x3b2; protein</Keyword><Keyword MajorTopicYN="N">chemical biology</Keyword><Keyword MajorTopicYN="N">intramembrane proteolysis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25009180</ArticleId><ArticleId IdType="pmc">PMC4115564</ArticleId><ArticleId IdType="doi">10.1073/pnas.1402171111</ArticleId><ArticleId IdType="pii">1402171111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: The challenge of the second century. Sci Transl Med. 2011;3(77):sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Iwatsubo T. Structural biology of presenilins and signal peptide peptidases. J Biol Chem. 2013;288(21):14673&#x2013;14680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3663492</ArticleId><ArticleId IdType="pubmed">23585568</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the &#x3b3;-secretase complex. Nature. 2003;422(6930):438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, et al. Longer forms of amyloid &#x3b2; protein: Implications for the mechanism of intramembrane cleavage by &#x3b3;-secretase. J Neurosci. 2005;25(2):436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, et al. &#x3b3;-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of &#x3b2;-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, et al. Visualization of A &#x3b2; 42(43) and A &#x3b2; 40 in senile plaques with end-specific A &#x3b2; monoclonals: Evidence that an initially deposited species is A &#x3b2; 42(43) Neuron. 1994;13(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, et al. Alzheimer&#x2019;s Disease Cooperative Study Steering Committee Semagacestat Study Group A phase 3 trial of semagacestat for treatment of Alzheimer&#x2019;s disease. N Engl J Med. 2013;369(4):341&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. A subset of NSAIDs lower amyloidogenic A&#x3b2;42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, et al. Modulation of &#x3b3;-secretase reduces &#x3b2;-amyloid deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuron. 2010;67(5):769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Oehlrich D, Berthelot DJ, Gijsen HJ. &#x3b3;-Secretase modulators as potential disease modifying anti-Alzheimer&#x2019;s drugs. J Med Chem. 2011;54(3):669&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21141968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebke A, et al. Novel &#x3b3;-secretase enzyme modulators directly target presenilin protein. J Biol Chem. 2011;286(43):37181&#x2013;37186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199465</ArticleId><ArticleId IdType="pubmed">21896486</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozdnyakov N, et al. &#x3b3;-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem. 2013;288(14):9710&#x2013;9720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617273</ArticleId><ArticleId IdType="pubmed">23396974</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493(7430):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C, et al. Triazole derivatives for treating alzheimer's disease and related conditions. International patent. 2008: WO2008156580.</Citation></Reference><Reference><Citation>Micchelli CA, et al. &#x3b3;-secretase/presenilin inhibitors for Alzheimer&#x2019;s disease phenocopy Notch mutations in Drosophila. FASEB J. 2003;17(1):79&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424225</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura Y, et al. Inhibition of &#x3b3;-secretase activity by helical &#x3b2;-peptide foldamers. J Am Chem Soc. 2009;131(21):7353&#x2013;7359.</Citation><ArticleIdList><ArticleId IdType="pubmed">19432477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of &#x3b3;-secretase is located on presenilin near the active site. Proc Natl Acad Sci USA. 2005;102(9):3230&#x2013;3235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552920</ArticleId><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, et al. Sulindac sulfide is a noncompetitive &#x3b3;-secretase inhibitor that preferentially reduces A&#x3b2; 42 generation. J Biol Chem. 2003;278(20):18664&#x2013;18670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi I, et al. Selective reconstitution and recovery of functional &#x3b3;-secretase complex on budded baculovirus particles. J Biol Chem. 2004;279(36):38040&#x2013;38046.</Citation><ArticleIdList><ArticleId IdType="pubmed">15215237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, et al. Three-dimensional structure of the &#x3b3;-secretase complex. Biochem Biophys Res Commun. 2006;343(2):525&#x2013;534. and correction (2006) 345(1):543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546128</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmery MR, et al. Partial purification and characterization of &#x3b3;-secretase from post-mortem human brain. J Biol Chem. 2003;278(27):24277&#x2013;24284.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697771</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimono K, et al. Production of functional bacteriorhodopsin by an Escherichia coli cell-free protein synthesis system supplemented with steroid detergent and lipid. Protein Sci. 2009;18(10):2160&#x2013;2171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786979</ArticleId><ArticleId IdType="pubmed">19746358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K, et al. Activation and intrinsic &#x3b3;-secretase activity of presenilin 1. Proc Natl Acad Sci USA. 2010;107(50):21435&#x2013;21440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="pubmed">21115843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki Y, et al. Phenylpiperidine-type &#x3b3;-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 2011;30(23):4815&#x2013;4824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243616</ArticleId><ArticleId IdType="pubmed">22002539</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, et al. Total inactivation of &#x3b3;-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2(7):461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J Neurosci. 2005;25(1):192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, et al. Generation of A&#x3b2;38 and A&#x3b2;42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and &#x3b3;-secretase modulation. J Biol Chem. 2008;283(2):677&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf C, Rein C, Piwnica D, Giordanetto F, Rognan D. Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem. 2011;6(12):2159&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pubmed">21994134</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi S, Tominaga A, Sato C, Tomita T, Iwatsubo T. Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the &#x3b3;-secretase. J Neurosci. 2010;30(47):15943&#x2013;15950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633739</ArticleId><ArticleId IdType="pubmed">21106832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of &#x3b3;-secretase probed by the accessibility of substituted cysteines. J Neurosci. 2006;26(46):12081&#x2013;12088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674866</ArticleId><ArticleId IdType="pubmed">17108181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, et al. The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and &#x3b3;-secretase activities of presenilins. J Biol Chem. 2001;276(35):33273&#x2013;33281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Takagi S, Tomita T, Iwatsubo T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the &#x3b3;-secretase. J Neurosci. 2008;28(24):6264&#x2013;6271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670534</ArticleId><ArticleId IdType="pubmed">18550769</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeo K, Watanabe N, Tomita T, Iwatsubo T. Contribution of the &#x3b3;-secretase subunits to the formation of catalytic pore of presenilin 1 protein. J Biol Chem. 2012;287(31):25834&#x2013;25843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406669</ArticleId><ArticleId IdType="pubmed">22689582</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ, et al. Piperidine acetic acid based &#x3b3;-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci. 2011;2(12):705&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249837</ArticleId><ArticleId IdType="pubmed">22229075</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, et al. &#x3b3;-secretase modulators and presenilin 1 mutants act differently on presenilin/&#x3b3;-secretase function to cleave A&#x3b2;42 and A&#x3b2;43. Cell Reports. 2013;3(1):42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23291095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, et al. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10):2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Acx H, et al. Signature amyloid &#x3b2; profiles are produced by different &#x3b3;-secretase complexes. J Biol Chem. 2014;289(7):4346&#x2013;4355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924297</ArticleId><ArticleId IdType="pubmed">24338474</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, et al. &#x3b3;-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer&#x2019;s disease. Science. 2009;324(5927):639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, et al. Functional analysis of the transmembrane domains of presenilin 1: Participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of &#x3b3;-secretase. J Biol Chem. 2010;285(26):19738&#x2013;19746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888384</ArticleId><ArticleId IdType="pubmed">20418378</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura K, et al. Substrate docking to &#x3b3;-secretase allows access of &#x3b3;-secretase modulators to an allosteric site. Nat Commun. 2010;1:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060602</ArticleId><ArticleId IdType="pubmed">21119643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki Y, et al. Binding of longer A&#x3b2; to transmembrane domain 1 of presenilin 1 impacts on A&#x3b2;42 generation. Mol Neurodegener. 2014;9:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896738</ArticleId><ArticleId IdType="pubmed">24410857</ArticleId></ArticleIdList></Reference><Reference><Citation>Focke PJ, Wang X, Larsson HP. Neurotransmitter transporters: Structure meets function. Structure. 2013;21(5):694&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654398</ArticleId><ArticleId IdType="pubmed">23664361</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, et al. Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of &#x3b3;-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem. 2010;285(49):38042&#x2013;38052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992238</ArticleId><ArticleId IdType="pubmed">20921220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondar AN, del Val C, White SH. Rhomboid protease dynamics and lipid interactions. Structure. 2009;17(3):395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679947</ArticleId><ArticleId IdType="pubmed">19278654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupardus PJ, Shen A, Bogyo M, Garcia KC. Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science. 2008;322(5899):265&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272704</ArticleId><ArticleId IdType="pubmed">18845756</ArticleId></ArticleIdList></Reference><Reference><Citation>Morohashi Y, et al. C-terminal fragment of presenilin is the molecular target of a dipeptidic &#x3b3;-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) J Biol Chem. 2006;281(21):14670&#x2013;14676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid &#x3b2; protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA. 1997;94(5):2025&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20036</ArticleId><ArticleId IdType="pubmed">9050898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24991031</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife.</ArticleTitle><Pagination><StartPage>486</StartPage><EndPage>493</EndPage><MedlinePgn>486-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000665</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Peripheral inflammatory markers are elevated in patients with dementia. In order to assess their etiologic role, we examined whether interleukin-6 (IL-6) and C-reactive protein (CRP) measured in midlife predict concurrently assessed cognition and subsequent cognitive decline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Mean value of IL-6 and CRP, assessed on 5,217 persons (27.9% women) in 1991-1993 and 1997-1999 in the Whitehall II longitudinal cohort study, were categorized into tertiles to examine 10-year decline (assessments in 1997-1999, 2002-2004, and 2007-2009) in standardized scores (mean = 0, SD = 1) of memory, reasoning, and verbal fluency using mixed models. Mini-Mental State Examination (MMSE) was administered in 2002-2004 and 2007-2009; decline &#x2265;3 points was modeled with logistic regression. Analyses were adjusted for baseline age, sex, education, and ethnicity; further analyses were also adjusted for smoking, obesity, Framingham cardiovascular risk score, and chronic diseases (cancer, coronary heart disease, stroke, diabetes, and depression).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In cross-sectional analysis, reasoning was 0.08 SD (95% confidence interval [CI] -0.14, -0.03) lower in participants with high compared to low IL-6. In longitudinal analysis, 10-year decline in reasoning was greater (ptrend = 0.01) among participants with high IL-6 (-0.35; 95% CI -0.37, -0.33) than those with low IL-6 (-0.29; 95% CI -0.31, -0.27). In addition, participants with high IL-6 had 1.81 times greater odds ratio of decline in MMSE (95% CI 1.20, 2.71). CRP was not associated with decline in any test.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Elevated IL-6 but not CRP in midlife predicts cognitive decline; the combined cross-sectional and longitudinal effects over the 10-year observation period corresponded to an age effect of 3.9 years.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh-Manoux</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France. Archana.Singh-Manoux@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugravot</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumari</LastName><ForeName>Meena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shipley</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbaz</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivimaki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From INSERM (A.S.-M., A.D., A.E.), U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, Villejuif Cedex, France; Department of Epidemiology and Public Health (A.S.-M., E.B., M. Kumari, M.S., A.E., M. Kivimaki), University College London, UK; Centre de G&#xe9;rontologie (A.S.-M.), H&#xf4;pital Ste P&#xe9;rine, AP-HP; and University Versailles St-Quentin en Yvelines (A.D.), France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K013351/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RG/13/2/30098</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG034454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL036310</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Aug 5;83(6):478-9. doi: 10.1212/WNL.0000000000000662.</RefSource><PMID Version="1">24991026</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Aug 5;83(6):480-1. doi: 10.1212/WNL.0000000000000663.</RefSource><PMID Version="1">24991028</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24991031</ArticleId><ArticleId IdType="pmc">PMC4141998</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000665</ArticleId><ArticleId IdType="pii">WNL.0000000000000665</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duong T, Nikolaeva M, Acton PJ. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res 1997;749:152&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pubmed">9070642</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto N, Nishiyama E, Ohwada J, Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994;177:23&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pubmed">7824175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann NY Acad Sci 2010;1207:155&#x2013;162</Citation><ArticleIdList><ArticleId IdType="pubmed">20955439</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 2004;61:668&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pubmed">15148142</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007;68:1902&#x2013;1908</Citation><ArticleIdList><ArticleId IdType="pubmed">17536046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundelof J, Kilander L, Helmersson J, et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009;18:79&#x2013;87</Citation><ArticleIdList><ArticleId IdType="pubmed">19542629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2288623</ArticleId><ArticleId IdType="pubmed">18399716</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol 2005;34:251&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">15576467</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A, Kivimaki M, Glymour MM, et al. Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ 2012;344:d7622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281313</ArticleId><ArticleId IdType="pubmed">22223828</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim AW. AH 4 Group Test of General Intelligence. Windsor, UK: NFER-Nelson Publishing Company Ltd.; 1970</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologica 1967;5:135&#x2013;140</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i&#x2013; 253</Citation><ArticleIdList><ArticleId IdType="pubmed">11234459</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agostino RB, Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743&#x2013;753</Citation><ArticleIdList><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539&#x2013;553</Citation><ArticleIdList><ArticleId IdType="pubmed">9686693</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963&#x2013;974</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005;64:1371&#x2013;1377</Citation><ArticleIdList><ArticleId IdType="pubmed">15851726</ArticleId></ArticleIdList></Reference><Reference><Citation>Alley DE, Crimmins EM, Karlamangla A, Hu P, Seeman TE. Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci 2008;63:50&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952346</ArticleId><ArticleId IdType="pubmed">18245760</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 2006;17:183&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pubmed">16477259</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">12847160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CJ, Cohen HJ, Pieper CF. Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J Am Geriatr Soc 2003;51:1374&#x2013;1381</Citation><ArticleIdList><ArticleId IdType="pubmed">14511156</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafnsson SB, Deary IJ, Smith FB, et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc 2007;55:700&#x2013;707</Citation><ArticleIdList><ArticleId IdType="pubmed">17493189</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002;59:371&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">12177370</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Arch Neurol 2010;67:87&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426905</ArticleId><ArticleId IdType="pubmed">20065134</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. The processing-speed theory of adult age differences in cognition. Psychol Rev 1996;103:403&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pubmed">8759042</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pubmed">12210786</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003;134:142&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">12507782</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007;68:1032&#x2013;1038</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758770</ArticleId><ArticleId IdType="pubmed">17389308</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012;78:720&#x2013;727</Citation><ArticleIdList><ArticleId IdType="pubmed">22357713</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008;39:1952&#x2013;1959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888487</ArticleId><ArticleId IdType="pubmed">18436879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21:1787&#x2013;1803</Citation><ArticleIdList><ArticleId IdType="pubmed">14508181</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pubmed">12210786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000;67:591&#x2013;602</Citation><ArticleIdList><ArticleId IdType="pubmed">10810997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115&#x2013;126</Citation><ArticleIdList><ArticleId IdType="pubmed">9887164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005;36:768&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">15746456</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011;25:5&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">21205781</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008;65:896&#x2013;905</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7:402&#x2013;411</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149804</ArticleId><ArticleId IdType="pubmed">21784351</ArticleId></ArticleIdList></Reference><Reference><Citation>van EE, Eikelenboom P, Comijs H, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 2009;66:1263&#x2013;1270</Citation><ArticleIdList><ArticleId IdType="pubmed">19884614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25009256</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>28</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice.</ArticleTitle><Pagination><StartPage>9222</StartPage><EndPage>9234</EndPage><MedlinePgn>9222-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1132-14.2014</ELocationID><Abstract><AbstractText>Tau pathogenicity in Alzheimer's disease and other tauopathies is thought to involve the generation of hyperphosphorylated, truncated, and oligomeric tau species with enhanced neurotoxicity, although the generative mechanisms and the implications for disease therapy are not well understood. Here, we report a striking rescue from mutant tau toxicity in the JNPL3 mouse model of tauopathy. We show that pathological activation of calpains gives rise to a range of potentially toxic forms of tau, directly, and by activating cdk5. Calpain overactivation in brains of these mice is accelerated as a result of the marked depletion of the endogenous calpain inhibitor, calpastatin. When levels of this inhibitor are restored in neurons of JNPL3 mice by overexpressing calpastatin, tauopathy is prevented, including calpain-mediated breakdown of cytoskeletal proteins, cdk5 activation, tau hyperphosphorylation, formation of potentially neurotoxic tau fragments by either calpain or caspase-3, and tau oligomerization. Calpastatin overexpression also prevents loss of motor axons, delays disease onset, and extends survival of JNPL3 mice by 3 months to within the range of normal lifespan. Our findings support the therapeutic promise of highly specific calpain inhibition in the treatment of tauopathies and other neurodegenerative states.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/349222-13$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Mala V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and Departments of Psychiatry and rao@nki.rfmh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBrayer</LastName><ForeName>Mary Kate</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Jabbar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Asok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashim</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurochemistry, Nathan Kline Institute, Orangeburg, New York 10962.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sershen</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurochemistry, Nathan Kline Institute, Orangeburg, New York 10962.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Masuo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and Departments of Psychiatry and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana 46285.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research and Departments of Psychiatry and Cell Biology, New York University Langone Medical Center, New York, New York 10016, and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG005604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG005604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>79079-11-1</RegistryNumber><NameOfSubstance UI="C033668">calpastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ambulatory movements</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">fractionation</Keyword><Keyword MajorTopicYN="N">insoluble extracts</Keyword><Keyword MajorTopicYN="N">nesting behavior</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25009256</ArticleId><ArticleId IdType="pmc">PMC4087203</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1132-14.2014</ArticleId><ArticleId IdType="pii">34/28/9222</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adamec E, Mohan P, Vonsattel JP, Nixon RA. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol. 2002;104:92&#x2013;104. doi: 10.1007/s00401-002-0528-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-002-0528-6</ArticleId><ArticleId IdType="pubmed">12070670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A. 2000;97:2910&#x2013;2915. doi: 10.1073/pnas.040577797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.040577797</ArticleId><ArticleId IdType="pmc">PMC16029</ArticleId><ArticleId IdType="pubmed">10706614</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagli J, Han Y, Stewart L, Yang D, Movsisyan A, Abounit K, Seyfried D. A novel calpastatin-based inhibitor improves postischemic neurological recovery. Biochem Biophys Res Commun. 2009;385:94&#x2013;99. doi: 10.1016/j.bbrc.2009.04.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.04.141</ArticleId><ArticleId IdType="pubmed">19422795</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 2004;1012:29&#x2013;41. doi: 10.1016/j.brainres.2004.02.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.02.081</ArticleId><ArticleId IdType="pubmed">15158158</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Sanders JL, Tsai LH, Hyman BT. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol. 2002;61:557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R. The calpain hypothesis of neurodegeneration: evidence for a common cytotoxic pathway. Neuroscientist. 1997;3:314&#x2013;327.</Citation></Reference><Reference><Citation>Bartus RT, Elliott PJ, Hayward NJ, Dean RL, Harbeson S, Straub JA, Li Z, Powers JC. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res. 1995;17:249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477738</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci. 2007;27:3650&#x2013;3662. doi: 10.1523/JNEUROSCI.0587-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0587-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 2005;1739:216&#x2013;223. doi: 10.1016/j.bbadis.2004.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.08.014</ArticleId><ArticleId IdType="pubmed">15615640</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Mu&#xf1;oz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of tau oligomers in hTau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis. 2014a;40:S97&#x2013;S111. doi: 10.3233/JAD-132477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-132477</ArticleId><ArticleId IdType="pubmed">24603946</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Sengupta U, Guerrero-Mu&#xf1;oz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014b;34:4260&#x2013;4272. doi: 10.1523/JNEUROSCI.3192-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3192-13.2014</ArticleId><ArticleId IdType="pmc">PMC6608097</ArticleId><ArticleId IdType="pubmed">24647946</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZH, Ip NY. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012;22:169&#x2013;175. doi: 10.1016/j.tcb.2011.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2011.11.003</ArticleId><ArticleId IdType="pubmed">22189166</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8:609&#x2013;622. doi: 10.4161/auto.19048.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.19048</ArticleId><ArticleId IdType="pmc">PMC3405840</ArticleId><ArticleId IdType="pubmed">22361619</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204. doi: 10.1038/nature08890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08890</ArticleId><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan PJ, Johnson GV. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem. 2010;285:21978&#x2013;21987. doi: 10.1074/jbc.M110.110940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.110940</ArticleId><ArticleId IdType="pmc">PMC2903354</ArticleId><ArticleId IdType="pubmed">20466727</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans CG, Jinwal UK, Makley LN, Dickey CA, Gestwicki JE. Identification of dihydropyridines that reduce cellular tau levels. Chem Commun (Camb) 2011;47:529&#x2013;531. doi: 10.1039/c0cc02253e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c0cc02253e</ArticleId><ArticleId IdType="pmc">PMC3251959</ArticleId><ArticleId IdType="pubmed">21082080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med. 2011;17:676&#x2013;685. doi: 10.2119/molmed.2010.00220.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2010.00220</ArticleId><ArticleId IdType="pmc">PMC3146621</ArticleId><ArticleId IdType="pubmed">21442128</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol. 2011;70:588&#x2013;595. doi: 10.1097/NEN.0b013e318220a658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318220a658</ArticleId><ArticleId IdType="pmc">PMC3118928</ArticleId><ArticleId IdType="pubmed">21666499</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, D'Souza I, Crudder CH, Onodera H, Itoyama Y, Poorkaj P, Bird TD, Schellenberg GD. Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism. Neuroreport. 2000;11:57&#x2013;60. doi: 10.1097/00001756-200001170-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200001170-00011</ArticleId><ArticleId IdType="pubmed">10683829</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Wang Y, Yao PJ, Fu W, Mattson MP, Itoyama Y, Onodera H, D'Souza I, Poorkaj PH, Bird TD, Schellenberg GD. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem. 2003;87:427&#x2013;436. doi: 10.1046/j.1471-4159.2003.02020.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02020.x</ArticleId><ArticleId IdType="pubmed">14511120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100:10032&#x2013;10037. doi: 10.1073/pnas.1630428100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1630428100</ArticleId><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Sierra F, Jarero-Basulto JJ, Kristofikova Z, Majer E, Binder LI, Ripova D. Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimer's disease. Brain Pathol. 2012;22:240&#x2013;250. doi: 10.1111/j.1750-3639.2011.00525.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2011.00525.x</ArticleId><ArticleId IdType="pmc">PMC8029281</ArticleId><ArticleId IdType="pubmed">21919991</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging. 2011;32:1&#x2013;14. doi: 10.1016/j.neurobiolaging.2010.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.09.008</ArticleId><ArticleId IdType="pubmed">20961659</ArticleId></ArticleIdList></Reference><Reference><Citation>Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. 1997;763:145&#x2013;158. doi: 10.1016/S0006-8993(97)00384-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00384-3</ArticleId><ArticleId IdType="pubmed">9296555</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ. The nucleator. J Microsc. 1988;151:3&#x2013;21. doi: 10.1111/j.1365-2818.1988.tb04609.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.1988.tb04609.x</ArticleId><ArticleId IdType="pubmed">3193456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem. 2002;277:44525&#x2013;44530. doi: 10.1074/jbc.M207426200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207426200</ArticleId><ArticleId IdType="pubmed">12226093</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, Saing T, Gylys KH. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol. 2012;22:826&#x2013;833. doi: 10.1111/j.1750-3639.2012.00598.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2012.00598.x</ArticleId><ArticleId IdType="pmc">PMC3410970</ArticleId><ArticleId IdType="pubmed">22486774</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Tomioka M, Takano J, Shirotani K, Iwata N, Masumoto H, Maki M, Itohara S, Saido TC. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem. 2005;280:15229&#x2013;15237. doi: 10.1074/jbc.M500939200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500939200</ArticleId><ArticleId IdType="pubmed">15699033</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, Maeda J, Ji B, Ono M, Staufenbiel M, Suhara T, Saido TC. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 2012;26:1204&#x2013;1217. doi: 10.1096/fj.11-187740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-187740</ArticleId><ArticleId IdType="pubmed">22173972</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci. 2004;24:7895&#x2013;7902. doi: 10.1523/JNEUROSCI.1988-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1988-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729917</ArticleId><ArticleId IdType="pubmed">15356202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, Hasegawa M. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One. 2012;7:e52389. doi: 10.1371/journal.pone.0052389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052389</ArticleId><ArticleId IdType="pmc">PMC3527507</ArticleId><ArticleId IdType="pubmed">23285020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagic-lysosmal system in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405832</ArticleId><ArticleId IdType="pubmed">22908190</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656&#x2013;664. doi: 10.2174/156720510793611592.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510793611592</ArticleId><ArticleId IdType="pmc">PMC3090074</ArticleId><ArticleId IdType="pubmed">20678074</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis. 2006;9(3 Suppl):243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914862</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, Tyynel&#xe4; J, Scherzer CR, Feany MB. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet. 2010;6:e1001026. doi: 10.1371/journal.pgen.1001026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001026</ArticleId><ArticleId IdType="pmc">PMC2904797</ArticleId><ArticleId IdType="pubmed">20664788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, K&#xf6;hler A, Glossmann H, Schneider R, Sutherland C, Schweiger S. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A. 2010;107:21830&#x2013;21835. doi: 10.1073/pnas.0912793107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912793107</ArticleId><ArticleId IdType="pmc">PMC3003072</ArticleId><ArticleId IdType="pubmed">21098287</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872. doi: 10.1038/nrn960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn960</ArticleId><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry. 2010;49:10039&#x2013;10041. doi: 10.1021/bi1016233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi1016233</ArticleId><ArticleId IdType="pubmed">21047142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2011a;8:659&#x2013;665. doi: 10.2174/156720511796717177.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511796717177</ArticleId><ArticleId IdType="pubmed">21605039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener. 2011b;6:39. doi: 10.1186/1750-1326-6-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-39</ArticleId><ArticleId IdType="pmc">PMC3224595</ArticleId><ArticleId IdType="pubmed">21645391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700. doi: 10.1038/srep00700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00700</ArticleId><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Corre S, Klafki HW, Plesnila N, H&#xfc;binger G, Obermeier A, Sahag&#xfa;n H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A. 2006;103:9673&#x2013;9678. doi: 10.1073/pnas.0602913103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602913103</ArticleId><ArticleId IdType="pmc">PMC1480465</ArticleId><ArticleId IdType="pubmed">16769887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179&#x2013;184. doi: 10.1038/nature09299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09299</ArticleId><ArticleId IdType="pmc">PMC2939003</ArticleId><ArticleId IdType="pubmed">20829789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360&#x2013;364. doi: 10.1038/35012636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35012636</ArticleId><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159. doi: 10.1146/annurev.neuro.24.1.1121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.1121</ArticleId><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168&#x2013;176. doi: 10.1038/nature05453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05453</ArticleId><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737&#x2013;27744. doi: 10.1074/jbc.M110.117960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.117960</ArticleId><ArticleId IdType="pmc">PMC2934641</ArticleId><ArticleId IdType="pubmed">20595388</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes JP, Agostinho P. Cdk5: multitasking between physiological and pathological conditions. Prog Neurobiol. 2011;94:49&#x2013;63. doi: 10.1016/j.pneurobio.2011.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.03.006</ArticleId><ArticleId IdType="pubmed">21473899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S, Shoshan MC. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol. 2002;22:3003&#x2013;3013. doi: 10.1128/MCB.22.9.3003-3013.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.22.9.3003-3013.2002</ArticleId><ArticleId IdType="pmc">PMC133754</ArticleId><ArticleId IdType="pubmed">11940658</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008;325:146&#x2013;153. doi: 10.1124/jpet.107.130526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.130526</ArticleId><ArticleId IdType="pubmed">18199809</ArticleId></ArticleIdList></Reference><Reference><Citation>McCollum AT, Jafarifar F, Lynn BC, Agu RU, Stinchcomb AL, Wang S, Chen Q, Guttmann RP. Inhibition of calpain-mediated cell death by a novel peptide inhibitor. Exp Neurol. 2006;202:506&#x2013;513. doi: 10.1016/j.expneurol.2006.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.07.016</ArticleId><ArticleId IdType="pubmed">16956607</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan PJ, Kraemer BC, Robinson L, Leverenz JB, Raskind M, Schellenberg G. Truncation of tau at E391 promotes early pathologic changes in transgenic mice. J Neuropathol Exp Neurol. 2011;70:1006&#x2013;1019. doi: 10.1097/NEN.0b013e31823557fb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31823557fb</ArticleId><ArticleId IdType="pmc">PMC3237612</ArticleId><ArticleId IdType="pubmed">22002427</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, Moeller A, Green KN, LaFerla FM. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 2012;181:616&#x2013;625. doi: 10.1016/j.ajpath.2012.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.04.020</ArticleId><ArticleId IdType="pubmed">22688056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Grynspan F, Nixon RA. Differential sensitivity to proteolysis by brain calpain of adult human tau, fetal human tau and PHF-tau. FEBS Lett. 1995;368:10&#x2013;14. doi: 10.1016/0014-5793(95)00590-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(95)00590-6</ArticleId><ArticleId IdType="pubmed">7615058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao S, Saido TC, Akita Y, Tsuchiya T, Suzuki K, Kawashima S. Calpain-calpastatin interactions in epidermoid carcinoma KB cells. J Biochem. 1994;115:1178&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7982901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol. 2000;150:887&#x2013;894. doi: 10.1083/jcb.150.4.887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.150.4.887</ArticleId><ArticleId IdType="pmc">PMC2175271</ArticleId><ArticleId IdType="pubmed">10953012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash KR, Lee DC, Hunt JB, Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging. 2013;34:1540&#x2013;1548. doi: 10.1016/j.neurobiolaging.2012.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.011</ArticleId><ArticleId IdType="pmc">PMC8970215</ArticleId><ArticleId IdType="pubmed">23332170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Julien JP. Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neurosignals. 2003;12:215&#x2013;220. doi: 10.1159/000074623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000074623</ArticleId><ArticleId IdType="pubmed">14673208</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The calpains in aging and aging-related diseases. Ageing Res Rev. 2003;2:407&#x2013;418. doi: 10.1016/S1568-1637(03)00029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-1637(03)00029-1</ArticleId><ArticleId IdType="pubmed">14522243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Saito KI, Grynspan F, Griffin WR, Katayama S, Honda T, Mohan PS, Shea TB, Beermann M. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann N Y Acad Sci. 1994;747:77&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis. 2007;26:134&#x2013;145. doi: 10.1016/j.nbd.2006.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.008</ArticleId><ArticleId IdType="pmc">PMC1876698</ArticleId><ArticleId IdType="pubmed">17258906</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates b-amyloid-induced neurodegeneration. J Neurosci. 2005;25:5365&#x2013;5375. doi: 10.1523/JNEUROSCI.1125-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1125-05.2005</ArticleId><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;622. doi: 10.1038/45159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/45159</ArticleId><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825. doi: 10.1002/ana.410430617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430617</ArticleId><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rami A, Volkmann T, Agarwal R, Schoninger S, N&#xfc;rnberger F, Saido TC, Winckler J. beta2-Adrenergic receptor responsiveness of the calpain-calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia. Neurosci Res. 2003;47:373&#x2013;382. doi: 10.1016/j.neures.2003.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2003.07.002</ArticleId><ArticleId IdType="pubmed">14630341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Campbell J, Yuan A, Kumar A, Gotow T, Uchiyama Y, Nixon RA. The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate. J Cell Biol. 2003;163:1021&#x2013;1031. doi: 10.1083/jcb.200308076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200308076</ArticleId><ArticleId IdType="pmc">PMC2173612</ArticleId><ArticleId IdType="pubmed">14662746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA. Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci. 2008;28:12241&#x2013;12254. doi: 10.1523/JNEUROSCI.4119-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4119-08.2008</ArticleId><ArticleId IdType="pmc">PMC2819018</ArticleId><ArticleId IdType="pubmed">19020018</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke JB, DeVos SL, McGrath JP, Shepard AM, Goncharoff DK, Tait DN, Fleming SR, Vincent MP, Steinhilb ML. Implicating calpain in tau-mediated toxicity in vivo. PLoS One. 2011;6:e23865. doi: 10.1371/journal.pone.0023865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023865</ArticleId><ArticleId IdType="pmc">PMC3157467</ArticleId><ArticleId IdType="pubmed">21858230</ArticleId></ArticleIdList></Reference><Reference><Citation>Reith ME, Ali S, Hashim A, Sheikh IS, Theddu N, Gaddiraju NV, Mehrotra S, Schmitt KC, Murray TF, Sershen H, Unterwald EM, Davis FA. Novel C-1 substituted cocaine analogs unlike cocaine or benztropine. J Pharmacol Exp Ther. 2012;343:413&#x2013;425. doi: 10.1124/jpet.112.193771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.112.193771</ArticleId><ArticleId IdType="pmc">PMC3477221</ArticleId><ArticleId IdType="pubmed">22895898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility 1017. J Neurochem. 2002;83:1498&#x2013;1508. doi: 10.1046/j.1471-4159.2002.01241.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01241.x</ArticleId><ArticleId IdType="pubmed">12472903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis. 2013;33:249&#x2013;263. doi: 10.3233/JAD-2012-121093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-121093</ArticleId><ArticleId IdType="pmc">PMC3514650</ArticleId><ArticleId IdType="pubmed">22941973</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 1993;90:2628&#x2013;2632. doi: 10.1073/pnas.90.7.2628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.7.2628</ArticleId><ArticleId IdType="pmc">PMC46148</ArticleId><ArticleId IdType="pubmed">8464868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Minegishi S, Takano J, Plattner F, Saito T, Asada A, Kawahara H, Iwata N, Saido TC, Hisanaga S. Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25. J Neurochem. 2011;117:504&#x2013;515. doi: 10.1111/j.1471-4159.2011.07222.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07222.x</ArticleId><ArticleId IdType="pubmed">21338355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Jiang Y, Nixon RA, Mathews PM. Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol Biol. 2005;299:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, Evans HN, Brelsfoard JM, Madathil SK, Takano J, Saido TC, Saatman KE. Calpastatin overexpression limits calpain-mediated proteolysis and behavioral deficits following traumatic brain injury. Exp Neurol. 2012;236:371&#x2013;382. doi: 10.1016/j.expneurol.2012.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.04.022</ArticleId><ArticleId IdType="pmc">PMC3392428</ArticleId><ArticleId IdType="pubmed">22572592</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, von Reyn CR, Bian J, Telling GC, Meaney DF, Saatman KE. Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. J Neurochem. 2013;125:909&#x2013;920. doi: 10.1111/jnc.12144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12144</ArticleId><ArticleId IdType="pmc">PMC3676438</ArticleId><ArticleId IdType="pubmed">23305291</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea TB. Restriction of microM-calcium-requiring calpain activation to the plasma membrane in human neuroblastoma cells: evidence for regionalized influence of a calpain activator protein. J Neurosci Res. 1997;48:543&#x2013;550. doi: 10.1002/(SICI)1097-4547(19970615)48:6&lt;543::AID-JNR7&gt;3.0.CO%3B2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19970615)48:6&lt;543::AID-JNR7&gt;3.0.CO%3B2-A</ArticleId><ArticleId IdType="pubmed">9210524</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res. 2012;43:655&#x2013;662. doi: 10.1016/j.arcmed.2012.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2012.10.015</ArticleId><ArticleId IdType="pmc">PMC3532552</ArticleId><ArticleId IdType="pubmed">23142263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers SA, Karanicolas J, Chang HW, Zhao A, Jiang L, Zirafi O, Stevens JT, M&#xfc;nch J, Baker D, Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature. 2011;475:96&#x2013;100. doi: 10.1038/nature10154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10154</ArticleId><ArticleId IdType="pmc">PMC4073670</ArticleId><ArticleId IdType="pubmed">21677644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau immunotherapy and imaging. Neurodegener Dis. 2014;13:103&#x2013;106. doi: 10.1159/000354491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000354491</ArticleId><ArticleId IdType="pmc">PMC3946316</ArticleId><ArticleId IdType="pubmed">24029727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf5;es AT, Gon&#xe7;alves N, Koeppen A, D&#xe9;glon N, K&#xfc;gler S, Duarte CB, Pereira de Almeida L. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain. 2012;135:2428&#x2013;2439. doi: 10.1093/brain/aws177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws177</ArticleId><ArticleId IdType="pubmed">22843411</ArticleId></ArticleIdList></Reference><Reference><Citation>Smiley JF, Rosoklija G, Mancevski B, Pergolizzi D, Figarsky K, Bleiwas C, Duma A, Mann JJ, Javitt DC, Dwork AJ. Hemispheric comparisons of neuron density in the planum temporale of schizophrenia and nonpsychiatric brains. Psychiatry Res. 2011;192:1&#x2013;11. doi: 10.1016/j.pscychresns.2010.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2010.11.007</ArticleId><ArticleId IdType="pmc">PMC3071586</ArticleId><ArticleId IdType="pubmed">21377842</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res. 2012;96:32&#x2013;37. doi: 10.1093/cvr/cvs163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvs163</ArticleId><ArticleId IdType="pmc">PMC3444233</ArticleId><ArticleId IdType="pubmed">22581845</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622. doi: 10.1016/S1474-4422(13)70090-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Su SC, Seo J, Pan JQ, Samuels BA, Rudenko A, Ericsson M, Neve RL, Yue DT, Tsai LH. Regulation of N-type voltage-gated calcium channels and presynaptic function by cyclin-dependent kinase 5. Neuron. 2012;75:675&#x2013;687. doi: 10.1016/j.neuron.2012.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.06.023</ArticleId><ArticleId IdType="pmc">PMC3428598</ArticleId><ArticleId IdType="pubmed">22920258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Zhao Y, Xu C. Cross-talk between calpain and caspase-3 in penumbra and core during focal cerebral ischemia-reperfusion. Cell Mol Neurobiol. 2008;28:71&#x2013;85. doi: 10.1007/s10571-007-9250-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-007-9250-1</ArticleId><ArticleId IdType="pmc">PMC11516530</ArticleId><ArticleId IdType="pubmed">18157632</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwanjang W, Phansuwan-Pujito P, Govitrapong P, Chetsawang B. The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma SH-SY5Y cultured cells. J Pineal Res. 2010;48:94&#x2013;101. doi: 10.1111/j.1600-079X.2009.00731.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2009.00731.x</ArticleId><ArticleId IdType="pubmed">20050990</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, Maki M, Saido TC. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem. 2005;280:16175&#x2013;16184. doi: 10.1074/jbc.M414552200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414552200</ArticleId><ArticleId IdType="pubmed">15691848</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett. 2001;306:37&#x2013;40. doi: 10.1016/S0304-3940(01)01864-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01864-X</ArticleId><ArticleId IdType="pubmed">11403952</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, L&#xf3;pez-Deber MP, Reis P, Hickman DT, Adolfsson O, Chuard N, Ndao DM, Borghgraef P, Devijver H, Van Leuven F, Pfeifer A, Muhs A. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301. doi: 10.1371/journal.pone.0072301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072301</ArticleId><ArticleId IdType="pmc">PMC3747157</ArticleId><ArticleId IdType="pubmed">23977276</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 2008;118:2796&#x2013;2807. doi: 10.1172/JCI34254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI34254</ArticleId><ArticleId IdType="pmc">PMC2441853</ArticleId><ArticleId IdType="pubmed">18596919</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeranna, Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, Peterhoff C, Cataldo A, Rudnicki A, Amin N, Li BS, Pant HC, Hungund BL, Arancio O, Nixon RA. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol. 2004;165:795&#x2013;805. doi: 10.1016/S0002-9440(10)63342-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63342-1</ArticleId><ArticleId IdType="pmc">PMC1618589</ArticleId><ArticleId IdType="pubmed">15331404</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalpando Rodriguez GE, Torriglia A. Calpain 1 induce lysosomal permeabilization by cleavage of lysosomal associated membrane protein 2. Biochim Biophys Acta. 2013;1833:2244&#x2013;2253. doi: 10.1016/j.bbamcr.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.05.019</ArticleId><ArticleId IdType="pubmed">23747342</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013;70:304&#x2013;310. doi: 10.1001/jamaneurol.2013.1453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.1453</ArticleId><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Santa-Maria I, Ho L, Ksiezak-Reding H, Ono K, Teplow DB, Pasinetti GM. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;22:653&#x2013;661. doi: 10.3233/JAD-2010-101074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101074</ArticleId><ArticleId IdType="pubmed">20858961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KK, Yuen PW. Development and therapeutic potential of calpain inhibitors. Adv Pharmacol. 1997;37:117&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">8891101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A. 2007;104:10252&#x2013;10257. doi: 10.1073/pnas.0703676104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0703676104</ArticleId><ArticleId IdType="pmc">PMC1891218</ArticleId><ArticleId IdType="pubmed">17535890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SM, Himmelstein DS, Lancia JK, Binder LI. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans. 2012;40:667&#x2013;671. doi: 10.1042/BST20120134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120134</ArticleId><ArticleId IdType="pmc">PMC3704193</ArticleId><ArticleId IdType="pubmed">22817713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SM, Himmelstein DS, Ren Y, Fu Y, Yu XW, Roberts K, Binder LI, Sahara N. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy. Neurobiol Dis. 2014;67:37&#x2013;48. doi: 10.1016/j.nbd.2014.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.03.002</ArticleId><ArticleId IdType="pmc">PMC4055868</ArticleId><ArticleId IdType="pubmed">24631720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson DW, Wilson DA. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res. 2011;216:408&#x2013;413. doi: 10.1016/j.bbr.2010.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2010.08.033</ArticleId><ArticleId IdType="pmc">PMC2975804</ArticleId><ArticleId IdType="pubmed">20804789</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashima T. Reconsider Alzheimer's disease by the &#x2018;calpain-cathepsin hypothesis&#x2019;&#x2014;a perspective review. Prog Neurobiol. 2013;105:1&#x2013;23. doi: 10.1016/j.pneurobio.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.02.004</ArticleId><ArticleId IdType="pubmed">23499711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006;8:1124&#x2013;1132. doi: 10.1038/ncb1482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1482</ArticleId><ArticleId IdType="pubmed">16998475</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo DJ. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8:393&#x2013;399. doi: 10.1038/nchembio.797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.797</ArticleId><ArticleId IdType="pubmed">22366723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB, 3rd, Lee VM, Brunden KR. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32:3601&#x2013;3611. doi: 10.1523/JNEUROSCI.4922-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4922-11.2012</ArticleId><ArticleId IdType="pmc">PMC3321513</ArticleId><ArticleId IdType="pubmed">22423084</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25023141</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Genome-wide analysis of the heritability of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1123</StartPage><EndPage>1134</EndPage><MedlinePgn>1123-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1184</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Considerable advances have been made in our understanding of the genetics underlying amyotrophic lateral sclerosis (ALS). Nevertheless, for the majority of patients who receive a diagnosis of ALS, the role played by genetics is unclear. Further elucidation of the genetic architecture of this disease will help clarify the role of genetic variation in ALS populations.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To estimate the relative importance of genetic factors in a complex disease such as ALS by accurately quantifying heritability using genome-wide data derived from genome-wide association studies.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We applied the genome-wide complex trait analysis algorithm to 3 genome-wide association study data sets that were generated from ALS case-control cohorts of European ancestry to estimate the heritability of ALS. Cumulatively, these data sets contained genotype data from 1223 cases and 1591 controls that had been previously generated and are publically available on the National Center for Biotechnology Information database of genotypes and phenotypes website (http://www.ncbi.nlm.nih.gov/gap). The cohorts genotyped as part of these genome-wide association study efforts include the InCHIANTI (aging in the Chianti area) Study, the Piemonte and Valle d'Aosta Register for Amyotrophic Lateral Sclerosis, the National Institute of Neurological Disorders and Stroke Repository, and an ALS specialty clinic in Helsinki, Finland.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">A linear mixed model was used to account for all known single-nucleotide polymorphisms simultaneously and to quantify the phenotypic variance present in ostensibly outbred individuals. Variance measures were used to estimate heritability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With our meta-analysis, which is based on genome-wide genotyping data, we estimated the overall heritability of ALS to be approximately 21.0% (95% CI, 17.1-24.9) (SE = 2.0%), indicating that additional genetic variation influencing risk of ALS loci remains to be identified. Furthermore, we identified 17 regions of the genome that display significantly high heritability estimates. Eleven of these regions represent novel candidate regions for ALS risk.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">We found the heritability of ALS to be significantly higher than previously reported. We also identified multiple, novel genomic regions that we hypothesize may contain causative risk variants that influence susceptibility to ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Margaux F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland2Department of Biological Anthropology, Temple University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Central Hospital and Molecular Neurology, Research Programs Unit, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laaksovirta</LastName><ForeName>Hannu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Central Hospital and Molecular Neurology, Research Programs Unit, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restagno</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Genetics Unit, Department of Clinical Pathology, ASO OIRM-St Anna, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi-Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES013244</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA AG000933</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES013244</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01AG000949-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2014 Oct;71(10):1328</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Oct;10(10):549-50. doi: 10.1038/nrneurol.2014.166.</RefSource><PMID Version="1">25201239</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Dec;71(12):1579-80. doi: 10.1001/jamaneurol.2014.3493.</RefSource><PMID Version="1">25486212</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Singleton, Tienari, and Traynor have a patent pending on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25023141</ArticleId><ArticleId IdType="mid">NIHMS719994</ArticleId><ArticleId IdType="pmc">PMC4566960</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1184</ArticleId><ArticleId IdType="pii">1886775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R PARALS. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72(8):725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">19237701</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson L, Miller JW, Gkazi AS, et al. Screening for OPTN mutations in a cohort of British amyotrophic lateral sclerosis patients. Neurobiol Aging. 2012;33(12):2948.e15&#x2013;2948.17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892313</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Kamel F, Lichtenstein P, et al. Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol. 2009;66(1):94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609703</ArticleId><ArticleId IdType="pubmed">19670447</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2007;16(R2):R233&#x2013;R242.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911166</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Schymick JC, Restagno G, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18(8):1524&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664150</ArticleId><ArticleId IdType="pubmed">19193627</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009;106(22):9004&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Van Miegroet H, et al. Follow-up study of susceptibility loci for Alzheimer&#x2019;s disease and onset age identified by genome-wide association. J Alzheimers Dis. 2010;19(4):1169&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Berger S, Ding J, et al. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet. 2008;17(5):768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057069</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007;6(10):869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827064</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 2010;9(10):978&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD. The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry. PLoS One. 2011;6(11):e27985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222666</ArticleId><ArticleId IdType="pubmed">22132186</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42(7):565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232052</ArticleId><ArticleId IdType="pubmed">20562875</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Manolio TA, Pasquale LR, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet. 2011;43(6):519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4295936</ArticleId><ArticleId IdType="pubmed">21552263</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Lee SH, Goddard ME, Visscher PM. Genome-wide complex trait analysis (GCTA): methods, data analyses, and interpretations. Methods Mol Biol. 2013;1019:215&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">23756893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Ratti A, Gellera C, et al. SLAGEN Consortium and Collaborators; ITALSGEN Consortium. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23(8):2220&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88(1):76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014363</ArticleId><ArticleId IdType="pubmed">21167468</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2007;6(4):322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362836</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Nalls M, Lai SL, et al. Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. Proc Natl Acad Sci U S A. 2010;107(27):12335&#x2013;12338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901467</ArticleId><ArticleId IdType="pubmed">20566859</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain M, Saut N, Greliche N, et al. Genetics of venous thrombosis: insights from a new genome wide association study. PLoS ONE. 2011;6(9):e25581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181335</ArticleId><ArticleId IdType="pubmed">21980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. Nat Rev Genet. 2010;11(7):459&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975875</ArticleId><ArticleId IdType="pubmed">20548291</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bakker PIW, Ferreira MAR, Jia X, Neale BM, Raychaudhuri S, Voight BF. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet. 2008;17(R2):R122&#x2013;R128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135(pt 9):2883&#x2013;2891.</Citation><ArticleIdList><ArticleId IdType="pubmed">22661746</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wicks P, Brownstein CA, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(8):853&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562391</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Jordan I, Elamin M, Hardiman O. Age at onset of amyotrophic lateral sclerosis is proportional to life expectancy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7&#x2013;8):604&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">23895536</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995&#x2013;1997: a population-based study. Neurology. 1999;52(3):504&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369(9578):2031&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Piemonte and Valle d&#x2019;Aosta Register for Amyotrophic Lateral Sclerosis (PARALS) Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology. 2001;56(2):239&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160962</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. EURALS . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire V, Longstreth WT, Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology. 1996;47(2):571&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757041</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, et al. ITALSGEN Consortium. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x2019;s disease. PLoS Genet. 2011;7(6):e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="pubmed">21738487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng JS, Arnett DK, Lee YC, et al. Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. PLoS ONE. 2013;8(10):e77442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810463</ArticleId><ArticleId IdType="pubmed">24204828</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Canosa A, et al. A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiol Aging. 2014;35(6):1513.e7&#x2013;1513.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961545</ArticleId><ArticleId IdType="pubmed">24439481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasperaviciute D, Weale ME, Shianna KV, et al. Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain. 2007;130(pt 9):2292&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">17439985</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Mok K, Newhouse S, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 2010;9(10):986&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257853</ArticleId><ArticleId IdType="pubmed">20801717</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti FL, Spataro R, Sproviero W, et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology. 2012;79(24):2315&#x2013;2320.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197749</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, van Vught PWJ, Blauw HM, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008;40(1):29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18084291</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M, Wei L, Zuo X, et al. Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat Genet. 2013;45(6):697&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">23624525</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander MD, Traynor BJ, Miller N, et al. &#x201c;True&#x201d; sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol. 2002;52(5):680&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, et al. A de novo missense mutation of the FUS gene in a &#x201c;true&#x201d; sporadic ALS case. Neurobiol Aging. 2011;32(3):553.e23&#x2013;553.e26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972379</ArticleId><ArticleId IdType="pubmed">20598774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesi A, Staahl BT, Jovi&#x10d;i&#x107; A, et al. Exome sequencing to identify de novo mutations in sporadic ALS trios. Nat Neurosci. 2013;16(7):851&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709464</ArticleId><ArticleId IdType="pubmed">23708140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25017010</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons.</ArticleTitle><Pagination><StartPage>1064</StartPage><EndPage>1072</EndPage><MedlinePgn>1064-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3761</ELocationID><Abstract><AbstractText>In Huntington's disease (HD), whether transneuronal spreading of mutant huntingtin (mHTT) occurs and its contribution to non-cell autonomous damage in brain networks is largely unknown. We found mHTT spreading in three different neural network models: human neurons integrated in the neural network of organotypic brain slices of HD mouse model, an ex vivo corticostriatal slice model and the corticostriatal pathway in vivo. Transneuronal propagation of mHTT was blocked by two different botulinum neurotoxins, each known for specifically inactivating a single critical component of the synaptic vesicle fusion machinery. Moreover, healthy human neurons in HD mouse model brain slices displayed non-cell autonomous changes in morphological integrity that were more pronounced when these neurons bore mHTT aggregates. Altogether, our findings suggest that transneuronal propagation of mHTT might be an important and underestimated contributor to the pathophysiology of HD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pecho-Vrieseling</LastName><ForeName>Eline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Novartis Institutes for Biomedical Research, Basel, Switzerland. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieker</LastName><ForeName>Claus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Novartis Institutes for Biomedical Research, Basel, Switzerland. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleckmann</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Maria Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>1] Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. [2] Biozentrum, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botta</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernhard</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;thi</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arber</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. [2] Biozentrum, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwmeester</LastName><ForeName>Tewis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Putten</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] Novartis Institutes for Biomedical Research, Basel, Switzerland. [2] National Contest for Life (NCL) Foundation against Batten Disease Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giorgio</LastName><ForeName>Francesco Paolo</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2014 Aug;17(8):1014-5. doi: 10.1038/nn.3770.</RefSource><PMID Version="1">25065434</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 Sep;15(9):565. doi: 10.1038/nrn3802.</RefSource><PMID Version="1">25074703</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2018 Sep;21(9):1291. doi: 10.1038/s41593-018-0201-6.</RefSource><PMID Version="1">30018355</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25017010</ArticleId><ArticleId IdType="doi">10.1038/nn.3761</ArticleId><ArticleId IdType="pii">nn.3761</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Expert Opin Investig Drugs. 2007 Dec;16(12):1933-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18042002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2013 Aug 15;126(Pt 16):3678-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23781027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1996 Nov 1;87(3):493-506</Citation><ArticleIdList><ArticleId IdType="pubmed">8898202</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2011 Dec 15;198:252-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21907762</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Dec 07;480(7377):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22158104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2014 Mar 10;211(3):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1999 Dec 13;147(6):1249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10601338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2006;1(5):2452-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17406491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol. 2012 Feb 24;19(2):264-75</Citation><ArticleIdList><ArticleId IdType="pubmed">22365609</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 2004;44:167-93</Citation><ArticleIdList><ArticleId IdType="pubmed">14744243</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 May 5;46(3):433-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15882643</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12483-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19620721</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Jan 10;278(2):1363-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12381720</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Mar 22;73(6):1216-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23341618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2011 Jan;10(1):31-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21130037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2013;4:2332</Citation><ArticleIdList><ArticleId IdType="pubmed">23945836</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2008 Jan;115(1):55-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17978822</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 16;338(6109):949-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 2009 Dec 1;395(1):8-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19664996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2001 Dec;86(6):2667-77</Citation><ArticleIdList><ArticleId IdType="pubmed">11731527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Mar 19;285(12):8808-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20086007</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2001 Oct-Nov 1;56(3-4):319-29</Citation><ArticleIdList><ArticleId IdType="pubmed">11719267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1999 Jul;8(7):1227-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10369868</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Nov 6;282(5391):1145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9804556</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Mar 22;73(6):1204-15</Citation><ArticleIdList><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(1):e30011</Citation><ArticleIdList><ArticleId IdType="pubmed">22253858</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(2):e31302</Citation><ArticleIdList><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotherapeutics. 2012 Apr;9(2):270-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22441874</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2013 Apr;14(4):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Development. 2014 Jun;141(12):2366-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24917496</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2012 Nov;238(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22200539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Biol. 2011 Dec 01;3(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">22026965</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jun 18;459(7249):924-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19536253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 May;10(5):608-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2014 Jan 30;2:14</Citation><ArticleIdList><ArticleId IdType="pubmed">24479894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Apr 1;19(7):2522-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10087066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2003 Aug 15;12(16):2021-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12913073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2011 Jan;10(1):83-98</Citation><ArticleIdList><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Jan 30;156(3):537-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24485459</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2008 Nov 11;157(1):280-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18805465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2013 Nov;14(11):755-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24105342</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2009 Feb;11(2):219-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19151706</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2014 Feb;20(2):130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2009 Mar;11(3):328-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Feb 1;23(3):961-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12574425</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e34805</Citation><ArticleIdList><ArticleId IdType="pubmed">22511966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Jun 11;28(24):6182-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18550760</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e47026</Citation><ArticleIdList><ArticleId IdType="pubmed">23056565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1993 Mar 26;72(6):971-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 2004;44:269-96</Citation><ArticleIdList><ArticleId IdType="pubmed">14744247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2012 Apr 6;10(4):455-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22424902</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Dec 24;64(6):783-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20064386</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 08;8(7):e68357</Citation><ArticleIdList><ArticleId IdType="pubmed">23861892</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Apr 17;508(7496):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24487621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Feb 23;73(4):685-97</Citation><ArticleIdList><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 6;72(1):57-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25043039</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>512</Volume><Issue>7513</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Three-dimensional structure of human &#x3b3;-secretase.</ArticleTitle><Pagination><StartPage>166</StartPage><EndPage>170</EndPage><MedlinePgn>166-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13567</ELocationID><Abstract><AbstractText>The &#x3b3;-secretase complex, comprising presenilin 1 (PS1), PEN-2, APH-1 and nicastrin, is a membrane-embedded protease that controls a number of important cellular functions through substrate cleavage. Aberrant cleavage of the amyloid precursor protein (APP) results in aggregation of amyloid-&#x3b2;, which accumulates in the brain and consequently causes Alzheimer's disease. Here we report the three-dimensional structure of an intact human &#x3b3;-secretase complex at 4.5 &#xc5; resolution, determined by cryo-electron-microscopy single-particle analysis. The &#x3b3;-secretase complex comprises a horseshoe-shaped transmembrane domain, which contains 19 transmembrane segments (TMs), and a large extracellular domain (ECD) from nicastrin, which sits immediately above the hollow space formed by the TM horseshoe. Intriguingly, nicastrin ECD is structurally similar to a large family of peptidases exemplified by the glutamate carboxypeptidase PSMA. This structure serves as an important basis for understanding the functional mechanisms of the &#x3b3;-secretase complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Peilong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bai</LastName><ForeName>Xiao-Chen</ForeName><Initials>XC</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Chuangye</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Bio-membrane and Membrane Biotechnology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Linfeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Bio-membrane and Membrane Biotechnology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yanyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4UPC</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2014 Jul 17;158(2):247-249. doi: 10.1016/j.cell.2014.06.043.</RefSource><PMID Version="1">25036627</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="Y">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS59474</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25043039</ArticleId><ArticleId IdType="mid">EMS59474</ArticleId><ArticleId IdType="pmc">PMC4134323</ArticleId><ArticleId IdType="doi">10.1038/nature13567</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-Secretase: Structure, Function, and Role in Alzheimer Disease. Cold Spring Harbor perspectives in medicine. 2012;2:a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Toward the structure of presenilin/gamma-secretase and presenilin homologs. Biochim Biophys Acta. 2013;1828:2886&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801419</ArticleId><ArticleId IdType="pubmed">24099007</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003;100:6382&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281:46&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24279329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem. 2003;278:7374&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471034</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, et al. Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem. 2003;278:37213&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857757</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Winkler E, Haass C. Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1. J Biol Chem. 2008;283:34677&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259863</ArticleId><ArticleId IdType="pubmed">18801744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, et al. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. Embo J. 2004;23:4738&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535090</ArticleId><ArticleId IdType="pubmed">15549135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, et al. Glu-333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem. 2009;284:29714&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:6889&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, et al. Three-dimensional structure of the gamma-secretase complex. Biochemical and biophysical research communications. 2006;343:525&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546128</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. Journal of molecular biology. 2009;385:642&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi F, et al. Structure of gamma-secretase and its trimeric pre-activation intermediate by single-particle electron microscopy. J Biol Chem. 2011;286:21440&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122203</ArticleId><ArticleId IdType="pubmed">21454611</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure. 2014;22:125&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887256</ArticleId><ArticleId IdType="pubmed">24210759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhanifar S, et al. Structural investigation of the C-terminal catalytic fragment of presenilin 1. Proc Natl Acad Sci U S A. 2010;107:9644&#x2013;9649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906861</ArticleId><ArticleId IdType="pubmed">20445084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai XC, Fernandez IS, McMullan G, Scheres SH. Ribosome structures to near-atomic resolution from thirty thousand cryo-EM particles. Elife. 2013;2:e00461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576727</ArticleId><ArticleId IdType="pubmed">23427024</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat Methods. 2013;10:584&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684049</ArticleId><ArticleId IdType="pubmed">23644547</ArticleId></ArticleIdList></Reference><Reference><Citation>Amunts A, et al. Structure of the yeast mitochondrial large ribosomal subunit. Science. 2014;343:1485&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046073</ArticleId><ArticleId IdType="pubmed">24675956</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegretti M, Mills DJ, McMullan G, Kuhlbrandt W, Vonck J. Atomic model of the F420-reducing [NiFe] hydrogenase by electron cryo-microscopy using a direct electron detector. Elife. 2014;3:e01963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930138</ArticleId><ArticleId IdType="pubmed">24569482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Cao E, Julius D, Cheng Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature. 2013;504:107&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078027</ArticleId><ArticleId IdType="pubmed">24305160</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci U S A. 2005;102:1719&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547495</ArticleId><ArticleId IdType="pubmed">15665098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Gershon ES. Genetic studies in Alzheimer&#x2019;s disease. Dialogues Clin Neurosci. 2003;5:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181712</ArticleId><ArticleId IdType="pubmed">22033785</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000;97:6138&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Das C, Wolfe MS. Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications. J Biol Chem. 2003;278:16470&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644463</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180:519&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol. 2003;333:721&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568533</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan R, Swindells M, Overington J, Weir M. Nicastrin, a presenilin-interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain. Trends Biochem Sci. 2001;26:213&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11295540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang AX, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965167</ArticleId><ArticleId IdType="pubmed">20726553</ArticleId></ArticleIdList></Reference><Reference><Citation>Bammens L, Chavez-Gutierrez L, Tolia A, Zwijsen A, De Strooper B. Functional and topological analysis of Pen-2, the fourth subunit of the gamma-secretase complex. J Biol Chem. 2011;286:12271&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069430</ArticleId><ArticleId IdType="pubmed">21296884</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, et al. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem. 2005;280:41967&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisodia SS. Evidence that the &#x201c;NF&#x201d; motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem. 2005;280:41953&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234243</ArticleId></ArticleIdList></Reference><Reference><Citation>Althoff T, Mills DJ, Popot JL, Kuhlbrandt W. Arrangement of electron transport chain components in bovine mitochondrial supercomplex I1III2IV1. EMBO J. 2011;30:4652&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243592</ArticleId><ArticleId IdType="pubmed">21909073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tribet C, Audebert R, Popot JL. Amphipols: polymers that keep membrane proteins soluble in aqueous solutions. Proc Natl Acad Sci U S A. 1996;93:15047&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26353</ArticleId><ArticleId IdType="pubmed">8986761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang Y, Ha Y. Crystal structure of a rhomboid family intramembrane protease. Nature. 2006;444:179&#x2013;180. Epub 2006 Oct 11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, et al. Structural analysis of a rhomboid family intramembrane protease reveals a gating mechanism for substrate entry. Nat Struct Mol Biol. 2006;13:1084&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shem A, Fass D, Bibi E. Structural basis for intramembrane proteolysis by rhomboid serine proteases. Proc Natl Acad Sci USA. 2007;104:462&#x2013;466. Epub 2006 Dec 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766407</ArticleId><ArticleId IdType="pubmed">17190827</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, et al. Structure of a site-2 protease family intramembrane metalloprotease. Science. 2007;318:1608&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063795</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. The PyMOL Molecular Graphics System. 2002 on World Wide Web  http://www.pymol.org.</Citation></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A. 2004;101:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314130</ArticleId><ArticleId IdType="pubmed">14603031</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandrov A, et al. A facile method for high-throughput co-expression of protein pairs. Mol Cell Proteomics. 2004;3:934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15240823</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheich C, Kummel D, Soumailakakis D, Heinemann U, Bussow K. Vectors for co-expression of an unrestricted number of proteins. Nucleic Acids Res. 2007;35:e43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874614</ArticleId><ArticleId IdType="pubmed">17311810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol. 2003;142:334&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781660</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmlund H, Elmlund D, Bengio S. PRIME: probabilistic initial 3D model generation for single-particle cryo-electron microscopy. Structure. 2013;21:1299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">23931142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukelbir A, Sigworth FJ, Tagare HD. Quantifying the local resolution of cryo-EM density maps. Nat Methods. 2014;11:63&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903095</ArticleId><ArticleId IdType="pubmed">24213166</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. 2004;60:2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67:355&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069751</ArticleId><ArticleId IdType="pubmed">21460454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls RA, Long F, Murshudov GN. Low-resolution refinement tools in REFMAC5. Acta Crystallogr D Biol Crystallogr. 2012;68:404&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322599</ArticleId><ArticleId IdType="pubmed">22505260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25064009</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.</ArticleTitle><Pagination><StartPage>989</StartPage><EndPage>993</EndPage><MedlinePgn>989-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3043</ELocationID><Abstract><AbstractText>We conducted a meta-analysis of Parkinson's disease genome-wide association studies using a common set of 7,893,274 variants across 13,708 cases and 95,282 controls. Twenty-six loci were identified as having genome-wide significant association; these and 6 additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls. Of the 32 tested SNPs, 24 replicated, including 6 newly identified loci. Conditional analyses within loci showed that four loci, including GBA, GAK-DGKQ, SNCA and the HLA region, contain a secondary independent risk variant. In total, we identified and replicated 28 independent risk variants for Parkinson's disease across 24 loci. Although the effect of each individual locus was small, risk profile analysis showed substantial cumulative risk in a comparison of the highest and lowest quintiles of genetic risk (odds ratio (OR) = 3.31, 95% confidence interval (CI) = 2.55-4.30; P = 2 &#xd7; 10(-16)). We also show six risk loci associated with proximal gene expression or DNA methylation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1] Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lill</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Chuong B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>23andMe, Inc., Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>1] Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. [2] Reta Lila Weston Institute, University College London Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Department of Biostatistics, University of Washington, Seattle, Washington, USA. [2] INSERM, UMR 1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France. [3] Paul Sabatier University, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. [2] Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. [3] National Heart, Lung, and Blood Institute (NHLBI) Framingham Heart Study, Framingham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kara</LastName><ForeName>Eleanna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Institute for Clinical Epidemiology and Applied Biometry, University of T&#xfc;bingen, T&#xfc;bingen, Germany. [2] Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Margaux F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edsall</LastName><ForeName>Connor</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjav&#xed;k, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinmin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pliner</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Parkinson's Disease Genomics Consortium (IPDGC)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>23andMe</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>GenePD</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>NeuroGenetics Research Consortium (NGRC)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Hussman Institute of Human Genomics (HIHG)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Ashkenazi Jewish Dataset Investigator</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>North American Brain Expression Consortium (NABEC)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>United Kingdom Brain Expression Consortium (UKBEC)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Greek Parkinson's Disease Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer Genetic Analysis Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1] Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. [2] Department of Radiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. [3] Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>John P A</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Stanford Prevention Research Center, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjigeorgiou</LastName><ForeName>Georgios M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Neuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] INSERM, UMR 1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France. [2] Paul Sabatier University, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>1] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA. [3] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. [3] Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. [4] Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA. [2] Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, New York, USA. [3] Department of Neurology, Columbia University Medical Center, New York, New York, USA. [4] Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiske</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Center, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiromerisiou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Neuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece. [2] Department of Neurology, Papageorgiou Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Lorraine N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>1] Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA. [2] The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjav&#xed;k, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, University College London Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Genome Biology for Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Honglei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Epidemiology Branch, National Institute of Environmental Health Sciences, US National Institutes of Health, Research Triangle, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>Haydeh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>New York State Department of Health Wadsworth Center, Albany, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Sorbonne Universit&#xe9;, UPMC Universit&#xe9; Paris 06, UM 75, INSERM U1127, Institut du Cerveau et de la Moelle, Paris, France. [2] CNRS, UMR 7225, Paris, France. [3] Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Department of Genetics and Cytogenetics, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>William K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Miami School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>23andMe, Inc., Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>J-0804</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100643</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>WT089698/Z/09/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0909</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NS036630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0802760</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01CA141668</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0802462</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000932</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS060113</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS050487</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL120393</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS082151</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F-1202</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>083948/Z/07/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>1K23NS070867</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G0901330</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>076113</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G108/638</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS17950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS073836</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501554/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG08122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089698</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS088538</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1KL2RR024154</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2UL1 RR024156</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG031287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100479</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30AG024826</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>085475</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>090355</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01-NS-36960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R44 HG006981</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_09003</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS071674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076843</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS071674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="Y">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare no competing financial interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheerin</LastName><ForeName>Una-Marie</ForeName><Initials>UM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saad</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sim&#xf3;n-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sveinbj&#xf6;rnsd&#xf3;ttir</LastName><ForeName>Sigurlaug</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben-Shlomo</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berendse</LastName><ForeName>Henk W</ForeName><Initials>HW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Bie</LastName><ForeName>Rob M A</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biffi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloem</LastName><ForeName>Bas</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bochdanovits</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonin</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charlesworth</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Honglei</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chong</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Carl E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>J Mark</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Counsell</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panos</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deuschl</LastName><ForeName>G&#xfc;nther</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dexter</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Karin D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durif</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xfc;rr</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edkins</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dong</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollenbeck</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wurster</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe4;tzler</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huttenlocher</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Illig</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf3;nsson</LastName><ForeName>P&#xe1;lmi V</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langford</LastName><ForeName>Cordelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtner</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Limousin</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Grisel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenz</LastName><ForeName>Delia</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNeill</LastName><ForeName>Alisdair</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moorby</LastName><ForeName>Catriona</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudanohwo</LastName><ForeName>Ese</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;tursson</LastName><ForeName>Hj&#xf6;rvar</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollak</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Post</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riess</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawcer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheffer</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>Chris C A</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bettella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stockton</LastName><ForeName>Joanna D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strange</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanner</LastName><ForeName>Carlie M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashakkori-Ghanbaria</LastName><ForeName>Avazeh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tison</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velseboer</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Warrenburg</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wickremaratchi</LastName><ForeName>Mirdhu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>K&#xe1;ri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Factor</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shill</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stacy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danielson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marlor</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scollins</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saunders-Pullman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costan-Toth</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohmann</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudarsky</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joubert</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chou</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannon</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvez-Jimenez</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podichetty</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewitt</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeberger</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dingmann</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Judd</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marder</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraser</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoni</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medalle</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chouinard</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panisset</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poiffaut</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calabrese</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberge</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wojcieszek</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marek</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendick</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunlop</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jog</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horn</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitti</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turk</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajax</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannetter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sethi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carpenter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dill</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatch</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ligon</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narayan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blindauer</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abou-Samra</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petit</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elmer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiken</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schell</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velickovic</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koller</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phipps</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feigin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamann</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Licari</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marotta-Kollarus</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winnick</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simuni</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Videnovic</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaczmarek</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostyk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hubble</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reider</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seward</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camicioli</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nutt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morehouse</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendis</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimes</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcorn-Costa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haas</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vendette</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutton</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchinson</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klassen</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shirley</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manyam</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whetteckey</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wulbrecht</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truong</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pathak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frei</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luong</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tra</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleiner- Fisman</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieves</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>So</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podskalny</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giffin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atchison</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wieler</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suchowersky</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furtado</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klimek</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niswonger</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shults</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontaine</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aminoff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christine</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diminno</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hevezi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalvi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalvi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahay</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gartner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwieterman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Culver</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derian</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demarcaida</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thurlow</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodnitzky</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gales</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dustin</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koller</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zelaya</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuite</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagen</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rolandelli</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schacherer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosowicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serrano</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roque</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurlan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardiner</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Ramos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zesiewicz</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfrath</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewey</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayward</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meacham</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estes</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neill</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racette</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swisher</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dijamco</LastName><ForeName>Cheri</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conley</LastName><ForeName>Emily Drabant</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorfman</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tung</LastName><ForeName>Joyce Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinds</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountain</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wojcicki</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lew</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suchowersky</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golbe</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wooten</LastName><ForeName>G F</ForeName><Initials>GF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guttman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racette</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marlor</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shill</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldwurm</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saint-Hilaire</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nance</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drasby</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pramstaller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-hinti</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moller</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roxburgh</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slevin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mark</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezzoli</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massood</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Itin</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corbett</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinnery</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostergaard</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snow</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cambi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kay</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samii</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nutt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molho</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Ami</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montimurro</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kusel</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yearout</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Factor</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zabetian</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taub</LastName><ForeName>R Cheng</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marder</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Louis</LastName><ForeName>E D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cote</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waters</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nuytemans</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung Hoan</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rice</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longstreth</LastName><ForeName>W T</ForeName><Initials>WT</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Ton</LastName><ForeName>Thanh G N</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Samay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verlinden</LastName><ForeName>Vincent J</ForeName><Initials>VJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zonderman</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longo</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Brug</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zielke</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Adaikalavan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kara</LastName><ForeName>Eleanna</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiromerisiou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dardiotis</LastName><ForeName>Efthimios</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsimourtou</LastName><ForeName>Vana</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spanaki</LastName><ForeName>Cleanthe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plaitakis</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozi</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanis</LastName><ForeName>Leonidas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vassilatis</LastName><ForeName>Dimitris</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koutsis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panas</LastName><ForeName>Marios</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadjigeorgiou</LastName><ForeName>Georgios M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunnon</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parkkinen</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25064009</ArticleId><ArticleId IdType="mid">NIHMS610183</ArticleId><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="doi">10.1038/ng.3043</ArticleId><ArticleId IdType="pii">ng.3043</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lill CM, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson&#x2019;s disease genetics: The PDGene database. PLoS Genet. 2012;8:e1002548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3305333</ArticleId><ArticleId IdType="pubmed">22438815</ArticleId></ArticleIdList></Reference><Reference><Citation>Do CB, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x2019;s disease. PLoS Genet. 2011;7:e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="pubmed">21738487</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson Disease Genomics Consortium et al. Imputation of sequence variants for identification of genetic risks for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) &amp; Wellcome Trust Case Control Consortium 2 (WTCCC2) A two-stage meta-analysis identifies several new loci for Parkinson&#x2019;s disease. PLoS Genet. 2011;7:e1002142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="pubmed">21738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards TL, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853717</ArticleId><ArticleId IdType="pubmed">20070850</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, et al. Meta-analysis of Parkinson&#x2019;s Disease: Identification of a novel locus, RIT2. Ann Neurol. 2012;71:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3354734</ArticleId><ArticleId IdType="pubmed">22451204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet EJHG. 2011;19:655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110043</ArticleId><ArticleId IdType="pubmed">21248740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza TH, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson&#x2019;s disease. Nat Genet. 2010;42:781&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930111</ArticleId><ArticleId IdType="pubmed">20711177</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. Genome-wide association study identifies candidate genes for Parkinson&#x2019;s disease in an Ashkenazi Jewish population. BMC Med Genet. 2011;12:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166909</ArticleId><ArticleId IdType="pubmed">21812969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez DG, et al. Genome wide assessment of young onset Parkinson&#x2019;s disease from Finland. PloS One. 2012;7:e41859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404082</ArticleId><ArticleId IdType="pubmed">22911860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlstr&#xf8;m L, et al. Supportive evidence for 11 loci from genome-wide association studies in Parkinson&#x2019;s disease. Neurobiol Aging. 2013;34:1708. e7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414661</ArticleId><ArticleId IdType="pubmed">22786590</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad M, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson&#x2019;s disease in the European population. Hum Mol Genet. 2011;20:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21084426</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson&#x2019;s disease. Nat Genet. 2009;41:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz A, et al. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol. 2011;69:778&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082599</ArticleId><ArticleId IdType="pubmed">21391235</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875693</ArticleId><ArticleId IdType="pubmed">20031568</ArticleId></ArticleIdList></Reference><Reference><Citation>Macleod DA, et al. RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson&#x2019;s Disease Risk. Neuron. 2013;77:425&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646583</ArticleId><ArticleId IdType="pubmed">23395371</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MF, et al. Using genome-wide complex trait analysis to quantify &#x2018;missing heritability&#x2019; in Parkinson&#x2019;s disease. Hum Mol Genet. 2012;21:4996&#x2013;5009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576713</ArticleId><ArticleId IdType="pubmed">22892372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, et al. Large Sample Size, Wide Variant Spectrum, and Advanced Machine-Learning Technique Boost Risk Prediction for Inflammatory Bowel Disease. Am J Hum Genet. 2013;92:1008&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675261</ArticleId><ArticleId IdType="pubmed">23731541</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems SM, Mihaescu R, Sijbrands EJG, van Duijn CM, Janssens ACJW. A Methodological Perspective on Genetic Risk Prediction Studies in Type 2 Diabetes: Recommendations for Future Research. Curr Diab Rep. 2011;11:511&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207129</ArticleId><ArticleId IdType="pubmed">21947855</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Consortium et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet. 2013 doi: 10.1038/ng.2671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2671</ArticleId><ArticleId IdType="pmc">PMC4030301</ArticleId><ArticleId IdType="pubmed">23770607</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042601</ArticleId><ArticleId IdType="pubmed">20981092</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bakker PIW, et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet. 2008;17:R122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Walt JM, et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet. 2004;74:1121&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182076</ArticleId><ArticleId IdType="pubmed">15122513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, et al. Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26:657&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168750</ArticleId><ArticleId IdType="pubmed">21877163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ton TG, et al. Post hoc Parkinson&#x2019;s disease: identifying an uncommon disease in the Cardiovascular Health Study. Neuroepidemiology. 2010;35:241&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978249</ArticleId><ArticleId IdType="pubmed">20881426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, et al. Genomewide association studies of stroke. N Engl J Med. 2009;360:1718&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768348</ArticleId><ArticleId IdType="pubmed">19369658</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson N, et al. Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet. 2012;13:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483246</ArticleId><ArticleId IdType="pubmed">22747683</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta- analysis of genomewide association scans. Bioinforma Oxf Engl. 2010;26:2190&#x2013; 2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet. 2011;88:586&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146723</ArticleId><ArticleId IdType="pubmed">21565292</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove ML, et al. Best Practices and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium. PloS One. 2013;8:e68095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709915</ArticleId><ArticleId IdType="pubmed">23874508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripatti S, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965351</ArticleId><ArticleId IdType="pubmed">20971364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez DG, et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet. 2011;20:1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043665</ArticleId><ArticleId IdType="pubmed">21216877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25069482</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Functional connectivity in autosomal dominant and late-onset Alzheimer disease.</ArticleTitle><Pagination><StartPage>1111</StartPage><EndPage>1122</EndPage><MedlinePgn>1111-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1654</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We analyzed functional connectivity in multiple brain resting state networks (RSNs) in a cross-sectional cohort of participants with ADAD (n = 79) and LOAD (n = 444), using resting-state functional connectivity magnetic resonance imaging at multiple international academic sites.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">For both types of AD, we quantified and compared functional connectivity changes in RSNs as a function of dementia severity measured by the Clinical Dementia Rating Scale. In ADAD, we qualitatively investigated functional connectivity changes with respect to estimated years from onset of symptoms within 5 RSNs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A decrease in functional connectivity with increasing Clinical Dementia Rating scores were similar for both LOAD and ADAD in multiple RSNs. Ordinal logistic regression models constructed in one type of Alzheimer disease accurately predicted clinical dementia rating scores in the other, further demonstrating the similarity of functional connectivity loss in each disease type. Among participants with ADAD, functional connectivity in multiple RSNs appeared qualitatively lower in asymptomatic mutation carriers near their anticipated age of symptom onset compared with asymptomatic mutation noncarriers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Resting-state functional connectivity magnetic resonance imaging changes with progressing AD severity are similar between ADAD and LOAD. Resting-state functional connectivity magnetic resonance imaging may be a useful end point for LOAD and ADAD therapy trials. Moreover, the disease process of ADAD may be an effective model for the LOAD disease process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jewell B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brier</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri2Department of Radiology, Washington University in St Louis, St Louis, Missouri4Department of Anatomy and Neurobiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Bloomington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Warren Alpert Medical School, Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ourselin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, Australia13School of Medical Sciences, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco17Department of Radiology, University of California, San Francisco18Department of Psychiatry, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry, Imaging Genetics Center, Laboratory of Neuroimaging, David Geffen School of Medicine at University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegeneration, Institute of Neurology, University College of London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazey</LastName><ForeName>Tyler M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulder</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NR012907</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR014449</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NR014449</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH099979</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>19-AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23MH081786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/J01107X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NR012657</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012907</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH081786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB020403</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG37551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012657</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21MH099979</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Sep;71(9):1087-8. doi: 10.1001/jamaneurol.2014.1747.</RefSource><PMID Version="1">25070071</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Sep;10(9):483. doi: 10.1038/nrneurol.2014.149.</RefSource><PMID Version="1">25134706</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25069482</ArticleId><ArticleId IdType="mid">NIHMS635331</ArticleId><ArticleId IdType="pmc">PMC4240274</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1654</ArticleId><ArticleId IdType="pii">1890783</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. The Lancet. 2006;368(9533):387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet neurology. 2006 Mar;5(3):228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan NS, Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomarkers in medicine. 2010 Feb;4(1):99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937872</ArticleId><ArticleId IdType="pubmed">20387306</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, Ito D, Okada Y, et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Human molecular genetics. 2011 Dec 1;20(23):4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's research &amp; therapy. 2011;3(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet neurology. 2012 Dec;11(12):1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. The Lancet Neurology. 2012;11(12):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Archives of neurology. 2009 Dec;66(12):1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behavioural neurology. 2009;21(1):63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872923</ArticleId><ArticleId IdType="pubmed">19847046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Johnson K, et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology. 2013 Aug 20;81(8):736&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776464</ArticleId><ArticleId IdType="pubmed">23884042</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B, Yetkin Z, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magnetic Resonance in Medicine. 1995;34(4):537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal BB, Mennes M, Zuo XN, et al. Toward discovery science of human brain function. Proceedings of the National Academy of Sciences of the United States of America. 2010 Mar 9;107(10):4734&#x2013;4739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842060</ArticleId><ArticleId IdType="pubmed">20176931</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2005 Aug 24;25(34):7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Tredici KD. Stages of the pathological process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Jones DT, Vemuri P, et al. Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Archives of neurology. 2011 Sep;68(9):1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392960</ArticleId><ArticleId IdType="pubmed">21555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Thomas JB, Snyder AZ, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012 Jun 27;32(26):8890&#x2013;8899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458508</ArticleId><ArticleId IdType="pubmed">22745490</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer's research &amp; therapy. 2013 Oct 17;5(5):48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer disease and associated disorders. 2006 Oct-Dec;20(4):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Blennow K, Froelich L, et al. Harmonized diagnostic criteria for Alzheimer's disease: recommendations. Journal of internal medicine. 2014 Mar;275(3):204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24605805</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of neurology. 2004 Mar;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in medicine. 2010 Feb;4(1):51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846664</ArticleId><ArticleId IdType="pubmed">20361010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Ee4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Annals of neurology. 2003;54:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Pope DL, Astafiev SV, McAvoy MP, Snyder AZ, Corbetta M. Right hemisphere dominance during spatial selective attention and target detection occurs outside the dorsal frontoparietal network. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010 Mar 10;30(10):3640&#x2013;3651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872555</ArticleId><ArticleId IdType="pubmed">20219998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallquist MN, Hwang K, Luna B. The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity. NeuroImage. 2013 Nov 15;82:208&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759585</ArticleId><ArticleId IdType="pubmed">23747457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Zhang D, Snyder AZ, Raichle ME. The global signal and observed anticorrelated resting state brain networks. Journal of neurophysiology. 2009 Jun;101(6):3270&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694109</ArticleId><ArticleId IdType="pubmed">19339462</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage. 2012 Feb 1;59(3):2142&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Menon V. Default-mode activity during a passive sensory task: uncoupled from deactivation but impacting activation. J Cogn Neurosci. 2004 Nov;16(9):1484&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15601513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory GC, Macdonald V, Schofield PR, Kril JJ, Halliday GM. Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging. 2006 Mar;27(3):387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Medina LD, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings JL. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Current Alzheimer research. 2009 Aug;6(4):341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887763</ArticleId><ArticleId IdType="pubmed">19689233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. The Journal of biological chemistry. 2012 Jun 1;287(23):19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer's disease. Acta neuropathologica. 2009 Jul;118(1):37&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Archives of neurology. 2012 Jul;69(7):856&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010 Mar 15;67(6):584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Roe CM, Snyder AZ, et al. Alzheimer disease family history impacts resting state functional connectivity. Annals of neurology. 2012 Oct;72(4):571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490438</ArticleId><ArticleId IdType="pubmed">23109152</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007 Feb 28;27(9):2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K, Birn RM, Handwerker DA, Jones TB, Bandettini PA. The impact of global signal regression on resting state correlations: are anti-correlated networks introduced? NeuroImage. 2009 Feb 1;44(3):893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750906</ArticleId><ArticleId IdType="pubmed">18976716</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholvinck ML, Maier A, Ye FQ, Duyn JH, Leopold DA. Neural basis of global resting- state fMRI activity. Proceedings of the National Academy of Sciences of the United States of America. 2010 Jun 1;107(22):10238&#x2013;10243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890438</ArticleId><ArticleId IdType="pubmed">20439733</ArticleId></ArticleIdList></Reference><Reference><Citation>Birn RM, Diamond JB, Smith MA, Bandettini PA. Separating respiratory-variation- related fluctuations from neuronal-activity-related fluctuations in fMRI. NeuroImage. 2006 Jul 15;31(4):1536&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632379</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to detect, characterize, and remove motion artifact in resting state fMRI. NeuroImage. 2013 Aug 29;84C:320&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849338</ArticleId><ArticleId IdType="pubmed">23994314</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller CJ, Bickel S, Honey CJ, et al. Neurophysiological investigation of spontaneous correlated and anticorrelated fluctuations of the BOLD signal. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013 Apr 10;33(15):6333&#x2013;6342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652257</ArticleId><ArticleId IdType="pubmed">23575832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25080588</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>31</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Multiple factors contribute to the peripheral induction of cerebral &#x3b2;-amyloidosis.</ArticleTitle><Pagination><StartPage>10264</StartPage><EndPage>10273</EndPage><MedlinePgn>10264-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1608-14.2014</ELocationID><Abstract><AbstractText>Deposition of aggregated amyloid-&#x3b2; (A&#x3b2;) peptide in brain is an early event and hallmark pathology of Alzheimer's disease and cerebral A&#x3b2; angiopathy. Experimental evidence supports the concept that A&#x3b2; multimers can act as seeds and structurally corrupt other A&#x3b2; peptides by a self-propagating mechanism. Here we compare the induction of cerebral &#x3b2;-amyloidosis by intraperitoneal applications of A&#x3b2;-containing brain extracts in three A&#x3b2;-precursor protein (APP) transgenic mouse lines that differ in levels of transgene expression in brain and periphery (APP23 mice, APP23 mice lacking murine APP, and R1.40 mice). Results revealed that beta-amyloidosis induction, which could be blocked with an anti-A&#x3b2; antibody, was dependent on the amount of inoculated brain extract and on the level of APP/A&#x3b2; expression in the brain but not in the periphery. The induced A&#x3b2; deposits in brain occurred in a characteristic pattern consistent with the entry of A&#x3b2; seeds at multiple brain locations. Intraperitoneally injected A&#x3b2; could be detected in blood monocytes and some peripheral tissues (liver, spleen) up to 30 d after the injection but escaped histological and biochemical detection thereafter. These results suggest that intraperitoneally inoculated A&#x3b2; seeds are transported from the periphery to the brain in which corruptive templating of host A&#x3b2; occurs at multiple sites, most efficiently in regions with high availability of soluble A&#x3b2;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3410264-10$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eisele</LastName><ForeName>Yvonne S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and yvonne.s.eisele@gmail.com mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, D-72074 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamaguchi</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xfc;ger</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skodras</LastName><ForeName>Angelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odenthal</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heikenwalder</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Virology, Technische Universit&#xe4;t M&#xfc;nchen/Helmholtz Zentrum M&#xfc;nchen, D-81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany, German Center for Neurodegenerative Diseases, D-72076 T&#xfc;bingen, Germany, and yvonne.s.eisele@gmail.com mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001773" MajorTopicYN="N">Blood Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004333" MajorTopicYN="N">Drug Administration Routes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010529" MajorTopicYN="N">Peritoneal Cavity</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abeta</Keyword><Keyword MajorTopicYN="N">cerebral beta-amyloidosis</Keyword><Keyword MajorTopicYN="N">peripheral induction</Keyword><Keyword MajorTopicYN="N">seeding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25080588</ArticleId><ArticleId IdType="pmc">PMC6608275</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1608-14.2014</ArticleId><ArticleId IdType="pii">34/31/10264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Nuvolone M, Zhu C. The immunobiology of prion diseases. Nat Rev Immunol. 2013;13:888&#x2013;902. doi: 10.1038/nri3553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3553</ArticleId><ArticleId IdType="pubmed">24189576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bett C, Joshi-Barr S, Lucero M, Trejo M, Liberski P, Kelly JW, Masliah E, Sigurdson CJ. Biochemical properties of highly neuroinvasive prion strains. PLoS Pathog. 2012;8:e1002522. doi: 10.1371/journal.ppat.1002522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002522</ArticleId><ArticleId IdType="pmc">PMC3271082</ArticleId><ArticleId IdType="pubmed">22319450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bl&#xe4;ttler T, Brandner S, Raeber AJ, Klein MA, Voigtl&#xe4;nder T, Weissmann C, Aguzzi A. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature. 1997;389:69&#x2013;73. doi: 10.1038/37981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/37981</ArticleId><ArticleId IdType="pubmed">9288968</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Stewart K, Ritchie DL, Mabbott NA, Williams A, Fraser H, Morrison WI, Bruce ME. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med. 1999;5:1308&#x2013;1312. doi: 10.1038/15264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/15264</ArticleId><ArticleId IdType="pubmed">10545999</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96:14088&#x2013;14093. doi: 10.1073/pnas.96.24.14088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.24.14088</ArticleId><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Soto C, Morales R. Peripherally administrated prions reach the brain at sub-infectious quantities in experimental hamsters. FEBS Lett. 2014;588:795&#x2013;800. doi: 10.1016/j.febslet.2014.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.01.038</ArticleId><ArticleId IdType="pmc">PMC3980850</ArticleId><ArticleId IdType="pubmed">24492001</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M, Tolnay M. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014;127:299&#x2013;301. doi: 10.1007/s00401-013-1231-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1231-5</ArticleId><ArticleId IdType="pmc">PMC4253855</ArticleId><ArticleId IdType="pubmed">24362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol. 2011;3:a006833. doi: 10.1101/cshperspect.a006833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006833</ArticleId><ArticleId IdType="pmc">PMC3003464</ArticleId><ArticleId IdType="pubmed">21421910</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913. doi: 10.1038/nm890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm890</ArticleId><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Domert J, Rao SB, Agholme L, Brorsson AC, Marcusson J, Hallbeck M, Nath S. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis. 2014;65C:82&#x2013;92. doi: 10.1016/j.nbd.2013.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.12.019</ArticleId><ArticleId IdType="pubmed">24412310</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A. 2009;106:12926&#x2013;12931. doi: 10.1073/pnas.0903200106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903200106</ArticleId><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Oberm&#xfc;ller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982. doi: 10.1126/science.1194516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M. The presence of Abeta seeds, and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathol. 2012;123:31&#x2013;37. doi: 10.1007/s00401-011-0912-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0912-1</ArticleId><ArticleId IdType="pmc">PMC3297471</ArticleId><ArticleId IdType="pubmed">22101366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl JK, Neher JJ, S&#xfc;hs RB, Kohsaka S, Skodras A, Jucker M. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell. 2014;13:60&#x2013;69. doi: 10.1111/acel.12149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12149</ArticleId><ArticleId IdType="pmc">PMC4326865</ArticleId><ArticleId IdType="pubmed">23953759</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51. doi: 10.1038/nature12481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12481</ArticleId><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai H, Shin RW, Ogino K, Hatsuta H, Murayama S, Kitamoto T. Enhanced antigen retrieval of amyloid beta immunohistochemistry: re-evaluation of amyloid beta pathology in Alzheimer disease and its mouse model. J Histochem Cytochem. 2012;60:761&#x2013;769. doi: 10.1369/0022155412456379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155412456379</ArticleId><ArticleId IdType="pmc">PMC3524564</ArticleId><ArticleId IdType="pubmed">22821668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Evidence for seeding of &#x3b2;-amyloid by intracerebral infusion of Alzheimer brain extracts in &#x3b2;-amyloid precursor protein-transgenic mice. J Neurosci. 2000;20:3606&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JG, Keshava C, Murphy AA, Pitas RE, Parthasarathy S. Fresh mouse peritoneal macrophages have low scavenger receptor activity. J Lipid Res. 1997;38:2207&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pubmed">9392418</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T, Aslund A, Simon RA, Johansson LB, Mason JJ, Nystr&#xf6;m S, Hammarstr&#xf6;m P, Nilsson KP. Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. Org Biomol Chem. 2011;9:8356&#x2013;8370. doi: 10.1039/c1ob05637a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c1ob05637a</ArticleId><ArticleId IdType="pmc">PMC3326384</ArticleId><ArticleId IdType="pubmed">22051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane LS, Lamb BT. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis. 2001;8:982&#x2013;992. doi: 10.1006/nbdi.2001.0446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0446</ArticleId><ArticleId IdType="pubmed">11741394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai AY, McLaurin J. Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 2012;7:165&#x2013;176. doi: 10.2217/fnl.12.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fnl.12.6</ArticleId><ArticleId IdType="pmc">PMC3380064</ArticleId><ArticleId IdType="pubmed">22737039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet. 1997;6:1535&#x2013;1541. doi: 10.1093/hmg/6.9.1535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/6.9.1535</ArticleId><ArticleId IdType="pubmed">9285791</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci. 2011;31:14488&#x2013;14495. doi: 10.1523/JNEUROSCI.3088-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3088-11.2011</ArticleId><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat Rev Microbiol. 2006;4:201&#x2013;211. doi: 10.1038/nrmicro1346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1346</ArticleId><ArticleId IdType="pubmed">16462753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol. 2002;38:303&#x2013;313. doi: 10.1016/S1537-1891(02)00198-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1537-1891(02)00198-2</ArticleId><ArticleId IdType="pubmed">12529925</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar A, Chung H, Dolios G, Wang R, Asamoah N, Lobel P, Maxfield FR. Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages. Neurobiol Aging. 2008;29:707&#x2013;715. doi: 10.1016/j.neurobiolaging.2006.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.12.001</ArticleId><ArticleId IdType="pmc">PMC2424018</ArticleId><ArticleId IdType="pubmed">17222479</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784. doi: 10.1126/science.1131864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131864</ArticleId><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud JP, Bellavance MA, Pr&#xe9;fontaine P, Rivest S. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep. 2013;5:646&#x2013;653. doi: 10.1016/j.celrep.2013.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.010</ArticleId><ArticleId IdType="pubmed">24210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry. 2012;17:1347&#x2013;1353. doi: 10.1038/mp.2011.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.120</ArticleId><ArticleId IdType="pubmed">21968933</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K, Gate D, Gowing G, Town T. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr Alzheimer Res. 2011;8:156&#x2013;163. doi: 10.2174/156720511795256017.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795256017</ArticleId><ArticleId IdType="pmc">PMC3086574</ArticleId><ArticleId IdType="pubmed">21345166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, LeVine H, 3rd, Jucker M, Walker LC. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem. 2012;120:660&#x2013;666. doi: 10.1111/j.1471-4159.2011.07551.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07551.x</ArticleId><ArticleId IdType="pmc">PMC3293176</ArticleId><ArticleId IdType="pubmed">22017494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sponarova J, Nystr&#xf6;m SN, Westermark GT. AA-Amyloidosis can be transferred by peripheral blood monocytes. PLoS One. 2008;3:e3308. doi: 10.1371/journal.pone.0003308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003308</ArticleId><ArticleId IdType="pmc">PMC2553266</ArticleId><ArticleId IdType="pubmed">18830411</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K. Purified and synthetic Alzheimer's amyloid beta (Abeta) prions. Proc Natl Acad Sci U S A. 2012;109:11025&#x2013;11030. doi: 10.1073/pnas.1206555109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206555109</ArticleId><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, Grathwohl SA, Baumann F, Liebig C, Bosch A, Brawek B, Thal DR, Charo IF, Heppner FL, Aguzzi A, Garaschuk O, Ransohoff RM, Jucker M. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci U S A. 2012;109:18150&#x2013;18155. doi: 10.1073/pnas.1210150109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1210150109</ArticleId><ArticleId IdType="pmc">PMC3497743</ArticleId><ArticleId IdType="pubmed">23071306</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A. 2011;108:2528&#x2013;2533. doi: 10.1073/pnas.1019034108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019034108</ArticleId><ArticleId IdType="pmc">PMC3038719</ArticleId><ArticleId IdType="pubmed">21262831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson M. Segmentation techniques in image analysis of microbes, Chap 6. In: Wilkinson MHF, Schut F, editors. Digital image analysis of microbes: images, morphometry, fluorometry and motility techniques and applications. New York: Wiley; 1998.</Citation></Reference><Reference><Citation>Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol. 2009;117:111&#x2013;124. doi: 10.1007/s00401-008-0481-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0481-0</ArticleId><ArticleId IdType="pmc">PMC5650912</ArticleId><ArticleId IdType="pubmed">19139910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25088144</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Single-cell phenotyping within transparent intact tissue through whole-body clearing.</ArticleTitle><Pagination><StartPage>945</StartPage><EndPage>958</EndPage><MedlinePgn>945-958</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.07.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00931-3</ELocationID><Abstract><AbstractText>Understanding the structure-function relationships at cellular, circuit, and organ-wide scale requires 3D anatomical and phenotypical maps, currently unavailable for many organs across species. At the root of this knowledge gap is the absence of a method that enables whole-organ imaging. Herein, we present techniques for tissue clearing in which whole organs and bodies are rendered macromolecule-permeable and optically transparent, thereby exposing their cellular structure with intact connectivity. We describe PACT (passive clarity technique), a protocol for passive tissue clearing and immunostaining of intact organs; RIMS (refractive index matching solution), a mounting media for imaging thick tissue; and PARS (perfusion-assisted agent release in situ), a method for whole-body clearing and immunolabeling. We show that in rodents PACT, RIMS, and PARS are compatible with endogenous-fluorescence, immunohistochemistry, RNA single-molecule FISH, long-term storage, and microscopy with cellular and subcellular resolution. These methods are applicable for high-resolution, high-content mapping and phenotyping of normal and pathological elements within intact organs and bodies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treweek</LastName><ForeName>Jennifer B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Rajan P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deverman</LastName><ForeName>Benjamin E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chun-Kan</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubeck</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sheel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinaru</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA. Electronic address: viviana@caltech.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007616</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008042</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH103824</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32GM07616</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS085910</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21MH103824-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 NS087949</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD075605</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32AR058921</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047664</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HD075605</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS085910-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002477" MajorTopicYN="N">Cells</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005453" MajorTopicYN="N">Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051598" MajorTopicYN="Y">Whole Body Imaging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25088144</ArticleId><ArticleId IdType="mid">NIHMS618884</ArticleId><ArticleId IdType="pmc">PMC4153367</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.07.017</ArticleId><ArticleId IdType="pii">S0092-8674(14)00931-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becker K, Jahrling N, Saghafi S, Dodt HU. Ultramicroscopy: light-sheet-based microscopy for imaging centimeter-sized objects with micrometer resolution. Cold Spring Harbor protocols. 2013;2013:704&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">23906921</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker K, Jahrling N, Saghafi S, Weiler R, Dodt HU. Chemical clearing and dehydration of GFP expressing mouse brains. PLoS One. 2012;7:e33916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3316521</ArticleId><ArticleId IdType="pubmed">22479475</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum AR, Wu B, Singer RH. Single &#x3b2;-Actin mRNA Detection in Neurons Reveals a Mechanism for Regulating Its Translatability. Science. 2014;343:419&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121734</ArticleId><ArticleId IdType="pubmed">24458642</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, Deisseroth K. CLARITY for mapping the nervous system. Nature methods. 2013;10:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">23722210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, Wallace J, Kim SY, Kalyanasundaram S, Andalman AS, Davidson TJ, Mirzabekov JJ, Zalocusky KA, Mattis J, Denisin AK, et al. Structural and molecular interrogation of intact biological systems. Nature. 2013;497:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092167</ArticleId><ArticleId IdType="pubmed">23575631</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth KA, Gradinaru V. Functional Targeted Brain Endoskeletonization. 2014</Citation></Reference><Reference><Citation>Dodt H-U, Leischner U, Schierloh A, Jahrling N, Mauch CP, Deininger K, Deussing JM, Eder M, Zieglgansberger W, Becker K. Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. Nature methods. 2007;4:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ert&#xfc;rk A, Becker K, J&#xe4;hrling N, Mauch CP, Hojer CD, Egen JG, Hellal F, Bradke F, Sheng M, Dodt H-U. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nature protocols. 2012;7:1983&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">23060243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ert&#xfc;rk A, Bradke F. High-resolution imaging of entire organs by 3-dimensional imaging of solvent cleared organs (3DISCO) Experimental neurology. 2013;242:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23124097</ArticleId></ArticleIdList></Reference><Reference><Citation>Famm K. Drug discovery: a jump-start for electroceuticals. Nature. 2013;496:300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179459</ArticleId><ArticleId IdType="pubmed">23579662</ArticleId></ArticleIdList></Reference><Reference><Citation>Femino AM, Fay FS, Fogarty K, Singer RH. Visualization of Single RNA Transcripts in Situ. Science. 1998;280:585&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage GJ, Kipke DR, Shain W. Whole animal perfusion fixation for rodents. Journal of visualized experiments : JoVE. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3476408</ArticleId><ArticleId IdType="pubmed">22871843</ArticleId></ArticleIdList></Reference><Reference><Citation>George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC. Vagus nerve stimulation: a new tool for brain research and therapy. Biological psychiatry. 2000;47:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama H, Kurokawa H, Kawano H, Ando R, Shimogori T, Noda H, Fukami K, Sakaue-Sawano A, Miyawaki A. Scale: a chemical approach for fluorescence imaging and reconstruction of transparent mouse brain. Nature neuroscience. 2011;14:1481&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pubmed">21878933</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Applied Microbiology and Biotechnology. 2007;77:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039825</ArticleId><ArticleId IdType="pubmed">17704915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman AS. Hydrogels for biomedical applications. Advanced Drug Delivery Reviews. 2002;54:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonkers B, Sterk J, Wouterlood F. Transcardial perfusion fixation of the CNS by means of a compressed-air-driven device. Journal of neuroscience methods. 1984;12:141&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">6527553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke M-T, Fujimoto S, Imai T. SeeDB: a simple and morphology-preserving optical clearing agent for neuronal circuit reconstruction. Nature neuroscience. 2013a;16:1154&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">23792946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Chung K, Deisseroth K. Light microscopy mapping of connections in the intact brain. Trends in Cognitive Sciences. 2013;17:596&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">24210964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwajima T, Sitko AA, Bhansali P, Jurgens C, Guido W, Mason C. Clear(T): a detergent- and solvent-free clearing method for neuronal and non-neuronal tissue. Development. 2013a;140:1364&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912244</ArticleId><ArticleId IdType="pubmed">23444362</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong SK, Ling EA. Labelling neurons with fluorescent dyes administered via intravenous, subcutaneous or intraperitoneal route. Journal of neuroscience methods. 1990;32:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">2186224</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Bourgeois JP, Celli S, Glacial F, Le Sourd AM, Mecheri S, Weksler B, Romero I, Couraud PO, Rougeon F, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012;26:3969&#x2013;3979.</Citation><ArticleIdList><ArticleId IdType="pubmed">22730440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther. 2010;21:1259&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957274</ArticleId><ArticleId IdType="pubmed">20497038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyubimova A, Itzkovitz S, Junker JP, Fan ZP, Wu X, van Oudenaarden A. Single-molecule mRNA detection and counting in mammalian tissue. Nat Protocols. 2013;8:1743&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">23949380</ArticleId></ArticleIdList></Reference><Reference><Citation>Moy AJ, Wiersma MP, Choi B. Optical histology: a method to visualize microvasculature in thick tissue sections of mouse brain. PLoS One. 2013;8:e53753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553090</ArticleId><ArticleId IdType="pubmed">23372668</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotnikov S, Juneja V, Isaacson AB, Mohler WA, Campagnola PJ. Optical clearing for improved contrast in second harmonic generation imaging of skeletal muscle. Biophysical journal. 2006;90:328&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1367031</ArticleId><ArticleId IdType="pubmed">16214853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Molecular therapy : the journal of the American Society of Gene Therapy. 2011;19:1070&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129791</ArticleId><ArticleId IdType="pubmed">21364538</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Meth. 2008;5:877&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126653</ArticleId><ArticleId IdType="pubmed">18806792</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalteholz W. &#xdc;ber das Durchsichtigmachen von menschlichen und tierischen Pr&#xe4;paraten. Leipzig: S. Hierzel; 1914.</Citation></Reference><Reference><Citation>Steinke H, Wolff W. A modified Spalteholz technique with preservation of the histology. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft. 2001;183:91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11206989</ArticleId></ArticleIdList></Reference><Reference><Citation>Susaki EA, Tainaka K, Perrin D, Kishino F, Tawara T, Watanabe TM, Yokoyama C, Onoe H, Eguchi M, Yamaguchi S. Whole-Brain Imaging with Single-Cell Resolution Using Chemical Cocktails and Computational Analysis. Cell. 2014a</Citation><ArticleIdList><ArticleId IdType="pubmed">24746791</ArticleId></ArticleIdList></Reference><Reference><Citation>Susaki EA, Tainaka K, Perrin D, Kishino F, Tawara T, Watanabe TM, Yokoyama C, Onoe H, Eguchi M, Yamaguchi S, et al. Whole-Brain Imaging with Single-Cell Resolution Using Chemical Cocktails and Computational Analysis. Cell. 2014b</Citation><ArticleIdList><ArticleId IdType="pubmed">24746791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomer R, Ye L, Hsueh B, Deisseroth K. Advanced CLARITY for rapid and high-resolution imaging of intact tissues. Nature protocols. 2014;9:1682&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096681</ArticleId><ArticleId IdType="pubmed">24945384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng SJ, Lee YH, Chen ZH, Lin HH, Lin CY, Tang SC. Integration of optical clearing and optical sectioning microscopy for three-dimensional imaging of natural biomaterial scaffolds in thin sections. Journal of biomedical optics. 2009;14:044004.</Citation><ArticleIdList><ArticleId IdType="pubmed">19725716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MD, Tortoriello G, Hsueh B, Tomer R, Ye L, Mitsios N, Borgius L, Grant G, Kiehn O, Watanabe M, et al. Neuronal calcium-binding proteins 1/2 localize to dorsal root ganglia and excitatory spinal neurons and are regulated by nerve injury. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:E1149&#x2013;E1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970515</ArticleId><ArticleId IdType="pubmed">24616509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25081482</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>345</Volume><Issue>6201</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.</ArticleTitle><Pagination><StartPage>1139</StartPage><EndPage>1145</EndPage><MedlinePgn>1139-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1254917</ELocationID><Abstract><AbstractText>Many RNA regulatory proteins controlling pre-messenger RNA splicing contain serine:arginine (SR) repeats. Here, we found that these SR domains bound hydrogel droplets composed of fibrous polymers of the low-complexity domain of heterogeneous ribonucleoprotein A2 (hnRNPA2). Hydrogel binding was reversed upon phosphorylation of the SR domain by CDC2-like kinases 1 and 2 (CLK1/2). Mutated variants of the SR domains changing serine to glycine (SR-to-GR variants) also bound to hnRNPA2 hydrogels but were not affected by CLK1/2. When expressed in mammalian cells, these variants bound nucleoli. The translation products of the sense and antisense transcripts of the expansion repeats associated with the C9orf72 gene altered in neurodegenerative disease encode GRn and PRn repeat polypeptides. Both peptides bound to hnRNPA2 hydrogels independent of CLK1/2 activity. When applied to cultured cells, both peptides entered cells, migrated to the nucleus, bound nucleoli, and poisoned RNA biogenesis, which caused cell death.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Ilmin</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Siheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Leeju</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theodoropoulos</LastName><ForeName>Pano</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Quantitative Biomedical Research Center, Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jiwoong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Quantitative Biomedical Research Center, Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Jonghyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Quantitative Biomedical Research Center, Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Quantitative Biomedical Research Center, Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. steven.mcknight@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 GM107623</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027342">Excitatory Amino Acid Transporter 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050491">Glutamate Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034481">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012335">RNA, Ribosomal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493397">SLC1A2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439768">hnRNP A2</NameOfSubstance></Chemical><Chemical><RegistryNumber>25852-47-5</RegistryNumber><NameOfSubstance UI="D020136">Hydrogel, Polyethylene Glycol Dimethacrylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C066780">Clk dual-specificity kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2014 Sep 5;345(6201):1118-9. doi: 10.1126/science.1259461.</RefSource><PMID Version="1">25190778</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002466" MajorTopicYN="N">Cell Nucleolus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027342" MajorTopicYN="N">Excitatory Amino Acid Transporter 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050491" MajorTopicYN="N">Glutamate Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034481" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020136" MajorTopicYN="N">Hydrogel, Polyethylene Glycol Dimethacrylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012335" MajorTopicYN="N">RNA, Ribosomal</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25081482</ArticleId><ArticleId IdType="mid">NIHMS696026</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pii">science.1254917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, H&#xf6;ltt&#xe4;-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chi&#xf2; A, Restagno G, Borghero G, Sabatelli M, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857. doi: 10.1007/s00401-013-1200-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1200-z</ArticleId><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, Ostrow LW, Rothstein JD, Troncoso JC, Ranum LP. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, Nan Z, Forster C, Low WC, Schoser B, Somia NV, Clark HB, Schmechel S, Bitterman PB, Gourdon G, Swanson MS, Moseley M, Ranum LP. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA. 2011;108:260&#x2013;265. doi: 10.1073/pnas.1013343108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1013343108</ArticleId><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, Boylan KB, Dickson DW, Petrucelli L. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, Maragakis N, Tienari PJ, Petrucelli L, Traynor BJ, Wang J, Rigo F, Bennett CF, Blackshaw S, Sattler R, Rothstein JD. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, Grishin NV, Frantz DE, Schneider JW, Chen S, Li L, Sawaya MR, Eisenberg D, Tycko R, McKnight SL. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767. doi: 10.1016/j.cell.2012.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.04.017</ArticleId><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, Mirzaei H, Han T, Xie S, Corden JL, McKnight SL. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell. 2013;155:1049&#x2013;1060. doi: 10.1016/j.cell.2013.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.10.033</ArticleId><ArticleId IdType="pmc">PMC4010232</ArticleId><ArticleId IdType="pubmed">24267890</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth MB, Murphy C, Gall JG. A monoclonal antibody that recognizes a phosphorylated epitope stains lampbrush chromosome loops and small granules in the amphibian germinal vesicle. J Cell Biol. 1990;111:2217&#x2013;2223. doi: 10.1083/jcb.111.6.2217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.111.6.2217</ArticleId><ArticleId IdType="pmc">PMC2116404</ArticleId><ArticleId IdType="pubmed">1703534</ArticleId></ArticleIdList></Reference><Reference><Citation>Neugebauer KM, Stolk JA, Roth MB. A conserved epitope on a subset of SR proteins defines a larger family of Pre-mRNA splicing factors. J Cell Biol. 1995;129:899&#x2013;908. doi: 10.1083/jcb.129.4.899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.129.4.899</ArticleId><ArticleId IdType="pmc">PMC2120486</ArticleId><ArticleId IdType="pubmed">7538140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahler AM, Lane WS, Stolk JA, Roth MB. SR proteins: A conserved family of pre-mRNA splicing factors. Genes Dev. 1992;6:837&#x2013;847. doi: 10.1101/gad.6.5.837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.6.5.837</ArticleId><ArticleId IdType="pubmed">1577277</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, Duncan PI. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J. 1996;15:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449941</ArticleId><ArticleId IdType="pubmed">8617202</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC. The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing. Exp Cell Res. 1998;241:300&#x2013;308. doi: 10.1006/excr.1998.4083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1998.4083</ArticleId><ArticleId IdType="pubmed">9637771</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegay HJ, Myers MP, Moeslein FM, Landreth GE. Biochemical characterization and localization of the dual specificity kinase CLK1. J Cell Sci. 2000;113:3241&#x2013;3253.</Citation><ArticleIdList><ArticleId IdType="pubmed">10954422</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubol BE, Plocinik RM, Hagopian JC, Ma CT, McGlone ML, Bandyopadhyay R, Fu XD, Adams JA. Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases. J Mol Biol. 2013;425:2894&#x2013;2909. doi: 10.1016/j.jmb.2013.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.05.013</ArticleId><ArticleId IdType="pmc">PMC3860265</ArticleId><ArticleId IdType="pubmed">23707382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamond AI, Spector DL. Nuclear speckles: A model for nuclear organelles. Nat Rev Mol Cell Biol. 2003;4:605&#x2013;612. doi: 10.1038/nrm1172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1172</ArticleId><ArticleId IdType="pubmed">12923522</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiry M. Behavior of interchromatin granules during the cell cycle. Eur J Cell Biol. 1995;68:14&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8549586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubulya PA, Prasanth KV, Deerinck TJ, Gerlich D, Beaudouin J, Ellisman MH, Ellenberg J, Spector DL. Hypophosphorylated SR splicing factors transiently localize around active nucleolar organizing regions in telophase daughter nuclei. J Cell Biol. 2004;167:51&#x2013;63. doi: 10.1083/jcb.200404120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200404120</ArticleId><ArticleId IdType="pmc">PMC2172523</ArticleId><ArticleId IdType="pubmed">15479736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589&#x2013;602. doi: 10.1016/S0896-6273(00)80997-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80997-6</ArticleId><ArticleId IdType="pubmed">9539131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalderon D, Roberts BL, Richardson WD, Smith AE. A short amino acid sequence able to specify nuclear location. Cell. 1984;39:499&#x2013;509. doi: 10.1016/0092-8674(84)90457-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(84)90457-4</ArticleId><ArticleId IdType="pubmed">6096007</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingwall C, Robbins J, Dilworth SM, Roberts B, Richardson WD. The nucleoplasmin nuclear location sequence is larger and more complex than that of SV-40 large T antigen. J Cell Biol. 1988;107:841&#x2013;849. doi: 10.1083/jcb.107.3.841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.107.3.841</ArticleId><ArticleId IdType="pmc">PMC2115281</ArticleId><ArticleId IdType="pubmed">3417784</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55:1189&#x2013;1193. doi: 10.1016/0092-8674(88)90263-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(88)90263-2</ArticleId><ArticleId IdType="pubmed">2849510</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, Rothstein JD, Wang J. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200. doi: 10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield P, Garrard S, Derewenda Z. Overcoming expression and purification problems of RhoGDI using a family of &#x201c;parallel&#x201d; expression vectors. Protein Expr Purif. 1999;15:34&#x2013;39. doi: 10.1006/prep.1998.1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/prep.1998.1003</ArticleId><ArticleId IdType="pubmed">10024467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball HL, Mascagni P. Chemical synthesis and purification of proteins: A methodology. Int J Pept Protein Res. 1996;48:31&#x2013;47. doi: 10.1111/j.1399-3011.1996.tb01104.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3011.1996.tb01104.x</ArticleId><ArticleId IdType="pubmed">8844261</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105&#x2013;1111. doi: 10.1093/bioinformatics/btp120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp120</ArticleId><ArticleId IdType="pmc">PMC2672628</ArticleId><ArticleId IdType="pubmed">19289445</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2013;31:46&#x2013;53. doi: 10.1038/nbt.2450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2450</ArticleId><ArticleId IdType="pmc">PMC3869392</ArticleId><ArticleId IdType="pubmed">23222703</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511&#x2013;515. doi: 10.1038/nbt.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1621</ArticleId><ArticleId IdType="pmc">PMC3146043</ArticleId><ArticleId IdType="pubmed">20436464</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens MA. EDF statistics for goodness of fit and some comparisons. J Am Stat Assoc. 1974;69:730&#x2013;737. doi: 10.1080/01621459.1974.10480196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1974.10480196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25090106</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study.</ArticleTitle><Pagination><StartPage>1218</StartPage><EndPage>1227</EndPage><MedlinePgn>1218-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1646</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Hypertension is a treatable potential cause of cognitive decline and dementia, but its greatest influence on cognition may occur in middle age.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association between midlife (48-67 years of age) hypertension and the 20-year change in cognitive performance.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Atherosclerosis Risk in Communities cohort (1990-1992 through 2011-2013) underwent evaluation at field centers in Washington County, Maryland, Forsyth County, North Carolina, Jackson, Mississippi, and the Minneapolis, Minnesota, suburbs. Of 13&#x2009;476 African American and white participants with baseline cognitive data, 58.0% of living participants completed the 20-year cognitive follow-up.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Hypertension, prehypertension, or normal blood pressure (BP) at visit 2 (1990-1992) constituted the primary exposure. Systolic BP at visit 2 or 5 (2011-2013) and indication for treatment at visit 2 based on the Eighth Joint National Committee (JNC-8) hypertension guidelines constituted the secondary exposures.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Prespecified outcomes included the 20-year change in scores on the Delayed Word Recall Test, Digit Symbol Substitution Test, and Word Fluency Test and in global cognition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 20 years, baseline hypertension was associated with an additional decline of 0.056 global z score points (95% CI, -0.100 to -0.012) and prehypertension was associated nonsignificantly with 0.040 more global z score points of decline (95% CI, -0.085 to 0.005) compared with normal BP. Individuals with hypertension who used antihypertensives had less decline during the 20 years than untreated individuals with hypertension (-0.050 [95% CI, -0.003 to -0.097] vs -0.079 [95% CI, -0.156 to -0.002] global z score points). Having a JNC-8-specified indication for initiating antihypertensive treatment at baseline was associated with a greater 20-year decline (-0.044 [95% CI, -0.085 to -0.003] global z score points) than not having an indication. We observed effect modification by race for the continuous systolic BP analyses (P&#x2009;=&#x2009;.01), with each 20-mm Hg increment at baseline associated with an additional decline of 0.048 (95% CI, -0.074 to -0.022) points in global cognitive z score in whites but not in African Americans (decline, -0.020 [95% CI, -0.026 to 0.066] points). Systolic BP at the end of follow-up was not associated with the preceding 20 years of cognitive change in either group. Methods to account for bias owing to attrition strengthened the magnitude of some associations.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Midlife hypertension and elevated midlife but not late-life systolic BP was associated with more cognitive decline during the 20 years of the study. Greater decline is found with higher midlife BP in whites than in African Americans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea L C</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandeen-Roche</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coresh</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Melinda C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawlings</LastName><ForeName>Andreea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharrett</LastName><ForeName>A Richey</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wruck</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201100012C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100010C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100011C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100008C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001079</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007024</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL 096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100006C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HL70825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL 096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32HL007024</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100009C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100005C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Oct;71(10):1211-3. doi: 10.1001/jamaneurol.2014.2014.</RefSource><PMID Version="1">25090029</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 May 19;313(19):1963-4. doi: 10.1001/jama.2015.3113.</RefSource><PMID Version="1">25988465</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058246" MajorTopicYN="N">Prehypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25090106</ArticleId><ArticleId IdType="mid">NIHMS636371</ArticleId><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1646</ArticleId><ArticleId IdType="pii">1891344</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke. 2006 Jan;37(1):33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339468</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995 Dec 20;274(23):1846&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. British Medical Journal. 2001;322(7300):1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001;56(12):1683&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425934</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Mosley TH, Jr, Gottesman RF, Catellier DJ, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. Journal of Neurology Neurosurgery and Psychiatry. 2009;80(11):1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783764</ArticleId><ArticleId IdType="pubmed">19692426</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology. 2007 Sep 4;69(10):998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785668</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77(5):461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146307</ArticleId><ArticleId IdType="pubmed">21810696</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. JAMA. 1999;281:438&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9952204</ArticleId></ArticleIdList></Reference><Reference><Citation>Swan GE, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998 Oct;51(4):986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781518</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Mosley TH, Catellier DJ, Coker LH Study ARiCSBM. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimer&#x2019;s and Dementia. 2009;5(3):207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaffashian S, Dugravot A, Elbaz A, et al. Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores. Neurology. 2013;80(14):1300&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656460</ArticleId><ArticleId IdType="pubmed">23547265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler S, Baars MA, Spauwen P, Schievink S, Verhey FR, van Boxtel MJ. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. Hypertension. 2013 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">24296281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ, Beiser A, Delano-Wood L, et al. APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. Journal of Stroke and Cerebrovascular Diseases. 2013 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849195</ArticleId><ArticleId IdType="pubmed">23601373</ArticleId></ArticleIdList></Reference><Reference><Citation>The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol. 1989;46(2):141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">2916953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Manual for the Wechsler Adult Intelligence Scale- Revised. New York: The Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Lezak M. Neuropsychological assessment. 3. New York: Oxford University Press; 1995.</Citation></Reference><Reference><Citation>Schneider ALC, Sharrett AR, Gottesman RF, et al. Normative data for eight common neuropsychological tests for blacks and whites from the Atherosclerosis Risk in Communities (ARIC) Study. Alzheimer&#x2019;s Disease and Associated Disorders. 2014 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206681</ArticleId><ArticleId IdType="pubmed">24759546</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL, Eslinger PJ, Damasio AR. Normative observations on neuropsychological test performances in old age. Journal of Clinica Neuropsychology. 1981;3(1):33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">7276195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei GS, Coady SA, Goff DC, Jr, et al. Blood pressure and the risk of developing diabetes in African Americans and Whites: ARIC, CARDIA, and the Framingham Heart Study. Diabetes Care. 2011;34:873&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064044</ArticleId><ArticleId IdType="pubmed">21346180</ArticleId></ArticleIdList></Reference><Reference><Citation>James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee (JNC 8) JAMA. 2013 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">24352797</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398023</ArticleId><ArticleId IdType="pubmed">22762315</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Tchetgen Tchetgen EJ, Glymour MM, et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology. 2012 Jan;23(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237815</ArticleId><ArticleId IdType="pubmed">21989136</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732954</ArticleId><ArticleId IdType="pubmed">18682488</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider AL, Gottesman RF, Mosley TH, Jr, et al. Cognition and incident dementia hospitalization: results from the Atherosclerosis Risk in Communities study. Neuroepidemiology. 2013;40(2):117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642775</ArticleId><ArticleId IdType="pubmed">23095770</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D, Boland LL, Mosley T, Jr, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56(1):42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148234</ArticleId></ArticleIdList></Reference><Reference><Citation>Euser SM, van Bemmel T, Schram MT, et al. The effect of age on the association between blood pressure and cognitive function later in life. J Am Geriatr Soc. 2009;57(7):1232&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332720</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor C, Tillin T, Chaturvedi N, et al. Midlife hypertensive status and cognitive function 20 years later: the Southall and Brent revisited study. J Am Geriatr Soc. 2013;61(9):1489&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902992</ArticleId><ArticleId IdType="pubmed">24028355</ArticleId></ArticleIdList></Reference><Reference><Citation>Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">1824642</ArticleId></ArticleIdList></Reference><Reference><Citation>Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34(6):1181&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10601115</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol. 1999;46(6):827&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589534</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614402</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Tchetgen EJ, Sparrow D, Schwartz J, Weisskopf MG. Blood pressure and cognition: factors that may account for their inconsistent association. Epidemiology. 2013;24(6):886&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818218</ArticleId><ArticleId IdType="pubmed">24030502</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider AL, Sharrett AR, Patel MD, et al. Education and cognitive change over 15 years: The Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2012;60(10):1847&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662980</ArticleId><ArticleId IdType="pubmed">23013064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Rawlings AM, Sharrett AR, et al. Impact of differential attrition in the association of education with cognitive change over 20 years of followup: the ARIC-Neurocognitive Study. Am J Epidemiol. 2014;179(8):956&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966720</ArticleId><ArticleId IdType="pubmed">24627572</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard G, Lackland DT, Kleindorfer DO, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Internal Medicine. 2013;173(1):46&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759226</ArticleId><ArticleId IdType="pubmed">23229778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885214</ArticleId><ArticleId IdType="pubmed">23911753</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Hughes T, Yu B, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/ Honolulu Asia Aging Study. Hypertension. 2010;55(6):1352&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241740</ArticleId><ArticleId IdType="pubmed">20404223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25100603</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>32</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.</ArticleTitle><Pagination><StartPage>10710</StartPage><EndPage>10728</EndPage><MedlinePgn>10710-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0433-14.2014</ELocationID><Abstract><AbstractText>Key neuropathological hallmarks of Alzheimer's disease (AD) are elevated levels of amyloid &#x3b2;-peptide (A&#x3b2;) species generated via amyloid precursor protein (APP) endoproteolysis and cleavage by the rate-limiting &#x3b2;-site enzyme 1 (BACE1). Because rodents do not develop amyloid pathologies, we here investigated whether AD-like endophenotypes can be created in mice by expression of human bace1. To avoid pitfalls of existing models, we introduced hbace1 via knock-in under the control of the CaMKII &#x3b1; promoter into the safe HPRT locus. We report amyloidogenic processing of murine APP in the hBACE1 mice (termed PLB4), resulting in the formation of toxic APP metabolites that accumulate intra- and extraneuronally in hippocampus and cortex. Pronounced accumulation of A&#x3b2;*56 and A&#x3b2; hexamers in the absence of plaque deposition was detected in brain tissue from symptomatic PLB4 mice. Heightened levels of inflammation (gliosis) also appeared in several AD-related brain regions (dentate gyrus, hippocampal area CA1, piriform and parietal cortices) at 6 and 12 months of age. Behaviorally, deficits in habituation to a novel environment and semantic-like memory (social transmission of food preference) were detected from 3 to 4 months of age. Impairments in spatial learning strategies in long-term reference (water maze) and working memory (Y-maze) tasks presented at 6 months, and were distinct from reductions in locomotor activity and anxiety. Overall, our data indicate for the first time that targeted, subtle forebrain-specific expression through single gene knock-in of hBACE1 is sufficient to generate AD-relevant cognitive impairments amid corresponding histopathologies, confirming human BACE as the key parameter in amyloid pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3410710-19$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pluci&#x144;ska</LastName><ForeName>Kaja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crouch</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koss</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Lianne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siebrecht</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom b.platt@abdn.ac.uk g.riedel@abdn.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom b.platt@abdn.ac.uk g.riedel@abdn.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003623" MajorTopicYN="N">Dark Adaptation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005518" MajorTopicYN="N">Food Preferences</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">circadian</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">strategy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25100603</ArticleId><ArticleId IdType="pmc">PMC4122804</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0433-14.2014</ArticleId><ArticleId IdType="pii">34/32/10710</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem. 2010;112:1045&#x2013;1053. doi: 10.1111/j.1471-4159.2009.06528.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06528.x</ArticleId><ArticleId IdType="pmc">PMC2819564</ArticleId><ArticleId IdType="pubmed">19968762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G. Amyloid &#x3b2; protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol. 1998;397:139&#x2013;147. doi: 10.1002/(SICI)1096-9861(19980720)397:1&lt;139::AID-CNE10&gt;3.3.CO;2-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(19980720)397:1&lt;139::AID-CNE10&gt;3.3.CO;2-7</ArticleId><ArticleId IdType="pubmed">9671284</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeau EJ, Didic M, Joubert S, Guedj E, Koric L, Felician O, Ranjeva JP, Cozzone P, Ceccaldi M. Extent and neural basis of semantic memory impairment in mild cognitive impairment. J Alzheimers Dis. 2012;28:823&#x2013;837. doi: 10.3233/JAD-2011-110989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110989</ArticleId><ArticleId IdType="pubmed">22112550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer TA, Wirths O. Intracellular accumulation of amyloid-beta: a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci. 2010;2:8. doi: 10.3389/fnagi.2010.00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2010.00008</ArticleId><ArticleId IdType="pmc">PMC2879032</ArticleId><ArticleId IdType="pubmed">20552046</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Green KN, McGaugh JL, LaFerla FM. Learning decreases A&#x3b2;*56 and tau pathology and ameliorates behavioural decline in 3xTg-AD mice. J Neurosci. 2007;27:751&#x2013;761. doi: 10.1523/JNEUROSCI.4800-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4800-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672918</ArticleId><ArticleId IdType="pubmed">17251414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P. Expression of human &#x3b2;-secretase in the mouse brain increases steady-state level of &#x3b2;-amyloid. J Neurochem. 2002;80:799&#x2013;806. doi: 10.1046/j.0022-3042.2002.00770.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2002.00770.x</ArticleId><ArticleId IdType="pubmed">11948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945. doi: 10.1016/S0896-6273(00)80974-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80974-5</ArticleId><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Morris water maze search strategy analysis in PDAPP mice before and after traumatic brain injury. Exp Neurol. 2006;197:330&#x2013;340. doi: 10.1016/j.expneurol.2005.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.10.020</ArticleId><ArticleId IdType="pmc">PMC1913184</ArticleId><ArticleId IdType="pubmed">16309676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase required for generation of A-beta peptides in neurons. Nat Neurosci. 2001;4:233&#x2013;234. doi: 10.1038/85064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassano T, Romano A, Macheda T, Colangeli R, Cimmino CS, Petrella A, LaFerla FM, Cuomo V, Gaetani S. Olfactory memory is impaired in a triple transgenic model of Alzheimer's disease. Behav Brain Res. 2011;224:408&#x2013;412. doi: 10.1016/j.bbr.2011.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2011.06.029</ArticleId><ArticleId IdType="pubmed">21741995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang X, Zhang YW, Rockenstein E, Bu G, Golde TE, Masliah E, Xu H. Alzheimer's &#x3b2;-secretase (BACE1) regulates cAMP/PKA/CREB pathway independently of &#x3b2;-amyloid. J Neurosci. 2012;32:11390&#x2013;11395. doi: 10.1523/JNEUROSCI.0757-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0757-12.2012</ArticleId><ArticleId IdType="pmc">PMC3446780</ArticleId><ArticleId IdType="pubmed">22895721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiocco MJ, Kulnane LS, Younkin L, Younkin S, Evin G, Lamb BT. Altered amyloid-&#x3b2; metabolism and deposition in genomic-based &#x3b2;-secretase transgenic mice. J Biol Chem. 2004;279:52535&#x2013;52542. doi: 10.1074/jbc.M409680200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409680200</ArticleId><ArticleId IdType="pmc">PMC2659546</ArticleId><ArticleId IdType="pubmed">15452128</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The basic biology of BACE1: A key therapeutic target for Alzheimer's disease. Curr Genomics. 2007;8:509&#x2013;530. doi: 10.2174/138920207783769512.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920207783769512</ArticleId><ArticleId IdType="pmc">PMC2647160</ArticleId><ArticleId IdType="pubmed">19415126</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN, Goodwin FK. Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 1980;13:167&#x2013;170. doi: 10.1016/0091-3057(80)90067-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-3057(80)90067-2</ArticleId><ArticleId IdType="pubmed">6106204</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79:447&#x2013;460. doi: 10.1016/j.neuron.2013.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.035</ArticleId><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Koros E, Bornemann KD, Rawlins JN. Aged Tg2576 mice are impaired on social memory and open field habituation tests. Behav Brain Res. 2009;197:466&#x2013;468. doi: 10.1016/j.bbr.2008.09.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2008.09.042</ArticleId><ArticleId IdType="pubmed">18977397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B, Lichtenthaler SF. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol. 2012;3:8. doi: 10.3389/fphys.2012.00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00008</ArticleId><ArticleId IdType="pmc">PMC3281277</ArticleId><ArticleId IdType="pubmed">22363289</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton SL, Roche SL, Llavero Hurtado M, Oldknow KJ, Farquharson C, Gillingwater TH, Wishart TM. Total protein analysis as a reliable loading control for quantative fluorescent Western blotting. PLoS One. 2013;8:e72457. doi: 10.1371/journal.pone.0072457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072457</ArticleId><ArticleId IdType="pmc">PMC3758299</ArticleId><ArticleId IdType="pubmed">24023619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. &#x3b2;-Secretase protein and activity are increased in the neocortex of Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389. doi: 10.1001/archneur.59.9.1381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.9.1381</ArticleId><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Galef BG, Wigmore SW. Transfer of information concerning distant foods: a laboratory investigation of the &#x201c;information-centre&#x201d; hypothesis. Animal Behav. 1983;31:748&#x2013;758. doi: 10.1016/S0003-3472(83)80232-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-3472(83)80232-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Garthe A, Behr J, Kempermann G. Adult-generated hippocampal neurons allow flexible use of spatially precise learning strategies. PLoS One. 2009;4:e5464. doi: 10.1371/journal.pone.0005464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005464</ArticleId><ArticleId IdType="pmc">PMC2674212</ArticleId><ArticleId IdType="pubmed">19421325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhardt FM, Scott HA, Dodd PR. Housekeepers for accurate transcript expression analysis in Alzheimer's disease autopsy brain tissue. Alzheimer's Dementia. 2010;6:465&#x2013;474. doi: 10.1016/j.jalz.2009.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.11.002</ArticleId><ArticleId IdType="pubmed">21044776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A. 2009;106:18367&#x2013;18372. doi: 10.1073/pnas.0907652106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907652106</ArticleId><ArticleId IdType="pmc">PMC2762847</ArticleId><ArticleId IdType="pubmed">19837693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Mohapel J, Brocardo PS, Choquette W, Gothard R, Simpson JM, Christie BR. Hippocampal neurogenesis levels predict water maze search strategies in the ageing brain. PLoS One. 2013;8:e75125. doi: 10.1371/journal.pone.0075125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075125</ArticleId><ArticleId IdType="pmc">PMC3781090</ArticleId><ArticleId IdType="pubmed">24086453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold G, Blouin JL, Herrmann FR, Michon A, Mulligan R, Duriaux Sa&#xef;l G, Bouras C, Giannakopoulos P, Antonarakis SE. Specific BACE1 genotypes provides additional risk for late-onset Alzheimer's disease in APOE &#x3b5;4 carriers. Am J Med Genet B Neuropsychiatr Genet. 2003;119B:44&#x2013;47. doi: 10.1002/ajmg.b.10010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.10010</ArticleId><ArticleId IdType="pubmed">12707937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal A&#x3b2;42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20. doi: 10.1016/S0002-9440(10)64700-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64700-1</ArticleId><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;ninger-Leitch F, Schlatter D, K&#xfc;ng E, Nelb&#xf6;ck P, D&#xf6;beli H. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem. 2002;277:4687&#x2013;4693. doi: 10.1074/jbc.M109266200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109266200</ArticleId><ArticleId IdType="pubmed">11741910</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, Gonzalez MI, Upton N, Pangalos MN, Dingwall C. BACE1(beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioural changes. Mol Cell Neurosci. 2003;24:646&#x2013;655. doi: 10.1016/S1044-7431(03)00227-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1044-7431(03)00227-6</ArticleId><ArticleId IdType="pubmed">14664815</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert SS, Horr&#xe9; K, Nicola&#xef; L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/&#x3b2;-secretase expression. Proc Natl Acad Sci U S A. 2008;105:6415&#x2013;6420. doi: 10.1073/pnas.0710263105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0710263105</ArticleId><ArticleId IdType="pmc">PMC2359789</ArticleId><ArticleId IdType="pubmed">18434550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of &#x3b2;-secretase (BACE1) substrates using quantitative proteomics. PLoS One. 2009;4:e8477. doi: 10.1371/journal.pone.0008477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008477</ArticleId><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirni DI, Kivisaari SL, Monsch AU, Taylor KI. Distinct neuroanatomical basis of episodic and semantic memory performance in Alzheimer's disease. Neuropsychologia. 2013;51:930&#x2013;937. doi: 10.1016/j.neuropsychologia.2013.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2013.01.013</ArticleId><ArticleId IdType="pubmed">23369803</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C. Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem. 2004;11:337&#x2013;346. doi: 10.1101/lm.70104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.70104</ArticleId><ArticleId IdType="pmc">PMC419737</ArticleId><ArticleId IdType="pubmed">15169864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G. Neuronal clearance of amyloid-&#x3b2; by endocytic receptor LRP1. J Neurosci. 2013;33:19276&#x2013;19283. doi: 10.1523/JNEUROSCI.3487-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3487-13.2013</ArticleId><ArticleId IdType="pmc">PMC3850043</ArticleId><ArticleId IdType="pubmed">24305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingel WH, He P, Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764. doi: 10.1038/ncb1602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1602</ArticleId><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Devi L, Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem. 2010;113:248&#x2013;261. doi: 10.1111/j.1471-4159.2010.06608.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06608.x</ArticleId><ArticleId IdType="pmc">PMC2921968</ArticleId><ArticleId IdType="pubmed">20089133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S, Morris RG, Chen KS. BACE1 gene deletion: impact on behavioural function in a model of Alzheimer's disease. Neurobiol Aging. 2008;29:861&#x2013;873. doi: 10.1016/j.neurobiolaging.2007.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.01.002</ArticleId><ArticleId IdType="pubmed">17331621</ArticleId></ArticleIdList></Reference><Reference><Citation>Koss DJ, Riedel G, Bence K, Platt B. Store-operated Ca2+ entry in hippocampal neurons: regulation by protein tyrosine phosphotase PTP1B. Cell Calcium. 2013a;53:125&#x2013;138. doi: 10.1016/j.ceca.2012.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2012.11.004</ArticleId><ArticleId IdType="pubmed">23218930</ArticleId></ArticleIdList></Reference><Reference><Citation>Koss DJ, Drever BD, Stoppelkamp S, Riedel G, Platt B. Age-dependent changes in hippocampal synaptic transmission and plasticity in the PLB1Triple Alzheimer mouse. Cell Mol Life Sci. 2013b;70:2585&#x2013;2601. doi: 10.1007/s00018-013-1273-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1273-9</ArticleId><ArticleId IdType="pmc">PMC11113876</ArticleId><ArticleId IdType="pubmed">23407662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Ro&#x3b2;ner S, Br&#xe4;se S, Lichtenthaler SF. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157&#x2013;3168. doi: 10.1038/emboj.2012.173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.173</ArticleId><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J. Early intraneuronal accumulation and increase aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. Acta Neuropathol. 2013;125:699&#x2013;709. doi: 10.1007/s00401-013-1107-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1107-8</ArticleId><ArticleId IdType="pubmed">23525537</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709. doi: 10.1523/JNEUROSCI.2766-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2766-05.2005</ArticleId><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Fukuchi K, Strazielle C. APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD) Neurosci Biobehav Rev. 2012;36:1357&#x2013;1375. doi: 10.1016/j.neubiorev.2012.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2012.02.011</ArticleId><ArticleId IdType="pmc">PMC3340431</ArticleId><ArticleId IdType="pubmed">22373961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; SE, Ming YK, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357. doi: 10.1038/nature04533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04533</ArticleId><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH. Brain amyloid-&#x3b2; oligomers in ageing and Alzheimer's disease. Brain. 2013;136:1383&#x2013;1398. doi: 10.1093/brain/awt062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt062</ArticleId><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232. doi: 10.1038/85059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85059</ArticleId><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I, Speakman JR, Howlett DR, Ashford ML. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J. 2012;441:285&#x2013;296. doi: 10.1042/BJ20110512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20110512</ArticleId><ArticleId IdType="pmc">PMC3242510</ArticleId><ArticleId IdType="pubmed">21880018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri MH, Saini KD, Nitsch RM. Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. J Neural Transm. 2004;111:413&#x2013;425. doi: 10.1007/s00702-003-0057-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-003-0057-z</ArticleId><ArticleId IdType="pubmed">14991462</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaou M, Song YQ, Sato CA, Orlacchio A, Kawarai T, Medeiros H, Liang Y, Sorbi S, Richard E, Rogaev EI, Moliaka Y, Bruni AC, Jorge R, Percy M, Duara R, Farrer LA, St Georg-Hyslop P, Rogaeva EA. Mutations in the open reading frame of the &#x3b2;-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease. Neurogenetics. 2001;3:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">11714100</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of A&#x3b2;. Am J Pathol. 2006;168:184&#x2013;194. doi: 10.2353/ajpath.2006.050593.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.050593</ArticleId><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh F, Leergaard TB, Boy J, Schmidt T, Riess O, Bjaalie JG. Atlas of transgenic Tet-Off Ca2+ /clmodulin-dependent protein kinase II and prion protein promoter activity in the mouse brain. Neuroimage. 2011;54:2603&#x2013;2611. doi: 10.1016/j.neuroimage.2010.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.11.032</ArticleId><ArticleId IdType="pubmed">21093594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis. 2007;26:134&#x2013;145. doi: 10.1016/j.nbd.2006.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.008</ArticleId><ArticleId IdType="pmc">PMC1876698</ArticleId><ArticleId IdType="pubmed">17258906</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14:149&#x2013;167. doi: 10.1016/0165-0270(85)90031-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(85)90031-7</ArticleId><ArticleId IdType="pubmed">2864480</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt B, Drever B, Koss D, Stoppelkamp S, Jyoti A, Plano A, Utan A, Merrick G, Ryan D, Melis V, Wan H, Mingarelli M, Porcu E, Scrocchi L, Welch A, Riedel G. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One. 2011;6:e27068. doi: 10.1371/journal.pone.0027068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027068</ArticleId><ArticleId IdType="pmc">PMC3214038</ArticleId><ArticleId IdType="pubmed">22096518</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonist show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol. 2009;156:1154&#x2013;1166. doi: 10.1111/j.1476-5381.2008.00107.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2008.00107.x</ArticleId><ArticleId IdType="pmc">PMC2697695</ArticleId><ArticleId IdType="pubmed">19378378</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, et al. BACE knock-out mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Molec Genet. 2001;10:1317&#x2013;1324. doi: 10.1093/hmg/10.12.1317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.12.1317</ArticleId><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson L, Guy J, McKay L, Brockett E, Spike RC, Selfridge J, De Sousa D, Merusi C, Riedel G, Bird A, Cobb SR. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain. 2012;135:2699&#x2013;2710. doi: 10.1093/brain/aws096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws096</ArticleId><ArticleId IdType="pmc">PMC3437019</ArticleId><ArticleId IdType="pubmed">22525157</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson L, Plano A, Cobb S, Riedel G. Long-term home cage activity scans reveal lowered exploratory behaviour in symptomatic female Rett mice. Behav Brain Res. 2013;250:148&#x2013;156. doi: 10.1016/j.bbr.2013.04.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2013.04.041</ArticleId><ArticleId IdType="pmc">PMC3885800</ArticleId><ArticleId IdType="pubmed">23643691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan D, Koss D, Porcu E, Woodcock H, Robinson L, Platt B, Riedel G. Spatial learning impairments in PLB1Triple knock-in Alzheimer's mice are task-specific and age-dependent. Cell Mol Life Sci. 2013;70:2603&#x2013;2619. doi: 10.1007/s00018-013-1314-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1314-4</ArticleId><ArticleId IdType="pmc">PMC11113905</ArticleId><ArticleId IdType="pubmed">23535719</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. Gene structure and organization of the human &#x3b2;-secretase (BACE) promoter. FASEB J. 2004;18:1034&#x2013;1036. doi: 10.1096/fj.03-1378fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-1378fje</ArticleId><ArticleId IdType="pubmed">15059975</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld R, Moenich N, Mueller FJ, Lehmann W, Leplow B. Search strategies in a human water maze analogue analysed with automatic classification methods. Behav Brain Res. 2010;208:169&#x2013;177. doi: 10.1016/j.bbr.2009.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2009.11.022</ArticleId><ArticleId IdType="pubmed">19931570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. Purification and cloning of amyloid precursor protein &#x3b2;-secretase from human brain. Nature. 1999;402:537&#x2013;540. doi: 10.1038/990114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990114</ArticleId><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S, Cacucci F, Lever C. Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. J Alzheimers Dis. 2011;26:105&#x2013;126. doi: 10.3233/JAD-2011-101827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101827</ArticleId><ArticleId IdType="pubmed">21558645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. &#x3b2;-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane asparyric protease BACE. Science. 1999;286:735&#x2013;741. doi: 10.1126/science.286.5440.735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Venneri A, McGeown WJ, Hietanen HM, Guerrini C, Ellis AW, Shanks MF. The anatomical bases of semantic retrieval deficits in early Alzheimer's disease. Neuropsychologia. 2008;46:497&#x2013;510. doi: 10.1016/j.neuropsychologia.2007.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2007.08.026</ArticleId><ArticleId IdType="pubmed">17936858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianna MR, Alonso M, Viola H, Quevedo J, de Paris F, Furman M, de Stein ML, Medina JH, Izquierdo I. Role of hippocampal signalling pathways in long-term memory formation of a nonassociative learning task in the rat. Learn Mem. 2000;7:333&#x2013;340. doi: 10.1101/lm.34600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.34600</ArticleId><ArticleId IdType="pmc">PMC311352</ArticleId><ArticleId IdType="pubmed">11040265</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JM, Fowler SW, Miller DK, Sun AY, Weisman GA, Wood WG, Sun GY, Simonyi A, Schachtman TR. Spatial learning and memory impairment and increase locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Behav Brain Res. 2011;222:169&#x2013;175. doi: 10.1016/j.bbr.2011.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2011.03.049</ArticleId><ArticleId IdType="pubmed">21443906</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid &#x3b2;-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839. doi: 10.1021/bi001048s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi001048s</ArticleId><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, van Echten-Deckert G. Cross-talk of membrane lipids and Alzheimer-related proteins. Mol Neurodegener. 2013;8:34. doi: 10.1186/1750-1326-8-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-34</ArticleId><ArticleId IdType="pmc">PMC4016522</ArticleId><ArticleId IdType="pubmed">24148205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Song L, Laird F, Wong PC, Lee HK. BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci. 2008;28:8677&#x2013;8681. doi: 10.1523/JNEUROSCI.2440-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2440-08.2008</ArticleId><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011;10:1416&#x2013;1419. doi: 10.1021/pr1011476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr1011476</ArticleId><ArticleId IdType="pubmed">21186791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson DW, Levy E, Nixon RA, Wilson DA. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci. 2010;30:505&#x2013;514. doi: 10.1523/JNEUROSCI.4622-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4622-09.2010</ArticleId><ArticleId IdType="pmc">PMC2826174</ArticleId><ArticleId IdType="pubmed">20071513</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666. doi: 10.1126/science.1132341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132341</ArticleId><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfer DP, Lipp HP. Dissecting the behaviour of transgenic mice: is it the mutation, the genetic background, or the environment? Exp Physiol. 2000;85:627&#x2013;634. doi: 10.1017/S0958067000020959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0958067000020959</ArticleId><ArticleId IdType="pubmed">11187958</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer's disease. Nat Med. 2003;9:3&#x2013;4. doi: 10.1038/nm0103-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0103-3</ArticleId><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Crawley JN. Simple behavioural assessment of mouse olfaction. Curr Protoc Neurosci. 2009;8:8.24. doi: 10.1002/0471142301.ns0824s48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142301.ns0824s48</ArticleId><ArticleId IdType="pmc">PMC2753229</ArticleId><ArticleId IdType="pubmed">19575474</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ. APOE4-sepcific changes in A&#x3b2; accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774&#x2013;41786. doi: 10.1074/jbc.M112.407957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.407957</ArticleId><ArticleId IdType="pmc">PMC3516726</ArticleId><ArticleId IdType="pubmed">23060451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25123310</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury.</ArticleTitle><Pagination><StartPage>789</StartPage><EndPage>796</EndPage><MedlinePgn>789-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.07.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00625-4</ELocationID><Abstract><AbstractText>Human induced pluripotent stem cells (iPSCs) from a healthy 86-year-old male were differentiated into neural stem cells and grafted into adult immunodeficient rats after spinal cord injury. Three months after C5 lateral hemisections, iPSCs survived and differentiated into neurons and glia and extended tens of thousands of axons from the lesion site over virtually the entire length of the rat CNS. These iPSC-derived axons extended through adult white matter of the injured spinal cord, frequently penetrating gray matter and forming synapses with rat neurons. In turn, host supraspinal motor axons penetrated human iPSC grafts and formed synapses. These findings indicate that intrinsic neuronal mechanisms readily overcome the inhibitory milieu of the adult injured spinal cord to extend many axons over very long distances; these capabilities persist even in neurons reprogrammed from very aged human cells.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Veterans Administration Medical Center, San Diego, CA 92161, USA; Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: plu@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaozhi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Lori</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Matt</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehle</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Ruhel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poplawski</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA; Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuszynski</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Veterans Administration Medical Center, San Diego, CA 92161, USA; Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: mtuszynski@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 NS009881</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS09881</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB014986</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB014986</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049881</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042291</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002574" MajorTopicYN="N">Cervical Vertebrae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25123310</ArticleId><ArticleId IdType="mid">NIHMS620097</ArticleId><ArticleId IdType="pmc">PMC4144679</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.07.014</ArticleId><ArticleId IdType="pii">S0896-6273(14)00625-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alto LT, Havton LA, Conner JM, Hollis ER, Blesch A, Tuszynski MH. Chemotropic guidance facilitates axonal regeneration and synapse formation after spinal cord injury. Nat. Neurosci. 2009;12:1106&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753201</ArticleId><ArticleId IdType="pubmed">19648914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Uchida N, Tamaki SJ, Salazar DL, Hooshmand M, Summers R, Gage FH, Anderson AJ. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc. Natl. Acad. Sci. 2005;102:14069&#x2013;14074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1216836</ArticleId><ArticleId IdType="pubmed">16172374</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto Y, Abematsu M, Falk A, Tsujimura K, Sanosaka T, Juliandi B, Semi K, Namihira M, Komiya S, Smith A, et al. Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells. Stem Cells. 2012;30:1163&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">22419556</ArticleId></ArticleIdList></Reference><Reference><Citation>Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, Steward O. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 2005;25:4694&#x2013;4705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724772</ArticleId><ArticleId IdType="pubmed">15888645</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, Blesch A, Graham L, Wang Y, Samara R, Banos K, Haringer V, Havton L, Weishaupt N, Bennett D, et al. Motor axonal regeneration after partial and complete spinal cord transection. J. Neurosci. 2012a;32:8208&#x2013;8218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407545</ArticleId><ArticleId IdType="pubmed">22699902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, Wang Y, Graham L, McHale K, Gao M, Wu D, Brock J, Blesch A, Rosenzweig ES, Havton LA, et al. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell. 2012b;150:1264&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445432</ArticleId><ArticleId IdType="pubmed">22980985</ArticleId></ArticleIdList></Reference><Reference><Citation>Musienko P, van den Brand R, M&#xe4;rzendorfer O, Roy RR, Gerasimenko Y, Edgerton VR, Courtine G. Controlling specific locomotor behaviors through multidimensional monoaminergic modulation of spinal circuitries. J Neurosci. 2011;31:9264&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422212</ArticleId><ArticleId IdType="pubmed">21697376</ArticleId></ArticleIdList></Reference><Reference><Citation>Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, Poli AM, Svendsen A, Torsvik A, Enger PO, Terzis JA, et al. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J. 2008;22:3120&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518261</ArticleId><ArticleId IdType="pubmed">18495755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc. Natl. Acad. Sci. 2011;108:16825&#x2013;16830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189018</ArticleId><ArticleId IdType="pubmed">21949375</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt SE, Chang EA, Suhr ST, Schlosser LO, Mondello SE, Moritz CT, Cibelli JB, Horner PJ. Caudalized human iPSC-derived neural progenitor cells produce neurons and glia but fail to restore function in an early chronic spinal cord injury model. Exp. Neurol. 2013;248:491&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109283</ArticleId><ArticleId IdType="pubmed">23891888</ArticleId></ArticleIdList></Reference><Reference><Citation>Plemel JR, Chojnacki A, Sparling JS, Liu J, Plunet W, Duncan GJ, Park SE, Weiss S, Tetzlaff W. Platelet-derived growth factor-responsive neural precursors give rise to myelinating oligodendrocytes after transplantation into the spinal cords of contused rats and dysmyelinated mice. Glia. 2011;59:1891&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">22407783</ArticleId></ArticleIdList></Reference><Reference><Citation>Pundir AS, Hameed LS, Dikshit PC, Kumar P, Mohan S, Radotra B, Shankar SK, Mahadevan A, Iyengar S. Expression of medium and heavy chain neurofilaments in the developing human auditory cortex. Brain Struct Funct. 2012;217:303&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21987049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribotta MG, Provencher J, Feraboli-Lohnherr D, Rossignol S, Privat A, Orsal D. Activation of locomotion in adult chronic spinal rats is achieved by transplantation of embryonic raphe cells reinnervating a precise lumbar level. J. Neurosci. 2000;20:5144&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772289</ArticleId><ArticleId IdType="pubmed">10864971</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab JM, Failli V, Chedotal A. Injury-related dynamic myelin/oligodendrocyte axon-outgrowth inhibition in the central nervous system. Lancet. 2005;365:2055&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15950719</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward O, Sharp K, Yee KM. Long-distance migration and colonization of transplanted neural stem cells. Cell. 2014;156:385&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">24485444</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor L, Jones L, Tuszynski MH, Blesch A. Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J. Neurosci. 2006;26:9713&#x2013;9721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674461</ArticleId><ArticleId IdType="pubmed">16988042</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen S, Ojala M, Hyysalo A, Ilmarinen T, Rajala K, Pekkanen-Mattila M, &#xc4;&#xe4;nismaa R, Lundin K, Palgi J, Weltner J, et al. Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. Stem Cell Transl Med. 2013;2:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659749</ArticleId><ArticleId IdType="pubmed">23341440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, et al. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 2010;107:12704&#x2013;12709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906548</ArticleId><ArticleId IdType="pubmed">20615974</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Steward O. Concepts and methods for the study of axonal regeneration in the CNS. Neuron. 2012;74:777&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387806</ArticleId><ArticleId IdType="pubmed">22681683</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Wang Y, Graham L, Gao M, Wu D, Brock J, Blesch A, Rosenzweig ES, Havton LA, Zheng B, et al. Neural stem cell dissemination after grafting to CNS injury sites. Cell. 2014;156:388&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">24485445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Bates J, Li X, Schanz S, Chandler-Militello D, Levine C, Maherali N, Studer L, Hochedlinger K, Windrem M, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell. 2013;12:252&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700553</ArticleId><ArticleId IdType="pubmed">23395447</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One. 2011;6:e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25103406</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>345</Volume><Issue>6201</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.</ArticleTitle><Pagination><StartPage>1192</StartPage><EndPage>1194</EndPage><MedlinePgn>1192-1194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1256800</ELocationID><Abstract><AbstractText>An expanded GGGGCC repeat in C9orf72 is the most common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis. A fundamental question is whether toxicity is driven by the repeat RNA itself and/or by dipeptide repeat proteins generated by repeat-associated, non-ATG translation. To address this question, we developed in vitro and in vivo models to dissect repeat RNA and dipeptide repeat protein toxicity. Expression of pure repeats, but not stop codon-interrupted "RNA-only" repeats in Drosophila caused adult-onset neurodegeneration. Thus, expanded repeats promoted neurodegeneration through dipeptide repeat proteins. Expression of individual dipeptide repeat proteins with a non-GGGGCC RNA sequence revealed that both poly-(glycine-arginine) and poly-(proline-arginine) proteins caused neurodegeneration. These findings are consistent with a dual toxicity mechanism, whereby both arginine-rich proteins and repeat RNA contribute to C9orf72-mediated neurodegeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mizielinska</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gr&#xf6;nke</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Strasse 9b, 50931 Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Niccoli</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, UCL, Darwin Building, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridler</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devoy</LastName><ForeName>Anny</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moens</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, UCL, Darwin Building, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norona</LastName><ForeName>Frances E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woollacott</LastName><ForeName>Ione O C</ForeName><Initials>IOC</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrzyk</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleverley</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Prion Unit, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Strasse 9b, 50931 Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabecinha</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, UCL, Darwin Building, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrich</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Strasse 9b, 50931 Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Elizabeth M C</ForeName><Initials>EMC</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partridge</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Strasse 9b, 50931 Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, UCL, Darwin Building, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089701</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K018523/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004022/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>081394</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701441</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>098565</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1000287</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L021056/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ISAACS/APR13/818-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2014 Sep 5;345(6201):1118-9. doi: 10.1126/science.1259461.</RefSource><PMID Version="1">25190778</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS69064</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25103406</ArticleId><ArticleId IdType="mid">EMS69064</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="doi">10.1126/science.1256800</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lillo P, Hodges JR. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci. 2009;16:1131&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">19556136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, et al. Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. Am J Hum Genet. 2013;92:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12:978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 2013;126:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms MB, et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol Aging. 2013;34:2234&#x2013;2239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679344</ArticleId><ArticleId IdType="pubmed">23597494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley T, Hardy J, Isaacs AM. RANTing about C9orf72. Neuron. 2013;77:597&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer DE, Chilkoti A. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules. 2002;3:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888323</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haro M, et al. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006;15:2138&#x2013;2145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16723374</ArticleId></ArticleIdList></Reference><Reference><Citation>Orengo JP, et al. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2008;105:2646&#x2013;2651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268190</ArticleId><ArticleId IdType="pubmed">18272483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto N, et al. GGA*TCC-interrupted triplets in long GAA*TTC repeats inhibit the formation of triplex and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities. J Biol Chem. 2001;276:27178&#x2013;27187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325966</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, et al. C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci Rep. 2012;2:1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527825</ArticleId><ArticleId IdType="pubmed">23264878</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy JB. GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis. 2002;34:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">12324939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126:859&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci. 2013;16:1725&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397902</ArticleId><ArticleId IdType="pubmed">24185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126:385&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci U S A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25111166</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.</ArticleTitle><Pagination><StartPage>1228</StartPage><EndPage>1236</EndPage><MedlinePgn>1228-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.2011</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The identification of a patient with a rare form of severe dysbetalipoproteinemia allowed the study of the consequences of total absence of apolipoprotein E (apoE).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To discover the molecular basis of this rare disorder and to determine the effects of complete absence of apoE on neurocognitive and visual function and on lipoprotein metabolism.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Whole-exome sequencing was performed on the patient's DNA. He underwent detailed neurological and visual function testing and lipoprotein analysis. Lipoprotein analysis was also performed in the Cardiovascular Research Institute, University of California, San Francisco, on blood samples from the proband's mother, wife, 2 daughters, and normolipidemic control participants.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Whole-exome sequencing, lipoprotein analysis, and neurocognitive function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient was homozygous for an ablative APOE frameshift mutation (c.291del, p.E97fs). No other mutations likely to contribute to the phenotype were discovered, with the possible exception of two, in ABCC2 (p.I670T) and LIPC (p.G137R). Despite complete absence of apoE, he had normal vision, exhibited normal cognitive, neurological, and retinal function, had normal findings on brain magnetic resonance imaging, and had normal cerebrospinal fluid levels of &#x3b2;-amyloid and tau proteins. He had no significant symptoms of cardiovascular disease except a suggestion of myocardial ischemia on treadmill testing and mild atherosclerosis noted on carotid ultrasonography. He had exceptionally high cholesterol content (760 mg/dL; to convert to millimoles per liter, multiply by 0.0259) and a high cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of small-diameter high-density lipoproteins, including high levels of prebeta-1 high-density lipoprotein. Intermediate-density lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I and apoA-IV levels. The patient's apoC-III and apoC-IV levels were decreased in very low-density lipoproteins. Electron microscopy revealed large lamellar particles having electron-opaque cores attached to electron-lucent zones in intermediate-density and low-density lipoproteins. Low-density lipoprotein particle diameters were distributed bimodally.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Despite a profound effect on lipoprotein metabolism, detailed neurocognitive and retinal studies failed to demonstrate any defects. This suggests that functions of apoE in the brain and eye are not essential or that redundant mechanisms exist whereby its role can be fulfilled. Targeted knockdown of apoE in the central nervous system might be a therapeutic modality in neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Angel C Y</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullinger</LastName><ForeName>Clive R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Ling Fung</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Jinny S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deo</LastName><ForeName>Rahul C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Touro University California, Vallejo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gugliucci</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Touro University California, Vallejo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Movsesyan</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Brian Y</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Boston Heart Diagnostics, Framingham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Darin M. Camarena Health Centers, Madera, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stock</LastName><ForeName>Eveline O</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Ernst J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Boston Heart Diagnostics, Framingham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asztalos</LastName><ForeName>Bela F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Boston Heart Diagnostics, Framingham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California7Center for Tissue Regeneration, Repair, and Restoration, VA Palo Alto Health Care System, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Jacque L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Pui-Yan</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malloy</LastName><ForeName>Mary J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR007175</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715087">ABCC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001054">Apolipoproteins A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001056">Apolipoproteins C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053442">High-Density Lipoproteins, Pre-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C504173">LIPC protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008079">Lipoproteins, VLDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089762">Multidrug Resistance-Associated Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027425">Multidrug Resistance-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.3</RegistryNumber><NameOfSubstance UI="D008049">Lipase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Oct;71(10):1213-5. doi: 10.1001/jamaneurol.2014.2013.</RefSource><PMID Version="1">25110920</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Dec;71(12):1578-9. doi: 10.1001/jamaneurol.2014.3342.</RefSource><PMID Version="1">25486210</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Dec;71(12):1579. doi: 10.1001/jamaneurol.2014.3345.</RefSource><PMID Version="1">25486213</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Apr;72(4):478. doi: 10.1001/jamaneurol.2014.4702.</RefSource><PMID Version="1">25867727</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Apr;72(4):479. doi: 10.1001/jamaneurol.2014.4699.</RefSource><PMID Version="1">25867729</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001054" MajorTopicYN="N">Apolipoproteins A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001056" MajorTopicYN="N">Apolipoproteins C</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002340" MajorTopicYN="N">Carotid Artery Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016368" MajorTopicYN="N">Frameshift Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053442" MajorTopicYN="N">High-Density Lipoproteins, Pre-beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006952" MajorTopicYN="N">Hyperlipoproteinemia Type III</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008049" MajorTopicYN="N">Lipase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008079" MajorTopicYN="N">Lipoproteins, VLDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089762" MajorTopicYN="N">Multidrug Resistance-Associated Protein 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027425" MajorTopicYN="N">Multidrug Resistance-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014973" MajorTopicYN="N">Xanthomatosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25111166</ArticleId><ArticleId IdType="mid">NIHMS732182</ArticleId><ArticleId IdType="pmc">PMC4714860</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.2011</ArticleId><ArticleId IdType="pii">1893443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoproteinmetabolism. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2007. [December 11, 2007].</Citation><ArticleIdList><ArticleId IdType="doi">10.1036/ommbid.148</ArticleId></ArticleIdList></Reference><Reference><Citation>Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J. 1987;113(2, pt 2):433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">3544759</ArticleId></ArticleIdList></Reference><Reference><Citation>de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4(3):178&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">7833947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiselli G, Schaefer EJ, Gascon P, Breser HB., Jr Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science. 1981;214(4526):1239&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">6795720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabuchi H, Itoh H, Takeda M, et al. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency. Metabolism. 1989;38(2):115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">2492364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosaka D, Teramoto T, Matsushima T, et al. Apolipoprotein E deficiencywith a depressedmRNA of normal size. Atherosclerosis. 1991;88(1):15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">1878006</ArticleId></ArticleIdList></Reference><Reference><Citation>Feussner G, Funke H, Weng W, Assmann G, Lackner KJ, Ziegler R. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/&#x2019;null&#x2019;genotype. Eur J Clin Invest. 1992;22(9):599&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">1360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohse P, Brewer HB, III, Meng MS, Skarlatos SI, LaRosa JC, Brewer HB., Jr Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J Lipid Res. 1992;33(11):1583&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361196</ArticleId></ArticleIdList></Reference><Reference><Citation>Feussner G, Dobmeyer J, Grone HJ, Lohmer S, Wohlfeil S. A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia. Am J Hum Genet. 1996;58(2):281&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914549</ArticleId><ArticleId IdType="pubmed">8571954</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet. 2010;11(1):31&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19997069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103(15):5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida BY, Bailey KR, Duncan KG, et al. Regulated expression of apolipoprotein E by human retinal pigment epithelial cells. J Lipid Res. 2004;45(2):263&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">14594998</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Handsaker B, Wysoker A, et al. 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34(9):1345&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC438705</ArticleId><ArticleId IdType="pubmed">13252080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL, Jr, Goerke J, Guo LSS, Williams MC, Havel RJ. Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique. J Lipid Res. 1980;21(8):981&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">7193233</ArticleId></ArticleIdList></Reference><Reference><Citation>Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169(3):291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">7548123</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasmawith a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33(3):369&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">1569386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotite L, Zhang L-H, Yu Z, Burlingame AL, Havel RJ. Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. J Lipid Res. 2003;44(7):1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700345</ArticleId></ArticleIdList></Reference><Reference><Citation>Leary ET, Wang T, Baker DJ, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem. 1998;44(12):2490&#x2013;2498.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunitake ST, O&#x2019;Connor P, Naya-Vigne J. Heterogeneity of high-density lipoproteins and apolipoprotein A-I as related to quantification of apolipoprotein A-I. Methods Enzymol. 1996;263:260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">8749013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman KJ. Amethod for quantitative scoring of the Farnsworth Panel D-15. Acta Ophthalmol (Copenh) 1982;60(6):907&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">6984998</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Humpel C. Identifying and validating biomarkers for Alzheimer&#x2019;s disease. Trends Biotechnol. 2011;29(1):26&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3016495</ArticleId><ArticleId IdType="pubmed">20971518</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke L, Zheng-Bradley X, Smith R, et al. 1000 Genomes Project Consortium. The 1000 Genomes Project: data management and community access. Nat Methods. 2012;9(5):459&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340611</ArticleId><ArticleId IdType="pubmed">22543379</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser R, Cogger VC, Dobbs B, et al. The liver sieve and atherosclerosis. Pathology. 2012;44(3):181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406487</ArticleId></ArticleIdList></Reference><Reference><Citation>Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron N, Kotite L, Verges M, et al. Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase. Proc Natl Acad Sci U S A. 1998;95(26):15647&#x2013;15652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28098</ArticleId><ArticleId IdType="pubmed">9861024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezdour H, Jones R, Dengremont C, Castro G, Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 1997;272(21):13570&#x2013;13575.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153204</ArticleId></ArticleIdList></Reference><Reference><Citation>Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25(10):2185&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16123324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi AA, Sampson M, Warnick R, et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56(7):1128&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763716</ArticleId><ArticleId IdType="pubmed">20511449</ArticleId></ArticleIdList></Reference><Reference><Citation>Guey LT, Pullinger CR, Ishida BY, et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol. 2011;108(3):360&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">21757044</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eck M, Herijgers N, Yates J, et al. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(11):3117&#x2013;3126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409301</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76(4):1501&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res. 2011;50(1):62&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022415</ArticleId><ArticleId IdType="pubmed">20854843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25129077</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1164</StartPage><EndPage>1170</EndPage><MedlinePgn>1164-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3782</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is characterized by progressive neuropathology and cognitive decline. We performed a cross-tissue analysis of methylomic variation in AD using samples from four independent human post-mortem brain cohorts. We identified a differentially methylated region in the ankyrin 1 (ANK1) gene that was associated with neuropathology in the entorhinal cortex, a primary site of AD manifestation. This region was confirmed as being substantially hypermethylated in two other cortical regions (superior temporal gyrus and prefrontal cortex), but not in the cerebellum, a region largely protected from neurodegeneration in AD, or whole blood obtained pre-mortem from the same individuals. Neuropathology-associated ANK1 hypermethylation was subsequently confirmed in cortical samples from three independent brain cohorts. This study represents, to the best of our knowledge, the first epigenome-wide association study of AD employing a sequential replication design across multiple tissues and highlights the power of this approach for identifying methylomic variation associated with complex disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lunnon</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannon</LastName><ForeName>Eilis</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Program in Medical and Population Genetics, Broad Institute, Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Gyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Program in Medical and Population Genetics, Broad Institute, Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volta</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sarraj</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrage</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Ruby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condliffe</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harries</LastName><ForeName>Lorna W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsel</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, USA. [2] Department of Neuroscience, The Icahn School of Medicine at Mount Sinai, New York, USA. [3] JJ Peters Virginia Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminsky</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. [2] Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joachim</LastName><ForeName>Catharine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Institute of Psychiatry, King's College London, London, UK. [2] Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schalkwyk</LastName><ForeName>Leonard C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>1] Institute of Psychiatry, King's College London, London, UK. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mill</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] University of Exeter Medical School, Exeter University, Exeter, UK. [2] Institute of Psychiatry, King's College London, London, UK. [3].</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH064673</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100695</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017155</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH064673</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024151</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L022656/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110202">ANK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017487">Ankyrins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2014 Sep;17(9):1138-40. doi: 10.1038/nn.3792.</RefSource><PMID Version="1">25157507</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Oct;10(10):548. doi: 10.1038/nrneurol.2014.164.</RefSource><PMID Version="1">25179259</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017487" MajorTopicYN="N">Ankyrins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25129077</ArticleId><ArticleId IdType="mid">NIHMS613258</ArticleId><ArticleId IdType="pmc">PMC4410018</ArticleId><ArticleId IdType="doi">10.1038/nn.3782</ArticleId><ArticleId IdType="pii">nn.3782</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3:186&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp M, Prince M, Dementia UK. The Full report. Alzheimer&#x2019;s Society. 2007</Citation></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk GL. Neuropathologic changes in Alzheimer&#x2019;s disease. J Clin Psychiatry. 2003;64 (Suppl 9):7&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12934968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Encode Project Consortium et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunnon K, Mill J. Epigenetic studies in Alzheimer&#x2019;s disease: current findings, caveats, and considerations for future studies. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:789&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947441</ArticleId><ArticleId IdType="pubmed">24038819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill J, Heijmans BT. From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet. 2013;14:585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23817309</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy TM, Mill J. Epigenetics in health and disease: heralding the EWAS era. Lancet. 2014;383:1952&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">24630775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pidsley R, et al. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics. 2013;14:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3769145</ArticleId><ArticleId IdType="pubmed">23631413</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordeli E, Bennett V. Distinct ankyrin isoforms at neuron cell bodies and nodes of Ranvier resolved using erythrocyte ankyrin-deficient mice. J Cell Biol. 1991;114:1243&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289136</ArticleId><ArticleId IdType="pubmed">1832678</ArticleId></ArticleIdList></Reference><Reference><Citation>Boiko T, et al. Ankyrin-dependent and -independent mechanisms orchestrate axonal compartmentalization of L1 family members neurofascin and L1/neuron-glia cell adhesion molecule. J Neurosci. 2007;27:590&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672792</ArticleId><ArticleId IdType="pubmed">17234591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SB, Janiesch C, Sander M. Expression of Nkx6 genes in the hindbrain and gut of the developing mouse. J Histochem Cytochem. 2005;53:787&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928328</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanentalo T, et al. Cloning and analysis of Nkx6.3 during CNS and gastrointestinal development. Gene Expr Patterns. 2006;6:162&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16326147</ArticleId></ArticleIdList></Reference><Reference><Citation>Guintivano J, Aryee M, Kaminsky Z. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669121</ArticleId><ArticleId IdType="pubmed">23426267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values. Bioinformatics. 2012;28:2986&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496335</ArticleId><ArticleId IdType="pubmed">22954632</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55:1185&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM. Brain banks: the Oxford experience. J Neural Transm Suppl. 1993;39:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103076</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, et al. Alzheimer&#x2019;s disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1 and other loci. Nat Neurosci. 2014 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="pubmed">25129075</ArticleId></ArticleIdList></Reference><Reference><Citation>Soranzo N, et al. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59:3229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992787</ArticleId><ArticleId IdType="pubmed">20858683</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura M, et al. A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations. Hum Mol Genet. 2012;21:3042&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456796</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder MN, et al. Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased beta-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish Inter99 cohort. J Clin Endocrinol Metab. 2013;98:E801&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23457408</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10:819&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S. Searching for biomarkers in neurodegeneration. Nat Med. 2010;16:1371&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">21135840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Lovestone S, Sainz-Fuertes R. Alzheimer&#x2019;s Disease, Diagnosis and the Need for Biomarkers. Biomark Insights. 2008;3:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688363</ArticleId><ArticleId IdType="pubmed">19578515</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehlbaum-Beurdeley P, et al. Toward an Alzheimer&#x2019;s disease diagnosis via high-resolution blood gene expression. Alzheimers Dement. 2010;6:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">20129318</ArticleId></ArticleIdList></Reference><Reference><Citation>Rye PD, et al. A novel blood test for the early detection of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;23:121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930265</ArticleId></ArticleIdList></Reference><Reference><Citation>Booij BB, et al. A gene expression pattern in blood for the early detection of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;23:109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunnon K, et al. A blood gene expression marker of early Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;33:737&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">23042217</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehlbaum-Beurdeley P, et al. Validation of AclarusDx, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer&#x2019;s Disease. J Alzheimers Dis. 2012;32:169&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">22785402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZC, et al. Association of DAPK1 genetic variations with Alzheimer&#x2019;s disease in Han Chinese. Brain Res. 2011;1374:129&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21167819</ArticleId></ArticleIdList></Reference><Reference><Citation>Laumet G, et al. Systematic analysis of candidate genes for Alzheimer&#x2019;s disease in a French, genome-wide association study. J Alzheimers Dis. 2010;20:1181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20413850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Vingtdeux V, Campagne F, Davies P, Marambaud P. Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet. 2011;20:2026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279048</ArticleId><ArticleId IdType="pubmed">21357679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunnon K, et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer&#x2019;s disease blood. J Alzheimers Dis. 2012;30:685&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">22466004</ArticleId></ArticleIdList></Reference><Reference><Citation>Meaburn EL, Schalkwyk LC, Mill J. Allele-specific methylation in the human genome: implications for genetic studies of complex disease. Epigenetics. 2010;5:578&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052843</ArticleId><ArticleId IdType="pubmed">20716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res. 2010;20:883&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892089</ArticleId><ArticleId IdType="pubmed">20418490</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MN, et al. Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol. 2012;13:R43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446315</ArticleId><ArticleId IdType="pubmed">22703893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempster EL, et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011;20:4786&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221539</ArticleId><ArticleId IdType="pubmed">21908516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CC, et al. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Mol Psychiatry. 2014;19:495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906213</ArticleId><ArticleId IdType="pubmed">23608919</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2012.</Citation></Reference><Reference><Citation>Gentleman RC, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Du P, Bilke S, Triche J, Bootwalla M. Methylumi: Handle Illumina Methylation Data. R package version 2.10.0. 2014</Citation></Reference><Reference><Citation>Chen YA, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8:203&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592906</ArticleId><ArticleId IdType="pubmed">23314698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25129075</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci.</ArticleTitle><Pagination><StartPage>1156</StartPage><EndPage>1163</EndPage><MedlinePgn>1156-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3786</ELocationID><Abstract><AbstractText>We used a collection of 708 prospectively collected autopsied brains to assess the methylation state of the brain's DNA in relation to Alzheimer's disease (AD). We found that the level of methylation at 71 of the 415,848 interrogated CpGs was significantly associated with the burden of AD pathology, including CpGs in the ABCA7 and BIN1 regions, which harbor known AD susceptibility variants. We validated 11 of the differentially methylated regions in an independent set of 117 subjects. Furthermore, we functionally validated these CpG associations and identified the nearby genes whose RNA expression was altered in AD: ANK1, CDH23, DIP2A, RHBDF2, RPL13, SERPINF1 and SERPINF2. Our analyses suggest that these DNA methylation changes may have a role in the onset of AD given that we observed them in presymptomatic subjects and that six of the validated genes connect to a known AD susceptibility gene network.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Gyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunnon</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] University of Exeter Medical School, University of Exeter, Exeter, UK. [2] Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. [2] Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schalkwyk</LastName><ForeName>Leonard C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000000170305756</Identifier><AffiliationInfo><Affiliation>1] University of Exeter Medical School, University of Exeter, Exeter, UK. [2] Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>1] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. [2] Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keenan</LastName><ForeName>Brendan T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. [2] Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCabe</LastName><ForeName>Cristin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Replogle</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodeur</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Genetic Analysis Platform, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetic Analysis Platform, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>High S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. [2] Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Curtis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Fanggeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szyf</LastName><ForeName>Moshe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Epigenomics Program, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Bradley E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>1] Harvard Medical School, Boston, Massachusetts, USA. [2] Epigenomics Program, Broad Institute, Cambridge, Massachusetts, USA. [3] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. [2] Epigenomics Program, Broad Institute, Cambridge, Massachusetts, USA. [3] Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. [2] Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>1] Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. [2] Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mill</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] University of Exeter Medical School, University of Exeter, Exeter, UK. [2] Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG004037</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG036039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017155</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024151</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110202">ANK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017487">Ankyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580845">RHBDF2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2014 Sep;17(9):1138-40. doi: 10.1038/nn.3792.</RefSource><PMID Version="1">25157507</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Oct;10(10):548. doi: 10.1038/nrneurol.2014.164.</RefSource><PMID Version="1">25179259</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017487" MajorTopicYN="N">Ankyrins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018899" MajorTopicYN="N">CpG Islands</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25129075</ArticleId><ArticleId IdType="mid">NIHMS614693</ArticleId><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="doi">10.1038/nn.3786</ArticleId><ArticleId IdType="pii">nn.3786</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One. 2008;3:e2698. doi:10.1371/journal.pone.0002698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444024</ArticleId><ArticleId IdType="pubmed">18628954</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg AP, et al. Personalized epigenomic signatures that are stable over time and covary with body mass index. Science translational medicine 2. 2010:49ra67. doi:10.1126/scitranslmed.3001262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137242</ArticleId><ArticleId IdType="pubmed">20844285</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nature biotechnology. 2013;31:142&#x2013;147. doi:10.1038/nbt.2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598632</ArticleId><ArticleId IdType="pubmed">23334450</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends in neurosciences. 2009;32:591&#x2013;601. doi:10.1016/j.tins.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771446</ArticleId><ArticleId IdType="pubmed">19775759</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff J, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483:222&#x2013;226. doi:10.1038/nature10849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498952</ArticleId><ArticleId IdType="pubmed">22388814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouliaras L, et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging. 2013 doi:10.1016/j.neurobiolaging.2013.02.021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955118</ArticleId><ArticleId IdType="pubmed">23582657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakulski KM, et al. Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. Journal of Alzheimer's disease : JAD. 2012;29:571&#x2013;588. doi:10.3233/JAD-2012-111223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652332</ArticleId><ArticleId IdType="pubmed">22451312</ArticleId></ArticleIdList></Reference><Reference><Citation>Numata S, et al. DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet. 2012;90:260&#x2013;272. doi:10.1016/j.ajhg.2011.12.020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276664</ArticleId><ArticleId IdType="pubmed">22305529</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S, Beeri MS, Haroutunian V. Epigenetic Determinants of Healthy and Diseased Brain Aging and Cognition. JAMA neurology. 2013:1&#x2013;8. doi:10.1001/jamaneurol.2013.1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932340</ArticleId><ArticleId IdType="pubmed">23571692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez DG, et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet. 2011;20:1164&#x2013;1172. doi:10.1093/hmg/ddq561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043665</ArticleId><ArticleId IdType="pubmed">21216877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell JT, et al. Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet. 2012;8:e1002629. doi:10.1371/journal.pgen.1002629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330116</ArticleId><ArticleId IdType="pubmed">22532803</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome biology. 2012;13:R97. doi:10.1186/gb-2012-13-10-r97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053733</ArticleId><ArticleId IdType="pubmed">23034122</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am J Hum Genet. 2012;90:720&#x2013;726. doi:10.1016/j.ajhg.2012.02.022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322230</ArticleId><ArticleId IdType="pubmed">22482808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Selected findings from the Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer's disease : JAD. 2013;33(Suppl 1):S397&#x2013;403. doi:10.3233/JAD-2012-129007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434299</ArticleId><ArticleId IdType="pubmed">22647261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock C, et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nature biotechnology. 2010;28:1106&#x2013;1114. doi:10.1038/nbt.1681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066564</ArticleId><ArticleId IdType="pubmed">20852634</ArticleId></ArticleIdList></Reference><Reference><Citation>Negash S, Bennett DA, Wilson RS, Schneider JA, Arnold SE. Cognition and neuropathology in aging: multidimensional perspectives from the Rush Religious Orders Study and Rush Memory And Aging Project. Current Alzheimer research. 2011;8:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157574</ArticleId><ArticleId IdType="pubmed">21222592</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72:599&#x2013;609. doi:10.1002/ana.23654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibnik LB, et al. CR1 is associated with amyloid plaque burden and age2 related cognitive decline. Ann Neurol. 2011;69:560&#x2013;569. doi:10.1002/ana.22277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066288</ArticleId><ArticleId IdType="pubmed">21391232</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 43:436&#x2013;441. doi:ng.801 [pii] 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840. doi:10.1001/jama.2010.574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435. doi:10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099. doi:10.1038/ng.439.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, et al. Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA neurology. 2013;70:1150&#x2013;1157. doi:10.1001/jamaneurol.2013.2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773291</ArticleId><ArticleId IdType="pubmed">23836404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunnon K, Smith R, hannon E, De Jager P, Srivastava G, Volta M, Troakes C, Al-Sarraj S, Burrage J, MacDonald R, Condliffe D, Harries LW, Katsel P, Haroutunian V, Kaminsky Z, Joachim C, Powell J, Lovestone S, Bennett DA, Schalkwyk, Mill J. Cross-tissue methylomic profiling strongly implicates a role for cortex-specific deregulation of ANK1 in Alzheimer's disease neuropathology. Nature neuroscience. 2014 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410018</ArticleId><ArticleId IdType="pubmed">25129077</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200&#x2013;208. doi:10.1002/ana.21706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; dementia : the journal of the Alzheimer's Association. 2011;7:280&#x2013;292. doi:10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nature biotechnology. 2010;28:817&#x2013;825. doi:10.1038/nbt.1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919626</ArticleId><ArticleId IdType="pubmed">20657582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Molecular psychiatry. 2013 doi:10.1038/mp.2013.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807661</ArticleId><ArticleId IdType="pubmed">23399914</ArticleId></ArticleIdList></Reference><Reference><Citation>European Alzheimer's Disease I, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2013;1458. doi:10.1038/ng.2802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, et al. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-beta superfamily proteins. The FEBS journal. 2010;277:4278&#x2013;4289. doi:10.1111/j.1742-4658.2010.07816.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">20860622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature. 2014;505:550&#x2013;554. doi:10.1038/nature12825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Roet KC, et al. A multilevel screening strategy defines a molecular fingerprint of proregenerative olfactory ensheathing cells and identifies SCARB2, a protein that improves regenerative sprouting of injured sensory spinal axons. J Neurosci. 2013;33:11116&#x2013;11135. doi:10.1523/JNEUROSCI.1002-13.2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618611</ArticleId><ArticleId IdType="pubmed">23825416</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335:225&#x2013;228. doi:10.1126/science.1214400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272371</ArticleId><ArticleId IdType="pubmed">22246777</ArticleId></ArticleIdList></Reference><Reference><Citation>Siggs OM, et al. iRhom2 is required for the secretion of mouse TNFalpha. Blood. 2012;119:5769&#x2013;5771. doi:10.1182/blood-2012-03-417949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382936</ArticleId><ArticleId IdType="pubmed">22550345</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlwain DR, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335:229&#x2013;232. doi:10.1126/science.1214448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250273</ArticleId><ArticleId IdType="pubmed">22246778</ArticleId></ArticleIdList></Reference><Reference><Citation>Maretzky T, et al. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc Natl Acad Sci U S A. 2013;110:11433&#x2013;11438. doi:10.1073/pnas.1302553110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710827</ArticleId><ArticleId IdType="pubmed">23801765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Gene expression profiling in human neurodegenerative disease. Nature reviews. Neurology. 2012;8:518&#x2013;530. doi:10.1038/nrneurol.2012.156.</Citation><ArticleIdList><ArticleId IdType="pubmed">22890216</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JE, et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer's pathology and APOE genotype. Neurobiol Aging. 2011;32:1795&#x2013;1807. doi:10.1016/j.neurobiolaging.2011.04.013.</Citation><ArticleIdList><ArticleId IdType="pubmed">21705112</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnertz C, et al. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One. 2009;4:e7480. doi:10.1371/journal.pone.0007480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759540</ArticleId><ArticleId IdType="pubmed">19834617</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner NA, et al. Transient acidification and subsequent proinflammatory cytokine stimulation of astrocytes induce distinct activation phenotypes. Journal of cellular physiology. 2013;228:1284&#x2013;1294. doi:10.1002/jcp.24283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582839</ArticleId><ArticleId IdType="pubmed">23154943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft AW, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013;27:187&#x2013;198. doi:10.1096/fj.12-208660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528309</ArticleId><ArticleId IdType="pubmed">23038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the rush Memory and Aging Project. Current Alzheimer research. 2012;9:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Current Alzheimer research. 2012;9:628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, et al. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012;79:221&#x2013;228. doi:10.1212/WNL.0b013e3182605801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398432</ArticleId><ArticleId IdType="pubmed">22722634</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8:e1002707. doi:10.1371/journal.pgen.1002707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369937</ArticleId><ArticleId IdType="pubmed">22685416</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24:1547&#x2013;1548. doi:10.1093/bioinformatics/btn224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18467348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic acids research. 2008;36:e11. doi:10.1093/nar/gkm1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2241869</ArticleId><ArticleId IdType="pubmed">18178591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844. doi:10.1212/01.wnl.0000219668.47116.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YA, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics : official journal of the DNA Methylation Society. 2013;8:203&#x2013;209. doi:10.4161/epi.23470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592906</ArticleId><ArticleId IdType="pubmed">23314698</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118&#x2013;127. doi:10.1093/biostatistics/kxj037.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Heaton C, Ripley BD. fastICA: FastICA algorithms perform ICA and projection pursuit. R package. 2007</Citation></Reference><Reference><Citation>Du P, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC bioinformatics. 2010;11:587. doi:10.1186/1471-2105-11-587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012676</ArticleId><ArticleId IdType="pubmed">21118553</ArticleId></ArticleIdList></Reference><Reference><Citation>Guintivano J, Aryee MJ, Kaminsky ZA. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics : official journal of the DNA Methylation Society. 2013;8:290&#x2013;302. doi:10.4161/epi.23924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669121</ArticleId><ArticleId IdType="pubmed">23426267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock C. Analysing and interpreting DNA methylation data. Nature reviews. Genetics. 2012;13:705&#x2013;719. doi:10.1038/nrg3273.</Citation><ArticleIdList><ArticleId IdType="pubmed">22986265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford CA, et al. Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell. 2013;153:1149&#x2013;1163. doi:10.1016/j.cell.2013.04.037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709577</ArticleId><ArticleId IdType="pubmed">23664763</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y, Li W. BSMAP: whole genome bisulfite sequence MAPping program. BMC bioinformatics. 2009;10:232. doi:10.1186/1471-2105-10-232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724425</ArticleId><ArticleId IdType="pubmed">19635165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziller MJ, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013;500:477&#x2013;481. doi:10.1038/nature12433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821869</ArticleId><ArticleId IdType="pubmed">23925113</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell. 2013;152:642&#x2013;654. doi:10.1016/j.cell.2012.12.033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563935</ArticleId><ArticleId IdType="pubmed">23333102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nature methods. 2012;9:215&#x2013;216. doi:10.1038/nmeth.1906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577932</ArticleId><ArticleId IdType="pubmed">22373907</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossin EJ, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS genetics. 2011;7:e1001273. doi:10.1371/journal.pgen.1001273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020935</ArticleId><ArticleId IdType="pubmed">21249183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage K, et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nature biotechnology. 2007;25:309&#x2013;316. doi:10.1038/nbt1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">17344885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25147279</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>346</Volume><Issue>6205</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>93</EndPage><MedlinePgn>89-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1252945</ELocationID><Abstract><AbstractText>Aging-associated cognitive decline is affected by factors produced inside and outside the brain. By using multiorgan genome-wide analysis of aged mice, we found that the choroid plexus, an interface between the brain and the circulation, shows a type I interferon (IFN-I)-dependent gene expression profile that was also found in aged human brains. In aged mice, this response was induced by brain-derived signals, present in the cerebrospinal fluid. Blocking IFN-I signaling within the aged brain partially restored cognitive function and hippocampal neurogenesis and reestablished IFN-II-dependent choroid plexus activity, which is lost in aging. Our data identify a chronic aging-induced IFN-I signature, often associated with antiviral response, at the brain's choroid plexus and demonstrate its negative influence on brain function, thereby suggesting a target for ameliorating cognitive decline in aging.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baruch</LastName><ForeName>Kuti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deczkowska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Omer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kertser</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkutzki</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett-Itzhaki</LastName><ForeName>Zohar</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezalel</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amit</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel. michal.schwartz@weizmann.ac.il ido.amit@weizmann.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel. michal.schwartz@weizmann.ac.il ido.amit@weizmann.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L022656/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017471">Receptors, Interferon</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2014 Oct 3;346(6205):36-7. doi: 10.1126/science.1260705.</RefSource><PMID Version="1">25278599</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="N">Choroid Plexus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050835" MajorTopicYN="N">Interferon Regulatory Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017471" MajorTopicYN="N">Receptors, Interferon</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000096743" MajorTopicYN="N">Interferon gamma Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25147279</ArticleId><ArticleId IdType="mid">NIHMS784957</ArticleId><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="doi">10.1126/science.1252945</ArticleId><ArticleId IdType="pii">science.1252945</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stranahan AM, Mattson MP. Nat Rev Neurosci. 2012;13:209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084510</ArticleId><ArticleId IdType="pubmed">22251954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoman M, Scutt G, Faragher R. Nat Rev Neurosci. 2012;13:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">22595787</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. Nature. 2011;477:90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. Nat Med. 2014;20:659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L, et al. Science. 2014;344:630&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Proc Natl Acad Sci U S A. 2013;110:2264&#x2013;2269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568380</ArticleId><ArticleId IdType="pubmed">23335631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. Nat Rev Immunol. 2012;12:623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Schwartz M. Brain Behav Immun. 2013;34:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23597431</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. EMBO J. 2013</Citation></Reference><Reference><Citation>Kunis G, et al. Brain. 2013;136:3427&#x2013;3440.</Citation><ArticleIdList><ArticleId IdType="pubmed">24088808</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcao AM, et al. Front Cell Neurosci. 2012;6:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414909</ArticleId><ArticleId IdType="pubmed">22907990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Navajas JM, Lee J, David M, Raz E. Nat Rev Immunol. 2012;12:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727154</ArticleId><ArticleId IdType="pubmed">22222875</ArticleId></ArticleIdList></Reference><Reference><Citation>Johanson C, et al. Toxicol Pathol. 2011;39:186&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">21189316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Neuron. 2009;64:110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo SJ, et al. Science. 2002;295:338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson EB, et al. Science. 2013;340:202&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704950</ArticleId><ArticleId IdType="pubmed">23580528</ArticleId></ArticleIdList></Reference><Reference><Citation>Teles RM, et al. Science. 2013;339:1448&#x2013;1453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653587</ArticleId><ArticleId IdType="pubmed">23449998</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro JR, et al. Science. 2013;340:207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640797</ArticleId><ArticleId IdType="pubmed">23580529</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerich DF, et al. Bioessays. 2005;27:262&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15714561</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Aimone JB, Gage FH. Nat Rev Neurosci. 2010;11:339&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886712</ArticleId><ArticleId IdType="pubmed">20354534</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AM, Hemstedt TJ, Bading H. Nat Neurosci. 2012;15:1111&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">22751036</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, et al. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekdahl CT, et al. Proc Natl Acad Sci U S A. 2003;100:13632&#x2013;13637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263865</ArticleId><ArticleId IdType="pubmed">14581618</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtell RC, Steinman L. Immunity. 2008;28:600&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">18482563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer MJ, Campbell IL. Cytokine Growth Factor Rev. 2013;24:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">23548179</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, et al. Immunity. 2008;28:675&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">18424188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichers M, Maes M. Int J Neuropsychopharmacol. 2002;5:375&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">12466036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25157130</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>36</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.</ArticleTitle><Pagination><StartPage>E3825</StartPage><EndPage>E3830</EndPage><MedlinePgn>E3825-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1410315111</ELocationID><Abstract><AbstractText>RS67333 is a partial serotonin subtype 4 receptor (5-HT4R) agonist that has been widely studied for its procognitive effect. More recently, it has been shown that its ability to promote the nonamyloidogenic cleavage of the precursor of the neurotoxic amyloid-&#x3b2; peptide leads to the secretion of the neurotrophic protein sAPP&#x3b1;. This effect has generated great interest in RS67333 as a potential treatment for Alzheimer's disease (AD). We show herein that RS67333 is also a submicromolar acetylcholinesterase (AChE) inhibitor and therefore, could contribute, through this effect, to the restoration of the cholinergic neurotransmission that becomes altered in AD. We planned to pharmacomodulate RS67333 to enhance its AChE inhibitory activity to take advantage of this pleiotropic pharmacological profile in the design of a novel multitarget-directed ligand that is able to exert not only a symptomatic but also, a disease-modifying effect against AD. These efforts allowed us to select donecopride as a valuable dual (h)5-HT4R partial agonist (Ki = 10.4 nM; 48.3% of control agonist response)/(h)AChEI (IC50 = 16 nM) that further promotes sAPP&#x3b1; release (EC50 = 11.3 nM). Donecopride, as a druggable lead, was assessed for its in vivo procognitive effects (0.1, 0.3, 1, and 3 mg/kg) with an improvement of memory performances observed at 0.3 and 1 mg/kg on the object recognition test. On the basis of these in vitro and in vivo activities, donecopride seems to be a promising drug candidate for AD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lecoutey</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedou</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freret</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Groupe M&#xe9;moire et Plasticit&#xe9; comportementale, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannoni</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche-5203, Institut de G&#xe9;nomique Fonctionnelle, F-34000 Montpellier, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale U661, F-34000 Montpellier, France; Universit&#xe9;s de Montpellier 1 and 2, Unit&#xe9; Mixte de Recherche-5203, F-34000 Montpellier, France; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaven</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche-5203, Institut de G&#xe9;nomique Fonctionnelle, F-34000 Montpellier, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale U661, F-34000 Montpellier, France; Universit&#xe9;s de Montpellier 1 and 2, Unit&#xe9; Mixte de Recherche-5203, F-34000 Montpellier, France; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Since</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouet</LastName><ForeName>Valentine</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Groupe M&#xe9;moire et Plasticit&#xe9; comportementale, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballandonne</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvaisier</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France; Universit&#xe9; de Caen Basse-Normandie, Groupe M&#xe9;moire et Plasticit&#xe9; comportementale, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malzert Fr&#xe9;on</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mignani</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cresteil</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut de Chimie des Substances Naturelles, Centre National de la Recherche Scientifique Unit&#xe9; Propre de Recherche 2301, F-91198 Gif sur Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulouard</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Groupe M&#xe9;moire et Plasticit&#xe9; comportementale, F-14032 Caen, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claeysen</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche-5203, Institut de G&#xe9;nomique Fonctionnelle, F-34000 Montpellier, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale U661, F-34000 Montpellier, France; Universit&#xe9;s de Montpellier 1 and 2, Unit&#xe9; Mixte de Recherche-5203, F-34000 Montpellier, France; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochais</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France; christophe.rochais@unicaen.fr patrick.dallemagne@unicaen.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dallemagne</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4845-615X</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Caen Basse-Normandie, Centre d'Etudes et de Recherche sur le M&#xe9;dicament de Normandie, F-14032 Caen, France; christophe.rochais@unicaen.fr patrick.dallemagne@unicaen.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072237">ERG1 Potassium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051638">Ether-A-Go-Go Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058828">Serotonin 5-HT4 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000596879">donecopride</NameOfSubstance></Chemical><Chemical><RegistryNumber>158165-40-3</RegistryNumber><NameOfSubstance UI="D044422">Receptors, Serotonin, 5-HT4</NameOfSubstance></Chemical><Chemical><RegistryNumber>160845-95-4</RegistryNumber><NameOfSubstance UI="C107826">RS 67333</NameOfSubstance></Chemical><Chemical><RegistryNumber>1N3CZ14C5O</RegistryNumber><NameOfSubstance UI="D020112">Rhodamine 123</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072237" MajorTopicYN="N">ERG1 Potassium Channel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051638" MajorTopicYN="N">Ether-A-Go-Go Potassium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044422" MajorTopicYN="N">Receptors, Serotonin, 5-HT4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020112" MajorTopicYN="N">Rhodamine 123</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058828" MajorTopicYN="N">Serotonin 5-HT4 Receptor Agonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25157130</ArticleId><ArticleId IdType="pmc">PMC4246933</ArticleId><ArticleId IdType="doi">10.1073/pnas.1410315111</ArticleId><ArticleId IdType="pii">1410315111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD. Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol. 1995;115(8):1387&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1908873</ArticleId><ArticleId IdType="pubmed">8564196</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-L&#xe1;zaro E, et al. Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(2):317&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">22561232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas G, et al. Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PLoS ONE. 2010;5(2):e9253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821932</ArticleId><ArticleId IdType="pubmed">20169084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas G, et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007;55(5):712&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilbinger H, Wolf D. Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol. 1992;345(3):270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">1620231</ArticleId></ArticleIdList></Reference><Reference><Citation>Consolo S, Arnaboldi S, Giorgi S, Russi G, Ladinsky H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport. 1994;5(10):1230&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">7919171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Barnes NM. 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol. 1996;117(7):1475&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1909436</ArticleId><ArticleId IdType="pubmed">8730742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas G, et al. Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function. Eur J Neurosci. 2001;13(5):889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264661</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, et al. Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: Behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther. 2001;296(3):676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi C, Rodi D, Marino S, Beani L, Siniscalchi A. Dual effects of 5-HT4 receptor activation on GABA release from guinea pig hippocampal slices. Neuroreport. 2002;13(17):2177&#x2013;2180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12488792</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsetti M, Dellarole A, Ferri S, Ghi P. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn Mem. 2003;10(5):420&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218008</ArticleId><ArticleId IdType="pubmed">14557615</ArticleId></ArticleIdList></Reference><Reference><Citation>Licht CL, Knudsen GM, Sharp T. Effects of the 5-HT(4) receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neurosci Lett. 2010;476(2):58&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">20381585</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward LJ, et al. Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. Br J Pharmacol. 1996;117(1):55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1909379</ArticleId><ArticleId IdType="pubmed">8825343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotte M, Dauphin F, Freret T, Boulouard M, Levallet G. A biphasic and brain-region selective down-regulation of cyclic adenosine monophosphate concentrations supports object recognition in the rat. PLoS ONE. 2012;7(2):e32244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281138</ArticleId><ArticleId IdType="pubmed">22359674</ArticleId></ArticleIdList></Reference><Reference><Citation>Levallet G, Hotte M, Boulouard M, Dauphin F. Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat. Psychopharmacology (Berl) 2009;202(1-3):125&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">18712363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamirault L, Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology. 2001;41(7):844&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">11684148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamirault L, Guillou C, Thal C, Simon H. Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):185&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12551743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology. 1997;36(4-5):689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225295</ArticleId></ArticleIdList></Reference><Reference><Citation>Musia&#x142; A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer&#x2019;s disease treatment. Curr Med Chem. 2007;14(25):2654&#x2013;2679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17979717</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer&#x2019;s disease. Arch Pharm Res. 2013;36(4):375&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">23435942</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuede CM, Dong H, Csernansky JG. Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol. 2007;18(5-6):347&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666934</ArticleId><ArticleId IdType="pubmed">17762506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of &#x3b2;-amyloid peptides and increases neuronal survival. Exp Neurol. 2007;203(1):274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">16978609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezoualc&#x2019;h F. 5-HT4 receptor and Alzheimer&#x2019;s disease: The amyloid connection. Exp Neurol. 2007;205(2):325&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17346704</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo O, et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: Application as amyloid cascade modulators and potential therapeutic utility in Alzheimer&#x2019;s disease. J Med Chem. 2009;52(8):2214&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">19334715</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa NC, et al. Acetylcholinesterase accelerates assembly of amyloid-&#x3b2;-peptides into Alzheimer&#x2019;s fibrils: Possible role of the peripheral site of the enzyme. Neuron. 1996;16(4):881&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608006</ArticleId></ArticleIdList></Reference><Reference><Citation>Freret T, et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav Brain Res. 2012;230(1):304&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">22348892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51(3):347&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">18181565</ArticleId></ArticleIdList></Reference><Reference><Citation>Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem. 2006;49(16):4961&#x2013;4970.</Citation><ArticleIdList><ArticleId IdType="pubmed">16884308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopkova-de Oliveira Santos J, et al. Virtual screening discovery of new acetylcholinesterase inhibitors issued from CERMN chemical library. J Chem Inf Model. 2010;50(3):422&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20196555</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodney MA, et al. Identification of multiple 5-HT&#x2084; partial agonist clinical candidates for the treatment of Alzheimer&#x2019;s disease. J Med Chem. 2012;55(21):9240&#x2013;9254.</Citation><ArticleIdList><ArticleId IdType="pubmed">22974325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai S, et al. Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as &#x3c3;2 receptor ligands. J Med Chem. 2014;57(10):4239&#x2013;4251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6818095</ArticleId><ArticleId IdType="pubmed">24821398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberry TL, Mallender WD, Thomas PJ, Szegletes T. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate. Chem Biol Interact. 1999;119-120:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10421442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem. 2000;7(3):303&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">10637367</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillet M, et al. Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat Cell Biol. 2003;5(7):633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">12819788</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochet M, et al. 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci. 2013;4(1):130&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3547471</ArticleId><ArticleId IdType="pubmed">23336052</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoni P, et al. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Front Aging Neurosci. 2013;5:96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871961</ArticleId><ArticleId IdType="pubmed">24399967</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard B, Martel S, Carrupt PA. High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media. Eur J Pharm Sci. 2008;33(3):230&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18207706</ArticleId></ArticleIdList></Reference><Reference><Citation>Avdeef A, et al. PAMPA&#x2014;critical factors for better predictions of absorption. J Pharm Sci. 2007;96(11):2893&#x2013;2909.</Citation><ArticleIdList><ArticleId IdType="pubmed">17803196</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser PC, et al. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther. 2002;302(2):731&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130738</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, et al. An antidepressant decreases CSF A&#x3b2; production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4269372</ArticleId><ArticleId IdType="pubmed">24828079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Serotonin signaling is associated with lower amyloid-&#x3b2; levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108(36):14968&#x2013;14973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="pubmed">21873225</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SW, et al. Genetic modulation of soluble A&#x3b2; rescues cognitive and synaptic impairment in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2014;34(23):7871&#x2013;7885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996;271(8):4188&#x2013;4194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626761</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosini M, Simoni E, Minarini A, Melchiorre C. Multi-target design strategies in the context of Alzheimer&#x2019;s disease: Acetyl-cholinesterase inhibition and NMDA receptor antagonism as the diving forces. Neurochem Res. 2014 doi: 10.1007/s11064-014-1250-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-014-1250-1</ArticleId><ArticleId IdType="pubmed">24493627</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Alzheimer&#x2019;s disease: Strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellman GL, Courtney KD, Andres V, Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">13726518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25155658</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography.</ArticleTitle><Pagination><StartPage>1282</StartPage><EndPage>1289</EndPage><MedlinePgn>1282-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1358</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine clinical practice can reliably predict cortical &#x3b2;-amyloid (A&#x3b2;) deposition.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To study whether CSF biomarkers, analyzed consecutively in routine clinical practice during 2 years, can predict cortical A&#x3b2; deposition and to establish a threshold for A&#x3b2;42 abnormality.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This cross-sectional study (The Swedish BioFINDER [Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably] Study) was conducted at 3 memory clinics. It involved consecutively referred, nondemented patients with mild cognitive symptoms (original cohort, n&#x2009;=&#x2009;118; validation cohort, n&#x2009;=&#x2009;38).</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Amyloid positron emission tomography imaging with 18F-flutemetamol.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Analyses of CSF A&#x3b2;42, total tau, and phosphorylated tau using an enzyme-linked immunosorbent assay (INNOTEST) in clinical samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The agreement between A&#x3b2; classification with CSF A&#x3b2;42 and 18F-flutemetamol positron emission tomography was very high (&#x3ba;&#x2009;=&#x2009;0.85). Of all the cases, 92% were classified identically using an A&#x3b2;42 cutoff of 647 pg/mL or less. Cerebrospinal fluid A&#x3b2;42 predicted abnormal cortical A&#x3b2; deposition accurately (odds ratio, 165; 95% CI, 39-693; area under the receiver operating characteristic curve, 0.94; 95% CI, 0.88-0.97). The association was independent of age, sex, APOE (apolipoprotein E) genotype, hippocampal volume, memory, and global cognition (adjusted odds ratio, 169; 95% CI, 25-1143). Using ratios of CSF A&#x3b2;42:tau or A&#x3b2;42:phosphorylated tau did not improve the prediction of A&#x3b2; deposition. Cerebrospinal fluid A&#x3b2;42 correlated significantly with A&#x3b2; deposition in all cortical regions. The highest correlations were in regions with high 18F-flutemetamol retention (eg, posterior cingulum and precuneus, r&#x2009;=&#x2009;-0.72). 18F-flutemetamol retention, but not CSF A&#x3b2;42, correlated significantly with global cognition (r&#x2009;=&#x2009;-0.32), memory function (r&#x2009;=&#x2009;-0.28), and hippocampal volume (r&#x2009;=&#x2009;-0.36) among those with abnormal A&#x3b2; deposition. Finally, the CSF A&#x3b2;42 cutoff derived from the original cohort (&#x2264;647 pg/mL) had an equally high agreement (95%; &#x3ba;&#x2009;=&#x2009;0.89) with 18F-flutemetamol positron emission tomography in the validation cohort.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Cerebrospinal fluid A&#x3b2;42 analyzed consecutively in routine clinical practice at an accredited laboratory can be used with high accuracy to determine whether a patient has normal or increased cortical A&#x3b2; deposition and so can be valuable for the early diagnosis of Alzheimer disease. Abnormal 18F-flutemetamol retention levels correlate with disease stage in patients with mild cognitive symptoms, but this is not the case for CSF A&#x3b2;42 measurements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden2Department of Neurology, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vestberg</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Geriatric Psychiatry Unit, Department of Clinical Sciences, Lund University, Lund, Sweden5Department of Psychology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Imperial College London, London, England7Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owenius</LastName><ForeName>Rikard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GE Healthcare, Life Sciences, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;gerstr&#xf6;m</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wollmer</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Physiology and Nuclear Medicine Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100810</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120036861</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0F3M7032P5</RegistryNumber><NameOfSubstance UI="C581552">flutemetamol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pii">1897095</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25176146</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-7420</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell metabolism</Title><ISOAbbreviation>Cell Metab</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; peptide induces mitochondrial dysfunction by inhibition of preprotein maturation.</ArticleTitle><Pagination><StartPage>662</StartPage><EndPage>669</EndPage><MedlinePgn>662-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2014.07.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1550-4131(14)00332-5</ELocationID><Abstract><AbstractText>Most mitochondrial proteins possess N-terminal presequences that are required for targeting and import into the organelle. Upon import, presequences are cleaved off by matrix processing peptidases and subsequently degraded by the peptidasome Cym1/PreP, which also degrades Amyloid-beta peptides (A&#x3b2;). Here we find that impaired turnover of presequence peptides results in feedback inhibition of presequence processing enzymes. Moreover, A&#x3b2; inhibits degradation of presequence peptides by PreP, resulting in accumulation of mitochondrial preproteins and processing intermediates. Dysfunctional preprotein maturation leads to rapid protein degradation and an imbalanced organellar proteome. Our findings reveal a general mechanism by which A&#x3b2; peptide can induce the multiple diverse mitochondrial dysfunctions accompanying Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mossmann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany; Trinationales Graduiertenkolleg 1478, University of Freiburg, 79104 Freiburg, Germany; Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xf6;gtle</LastName><ForeName>F-Nora</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taskin</LastName><ForeName>Asli Aras</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany; Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany; Spemann Graduate School of Biology and Medicine, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Pedro Filipe</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Stockholm University, 10691 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ring</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkhart</LastName><ForeName>Julia M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burger</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinho</LastName><ForeName>Catarina Moreira</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Stockholm University, 10691 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loreth</LastName><ForeName>Desiree</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroanatomy, University of Freiburg, 79104 Freiburg, Germany; Neurocenter, Department of Neurology, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center, Karolinska Institutet, 14186 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., pRED Pharma Research &amp; Early Development, DTA Neuroscience, 4070 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sickmann</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany; Medinzinisches Proteom Center, 44801 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kretz</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neuroanatomy, University of Freiburg, 79104 Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiedemann</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahedi</LastName><ForeName>Ren&#xe9; P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madeo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaser</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Stockholm University, 10691 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisinger</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Biochemie und Molekularbiologie, ZBMZ, University of Freiburg, 79104 Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany. Electronic address: chris.meisinger@biochemie.uni-freiburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I 1000</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P 23490</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P 24381</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Metab</MedlineTA><NlmUniqueID>101233170</NlmUniqueID><ISSNLinking>1550-4131</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090063">Proto-Oncogene Mas</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C431683">superoxide dismutase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.21.25</RegistryNumber><NameOfSubstance UI="C514899">PREP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C501750">CYM1 protein, S cerevisiae</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045726" MajorTopicYN="N">Metalloproteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090063" MajorTopicYN="N">Proto-Oncogene Mas</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029701" MajorTopicYN="N">Saccharomyces cerevisiae Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25176146</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2014.07.024</ArticleId><ArticleId IdType="pii">S1550-4131(14)00332-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25162367</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.</ArticleTitle><Pagination><StartPage>1183</StartPage><EndPage>1191</EndPage><MedlinePgn>1183-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2014.1060</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Several studies suggest that the apolipoprotein E (APOE) &#x3b5;4 allele modulates cerebrospinal fluid (CSF) levels of &#x3b2;-amyloid 42 (A&#x3b2;42). Whether this effect is secondary to the association of the APOE &#x3b5;4 allele with cortical A&#x3b2; deposition or whether APOE &#x3b5;4 directly influences CSF levels of A&#x3b2;42 independently of A&#x3b2; pathology remains unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate whether the APOE genotype affects the diagnostic accuracy of CSF biomarkers for Alzheimer disease (AD), in particular A&#x3b2;42 levels, and whether the association of APOE &#x3b5;4 with CSF biomarkers depends on cortical A&#x3b2; status.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We collected data from 4 different centers in Sweden, Finland, and Germany. Cohort A consisted of 1345 individuals aged 23 to 99 years with baseline CSF samples, including 309 with AD, 287 with prodromal AD, 399 with stable mild cognitive impairment, 99 with dementias other than AD, and 251 controls. Cohort B included 105 nondemented younger individuals (aged 20-34 years) with CSF samples available. Cohort C included 118 patients aged 60 to 80 years with mild cognitive symptoms who underwent flutemetamol F 18 ([18F]flumetamol) positron emission tomography amyloid imaging and CSF tap.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Standard care.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Cerebrospinal fluid levels of A&#x3b2;42 and total and phosphorylated tau in relation to the APOE &#x3b5;2/&#x3b5;3/&#x3b5;4 polymorphism in different diagnostic groups and in cases with or without cortical uptake of [18F]flutemetamol.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CSF levels of A&#x3b2;42 but not total and phosphorylated tau were lower in APOE &#x3b5;4 carriers compared with noncarriers irrespective of diagnostic group (cohort A). Despite this, CSF levels of A&#x3b2;42 differed between participants with AD when compared with controls and those with stable mild cognitive impairment, even when stratifying for APOE genotype (P&#x2009;&lt;&#x2009;.001 to P&#x2009;=&#x2009;.006). Multiple binary logistic regression revealed that CSF levels of A&#x3b2;42 and APOE &#x3b5;4 genotype were independent predictors of AD diagnosis. In cohort B, APOE &#x3b5;4 carrier status did not influence CSF levels of A&#x3b2;42. Moreover, when stratifying for cortical uptake of [18F]flutemetamol in cohort C, APOE &#x3b5;4 genotype did not influence CSF levels of A&#x3b2;42. This result was replicated in a cohort with individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) using carbon 11-labeled Pittsburgh Compound B scanning.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Cerebrospinal fluid levels of A&#x3b2;42 are strongly associated with the diagnosis of AD and cortical A&#x3b2; accumulation independent of APOE genotype. The clinical cutoff for CSF levels of A&#x3b2;42 should be the same for all APOE genotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lautner</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden3Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden4Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe5;lsson</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakobsson</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owenius</LastName><ForeName>Rikard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GE Healthcare, Life Sciences, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Bob</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer, Universit&#xe9; Pierre et Marie Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Halle, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Land&#xe9;n</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden9Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden3Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg and M&#xf6;lndal, Sweden10Institute of Neurology, University College of London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden3Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25162367</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2014.1060</ArticleId><ArticleId IdType="pii">1899255</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25171414</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions.</ArticleTitle><Pagination><StartPage>1159</StartPage><EndPage>1172</EndPage><MedlinePgn>1159-1172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.07.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00877-0</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD) brain, exposure of axons to A&#x3b2; causes pathogenic changes that spread retrogradely by unknown mechanisms, affecting the entire neuron. We found that locally applied A&#x3b2;1-42 initiates axonal synthesis of a defined set of proteins including the transcription factor ATF4. Inhibition of local translation and retrograde transport or knockdown of axonal Atf4 mRNA abolished A&#x3b2;-induced ATF4 transcriptional activity and cell loss. A&#x3b2;1-42 injection into the dentate gyrus (DG) of mice caused loss of forebrain neurons whose axons project to the DG. Protein synthesis and Atf4 mRNA were upregulated in these axons, and coinjection of Atf4 siRNA into the DG reduced the effects of A&#x3b2;1-42 in the forebrain. ATF4 protein and transcripts were found with greater frequency in axons in the brain of AD patients. These results reveal an active role for intra-axonal translation in neurodegeneration and identify ATF4 as a mediator for the spread of AD pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baleriola</LastName><ForeName>Jimena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Chandler A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Integrated Program in Cellular, Molecular and Biomedical Studies, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jean</LastName><ForeName>Ying Y</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troy</LastName><ForeName>Carol M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hengst</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. Electronic address: uh2112@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH096702</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS043089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS081333</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081333</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497109">ATF4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015852">Eukaryotic Initiation Factor-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>145891-90-3</RegistryNumber><NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-12-7</RegistryNumber><NameOfSubstance UI="D051742">Transcription Factor CHOP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>CNS Neurol Disord Drug Targets. 2014;13(9):1483-4. doi: 10.2174/1871527313666141110125829.</RefSource><PMID Version="1">25382233</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051701" MajorTopicYN="N">Activating Transcription Factor 4</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015852" MajorTopicYN="N">Eukaryotic Initiation Factor-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051742" MajorTopicYN="N">Transcription Factor CHOP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25171414</ArticleId><ArticleId IdType="mid">NIHMS612228</ArticleId><ArticleId IdType="pmc">PMC4149755</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.07.001</ArticleId><ArticleId IdType="pii">S0092-8674(14)00877-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol. 2008;40:14&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17466566</ArticleId></ArticleIdList></Reference><Reference><Citation>Averous J, Bruhat A, Jousse C, Carraro V, Thiel G, Fafournoux P. Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation. J Biol Chem. 2004;279:5288&#x2013;5297.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630918</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox LJ, Hengst U, Gurskaya NG, Lukyanov KA, Jaffrey SR. Intra-axonal translation and retrograde trafficking of CREB promotes neuronal survival. Nat Cell Biol. 2008;10:149&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153364</ArticleId><ArticleId IdType="pubmed">18193038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubacq C, Jamet S, Trembleau A. Evidence for developmentally regulated local translation of odorant receptor mRNAs in the axons of olfactory sensory neurons. J Neurosci. 2009;29:10184&#x2013;10190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665787</ArticleId><ArticleId IdType="pubmed">19692593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumy LF, Yeo GS, Tung YC, Zivraj KH, Willis D, Coppola G, Lam BY, Twiss JL, Holt CE, Fawcett JW. Transcriptome analysis of embryonic and adult sensory axons reveals changes in mRNA repertoire localization. RNA. 2011;17:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004069</ArticleId><ArticleId IdType="pubmed">21098654</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengst U, Cox LJ, Macosko EZ, Jaffrey SR. Functional and selective RNA interference in developing axons and growth cones. J Neurosci. 2006;26:5727&#x2013;5732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675254</ArticleId><ArticleId IdType="pubmed">16723529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengst U, Deglincerti A, Kim HJ, Jeon NL, Jaffrey SR. Axonal elongation triggered by stimulus-induced local translation of a polarity complex protein. Nat Cell Biol. 2009;11:1024&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724225</ArticleId><ArticleId IdType="pubmed">19620967</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118:53&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872491</ArticleId><ArticleId IdType="pubmed">19184068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivins KJ, Bui ET, Cotman CW. &#x3b2;-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis. 1998;5:365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10069579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji SJ, Jaffrey SR. Axonal transcription factors: novel regulators of growth cone-to-nucleus signaling. Dev Neurobiol. 2014;74:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4136532</ArticleId><ArticleId IdType="pubmed">23897628</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Gkogkas CG, Sonenberg N, Holt CE. Remote control of gene function by local translation. Cell. 2014;157:26&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988848</ArticleId><ArticleId IdType="pubmed">24679524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar AN, Sun CY, Reichard K, Gervasi NM, Pickel J, Nakazawa K, Gioio AE, Kaplan BB. Dysregulation of the axonal trafficking of nuclear-encoded mitochondrial mRNA alters neuronal mitochondrial activity and mouse behavior. Dev Neurobiol. 2014;74:333&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133933</ArticleId><ArticleId IdType="pubmed">24151253</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, Small SA. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci. 2014;17:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman R, Banker G, Steward O. Development of subcellular mRNA compartmentation in hippocampal neurons in culture. J Neurosci. 1994;14:1130&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577594</ArticleId><ArticleId IdType="pubmed">7509864</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013;9:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Leranth C, Frotscher M. Organization of the septal region in the rat brain: cholinergic-GABAergic interconnections and the termination of hippocampo-septal fibers. J Comp Neurol. 1989;289:304&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808769</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2008;28:13805&#x2013;13814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671923</ArticleId><ArticleId IdType="pubmed">19091971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, Cavener DR, Klann E. Suppression of eIF2&#x3b1; kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci. 2013;16:1299&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756900</ArticleId><ArticleId IdType="pubmed">23933749</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcyniuk B, Mann DM, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci. 1986;76:335&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">3794754</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Geschwind DH. Transcriptional Changes in Alzheimer&#x2019;s Disease. In: Choi S, editor. In Systems Biology for Signaling Networks. New York: Springer; 2010. pp. 611&#x2013;643.</Citation></Reference><Reference><Citation>Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA, et al. Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice. Sci Transl Med. 2013;5 206ra138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24107777</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlson E, Maday S, Fu MM, Moughamian AJ, Holzbaur EL. Retrograde axonal transport: pathways to cell death? Trends Neurosci. 2010;33:335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902719</ArticleId><ArticleId IdType="pubmed">20434225</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon WW, Carlos AJ, Aguilar BL, Berchtold NC, Kawano CK, Zograbyan V, Yaopruke T, Shelanski M, Cotman CW. &#x3b2;-Amyloid (A&#x3b2;) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1. J Biol Chem. 2013;288:16937&#x2013;16948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675626</ArticleId><ArticleId IdType="pubmed">23599427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rishal I, Fainzilber M. Axon-soma communication in neuronal injury. Nat Rev Neurosci. 2014;15:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24326686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ron D, Harding HP. Protein-folding homeostasis in the endoplasmic reticulum and nutritional regulation. Cold Spring Harb Perspect Biol. 2012;4:a013177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504434</ArticleId><ArticleId IdType="pubmed">23209157</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Imboywa S, Giagtzoglou N, Powers MP, Hu Y, Devenport D, Chipendo P, Chibnik LB, Diamond A, Perrimon N, et al. Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. Hum Mol Genet. 2014;23:870&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900103</ArticleId><ArticleId IdType="pubmed">24067533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife. 2013;2:e00498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667625</ArticleId><ArticleId IdType="pubmed">23741617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. &#x3b2;-amyloid1&#x2013;42 induces neuronal death through the p75 neurotrophin receptor. J Neurosci. 2008;28:3941&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670462</ArticleId><ArticleId IdType="pubmed">18400893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-&#x3b2; peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Blurton-Jones M, Rhee SW, Cribbs DH, Cotman CW, Jeon NL. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods. 2005;2:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Toepke MW, Beebe DJ. PDMS absorption of small molecules and consequences in microfluidic applications. Lab on a Chip. 2006;6:1484&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain A&#x3b2; distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Shen J, Arenzana N, Tirasophon W, Kaufman RJ, Prywes R. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem. 2000;275:27013&#x2013;27020.</Citation><ArticleIdList><ArticleId IdType="pubmed">10856300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006;34:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246168</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis DE, Xu M, Donnelly CJ, Tep C, Kendall M, Erenstheyn M, English AW, Schanen NC, Kirn-Safran CB, Yoon SO, et al. Axonal Localization of transgene mRNA in mature PNS and CNS neurons. J Neurosci. 2011;31:14481&#x2013;14487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205917</ArticleId><ArticleId IdType="pubmed">21994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon BC, Jung H, Dwivedy A, O'Hare CM, Zivraj KH, Holt CE. Local translation of extranuclear lamin B promotes axon maintenance. Cell. 2012;148:752&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314965</ArticleId><ArticleId IdType="pubmed">22341447</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12:982&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316680</ArticleId><ArticleId IdType="pubmed">9531536</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25170153</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>345</Volume><Issue>6200</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Targeted enhancement of cortical-hippocampal brain networks and associative memory.</ArticleTitle><Pagination><StartPage>1054</StartPage><EndPage>1057</EndPage><MedlinePgn>1054-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1252900</ELocationID><Abstract><AbstractText>The influential notion that the hippocampus supports associative memory by interacting with functionally distinct and distributed brain regions has not been directly tested in humans. We therefore used targeted noninvasive electromagnetic stimulation to modulate human cortical-hippocampal networks and tested effects of this manipulation on memory. Multiple-session stimulation increased functional connectivity among distributed cortical-hippocampal network regions and concomitantly improved associative memory performance. These alterations involved localized long-term plasticity because increases were highly selective to the targeted brain regions, and enhancements of connectivity and associative memory persisted for ~24 hours after stimulation. Targeted cortical-hippocampal networks can thus be enhanced noninvasively, demonstrating their role in associative memory.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jane X</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Lynn M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>The Sensory Motor Performance Program, Rehabilitation Institute of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Evan Z</ForeName><Initials>EZ</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryals</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dokucu</LastName><ForeName>Mehmet E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandstatt</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermiller</LastName><ForeName>Molly S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Joel L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Ken and Ruth Davee Department of Neurology, and Interdepartmental Neuroscience Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. joel-voss@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS083340</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH094263</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32-NS083340</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-MH094263</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001244" MajorTopicYN="Y">Association</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="Y">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25170153</ArticleId><ArticleId IdType="mid">NIHMS655169</ArticleId><ArticleId IdType="pmc">PMC4307924</ArticleId><ArticleId IdType="doi">10.1126/science.1252900</ArticleId><ArticleId IdType="pii">345/6200/1054</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eichenbaum H, Yonelinas AP, Ranganath C. The medial temporal lobe and recognition memory. Annu Rev Neurosci. 2007;30:123&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064941</ArticleId><ArticleId IdType="pubmed">17417939</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenbaum H, Cohen NJ. From conditioning to conscious recollection: Memory systems of the brain. New York City, NY: Oxford University Press; 2001.</Citation></Reference><Reference><Citation>Battaglia FP, Benchenane K, Sirota A, Pennartz CM, Wiener SI. The hippocampus: hub of brain network communication for memory. Trends Cogn Sci. 2011;15:310&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">21696996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci. 2012;13:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">22992647</ArticleId></ArticleIdList></Reference><Reference><Citation>Staresina BP, Cooper E, Henson RN. Reversible information flow across the medial temporal lobe: the hippocampus links cortical modules during memory retrieval. J Neurosci. 2013;33:14184&#x2013;14192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756762</ArticleId><ArticleId IdType="pubmed">23986252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Shannon BJ, Kahn I, Buckner RL. Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci. 2005;9:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn I, Andrews-Hanna JR, Vincent JL, Snyder AZ, Buckner RL. Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493488</ArticleId><ArticleId IdType="pubmed">18385483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavada C, Goldman-Rakic PS. Posterior parietal cortex in rhesus monkey: I. Parcellation of areas based on distinctive limbic and sensory corticocortical connections. J Comp Neurol. 1989;287:393&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">2477405</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Van Hoesen GW, Pandya DN, Geschwind N. Limbic and sensory connections of the inferior parietal lobule (area PG) in the rhesus monkey: a study with a new method for horseradish peroxidase histochemistry. Brain Res. 1977;136:393&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">411543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Halko MA, Eldaief MC, Pascual-Leone A. Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS) Neuroimage. 2012;62:2232&#x2013;2243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518426</ArticleId><ArticleId IdType="pubmed">22465297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanto TP, Rubens MT, Thangavel A, Gazzaley A. Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory. Nat Neurosci. 2011;14:656&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083493</ArticleId><ArticleId IdType="pubmed">21441920</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassermann EM, Zimmermann T. Transcranial magnetic brain stimulation: therapeutic promises and scientific gaps. Pharmacol Ther. 2012;133:98&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241868</ArticleId><ArticleId IdType="pubmed">21924290</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggleton JP. Multiple anatomical systems embedded within the primate medial temporal lobe: implications for hippocampal function. Neurosci Biobehav Rev. 2012;36:1579&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">21964564</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Reidler JS, Sepulcre J, Poulin R, Buckner RL. Functional-anatomic fractionation of the brain's default network. Neuron. 2010;65:550&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848443</ArticleId><ArticleId IdType="pubmed">20188659</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthana N, et al. Memory enhancement and deep-brain stimulation of the entorhinal area. N Engl J Med. 2012;366:502&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3447081</ArticleId><ArticleId IdType="pubmed">22316444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350458</ArticleId><ArticleId IdType="pubmed">4727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TH, Chapman PF, Kairiss EW, Keenan CL. Long-term synaptic potentiation. Science. 1988;242:724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">2903551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan E, Censor N, Buch ER, Sandrini M, Cohen LG. Noninvasive brain stimulation: from physiology to network dynamics and back. Nat Neurosci. 2013;16:838&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876726</ArticleId><ArticleId IdType="pubmed">23799477</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Salvado E, Pallares V, Moreno A, Canals S. Functional MRI of long-term potentiation: imaging network plasticity. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130&#x2013;20152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843884</ArticleId><ArticleId IdType="pubmed">24298154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shohamy D, Turk-Browne NB. Mechanisms for widespread hippocampal involvement in cognition. J Exp Psychol Gen. 2013;142:1159&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065494</ArticleId><ArticleId IdType="pubmed">24246058</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RK, Moses SN, Riggs L, Ryan JD. The hippocampus supports multiple cognitive processes through relational binding and comparison. Front Hum Neurosci. 2012;6:146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363343</ArticleId><ArticleId IdType="pubmed">22661938</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullally SL, Hassabis D, Maguire EA. Scene construction in amnesia: an FMRI study. J Neurosci. 2012;32:5646&#x2013;5653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330271</ArticleId><ArticleId IdType="pubmed">22514326</ArticleId></ArticleIdList></Reference><Reference><Citation>Finke C, Bruehl H, Duzel E, Heekeren HR, Ploner CJ. Neural correlates of short-term memory reorganization in humans with hippocampal damage. J Neurosci. 2013;33:11061&#x2013;11069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618604</ArticleId><ArticleId IdType="pubmed">23825411</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, et al. Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer's and semantic dementia-targeted networks. Neuron. 2014;81:1417&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pubmed">24656258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25164658</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>35</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Combined treatment with a BACE inhibitor and anti-A&#x3b2; antibody gantenerumab enhances amyloid reduction in APPLondon mice.</ArticleTitle><Pagination><StartPage>11621</StartPage><EndPage>11630</EndPage><MedlinePgn>11621-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1405-14.2014</ELocationID><Abstract><AbstractText>Therapeutic approaches for prevention or reduction of amyloidosis are currently a main objective in basic and clinical research on Alzheimer's disease. Among the agents explored in clinical trials are anti-A&#x3b2; peptide antibodies and secretase inhibitors. Most anti-A&#x3b2; antibodies are considered to act via inhibition of amyloidosis and enhanced clearance of existing amyloid, although secretase inhibitors reduce the de novo production of A&#x3b2;. Limited information is currently available on the efficacy and potential advantages of combinatorial antiamyloid treatment. We performed a chronic study in APPLondon transgenic mice that received treatment with anti-A&#x3b2; antibody gantenerumab and BACE inhibitor RO5508887, either as mono- or combination treatment. Treatment aimed to evaluate efficacy on amyloid progression, similar to preexisting amyloidosis as present in Alzheimer's disease patients. Mono-treatments with either compound caused a dose-dependent reduction of total brain A&#x3b2; and amyloid burden. Combination treatment with both compounds significantly enhanced the antiamyloid effect. The observed combination effect was most pronounced for lowering of amyloid plaque load and plaque number, which suggests effective inhibition of de novo plaque formation. Moreover, significantly enhanced clearance of pre-existing amyloid plaques was observed when gantenerumab was coadministered with RO5508887. BACE inhibition led to a significant time- and dose-dependent decrease in CSF A&#x3b2;, which was not observed for gantenerumab treatment. Our results demonstrate that combining these two antiamyloid agents enhances overall efficacy and suggests that combination treatments may be of clinical relevance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3411621-10$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research &amp; Early Development, DTA Neuroscience, helmut.jacobsen@roche.com bernd.bohrmann@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozmen</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research &amp; Early Development, DTA Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Antonello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narquizian</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Small Molecule Research, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilpert</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Small Molecule Research, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Bjoern</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0782-6190</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terwel</LastName><ForeName>Dick</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2638-8336</Identifier><AffiliationInfo><Affiliation>reMYND, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanghe</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>reMYND, 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohrmann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research &amp; Early Development, DTA Neuroscience, helmut.jacobsen@roche.com bernd.bohrmann@roche.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4DF060P933</RegistryNumber><NameOfSubstance UI="C571128">gantenerumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;-antibody</Keyword><Keyword MajorTopicYN="N">BACE</Keyword><Keyword MajorTopicYN="N">amyloidosis</Keyword><Keyword MajorTopicYN="N">tg-APP mouse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25164658</ArticleId><ArticleId IdType="pmc">PMC4145168</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1405-14.2014</ArticleId><ArticleId IdType="pii">34/35/11621</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6:239&#x2013;246. doi: 10.1016/j.jalz.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.006</ArticleId><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Aytan N, Choi JK, Carreras I, Kowall NW, Jenkins BG, Dedeoglu A. Combination therapy in a transgenic model of Alzheimer's disease. Exp Neurol. 2013;250:228&#x2013;238. doi: 10.1016/j.expneurol.2013.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.10.001</ArticleId><ArticleId IdType="pmc">PMC3926203</ArticleId><ArticleId IdType="pubmed">24120437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:1019&#x2013;1031. doi: 10.1016/S0140-6736(10)61349-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61349-9</ArticleId><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919. doi: 10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (A&#x3b2;) assembly: A&#x3b2;40 and A&#x3b2;42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003a;100:330&#x2013;335. doi: 10.1073/pnas.222681699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.222681699</ArticleId><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem. 2003b;278:34882&#x2013;34889. doi: 10.1074/jbc.M300825200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300825200</ArticleId><ArticleId IdType="pubmed">12840029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H. Gantenerumab: a novel human anti-A&#x3b2; antibody demonstrates sustained cerebral amyloid-&#x3b2; binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28:49&#x2013;69. doi: 10.3233/JAD-2011-110977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110977</ArticleId><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockhaus M, Gr&#xfc;nberg J, R&#xf6;hrig S, Loetscher H, Wittenburg N, Baumeister R, Jacobsen H, Haass C. Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport. 1998;9:1481&#x2013;1486. doi: 10.1097/00001756-199805110-00043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199805110-00043</ArticleId><ArticleId IdType="pubmed">9631452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175&#x2013;193. doi: 10.1146/annurev.neuro.31.060407.125529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125529</ArticleId><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of A&#x3b2; peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234. doi: 10.1038/85064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T, Wong PC. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med. 2010;2:13ra1. doi: 10.1126/scitranslmed.3000337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000337</ArticleId><ArticleId IdType="pmc">PMC2852193</ArticleId><ArticleId IdType="pubmed">20371462</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DZ, Bayer TA, Wirths O. Intracellular A&#x3b2; triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging. 2010;31:1153&#x2013;1163. doi: 10.1016/j.neurobiolaging.2008.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.07.022</ArticleId><ArticleId IdType="pubmed">18771817</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Emerging Alzheimer's disease therapies: inhibition of beta-secretase. Neurobiol Aging. 2002;23:1017&#x2013;1022. doi: 10.1016/S0197-4580(02)00122-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00122-7</ArticleId><ArticleId IdType="pubmed">12470797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer's disease &#x3b2;-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22. doi: 10.1186/1750-1326-2-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-22</ArticleId><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76:908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107. doi: 10.1038/nrneurol.2009.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.218</ArticleId><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B, Lichtenthaler SF. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol. 2012;3:8. doi: 10.3389/fphys.2012.00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00008</ArticleId><ArticleId IdType="pmc">PMC3281277</ArticleId><ArticleId IdType="pubmed">22363289</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311&#x2013;321. doi: 10.1056/NEJMoa1312889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada Y, Kiso Y. Advances in the identification of beta-secretase inhibitors. Expert Opin Drug Discov. 2013;8:709&#x2013;731. doi: 10.1517/17460441.2013.784267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2013.784267</ArticleId><ArticleId IdType="pubmed">23565721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K. Prediction of Alzheimer's disease using the CSF A&#x3b2;42/A&#x3b2;40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23:316&#x2013;320. doi: 10.1159/000100926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000100926</ArticleId><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H, Mayweg AV, Rogers-Evans M, Humm R, Krummenacher D, Muser T, Schnider C, Jacobsen H, Ozmen L, Bergadano A, Banner DW, Hochstrasser R, Kuglstatter A, David-Pierson P, Fischer H, Polara A, Narquizian R. &#x3b2;-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013;56:3980&#x2013;3995. doi: 10.1021/jm400225m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm400225m</ArticleId><ArticleId IdType="pubmed">23590342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation. J Neurosci. 2011;31:15861&#x2013;15869. doi: 10.1523/JNEUROSCI.3272-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3272-11.2011</ArticleId><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob-Roetne R, Jacobsen H. Alzheimer's disease: from pathology to therapeutic approaches. Angewandte Chemie. 2009;48:3030&#x2013;3059. doi: 10.1002/anie.200802808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200802808</ArticleId><ArticleId IdType="pubmed">19330877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF A&#x3b2;42, A&#x3b2;42/A&#x3b2;40 ratio and total tau. Neurobiol Aging. 2004;25:273&#x2013;281. doi: 10.1016/S0197-4580(03)00086-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00086-1</ArticleId><ArticleId IdType="pubmed">15123331</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE. Robust central reduction of amyloid-&#x3b2; in humans with an orally available, non-peptidic &#x3b2;-secretase inhibitor. J Neurosci. 2011;31:16507&#x2013;16516. doi: 10.1523/JNEUROSCI.3647-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3647-11.2011</ArticleId><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="pubmed">22090477</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007;282:26326&#x2013;26334. doi: 10.1074/jbc.M611687200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611687200</ArticleId><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Revers&#xe9; D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492. doi: 10.1074/jbc.274.10.6483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.10.6483</ArticleId><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198&#x2013;207. doi: 10.1001/archneurol.2011.1538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.1538</ArticleId><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003;23:8989&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740398</ArticleId><ArticleId IdType="pubmed">14523101</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Esh CL, Kokjohn TA, Casta&#xf1;o EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009;5:18&#x2013;29. doi: 10.1016/j.jalz.2008.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2008.10.004</ArticleId><ArticleId IdType="pmc">PMC2663406</ArticleId><ArticleId IdType="pubmed">19118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid &#x3b2;-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25. doi: 10.1111/j.1749-6632.2000.tb05554.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb05554.x</ArticleId><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol. 2007;30:317&#x2013;325. doi: 10.1097/WNF.0b013e31805b7660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNF.0b013e31805b7660</ArticleId><ArticleId IdType="pubmed">18090456</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126&#x2013;132. doi: 10.1097/01.wnf.0000167360.27670.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnf.0000167360.27670.29</ArticleId><ArticleId IdType="pubmed">15965311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanghe A, Termont A, Merchiers P, Schilling S, Demuth HU, Scrocchi L, Van Leuven F, Griffioen G, Van Dooren T. Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. Int J Alzheimers Dis. 2010;2010:417314. doi: 10.4061/2010/417314.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/417314</ArticleId><ArticleId IdType="pmc">PMC2939388</ArticleId><ArticleId IdType="pubmed">20862386</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci. 2001;17:157&#x2013;170. doi: 10.1385/JMN:17:2:157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:17:2:157</ArticleId><ArticleId IdType="pubmed">11816789</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Citron M. A&#x3b2;-generating enzymes: recent advances in &#x3b2;- and &#x3b3;-secretase research. Neuron. 2000;27:419&#x2013;422. doi: 10.1016/S0896-6273(00)00051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00051-9</ArticleId><ArticleId IdType="pubmed">11055423</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193. doi: 10.1016/j.neuron.2004.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.09.010</ArticleId><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-&#x3b2; immunotherapy. J Neurosci. 2011;31:4124&#x2013;4136. doi: 10.1523/JNEUROSCI.5077-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5077-10.2011</ArticleId><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The &#x3b3;-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006;45:7931&#x2013;7939. doi: 10.1021/bi060799c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi060799c</ArticleId><ArticleId IdType="pubmed">16800619</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X. &#x3b3;-Secretase catalyzes sequential cleavages of the A&#x3b2;PP transmembrane domain. J Alzheimers Dis. 2009;16:211&#x2013;224. doi: 10.3233/JAD-2009-0957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-0957</ArticleId><ArticleId IdType="pmc">PMC2696591</ArticleId><ArticleId IdType="pubmed">19221413</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa H, Yagishita S, Futai E, Ishiura S. &#x3b2;-Secretase inhibitor potency is decreased by aberrant &#x3b2;-cleavage location of the &#x201c;Swedish mutant&#x201d; amyloid precursor protein. J Biol Chem. 2010;285:1634&#x2013;1642. doi: 10.1074/jbc.M109.066753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.066753</ArticleId><ArticleId IdType="pmc">PMC2804321</ArticleId><ArticleId IdType="pubmed">19926793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Shi JM, Bai CJ, Wang H, Li HY, Wu Y, Ji SR. Intra-membrane oligomerization and extra-membrane oligomerization of amyloid-beta peptide are competing processes as a result of distinct patterns of motif interplay. J Biol Chem. 2012;287:748&#x2013;756. doi: 10.1074/jbc.M111.281295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.281295</ArticleId><ArticleId IdType="pmc">PMC3249129</ArticleId><ArticleId IdType="pubmed">22105077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25178429</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.</ArticleTitle><Pagination><StartPage>1405</StartPage><EndPage>1412</EndPage><MedlinePgn>1405-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1455</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Cognitive impairment is a common and disabling problem in Parkinson disease (PD) that is not well understood and is difficult to treat. Identification of genetic variants that influence the rate of cognitive decline or pattern of early cognitive deficits in PD might provide a clearer understanding of the etiopathogenesis of this important nonmotor feature.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive performance in patients with PD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We studied 1079 PD patients from 6 academic centers in the United States who underwent assessments of memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), attention and executive function (Letter-Number Sequencing Test and Trail Making Test), language processing (semantic and phonemic verbal fluency tests), visuospatial skills (Benton Judgment of Line Orientation test), and global cognitive function (Montreal Cognitive Assessment). Participants underwent genotyping for the APOE &#x3b5;2/&#x3b5;3/&#x3b5;4 alleles, MAPT H1/H2 haplotypes, and SNCA rs356219. We used linear regression to test for association between genotype and baseline cognitive performance with adjustment for age, sex, years of education, disease duration, and site. We used a Bonferroni correction to adjust for the 9 comparisons that were performed for each gene.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Nine variables derived from 7 psychometric tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The APOE &#x3b5;4 allele was associated with lower performance on the HVLT-R Total Recall (P = 6.7 &#xd7; 10(-6); corrected P [Pc]&#x2009;= 6.0 &#xd7; 10(-5)), Delayed Recall (P =&#x2009;.001; Pc =&#x2009;.009), and Recognition Discrimination Index (P =&#x2009;.004; Pc =&#x2009;.04); a semantic verbal fluency test (P =&#x2009;.002; Pc =&#x2009;.02); the Letter-Number Sequencing Test (P = 1 &#xd7; 10(-5); Pc = 9 &#xd7; 10(-5)); and Trail Making Test B minus Trail Making Test A (P =&#x2009;.002; Pc =&#x2009;.02). In a subset of 645 patients without dementia, the APOE &#x3b5;4 allele was associated with lower scores on the HVLT-R Total Recall (P =&#x2009;.005; Pc =&#x2009;.045) and the semantic verbal fluency (P =&#x2009;.005; Pc =&#x2009;.045) measures. Variants of MAPT and SNCA were not associated with scores on any tests.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Our data indicate that the APOE &#x3b5;4 allele is an important predictor of cognitive function in PD across multiple domains. Among PD patients without dementia, the APOE &#x3b5;4 allele was only associated with lower performance on word list learning and semantic verbal fluency, a pattern more typical of the cognitive deficits seen in early Alzheimer disease than PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mata</LastName><ForeName>Ignacio F</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington3Department of Neurology, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington2Parkinson's Disease Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington3Dep.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia7Department of Psychiatry, University of Pennsylvania, Philadelphia8Parkinson's Disease Research, Education, and Clinical Center and Mental Illness Research, Education, and Clinical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia10Institute on Aging, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurtig</LastName><ForeName>Howard I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritz</LastName><ForeName>Beate</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of California, Los Angeles12Department of Environmental Health Sciences, School of Public Health, University of California, Los Angeles13Department of Neurology, University of California, Los.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rausch</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhodes</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Factor</LastName><ForeName>Stewart A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood-Siverio</LastName><ForeName>Cathy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Parkinson's Disease Research, Education, and Clinical Center,Portland Veterans Affairs Medical Center, Portland, Oregon16Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Parkinson's Disease Research, Education, and Clinical Center,Portland Veterans Affairs Medical Center, Portland, Oregon16Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Amie L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Parkinson's Disease Research, Education, and Clinical Center,Portland Veterans Affairs Medical Center, Portland, Oregon16Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espay</LastName><ForeName>Alberto J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revilla</LastName><ForeName>Fredy J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio18Department of Neurology, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devoto</LastName><ForeName>Johnna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shu-Ching</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington2Parkinson's Disease Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington3Dep.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cholerton</LastName><ForeName>Brenna A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington4Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Jia Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle20currently with Department of Epidemiology, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle20currently with Department of Epidemiology, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabetian</LastName><ForeName>Cyrus P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington2Parkinson's Disease Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington3Dep.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS071675</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038367</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES017462</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS070202</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG036468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA149051</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 ES012078</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS077350</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX000531</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065070</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH092735</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 TR000903</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES010544</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG029213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 ES016732</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25178429</ArticleId><ArticleId IdType="mid">NIHMS610339</ArticleId><ArticleId IdType="pmc">PMC4227942</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1455</ArticleId><ArticleId IdType="pii">1900308</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002 Dec 10;59(11):1708&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473757</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson&#x2019;s disease: a population-based, prospective study. J Am Geriatr Soc. 2000 Aug;48(8):938&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10968298</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson&#x2019;s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999 Oct;14(10):866&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521886</ArticleId></ArticleIdList></Reference><Reference><Citation>Klepac N, Trkulja V, Relja M, Babic T. Is quality of life in non-demented Parkinson&#x2019;s disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol. 2008 Feb;15(2):128&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">18217883</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Norwegian ParkWest Study G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009 Mar 31;72(13):1121&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">19020293</ArticleId></ArticleIdList></Reference><Reference><Citation>Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005 Oct 25;65(8):1239&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247051</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003 Mar;60(3):387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson&#x2019;s disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004 Dec;61(12):1906&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596611</ArticleId></ArticleIdList></Reference><Reference><Citation>Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson&#x2019;s disease: progression to dementia. Mov Disord. 2006 Sep;21(9):1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16721732</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997 Oct 22-29;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004 Dec;19(4):592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiology of aging. 2011 Jan;32(1):63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson&#x2019;s disease and a higher risk with dementia. Mov Disord. 2006 Jan;21(1):45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116614</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson&#x2019;s disease. Mov Disord. 2012 Apr;27(4):512&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323737</ArticleId><ArticleId IdType="pubmed">22344634</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson&#x2019;s disease. J Neurol. 2009 Mar;256(3):493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">19308307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol. 2009 Sep;22(3):166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19321880</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet. 2006 Oct 15;15(Suppl 2):R188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987883</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson&#x2019;s disease. Ann Neurol. 2007 May 18;62(2):137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836920</ArticleId><ArticleId IdType="pubmed">17514749</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011 Mar;68(3):359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">21403021</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson&#x2019;s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009 Nov;132(Pt 11):2958&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">19812213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007 Mar 20;68(12):916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251522</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlstrom L, Toft M. Genetic variability in SNCA and Parkinson&#x2019;s disease. Neurogenetics. 2011 Nov;12(4):283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">21800132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson&#x2019;s disease in a central California population-based study. Mov Disord. 2005 Sep;20(9):1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643967</ArticleId><ArticleId IdType="pubmed">15954133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013 Jul;70(7):852&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3762458</ArticleId><ArticleId IdType="pubmed">23699752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis. 2013;3(2):205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779428</ArticleId><ArticleId IdType="pubmed">23938350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottingham ME, Hawkins KA. Verbal fluency deficits co-occur with memory deficits in geriatric patients at risk for dementia: Implications for the concept of mild cognitive impairment. Behav Neurol. 2010;22(3-4):73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434323</ArticleId><ArticleId IdType="pubmed">20595739</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KJ, Rich JB, Troyer AK. Verbal fluency patterns in amnestic mild cognitive impairment are characteristic of Alzheimer&#x2019;s type dementia. J Int Neuropsychol Soc. 2006 Jul;12(4):570&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16981610</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Ropacki SA, Bondi MW. Neuropsychological and neuroimaging changes in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2006 Sep;12(5):707&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621044</ArticleId><ArticleId IdType="pubmed">16961952</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006 Jan;63(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldo JV, Schwartz S, Wilkins D, Dronkers NF. Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. J Int Neuropsychol Soc. 2006 Nov;12(6):896&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">17064451</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson&#x2019;s disease. Brain Pathol. 2010 May;20(3):640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049172</ArticleId><ArticleId IdType="pubmed">20522089</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson&#x2019;s disease. Mov Disord. 2012 Aug;27(9):1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412930</ArticleId><ArticleId IdType="pubmed">22778009</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012 Oct;72(4):587&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013 Jan 1;80(1):85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589197</ArticleId><ArticleId IdType="pubmed">23243071</ArticleId></ArticleIdList></Reference><Reference><Citation>Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson&#x2019;s disease. Neurobiol Dis. 2012 May;46(2):389&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323723</ArticleId><ArticleId IdType="pubmed">22349451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu HG, Kwon OD. Apolipoprotein E epsilon 4 allele is not associated with age at onset or MMSE of Parkinson&#x2019;s disease in a Korean study. Parkinsonism Relat Disord. 2010 Nov;16(9):615&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">20674461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Leverenz JB, Lopez OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013 Feb;70(2):223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24;73(21):1738&#x2013;1745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788810</ArticleId><ArticleId IdType="pubmed">19933974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson&#x2019;s disease. Neurosci Lett. 2008 Dec 19;448(1):20&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930114</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25174004</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetic variability in the regulation of gene expression in ten regions of the human brain.</ArticleTitle><Pagination><StartPage>1418</StartPage><EndPage>1428</EndPage><MedlinePgn>1418-1428</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3801</ELocationID><Abstract><AbstractText>Germ-line genetic control of gene expression occurs via expression quantitative trait loci (eQTLs). We present a large, exon-specific eQTL data set covering ten human brain regions. We found that cis-eQTL signals (within 1 Mb of their target gene) were numerous, and many acted heterogeneously among regions and exons. Co-regulation analysis of shared eQTL signals produced well-defined modules of region-specific co-regulated genes, in contrast to standard coexpression analysis of the same samples. We report cis-eQTL signals for 23.1% of catalogued genome-wide association study hits for adult-onset neurological disorders. The data set is publicly available via public data repositories and via http://www.braineac.org/. Our study increases our understanding of the regulation of gene expression in the human brain and will be of value to others pursuing functional follow-up of disease-associated variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ramasamy</LastName><ForeName>Adaikalavan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical &amp; Molecular Genetics, King's College London, Guy's Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Guelfi</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Vibin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical &amp; Molecular Genetics, King's College London, Guy's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, MRC Sudden Death Brain Bank Project, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, MRC Sudden Death Brain Bank Project, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De</LastName><ForeName>Tisham</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>UK Brain Expression Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>North American Brain Expression Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Coin</LastName><ForeName>Lachlan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Bioscience, The University of Queensland, Brisbane St Lucia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical &amp; Molecular Genetics, King's College London, Guy's Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medical &amp; Molecular Genetics, King's College London, Guy's Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE46706</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>dbGaP</DataBankName><AccessionNumberList><AccessionNumber>UNKNOWN</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG000947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089698</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K-1212</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0802462</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="Y">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS60572</OtherID><InvestigatorList><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guelfi</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Adaikalavan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forabosco</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Brug</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zielke</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longo</LastName><ForeName>Dan L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zonderman</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25174004</ArticleId><ArticleId IdType="mid">EMS60572</ArticleId><ArticleId IdType="pmc">PMC4208299</ArticleId><ArticleId IdType="doi">10.1038/nn.3801</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) Wellcome Trust Case Control Consortium 2 (WTCCC2) A two-stage meta-analysis identifies several new loci for Parkinson&#x2019;s disease. PLoS Genet. 2011;7:e1002142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="pubmed">21738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamshere ML, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol. Psychiatry. 2013;18:708&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724864</ArticleId><ArticleId IdType="pubmed">22614287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 2009;360:1759&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422859</ArticleId><ArticleId IdType="pubmed">19369657</ArticleId></ArticleIdList></Reference><Reference><Citation>Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am. J. Hum. Genet. 2012;90:7&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257326</ArticleId><ArticleId IdType="pubmed">22243964</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson V, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344981</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffatt MF, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007;448:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">17611496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K. Recent Developments in Parkinson&#x2019;s Disease. Raven; 1986. pp. 33&#x2013;36.</Citation></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ET, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593745</ArticleId><ArticleId IdType="pubmed">18978772</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Lee JA, Black DL. Neuronal regulation of alternative pre-mRNA splicing. Nat. Rev. Neurosci. 2007;8:819&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895907</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris AD, Calarco JA. Emerging roles of alternative pre-mRNA splicing regulation in neuronal development and function. Front. Neurosci. 2012;6:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3424503</ArticleId><ArticleId IdType="pubmed">22936897</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. A survey of genetic human cortical gene expression. Nat. Genet. 2007;39:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzen EL, et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol. 2008;6:e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605930</ArticleId><ArticleId IdType="pubmed">19222302</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, et al. Whole-genome association mapping of gene expression in the human prefrontal cortex. Mol. Psychiatry. 2010;15:779&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057235</ArticleId><ArticleId IdType="pubmed">20351726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478:483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566780</ArticleId><ArticleId IdType="pubmed">22031440</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantuoni C, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature. 2011;478:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510670</ArticleId><ArticleId IdType="pubmed">22031444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez DG, et al. Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol. Dis. 2012;47:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3358430</ArticleId><ArticleId IdType="pubmed">22433082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Cho H, Lee D, Webster MJ. Association between SNPs and gene expression in multiple regions of the human brain. Transl. Psychiatry. 2012;2:e113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365261</ArticleId><ArticleId IdType="pubmed">22832957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8:e1002707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369937</ArticleId><ArticleId IdType="pubmed">22685416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy A, et al. Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res. 2013;41:e88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627570</ArticleId><ArticleId IdType="pubmed">23435227</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, et al. Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J. Neurochem. 2011;119:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664422</ArticleId><ArticleId IdType="pubmed">21848658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeller T, et al. Genetics and beyond&#x2014;the transcriptome of human monocytes and disease susceptibility. PLoS ONE. 2010;5:e10693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872668</ArticleId><ArticleId IdType="pubmed">20502693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat. Genet. 2012;44:502&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437404</ArticleId><ArticleId IdType="pubmed">22446964</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 2012;44:1084&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784328</ArticleId><ArticleId IdType="pubmed">22941192</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert FW, Treusch S, Shockley AH, Bloom JS, Kruglyak L. Genetics of single-cell protein abundance variation in large yeast populations. Nature. 2014;506:494&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285441</ArticleId><ArticleId IdType="pubmed">24402228</ArticleId></ArticleIdList></Reference><Reference><Citation>Schorge S, van de Leemput J, Singleton A, Houlden H, Hardy J. Human ataxias: a genetic dissection of inositol triphosphate receptor (ITPR1)-dependent signaling. Trends Neurosci. 2010;33:211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684264</ArticleId><ArticleId IdType="pubmed">20226542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. The role of autophagy in neurodegenerative disease. Nat. Med. 2013;19:983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL. AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res. 2011;39:D66&#x2013;D69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013810</ArticleId><ArticleId IdType="pubmed">21071424</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, et al. Meta-analysis of Parkinson&#x2019;s disease: identification of a novel locus, RIT2. Ann. Neurol. 2012;71:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3354734</ArticleId><ArticleId IdType="pubmed">22451204</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin I, Rosenmund C, Sudhof TC, Brose N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440375</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F, et al. Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc. Natl. Acad. Sci. USA. 2002;99:9037&#x2013;9042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124419</ArticleId><ArticleId IdType="pubmed">12070347</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler M, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273:1709&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">8781233</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay JD, et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 2008;40:1404&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748187</ArticleId><ArticleId IdType="pubmed">18978790</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorgeirsson TE, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539558</ArticleId><ArticleId IdType="pubmed">18385739</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorgeirsson TE, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 2010;42:448&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3080600</ArticleId><ArticleId IdType="pubmed">20418888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobacco and Genetics Consortium Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 2010;42:441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914600</ArticleId><ArticleId IdType="pubmed">20418890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 2010;42:436&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612983</ArticleId><ArticleId IdType="pubmed">20418889</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi MT, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am. J. Hum. Genet. 2009;85:679&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775843</ArticleId><ArticleId IdType="pubmed">19836008</ArticleId></ArticleIdList></Reference><Reference><Citation>Capasso M, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 2009;41:718&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753610</ArticleId><ArticleId IdType="pubmed">19412175</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Plagnol V, Smyth DJ, Todd JA, Clayton DG. Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13. Biostatistics. 2009;10:327&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648905</ArticleId><ArticleId IdType="pubmed">19039033</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar T, et al. Tissue and organ donation for research in forensic pathology: the MRC Sudden Death Brain and Tissue Bank. J. Pathol. 2007;213:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">17990279</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, et al. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank. 2008;9:229&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493521</ArticleId><ArticleId IdType="pubmed">18347928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth RB, et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics. 2006;7:67&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16572319</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu. Rev. Genomics Hum. Genet. 2009;10:387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925172</ArticleId><ArticleId IdType="pubmed">19715440</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 2010;34:816&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Coin LJ, et al. cnvHap: an integrative population and haplotype-based multiplatform model of SNPs and CNVs. Nat. Methods. 2010;7:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">20512141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28:1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348564</ArticleId><ArticleId IdType="pubmed">22492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. A Stat. Soc. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Hindorff LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA. 2009;106:9362&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687147</ArticleId><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Obenchain V, Morgan M, Lawrence M. R Package Version 1.4.8. Bioconductor; 2012.</Citation></Reference><Reference><Citation>Barbosa-Morais NL, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2010;38:e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817484</ArticleId><ArticleId IdType="pubmed">19923232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25193240</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2; seeds resist inactivation by formaldehyde.</ArticleTitle><Pagination><StartPage>477</StartPage><EndPage>484</EndPage><MedlinePgn>477-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-014-1339-2</ELocationID><Abstract><AbstractText>Cerebral &#x3b2;-amyloidosis can be exogenously induced by the intracerebral injection of brain extracts containing aggregated &#x3b2;-amyloid (A&#x3b2;) into young, pre-depositing A&#x3b2; precursor protein- (APP) transgenic mice. Previous work has shown that the induction involves a prion-like seeding mechanism in which the seeding agent is aggregated A&#x3b2; itself. Here we report that the &#x3b2;-amyloid-inducing activity of Alzheimer's disease (AD) brain tissue or aged APP-transgenic mouse brain tissue is preserved, albeit with reduced efficacy, after formaldehyde fixation. Moreover, spectral analysis with amyloid conformation-sensitive luminescent conjugated oligothiophene dyes reveals that the strain-like properties of aggregated A&#x3b2; are maintained in fixed tissues. The resistance of A&#x3b2; seeds to inactivation and structural modification by formaldehyde underscores their remarkable durability, which in turn may contribute to their persistence and spread within the body. The present findings can be exploited to establish the relationship between the molecular structure of A&#x3b2; aggregates and the variable clinical features and disease progression of AD even in archived, formalin-fixed autopsy material.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cintron</LastName><ForeName>Amarallys</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Lan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>B&#xfc;hler</LastName><ForeName>Anika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>K Peter R</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Hammarstr&#xf6;m</LastName><ForeName>Per</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P51 OD011132</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R36 AG043646</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51OD11132</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG040589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R36AG043646</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG040589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51RR165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005404">Fixatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005404" MajorTopicYN="N">Fixatives</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25193240</ArticleId><ArticleId IdType="mid">NIHMS626388</ArticleId><ArticleId IdType="pmc">PMC4169116</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1339-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold K-H, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. Journal of Neuroscience. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown F. Inactivation of viruses by aziridines. Vaccine. 2001;20:322&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672893</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Brandel J-P, Sato T, Nakamura Y, MacKenzie J, Will RG, Ladogana A, Pocchiari M, Leschek EW, Schonberger LB. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerging Infect Dis. 2012;18:901&#x2013;907. doi: 10.3201/eid1806.120116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1806.120116</ArticleId><ArticleId IdType="pmc">PMC3358170</ArticleId><ArticleId IdType="pubmed">22607808</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Gibbs CJ, Gajdusek DC, Cathala F, LaBauge R. Transmission of Creutzfeldt-Jakob disease from formalin-fixed, paraffin-embedded human brain tissue. N Engl J Med. 1986;315:1614&#x2013;1615. doi: 10.1056/NEJM198612183152516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198612183152516</ArticleId><ArticleId IdType="pubmed">3537790</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Liberski PP, Wolff A, Gajdusek DC. Resistance of scrapie infectivity to steam autoclaving after formaldehyde fixation and limited survival after ashing at 360 degrees C: practical and theoretical implications. J Infect Dis. 1990a;161:467&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">2107265</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Wolff A, Gajdusek DC. A simple and effective method for inactivating virus infectivity in formalin-fixed tissue samples from patients with Creutzfeldt-Jakob disease. Neurology. 1990b;40:887&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">1693181</ArticleId></ArticleIdList></Reference><Reference><Citation>Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines. 2012;11:695&#x2013;719. doi: 10.1586/erv.12.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.12.38</ArticleId><ArticleId IdType="pubmed">22873127</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan Z-X, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proceedings of the National Academy of Sciences. 2009;106:12926&#x2013;12931. doi: 10.1073/pnas.0903200106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903200106</ArticleId><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Oberm&#xfc;ller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982. doi: 10.1126/science.1194516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon WS. Advances in veterinary research. Vet Rec. 1946;58:516&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">20279638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M. The presence of A&#x3b2; seeds, and not age per se, is critical to the initiation of A&#x3b2; deposition in the brain. Acta Neuropathol. 2012;123:31&#x2013;37. doi: 10.1007/s00401-011-0912-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0912-1</ArticleId><ArticleId IdType="pmc">PMC3297471</ArticleId><ArticleId IdType="pubmed">22101366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi:0.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, Nagarathinam A, Aslund A, Hammarstr&#xf6;m P, Nilsson KPR, Jucker M. Seeded strain-like transmission of &#x3b2;-amyloid morphotypes in APP transgenic mice. EMBO Rep. 2013;14:1017&#x2013;1022. doi: 10.1038/embor.2013.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.137</ArticleId><ArticleId IdType="pmc">PMC3818077</ArticleId><ArticleId IdType="pubmed">23999102</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012 doi: 10.1101/cshperspect.a011585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a011585</ArticleId><ArticleId IdType="pmc">PMC3543098</ArticleId><ArticleId IdType="pubmed">23125202</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VM-Y, Trojanowski JQ. Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone. JAMA Neurol. 2013;70:462. doi: 10.1001/jamaneurol.2013.1933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.1933</ArticleId><ArticleId IdType="pmc">PMC3678373</ArticleId><ArticleId IdType="pubmed">23380910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51. doi: 10.1038/nature12481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12481</ArticleId><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. Journal of Neuroscience. 2000;20:3606&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T, Aslund A, Simon RA, Johansson LBG, Mason JJ, Nystr&#xf6;m S, Hammarstr&#xf6;m P, Nilsson KPR. Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. Org Biomol Chem. 2011;9:8356&#x2013;8370. doi: 10.1039/c1ob05637a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c1ob05637a</ArticleId><ArticleId IdType="pmc">PMC3326384</ArticleId><ArticleId IdType="pubmed">22051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble A{beta} Seeds Are Potent Inducers of Cerebral {beta}-Amyloid Deposition. Journal of Neuroscience. 2011;31:14488&#x2013;14495. doi: 10.1523/JNEUROSCI.3088-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3088-11.2011</ArticleId><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret J-M, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784. doi: 10.1126/science.1131864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131864</ArticleId><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-&#x3b2; deposition in vivo. Mol Psychiatry. 2011;17:1347&#x2013;1353. doi: 10.1038/mp.2011.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.120</ArticleId><ArticleId IdType="pubmed">21968933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarathinam A, H&#xf6;flinger P, B&#xfc;hler A, Sch&#xe4;fer C, McGovern G, Jeffrey M, Staufenbiel M, Jucker M, Baumann F. Membrane-anchored a&#x3b2; accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. Journal of Neuroscience. 2013;33:19284&#x2013;19294. doi: 10.1523/JNEUROSCI.2542-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2542-13.2013</ArticleId><ArticleId IdType="pmc">PMC6618790</ArticleId><ArticleId IdType="pubmed">24305824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattison IH. Resistance of the scrapie agent to formalin. J Comp Pathol. 1965;75:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">14317615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattison IH. Scrapie--a personal view. J Clin Pathol Suppl (R Coll Pathol) 1972;6:110&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347259</ArticleId><ArticleId IdType="pubmed">4218240</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601&#x2013;623. doi: 10.1146/annurev-genet-110711-155524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genet-110711-155524</ArticleId><ArticleId IdType="pmc">PMC4010318</ArticleId><ArticleId IdType="pubmed">24274755</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, Levine H, Jucker M, Walker LC. Exogenous seeding of cerebral &#x3b2;-amyloid deposition in &#x3b2;APP-transgenic rats. J Neurochem. 2012;120:660&#x2013;666. doi: 10.1111/j.1471-4159.2011.07551.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07551.x</ArticleId><ArticleId IdType="pmc">PMC3293176</ArticleId><ArticleId IdType="pubmed">22017494</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutala WA, Weber DJ Society for Healthcare Epidemiology of America. Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol. 2010;31:107&#x2013;117. doi: 10.1086/650197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/650197</ArticleId><ArticleId IdType="pubmed">20055640</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proceedings of the National Academy of Sciences. 2012;109:11025&#x2013;11030. doi: 10.1073/pnas.1206555109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206555109</ArticleId><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DM, Brown JM, Fernie K, McConnell I. The effect of formic acid on BSE and scrapie infectivity in fixed and unfixed brain-tissue. Vet Microbiol. 1997;58:167&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453128</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DM, McConnell I. Autoclaving does not decontaminate formol-fixed scrapie tissues. Lancet. 1988;1:1463&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2455203</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides. 2002;23:1241&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12128081</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences. 2011;108:2528&#x2013;2533. doi: 10.1073/pnas.1019034108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019034108</ArticleId><ArticleId IdType="pmc">PMC3038719</ArticleId><ArticleId IdType="pubmed">21262831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25197054</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>37</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Crystal structure of the &#x3b3;-secretase component nicastrin.</ArticleTitle><Pagination><StartPage>13349</StartPage><EndPage>13354</EndPage><MedlinePgn>13349-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1414837111</ELocationID><Abstract><AbstractText>&#x3b3;-Secretase is an intramembrane protease responsible for the generation of amyloid-&#x3b2; (A&#x3b2;) peptides. Aberrant accumulation of A&#x3b2; leads to the formation of amyloid plaques in the brain of patients with Alzheimer's disease. Nicastrin is the putative substrate-recruiting component of the &#x3b3;-secretase complex. No atomic-resolution structure had been identified on &#x3b3;-secretase or any of its four components, hindering mechanistic understanding of &#x3b3;-secretase function. Here we report the crystal structure of nicastrin from Dictyostelium purpureum at 1.95-&#xc5; resolution. The extracellular domain of nicastrin contains a large lobe and a small lobe. The large lobe of nicastrin, thought to be responsible for substrate recognition, associates with the small lobe through a hydrophobic pivot at the center. The putative substrate-binding pocket is shielded from the small lobe by a lid, which blocks substrate entry. These structural features suggest a working model of nicastrin function. Analysis of nicastrin structure provides insights into the assembly and architecture of the &#x3b3;-secretase complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Chuangye</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China State Key Laboratory of Bio-Membrane and Membrane Biotechnology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yanyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Linfeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China State Key Laboratory of Bio-Membrane and Membrane Biotechnology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Peilong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China shi-lab@tsinghua.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4R12</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14643-4. doi: 10.1073/pnas.1416637111.</RefSource><PMID Version="1">25267656</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004023" MajorTopicYN="N">Dictyostelium</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25197054</ArticleId><ArticleId IdType="pmc">PMC4169925</ArticleId><ArticleId IdType="doi">10.1073/pnas.1414837111</ArticleId><ArticleId IdType="pii">1414837111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 2008;6(10):e257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570425</ArticleId><ArticleId IdType="pubmed">18942891</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kovacs DM. The many substrates of presenilin/&#x3b3;-secretase. J Alzheimers Dis. 2011;25(1):3&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281584</ArticleId><ArticleId IdType="pubmed">21335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, Yu G. Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2008;5(2):132&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474811</ArticleId><ArticleId IdType="pubmed">18393798</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and &#x3b3;-secretase: Structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012;2(1):a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ, Johnson DS, Li YM. Development and mechanism of &#x3b3;-secretase modulators for Alzheimer&#x2019;s disease. Biochemistry. 2013;52(19):3197&#x2013;3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796170</ArticleId><ArticleId IdType="pubmed">23614767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T. At the frontline of Alzheimer&#x2019;s disease treatment: Gamma-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18038124</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, et al. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004;43(30):9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA. 2003;100(11):6382&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5(5):486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoglio B, Golde TE. Intramembrane-cleaving aspartic proteases and disease: Presenilins, signal peptide peptidase and their homologs. Hum Mol Genet. 2003;12(Spec No 2):R201&#x2013;R206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. When loss is gain: Reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8(2):136&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796780</ArticleId><ArticleId IdType="pubmed">17268504</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493(7430):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3(1):85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA. 2002;99(2):775&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281(1):46&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24279329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407(6800):48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122(3):435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Goo JS, et al. Nicastrin overexpression in transgenic mice induces aberrant behavior and APP processing. Mol Neurobiol. 2013;48(1):232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">23595812</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, et al. Glu-333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem. 2009;284(43):29714&#x2013;29724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA. 2006;103(18):6889&#x2013;6894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, et al. Three-dimensional structure of the gamma-secretase complex. Biochem Biophys Res Commun. 2006;343(2):525&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546128</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol. 2009;385(2):642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi F, et al. Structure of gamma-secretase and its trimeric pre-activation intermediate by single-particle electron microscopy. J Biol Chem. 2011;286(24):21440&#x2013;21449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122203</ArticleId><ArticleId IdType="pubmed">21454611</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure. 2014;22(1):125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887256</ArticleId><ArticleId IdType="pubmed">24210759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhanifar S, et al. Structural investigation of the C-terminal catalytic fragment of presenilin 1. Proc Natl Acad Sci USA. 2010;107(21):9644&#x2013;9649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906861</ArticleId><ArticleId IdType="pubmed">20445084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, et al. Three-dimensional structure of human gamma-secretase. Nature. 2014;512(7513):166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134323</ArticleId><ArticleId IdType="pubmed">25043039</ArticleId></ArticleIdList></Reference><Reference><Citation>McMains VC, Myre M, Kreppel L, Kimmel AR. Dictyostelium possesses highly diverged presenilin/gamma-secretase that regulates growth and cell-fate specification and can accurately process human APP: A system for functional studies of the presenilin/gamma-secretase complex. Dis Model Mech. 2010;3(9-10):581&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931536</ArticleId><ArticleId IdType="pubmed">20699477</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol. 1993;233(1):123&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">8377180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, et al. Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry. 2004;43(2):323&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisodia SS. Evidence that the &#x201c;NF&#x201d; motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem. 2005;280(51):41953&#x2013;41966.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234243</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, et al. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem. 2005;280(51):41967&#x2013;41975.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234244</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, et al. gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci. 2003;116(Pt 6):1127&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. J Biol Chem. 2005;280(17):17020&#x2013;17026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Computational Project, Number 4 The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50(Pt 5):760&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299374</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ, et al. Phaser crystallographic software. J Appl Cryst. 2007;40(Pt 4):658&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwilliger TC, et al. Decision-making in structure solution using Bayesian estimates of map quality: The PHENIX AutoSol wizard. Acta Crystallogr D Biol Crystallogr. 2009;65(Pt 6):582&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685735</ArticleId><ArticleId IdType="pubmed">19465773</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrakis A, Harkiolaki M, Wilson KS, Lamzin VS. ARP/wARP and molecular replacement. Acta Crystallogr D Biol Crystallogr. 2001;57(Pt 10):1445&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567158</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt):2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002;58(Pt 11):1948&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393927</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph. 1996;14(1):33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;dinger, LLC (2010) The PyMOL Molecular Graphics System (Schr&#xf6;dinger, San Diego), Version 1.5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25199842</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.</ArticleTitle><Pagination><StartPage>1394</StartPage><EndPage>1404</EndPage><MedlinePgn>1394-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1491</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the effects of known Alzheimer disease risk loci in modifying AAO and to estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Alzheimer Disease Genetics Consortium comprises 14 case-control, prospective, and family-based data sets with data on 9162 participants of white race/ethnicity with Alzheimer disease occurring after age 60 years who also had complete AAO information, gathered between 1989 and 2011 at multiple sites by participating studies. Data on genotyped or imputed single-nucleotide polymorphisms most significantly associated with risk at 10 confirmed LOAD loci were examined in linear modeling of AAO, and individual data set results were combined using a random-effects, inverse variance-weighted meta-analysis approach to determine whether they contribute to variation in AAO. Aggregate effects of all risk loci on AAO were examined in a burden analysis using genotype scores weighted by risk effect sizes.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Age at disease onset abstracted from medical records among participants with LOAD diagnosed per standard criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis confirmed the association of APOE with earlier AAO (P = 3.3 &#xd7; 10(-96)), with associations in CR1 (rs6701713, P = 7.2 &#xd7; 10(-4)), BIN1 (rs7561528, P = 4.8 &#xd7; 10(-4)), and PICALM (rs561655, P = 2.2 &#xd7; 10(-3)) reaching statistical significance (P &lt;&#x2009;.005). Risk alleles individually reduced AAO by 3 to 6 months. Burden analyses demonstrated that APOE contributes to 3.7% of the variation in AAO (R(2) = 0.256) over baseline (R(2) = 0.221), whereas the other 9 loci together contribute to 2.2% of the variation (R(2) = 0.242).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">We confirmed an association of APOE (OMIM 107741) variants with AAO among affected participants with LOAD and observed novel associations of CR1 (OMIM 120620), BIN1 (OMIM 601248), and PICALM (OMIM 603025) with AAO. In contrast to earlier hypothetical modeling, we show that the combined effects of Alzheimer disease risk variants on AAO are on the scale of, but do not exceed, the APOE effect. While the aggregate effects of risk loci on AAO may be significant, additional genetic contributions to AAO are individually likely to be small.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genetics Program, Department of Medicine, Boston University, Boston, Massachusetts4Department of Biostatistics, Boston University, Boston, Massachusetts5Department of Ophthalmology, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York7Gertrude H. Sergievsky Center, Columbia University, New York, New York8Department of Neurology, Columbia University, New York, New.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yo Son</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida9The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajbhandary</LastName><ForeName>Ruchita A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle15Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Genetics Program, Department of Medicine, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle18Division of Medical Genetics, Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>M Michael</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirci</LastName><ForeName>F Yesim</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, School of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp; Science University, Portland24Department of Molecular and Medical Genetics, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida26Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida26Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Genetics, Department of Medicine, and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle29Group Health Research Institute, Group Health Cooperative, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada30Cambridge Institute for Medical Research, Department of Clinical Neurosciences, University of Cambridge, Cambridge, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York32Department of Psychiatry, Mount Sinai School of Medicine, New York, New York33Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois36Neuropathology, Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania37Alheimer Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis39Department of Radiology and Imaging Sciences, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona40Arizona Alzheimer's Consortium, Phoenix41Department of Psychiatry, University of Arizona, Phoenix42Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology and Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts44Program in Medical and Population Genetics, Broad Ins.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois45Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri47Department of Neurology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, School of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts50Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington51Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida9The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee55Vanderbilit Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York57Gertrude H. Sergievsky Center, Columbia University, New York, New York58Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Genetics Program, Department of Medicine, Boston University, Boston, Massachusetts4Department of Biostatistics, Boston University, Boston, Massachusetts5Department of Ophthalmology, Boston University, Boston, Massachusetts59Department of Epidemiology, Bos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida9The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer Disease Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor63Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System (VAAAHS), Ann Arbor, Michigan64Michigan Alzheimer Disease Center, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois68Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Neurology, and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois73Cognitive Neurology and Alzheimer's Disease Center, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Swedish Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crocco</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>University of Virginia School of Medicine, Charlottesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia93Emory Alzheimer's Disease Center, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Neurogenetics Program, University of California Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida9The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department Neurology, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp; Science University, Portland103Department of Neurology, Portland Veterans Affairs Medical Center, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University, Boston, Massachusetts105Department of Pathology, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neuropsychology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chiao-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alheimer Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine - Pulmonary, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla113Department of Pathology, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>School of Nursing Northwest Research Group on Aging, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University, Boston, Massachusetts105Department of Pathology, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University, Chicago, Illinois115Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murrell</LastName><ForeName>Jill R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis95Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Vernon S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota119Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulson</LastName><ForeName>Henry L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University, New York120Alzheimer's Disease Center, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Southwestern, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles122Department of Psychiatry, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thornton-Wells</LastName><ForeName>Tricia A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Vanderbilit Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles125Department of Pathology &amp; Laboratory Medicine, University of California Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Pathology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University, Chicago, Illinois127Department of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, North Carolina128Department of Psychiatry &amp; Behavioral Sciences, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wishnek</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Evelyn F. McKnight Brain Institute, Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH060451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA137788</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH60451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035137</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036502</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG035137</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG041718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG33193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA132378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RC2AG036502</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES013508</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000135</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129769</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG30146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>100140</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1RR00096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR02777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2014 Nov;71(11):1457</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25199842</ArticleId><ArticleId IdType="mid">NIHMS655138</ArticleId><ArticleId IdType="pmc">PMC4314944</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1491</ArticleId><ArticleId IdType="pii">1900799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992 Jan;42(1):115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer&#x2019;s disease in a community population of older persons. Higher than previously reported. Jama. 1989 Nov 10;262(18):2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Study of Health and Aging Working Group Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994 Mar 15;150(6):899&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1486712</ArticleId><ArticleId IdType="pubmed">8131123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999 Nov;15(5):365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011 May;43(5):429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011 May;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YJ, Oliveira SA, Xu P, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15;12(24):3259&#x2013;3267.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570706</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology. 1996 Mar;46(3):673&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618665</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Cache County Study I. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry. 2004 May;61(5):518&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123497</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Tanaka T. Alzheimer&#x2019;s disease risk genes and the age-at-onset phenotype. Neurobiol Aging. 2013 Nov;34(11):2696&#x2013;e2691-2695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038407</ArticleId><ArticleId IdType="pubmed">23870418</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JT, Li L, Yuan J, Zhang ZX. Correlation between Apolipoprotein E polymorphism and age at onset of Alzheimer&#x2019;s disease in a Chinese Han population] Zhonghua yi xue za zhi. 2013 Jan 15;93(3):182&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">23570590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon OD, Khaleeq A, Chan W, Pavlik VN, Doody RS. Apolipoprotein E polymorphism and age at onset of Alzheimer&#x2019;s disease in a quadriethnic sample. Dement Geriatr Cogn Disord. 2010;30(6):486&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">21252542</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993 Aug 13;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer&#x2019;s disease: the NIMH genetics initiative. Neurology. 1997 Jan;48(1):139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr;70(4):985&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379130</ArticleId><ArticleId IdType="pubmed">11875758</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Marchani EE, Bird TD, Steinbart EJ, Blacker D, Wijsman EM. Genome scan of age-at-onset in the NIMH Alzheimer disease sample uncovers multiple loci, along with evidence of both genetic and sample heterogeneity. Am J Med Genet B Neuropsychiatr Genet. 2011 Dec;156B(7):785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168696</ArticleId><ArticleId IdType="pubmed">21812099</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmans P, Hamshere M, Hollingworth P, et al. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet. 2005 May 5;135B(1):24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15729734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson MR, Li J, Wiener HW, et al. A genomic scan for age at onset of Alzheimer&#x2019;s disease in 437 families from the NIMH Genetic Initiative. Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):784&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661765</ArticleId><ArticleId IdType="pubmed">18189239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Barral S, Cheng R, et al. Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer&#x2019;s disease. Neurogenetics. 2008 Feb;9(1):51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701253</ArticleId><ArticleId IdType="pubmed">17940814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Barmada MM, Demirci FY, et al. Genome-wide association analysis of age-at-onset in Alzheimer&#x2019;s disease. Mol Psychiatry. 2012 Oct 18;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262952</ArticleId><ArticleId IdType="pubmed">22005931</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 Sep;81(3):559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>McPeek MS, Sun L. Statistical tests for detection of misspecified relationships by use of genome-screen data. Am J Hum Genet. 2000 Mar;66(3):1076&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288143</ArticleId><ArticleId IdType="pubmed">10712219</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet. 2010 Jul;11(7):499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">20517342</ArticleId></ArticleIdList></Reference><Reference><Citation>R: a language and environment for statistical computing. computer program.</Citation></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006 Aug;38(8):904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010 Sep 1;26(17):2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. 2006 computer program.</Citation></Reference><Reference><Citation>Daw EW, Payami H, Nemens EJ, et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000 Jan;66(1):196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="pubmed">10631151</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PLoS One. 2012;7(11):e50976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EL, Mok K, Hanney M, et al. Evidence that PICALM affects age at onset of Alzheimer&#x2019;s dementia in Down syndrome. Neurobiol Aging. 2013 Oct;34(10):2441 e2441&#x2013;2445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898582</ArticleId><ArticleId IdType="pubmed">23601808</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutation research. 2009 Jul 10;667(1-2):82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">19026668</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. TREM2 Variants in Alzheimer&#x2019;s Disease. N Engl J Med. 2012 Nov 14;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Ph DS, et al. Variant of TREM2 Associated with the Risk of Alzheimer&#x2019;s Disease. N Engl J Med. 2012 Nov 14;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010 May 7;328(5979):753&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448184</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JF, Fletcher BR, Kelley-Bell B, Kim DH, Gallagher M, Rapp PR. Age-related memory impairment is associated with disrupted multivariate epigenetic coordination in the hippocampus. PLoS One. 2012;7(3):e33249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3305324</ArticleId><ArticleId IdType="pubmed">22438904</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer&#x2019;s disease. Neurology. 1995 Mar;45(3 Pt 1):555&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898715</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25201279</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Use of medications of questionable benefit in advanced dementia.</ArticleTitle><Pagination><StartPage>1763</StartPage><EndPage>1771</EndPage><MedlinePgn>1763-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2014.4103</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Advanced dementia is characterized by severe cognitive impairment and complete functional dependence. Patients' goals of care should guide the prescribing of medication during such terminal illness. Medications that do not promote the primary goal of care should be minimized.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate the prevalence of medications with questionable benefit used by nursing home residents with advanced dementia, identify resident- and facility-level characteristics associated with such use, and estimate associated medication expenditures.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional study of medication use by nursing home residents with advanced dementia using a nationwide long-term care pharmacy database linked to the Minimum Data Set (460 facilities) between October 1, 2009, and September 30, 2010.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Use of medication deemed of questionable benefit in advanced dementia based on previously published criteria and mean 90-day expenditures attributable to these medications per resident. Generalized estimating equations using the logit link function were used to identify resident- and facility-related factors independently associated with the likelihood of receiving medications of questionable benefit after accounting for clustering within nursing homes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 5406 nursing home residents with advanced dementia, 2911 (53.9%) received at least 1 medication with questionable benefit (range, 44.7% in the Mid-Atlantic census region to 65.0% in the West South Central census region). Cholinesterase inhibitors (36.4%), memantine hydrochloride (25.2%), and lipid-lowering agents (22.4%) were the most commonly prescribed. In adjusted analyses, having eating problems (adjusted odds ratio [AOR], 0.68; 95% CI, 0.59-0.78), a feeding tube (AOR, 0.58; 95% CI, 0.48-0.70), or a do-not-resuscitate order (AOR, 0.65; 95% CI, 0.57-0.75), and enrolling in hospice (AOR, 0.69; 95% CI, 0.58-0.82) lowered the likelihood of receiving these medications. High facility-level use of feeding tubes increased the likelihood of receiving these medications (AOR, 1.45; 95% CI, 1.12-1.87). The mean (SD) 90-day expenditure for medications with questionable benefit was $816 ($553), accounting for 35.2% of the total average 90-day medication expenditures for residents with advanced dementia who were prescribed these medications.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Most nursing home residents with advanced dementia receive medications with questionable benefit that incur substantial associated costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tjia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briesacher</LastName><ForeName>Becky A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Meyers Primary Care Institute, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Wistar Institute, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Meyers Primary Care Institute, Worcester, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Hebrew Senior Life, Institute for Aging Research, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG031836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HS019579</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG031836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG033640</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24AG033640</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HS19579</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Intern Med. 2014 Dec;174(12):2037</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2014 Nov;174(11):1771-2. doi: 10.1001/jamainternmed.2014.3277.</RefSource><PMID Version="1">25200598</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2015 Feb;175(2):315. doi: 10.1001/jamainternmed.2014.7026.</RefSource><PMID Version="1">25642674</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2015 Feb;175(2):315-6. doi: 10.1001/jamainternmed.2014.7029.</RefSource><PMID Version="1">25642675</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006300" MajorTopicYN="N">Health Services Misuse</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057970" MajorTopicYN="N">Inappropriate Prescribing</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013727" MajorTopicYN="N">Terminal Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25201279</ArticleId><ArticleId IdType="mid">NIHMS742215</ArticleId><ArticleId IdType="pmc">PMC4689196</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2014.4103</ArticleId><ArticleId IdType="pii">1901117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778850</ArticleId><ArticleId IdType="pubmed">19828530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010;58(5):880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910133</ArticleId><ArticleId IdType="pubmed">20406320</ArticleId></ArticleIdList></Reference><Reference><Citation>Blass DM, Black BS, Phillips H, et al. Medication use in nursing home residents with advanced dementia. Int J Geriatr Psychiatry. 2008;23(5):490&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944007</ArticleId></ArticleIdList></Reference><Reference><Citation>Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17397439</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchins DJ, Hanrahan P. What is appropriate health care for end-stage dementia? J Am Geriatr Soc. 1993;41(1):25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7678104</ArticleId></ArticleIdList></Reference><Reference><Citation>Field MJ, Cassel CK, editors. Committee on Care at the End of Life, Institute of Medicine. Approaching Death: Improving Care at the End of Life. Washington, DC: National Academy Press; 1998. Introduction.</Citation></Reference><Reference><Citation>Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc. 2008;56(7):1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">18482301</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567597</ArticleId></ArticleIdList></Reference><Reference><Citation>Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med. 2008;11(5):738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">18588406</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons C, Briesacher BA, Givens JL, Chen Y, Tjia J. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841243</ArticleId><ArticleId IdType="pubmed">21668913</ArticleId></ArticleIdList></Reference><Reference><Citation>Briesacher BA, Soumerai SB, Field TS, Fouayzi H, Gurwitz JH. Medicare Part D&#x2019;s exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010;170(8):693&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907144</ArticleId><ArticleId IdType="pubmed">20421554</ArticleId></ArticleIdList></Reference><Reference><Citation>Research Department American Health Care Association (AHCA) OSCAR data report: nursing facility patient characteristics report.  [January 26, 2013];  http://www.ahcancal.org/research_data/oscar_data/NursingFacilityPatientCharacteristics/HISTORICAL_HSNF_OSCAR%20Data%20Report_2006Q2.pdf.</Citation></Reference><Reference><Citation>Mor V. A comprehensive clinical assessment tool to inform policy and practice: applications of the Minimum Data Set. Med Care. 2004;42(4) suppl:III50&#x2013;III59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897009</ArticleId><ArticleId IdType="pubmed">20065204</ArticleId></ArticleIdList></Reference><Reference><Citation>Briesacher BA, Tjia J, Field T, Peterson D, Gurwitz JH. Antipsychotic use among nursing home residents. JAMA. 2013;309(5):440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522614</ArticleId><ArticleId IdType="pubmed">23385262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawes C, Phillips CD, Mor V, Fries BE, Morris JN. MDS data should be used for research. Gerontologist. 1992;32(4):563&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">1427264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmaier SL, Sloane PD, Guess HA, Koch GG. The MDS Cognition Scale: a valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set. J Am Geriatr Soc. 1994;42(11):1173&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">7963204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49(4):M174&#x2013;M182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8014392</ArticleId></ArticleIdList></Reference><Reference><Citation>Assistant Secretary for Planning and Evaluation, Office of Disability, Aging and Long-Term Care Policy, US Department of Health and Human Services. Hospitalizations of nursing home residents.  [February 19, 2014];  http://aspe.hhs.gov/daltcp/reports/2011/NHResHosp.pdf.</Citation></Reference><Reference><Citation>Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc. 2005;53(3):438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">15743286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64(9):1106&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">14628988</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">12919245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell SL, Miller SC, Teno JM, Kiely DK, Davis RB, Shaffer ML. Prediction of 6-month survival of nursing home residents with advanced dementia using ADEPT vs hospice eligibility guidelines. JAMA. 2010;304(17):1929&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017367</ArticleId><ArticleId IdType="pubmed">21045099</ArticleId></ArticleIdList></Reference><Reference><Citation>Red Book. Greenwood Village, CO: Thomson Reuters; 2010.  [November 19, 2012].   http://www.redbook.com/redbook/awp/</Citation></Reference><Reference><Citation>US Department of Health and Human Services, Office of Inspector General. Medicaid&#x2019;s Use of Revised Average Wholesale Prices. Washington, DC: US Department of Health and Human Services; 2001.</Citation></Reference><Reference><Citation>Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA. 2000;283(24):3230&#x2013;3235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10866871</ArticleId></ArticleIdList></Reference><Reference><Citation>Laroche ML, Perault-Pochat M-C, Ingrand I, et al. French Centres of Pharmacovigilance Network. Adverse drug reactions in patients with Alzheimer&#x2019;s disease and related dementia in France. Pharmacoepidemiol Drug Saf. 2013;22(9):952&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">23794320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganjavi H, Herrmann N, Rochon PA, et al. Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord. 2007;23(6):395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">17396031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourhash&#xe9;mi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(1):21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjia J, Field TS, Mazor KM, et al. Dementia and risk of adverse warfarin-related events in the nursing home setting. Am J Geriatr Pharmacother. 2012;10(5):323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063288</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick WC, Kukull WA, van Belle G, Bowen JD, Teri L, Larson EB. Symptom patterns and comorbidity in the early stages of Alzheimer&#x2019;s disease. J Am Geriatr Soc. 1994;42(5):517&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">8176147</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol. 2002;58(5):371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12185561</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2003;51(7):937&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834513</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyer VA US Preventive Services Task Force. Screening for cognitive impairment in older adults: US Preventive Services task force recommendation statement. Ann Intern Med. 2014;160(11):791&#x2013;797. doi: 10.7326/M14-0496.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0496</ArticleId><ArticleId IdType="pubmed">24663815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988459</ArticleId><ArticleId IdType="pubmed">19622011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Kilander L, Eriksson S, et al. Severe Alzheimer&#x2019;s Disease Study Group. Donepezil in patients with severe Alzheimer&#x2019;s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581404</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine) Int J Geriatr Psychiatry. 1999;14(2):135&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">10885864</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer&#x2019;s disease. N Engl J Med. 2012;366(10):893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">22397651</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life. Drugs Aging. 2010;27(6):435&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">20524704</ArticleId></ArticleIdList></Reference><Reference><Citation>Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19447360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824303</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">21342078</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs.  [January 15, 2013];  http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.</Citation></Reference><Reference><Citation>Gozalo P, Teno JM, Mitchell SL, et al. End-of-life transitions among nursing home residents with cognitive issues. N Engl J Med. 2011;365(13):1212&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236369</ArticleId><ArticleId IdType="pubmed">21991894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell SL, Teno JM, Roy J, Kabumoto G, Mor V. Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment. JAMA. 2003;290(1):73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessert CE, Haller IV, Johnson BP. Regional variation in care at the end of life. BMC Geriatr. 2013;13:39. doi: 10.1186/1471-2318-13-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-13-39</ArticleId><ArticleId IdType="pmc">PMC3649921</ArticleId><ArticleId IdType="pubmed">23635315</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman DC, Esty AR, Fisher ES, Chang CH. Trends and variation in end-of-life care for Medicare beneficiaries with severe chronic illness: a report of the Dartmouth Atlas Project.  [May 27, 2014];  www.dartmouthatlas.org/downloads/reports/EOL_Trend_Report_0411.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">36516285</ArticleId></ArticleIdList></Reference><Reference><Citation>American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616&#x2013;631. doi: 10.1111/j.1532-5415.2012.03923.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2012.03923.x</ArticleId><ArticleId IdType="pmc">PMC3571677</ArticleId><ArticleId IdType="pubmed">22376048</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher DS. Cost-effectiveness of drug therapies for Alzheimer&#x2019;s disease: a brief review. Neuropsychiatr Dis Treat. 2008;4(3):549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526383</ArticleId><ArticleId IdType="pubmed">18830441</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoni-Wastila L, Shaffer T, Stuart B US Department of Health and Human Services. National estimates of prescription drug utilization and expenditures in long-term care facilities.  [February 19, 2014];  http://aspe.hhs.gov/daltcp/reports/2006/pdnatest.pdf.</Citation></Reference><Reference><Citation>Sisko AM, Truffer CJ, Keehan SP, Poisal JA, Clemens MK, Madison AJ. National health spending projections. Health Aff (Millwood) 2010;29(10):1933&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">20829295</ArticleId></ArticleIdList></Reference><Reference><Citation>Omnibus Budget Reconciliation Act of 1987, OBRA-87, Public Law No. 100&#x2013;203 Subtitle C: Nursing Home Reform, F329 Unnecessary drugs; 100th Cong; 1987.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25176015</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>371</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Angiotensin-neprilysin inhibition versus enalapril in heart failure.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1004</EndPage><MedlinePgn>993-1004</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1409077</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P&lt;0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P&lt;0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P&lt;0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P&lt;0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMurray</LastName><ForeName>John J V</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the British Heart Foundation (BHF) Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (J.J.V.M.); the Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas (M.P.); the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston (A.S.D., S.D.S.); Novartis Pharmaceuticals, East Hanover, NJ (J.G., M.P.L., A.R.R., V.C.S.); Institut de Cardiologie de Montr&#xe9;al, Universit&#xe9; de Montr&#xe9;al, Montreal (J.L.R.); the Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden (K.S.); National Heart and Lung Institute, Imperial College London, London (K.S.); and the Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston (M.R.Z.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Packer</LastName><ForeName>Milton</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Akshay S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Jianjian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lefkowitz</LastName><ForeName>Martin P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Rizkala</LastName><ForeName>Adel R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Jean L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Victor C</ForeName><Initials>VC</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Swedberg</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zile</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><CollectiveName>PARADIGM-HF Investigators and Committees</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01035255</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000613">Aminobutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>69PN84IO1A</RegistryNumber><NameOfSubstance UI="D004656">Enalapril</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WB8FT61183</RegistryNumber><NameOfSubstance UI="C549068">sacubitril and valsartan sodium hydrate drug combination</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Sep 11;371(11):1062-4. doi: 10.1056/NEJMe1409898.</RefSource><PMID Version="1">25176014</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2014 Nov;11(11):618. doi: 10.1038/nrcardio.2014.139.</RefSource><PMID Version="1">25223453</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Dec 11;371(24):2336-7. doi: 10.1056/NEJMc1412654.</RefSource><PMID Version="1">25494275</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Dec 11;371(24):2335. doi: 10.1056/NEJMc1412654.</RefSource><PMID Version="1">25494276</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Dec 11;371(24):2335-6. doi: 10.1056/NEJMc1412654.</RefSource><PMID Version="1">25494277</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Dec 11;371(24):2336. doi: 10.1056/NEJMc1412654.</RefSource><PMID Version="1">25494278</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>G Ital Cardiol (Rome). 2014 Dec;15(12):651-5. doi: 10.1714/1718.18762.</RefSource><PMID Version="1">25533113</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Perspect Infirm. 2015 Jan-Feb;12(1):61.</RefSource><PMID Version="1">25651686</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2015 Apr;20(2):61. doi: 10.1136/ebmed-2014-110112.</RefSource><PMID Version="1">25659916</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2015 Feb 17;162(4):JC2. doi: 10.7326/ACPJC-2015-162-4-002.</RefSource><PMID Version="1">25686189</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Ther. 2017 Mar/Apr;24(2):e109-e110. doi: 10.1097/MJT.0000000000000571.</RefSource><PMID Version="1">28266964</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000613" MajorTopicYN="N">Aminobutyrates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004656" MajorTopicYN="N">Enalapril</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packer</LastName><ForeName>Milton</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swedberg</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zile</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefkowitz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Felipe</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhaecke</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramires</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katova</LastName><ForeName>Tzvetana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez</LastName><ForeName>Efrain</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belohlavek</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Refsgaard</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lederballe</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>Yan Carlo</ForeName><Initials>YC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Arvo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peuhkurinen</LastName><ForeName>Keijo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagege</LastName><ForeName>Alber-Alain</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arango</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merkely</LastName><ForeName>Bela</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senni</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erglis</LastName><ForeName>Andrejs</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrulioniene</LastName><ForeName>Zaneta</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llamas</LastName><ForeName>Edmundo Bayram</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosterd</LastName><ForeName>Arend</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sibulo</LastName><ForeName>Antonio S</ForeName><Initials>AS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Negrusz-Kawecka</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silva-Cardoso</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinereanu</LastName><ForeName>Dragos</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boytsov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dukat</LastName><ForeName>Andrej</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgess</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Kee-Sik</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fu</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>C-H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiatchoosakun</LastName><ForeName>Songsak</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozan</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squire</LastName><ForeName>Iain</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starling</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teerlink</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dargie</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foley</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komajda</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pocock</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>Akshay S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barkoudah</LastName><ForeName>Ebrahim</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brahimi</LastName><ForeName>Abdel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charytan</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duong</LastName><ForeName>Chau</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finn</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartley</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jhund</LastName><ForeName>Pardeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vazir</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinrauch</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Allen P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zuraw</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenlaw</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Felipe</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albisu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarisqueta</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amuchastegui</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Astesiano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avila</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beloscar</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrego</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustos</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calella</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carbajales</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caruso</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caruso</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casab&#xe9;</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cimbaro Canella</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colombo Berra</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colque</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costello</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dran</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferre Pacora</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabito</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glenny</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guzman</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iba&#xf1;ez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingaramo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kotliar</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon de la Fuente</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liberman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liniado</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llanos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobo Marquez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luquez</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackinnon</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallagray</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martingano</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercado</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moises Azize</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parody</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez Rey</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petenian</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rojas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvatierra Ruiz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarjanovich</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarries</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiavi</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sessa</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vico</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaidman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanhaecke</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decroly</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dendale</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ector</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friart</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyse</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Missault</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulleners</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smolders</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandekerckhove</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weytjens</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wollaert</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramires</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrade</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bassan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borelli</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Botelho</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braga</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braile</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duda</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandes</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaeger</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koehler</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luiz Rech</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesquita</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moraes</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Neto</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuenschwander</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paiva</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rassi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reis</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabelo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reis</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saporito</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simoes</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Souza</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilas Boas</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katova</LastName><ForeName>Tzvetana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benov</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeva-Chompalova</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chobanska</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denchev</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dimov</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donova</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Georgiev</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gotchev</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goudev</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gruev</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hergeldjieva</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazov</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manukov</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchev</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihov</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milanova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mileva-Manolova</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mincheva-Kabakchieva</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parvanova</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pencheva</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petranov</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raev</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramshev</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirakova</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staneva</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tisheva-Gospodinova</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todorov</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tokmakova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tzekova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valchanova</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yotov</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhelev</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergeron</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cha</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeGr&#xe2;ce</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deslongchamps</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dion</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannetti</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huynh</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klinke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornder</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labonte</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lauzon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepage</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mak</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moe</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murthy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pandey</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajda</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rupka</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabe-Affaki</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sestier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheppard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yao</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albornoz</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avenda&#xf1;o</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cobos</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escobar</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jalil</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanas</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sepulveda</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stockins</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yovaniniz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gui</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>H D</ForeName><Initials>HD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ke</LastName><ForeName>Y N</ForeName><Initials>YN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>L G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>X D</ForeName><Initials>XD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>X L</ForeName><Initials>XL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>S W</ForeName><Initials>SW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>X H</ForeName><Initials>XH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>N L</ForeName><Initials>NL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuan</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez</LastName><ForeName>Efrain</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Accini</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almanzar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coronel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Echeverria</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manzur</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;a</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynales</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sotomayor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velasquez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xe9;lez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vesga</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belohlavek</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burianova</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carda</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cech</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cepelak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanustiakova</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horny</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krupicka</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kvasnicka</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindovsky</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenc</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malek</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malik</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandovec</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrova</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podzemska</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Povolny</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radvan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richter</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riha</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabl</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slaby</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svejda</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Telekes</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vomacka</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zemek</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lederballe</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Refsgaard</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egstrup</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elming</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eske</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf8;tzsche</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jensen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xf8;ber</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>May</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rickers</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steffensen</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulino</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>Yan Carlos</ForeName><Initials>YC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>F L</ForeName><Initials>FL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mariscal</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marmol</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Arvo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaasik</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaik</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laane</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peuhkurinen</LastName><ForeName>Keijo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe4;&#xe4;skel&#xe4;inen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiilavuori</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taurio</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagege</LastName><ForeName>Albert Alain</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexeeva-Kovalchuk</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berdague</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berneau</LastName><ForeName>J-B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouvier</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damien</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damy</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davy</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decoulx</LastName><ForeName>D Eric</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>El-Mansour</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etchecopar</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galinier</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibelin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gosse</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guetlin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labeque</LastName><ForeName>J-N</ForeName><Initials>JN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livarek</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Logeart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martelet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nazeyrollas</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuder</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nourredine</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poulard</LastName><ForeName>J-E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>RaidRihani</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatier</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>N-T To</ForeName><Initials>NT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yannick</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zannad</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xf6;hm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adelberger</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Zoebi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bastian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behrens</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessler</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braun</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brehm</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buhr</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cieslinski</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>vom Dahl</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daut</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demmig</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denny</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ebert</LastName><ForeName>H-H</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fechtrup</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fischer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frick</LastName><ForeName>H-M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genth-Zotz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerbaulet</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germann</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ge&#xdf;ner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gola</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gr&#xf6;nefeld</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagenow</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hampf</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartmann</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauf</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hegeler-Molkewehrum</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hegemann</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermes</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Himpel-B&#xf6;nninghoff</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoeltz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerwan-Keim</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kindermann</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knapp</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krause</LastName><ForeName>K-H</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krosse</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xfc;hne</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuhrs</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leicht</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf6;be</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loos</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehling</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melchior</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menzel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;nzel</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Natour</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naudts</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naumann</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nischik</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olbrich</LastName><ForeName>H-G</ForeName><Initials>HG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pohl</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prohaska</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proskynitopoulus</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reimer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roeder</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rummel</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salbach</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaum</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schenkenberger</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schnabel</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreckenberg</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreibm&#xfc;ller</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreiner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schumacher</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segner</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seibert</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siao</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siao</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohn</LastName><ForeName>H-Y</ForeName><Initials>HY</Initials></Investigator><Investigator ValidYN="Y"><LastName>St&#xf6;hring</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tangerding</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taubert</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terhorst</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tesch</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toursarkissian</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uebel</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weyland</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilke</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zemmrich</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeh</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zotz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arango</LastName><ForeName>Juan Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arriola</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corona</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leal</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ovando</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paniagua</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velasquez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wyss</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tse</LastName><ForeName>H F</ForeName><Initials>HF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>S K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yip</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merkely</LastName><ForeName>Bela</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrassy</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreka</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakai</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Csapo</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cziraki</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xc9;des</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forster</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hajko</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Illes</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xe1;noskuti</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalina</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xe1;szl&#xf3;</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupkovics</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matoltsy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noori</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyolczas</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papp</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salamon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sz&#xe1;ntai</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szocs</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomcs&#xe1;nyi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toth</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varj&#xfa;</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veress</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vertes</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Z&#xe1;molyi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zilahi</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gudnason</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorgeirsson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abhyankar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>D K</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagirath</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banker</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bisne</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohra</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chopra</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dharmadhikari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulwani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gadkari</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghaisas</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basavanagowdappa</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiremath</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagtap</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jindal</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerkar</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumbla</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malipeddi</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathan</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murthy</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pai</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pandey</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prakash</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>M Srinivasa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>N Srinivasa</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarma</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shamsudden</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakkar</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thanvi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trivedi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vijan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yugandhar</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aronson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben Gal</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goland</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marmor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayler</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shochat</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senni</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anastasio</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldin</LastName><ForeName>M G</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunelli</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casolo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coppolino</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosmi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danzi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Destro</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Napoli</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Ospina</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fucili</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gigantino</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liberato</LastName><ForeName>N L</ForeName><Initials>NL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lembo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magrini</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannarino</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchese</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minneci</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modena</LastName><ForeName>M G</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mos</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Napoli</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Opasich</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pajes</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perticone</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pileri</LastName><ForeName>P V</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poddighe</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronchi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saba</LastName><ForeName>P S</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sicuro</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvestri</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salerno Uriarte</LastName><ForeName>J A</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spagnuolo</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sprovieri</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terrosu</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tespili</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uriarte</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vergoni</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volterrani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erglis</LastName><ForeName>Andrejs</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dormidontova</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eglite</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lvova</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rancane</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sime</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrulioniene</LastName><ForeName>Zaneta</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luksiene</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maleckas</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazutavicius</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miliuniene</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrulioniene</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slapikas</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmad</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chew</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ong</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llamas</LastName><ForeName>Edmundo Bayram</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilera</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arenas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llamas</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meaney</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orihuela</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pav&#xed;a</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salcido</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solache</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velasco</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosterd</LastName><ForeName>Arend</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellersen</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derks</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dijkgraaf</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunselman</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Eck</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurlek</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>den Hartog</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoedemaker</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koolen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liem</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milhous</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Nooijer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pronk</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunner-la Rocca</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronner</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swart</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tjeerdsma</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willems</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avil&#xe9;s</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frago</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieto</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alegre</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aza&#xf1;ero</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godoy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heredia</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orihuela</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roldan</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urquiaga</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sibulo</LastName><ForeName>Antonio S</ForeName><Initials>AS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Anonuevo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atilano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borromeo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castillo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrolino</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerrero</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locnen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manlutac</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogelio</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosita</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruales</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilela</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Negrusz-Kawecka</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bebenek</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobkowicz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cymerman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dabrowska</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foczpaniak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jazwinska-Tarnawska</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kabara</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kania</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolaczyk</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kucharski</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landa</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirek-Bryniarska</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piepiorka</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijanowski</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sciborski</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szpajer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyminski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weglarz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wojciechowska</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wronska</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardoso</LastName><ForeName>J Silva</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almeida</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrade</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braganca</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carvalho</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fonseca</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliveira</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padua</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvestre</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soares</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinereanu</LastName><ForeName>Dragos</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andor</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartos</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basarab</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coman</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Copaci</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cristea</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dragulescu</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enache</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fruntelata</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iliescu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Istratoaie</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lighezan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Militaru</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nanea</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nechita</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puschita</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomescu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tudoran</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boitsov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ageev</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Averkov</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akimov</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ballyuzek</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baranov</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baranova</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbarash</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkovich</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berns</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessonova</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyarkin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulashova</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chernetsov</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chukaeva</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamensky</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dovgalevsky</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dovgolis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duplyakov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ermoshkina</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitilev</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galyavich</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gendlin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gofman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goloschekin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomova</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordienko</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karpov</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kastanayan</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khromtsova</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kisliak</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kobalava</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konradi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korolev</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosmacheva</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostenko</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koziolova</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuimov</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulibaba</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebedev</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesnov</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libis</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopatin</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makukhin</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masterov</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moiseeva</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morozova</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motylev</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murashkina</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nosov</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oleynikov</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palatkina</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parmon</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pimenov</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Privalov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rafalsky</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rebrov</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reznik</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruda</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saifutdinov</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayganov</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shvarts</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shpagina</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shustov</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shutemova</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sitnikova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sizova</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smolenskaya</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solovieva</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staroverov</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struk</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svistov</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarasov</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarlovskaya</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tereschenko</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trofimov</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uspensky</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasilieva</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vezikova</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vishnevsky</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volkov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yakhontov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yakovlev</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yavdosyuk</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zateyshchikova</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zharkov</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhilyaev</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zotov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zrazhevsky</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ong</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duk&#xe1;t</LastName><ForeName>Andrej</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antal&#xed;k</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ban&#xed;kov&#xe1;</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deme&#x161;ov&#xe1;</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dvor&#x17e;&#xe1;k</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fazeka&#x161;</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foldiov&#xe1;</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>F&#xfc;l&#xf6;p</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kabaivanov</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kov&#xe1;cs</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma&#x10d;ek</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majer&#x10d;&#xe1;k</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maz&#xfa;r</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihal&#xed;kov&#xe1;</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olexa</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pacherov&#xe1;</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palinsk&#xfd;</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe1;lka</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pella</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remi&#x161;ov&#xe1;</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schichorov&#xe1;</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smik</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sokolov&#xe1;</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#x160;uch</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vi&#x148;ansk&#xe1;</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgess</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baben</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bester</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruning</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delport</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dindar</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foccart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerntholtz</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellstrom</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horak</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jamjam</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapp</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latiff</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerumo</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombaard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manga</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Merwe</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mkhwanazi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mpe</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naidoo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padayachee</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranjith</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Rensburg</LastName><ForeName>D Jansen</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saaiman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebopa</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tayob</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Theron</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vally</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venter</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wellmann</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Zyl</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Kee-Sik</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baek</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zo</LastName><ForeName>J-H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>G-R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>D-H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>S-M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>D-S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>B-J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>D-G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shin</LastName><ForeName>J-H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoo</LastName><ForeName>B-S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luis-Arias</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arias-Casta&#xf1;o</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Com&#xed;n</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Teresa</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez-Aviles</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Huelgas</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez-Bueno</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cos&#xed;n</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cremer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crespo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deben</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freixa</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galve</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mainar</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez-Sell&#xe9;s</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzal</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>N&#xfa;&#xf1;ez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pe&#xf1;a</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyes</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanmart&#xed;n</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vida</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fu</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahlstr&#xf6;m</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagerman</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hajimirsadeghi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kempe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thors&#xe9;n</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zethson-Halld&#xe9;n</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsu</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>L Y</ForeName><Initials>LY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pai</LastName><ForeName>P Y</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsao</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tzeng</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiatchoosakun</LastName><ForeName>Songsak</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hengrussamee</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piyayotai</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanguanwong</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thongsri</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozan</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aktoz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barcin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birdane</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camsari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ermis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guray</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kudat</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ural</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yavuzgil</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yenigun</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yigit</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokusoglu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squire</LastName><ForeName>Iain</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolakis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banerjee</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barr</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatia</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bogle</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boos</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brigden</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulugahapitiya</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dayer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutka</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>El-Harari</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaballa</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghandi</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glover</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadr</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalra</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kardos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leslie</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynch</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacFadyen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahmood</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mamas</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Megarry</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohindra</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>More</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moriarty</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muthusamy</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neyses</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nightingale</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Toole</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purvis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryding</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobolewska</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soo</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strain</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trelawny</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trevelyan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkin</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witherow</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woldman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yousef</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starling</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teerlink</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adamson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akinboboye</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akyea-Djamson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amkieh</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anand</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awasty</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banish</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bank</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargout</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnard</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beacom</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berk</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Best</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bilazarian</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouchard</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozkurt</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breisblatt</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brookfield</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Browne</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canadas-Zizzias</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carr</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chung</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denning</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dexter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dharma</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Efstratiadis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fattal</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenster</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Floro</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frivold</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuhs</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldscher</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gould</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grazette</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laufer</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieber</LastName><ForeName>I H</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haas</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habet</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hack</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haidar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halpern</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hargrove</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hass</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hattler</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazelrigg</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heilman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heroux</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzog</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hotchkiss</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iteld</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaffrani</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janik</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jardula</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaneshige</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klapholz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koren</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larrain</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lasala</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laufer</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieber</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magno</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maher</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maisel</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maislos</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malkowski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallis</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandviwala</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mani</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markham</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marple</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maurer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKenzie</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehrle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mishkin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mody</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naidu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neutel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ooi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orchard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrott</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Poling</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prodafikas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ptacin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinlan</LastName><ForeName>E</ForeName><Initials>E</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rama</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rawitscher</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosado</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oberoi</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samal</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmalfuss</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seals</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selektor</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaefer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seto</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shanes</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sims</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sooudi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sotolongo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suiter</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunderam</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thadani</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thrasher</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trichon</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicuna</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vranian</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallach</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wickemeyer</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wight</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zebrack</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendoza</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avenda&#xf1;o</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silva</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vergara</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25176015</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1409077</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25209273</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>37</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Differential release of &#x3b2;-amyloid from dendrite- versus axon-targeted APP.</ArticleTitle><Pagination><StartPage>12313</StartPage><EndPage>12327</EndPage><MedlinePgn>12313-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2255-14.2014</ELocationID><Abstract><AbstractText>The &#x3b2;-amyloid precursor protein (APP) plays a central role in the pathogenesis of Alzheimer's disease. APP is processed in neurons, but little is known about the relative contributions of presynaptic or postsynaptic compartments to the release of A&#x3b2; peptides. To address this issue, we transduced primary neurons from Sprague-Dawley rats or APP(-/-) mice (B6.129S7-App(tm1Dbo)/J) with lentiviral constructs expressing APP chimeras harboring targeting motifs from low-density lipoprotein receptor or neuron-glia cell-adhesion molecule to polarize expression to either dendritic or axonal membranes, respectively. Using imaging and quantitative biochemical approaches, we now report that APP selectively targeted to either axons or dendrites leads to the secretion of full-length A&#x3b2; peptides with significantly elevated release from dendritic compartments. These findings reveal that the enzymatic machinery required for production of A&#x3b2; peptides are operative both in presynaptic and postsynaptic compartments of primary neurons, leading to the suggestion that A&#x3b2;-mediated impairments in glutamatergic neurotransmission is the result of A&#x3b2; release from both local and distal neuronal compartments.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3412313-15$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeBoer</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Committee on Neurobiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolios</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, Illinois 60637, and ssisodia@bsd.uchicago.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 AG034001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS061777</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30AG034001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">axonal targeting</Keyword><Keyword MajorTopicYN="N">dendritic targeting</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25209273</ArticleId><ArticleId IdType="pmc">PMC4160770</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2255-14.2014</ArticleId><ArticleId IdType="pii">34/37/12313</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buggia-Pr&#xe9;vot V, Fernandez CG, Udayar V, Vetrivel KS, Elie A, Roseman J, Sasse VA, Lefkow M, Meckler X, Bhattacharyya S, George M, Kar S, Bindokas VP, Parent AT, Rajendran L, Band H, Vassar R, Thinakaran G. A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease A&#x3b2; production. Cell Rep. 2013;5:1552&#x2013;1563. doi: 10.1016/j.celrep.2013.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.12.006</ArticleId><ArticleId IdType="pmc">PMC3932704</ArticleId><ArticleId IdType="pubmed">24373286</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Hartmann H, Lorenzo A, Wong C, Baumann K, Sommer B, Staufenbiel M, Yankner BA. Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. J Neurosci. 1997;17:5101&#x2013;5107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573321</ArticleId><ArticleId IdType="pubmed">9185547</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci. 1998;18:9629&#x2013;9637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793291</ArticleId><ArticleId IdType="pubmed">9822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234. doi: 10.1038/85064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Meyn L, Fluhrer R, Teplow DB, Walter J, Haass C. Apical sorting of beta-secretase limits amyloid beta-peptide production. J Biol Chem. 2002;277:5637&#x2013;5643. doi: 10.1074/jbc.M109119200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109119200</ArticleId><ArticleId IdType="pubmed">11741885</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360:672&#x2013;674. doi: 10.1038/360672a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/360672a0</ArticleId><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Sung JC, Golde TE, Felsenstein KM, Wojczyk BS, Tanzi RE, Trojanowski JQ, Lee VM, Doms RW. Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Proc Natl Acad Sci U S A. 1996;93:9223&#x2013;9228. doi: 10.1073/pnas.93.17.9223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.17.9223</ArticleId><ArticleId IdType="pmc">PMC38623</ArticleId><ArticleId IdType="pubmed">8799182</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SS, Banker GA. The role of protein interaction motifs in regulating the polarity and clustering of the metabotropic glutamate receptor mGluR1a. J Neurosci. 2006;26:8115&#x2013;8125. doi: 10.1523/JNEUROSCI.1015-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1015-06.2006</ArticleId><ArticleId IdType="pmc">PMC6673791</ArticleId><ArticleId IdType="pubmed">16885225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Caceres A, Kosik KS. Intraneuronal compartments of the amyloid precursor protein. J Neurosci. 1993;13:3112&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576677</ArticleId><ArticleId IdType="pubmed">8331388</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ. &#x3b2;-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem. 1993;268:3021&#x2013;3024.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2:a006270. doi: 10.1101/cshperspect.a006270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006270</ArticleId><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung AY, Koo EH, Haass C, Selkoe DJ. Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. Proc Natl Acad Sci U S A. 1992;89:9439&#x2013;9443. doi: 10.1073/pnas.89.20.9439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.20.9439</ArticleId><ArticleId IdType="pmc">PMC50147</ArticleId><ArticleId IdType="pubmed">1409654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jareb M, Banker G. The polarized sorting of membrane proteins expressed in cultured hippocampal neurons using viral vectors. Neuron. 1998;20:855&#x2013;867. doi: 10.1016/S0896-6273(00)80468-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80468-7</ArticleId><ArticleId IdType="pubmed">9620691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406&#x2013;2415. doi: 10.1038/nprot.2006.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.356</ArticleId><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Skehel P, Dotti CG. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell. 2000;11:1213&#x2013;1224. doi: 10.1091/mbc.11.4.1213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.11.4.1213</ArticleId><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937. doi: 10.1016/S0896-6273(03)00124-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00124-7</ArticleId><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci. 2003;116:3339&#x2013;3346. doi: 10.1242/jcs.00643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00643</ArticleId><ArticleId IdType="pubmed">12829747</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A. 1990;87:1561&#x2013;1565. doi: 10.1073/pnas.87.4.1561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.4.1561</ArticleId><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224&#x2013;229. doi: 10.1038/nm0296-224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0296-224</ArticleId><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released &#x3b2;-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo AC, Haass C, Wagner SL, Teplow DB, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in Madin-Darby canine kidney cells. J Biol Chem. 1994;269:30966&#x2013;30973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7983032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyckman AW, Confaloni AM, Thinakaran G, Sisodia SS, Moya KL. Post-translational processing and turnover kinetics of presynaptically targeted amyloid precursor superfamily proteins in the central nervous system. J Biol Chem. 1998;273:11100&#x2013;11106. doi: 10.1074/jbc.273.18.11100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.18.11100</ArticleId><ArticleId IdType="pubmed">9556595</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, Borroni B, Cattabeni F, Sala C, Padovani A, Di Luca M. Synapse-associated protein-97 mediates &#x3b1;-secretase ADAM10 trafficking and promotes its activity. J Neurosci. 2007;27:1682&#x2013;1691. doi: 10.1523/JNEUROSCI.3439-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3439-06.2007</ArticleId><ArticleId IdType="pmc">PMC6673742</ArticleId><ArticleId IdType="pubmed">17301176</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan V, Varvel NH, Lamb BT, Muresan Z. The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci. 2009;29:3565&#x2013;3578. doi: 10.1523/JNEUROSCI.2558-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2558-08.2009</ArticleId><ArticleId IdType="pmc">PMC2669751</ArticleId><ArticleId IdType="pubmed">19295161</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479&#x2013;505. doi: 10.1146/annurev.neuro.21.1.479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.21.1.479</ArticleId><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R. Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem. 2004;279:39010&#x2013;39016. doi: 10.1074/jbc.M407101200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407101200</ArticleId><ArticleId IdType="pubmed">15234966</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman MA, Peck R, Glover G, He C, Carlin C, Banker G. Motifs that mediate dendritic targeting in hippocampal neurons: a comparison with basolateral targeting signals. Mol Cell Neurosci. 2005;29:173&#x2013;180. doi: 10.1016/j.mcn.2005.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.02.008</ArticleId><ArticleId IdType="pubmed">15911342</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Ikonen E, Tienari PJ, Cid-Arregui A, M&#xf6;nning U, Beyreuther K, Dotti CG. Intracellular routing of human amyloid protein precursor: axonal delivery followed by transport to the dendrites. J Neurosci Res. 1995;41:121&#x2013;128. doi: 10.1002/jnr.490410114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490410114</ArticleId><ArticleId IdType="pubmed">7674373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A. 1992;89:6075&#x2013;6079. doi: 10.1073/pnas.89.13.6075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.13.6075</ArticleId><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Koo EH, Hoffman PN, Perry G, Price DL. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci. 1993;13:3136&#x2013;3142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576678</ArticleId><ArticleId IdType="pubmed">8331390</ArticleId></ArticleIdList></Reference><Reference><Citation>Szodorai A, Kuan YH, Hunzelmann S, Engel U, Sakane A, Sasaki T, Takai Y, Kirsch J, M&#xfc;ller U, Beyreuther K, Brady S, Morfini G, Kins S. APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle. J Neurosci. 2009;29:14534&#x2013;14544. doi: 10.1523/JNEUROSCI.1546-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1546-09.2009</ArticleId><ArticleId IdType="pmc">PMC2849269</ArticleId><ArticleId IdType="pubmed">19923287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Crump CJ, Li YM. Dual role of &#x3b1;-secretase cleavage in the regulation of &#x3b3;-secretase activity for amyloid production. J Biol Chem. 2010;285:32549&#x2013;32556. doi: 10.1074/jbc.M110.128439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.128439</ArticleId><ArticleId IdType="pmc">PMC2952257</ArticleId><ArticleId IdType="pubmed">20675367</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW, Cunningham DD. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature. 1989;341:546&#x2013;549. doi: 10.1038/341546a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/341546a0</ArticleId><ArticleId IdType="pubmed">2507928</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196. doi: 10.1038/nn.2476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Selkoe DJ, Koo EH. Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995;129:431&#x2013;442. doi: 10.1083/jcb.129.2.431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.129.2.431</ArticleId><ArticleId IdType="pmc">PMC2199904</ArticleId><ArticleId IdType="pubmed">7721945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CC, Nokes RL, Wisco D, Anderson E, F&#xf6;lsch H, Winckler B. Pathway selection to the axon depends on multiple targeting signals in NgCAM. J Cell Sci. 2008;121:1514&#x2013;1525. doi: 10.1242/jcs.022442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.022442</ArticleId><ArticleId IdType="pubmed">18411247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van der Ploeg LH. &#x3b2;-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531. doi: 10.1016/0092-8674(95)90073-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90073-X</ArticleId><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25208536</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>349</Volume><PubDate><Year>2014</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Benzodiazepine use and risk of Alzheimer's disease: case-control study.</ArticleTitle><Pagination><StartPage>g5205</StartPage><MedlinePgn>g5205</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">g5205</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.g5205</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the relation between the risk of Alzheimer's disease and exposure to benzodiazepines started at least five years before, considering both the dose-response relation and prodromes (anxiety, depression, insomnia) possibly linked with treatment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Case-control study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The Quebec health insurance program database (RAMQ).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">1796 people with a first diagnosis of Alzheimer's disease and followed up for at least six years before were matched with 7184 controls on sex, age group, and duration of follow-up. Both groups were randomly sampled from older people (age &gt;66) living in the community in 2000-09.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">The association between Alzheimer's disease and benzodiazepine use started at least five years before diagnosis was assessed by using multivariable conditional logistic regression. Ever exposure to benzodiazepines was first considered and then categorised according to the cumulative dose expressed as prescribed daily doses (1-90, 91-180, &gt;180) and the drug elimination half life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Benzodiazepine ever use was associated with an increased risk of Alzheimer's disease (adjusted odds ratio 1.51, 95% confidence interval 1.36 to 1.69; further adjustment on anxiety, depression, and insomnia did not markedly alter this result: 1.43, 1.28 to 1.60). No association was found for a cumulative dose &lt;91 prescribed daily doses. The strength of association increased with exposure density (1.32 (1.01 to 1.74) for 91-180 prescribed daily doses and 1.84 (1.62 to 2.08) for &gt;180 prescribed daily doses) and with the drug half life (1.43 (1.27 to 1.61) for short acting drugs and 1.70 (1.46 to 1.98) for long acting ones).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Benzodiazepine use is associated with an increased risk of Alzheimer's disease. The stronger association observed for long term exposures reinforces the suspicion of a possible direct association, even if benzodiazepine use might also be an early marker of a condition associated with an increased risk of dementia. Unwarranted long term use of these drugs should be considered as a public health concern.</AbstractText><CopyrightInformation>&#xa9; Billioti de Gage et al 2014.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Billioti de Gage</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM, U657-Pharmacoepidemiology, Universit&#xe9; de Bordeaux, F-33000 Bordeaux, France sophie.billioti-de-gage@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moride</LastName><ForeName>Yola</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Center, University of Montreal Hospital Center, Montreal, Canada Faculty of Pharmacy, University of Montreal, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Center, University of Montreal Hospital Center, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurth</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Inserm Research Center for Epidemiology and Biostatistics, U897-Team Neuroepidemiology, F-33000 Bordeaux, France University of Bordeaux, College of Health Sciences, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdoux</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>INSERM, U657-Pharmacoepidemiology, Universit&#xe9; de Bordeaux, F-33000 Bordeaux, France Centre Hospitalier Charles Perrens, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tournier</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, U657-Pharmacoepidemiology, Universit&#xe9; de Bordeaux, F-33000 Bordeaux, France Centre Hospitalier Charles Perrens, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, U657-Pharmacoepidemiology, Universit&#xe9; de Bordeaux, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;gaud</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM, U657-Pharmacoepidemiology, Universit&#xe9; de Bordeaux, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2014 Sep 09;349:g5312. doi: 10.1136/bmj.g5312.</RefSource><PMID Version="1">25205606</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2014 Sep 10;349:g5555. doi: 10.1136/bmj.g5555.</RefSource><PMID Version="1">25209671</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychopharmacol. 2015 Feb;35(1):1-3. doi: 10.1097/JCP.0000000000000247.</RefSource><PMID Version="1">25407694</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Soins Gerontol. 2014 Nov-Dec;(110):7.</RefSource><PMID Version="1">25597061</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2015 Apr;20(2):75. doi: 10.1136/ebmed-2014-110117.</RefSource><PMID Version="1">25666019</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am Fam Physician. 2015 Feb 1;91(3):191-2.</RefSource><PMID Version="1">25822273</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that TK has received investigator-initiated research funding from the French National Research Agency and the US National Institutes of Health within the past two years and honorariums from <i>BMJ</i> and <i>Cephalalgia</i> for editorial services; MT received honorariums as a speaker from Astra Zeneca, BMS, and Janssen; AP participated in studies conducted by the Clinical Research Center of the Bordeaux Teaching Hospital and funded by Novartis, Sanofi-Aventis, Lundbeck, and Vivatech, none of which were related to the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25208536</ArticleId><ArticleId IdType="pmc">PMC4159609</ArticleId><ArticleId IdType="doi">10.1136/bmj.g5205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Alzheimer Report 2009. Alzheimer Disease International, 2009.</Citation></Reference><Reference><Citation>Dementia: a public health priority. World Health Organization, 2012.</Citation></Reference><Reference><Citation>Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand 2011;124:384-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21838738</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al. The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol 2013;27:761-70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778981</ArticleId><ArticleId IdType="pubmed">23884863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009;17:614-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19546656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011;19:151-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20808131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002;55:314-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11864804</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012;66:869-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22034632</ArticleId></ArticleIdList></Reference><Reference><Citation>Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460255</ArticleId><ArticleId IdType="pubmed">23045258</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Summary of product characteristics for benzodiazepines as anxiolytics or hypnotics. EMA, 1994.</Citation></Reference><Reference><Citation>Donoghue J, Lader M. Usage of benzodiazepines. A review. Int J Psychiatry in Clin Pract 2010;14:78-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">24922466</ArticleId></ArticleIdList></Reference><Reference><Citation>Dell&#x2019;osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013;28:7-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521806</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JS, Huang WF, Lin KM, Shih YT. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry 2008;23:618-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18058834</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf 2007;16:560-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286304</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharmacol Sci 2012;2012:416864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321276</ArticleId><ArticleId IdType="pubmed">22536226</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyares D, Guilleminault C, Ohayon MM, Tufik S. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004;38:327-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003439</ArticleId></ArticleIdList></Reference><Reference><Citation>Monane M, Glynn RJ, Avorn J. The impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residents. Clin Pharmacol Ther 1996;59:83-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8549038</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003;33:1223-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">14580077</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005;17:189-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16194790</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc 2000;48:811-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985;9:87-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2858084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anesthesiology 1990;72:926-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">1971164</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 1986;23:179-213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2878691</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812249</ArticleId></ArticleIdList></Reference><Reference><Citation>Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Lon L, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry 2009;70:584-92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711522</ArticleId><ArticleId IdType="pubmed">19323967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry 2011;26:364-72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204866</ArticleId><ArticleId IdType="pubmed">20845402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer&#x2019;s disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067364</ArticleId></ArticleIdList></Reference><Reference><Citation>Introduction to drug utilization research. World Health Organization, 2003.</Citation></Reference><Reference><Citation>Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011;76:1485-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">21490316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer&#x2019;s disease. Lancet 2011;377:1019-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechevallier N, Fourrier A, Berr C. [Benzodiazepine use in the elderly: the EVA Study]. Rev Epidemiol Sante Publique 2003;51:317-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">13130212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourrier A, Letenneur L, Dartigues JF, Moore N, Begaud B. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol 2001;57:419-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11599660</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010;75:27-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906403</ArticleId><ArticleId IdType="pubmed">20603482</ArticleId></ArticleIdList></Reference><Reference><Citation>Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011;7:323-31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327554</ArticleId><ArticleId IdType="pubmed">21537355</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Marien P, et al. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer&#x2019;s disease and healthy older adults. Int J Geriatr Psychiatry 2013;28:265-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22549770</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson L, Guo X, Waern M, Ostling S, Gustafson D, Bengtsson C, et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010;133:2217-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">20488887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterniczuk R, Theou O, Rusak B, Rockwood K. Sleep disturbance is associated with incident dementia and mortality. Curr Alzheimer Res 2013;10:767-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23905991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology&#x2014;a bidirectional relationship. Nat Rev Neurol 2014;10:115-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Assem-Hilger E, Jungwirth S, Weissgram S, Kirchmeyr W, Fischer P, Barnas C. Benzodiazepine use in the elderly: an indicator for inappropriately treated geriatric depression? Int J Geriatr Psychiatry 2009;24:563-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19016456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagnaoui R, Tournier M, Moride Y, Wolfson C, Ducruet T, Begaud B, et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing 2009;38:226-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Dis 1998;12:14-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539405</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaen G, van Amelsvoort L. A weight of evidence approach to causal inference. J Clin Epidemiol 2009;62:270-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18834711</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostbye T, Kristjansson B, Hill G, Newman SC, Brouwer RN, McDowell I. Prevalence and predictors of depression in elderly Canadians: the Canadian Study of Health and Aging. Chronic Dis Can 2005;26:93-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16390626</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman AT, Bremmer MA, Deeg DJ, van Balkom AJ, Smit JH, de Beurs E, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998;13:717-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9818308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemeshow S, Letenneur L, Dartigues JF, Lafont S, Orgogozo JM, Commenges D. Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study. Personnes Ages Quid. Am J Epidemiol 1998;148:298-306.</Citation><ArticleIdList><ArticleId IdType="pubmed">9690368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilomaki J, Bell JS, Kauhanen J, Enlund H. Heavy drinking and use of sedative or anxiolytic drugs among aging men: an 11-year follow-up of the FinDrink study. Ann Pharmacother 2011;45:1240-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21896919</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. Psychol Med 2006;36:441-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207391</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer&#x2019;s disease. JAMA 1994;271:1004-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003;51:671-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandstra SM, Van Rijswijk E, Rijnders CA, Van De Lisdonk EH, Bor JH, Van Weel C, et al. Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam Pract 2004;21:266-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128687</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese A, Garatti M, Cipriani A, Barbui C. Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. Eur J Clin Pharmacol 2007;63:867-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17619867</ArticleId></ArticleIdList></Reference><Reference><Citation>Espana J, Gimenez-Llort L, Valero J, Minano A, Rabano A, Rodriguez-Alvarez J, et al. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer&#x2019;s disease transgenic mice. Biol Psychiatry 2010;67:513-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19664757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012;29:639-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">22812538</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006;67:2176-85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson MA, Smith PF, Darlington CL. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog Neurobiol 1996;49:73-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988;23:404-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2837978</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008;25:61-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25212850</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><Issue>Pt 11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Highly potent soluble amyloid-&#x3b2; seeds in human Alzheimer brain but not cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>2909</StartPage><EndPage>2915</EndPage><MedlinePgn>2909-2915</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awu255</ELocationID><Abstract><AbstractText>The soluble fraction of brain samples from patients with Alzheimer's disease contains highly biologically active amyloid-&#x3b2; seeds. In this study, we sought to assess the potency of soluble amyloid-&#x3b2; seeds derived from the brain and cerebrospinal fluid. Soluble Alzheimer's disease brain extracts were serially diluted and then injected into the hippocampus of young, APP transgenic mice. Eight months later, seeded amyloid-&#x3b2; deposition was evident even when the hippocampus received subattomole amounts of brain-derived amyloid-&#x3b2;. In contrast, cerebrospinal fluid from patients with Alzheimer's disease, which contained more than 10-fold higher levels of amyloid-&#x3b2; peptide than the most concentrated soluble brain extracts, did not induce detectable seeding activity in vivo. Similarly, cerebrospinal fluid from aged APP-transgenic donor mice failed to induce cerebral amyloid-&#x3b2; deposition. In comparison to the soluble brain fraction, cerebrospinal fluid largely lacked N-terminally truncated amyloid-&#x3b2; species and exhibited smaller amyloid-&#x3b2;-positive particles, features that may contribute to the lack of in vivo seeding by cerebrospinal fluid. Interestingly, the same cerebrospinal fluid showed at least some seeding activity in an in vitro assay. The present results indicate that the biological seeding activity of soluble amyloid-&#x3b2; species is orders of magnitude greater in brain extracts than in the cerebrospinal fluid.</AbstractText><CopyrightInformation>&#xa9; The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, D-72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Langer</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-43180 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinotsi</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski</LastName><ForeName>Clemens F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Institute of Pathology, University Hospital Basel, CH-4003 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maetzler</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyvani</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Duisburg-Essen, D-45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitzer</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, D-45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Centre, D-37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski Schierle</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-43180 M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>065807</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K02292X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2014 Nov;137(Pt 11):2874-5. doi: 10.1093/brain/awu261.</RefSource><PMID Version="1">25344080</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">seeding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25212850</ArticleId><ArticleId IdType="mid">EMS71883</ArticleId><ArticleId IdType="pmc">PMC5367518</ArticleId><ArticleId IdType="doi">10.1093/brain/awu255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426814</ArticleId><ArticleId IdType="pubmed">22951438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold K-H, Walker L, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774781</ArticleId><ArticleId IdType="pubmed">17889968</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Oberm&#xfc;ller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-&#x3b2; oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73:104&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT. Models of amyloid seeding in Alzheimer&#x2019;s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Trans Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ltt&#xe4; M, Hansson O, Andreasson U, Hertze J, Minthon L, N&#xe4;gga K, et al. Evaluating amyloid-&#x3b2; oligomers in cerebrospinal fluid as a biomarker for Alzheimer&#x2019;s disease. PLoS One. 2013;8:e66381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682966</ArticleId><ArticleId IdType="pubmed">23799095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda T, Ono K, Elashoff D, Condron MM, Noguchi-Shinohara M, Yoshita M, et al. Cerebrospinal Fluid from Alzheimer&#x2019;s disease patients promotes amyloid beta-protein oligomerization. J Alzheimers Dis. 2010;21:81&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20413863</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski Schierle GS, van de Linde S, Erdelyi M, Esbj&#xf6;rner EK, Klein T, Rees E, et al. In situ measurements of the formation and morphology of intracellular &#x3b2;-amyloid fibrils by super-resolution fluorescence imaging. J Am Chem Soc. 2011;133:12902&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21793568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, et al. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci. 2000;20:3606&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble A{beta} seeds are potent inducers of cerebral {beta}-Amyloid deposition. J Neurosci. 2011;31:14488&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-&#x3b2; oligomers in ageing and Alzheimer&#x2019;s disease. Brain. 2013;136:1383&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in Amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Trans Med. 2013;5:194re2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem. 2009;284:32895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinotsi D, Buell AK, Galvagnion C, Dobson CM, Kaminski Schierle GS, Kaminski CF. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano Lett. 2014;14:339&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901574</ArticleId><ArticleId IdType="pubmed">24303845</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 2010;120:185&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C. Detection of misfolded A&#x3b2; oligomers for sensitive biochemical diagnosis of Alzheimer&#x2019;s disease. Cell Rep. 2014;7:261&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24656814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NSM. Effects of Processing and Storage Conditions on Amyloid (1-42) and Tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem. 2004;51:189&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15539465</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB. Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol. 2006;413:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer&#x2019;s disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber P, Giese A, Piening N, Mitteregger G, Thomzig A, Beekes M, et al. Cell-free formation of misfolded prion protein with authentic prion infectivity. Proc Natl Acad Sci USA. 2006;103:15818&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635086</ArticleId><ArticleId IdType="pubmed">17030802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano E, Ghiso J, Frangione B. Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. Ann Neurol. 1993;34:631&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8215255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O&#x2019;Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid {beta}-protein detect natural A{beta} oligomers in human brain but not CSF. Alzheimers Dement. 2013;9:99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25217640</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>289</Volume><Issue>44</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.</ArticleTitle><Pagination><StartPage>30538</StartPage><EndPage>30555</EndPage><MedlinePgn>30538-30555</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M114.600833</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)37260-4</ELocationID><Abstract><AbstractText>Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-&#x3b2; (A&#x3b2;) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation. However, although the mechanism of action of RXR agonists remains unclear, a major concern for their use is human (h)-APOE4, the greatest AD genetic risk factor. If APOE4 imparts a toxic gain-of-function, then increasing apoE4 may increase soluble A&#x3b2;, likely the proximal AD neurotoxin. If the APOE4 loss-of-function is lipidation of apoE4, then induction of ABCA1/ABCG1 may be beneficial. In novel EFAD-Tg mice (overexpressing h-A&#x3b2;42 with h-APOE), levels of soluble A&#x3b2; (A&#x3b2;42 and oligomeric A&#x3b2;) are highest in E4FAD hippocampus (HP) &gt; E3FAD-HP &gt; E4FAD cortex (CX) &gt; E3FAD-CX, whereas levels of lipoprotein-associated/lipidated apoE have the opposite pattern (6 months). In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/A&#x3b2; complex, decreased soluble A&#x3b2;, and increased PSD95. In addition, hydrogel delivery, which mimics low sustained release, was equally effective as gavage for Bex and LG100268. RXR agonists induced no beneficial effects in the E4FAD-HP in a prevention protocol (5-6 months) and actually increased soluble A&#x3b2; levels in E3FAD-CX and E4FAD-CX with the short-term protocol, possibly the result of systemic hepatomegaly. Thus, RXR agonists address the loss-of-function associated with APOE4 and exacerbated by A&#x3b2; pathology, i.e. low levels of apoE4 lipoprotein association/lipidation. Further studies are vital to address whether RXR agonists are an APOE4-specific AD therapeutic and the systemic side effects that limit translational application.</AbstractText><CopyrightInformation>&#xa9; 2014 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Leon M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koster</LastName><ForeName>Kevin P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sue H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>UICentre (Drug Discovery at UIC), University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Aissa</LastName><ForeName>Manel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thatcher</LastName><ForeName>Gregory R J</ForeName><Initials>GRJ</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and University of Illinois at Chicago, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaDu</LastName><ForeName>Mary Jo</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612. Electronic address: mladu@uic.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029879</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR029879</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577833">ABCA1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487540">ABCG1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070998">ATP Binding Cassette Transporter, Subfamily G, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009539">Nicotinic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047488">Retinoid X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.8</RegistryNumber><NameOfSubstance UI="D051528">Guanylate Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>UVU4X1103P</RegistryNumber><NameOfSubstance UI="C095104">LG 100268</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070998" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily G, Member 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051528" MajorTopicYN="N">Guanylate Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009539" MajorTopicYN="N">Nicotinic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047488" MajorTopicYN="N">Retinoid X Receptors</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABCA1/ABCG1 Lipid Transporters</Keyword><Keyword MajorTopicYN="N">Alzheimer Disease</Keyword><Keyword MajorTopicYN="N">Amyloid-&#x3b2; (AB)</Keyword><Keyword MajorTopicYN="N">ApoE/A&#x3b2; Complex</Keyword><Keyword MajorTopicYN="N">Apolipoprotein E (ApoE)</Keyword><Keyword MajorTopicYN="N">Drug Action</Keyword><Keyword MajorTopicYN="N">Drug Delivery</Keyword><Keyword MajorTopicYN="N">Hepatomegaly</Keyword><Keyword MajorTopicYN="N">Oligomeric A&#x3b2;</Keyword><Keyword MajorTopicYN="N">RXR Agonists</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25217640</ArticleId><ArticleId IdType="pmc">PMC4215234</ArticleId><ArticleId IdType="doi">10.1074/jbc.M114.600833</ArticleId><ArticleId IdType="pii">S0021-9258(20)37260-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thies W., Bleiler L. (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 9, 208&#x2013;245</Citation><ArticleIdList><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E., Rogers J. (1999) Soluble amyloid &#x3b2; peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853&#x2013;862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I., Masters C. L. (1999) Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860&#x2013;866</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Dickson D. W., Trojanowski J. Q., Lee V. M. (1999) The levels of soluble versus insoluble brain A&#x3b2; distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328&#x2013;337</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic J. L., Pensalfini A., Head E., Glabe C. G. (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352&#x2013;358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D. J. (2011) Soluble amyloid &#x3b2;-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819&#x2013;5824</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y. M., Emmerling M. R., Vigo-Pelfrey C., Kasunic T. C., Kirkpatrick J. B., Murdoch G. H., Ball M. J., Roher A. E. (1996) Water-soluble A&#x3b2; (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077&#x2013;4081</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060&#x2013;1065</Citation><ArticleIdList><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E., Hardy J. (2014) Antiamyloid therapy for Alzheimer's disease&#x2013;are we on the right road? N. Engl. J. Med. 370, 377&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">24450897</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulca J. A., Nguyen V., Gajdosik D. A., Teklu S. G., Giunta E. A., Lessa E. A., Tran C. H., Terak E. C., Raffa R. B. (2014) Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J. Clin. Pharm. Ther. 39, 25&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">24313554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer P. E., Cirrito J. R., Wesson D. W., Lee C. Y., Karlo J. C., Zinn A. E., Casali B. T., Restivo J. L., Goebel W. D., James M. J., Brunden K. R., Wilson D. A., Landreth G. E. (2012) ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 335, 1503&#x2013;1506</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair K. D., Manaye K. F., Lee D. L., Allard J. S., Savonenko A. V., Troncoso J. C., Wong P. C. (2013) Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener. 8, 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693923</ArticleId><ArticleId IdType="pubmed">23764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz N. F., Cronican A. A., Lefterov I., Koldamova R. (2013) Comment on apoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 340, 924-c</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086452</ArticleId><ArticleId IdType="pubmed">23704552</ArticleId></ArticleIdList></Reference><Reference><Citation>Price A. R., Xu G., Siemienski Z. B., Smithson L. A., Borchelt D. R., Golde T. E., Felsenstein K. M. (2013) Comment on apoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 340, 924-d</Citation><ArticleIdList><ArticleId IdType="pubmed">23704553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I., Lo A. C., Roberfroid A., Dietvorst S., Van Broeck B., Borgers M., Gijsen H., Moechars D., Mercken M., Kemp J., D'Hooge R., De Strooper B. (2013) Comment on apoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 340, 924-e</Citation><ArticleIdList><ArticleId IdType="pubmed">23704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K., Zhang C., Miller S., Hefendehl J. K., Rajapaksha T. W., Ulrich J., Jucker M., Holtzman D. M., Tanzi R. E., Vassar R., Sisodia S. S. (2013) Comment on apoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 340, 924-f</Citation><ArticleIdList><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C., Youmans K. L., LaDu M. J. (2010) Proposed mechanism for lipoprotein remodelling in the brain. Biochim. Biophys. Acta 1801, 819&#x2013;823</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253707</ArticleId><ArticleId IdType="pubmed">20470897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., Zhou S., Burgess B. L., Bernier L., McIsaac S. A., Chan J. Y., Tansley G. H., Cohn J. S., Hayden M. R., Wellington C. L. (2004) Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279, 41197&#x2013;41207</Citation><ArticleIdList><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S. E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J. D., Kowalewski T., Holtzman D. M. (2004) ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987&#x2013;40993</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V., Maia L. F., Burgess B. L., Blain J. F., Naus K. E., McIsaac S. A., Parkinson P. F., Chan J. Y., Tansley G. H., Hayden M. R., Poirier J., Van Nostrand W., Wellington C. L. (2005) The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. J. Biol. Chem. 280, 43243&#x2013;43256</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R., Staufenbiel M., Lefterov I. (2005) Lack of ABCA1 considerably decreases brain apoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 43224&#x2013;43235</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S. E., Jiang H., Parsadanian M., Hartman R. E., Bales K. R., Paul S. M., Holtzman D. M. (2005) Deletion of Abca1 increases A&#x3b2; deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236&#x2013;43242</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E. G., Landreth G. E., Vinters H. V., Tontonoz P. (2007) Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U.S.A. 104, 10601&#x2013;10606</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S. E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C. L., Bales K. R., Paul S. M., Holtzman D. M. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671&#x2013;682</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C., Mayeux R. (2010) Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. J. Alzheimers Dis. 19, 229&#x2013;251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908485</ArticleId><ArticleId IdType="pubmed">20061642</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni V. (2011) The effect of apolipoprotein E (apoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin. Chem. Lab. Med. 49, 375&#x2013;383</Citation><ArticleIdList><ArticleId IdType="pubmed">21388338</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W. Q., Mwamburi M., Besser L. M., Zhu H., Li H., Wallack M., Phillips L., Qiao L., Budson A. E., Stern R., Kowall N. (2013) Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J. Alzheimers Dis. 37, 421&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972060</ArticleId><ArticleId IdType="pubmed">23948883</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R., Salloway S., Brooks D. J., Tampieri D., Barakos J., Fox N. C., Raskind M., Sabbagh M., Honig L. S., Porsteinsson A. P., Lieberburg I., Arrighi H. M., Morris K. A., Lu Y., Liu E., Gregg K. M., Brashear H. R., Kinney G. G., Black R., Grundman M. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M. R., Lahiri D. K., Poirier J., Davignon J., Schneider L., Hui S. L. (1998) Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50, 669&#x2013;677</Citation><ArticleIdList><ArticleId IdType="pubmed">9521254</ArticleId></ArticleIdList></Reference><Reference><Citation>Risner M. E., Saunders A. M., Altman J. F., Ormandy G. C., Craft S., Foley I. M., Zvartau-Hind M. E., Hosford D. A., Roses A. D. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246&#x2013;254</Citation><ArticleIdList><ArticleId IdType="pubmed">16446752</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans K. L., Tai L. M., Nwabuisi-Heath E., Jungbauer L., Kanekiyo T., Gan M., Kim J., Eimer W. A., Estus S., Rebeck G. W., Weeber E. J., Bu G., Yu C., Ladu M. J. (2012) APOE4-specific changes in A&#x3b2; accumulation in a new transgenic mouse model of Alzheimer disease. J. Biol. Chem. 287, 41774&#x2013;41786</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516726</ArticleId><ArticleId IdType="pubmed">23060451</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese P. B., Castellano J. M., Holtzman D. M. (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241&#x2013;252</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132088</ArticleId><ArticleId IdType="pubmed">21349439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai L. M., Mehra S., Shete V., Estus S., Rebeck G. W., Bu G., LaDu M. J. (2014) Soluble apoE/A&#x3b2; complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol. Neurodegener. 9, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897976</ArticleId><ArticleId IdType="pubmed">24386905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai L. M., Youmans K. L., Jungbauer L., Yu C., Ladu M. J. (2011) Introducing human APOE into A&#x3b2; transgenic mouse models. Int. J. Alzheimers Dis. 2011, 810981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199079</ArticleId><ArticleId IdType="pubmed">22028984</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm-Cagan A., Michaelson D. M. (2014) Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J. Neurosci. 34, 7293&#x2013;7301</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608187</ArticleId><ArticleId IdType="pubmed">24849361</ArticleId></ArticleIdList></Reference><Reference><Citation>Torino F., Barnabei A., Paragliola R., Baldelli R., Appetecchia M., Corsello S. M. (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23, 1345&#x2013;1366</Citation><ArticleIdList><ArticleId IdType="pubmed">23750887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman S. I. (2003) Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin. Lymphoma 3, 249&#x2013;252</Citation><ArticleIdList><ArticleId IdType="pubmed">12672276</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Ogilvie K. M., Klausing K., Lawson M. A., Jolley D., Li D., Bilakovics J., Pascual B., Hein N., Urcan M., Leibowitz M. D. (2002) Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 143, 2880&#x2013;2885</Citation><ArticleIdList><ArticleId IdType="pubmed">12130551</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries-van der Weij J., de Haan W., Hu L., Kuif M., Oei H. L., van der Hoorn J. W., Havekes L. M., Princen H. M., Romijn J. A., Smit J. W., Rensen P. C. (2009) Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 150, 2368&#x2013;2375</Citation><ArticleIdList><ArticleId IdType="pubmed">19147676</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm M. F., Zhang L., Zhi L., McClurg M. R., Berger E., Wagoner M., Mais D. E., Suto C. M., Davies J. A., Heyman R. A. (1995) Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 38, 3146&#x2013;3155</Citation><ArticleIdList><ArticleId IdType="pubmed">7636877</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurutka P. W., Kaneko I., Yang J., Bhogal J. S., Swierski J. C., Tabacaru C. R., Montano L. A., Huynh C. C., Jama R. A., Mahelona R. D., Sarnowski J. T., Marcus L. M., Quezada A., Lemming B., Tedesco M. A., Fischer A. J., Mohamed S. A., Ziller J. W., Ma N., Gray G. M., van der Vaart A., Marshall P. A., Wagner C. E. (2013) Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254). J. Med. Chem. 56, 8432&#x2013;8454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916150</ArticleId><ArticleId IdType="pubmed">24180745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yao R., Maciag A., Grubbs C. J., Lubet R. A., You M. (2006) Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Mol. Cancer Ther. 5, 1060&#x2013;1072</Citation><ArticleIdList><ArticleId IdType="pubmed">16648578</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte S. M. (2014) Relationships between diabetes and cognitive impairment. Endocrinol. Metab. Clin. North Am. 43, 245&#x2013;267</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978517</ArticleId><ArticleId IdType="pubmed">24582101</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenborn K., Bokemeyer M., Krause J., Ennen J., Ahl B. (2005) Neurological and neuropsychiatric syndromes associated with liver disease. AIDS 19, S93&#x2013;S98</Citation><ArticleIdList><ArticleId IdType="pubmed">16251835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis M., Howdle P. D. (2003) The neurology of liver failure. QJM 96, 623&#x2013;633</Citation><ArticleIdList><ArticleId IdType="pubmed">12925717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonneville R., Verdonk F., Rauturier C., Klein I. F., Wolff M., Annane D., Chretien F., Sharshar T. (2013) Understanding brain dysfunction in sepsis. Ann. Inten. Care 3, 15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673822</ArticleId><ArticleId IdType="pubmed">23718252</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul M. M., Ratz A. M., Sullivan K. A., Trankle W. G., Winneroski L. L. (2001) Synthesis of novel retinoid X receptor-selective retinoids. J. Org. Chem. 66, 5772&#x2013;5782</Citation><ArticleIdList><ArticleId IdType="pubmed">11511251</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. (2006) Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan P. M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R. L., Quarfordt S. H., Maeda N. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272, 17972&#x2013;17980</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer J. D., Simmons K., Parsadanian M., Bales K. R., Paul S. M., Sullivan P. M., Holtzman D. M. (2005) Human apolipoprotein E4 alters the amyloid-&#x3b2; 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25, 2803&#x2013;2810</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K. R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J. C., Sullivan P. M., Paul S. M. (2009) Human APOE isoform-dependent effects on brain &#x3b2;-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771&#x2013;6779</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai L. M., Bilousova T., Jungbauer L., Roeske S. K., Youmans K. L., Yu C., Poon W. W., Cornwell L. B., Miller C. A., Vinters H. V., Van Eldik L. J., Fardo D. W., Estus S., Bu G., Gylys K. H., Ladu M. J. (2013) Levels of soluble apolipoprotein E/amyloid-&#x3b2; (A&#x3b2;) complex are reduced and oligomeric A&#x3b2; increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J. Biol. Chem. 288, 5914&#x2013;5926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581407</ArticleId><ArticleId IdType="pubmed">23293020</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk C. R., Borgia J. A., Mufson E. J. (2011) A novel approach for long term oral drug administration in animal research. J. Neurosci. Methods 195, 194&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026878</ArticleId><ArticleId IdType="pubmed">21163304</ArticleId></ArticleIdList></Reference><Reference><Citation>Janakiram N. B., Mohammed A., Qian L., Choi C. I., Steele V. E., Rao C. V. (2012) Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia 14, 159&#x2013;168</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306261</ArticleId><ArticleId IdType="pubmed">22431924</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk C. R., Lu P. Y., Wang Y. T., Choi J., Shaw J. W., Thatcher G. R., Mufson E. J. (2012) Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice. Neurobiol. Dis. 45, 479&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225601</ArticleId><ArticleId IdType="pubmed">21945538</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell S. R., Shirley M. A., Grese T. A., Neel D. A., Wells K. E., Ulm E. H. (2001) Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab. Dispos. 29, 990&#x2013;998</Citation><ArticleIdList><ArticleId IdType="pubmed">11408365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Kim H. T., Rodriquez J. L., Hilsenbeck S. G., Mohsin S. K., Xu X. C., Lamph W. W., Kuhn J. G., Green J. E., Brown P. H. (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev. 11, 467&#x2013;474</Citation><ArticleIdList><ArticleId IdType="pubmed">12010861</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans K. L., Leung S., Zhang J., Maus E., Baysac K., Bu G., Vassar R., Yu C., LaDu M. J. (2011) Amyloid-&#x3b2;42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J. Neurosci. Methods 196, 51&#x2013;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049315</ArticleId><ArticleId IdType="pubmed">21219931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana R., Banks W. A., Butterfield D. A. (2010) Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of A&#x3b2;, and neurodegeneration in a prodromal stage of Alzheimer's disease. J. Neurosci. Res. 88, 469&#x2013;477</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843415</ArticleId><ArticleId IdType="pubmed">19774677</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie R. M., Meyer-Luehmann M., Hashimoto T., Adams K. W., Mielke M. L., Garcia-Alloza M., Micheva K. D., Smith S. J., Kim M. L., Lee V. M., Hyman B. T., Spires-Jones T. L. (2009) Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 106, 4012&#x2013;4017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida C. G., Tampellini D., Takahashi R. H., Greengard P., Lin M. T., Snyder E. M., Gouras G. K. (2005) &#x3b2;-Amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 20, 187&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter A. D., Watterson D. M., Van Eldik L. J. (2014) Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38&#x3b1; MAPK inhibitors. J. Neuroimmune Pharmacol. 9, 454&#x2013;460</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122817</ArticleId><ArticleId IdType="pubmed">24789302</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q., Lee C. Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T. M., Collins J. L., Richardson J. C., Smith J. D., Comery T. A., Riddell D., Holtzman D. M., Tontonoz P., Landreth G. E. (2008) ApoE promotes the proteolytic degradation of A&#x3b2;. Neuron 58, 681&#x2013;693</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano J. M., Kim J., Stewart F. R., Jiang H., DeMattos R. B., Patterson B. W., Fagan A. M., Morris J. C., Mawuenyega K. G., Cruchaga C., Goate A. M., Bales K. R., Paul S. M., Bateman R. J., Holtzman D. M. (2011) Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci. Transl. Med. 3, 89ra57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Kanekiyo T., Shinohara M., Zhang Y., LaDu M. J., Xu H., Bu G. (2012) Differential regulation of amyloid-&#x3b2; endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J. Biol. Chem. 287, 44593&#x2013;44601</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531774</ArticleId><ArticleId IdType="pubmed">23132858</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M. B., Holtzman D. M., Zlokovic B. V. (2008) ApoE isoform-specific disruption of amyloid &#x3b2; peptide clearance from mouse brain. J. Clin. Invest. 118, 4002&#x2013;4013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese P. B., Castellano J. M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C., Holtzman D. M. (2013) ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc. Natl. Acad. Sci. U.S.A. 110, E1807&#x2013;E1816</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly S., Altman R., Petrlova J., Lin Y., Hilt S., Huser T., Laurence T. A., Voss J. C. (2013) Binding of apolipoprotein E inhibits the oligomer growth of amyloid-&#x3b2; peptide in solution as determined by fluorescence cross-correlation spectroscopy. J. Biol. Chem. 288, 11628&#x2013;11635</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636854</ArticleId><ArticleId IdType="pubmed">23430745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T., Serrano-Pozo A., Hori Y., Adams K. W., Takeda S., Banerji A. O., Mitani A., Joyner D., Thyssen D. H., Bacskai B. J., Frosch M. P., Spires-Jones T. L., Finn M. B., Holtzman D. M., Hyman B. T. (2012) Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid &#x3b2; peptide. J. Neurosci. 32, 15181&#x2013;15192</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M. E., Lesne S. E. (2012) Soluble A&#x3b2; oligomer production and toxicity. J. Neurochem. 120, 125&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254782</ArticleId><ArticleId IdType="pubmed">22121920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler S. W., Chiang A. C., Savjani R. R., Larson M. E., Sherman M. A., Schuler D. R., Cirrito J. R., Lesn&#xe9; S. E., Jankowsky J. L. (2014) Genetic modulation of soluble A&#x3b2; rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34, 7871&#x2013;7885</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Quintero-Monzon O., Ostaszewski B. L., Podlisny D. R., Cavanaugh W. T., Yang T., Holtzman D. M., Cirrito J. R., Selkoe D. J. (2011) Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation. J. Neurosci. 31, 15861&#x2013;15869</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E., Dashkoff J., Roe A. D., Takeda S., Koffie R. M., Hashimoto T., Scheel M., Spires-Jones T., Arbel-Ornath M., Betensky R., Davidson B. L., Hyman B. T. (2013) Gene transfer of human apoE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl. Med. 5, 212ra161</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J., Quinn C. M., Brown A. J. (2006) SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem. J. 400, 485&#x2013;491</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698594</ArticleId><ArticleId IdType="pubmed">16901265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A., Saavedra L., Di Pardo A., Sipione S., Posse de Chaves E. (2012) &#x3b2;-Amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. J. Neurosci. 32, 6490&#x2013;6500</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621131</ArticleId><ArticleId IdType="pubmed">22573671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W. L., Martins I. J., Martins R. N. (2014) The involvement of lipids in Alzheimer's disease. J. Genet. Genomics 41, 261&#x2013;274</Citation><ArticleIdList><ArticleId IdType="pubmed">24894353</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A., Tian L., Henderson V. W., Greicius M. D. (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. Ann. Neurol. 75, 563&#x2013;573</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretsky P. M., Buckwalter J. G., Seeman T. E., Miller C. A., Poirier J., Schellenberg G. D., Finch C. E., Henderson V. W. (1999) Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 13, 216&#x2013;221</Citation><ArticleIdList><ArticleId IdType="pubmed">10609670</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H., Zareparsi S., Montee K. R., Sexton G. J., Kaye J. A., Bird T. D., Yu C. E., Wijsman E. M., Heston L. L., Litt M., Schellenberg G. D. (1996) Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet. 58, 803&#x2013;811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914663</ArticleId><ArticleId IdType="pubmed">8644745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K., Haan M., Byers A., Tangen C., Kuller L. (2000) Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54, 1949&#x2013;1954</Citation><ArticleIdList><ArticleId IdType="pubmed">10822435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs E. G., Kroenke C., Lin J., Epel E. S., Kenna H. A., Blackburn E. H., Rasgon N. L. (2013) Accelerated cell aging in female APOE-&#x3f5;4 carriers: implications for hormone therapy use. PLoS One 8, e54713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572118</ArticleId><ArticleId IdType="pubmed">23418430</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunzler J., Youmans K. L., Yu C., Ladu M. J., Tai L. (2014) APOE modulates the effect of estrogen therapy on A&#x3b2; accumulation EFAD-Tg mice. Neurosci. Lett. 560, 131&#x2013;136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955876</ArticleId><ArticleId IdType="pubmed">24368217</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez E., Bourguet W., Gronemeyer H., de Lera A. R. (2012) Modulation of RXR function through ligand design. Biochim. Biophys. Acta 1821, 57&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">21515403</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarisbrick J. J., Morris S., Azurdia R., Illidge T., Parry E., Graham-Brown R., Cowan R., Gallop-Evans E., Wachsmuth R., Eagle M., Wierzbicki A. S., Soran H., Whittaker S., Wain E. M. (2013) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br. J. Dermatol. 168, 192&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">22963233</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe4;kev&#xe4; L., Ranki A., Hahtola S. (2012) Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm. Venereol. 92, 258&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pubmed">22678563</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbas O., Sarac F., Aktug H., Peker G. (2014) Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogues (exenatide) on cognitive function in hepatosteatosis. Scientific World J. 2014, 946265</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967460</ArticleId><ArticleId IdType="pubmed">24741367</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott C., Frith J., Day C. P., Jones D. E., Newton J. L. (2013) Functional impairment in alcoholic liver disease and nonalcoholic fatty liver disease is significant and persists over 3 years of follow-up. Digest. Dis. Sci. 58, 2383&#x2013;2391</Citation><ArticleIdList><ArticleId IdType="pubmed">23609794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25222039</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.</ArticleTitle><Pagination><StartPage>1379</StartPage><EndPage>1385</EndPage><MedlinePgn>1379-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.2031</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Assessing the ability of Alzheimer disease neuroimaging markers to predict short-term cognitive decline among clinically normal (CN) individuals is critical for upcoming secondary prevention trials using cognitive outcomes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether neuroimaging markers of &#x3b2;-amyloid (A&#x3b2;) and neurodegeneration (ND) are independently or synergistically associated with longitudinal cognitive decline in CN individuals.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Academic medical center longitudinal natural history study among 166 CN individuals (median age, 74 years; 92 women).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The A&#x3b2; status was determined with Pittsburgh Compound B-positron emission tomography, while ND was assessed using 2 a priori measures, hippocampus volume (magnetic resonance imaging) and glucose metabolism (positron emission tomography with fludeoxyglucose F 18), extracted from Alzheimer disease-vulnerable regions. Based on imaging markers, CN individuals were categorized into the following preclinical Alzheimer disease stages: stage 0 (A&#x3b2;-/ND-), stage 1 (A&#x3b2;(+)/ND-), stage 2 (A&#x3b2;(+)/ND(+)), and suspected non-Alzheimer disease pathology (A&#x3b2;-/ND(+)). Cognition was assessed with a composite of neuropsychological tests administered annually.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The A&#x3b2;(+) CN individuals were more likely to be classified as ND+: 59.6% of A&#x3b2;(+) CN individuals were ND(+), whereas 31.9% of A&#x3b2;- CN individuals were ND(+) (odds ratio, 3.14; 95% CI, 1.44-7.02; P =&#x2009;.004). In assessing longitudinal cognitive performance, practice effects were evident in CN individuals negative for both A&#x3b2; and ND, whereas diminished practice effects were observed in CN individuals positive for either A&#x3b2; or ND. Decline over time was observed only in CN individuals positive for both A&#x3b2; and ND, and decline in this group was significantly greater than that in all other groups (P &lt;&#x2009;.001 for all). A significant interaction term between A&#x3b2; and ND confirmed that this decline was greater than the additive contributions of A&#x3b2; and ND (P =&#x2009;.04).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The co-occurrence of A&#x3b2; and ND accelerates cognitive decline in CN individuals. Therefore, both factors are important to consider in upcoming secondary prevention trials targeting CN individuals at high risk for progression to the symptomatic stages of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betensky</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown4Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston5Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston5Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston4Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston5Center for Alzheimer Research and Treatment, Department of Neurology, Brigham a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston4Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston5Center for Alzheimer Research and Treatment, Department of Neurology, Brigham a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AG044054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 CA165070</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01EB014894</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS048005</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG038994</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13U19 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB014894</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA006516</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026484</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13 AG042201174210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG044054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA075971</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS051343</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS070834</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025758</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH090291</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG040197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Nov;71(11):1357-8. doi: 10.1001/jamaneurol.2014.2462.</RefSource><PMID Version="1">25221849</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Mormino reported receiving funding by grants F32AG044054 and P01 AG036694 from the National Institutes of Health. Dr Betensky reported receiving funding by grants R01 CA075971, R03 CA165070, UL 1RR025758, P50 NS051343, P50 NS051343, P30 CA006516, P50 AG005134, P01 AG036694, R01 NS070834, R01 NS070834, and R01 AG026484 from the National Institutes of Health. Dr Hedden reported receiving funding by grants K01 AG040197, P01 AG036694, and R01 AG034556 from the National Institutes of Health. Dr Schultz reported serving as a paid consultant on an advisory board for Janssen Pharmaceuticals Inc. Dr Amariglio reported receiving funding by grant NIRG-12-243012 from the Alzheimer&#x2019;s Association and by grants P01AG036694 and RO1-AG027435 from the National Institutes of Health. Dr Rentz reported receiving research support by grants P01 AG036694, R01 MH090291, U01 AG024904, R01 AG027435, R01 AG037497, and P50 AG005134 from the National Institutes of Health and by grant IIRG-08-90934 from the Alzheimer&#x2019;s Association. Dr Johnson reported serving as paid consultant for Bayer, Bristol-Myers Squibb, GE Healthcare, Genzyme, Janssen Alzheimer&#x2019;s Immunotherapy, and Siemens Medical Solutions. He reported serving as a site coinvestigator for Bristol-Myers Squibb, Janssen Immunotherapy, Lilly/Avid, Navidea, and Pfizer. He reported speaking at symposia sponsored by Janssen Alzheimer&#x2019;s Immunotherapy and Pfizer. He reported receiving funding by grants R01EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435, and R01 AG037497 from the National Institutes of Health and by grant ZEN-10-174210 from the Alzheimer&#x2019;s Association. Dr Sperling reported serving as a paid consultant for Bristol-Myers Squibb, Eisai, Janssen Alzheimer Immunotherapy, Merck, Pfizer, and Roche and reported serving as an unpaid consultant to Avid and Eli Lilly. She reported serving as a site coinvestigator for Avid, Bristol-Myers Squibb, Janssen Alzheimer Immunotherapy, and Pfizer clinical trials. She reported speaking at symposia sponsored by Eli Lilly, Janssen Alzheimer Immunotherapy, and Pfizer. She reported that these relationships are not related to the content in the present article. She reported receiving research support by grants U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, K24 AG035007, P50 AG005134, U19 AG010483, R01 AG027435, and P01 AG036694 from the National Institutes of Health and by grant ZEN-10-174210 from the Alzheimer&#x2019;s Association.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25222039</ArticleId><ArticleId IdType="mid">NIHMS652642</ArticleId><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.2031</ArticleId><ArticleId IdType="pii">1902914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated &#x3b2;-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on &#x3b2;-amyloid in normal elderly. Ann Neurol. 2013;73(4):472&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660408</ArticleId><ArticleId IdType="pubmed">23424032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer&#x2019;s disease neurodegenerative biomarkers are associated with decreased cognitive function but not &#x3b2;-amyloid in cognitively normal older individuals. J Neurosci. 2013;33(13):5553&#x2013;5563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687777</ArticleId><ArticleId IdType="pubmed">23536070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78 (20):1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Amyloid-&#x3b2;&#x2013;associated clinical decline occurs only in the presence of elevated p-tau. Arch Neurol. 2012;69(6):709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G. Alzheimer disease: A&#x3b2;-independent processes: rethinking preclinical AD. Nat Rev Neurol. 2013;9(3):123&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935395</ArticleId><ArticleId IdType="pubmed">23399647</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with &#x3b2;-amyloidosis. JAMA Neurol. 2013;70(8):1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884555</ArticleId><ArticleId IdType="pubmed">23797806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE &#x3d5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62(3):229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging&#x2013;Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71 (6):765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; the Alzheimer&#x2019;s Disease Neuroimaging Initiative; and the Alzheimer&#x2019;s Disease Cooperative Study. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline [published online June 2, 2014] JAMA Neurol. doi: 10.1001/jamaneurol.2014.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Coleman RE, et al. AV45-A11 Study Group. Amyloid-&#x3b2; assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79 (16):1636&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468774</ArticleId><ArticleId IdType="pubmed">22786606</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72 (4):578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-&#x3b2; measured by [11C]PiB. Neurology. 2010;74(10):807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1987.</Citation></Reference><Reference><Citation>Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK. Distinguishing normal and demented elderly with the Selective Reminding Test. J Clin Exp Neuropsychol. 1989;11(5):615&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808653</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Frishe K, Olson LE, et al. Validation of the Face Name Associative Memory Exam in cognitively normal older individuals. J Clin Exp Neuropsychol. 2012;34(6):580&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391747</ArticleId><ArticleId IdType="pubmed">22765048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Amariglio RE, Becker JA, et al. Face-Name Associative Memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49(9):2776&#x2013;2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137730</ArticleId><ArticleId IdType="pubmed">21689670</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL, Hamsher K, Varney NR, Spreen O. Contributions to Neuropsychological Assessment: A Clinical Manual. New York, NY: Oxford; 1983.</Citation></Reference><Reference><Citation>Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, Thal LJ. Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol. 1992;49(12):1253&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">1449404</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale&#x2013;Revised. San Antonio, TX: Psychological Corp; 1981.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A&#x3b2;1-42. Ann Neurol. 2010;68 (6):825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer&#x2019;s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dor&#xe9; V, Villemagne VL, Bourgeat P, et al. Cross-sectional and longitudinal analysis of the relationship between A&#x3b2; deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013;70(7):903&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">23712469</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-&#x3b2; peptide deposition identified with Pittsburgh Compound B: cognitive decline associated with A&#x3b2; deposition. Arch Neurol. 2009;66(12):1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Pike KE, et al. Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low &#x3b2;-amyloid deposition. Brain. 2010;133(11):3349&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Tosakulwong N, Weigand SD, et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin. 2013;2:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778266</ArticleId><ArticleId IdType="pubmed">24179779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70(12):1512&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013;77(2):219&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558930</ArticleId><ArticleId IdType="pubmed">23352159</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB Alzheimer&#x2019;s Disease Neuroimaging Initiative. Brain changes in older adults at very low risk for Alzheimer&#x2019;s disease. J Neurosci. 2013;33(19):8237&#x2013;8242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050197</ArticleId><ArticleId IdType="pubmed">23658162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12468894</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Jr, Parisi JE, et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology. 2010;75(24):2212&#x2013;2220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013590</ArticleId><ArticleId IdType="pubmed">21172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science. 1997;278(5337):412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334292</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Pankratz VS, Christianson TJ, et al. Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. Clin Neuropsychol. 2013;27(8):1247&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869900</ArticleId><ArticleId IdType="pubmed">24041121</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, G&#xf6;tz J. Amyloid-&#x3b2; and tau: a toxic pas de deux in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2011;12(2):65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs213. doi: 10.1126/scitranslmed.3007941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68(8):1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25217827</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neural compensation in older people with brain amyloid-&#x3b2; deposition.</ArticleTitle><Pagination><StartPage>1316</StartPage><EndPage>1318</EndPage><MedlinePgn>1316-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3806</ELocationID><Abstract><AbstractText>Recruitment of extra neural resources may allow people to maintain normal cognition despite amyloid-&#x3b2; (A&#x3b2;) plaques. Previous fMRI studies have reported such hyperactivation, but it is unclear whether increases represent compensation or aberrant overexcitation. We found that older adults with A&#x3b2; deposition had reduced deactivations in task-negative regions, but increased activation in task-positive regions related to more detailed memory encoding. The association between higher activity and more detailed memories suggests that A&#x3b2;-related hyperactivation is compensatory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hwamee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>Cindee M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Shawn M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000000198848461</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>1] Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA. [2] Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25217827</ArticleId><ArticleId IdType="mid">NIHMS621286</ArticleId><ArticleId IdType="pmc">PMC4177011</ArticleId><ArticleId IdType="doi">10.1038/nn.3806</ArticleId><ArticleId IdType="pii">nn.3806</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. A&#x3b2; Deposition in Aging Is Associated with Increases in Brain Activation During Successful Memory Encoding. Cereb Cortex. 2011 doi: 10.1093/cercor/bhr255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhr255</ArticleId><ArticleId IdType="pmc">PMC3388896</ArticleId><ArticleId IdType="pubmed">21945849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, van Marle HJF, Hermans EJ, Fern&#xe1;ndez G. Subjective Sense of Memory Strength and the Objective Amount of Information Accurately Remembered Are Related to Distinct Neural Correlates at Encoding. J Neurosci. 2011;31:8920&#x2013;8927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622961</ArticleId><ArticleId IdType="pubmed">21677175</ArticleId></ArticleIdList></Reference><Reference><Citation>Naghavi HR, Nyberg L. Common fronto-parietal activity in attention, memory, and consciousness: shared demands on integration? Conscious Cogn. 2005;14:390&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">15950889</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Jagust WJ. Frontotemporal Network Connectivity during Memory Encoding Is Increased with Aging and Disrupted by Beta-Amyloid. J Neurosci. 2013;33:18425&#x2013;18437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834050</ArticleId><ArticleId IdType="pubmed">24259567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcom AM, Li J, Rugg MD. Age Effects on the Neural Correlates of Episodic Retrieval: Increased Cortical Recruitment with Matched Performance. Cereb Cortex bhl155. 2007 doi: 10.1093/cercor/bhl155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhl155</ArticleId><ArticleId IdType="pubmed">17204820</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreng RN, Wojtowicz M, Grady CL. Reliable differences in brain activity between young and old adults: A quantitative meta-analysis across multiple cognitive domains. Neurosci Biobehav Rev. 2010;34:1178&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamboni G, et al. Resting Functional Connectivity Reveals Residual Functional Activity in Alzheimer's Disease. Biol Psychiatry. 2013;74:375&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726515</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JL, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-&#x3b2; Levels In Vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Mormino EC. Lifespan brain activity, &#x3b2;-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206968</ArticleId><ArticleId IdType="pubmed">21983147</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in A&#x3b2; deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp. 2014;35:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600112</ArticleId><ArticleId IdType="pubmed">22965806</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, et al. Apolipoprotein E &#x3b5;4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci. 2009;106:2018&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644156</ArticleId><ArticleId IdType="pubmed">19164761</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD. Statistical Parametric Mapping: The Analysis of Functional Brain Images: The Analysis of Functional Brain Images. Academic Press; 2011.</Citation></Reference><Reference><Citation>Logan J, et al. Distribution Volume Ratios Without Blood Sampling from Graphical Analysis of PET Data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical Surface-Based Analysis: I Segmentation and Surface Reconstruction. NeuroImage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, et al. Biological Parametric Mapping: A Statistical Toolbox for Multi-Modality Brain Image Analysis. NeuroImage. 2007;34:137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994117</ArticleId><ArticleId IdType="pubmed">17070709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Beason-Held L, Resnick SM, Landman BA. Biological parametric mapping with robust and non-parametric statistics. NeuroImage. 2011;57:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114289</ArticleId><ArticleId IdType="pubmed">21569856</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC. A population-average, landmark-and surface-based (PALS) atlas of human cerebral cortex. NeuroImage. 2005;28:635&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25215490</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.</ArticleTitle><Pagination><StartPage>1324</StartPage><EndPage>1334</EndPage><MedlinePgn>1324-1334</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.07.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00990-8</ELocationID><Abstract><AbstractText>The P7C3 class of aminopropyl carbazole chemicals fosters the survival of neurons in a variety of rodent models of neurodegeneration or nerve cell injury. To uncover its mechanism of action, an active derivative of P7C3 was modified to contain both a benzophenone for photocrosslinking and an alkyne for CLICK chemistry. This derivative was found to bind nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme involved in the conversion of nicotinamide into nicotinamide adenine dinucleotide (NAD). Administration of active P7C3 chemicals to cells treated with doxorubicin, which induces NAD depletion, led to a rebound in intracellular levels of NAD and concomitant protection from doxorubicin-mediated toxicity. Active P7C3 variants likewise enhanced the activity of the purified NAMPT enzyme, providing further evidence that they act by increasing NAD levels through its NAMPT-mediated salvage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gelin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nijhawan</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA; Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theodoropoulos</LastName><ForeName>Pano</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidoo</LastName><ForeName>Jacinth</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadavalli</LastName><ForeName>Sivaramakrishnan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzaei</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieper</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA&#xa0;52242, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ready</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: joseph.ready@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: steven.mcknight@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH087986</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5-R01-MH087986</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552520">P7C3 compound</NameOfSubstance></Chemical><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.12</RegistryNumber><NameOfSubstance UI="D054409">Nicotinamide Phosphoribosyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.12</RegistryNumber><NameOfSubstance UI="C085455">nicotinamide phosphoribosyltransferase, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054409" MajorTopicYN="N">Nicotinamide Phosphoribosyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25215490</ArticleId><ArticleId IdType="mid">NIHMS619251</ArticleId><ArticleId IdType="pmc">PMC4163014</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.07.040</ArticleId><ArticleId IdType="pii">S0092-8674(14)00990-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, Manchester JK, Gordon JI, Sinclair DA. Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. The Journal of biological chemistry. 2002;277:18881&#x2013;18890.</Citation><ArticleIdList><ArticleId IdType="pubmed">11884393</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305:1010&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">15310905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay S, Bong D. Synthesis of trifunctional phosphatidylserine probes for identification of lipid-binding proteins. Eur J Org Chem. 2011;2011:751&#x2013;758.</Citation></Reference><Reference><Citation>Coleman MP, Conforti L, Buckmaster EA, Tarlton A, Ewing RM, Brown MC, Lyon MF, Perry VH. An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:9985&#x2013;9990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21448</ArticleId><ArticleId IdType="pubmed">9707587</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, Wagner D, Perry VH, Coleman MP. A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:11377&#x2013;11382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17208</ArticleId><ArticleId IdType="pubmed">11027338</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jesus-Cortes H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S, Britt J, Tesla R, Morlock L, Naidoo J, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:17010&#x2013;17015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479520</ArticleId><ArticleId IdType="pubmed">23027934</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155:1624&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076149</ArticleId><ArticleId IdType="pubmed">24360282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nature structural &amp; molecular biology. 2006;13:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WR, Park OH, Choi S, Choi SY, Park SK, Lee KJ, Rhyu IJ, Kim H, Lee YK, Kim HT, et al. The maintenance of specific aspects of neuronal function and behavior is dependent on programmed cell death of adult-generated neurons in the dentate gyrus. Eur J Neurosci. 2009;29:1408&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802284</ArticleId><ArticleId IdType="pubmed">19519627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SE, Ko IG, Kim BK, Shin MS, Cho S, Kim CJ, Kim SH, Baek SS, Lee EK, Jee YS. Treadmill exercise prevents aging induced failure of memory through an increase in neurogenesis and suppression of apoptosis in rat hippocampus. Exp Gerontol. 2010;45:357&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">20156544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angewandte Chemie (International ed. 2001;40:2004&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Biebl M, Wilhelm D, Li M, Friedlander RM, Winkler J. Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. Eur J Neurosci. 2005;22:1907&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">16262630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S. Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. The European journal of neuroscience. 1989;1:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12106171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nature neuroscience. 2001;4:1199&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770485</ArticleId></ArticleIdList></Reference><Reference><Citation>MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, Huntington PJ, Estill SJ, Longgood J, Becker GL, et al. Development of proneurogenic, neuroprotective small molecules. Journal of the American Chemical Society. 2011;133:1428&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033481</ArticleId><ArticleId IdType="pubmed">21210688</ArticleId></ArticleIdList></Reference><Reference><Citation>Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2000;20:9104&#x2013;9110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773038</ArticleId><ArticleId IdType="pubmed">11124987</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Gamez JA, Rodriguez-Vargas JM, Quiles-Perez R, Aguilar-Quesada R, Martin-Oliva D, de Murcia G, Menissier de Murcia J, Almendros A, Ruiz de Almodovar M, Oliver FJ. PARP-1 is involved in autophagy induced by DNA damage. Autophagy. 2009;5:61&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19001878</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidoo J, De Jesus-Cortes H, Huntington P, Estill S, Morlock LK, Starwalt R, Mangano TJ, Williams NS, Pieper AA, Ready JM. Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(&#x2212;)-P7C3-S243], with Improved Druglike Properties. Journal of medicinal chemistry. 2014;57:3746&#x2013;3754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206694</ArticleId><ArticleId IdType="pubmed">24697290</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. The Journal of pharmacology and experimental therapeutics. 2002;300:862&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861791</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper AA, McKnight SL, Ready JM. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chemical Society reviews 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237066</ArticleId><ArticleId IdType="pubmed">24514864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM, Becker GL, Huntington P, Goldman SE, Shen CH, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930815</ArticleId><ArticleId IdType="pubmed">20603013</ArticleId></ArticleIdList></Reference><Reference><Citation>Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. The Journal of biological chemistry. 1958;233:488&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">13563526</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein LR, Imai SI. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. The EMBO journal. 2014;33:937&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194122</ArticleId><ArticleId IdType="pubmed">24811750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Winseck A, Vinsant S, Park OH, Kim H, Oppenheim RW. Programmed cell death of adult-generated hippocampal neurons is mediated by the proapoptotic gene Bax. J Neurosci. 2004;24:11205&#x2013;11213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730275</ArticleId><ArticleId IdType="pubmed">15590937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P, McDaniel L, Knobbe W, Burket A, Tran S, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:17016&#x2013;17021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479516</ArticleId><ArticleId IdType="pubmed">23027932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu BP, Mohler RE, Liu JC, Dombek KM, Young ET, Synovec RE, McKnight SL. Cyclic changes in metabolic state during the life of a yeast cell. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:16886&#x2013;16891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040445</ArticleId><ArticleId IdType="pubmed">17940006</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Alexander P, Wu L, Hammer R, Cleaver O, McKnight SL. Dependence of mouse embryonic stem cells on threonine catabolism. Science. 2009;325:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373593</ArticleId><ArticleId IdType="pubmed">19589965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nature structural &amp; molecular biology. 2006;13:661&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366687</ArticleId><ArticleId IdType="pubmed">17889652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Kurnasov O, Tomchick DR, Binns DD, Grishin NV, Marquez VE, Osterman AL, Zhang H. Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. The Journal of biological chemistry. 2002;277:13148&#x2013;13154.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorn JA, Wells JA. Turning enzymes ON with small molecules. Nature chemical biology. 2010;6:179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">20154666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25242217</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>77</EndPage><MedlinePgn>63-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.08.048</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00749-1</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is an age-related neurological disorder characterized by synaptic loss and dementia. The low-density lipoprotein receptor-related protein 6 (LRP6) is an essential coreceptor for Wnt signaling, and its genetic variants have been linked to AD risk. Here we report that neuronal LRP6-mediated Wnt signaling is critical for synaptic function and cognition. Conditional deletion of Lrp6 gene in mouse forebrain neurons leads to age-dependent deficits in synaptic integrity and memory. Neuronal LRP6 deficiency in an amyloid mouse model also leads to exacerbated amyloid pathology due to increased APP processing to amyloid-&#x3b2;. In humans, LRP6 and Wnt signaling are significantly downregulated in AD brains, likely by a mechanism that depends on amyloid-&#x3b2;. Our results define a critical pathway in which decreased LRP6-mediated Wnt signaling, synaptic dysfunction, and elevated A&#x3b2; synergistically accelerate AD progression and suggest that restoring LRP6-mediated Wnt signaling can be explored as a viable strategy for AD therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deak</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Reynolds Oklahoma Center on Aging, Department of Geriatric Medicine, University of Oklahoma HSC, Oklahoma City, OK 73104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penuliar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>You Me</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University, Washington, D.C. 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maher</LastName><ForeName>James N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University, Washington, D.C. 20057, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estus</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoe</LastName><ForeName>Hyang-Sook</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University, Washington, D.C. 20057, USA; Convergence Brain Research Department, Korea Brain Research Institute (KBRI), 425, Jungang-daero, Jung-gu, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neurobiology of Disease Graduate Program, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA; Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, China. Electronic address: bu.guojun@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044420</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C555475">LRP6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060488">Low Density Lipoprotein Receptor-Related Protein-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060488" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-6</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25242217</ArticleId><ArticleId IdType="mid">NIHMS631276</ArticleId><ArticleId IdType="pmc">PMC4199382</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.08.048</ArticleId><ArticleId IdType="pii">S0896-6273(14)00749-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alarcon MA, Medina MA, Hu Q, Avila ME, Bustos BI, Perez-Palma E, Peralta A, Salazar P, Ugarte GD, Reyes AE, et al. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34:1709, e1709&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">23218566</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 2004;297:186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194435</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Synaptic degeneration in Alzheimer&#x2019;s disease. Acta Neuropathol. 2009;118:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ataman B, Ashley J, Gorczyca M, Ramachandran P, Fouquet W, Sigrist SJ, Budnik V. Rapid activity-dependent modifications in synaptic structure and function require bidirectional Wnt signaling. Neuron. 2008;57:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435264</ArticleId><ArticleId IdType="pubmed">18341991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Ann Rev Neurosci. 2008;31:47&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561948</ArticleId><ArticleId IdType="pubmed">18284372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 1994;79:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923378</ArticleId></ArticleIdList></Reference><Reference><Citation>Budnik V, Salinas PC. Wnt signaling during synaptic development and plasticity. Curr Opin Neurobiol. 2011;21:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499977</ArticleId><ArticleId IdType="pubmed">21239163</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005;6:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208872</ArticleId><ArticleId IdType="pubmed">16095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer&#x2019;s brain. J Neurosci. 2004;24:6021&#x2013;6027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729239</ArticleId><ArticleId IdType="pubmed">15229249</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo-Branco G, Andersson ER, Minina E, Sousa KM, Ribeiro D, Kokubu C, Imai K, Prakash N, Wurst W, Arenas E. Delayed dopaminergic neuron differentiation in Lrp6 mutant mice. Dev Dyn. 2010;239:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">19795519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W, Gambrill A, Inestrosa NC, Barria A. Regulation of NMDA-receptor synaptic transmission by Wnt signaling. J Neurosci. 2011;31:9466&#x2013;9471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141819</ArticleId><ArticleId IdType="pubmed">21715611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W, Godoy JA, Alfaro I, Farias GG, Metcalfe MJ, Fuentealba R, Bonansco C, Inestrosa NC. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008;283:5918&#x2013;5927.</Citation><ArticleIdList><ArticleId IdType="pubmed">18096705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer&#x2019;s disease. Mol Neurodegener. 2012;7:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507664</ArticleId><ArticleId IdType="pubmed">23039869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer&#x2019;s disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2007;104:9434&#x2013;9439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890512</ArticleId><ArticleId IdType="pubmed">17517621</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#xe1;k F, Sonntag WE. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. The journals of gerontology. J Gerontol A Biol Sci Med Sci. 2012;67:611&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348499</ArticleId><ArticleId IdType="pubmed">22503992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA. 2011;108:E279&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136266</ArticleId><ArticleId IdType="pubmed">21690377</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Lathrop W, Weaver D, Qiu Q, Cini J, Bertolini D, Chen D. Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. Biochem Biophys Res Commun. 1998;251:784&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">9790987</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719191</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012;148:1015&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3305806</ArticleId><ArticleId IdType="pubmed">22385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ. beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem. 1993;268:3021&#x2013;3024.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, Olson L, Kenealy SJ, Hauser M, Gilbert JR, Pericak-Vance MA. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47:329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16384981</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer&#x2019;s disease. J Neurosci. 2009;29:6545&#x2013;6557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618977</ArticleId><ArticleId IdType="pubmed">19458225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee KJ, Carney RS, Lee J, Markova A, Lee JY, Howell BW, Hyman BT, Pak DT, Bu G, Rebeck GW. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci. 2009;29:7459&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="pubmed">19515914</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer&#x2019;s disease. J Neurochem. 2008;104:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010;11:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010950</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer&#x2019;s Disease. Mol Neurodegener. 2008;3:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515306</ArticleId><ArticleId IdType="pubmed">18652670</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa NC, Varela-Nallar L. Wnt Signaling Roles on the Structure and Function of the Central Synapses: Involvement in Alzheimer&#x2019;s Disease 2013</Citation></Reference><Reference><Citation>Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M. Synaptotoxicity in Alzheimer&#x2019;s disease: the Wnt signaling pathway as a molecular target. IUBMB Life. 2007;59:316&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">17505971</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M, Hoerndli FJ, Brockie PJ, Wang R, Johnson E, Maxfield D, Francis MM, Madsen DM, Maricq AV. Wnt signaling regulates acetylcholine receptor translocation and synaptic plasticity in the adult nervous system. Cell. 2012;149:173&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375111</ArticleId><ArticleId IdType="pubmed">22464329</ArticleId></ArticleIdList></Reference><Reference><Citation>Joeng KS, Schumacher CA, Zylstra-Diegel CR, Long F, Williams BO. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. Dev Biol. 2011;359:222&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220949</ArticleId><ArticleId IdType="pubmed">21924256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuron. 2010;67:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA. 2010a;107:5136&#x2013;5141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841938</ArticleId><ArticleId IdType="pubmed">20194742</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J, Han X, Weeber EJ, Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci. 2010b;30:17068&#x2013;17078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146802</ArticleId><ArticleId IdType="pubmed">21159977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007;315:1278&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945222</ArticleId><ArticleId IdType="pubmed">17332414</ArticleId></ArticleIdList></Reference><Reference><Citation>Megill A, Lee T, DiBattista AM, Song JM, Spitzer MH, Rubinshtein M, Habib LK, Capule CC, Mayer M, Turner RS, et al. A tetra(ethylene glycol) derivative of benzothiazole aniline enhances Ras-mediated spinogenesis. J Neurosci. 2013;33:9306&#x2013;9318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865503</ArticleId><ArticleId IdType="pubmed">23719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi K, Johnson GV. Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. J Cell Biochem. 2005;95:328&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372896</ArticleId><ArticleId IdType="pubmed">15001769</ArticleId></ArticleIdList></Reference><Reference><Citation>Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13:767&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151663</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F, Milman P, Holmes E, Liang Y, Kawarai T, et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med. 1999;5:164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930863</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990&#x2013;6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka H, Shimono K, Ogawa R, Sugihara H, Taketani M. A new planar multielectrode array for extracellular recording: application to hippocampal acute slice. J Neurosci Methods. 1999;93:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10598865</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachet A, Wisniewski A. The effects of lithium on cognition: an updated review. Psychopharmacology. 2003;170:225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504681</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Shen K. WNTs in synapse formation and neuronal circuitry. EMBO J. 2012;31:2697&#x2013;2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3380216</ArticleId><ArticleId IdType="pubmed">22617419</ArticleId></ArticleIdList></Reference><Reference><Citation>Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J Neurosci. 2012;32:3492&#x2013;3498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621056</ArticleId><ArticleId IdType="pubmed">22399772</ArticleId></ArticleIdList></Reference><Reference><Citation>Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol. 2007;64:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, Kobayashi A, Lang RA, Hadjantonakis AK, Moon RT, Duffield JS. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA. 2013;110:1440&#x2013;1445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557093</ArticleId><ArticleId IdType="pubmed">23302695</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer&#x2019;s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci. 2007;27:1981&#x2013;1991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673566</ArticleId><ArticleId IdType="pubmed">17314294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahores M, Gibb A, Salinas PC. Frizzled-5, a receptor for the synaptic organizer Wnt7a, regulates activity-mediated synaptogenesis. Development. 2010;137:2215&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882138</ArticleId><ArticleId IdType="pubmed">20530549</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6:551&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199576</ArticleId><ArticleId IdType="pubmed">20842183</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, De Aguiar RB, Naik S, Mani S, Ostadsharif K, Wencker D, Sotoudeh M, Malekzadeh R, Sherwin RS, Mani A. LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans. Cell Metab. 2013;17:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589523</ArticleId><ArticleId IdType="pubmed">23395167</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol. 2000;1:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer&#x2019;s disease. Neuropharmacology. 2010;59:310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913164</ArticleId><ArticleId IdType="pubmed">20394760</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies W, Bleiler L. 2013 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2013;9:208&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer&#x2019;s disease. Mol Psychiatry. 2010;15:272&#x2013;285. 228.</Citation><ArticleIdList><ArticleId IdType="pubmed">19621015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996;87:1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980237</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meurs JB, Rivadeneira F, Jhamai M, Hugens W, Hofman A, van Leeuwen JP, Pols HA, Uitterlinden AG. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J Bone Miner Res. 2006;21:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">16355283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Thinakaran G. Amyloidogenic processing of &#x3b2;-amyloid precursor protein in intracellular compartments. Neurology. 2006;66:S69&#x2013;S73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan M, Li J, Herbst K, Zhang J, Yu B, Wu X, Qiu T, Lei W, Lindvall C, Williams BO, et al. LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Galpha(s) Sci Signal. 2011;4:ra15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711537</ArticleId><ArticleId IdType="pubmed">21406690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan W, Xia S, Kalionis B, Liu L, Li Y. The Role of Wnt Signaling in the Development of Alzheimer&#x2019;s Disease: A Potential Therapeutic Target? Biomed Res Int. 2014;2014:301575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026919</ArticleId><ArticleId IdType="pubmed">24883305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Adhikari N, Li Q, Hall JL. LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;287:H2376&#x2013;2383.</Citation><ArticleIdList><ArticleId IdType="pubmed">15271658</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, LaDu MJ. Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods. 2011;196:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049315</ArticleId><ArticleId IdType="pubmed">21219931</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste R, Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Ann Rev Neurosci. 2001;24:1071&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Baker JJ, Zylstra-Diegel CR, Williams BO. Lrp5 and Lrp6 play compensatory roles in mouse intestinal development. J Cell Biochem. 2012;113:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245350</ArticleId><ArticleId IdType="pubmed">21866564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Gong K, Song B, Ma T, van Laar T, Gong Y, Zhang L. The APP intracellular domain (AICD) inhibits Wnt signalling and promotes neurite outgrowth. Biochim Biophys Acta. 2012;1823:1233&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">22613765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25246573</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>40</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation.</ArticleTitle><Pagination><StartPage>E4274</StartPage><EndPage>E4283</EndPage><MedlinePgn>E4274-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1416598111</ELocationID><Abstract><AbstractText>Physiologically, &#x3b1;-synuclein chaperones soluble NSF attachment protein receptor (SNARE) complex assembly and may also perform other functions; pathologically, in contrast, &#x3b1;-synuclein misfolds into neurotoxic aggregates that mediate neurodegeneration and propagate between neurons. In neurons, &#x3b1;-synuclein exists in an equilibrium between cytosolic and membrane-bound states. Cytosolic &#x3b1;-synuclein appears to be natively unfolded, whereas membrane-bound &#x3b1;-synuclein adopts an &#x3b1;-helical conformation. Although the majority of studies showed that cytosolic &#x3b1;-synuclein is monomeric, it is unknown whether membrane-bound &#x3b1;-synuclein is also monomeric, and whether chaperoning of SNARE complex assembly by &#x3b1;-synuclein involves its cytosolic or membrane-bound state. Here, we show using chemical cross-linking and fluorescence resonance energy transfer (FRET) that &#x3b1;-synuclein multimerizes into large homomeric complexes upon membrane binding. The FRET experiments indicated that the multimers of membrane-bound &#x3b1;-synuclein exhibit defined intermolecular contacts, suggesting an ordered array. Moreover, we demonstrate that &#x3b1;-synuclein promotes SNARE complex assembly at the presynaptic plasma membrane in its multimeric membrane-bound state, but not in its monomeric cytosolic state. Our data delineate a folding pathway for &#x3b1;-synuclein that ranges from a monomeric, natively unfolded form in cytosol to a physiologically functional, multimeric form upon membrane binding, and show that only the latter but not the former acts as a SNARE complex chaperone at the presynaptic terminal, and may protect against neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burr&#xe9;</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University Medical School, Stanford, CA 94305 tcs1@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077906</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS077906</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050988">Vesicle-Associated Membrane Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050988" MajorTopicYN="N">Vesicle-Associated Membrane Protein 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">SNARE proteins</Keyword><Keyword MajorTopicYN="N">membrane fusion</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25246573</ArticleId><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="doi">10.1073/pnas.1416598111</ArticleId><ArticleId IdType="pii">1416598111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995;15(2):361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646890</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A, et al. The precursor protein of non-A beta component of Alzheimer&#x2019;s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14(2):467&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857654</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. &#x3b1;-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329(5999):1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276(5321):2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R, et al. Ala30Pro mutation in the gene encoding &#x3b1;-synuclein in Parkinson&#x2019;s disease. Nat Genet. 1998;18(2):106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. The new mutation, E46K, of &#x3b1;-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely AP, et al. &#x3b1;-Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson&#x2019;s disease and multiple system atrophy? Acta Neuropathol. 2013;125(5):753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681325</ArticleId><ArticleId IdType="pubmed">23404372</ArticleId></ArticleIdList></Reference><Reference><Citation>Proukakis C, et al. A novel &#x3b1;-synuclein missense mutation in Parkinson disease. Neurology. 2013;80(11):1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653201</ArticleId><ArticleId IdType="pubmed">23427326</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. &#x3b1;-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302(5646):841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez P, et al. Causal relation between &#x3b1;-synuclein gene duplication and familial Parkinson&#x2019;s disease. Lancet. 2004;364(9440):1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. &#x3b1;-Synuclein in Lewy bodies. Nature. 1997;388(6645):839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson&#x2019;s disease. Neurosci Lett. 1997;239(1):45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">9547168</ArticleId></ArticleIdList></Reference><Reference><Citation>Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for &#x3b1;-synuclein. Neurology. 1998;51(3):887&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: A new &#x3b1;-synuclein disease? Lancet. 1998;352(9127):547&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9716068</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of &#x3b1;-synuclein. Proc Natl Acad Sci USA. 2009;106(31):13010&#x2013;13015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, et al. Exogenous &#x3b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human &#x3b1;-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 2013;126(4):555&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789892</ArticleId><ArticleId IdType="pubmed">23925565</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of &#x3b1;-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. &#x3b1;-Synuclein membrane interactions and lipid specificity. J Biol Chem. 2000;275(44):34328&#x2013;34334.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915790</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuscher B, et al. &#x3b1;-Synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. J Biol Chem. 2004;279(21):21966&#x2013;21975.</Citation><ArticleIdList><ArticleId IdType="pubmed">15028717</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. Binding of &#x3b1;-synuclein to brain vesicles is abolished by familial Parkinson&#x2019;s disease mutation. J Biol Chem. 1998;273(41):26292&#x2013;26294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, et al. Subcellular localization of wild-type and Parkinson&#x2019;s disease-associated mutant &#x3b1;-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20(17):6365&#x2013;6373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DL, et al. Lipid rafts mediate the synaptic localization of &#x3b1;-synuclein. J Neurosci. 2004;24(30):6715&#x2013;6723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729723</ArticleId><ArticleId IdType="pubmed">15282274</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr NACP, a protein implicated in Alzheimer&#x2019;s disease and learning, is natively unfolded. Biochemistry. 1996;35(43):13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. Evidence that the precursor protein of non-A &#x3b2; component of Alzheimer&#x2019;s disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells. 1997;7(1):78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9085269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Chen X, Rizo J, Jahn R, S&#xfc;dhof TC. A broken alpha-helix in folded alpha-Synuclein. J Biol Chem. 2003;278(17):15313&#x2013;15318.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586824</ArticleId></ArticleIdList></Reference><Reference><Citation>Jao CC, Der-Sarkissian A, Chen J, Langen R. Structure of membrane-bound &#x3b1;-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci USA. 2004;101(22):8331&#x2013;8336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420394</ArticleId><ArticleId IdType="pubmed">15155902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer TS, Bax A. Comparison of structure and dynamics of micelle-bound human &#x3b1;-synuclein and Parkinson disease variants. J Biol Chem. 2005;280(52):43179&#x2013;43187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16166095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokappa SB, Ulmer TS. &#x3b1;-Synuclein populates both elongated and broken helix states on small unilamellar vesicles. J Biol Chem. 2011;286(24):21450&#x2013;21457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122204</ArticleId><ArticleId IdType="pubmed">21524999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B, et al. &#x3b1;-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287(19):15345&#x2013;15364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. Properties of native brain &#x3b1;-synuclein. Nature. 2013;498(7453):E4&#x2013;E6, discussion E6&#x2013;E7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255827</ArticleId><ArticleId IdType="pubmed">23765500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477(7362):107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of &#x3b1;-synuclein and &#x3b2;-synuclein in neurons and non-neural cells. J Biol Chem. 2013;288(9):6371&#x2013;6385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, de Messieres M, Lee JC. Membrane remodeling by &#x3b1;-synuclein and effects on amyloid formation. J Am Chem Soc. 2013;135(43):15970&#x2013;15973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859146</ArticleId><ArticleId IdType="pubmed">24099487</ArticleId></ArticleIdList></Reference><Reference><Citation>Varkey J, et al. &#x3b1;-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J Biol Chem. 2013;288(24):17620&#x2013;17630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682563</ArticleId><ArticleId IdType="pubmed">23609437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouberai MM, et al. &#x3b1;-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem. 2013;288(29):20883&#x2013;20895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3774359</ArticleId><ArticleId IdType="pubmed">23740253</ArticleId></ArticleIdList></Reference><Reference><Citation>Leftin A, Job C, Beyer K, Brown MF. Solid-state &#xb9;&#xb3;C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein &#x3b1;-Synuclein. J Mol Biol. 2013;425(16):2973&#x2013;2987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5276865</ArticleId><ArticleId IdType="pubmed">23583776</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao J, et al. Native &#x3b1;-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. eLife. 2013;2:e00592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639508</ArticleId><ArticleId IdType="pubmed">23638301</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan V, Scarlata S. Membrane binding and self-association of &#x3b1;-synucleins. Biochemistry. 2001;40(33):9927&#x2013;9934.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole NB, et al. Lipid droplet binding and oligomerization properties of the Parkinson&#x2019;s disease protein &#x3b1;-synuclein. J Biol Chem. 2002;277(8):6344&#x2013;6352.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Choi C, Lee SJ. Membrane-bound &#x3b1;-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem. 2002;277(1):671&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M, Fink AL. Lipid binding inhibits &#x3b1;-synuclein fibril formation. J Biol Chem. 2003;278(19):16873&#x2013;16877.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E, et al. &#x3b1;-Synuclein-synaptosomal membrane interactions: Implications for fibrillogenesis. Eur J Biochem. 2004;271(15):3180&#x2013;3189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265037</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, S&#xfc;dhof TC. Systematic mutagenesis of &#x3b1;-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci. 2012;32(43):15227&#x2013;15242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506191</ArticleId><ArticleId IdType="pubmed">23100443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, et al. Synaptic vesicle membrane fusion complex: Action of clostridial neurotoxins on assembly. EMBO J. 1994;13(21):5051&#x2013;5061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395451</ArticleId><ArticleId IdType="pubmed">7957071</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcher K. New chemical crosslinking methods for the identification of transient protein-protein interactions with multiprotein complexes. Curr Protein Pept Sci. 2004;5(4):287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">15320735</ArticleId></ArticleIdList></Reference><Reference><Citation>Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: Behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. Biotechniques. 2004;37(5):790&#x2013;796, 798&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">15560135</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AJ, Selkoe D, Dettmer U. A new method for quantitative immunoblotting of endogenous &#x3b1;-synuclein. PLoS One. 2013;8(11):e81314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835431</ArticleId><ArticleId IdType="pubmed">24278419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E, Fuller N, Rand RP, St George-Hyslop P, Fraser PE. Defective membrane interactions of familial Parkinson&#x2019;s disease mutant A30P &#x3b1;-synuclein. J Mol Biol. 2002;315(4):799&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner CR, Maltsev AS, Dobson CM, Bax A. Differential phospholipid binding of &#x3b1;-synuclein variants implicated in Parkinson&#x2019;s disease revealed by solution NMR spectroscopy. Biochemistry. 2010;49(5):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815556</ArticleId><ArticleId IdType="pubmed">20041693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer TS, Bax A, Cole NB, Nussbaum RL. Structure and dynamics of micelle-bound human &#x3b1;-synuclein. J Biol Chem. 2005;280(10):9595&#x2013;9603.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615727</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. Analysis of the synaptic vesicle proteome using three gel-based protein separation techniques. Proteomics. 2006;6(23):6250&#x2013;6262.</Citation><ArticleIdList><ArticleId IdType="pubmed">17080482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. A soluble &#x3b1;-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA. 2011;108(43):17797&#x2013;17802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203798</ArticleId><ArticleId IdType="pubmed">22006323</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallop JL, McMahon HT. BAR domains and membrane curvature: Bringing your curves to the BAR. Biochem Soc Symp. 2005;72(72):223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649145</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumke O, Roux A, Haucke V. BAR domain scaffolds in dynamin-mediated membrane fission. Cell. 2014;156(5):882&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">24581490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25253858</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>39</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Deficiency of GDNF Receptor GFR&#x3b1;1 in Alzheimer's Neurons Results in Neuronal Death.</ArticleTitle><Pagination><StartPage>13127</StartPage><EndPage>13138</EndPage><MedlinePgn>13127-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2582-13.2014</ELocationID><Abstract><AbstractText>We have recently developed aged cortical neuron cultures from autopsied human brains with Alzheimer's disease (AD). During the culturing process, we found that glutamatergic cortical neurons from the AD brain lacked a response to glial cell line-derived neurotrophic factor (GDNF), including no axonal regrowth, and were starting to undergo apoptosis. Here we showed that, in cortical neurons from age- and gender-matched cognitively normal control (NC) subjects (NC neurons), GDNF enhanced the expression of GDNF family receptor subtype &#x3b1;1 (GFR&#x3b1;1), but not the other three subtypes (GFR&#x3b1;2, GFR&#x3b1;3, and GFR&#x3b1;4), whereas GDNF failed to induce GFR&#x3b1;1 expression in cortical neurons from the AD brain (AD neurons). The exogenous introduction of GFR&#x3b1;1, but not of its binding partner &#x3b1;1-neural cell adhesion molecule, or RET into AD neurons restored the effect of GDNF on neuronal survival. Moreover, between NC and AD neurons, the AMPA receptor blocker CNQX and the NMDA receptor blocker AP-5 had opposite effects on the GFR&#x3b1;1 expression induced by GDNF. In NC neurons, the presence of glutamate receptors was necessary for GDNF-linked GFR&#x3b1;1 expression, while in AD neurons the absence of glutamate receptors was required for GFR&#x3b1;1 expression by GDNF stimulation. These results suggest that, in AD neurons, specific impairments of GFR&#x3b1;1, which may be linked to glutamatergic neurotransmission, shed light on developing potential therapeutic strategies for AD by upregulation of GFR&#x3b1;1 expression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3413127-12$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konishi</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, and Department of Clinical Research, National Tottori Medical Center, Tottori 689-0203, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Li-Bang</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bai</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Section on Synaptic Development, National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rena</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, Florida 34243, Beijing Institute for Brain Disorders, Beijing, China 100069, yshen@rfdn.org rli@rfdn.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, and Center for Advance Therapeutics Strategies for Brain Disorders, Roskamp Institute, Sarasota, Florida 34243, Department of Neurology, University of Florida College of Medicine, Gainesville, Florida 31620, and The School of Life Sciences and Medical Research Center, University of Science and Technology, Hefei, Anhui 230027 China yshen@rfdn.org rli@rfdn.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494987">GFRA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051097">Glial Cell Line-Derived Neurotrophic Factor Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019006">Neural Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6OTE87SCCW</RegistryNumber><NameOfSubstance UI="D018750">6-Cyano-7-nitroquinoxaline-2,3-dione</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018750" MajorTopicYN="N">6-Cyano-7-nitroquinoxaline-2,3-dione</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051097" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor Receptors</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019006" MajorTopicYN="N">Neural Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051096" MajorTopicYN="N">Proto-Oncogene Proteins c-ret</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuron</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25253858</ArticleId><ArticleId IdType="pmc">PMC4172805</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2582-13.2014</ArticleId><ArticleId IdType="pii">34/39/13127</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe K, Saito H. Amyloid &#x3b2; protein inhibits cellular MTT reduction not by suppression of mitochondrial succinate dehydrogenase but by acceleration of MTT formazan exocytosis in cultured rat cortical astrocytes. Neurosci Res. 1998;31:295&#x2013;305. doi: 10.1016/S0168-0102(98)00055-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-0102(98)00055-8</ArticleId><ArticleId IdType="pubmed">9809588</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Kaneko T, Mizuno N, McGeer PL. Distribution of phosphate-activated glutaminase in the human cerebral cortex. J Comp Neurol. 1990;297:239&#x2013;252. doi: 10.1002/cne.902970207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.902970207</ArticleId><ArticleId IdType="pubmed">2196285</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138:155&#x2013;175. doi: 10.1016/j.pharmthera.2013.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.01.004</ArticleId><ArticleId IdType="pubmed">23348013</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association. Thies W, Bleiler L. Alzheimer's Association Report. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7:208&#x2013;244. doi: 10.1016/j.jalz.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.02.004</ArticleId><ArticleId IdType="pubmed">21414557</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas E. GDNF, a multispecific neurotrophic factor with potential therapeutic applications in neurodegenerative disorders. Mol Psychiatry. 1996;1:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118339</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM, Jr, Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron. 1998;21:1291&#x2013;1302. doi: 10.1016/S0896-6273(00)80649-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80649-2</ArticleId><ArticleId IdType="pubmed">9883723</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J. The Sun Health Research Institute Brain Donation Program: description and experience, 1987&#x2013;2007. Cell Tissue Bank. 2008;9:229&#x2013;245. doi: 10.1007/s10561-008-9067-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10561-008-9067-2</ArticleId><ArticleId IdType="pmc">PMC2493521</ArticleId><ArticleId IdType="pubmed">18347928</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaheta RA, Beecken WD, Engl T, Jonas D, Oppermann E, Hundemer M, Doerr HW, Scholz M, Cinatl J. Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia. 2004;6:323&#x2013;331. doi: 10.1593/neo.03418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.03418</ArticleId><ArticleId IdType="pmc">PMC1502118</ArticleId><ArticleId IdType="pubmed">15256054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanomi D, Chivatakarn O, Bai G, Abdesselem H, Lettieri K, Marquardt T, Pierchala BA, Pfaff SL. Ret is a multifunctional coreceptor that integrates diffusible- and contact-axon guidance signals. Cell. 2012;148:568&#x2013;582. doi: 10.1016/j.cell.2012.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.01.024</ArticleId><ArticleId IdType="pmc">PMC3286831</ArticleId><ArticleId IdType="pubmed">22304922</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, Rathjen FG, Raper JA. Extension of neurites on axons is impaired by antibodies against specific neural cell surface glycoproteins. J Cell Biol. 1987;104:355&#x2013;362. doi: 10.1083/jcb.104.2.355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.104.2.355</ArticleId><ArticleId IdType="pmc">PMC2114414</ArticleId><ArticleId IdType="pubmed">3543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110:1129&#x2013;1134. doi: 10.1111/j.1471-4159.2009.06181.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06181.x</ArticleId><ArticleId IdType="pubmed">19457065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol. 2007;178:829&#x2013;841. doi: 10.1083/jcb.200705042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200705042</ArticleId><ArticleId IdType="pmc">PMC2064547</ArticleId><ArticleId IdType="pubmed">17724122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendry SH, Schwark HD, Jones EG, Yan J. Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex. J Neurosci. 1987;7:1503&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568832</ArticleId><ArticleId IdType="pubmed">3033170</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222. doi: 10.1016/j.cell.2012.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.040</ArticleId><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A. Therapeutic intervention for Alzheimer's disease with &#x3b3;-secretase inhibitors: still a viable option? Expert Opin Investig Drugs. 2011;20:325&#x2013;341. doi: 10.1517/13543784.2011.550572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2011.550572</ArticleId><ArticleId IdType="pubmed">21222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwase T, Jung CG, Bae H, Zhang M, Soliven B. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J Neurochem. 2005;94:1488&#x2013;1499. doi: 10.1111/j.1471-4159.2005.03290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03290.x</ArticleId><ArticleId IdType="pubmed">16086701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol. 1994;47:157&#x2013;166. doi: 10.7883/yoken1952.47.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken1952.47.157</ArticleId><ArticleId IdType="pubmed">7823411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko T, Urade Y, Watanabe Y, Mizuno N. Production, characterization, and immunohistochemical application of monoclonal antibodies to glutaminase purified from rat brain. J Neurosci. 1987;7:302&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568863</ArticleId><ArticleId IdType="pubmed">2879897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasashima S, Kawashima A, Muroishi Y, Futakuchi H, Nakanishi I, Oda Y. Neurons with choline acetyltransferase immunoreactivity and mRNA are present in the human cerebral cortex. Histochem Cell Biol. 1999;111:197&#x2013;207. doi: 10.1007/s004180050349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004180050349</ArticleId><ArticleId IdType="pubmed">10094416</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi Y, Lindholm K, Yang LB, Li R, Shen Y. Isolation of living neurons from human elderly brains using the immunomagnetic sorting DNA-linker system. Am J Pathol. 2002;161:1567&#x2013;1576. doi: 10.1016/S0002-9440(10)64435-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64435-5</ArticleId><ArticleId IdType="pmc">PMC1850778</ArticleId><ArticleId IdType="pubmed">12414505</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci U S A. 1998;95:10235&#x2013;10239. doi: 10.1073/pnas.95.17.10235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.17.10235</ArticleId><ArticleId IdType="pmc">PMC21491</ArticleId><ArticleId IdType="pubmed">9707630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2:155&#x2013;165. doi: 10.2174/1567205053585846.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205053585846</ArticleId><ArticleId IdType="pubmed">15974913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano AM, Schmidt M, Roach A. A convenient in vitro assay for the inhibition of neurite outgrowth by adult mammalian CNS myelin using immortalized neuronal cells. J Neurosci Methods. 1995;63:23&#x2013;28. doi: 10.1016/0165-0270(95)00081-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(95)00081-X</ArticleId><ArticleId IdType="pubmed">8788044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. &#x3b2;-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to exciyoyoxicity. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486. doi: 10.1212/WNL.41.4.479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell PJ, Hanson JC, Quets-Nguyen AT, Bergeron M, Smith RC. A quantitative method for analysis of in vitro neurite outgrowth. J Neurosci Methods. 2007;164:350&#x2013;362. doi: 10.1016/j.jneumeth.2007.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2007.04.021</ArticleId><ArticleId IdType="pubmed">17570533</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A. 1996;93:1320&#x2013;1324. doi: 10.1073/pnas.93.3.1320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.3.1320</ArticleId><ArticleId IdType="pmc">PMC40078</ArticleId><ArticleId IdType="pubmed">8577762</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci. 2001;21:3024&#x2013;3033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762559</ArticleId><ArticleId IdType="pubmed">11312287</ArticleId></ArticleIdList></Reference><Reference><Citation>Paratcha G, Ledda F, Ib&#xe1;&#xf1;ez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell. 2003;113:867&#x2013;879. doi: 10.1016/S0092-8674(03)00435-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00435-5</ArticleId><ArticleId IdType="pubmed">12837245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy S, Soderstrom KE, Kordower JH. Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009;175:201&#x2013;216. doi: 10.1016/S0079-6123(09)17514-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(09)17514-3</ArticleId><ArticleId IdType="pmc">PMC3430519</ArticleId><ArticleId IdType="pubmed">19660658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal A. The GDNF protein family: gene ablation studies reveal what they really do and how. Neuron. 1999;22:201&#x2013;203. doi: 10.1016/S0896-6273(00)81077-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81077-6</ArticleId><ArticleId IdType="pubmed">10069322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakakibara S, Okano H. Expression of neural RNA-binding proteins in the postnatal CNS: implications of their roles in neuronal and glial cell development. J Neurosci. 1997;17:8300&#x2013;8312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573750</ArticleId><ArticleId IdType="pubmed">9334405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci. 2003;116:3855&#x2013;3862. doi: 10.1242/jcs.00786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00786</ArticleId><ArticleId IdType="pubmed">12953054</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoca R, Ziegler U, Sonderegger P. Effects of L-serine on neurons in vitro. J Neurosci Methods. 1995;61:159&#x2013;167. doi: 10.1016/0165-0270(95)00038-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(95)00038-V</ArticleId><ArticleId IdType="pubmed">8618415</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmutzler BS, Roy S, Pittman SK, Meadows RM, Hingtgen CM. Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization. Mol Pain. 2011;7:22. doi: 10.1186/1744-8069-7-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-8069-7-22</ArticleId><ArticleId IdType="pmc">PMC3078874</ArticleId><ArticleId IdType="pubmed">21450093</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 1999;47:719&#x2013;730. doi: 10.1177/002215549904700601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215549904700601</ArticleId><ArticleId IdType="pubmed">10330448</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid. The next generation of Alzheimer's disease therapeutics. Mol Interv. 2007;7:261&#x2013;270. doi: 10.1124/mi.7.5.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.7.5.8</ArticleId><ArticleId IdType="pubmed">17932415</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev. 2000;33:199&#x2013;227. doi: 10.1016/S0165-0173(00)00030-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(00)00030-8</ArticleId><ArticleId IdType="pubmed">11011066</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature. 1996;382:80&#x2013;83. doi: 10.1038/382080a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382080a0</ArticleId><ArticleId IdType="pubmed">8657309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, H&#xf6;kfelt T, Broberger C, Porreca F, Lai J, Ren K, Ossipov M, Koshkin A, Jakobsen N, Skouv J, Oerum H, Jacobsen MH, Wengel J. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 2000;97:5633&#x2013;5638. doi: 10.1073/pnas.97.10.5633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.10.5633</ArticleId><ArticleId IdType="pmc">PMC25880</ArticleId><ArticleId IdType="pubmed">10805816</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton KM. GDNF: a novel factor with therapeutic potential for neurodegenerative disorders. Mol Neurobiol. 1999;19:43&#x2013;59. doi: 10.1007/BF02741377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02741377</ArticleId><ArticleId IdType="pubmed">10321971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Baloh RH, Milbrandt J, Garcia KC. Structure of artemin complexed with its receptor GFR&#x3b1;3: convergent recognition og glial cell line-derived neurotrophic factors. Structure. 2006;14:1083&#x2013;1092. doi: 10.1016/j.str.2006.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2006.05.010</ArticleId><ArticleId IdType="pubmed">16765900</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012;1:14. doi: 10.1186/2047-9158-1-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-9158-1-14</ArticleId><ArticleId IdType="pmc">PMC3542569</ArticleId><ArticleId IdType="pubmed">23210531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zihlmann KB, Ducray AD, Schaller B, Huber AW, Krebs SH, Andres RH, Seiler RW, Meyer M, Widmer HR. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res Bull. 2005;68:42&#x2013;53. doi: 10.1016/j.brainresbull.2004.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2004.10.012</ArticleId><ArticleId IdType="pubmed">16325003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25261551</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>41</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Proteopathic tau seeding predicts tauopathy in vivo.</ArticleTitle><Pagination><StartPage>E4376</StartPage><EndPage>E4385</EndPage><MedlinePgn>E4376-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1411649111</ELocationID><Abstract><AbstractText>Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer's disease, this model predicts that tau seeds propagate pathology through the brain via cell-cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (&#x223c; 300 fM) and synuclein (&#x223c; 300 pM) fibrils. This assay readily discriminates Alzheimer's disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, &gt;1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Brandon B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furman</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Tritia R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirbaha</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eades</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Oncology, Section of Stem Cell Biology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belaygorod</LastName><ForeName>Larisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, and marc.diamond@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS079039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR0227552</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS087805</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F32NS087805</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31NS079039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015374" MajorTopicYN="N">Biosensing Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25261551</ArticleId><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="doi">10.1073/pnas.1411649111</ArticleId><ArticleId IdType="pii">1411649111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73(6):1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271&#x2013;278, discussion 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Some speculations about prions, amyloid, and Alzheimer&#x2019;s disease. N Engl J Med. 1984;310(10):661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">6363926</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Shattuck lecture&#x2014;Neurodegenerative diseases and prions. N Engl J Med. 2001;344(20):1516&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">11357156</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VMY. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286(17):15317&#x2013;15331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 2012;7(2):e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73(4):685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA. 2013;110(33):E3138&#x2013;E3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33(3):1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, et al. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis. 2010;19(2):647&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110609</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem. 2013;288(3):1856&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014;2(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922636</ArticleId><ArticleId IdType="pubmed">24479894</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110(23):9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211(3):387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollitt SK, et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003;40(4):685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287(23):19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA. 1988;85(13):4884&#x2013;4888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperfeld AD, et al. FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol. 1999;46(5):708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10553987</ArticleId></ArticleIdList></Reference><Reference><Citation>Banning C, et al. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS ONE. 2010;5(2):e9344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825263</ArticleId><ArticleId IdType="pubmed">20179761</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel CH, et al. Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J Biol Chem. 2014;289(2):956&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887218</ArticleId><ArticleId IdType="pubmed">24235150</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA. 2009;106(47):20051&#x2013;20056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33(9):2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J Exp Med. 2012;209(5):975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276(5321):2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11(3):155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI. Prion-like Properties of tau protein: The importance of extracellular tau as a therapeutic target. J Biol Chem. 2014;289(29):19855&#x2013;19861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106306</ArticleId><ArticleId IdType="pubmed">24860099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vascellari S, et al. Prion seeding activities of mouse scrapie strains with divergent PrPSc protease sensitivities and amyloid plaque content using RT-QuIC and eQuIC. PLoS ONE. 2012;7(11):e48969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489776</ArticleId><ArticleId IdType="pubmed">23139828</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama Y, et al. Ultrasensitive detection of PrPSc in the cerebrospinal fluid and blood of macaques infected with bovine spongiform encephalopathy prion. J Gen Virol. 2014 doi: 10.1099/vir.0.066225-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.066225-0</ArticleId><ArticleId IdType="pubmed">25024281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE. 2011;6(6):e21050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31(37):13110&#x2013;13117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging Alzheimer&#x2019;s Association National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathol. 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21(5):719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992;11(4):1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, et al. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer&#x2019;s disease. J Neurosci. 1999;19(17):7486&#x2013;7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Mar&#xed;a I, P&#xe9;rez M, Hern&#xe1;ndez F, Avila J, Moreno FJ. Characteristics of the binding of Thioflavin S to tau paired helical filaments. J Alzheimers Dis. 2006;9(3):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby DW, et al. Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA. 2007;104(52):20914&#x2013;20919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409241</ArticleId><ArticleId IdType="pubmed">18096717</ArticleId></ArticleIdList></Reference><Reference><Citation>Du D, et al. A kinetic aggregation assay allowing selective and sensitive amyloid-&#x3b2; quantification in cells and tissues. Biochemistry. 2011;50(10):1607&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051019</ArticleId><ArticleId IdType="pubmed">21268584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Jie S, Colby DW. Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay. J Biol Chem. 2012;287(13):9982&#x2013;9989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323021</ArticleId><ArticleId IdType="pubmed">22187438</ArticleId></ArticleIdList></Reference><Reference><Citation>Morozova OA, March ZM, Robinson AS, Colby DW. Conformational features of tau fibrils from Alzheimer&#x2019;s disease brain are faithfully propagated by unmodified recombinant protein. Biochemistry. 2013;52(40):6960&#x2013;6967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142060</ArticleId><ArticleId IdType="pubmed">24033133</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C. Detection of misfolded A2 oligomers for sensitive biochemical diagnosis of Alzheimer s disease. Cell Rep. 2014;7(1):261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">24656814</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300(5619):636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbauer PT, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson&#x2019;s disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004;187(2):279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15144854</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, et al. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging. 2007;28(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16343696</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189(3):167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1(1):103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25264250</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0445</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>19</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling.</ArticleTitle><Pagination><StartPage>2319</StartPage><EndPage>2326</EndPage><MedlinePgn>2319-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cub.2014.08.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0960-9822(14)01040-9</ELocationID><Abstract><AbstractText>The normal functions and pathologic facets of the small presynaptic protein &#x3b1;-synuclein (&#x3b1;-syn) are of exceptional interest. In previous studies, we found that &#x3b1;-syn attenuates synaptic exo/endocytosis; however, underlying mechanisms remain unknown. More recent evidence suggests that &#x3b1;-syn exists as metastable multimers and not solely as a natively unfolded monomer. However, conformations of &#x3b1;-syn at synapses--its physiologic locale--are unclear, and potential implications of such higher-order conformations to synaptic function are unknown. Exploring &#x3b1;-syn conformations and synaptic function in neurons, we found that &#x3b1;-syn promptly organizes into physiological multimers at synapses. Furthermore, our experiments indicate that &#x3b1;-syn multimers cluster synaptic vesicles and restrict their motility, suggesting a novel role for these higher-order structures. Supporting this, &#x3b1;-syn mutations that disrupt multimerization also fail to restrict synaptic vesicle motility or attenuate exo/endocytosis. We propose a model in which &#x3b1;-syn multimers cluster synaptic vesicles, restricting their trafficking and recycling, and consequently attenuate neurotransmitter release.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Utpal</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Subhojit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. Electronic address: s1roy@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073740</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25264250</ArticleId><ArticleId IdType="mid">NIHMS631185</ArticleId><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2014.08.027</ArticleId><ArticleId IdType="pii">S0960-9822(14)01040-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083&#x2013;8095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901533</ArticleId><ArticleId IdType="pubmed">20554859</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D, Roy S. alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci. 2012;32:10129&#x2013;10135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426499</ArticleId><ArticleId IdType="pubmed">22836248</ArticleId></ArticleIdList></Reference><Reference><Citation>Staras K, Branco T, Burden JJ, Pozo K, Darcy K, Marra V, Ratnayaka A, Goda Y. A vesicle superpool spans multiple presynaptic terminals in hippocampal neurons. Neuron. 2010;66:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908741</ArticleId><ArticleId IdType="pubmed">20399727</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci. 2006;26:11915&#x2013;11922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674868</ArticleId><ArticleId IdType="pubmed">17108165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A. 2012;109:3213&#x2013;3219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295273</ArticleId><ArticleId IdType="pubmed">22315428</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, et al. alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A. 2010;107:19573&#x2013;19578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984188</ArticleId><ArticleId IdType="pubmed">20974939</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, et al. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci. 2011;31:7264&#x2013;7274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154647</ArticleId><ArticleId IdType="pubmed">21593311</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287:15345&#x2013;15364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Burre J, Vivona S, Diao J, Sharma M, Brunger AT, Sudhof TC. Properties of native brain alpha-synuclein. Nature. 2013;498:E4&#x2013;6. discussion E6-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255827</ArticleId><ArticleId IdType="pubmed">23765500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould N, Mor D, Lightfoot R, Malkus K, Giasson B, Ischiropoulos H. Evidence of Native alpha-Synuclein Conformers in the Human Brain. J Biol Chem. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953303</ArticleId><ArticleId IdType="pubmed">24474688</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J Biol Chem. 2013;288:6371&#x2013;6385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK, et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A. 2011;108:17797&#x2013;17802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203798</ArticleId><ArticleId IdType="pubmed">22006323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerppola TK. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat Protoc. 2006;1:1278&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518326</ArticleId><ArticleId IdType="pubmed">17406412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama Y, Hu CD. Bimolecular fluorescence complementation (BiFC): a 5-year update and future perspectives. Biotechniques. 2012;53:285&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">23148879</ArticleId></ArticleIdList></Reference><Reference><Citation>Schluter OM, Xu W, Malenka RC. Alternative N-terminal domains of PSD-95 and SAP97 govern activity-dependent regulation of synaptic AMPA receptor function. Neuron. 2006;51:99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815335</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One. 2008;3:e1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270899</ArticleId><ArticleId IdType="pubmed">18382657</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Scott D, Das U, Gitler D, Ganguly A, Roy S. Fast vesicle transport is required for the slow axonal transport of synapsin. J Neurosci. 2013;33:15362&#x2013;15375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782618</ArticleId><ArticleId IdType="pubmed">24068803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Atluri PP, Ryan TA. Actin has a molecular scaffolding, not propulsive, role in presynaptic function. Nat.Neurosci. 2003;6:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536209</ArticleId></ArticleIdList></Reference><Reference><Citation>Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, Burd CG, Lee VM. {alpha}-Synuclein-induced Aggregation of Cytoplasmic Vesicles in Saccharomyces cerevisiae. Mol Biol Cell. 2008;19:1093&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2262993</ArticleId><ArticleId IdType="pubmed">18172022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc.Natl.Acad.Sci.U.S.A. 2008;105:145&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of alpha-synuclein. J.Neurosci. 2005;25:10913&#x2013;10921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725870</ArticleId><ArticleId IdType="pubmed">16306404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Ryan TA. Real-time measurements of vesicle-SNARE recycling in synapses of the central nervous system. Nat Cell Biol. 2000;2:197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wislet-Gendebien S, D'Souza C, Kawarai T, St George-Hyslop P, Westaway D, Fraser P, Tandon A. Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. J Biol Chem. 2006;281:32148&#x2013;32155.</Citation><ArticleIdList><ArticleId IdType="pubmed">16926154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A. Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors. BMC Neurosci. 2008;9:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562387</ArticleId><ArticleId IdType="pubmed">18808659</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J.Biol.Chem. 1998;273:9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E, McLaurin J, Yip CM, George-Hyslop P, Fraser PE. alpha-Synuclein membrane interactions and lipid specificity. J.Biol.Chem. 2000;275:34328&#x2013;34334.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer TS, Bax A. Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. J.Biol.Chem. 2005;280:43179&#x2013;43187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16166095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E, Lewis PA, Ling H, Proukakis C, Houlden H, Hardy J. alpha-Synuclein mutations cluster around a putative protein loop. Neurosci Lett. 2013;546:67&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694303</ArticleId><ArticleId IdType="pubmed">23669636</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Woods WS, Clayton DF, George JM. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J.Biol.Chem. 2000;275:34393&#x2013;34398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952980</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrone J, Li Z, Murthy VN. Studying vesicle cycling in presynaptic terminals using the genetically encoded probe synaptopHluorin. Nat Protoc. 2006;1:2970&#x2013;2978.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406557</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaji J, Ryan TA. Single-vesicle imaging reveals that synaptic vesicle exocytosis and endocytosis are coupled by a single stochastic mode. Proc Natl Acad Sci U S A. 2007;104:20576&#x2013;20581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2154473</ArticleId><ArticleId IdType="pubmed">18077369</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao J, Burre J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Sudhof TC, Brunger AT. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife. 2013;2:e00592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639508</ArticleId><ArticleId IdType="pubmed">23638301</ArticleId></ArticleIdList></Reference><Reference><Citation>Varkey J, Mizuno N, Hegde BG, Cheng N, Steven AC, Langen R. alpha-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J Biol Chem. 2013;288:17620&#x2013;17630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682563</ArticleId><ArticleId IdType="pubmed">23609437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci. 2014;34:9364&#x2013;9376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087213</ArticleId><ArticleId IdType="pubmed">25009269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25261995</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Progranulin protects against amyloid &#x3b2; deposition and toxicity in Alzheimer's disease mouse models.</ArticleTitle><Pagination><StartPage>1157</StartPage><EndPage>1164</EndPage><MedlinePgn>1157-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3672</ELocationID><Abstract><AbstractText>Haploinsufficiency of the progranulin (PGRN) gene (GRN) causes familial frontotemporal lobar degeneration (FTLD) and modulates an innate immune response in humans and in mouse models. GRN polymorphism may be linked to late-onset Alzheimer's disease (AD). However, the role of PGRN in AD pathogenesis is unknown. Here we show that PGRN inhibits amyloid &#x3b2; (A&#x3b2;) deposition. Selectively reducing microglial expression of PGRN in AD mouse models impaired phagocytosis, increased plaque load threefold and exacerbated cognitive deficits. Lentivirus-mediated PGRN overexpression lowered plaque load in AD mice with aggressive amyloid plaque pathology. A&#x3b2; plaque load correlated negatively with levels of hippocampal PGRN, showing the dose-dependent inhibitory effects of PGRN on plaque deposition. PGRN also protected against A&#x3b2; toxicity. Lentivirus-mediated PGRN overexpression prevented spatial memory deficits and hippocampal neuronal loss in AD mice. The protective effects of PGRN against A&#x3b2; deposition and toxicity have important therapeutic implications. We propose enhancing PGRN as a potential treatment for PGRN-deficient FTLD and AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>S Sakura</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krabbe</LastName><ForeName>Grietje</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asgarov</LastName><ForeName>Rustam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Graduate Program in Neurochemistry with Molecular Neurobiology, Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaqiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Lauren H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elia</LastName><ForeName>Lisa P</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farese</LastName><ForeName>Robert V</ForeName><Initials>RV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>1] Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA. [2] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [3] Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS076239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG034793</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32NS076239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31AG034793</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2014 Oct;20(10):1099-100. doi: 10.1038/nm.3712.</RefSource><PMID Version="1">25295938</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25261995</ArticleId><ArticleId IdType="mid">NIHMS617867</ArticleId><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="doi">10.1038/nm.3672</ArticleId><ArticleId IdType="pii">nm.3672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48:999&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858277</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel R, Daniels E, He Z, Bateman A. Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn. 2003;227:593&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889069</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, et al. Progranulin expression in the developing and adult murine brain. J Comp Neurol. 2010;518:3931&#x2013;3947.</Citation><ArticleIdList><ArticleId IdType="pubmed">20737593</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis. 2012;45:711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, et al. Dissociation of Frontotemporal Dementia-Related Deficits and Neuroinflammation in Progranulin Haploinsufficient Mice. J Neurosci. 2013;33:5352&#x2013;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122:3955&#x2013;3959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, et al. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21:195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006;9:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914866</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. 2009;4:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784760</ArticleId><ArticleId IdType="pubmed">19917131</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortini F, et al. Novel exon 1 progranulin gene variant in Alzheimer&#x2019;s disease. Eur J Neurol. 2008;15:1111&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752597</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan J, et al. An association study between granulin gene polymorphisms and Alzheimer&#x2019;s disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:747&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">19016491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley BJ, et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol. 2010;67:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902004</ArticleId><ArticleId IdType="pubmed">20142525</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, et al. Progranulin Mutations as Risk Factors for Alzheimer Disease. JAMA Neurol. 2013:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereson S, et al. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol. 2009;219:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">19557827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliebus G, Rosso A, Lippa CF. Progranulin and beta-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. Am J Alzheimers Dis Other Demen. 2009;24:456&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846111</ArticleId><ArticleId IdType="pubmed">19776335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">10621974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, et al. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol. 2011;178:284&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070582</ArticleId><ArticleId IdType="pubmed">21224065</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, et al. SIRT1 Protects against Microglia-dependent Amyloid-{beta} Toxicity through Inhibiting NF-{kappa}B Signaling. J Biol Chem. 2005;280:40364&#x2013;40374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener. 2013;8:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33:196 e129&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh HS, Choi N, Tarassishin L, Lee SC. Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12) PLoS One. 2012;7:e35115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324426</ArticleId><ArticleId IdType="pubmed">22509390</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem. 2012;287:32298&#x2013;32306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463300</ArticleId><ArticleId IdType="pubmed">22859297</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90:1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352&#x2013;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottis P, et al. Human and rat brain lipofuscin proteome. Proteomics. 2012;12:2445&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pubmed">22707227</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33:611&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">12208347</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AS, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One. 2010;5:e13368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CL, et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 2009;10:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779192</ArticleId><ArticleId IdType="pubmed">19860916</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol Aging. 2011;32:2326 e2325&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375317</ArticleId><ArticleId IdType="pubmed">21820214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci U S A. 2011;108:4441&#x2013;4446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060230</ArticleId><ArticleId IdType="pubmed">21368173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan XD, et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer&#x2019;s disease. Mol Neurodegener. 2011;6:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149591</ArticleId><ArticleId IdType="pubmed">21718498</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer&#x2019;s disease. Neuron. 2006;51:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer&#x2019;s disease. Neuron. 2008;60:247&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem. 2005;280:40364&#x2013;40374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183991</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8:e60921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Gan L. Manipulation of gene expression in the central nervous system with lentiviral vectors. Methods Mol Biol. 2011;670:155&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">20967590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev. 2004;28:497&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465137</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ. 2011;343:d2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">22803193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25271633</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Olfactory dysfunction predicts 5-year mortality in older adults.</ArticleTitle><Pagination><StartPage>e107541</StartPage><MedlinePgn>e107541</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e107541</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0107541</ELocationID><Abstract><AbstractText>Prediction of mortality has focused on disease and frailty, although antecedent biomarkers may herald broad physiological decline. Olfaction, an ancestral chemical system, is a strong candidate biomarker because it is linked to diverse physiological processes. We sought to determine if olfactory dysfunction is a harbinger of 5-year mortality in the National Social Life, Health and Aging Project [NSHAP], a nationally representative sample of older U.S. adults. 3,005 community-dwelling adults aged 57-85 were studied in 2005-6 (Wave 1) and their mortality determined in 2010-11 (Wave 2). Olfactory dysfunction, determined objectively at Wave 1, was used to estimate the odds of 5-year, all cause mortality via logistic regression, controlling for demographics and health factors. Mortality for anosmic older adults was four times that of normosmic individuals while hyposmic individuals had intermediate mortality (p&lt;0.001), a "dose-dependent" effect present across the age range. In a comprehensive model that included potential confounding factors, anosmic older adults had over three times the odds of death compared to normosmic individuals (OR, 3.37 [95%CI 2.04, 5.57]), higher than and independent of known leading causes of death, and did not result from the following mechanisms: nutrition, cognitive function, mental health, smoking and alcohol abuse or frailty. Olfactory function is thus one of the strongest predictors of 5-year mortality and may serve as a bellwether for slowed cellular regeneration or as a marker of cumulative toxic environmental exposures. This finding provides clues for pinpointing an underlying mechanism related to a fundamental component of the aging process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Jayant M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Section of Otolaryngology-Head and Neck Surgery, Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wroblewski</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Health Studies, The University of Chicago, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Comparative Human Development and The Institute for Mind and Biology, The University of Chicago, Chicago, Illinois, United States of America; The Center on the Demography and Economics of Aging, National Opinion Research Center, The University of Chicago, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumm</LastName><ForeName>L Philip</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Health Studies, The University of Chicago, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McClintock</LastName><ForeName>Martha K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Comparative Human Development and The Institute for Mind and Biology, The University of Chicago, Chicago, Illinois, United States of America; The Center on the Demography and Economics of Aging, National Opinion Research Center, The University of Chicago, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG029795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033903</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024999</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG036762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR025000</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T35 AG029795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32000243</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2RR025000</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG030481</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR024999</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG036762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033903-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009830" MajorTopicYN="N">Olfactory Bulb</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25271633</ArticleId><ArticleId IdType="pmc">PMC4182669</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0107541</ArticleId><ArticleId IdType="pii">PONE-D-14-20307</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Niimura Y (2009) Evolutionary dynamics of olfactory receptor genes in chordates: interaction between environments and genomic contents. Hum Genomics 4: 107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525206</ArticleId><ArticleId IdType="pubmed">20038498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennella JA, Jagnow CP, Beauchamp GK (2001) Prenatal and postnatal flavor learning by human infants. Pediatrics 107: E88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351272</ArticleId><ArticleId IdType="pubmed">11389286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays NP, Roberts SB (2006) The anorexia of aging in humans. Physiol Behav 88: 257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, McClintock MK, Zelano B, Ober C (2002) Paternally inherited HLA alleles are associated with women's choice of male odor. Nat Genet 30: 175&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799397</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Garcia S, Hayreh D, McClintock MK (2002) Psychological effects of musky compounds: comparison of androstadienone with androstenol and muscone. Horm Behav 42: 274&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460587</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucet S, Soussignan R, Sagot P, Schaal B (2009) The secretion of areolar (Montgomery's) glands from lactating women elicits selective, unconditional responses in neonates. PLoS One 4: e7579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761488</ArticleId><ArticleId IdType="pubmed">19851461</ArticleId></ArticleIdList></Reference><Reference><Citation>Welge-Lussen A (2009) Ageing, neurodegeneration, and olfactory and gustatory loss. B-Ent 5 Suppl 13129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">20084814</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton SD, Ermentrout GB, Urban NN (2012) Intrinsic heterogeneity in oscillatory dynamics limits correlation-induced neural synchronization. J Neurophysiol 108: 2115&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545024</ArticleId><ArticleId IdType="pubmed">22815400</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Esparcia P, Schluter A, Carmona M, Moreno J, Ansoleaga B, et al. (2013) Functional genomics reveals dysregulation of cortical olfactory receptors in Parkinson disease: novel putative chemoreceptors in the human brain. J Neuropathol Exp Neurol 72: 524&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656994</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano SF, Impagnatiello F, Girelli M, Cova L, Grioni E, et al. (2000) Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 18: 295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924096</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS, Wang S, Jiang L, Kang J, Benraiss A, et al. (2000) In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med 6: 271&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">10700228</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwob JE (2002) Neural regeneration and the peripheral olfactory system. Anat Rec 269: 33&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891623</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe-Rudolph M, Begus-Nahrmann Y, Lechel A, Rolyan H, Scheithauer MO, et al. (2011) Telomere shortening impairs regeneration of the olfactory epithelium in response to injury but not under homeostatic conditions. PLoS One 6: e27801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218037</ArticleId><ArticleId IdType="pubmed">22110763</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter for Disease Control (2013) Mortality Tables. Available: http://www.cdc.gov/nchs/nvss/mortality_tables.htm. CDC.</Citation></Reference><Reference><Citation>Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, et al. (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253156</ArticleId></ArticleIdList></Reference><Reference><Citation>Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, et al. (2010) Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 210: 901&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">20510798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, et al. (2009) Olfactory impairment in presymptomatic Alzheimer's disease. Ann N Y Acad Sci 1170: 730&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857767</ArticleId><ArticleId IdType="pubmed">19686220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Arnold SE, Buchman AS, Tang Y, Bennett DA (2008) Odor identification and progression of parkinsonian signs in older persons. Exp Aging Res 34: 173&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142656</ArticleId><ArticleId IdType="pubmed">18568978</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamps JJ, Bartoshuk LM, Heilman KM (2013) A brief olfactory test for Alzheimer's disease. J Neurol Sci 333: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823377</ArticleId><ArticleId IdType="pubmed">23927938</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzman R (2009) The National Social Life, Health, and Aging Project: an introduction. J Gerontol B Psychol Sci Soc Sci 64 Suppl 1i5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763520</ArticleId><ArticleId IdType="pubmed">19837963</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Muircheartaigh C, Eckman S, Smith S (2009) Statistical design and estimation for the national social life, health, and aging project. J Gerontol B Psychol Sci Soc Sci 64 Suppl 1i12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763522</ArticleId><ArticleId IdType="pubmed">19567827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto JM, Schumm LP, Wroblewski KE, Kern DW, McClintock MK (2013) Racial Disparities in Olfactory Loss Among Older Adults in the United States. J Gerontol A Biol Sci Med Sci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976135</ArticleId><ArticleId IdType="pubmed">23689829</ArticleId></ArticleIdList></Reference><Reference><Citation>Qato DM LS, Conti RM, Schumm LP, Alexander GC (2010) Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiol Drug Saf 19: 834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586253</ArticleId><ArticleId IdType="pubmed">20681002</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite LJ, Laumann EO, Das A, Schumm LP (2009) Sexuality: measures of partnerships, practices, attitudes, and problems in the National Social Life, Health, and Aging Study. J Gerontol B Psychol Sci Soc Sci 64 Suppl 1i56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763521</ArticleId><ArticleId IdType="pubmed">19497930</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon-Garciduenas L, Solt AC, Henriquez-Roldan C, Torres-Jardon R, Nuse B, et al. (2008) Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. Toxicol Pathol 36: 289&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">18349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumm LP, McClintock M, Williams S, Leitsch S, Lundstrom J, et al. (2009) Assessment of sensory function in the National Social Life, Health, and Aging Project. J Gerontol B Psychol Sci Soc Sci 64 Suppl 1i76&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981468</ArticleId><ArticleId IdType="pubmed">19549923</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, et al. (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357: 762&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2426743</ArticleId><ArticleId IdType="pubmed">17715410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Renner B (2006) A new procedure for the short screening of olfactory function using five items from the "Sniffin' Sticks" identification test kit. Am J Rhinol 20: 113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern DW, Wroblewski KE, Schumm LP, Pinto JM, McClintock MK Field Survey Measures of Olfaction: The Olfactory Function Field Exam (OFFE). Field Methods In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876959</ArticleId><ArticleId IdType="pubmed">27226782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Renner B (2006) A new procedure for the short screening of olfactory function using five items from the "Sniffin' Sticks" identification test kit. American Journal of Rhinology 20: 113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539306</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Muircheartaigh CA, Eckman S, Smith SN (2009) Statistical design and estimation for the national social life, health, and aging project. The Journals of Gerontology Series B, Psychological Sciences and Social Sciences 64 Suppl 1i12&#x2013;i19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763522</ArticleId><ArticleId IdType="pubmed">19567827</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz JN CL, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34: 73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8551813</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SR, Pham-Kanter G, Leitsch SA (2009) Measures of chronic conditions and diseases associated with aging in the national social life, health, and aging project. J Gerontol B Psychol Sci Soc Sci 64 Suppl 1i67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763523</ArticleId><ArticleId IdType="pubmed">19204070</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer E (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23: 433&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">1159263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewing JA (1984) Detecting alcoholism. The CAGE questionnaire. Jama 252: 1905&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471323</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder DA (1983) On the variances of asymptotically normal estimators from complex surveys. International Statistical Review 51: 279&#x2013;292.</Citation></Reference><Reference><Citation>Administration SS (2014) Available: http://www.ssa.gov/OACT/STATS/table4c6.html.</Citation></Reference><Reference><Citation>Locher JL, Roth DL, Ritchie CS, Cox K, Sawyer P, et al. (2007) Body mass index, weight loss, and mortality in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 62: 1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750037</ArticleId><ArticleId IdType="pubmed">18166690</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Moineddin R, Urquia ML, Razak F, Ray JG (2014) J-shapedness: an often missed, often miscalculated relation: the example of weight and mortality. J Epidemiol Community Health 68: 683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">24683176</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309: 71&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855514</ArticleId><ArticleId IdType="pubmed">23280227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullol J, Alobid I, Marino-Sanchez F, Quinto L, de Haro J, et al... (2012) Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533119</ArticleId><ArticleId IdType="pubmed">23135536</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A, Hempstead M, Gomez IA, Gilbert AN, Vosshall LB (2012) An olfactory demography of a diverse metropolitan population. BMC Neurosci 13: 122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493268</ArticleId><ArticleId IdType="pubmed">23046643</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63: 7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18232016</ArticleId></ArticleIdList></Reference><Reference><Citation>Prediger RD, Aguiar AS Jr, Matheus FC, Walz R, Antoury L, et al. (2012) Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 21: 90&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan WQ, FitzGerald JM, Carlsten C, Sadatsafavi M, Brauer M (2013) Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med 187: 721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">23392442</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, et al. (2009) Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338: a3083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615548</ArticleId><ArticleId IdType="pubmed">19131384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18480203</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman N, Turra CM, Glei DA, Seplaki CL, Lin YH, et al. (2006) Predicting mortality from clinical and nonclinical biomarkers. J Gerontol A Biol Sci Med Sci 61: 1070&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, et al. (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811980</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, et al. (1998) Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 279: 585&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">9486752</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti MC, Guralnik JM, Salive ME, Sorkin JD (1994) Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 272: 1036&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosero-Bixby L, Dow WH (2012) Predicting mortality with biomarkers: a population-based prospective cohort study for elderly Costa Ricans. Popul Health Metr 10: 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507767</ArticleId><ArticleId IdType="pubmed">22694922</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, et al. (2002) Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 50: 638&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">11982663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25285942</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of potent &#x3b3;-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers.</ArticleTitle><Pagination><StartPage>1481</StartPage><EndPage>1489</EndPage><MedlinePgn>1481-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.2482</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Although considerable effort has been expended developing drug candidates for Alzheimer disease, none have yet succeeded owing to the lack of efficacy or to safety concerns. One potential shortcoming of current approaches to Alzheimer disease drug discovery and development is that they rely primarily on transformed cell lines and animal models that substantially overexpress wild-type or mutant proteins. It is possible that drug development failures thus far are caused in part by the limits of these approaches, which do not accurately reveal how drug candidates will behave in naive human neuronal cells.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze purified neurons derived from human induced pluripotent stem cells from patients carrying 3 different presenilin 1 (PS1) mutations and nondemented control individuals in the absence of any overexpression. We tested the efficacy of &#x3b3;-secretase inhibitor and &#x3b3;-secretase modulator (GSM) in neurons derived from both normal control and 3 PS1 mutations (A246E, H163R, and M146L).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Adult human skin biopsies were obtained from volunteers at the Alzheimer Disease Research Center, University of California, San Diego. Cell cultures were treated with &#x3b3;-secretase inhibitor or GSM. Comparisons of total &#x3b2;-amyloid (A&#x3b2;) and A&#x3b2; peptides 38, 40, and 42 in the media were made between vehicle- vs drug-treated cultures.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Soluble A&#x3b2; levels in the media were measured by enzyme-linked immunosorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As predicted, mutant PS1 neurons exhibited an elevated A&#x3b2;42:A&#x3b2;40 ratio (P &lt; .05) at the basal state as compared with the nondemented control neurons. Treatment with a potent non-nonsteroidal anti-inflammatory druglike GSM revealed a new biomarker signature that differs from all previous cell types and animals tested. This new signature was the same in both the mutant and control neurons and consisted of a reduction in A&#x3b2;42, A&#x3b2;40, and A&#x3b2;38 and in the A&#x3b2;42:A&#x3b2;40 ratio, with no change in the total A&#x3b2; levels.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This biomarker discrepancy is likely due to overexpression of amyloid precursor protein in the transformed cellular models. Our results suggest that biomarker signatures obtained with such models are misleading and that human neurons derived from human induced pluripotent stem cells provide a unique signature that will more accurately reflect drug response in human patients and in cerebrospinal fluid biomarker changes observed during GSM treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waltz</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla3Capitalbio, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israel</LastName><ForeName>Mason A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla4Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarsoza</LastName><ForeName>Floyd</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Mary S Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shauna H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX000531</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131-26</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG016750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045860</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG034550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035075</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS075094</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS074501</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-NS074501</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 MH069281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13 AG026970</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Dec;71(12):1475-6. doi: 10.1001/jamaneurol.2014.2802.</RefSource><PMID Version="1">25285675</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Tanzi and Wagner are shareholders and cofounders of a privately held company (Neurogenetic Pharmaceuticals Inc) that holds rights to a &#x3b3;-secretase modulator currently in preclinical development. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25285942</ArticleId><ArticleId IdType="mid">NIHMS670034</ArticleId><ArticleId IdType="pmc">PMC4374637</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.2482</ArticleId><ArticleId IdType="pii">1910854</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3(77):sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk C, Sabbagh MN. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging. 2013;30(10):783&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000701</ArticleId><ArticleId IdType="pubmed">23943247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286737</ArticleId></ArticleIdList></Reference><Reference><Citation>Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells: opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011;10(12):915&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">22076509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Bammens L, Benilova I, et al. The mechanism of &#x3b3;-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10):2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Shaner M. Bioengineered stem cells in neural development and neurodegeneration research. Ageing Res Rev. 2013;12(3):739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742639</ArticleId><ArticleId IdType="pubmed">23651546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Danks AM, Cheng S, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron. 2010;67(5):769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Ramirez CN, Kim H, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012;30(12):1244&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711177</ArticleId><ArticleId IdType="pubmed">23159879</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Liu Q, Rao MS, Zeng X. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen. 2013;18(5):522&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">23364514</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan EM, Ratanasirintrawoot S, Park IH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol. 2009;27(11):1033&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">19826408</ArticleId></ArticleIdList></Reference><Reference><Citation>Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334647</ArticleId><ArticleId IdType="pubmed">18568017</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482(7384):216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One. 2011;6(3):e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28(1):31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086981</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756723</ArticleId><ArticleId IdType="pubmed">19252484</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P, Tamboli IY, Mertens J, et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of &#x3b3;-secretase activity in endogenous amyloid-&#x3b2; generation. Am J Pathol. 2012;180(6):2404&#x2013;2416.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y, Yarimizu J, Saita K, et al. Differential effects between &#x3b3;-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32(6):2037&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621706</ArticleId><ArticleId IdType="pubmed">22323718</ArticleId></ArticleIdList></Reference><Reference><Citation>Oehlrich D, Berthelot DJC, Gijsen HJ. &#x3b3;-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem. 2011;54(3):669&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21141968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27(7):686&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, et al. Gamma-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324(5927):639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7(3):172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner SL, Zhang C, Cheng S, et al. Soluble &#x3b3;-secretase modulators selectively inhibit the production of the 42-amino acid amyloid &#x3b2; peptide variant and augment the production of multiple carboxy-truncated amyloid &#x3b2; species. Biochemistry. 2014;53(4):702&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929337</ArticleId><ArticleId IdType="pubmed">24401146</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, et al. Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Tagami S, Yanagida K, et al. &#x3b3;-Secretase modulators and presenilin 1 mutants act differently on presenilin/&#x3b3;-secretase function to cleave A&#x3b2;42 and A&#x3b2;43. Cell Rep. 2013;3(1):42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23291095</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ, Johnson DS, Li YM. Development and mechanism of &#x3b3;-secretase modulators for Alzheimer's disease. Biochemistry. 2013;52(19):3197&#x2013;3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796170</ArticleId><ArticleId IdType="pubmed">23614767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretner B, Fukumori A, Gutsmiedl A, et al. Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem. 2011;286(17):15240&#x2013;15251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083200</ArticleId><ArticleId IdType="pubmed">21357415</ArticleId></ArticleIdList></Reference><Reference><Citation>Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the &#x3b3;-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69(11):1430&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892585</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25288138</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>APOE and BDNF polymorphisms moderate amyloid &#x3b2;-related cognitive decline in preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1322</StartPage><EndPage>1328</EndPage><MedlinePgn>1322-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2014.123</ELocationID><Abstract><AbstractText>Accumulation of &#x3b2;-amyloid (A&#x3b2;) in the brain is associated with memory decline in healthy individuals as a prelude to Alzheimer's disease (AD). Genetic factors may moderate this decline. We examined the role of apolipoprotein E (&#x25b;4 carrier[&#x25b;4(+)], &#x25b;4 non-carrier[&#x25b;4(-)]) and brain-derived neurotrophic factor (BDNF(Val/Val), BDNF(Met)) in the extent to which they moderate A&#x3b2;-related memory decline. Healthy adults (n=333, Mage=70 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent A&#x3b2; neuroimaging. Neuropsychological assessments were conducted at baseline, 18-, 36- and 54-month follow-ups. A&#x3b2; positron emission tomography neuroimaging was used to classify participants as A&#x3b2;(-) or A&#x3b2;(+). Relative to A&#x3b2;(-)&#x25b;4(-), A&#x3b2;(+)&#x25b;4(+) individuals showed significantly faster rates of cognitive decline over 54 months across all domains (d=0.40-1.22), while A&#x3b2;(+)&#x25b;4(-) individuals showed significantly faster decline only on verbal episodic memory (EM). There were no differences in rates of cognitive change between A&#x3b2;(-)&#x25b;4(-) and A&#x3b2;(-)&#x25b;4(+) groups. Among A&#x3b2;(+) individuals, &#x25b;4(+)/BDNF(Met) participants showed a significantly faster rate of decline on verbal and visual EM, and language over 54 months compared with &#x25b;4(-)/BDNF(Val/Val) participants (d=0.90-1.02). At least two genetic loci affect the rate of A&#x3b2;-related cognitive decline. A&#x3b2;(+)&#x25b;4(+)/BDNF(Met) individuals can expect to show clinically significant memory impairment after 3 years, whereas A&#x3b2;(+)&#x25b;4(+)/BDNF(Val/Val) individuals can expect a similar degree of impairment after 10 years. Little decline over 54 months was observed in the A&#x3b2;(-) and A&#x3b2;(+) &#x25b;4(-) groups, irrespective of BDNF status. These data raise important prognostic issues in managing preclinical AD, and should be considered in designing secondary preventative clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Y Y</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>V L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laws</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Co-operative Research Centre for Mental Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrzak</LastName><ForeName>R H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Rhode Island Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, Department of Psychiatry, St. Vincent's Health, University of Melbourne, Kew, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Ageing Research Institute, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>K A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Ageing Research Institute, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rembach</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>R N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CogState Ltd, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>CLM is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. RHP and PJS are scientific consultants to Cogstate Ltd. PM is a full-time employee of Cogstate Ltd. DA has served on scientific advisory boards for Novartis, Eli Lilly, Janssen and Pfizer Inc. RNM is a consultant to Alzhyme. CCR has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca, has received speaker honoraria from Bayer Pharma and GE Healthcare and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. VLV served as a consultant for Bayer Pharma and has received research support from a NEDO grant from Japan. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25288138</ArticleId><ArticleId IdType="pmc">PMC4759101</ArticleId><ArticleId IdType="doi">10.1038/mp.2014.123</ArticleId><ArticleId IdType="pii">mp2014123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>1Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al. Amyloid &#x3b2; deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>2Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's Disease Neuroimaging Initiative cohort. NeuroImage 2012; 63: 1478&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>3Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>4Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-&#x3b2; and memory loss. Future Neurol 2011; 6: 627&#x2013;639.</Citation></Reference><Reference><Citation>5Lee CYD, Tse W, Smith JD, Landreth GE. Apolipoprotein E promotes &#x3b2;-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 2012; 287: 2032&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265883</ArticleId><ArticleId IdType="pubmed">22130662</ArticleId></ArticleIdList></Reference><Reference><Citation>6Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A et al. ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc Natl Acad Sci USA 2013; 110: 1807&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>7Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T et al. Gene transfer of human Apoe isoform results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013; 5: 212ra161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>8Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013; 70: 440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference><Reference><Citation>9Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W et al. Amyloid and APOE4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 2014; 82: 1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>10Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL et al. Longitudinal modeling of age-related memory decline and the APOE &#x25b;4 effect. N Engl J Med 2009; 361: 255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="pubmed">19605830</ArticleId></ArticleIdList></Reference><Reference><Citation>11Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M et al. APOE &#x25b;4 allele predicts faster cognitive decline in mild Alzheimer's disease. Neurology 2008; 70: 1842&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676693</ArticleId><ArticleId IdType="pubmed">18401023</ArticleId></ArticleIdList></Reference><Reference><Citation>12Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14: 7&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254191</ArticleId></ArticleIdList></Reference><Reference><Citation>13Anastasia A, Deinhardt K, Chao MV, Will NE, Irmady K, Lee FS et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun 2013; 4: 2490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820160</ArticleId><ArticleId IdType="pubmed">24048383</ArticleId></ArticleIdList></Reference><Reference><Citation>14Ramser EM, Gan KJ, Decker H, Fan EY, Suzuki MM, Ferreira ST et al. Amyloid-&#x3b2; oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell 2013; 24: 2494&#x2013;2505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744947</ArticleId><ArticleId IdType="pubmed">23783030</ArticleId></ArticleIdList></Reference><Reference><Citation>15Feng S, Sevigny J, Verma A, Bennett D, Lim YY, Maruff P. Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations of early Alzheimer's disease. Alzheimer Dement 2013; 9: 178.</Citation></Reference><Reference><Citation>16Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. BDNF Val66Met moderates A&#x3b2;-related memory decline and hippocampal atrophy in prodromal Alzheimer's disease: A preliminary study. PLoS ONE 2014; 9: e86498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903533</ArticleId><ArticleId IdType="pubmed">24475133</ArticleId></ArticleIdList></Reference><Reference><Citation>17Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. BDNF Val66Met, A&#x3b2; amyloid and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging 2013; 34: 2457&#x2013;2464.</Citation><ArticleIdList><ArticleId IdType="pubmed">23769397</ArticleId></ArticleIdList></Reference><Reference><Citation>18Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>19Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>20Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>21Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-amyloid pathology. J Am Med Soc 2011; 305: 275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>22Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R et al. Predicting Alzheimer disease with &#x3b2;-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2014; 74: 905&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448836</ArticleId></ArticleIdList></Reference><Reference><Citation>23Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014; 137: 221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24176981</ArticleId></ArticleIdList></Reference><Reference><Citation>24Harrington K, Lim YY, Ellis KA, Copolov C, Ames D, Darby D et al. The effect of A&#x3b2; amyloid and APOE &#x25b;4 on composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr 2013; 25: 1667&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pubmed">23866942</ArticleId></ArticleIdList></Reference><Reference><Citation>25Jack CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology 2013; 80: 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>26Cohen J. A power primer. Psychol Bull 1992; 112: 155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19565683</ArticleId></ArticleIdList></Reference><Reference><Citation>27Petersen RC. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>28Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">23071163</ArticleId></ArticleIdList></Reference><Reference><Citation>29Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>30Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD et al. Amyloid-&#x3b2; assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology 2012; 79: 1636&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468774</ArticleId><ArticleId IdType="pubmed">22786606</ArticleId></ArticleIdList></Reference><Reference><Citation>31Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X et al. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimer Dement 2014; 10: e1&#x2013;e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713087</ArticleId><ArticleId IdType="pubmed">23583233</ArticleId></ArticleIdList></Reference><Reference><Citation>32Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11070951</ArticleId><ArticleId IdType="pubmed">18195144</ArticleId></ArticleIdList></Reference><Reference><Citation>33Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>34Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr 2013; 25: 1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">23693133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25297016</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.</ArticleTitle><Pagination><StartPage>1092</StartPage><EndPage>1099</EndPage><MedlinePgn>1092-1099</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(14)70198-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(14)70198-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In human beings, 5-HT6 receptors are almost exclusively expressed in the brain, particularly in areas relevant for cognition, such as the hippocampus and frontal cortex. We assessed the effect on cognitive performance of Lu AE58054 (idalopirdine), a selective 5-HT6 receptor antagonist, in donepezil-treated patients with moderate Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For this randomised, double-blind, placebo-controlled phase 2 trial (LADDER), we recruited patients from 48 outpatient clinical sites in seven countries. Patients were 50 years or older, had moderate Alzheimer's disease (a mini-mental state examination score of 12-19), and had been stably treated with donepezil 10 mg per day for 3 or more months. Using a computer-generated sequence, we randomly assigned patients (1:1, stratified by site) to receive either idalopirdine 90 mg per day (30 mg thrice daily) or placebo. The primary endpoint was change from baseline in the 11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at week 24. We analysed all efficacy endpoints in the full-analysis set (modified intention-to-treat analysis). This trial is registered with ClinicalTrials.gov, number NCT01019421.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Dec 8, 2009, and Dec 23, 2011, we randomly allocated 278 patients to treatment: 133 to placebo and 145 to idalopirdine. 132 patients in the placebo group and 140 in the experimental group were included in the final analysis. At week 24, the change from baseline in ADAS-cog total score was +1&#xb7;38 (SD 0&#xb7;53) in the placebo group and -0&#xb7;77 (0&#xb7;55) in the idalopirdine group (treatment difference of -2&#xb7;16 points, 95% CI -3&#xb7;62 to -0&#xb7;69; p=0&#xb7;0040). 25 patients (seven taking placebo and 18 taking idalopirdine) discontinued treatment because of adverse events, the difference between groups being mainly due to asymptomatic transient increases in transaminase concentrations in some idalopirdine-treated patients. The most common adverse events (occurring in &gt;3% of patients) were increased &#x3b3;-glutamyltransferase (14 [10%] patients in the idalopirdine group vs two [2%] in the placebo group), diarrhoea (six [4%] vs nine [7%]), urinary tract infection (three [2%] vs nine [7%]), fall (three [2%] vs eight [6%]), increased alanine aminotransferase (nine [6%] vs none), and benign prostatic hyperplasia (two [5%] vs none). Serious adverse events were reported by 14 (10%) patients in the idalopirdine group and 13 (10%) patients in the placebo group. One death occurred in each treatment group, neither were regarded as being related to treatment.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Idalopirdine improved cognitive function in donepezil-treated patients with moderate Alzheimer's disease. Larger studies in a broader population of patients are ongoing to substantiate the effects reported here.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">H Lundbeck A/S.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK. Electronic address: david.wilkinson@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windfeld</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>H Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colding-J&#xf8;rgensen</LastName><ForeName>Eskild</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>H Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01019421</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568612">(2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097216">serotonin 6 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2014 Nov;13(11):1063-1065. doi: 10.1016/S1474-4422(14)70232-7.</RefSource><PMID Version="1">25297011</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="Y">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25297016</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70198-X</ArticleId><ArticleId IdType="pii">S1474-4422(14)70198-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25297104</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>41</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Early alterations in functional connectivity and white matter structure in a transgenic mouse model of cerebral amyloidosis.</ArticleTitle><Pagination><StartPage>13780</StartPage><EndPage>13789</EndPage><MedlinePgn>13780-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4762-13.2014</ELocationID><Abstract><AbstractText>Impairment of brain functional connectivity (FC) is thought to be an early event occurring in diseases with cerebral amyloidosis, such as Alzheimer's disease. Regions sustaining altered functional networks have been shown to colocalize with regions marked with amyloid plaques burden suggesting a strong link between FC and amyloidosis. Whether the decline in FC precedes amyloid plaque deposition or is a consequence thereof is currently unknown. The sequence of events during early stages of the disease is difficult to capture in humans due to the difficulties in providing an early diagnosis and also in view of the heterogeneity among patients. Transgenic mouse lines overexpressing amyloid precursor proteins develop cerebral amyloidosis and constitute an attractive model system for studying the relationship between plaque and functional changes. In this study, ArcA&#x3b2; transgenic and wild-type mice were imaged using resting-state fMRI methods across their life-span in a cross-sectional design to analyze changes in FC in relation to the pathology. Transgenic mice show compromised development of FC during the first months of postnatal life compared with wild-type animals, resulting in functional impairments that affect in particular the sensory-motor cortex already in preplaque stage. These functional alterations were accompanied by structural changes as reflected by reduced fractional anisotropy values, as derived from diffusion tensor imaging. Our results suggest cerebral amyloidosis in mice is preceded by impairment of neuronal networks and white matter structures. FC analysis in mice is an attractive tool for studying the implications of impaired neuronal networks in models of cerebral amyloid pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3413780-10$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grandjean</LastName><ForeName>Joanes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, and Center for Neuroscience Research, University and ETH Zurich, 8093 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Aileen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Information Technology and Electrical Engineering, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanadini</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Seminar for Statistics, ETH Zurich, 8092 Zurich, Switzerland, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keist</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krstic</LastName><ForeName>Dimitrije</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology and Toxicology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konietzko</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for Neuroscience Research, University and ETH Zurich, 8093 Zurich, Switzerland, Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klohs</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, and Center for Neuroscience Research, University and ETH Zurich, 8093 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsch</LastName><ForeName>Roger M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Center for Neuroscience Research, University and ETH Zurich, 8093 Zurich, Switzerland, Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudin</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Engineering, and Center for Neuroscience Research, University and ETH Zurich, 8093 Zurich, Switzerland, Institute of Pharmacology and Toxicology and rudin@biomed.ee.ethz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ArcA&#x3b2;</Keyword><Keyword MajorTopicYN="N">diffusion tensor imaging</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">functional connectivity</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">resting state</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25297104</ArticleId><ArticleId IdType="pmc">PMC6608375</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4762-13.2014</ArticleId><ArticleId IdType="pii">34/41/13780</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adriaanse SM, Sanz-Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Rombouts SA, Barkhof F, van Berckel BN. Amyloid and its association with default network integrity in Alzheimer's disease. Hum Brain Mapp. 2014;35:779&#x2013;791. doi: 10.1002/hbm.22213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22213</ArticleId><ArticleId IdType="pmc">PMC6869670</ArticleId><ArticleId IdType="pubmed">23238869</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Forloni G. APP transgenic mice: their use and limitations. Neuromolecular Med. 2011;13:117&#x2013;137. doi: 10.1007/s12017-010-8141-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-010-8141-7</ArticleId><ArticleId IdType="pubmed">21152995</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain. J Neurosci. 2012;32:4334&#x2013;4340. doi: 10.1523/JNEUROSCI.5845-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5845-11.2012</ArticleId><ArticleId IdType="pmc">PMC3326343</ArticleId><ArticleId IdType="pubmed">22457485</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuet L, Tellado I, Couceiro V, Fraile C, Fernandez-Novoa L, Ishii R, Takeda M, Cacabelos R. Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study. PLoS One. 2012;7:e46289. doi: 10.1371/journal.pone.0046289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046289</ArticleId><ArticleId IdType="pmc">PMC3457973</ArticleId><ArticleId IdType="pubmed">23050006</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW. A&#x3b2; alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nat Commun. 2012;3:1009. doi: 10.1038/ncomms2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2013</ArticleId><ArticleId IdType="pmc">PMC3529477</ArticleId><ArticleId IdType="pubmed">22910355</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging. 2004;25:599&#x2013;602. doi: 10.1016/j.neurobiolaging.2003.12.019. discussion 603&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.12.019</ArticleId><ArticleId IdType="pubmed">15172735</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A. 2006;103:13848&#x2013;13853. doi: 10.1073/pnas.0601417103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0601417103</ArticleId><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover GH, Li TQ, Ress D. Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR. Magn Reson Med. 2000;44:162&#x2013;167. doi: 10.1002/1522-2594(200007)44:1&lt;162::AID-MRM23&gt;3.3.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1522-2594(200007)44:1&lt;162::AID-MRM23&gt;3.3.CO;2-5</ArticleId><ArticleId IdType="pubmed">10893535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002;173:183&#x2013;195. doi: 10.1006/exnr.2001.7754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7754</ArticleId><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258. doi: 10.1073/pnas.0135058100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0135058100</ArticleId><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642. doi: 10.1073/pnas.0308627101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308627101</ArticleId><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert F, Grand'maison M, Ho MK, Lerch JP, Hamel E, Bedell BJ. Cortical atrophy and hypoperfusion in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:1644&#x2013;1652. doi: 10.1016/j.neurobiolaging.2012.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.11.022</ArticleId><ArticleId IdType="pubmed">23273599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694. doi: 10.1523/JNEUROSCI.3189-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3189-09.2009</ArticleId><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45&#x2013;53. doi: 10.1016/0896-6273(94)90458-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(94)90458-8</ArticleId><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213. doi: 10.1101/cshperspect.a006213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006213</ArticleId><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonckers E, Delgado YPR, Shah D, Guglielmetti C, Verhoye M, Van der Linden A. Different anesthesia regimes modulate the functional connectivity outcome in mice. Magn Reson Med. 2013 doi: 10.1002/mrm.24990.. doi: 10.1002/mrm.24990. Advance online publication. Retrieved April 9, 2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.24990.</ArticleId><ArticleId IdType="doi">10.1002/mrm.24990</ArticleId><ArticleId IdType="pubmed">24285608</ArticleId></ArticleIdList></Reference><Reference><Citation>Klohs J, Deistung A, Schweser F, Grandjean J, Dominietto M, Waschkies C, Nitsch RM, Knuesel I, Reichenbach JR, Rudin M. Detection of cerebral microbleeds with quantitative susceptibility mapping in the ArcA&#x3b2; mouse model of cerebral amyloidosis. J Cereb Blood Flow Metab. 2011;31:2282&#x2013;2292. doi: 10.1038/jcbfm.2011.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2011.118</ArticleId><ArticleId IdType="pmc">PMC3323188</ArticleId><ArticleId IdType="pubmed">21847134</ArticleId></ArticleIdList></Reference><Reference><Citation>Klohs J, Baltes C, Princz-Kranz F, Ratering D, Nitsch RM, Knuesel I, Rudin M. Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcA&#x3b2; mice. J Neurosci. 2012;32:1705&#x2013;1713. doi: 10.1523/JNEUROSCI.5626-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5626-11.2012</ArticleId><ArticleId IdType="pmc">PMC6703349</ArticleId><ArticleId IdType="pubmed">22302811</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. A&#x3b2; oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci. 2007a;27:7648&#x2013;7653. doi: 10.1523/JNEUROSCI.0395-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0395-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672892</ArticleId><ArticleId IdType="pubmed">17634359</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular A&#x3b2; and cognitive deficits precede beta-amyloid deposition in transgenic arcA&#x3b2; mice. Neurobiol Aging. 2007b;28:1297&#x2013;1306. doi: 10.1016/j.neurobiolaging.2006.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.06.019</ArticleId><ArticleId IdType="pubmed">16876915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotani N, Akaike N. The effects of volatile anesthetics on synaptic and extrasynaptic GABA-induced neurotransmission. Brain Res Bull. 2013;93:69&#x2013;79. doi: 10.1016/j.brainresbull.2012.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2012.08.001</ArticleId><ArticleId IdType="pubmed">22925739</ArticleId></ArticleIdList></Reference><Reference><Citation>Krantic S, Isorce N, Mechawar N, Davoli MA, Vignault E, Albuquerque M, Chabot JG, Moyse E, Chauvin JP, Aubert I, McLaurin J, Quirion R. Hippocampal GABAergic neurons are susceptible to amyloid-&#x3b2; toxicity in vitro and are decreased in number in the Alzheimer's disease TgCRND8 mouse model. J Alzheimers Dis. 2012;29:293&#x2013;308. doi: 10.3233/JAD-2011-110830.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110830</ArticleId><ArticleId IdType="pubmed">22232004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225. doi: 10.1016/j.neuron.2008.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.06.008</ArticleId><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, King J, Zhang N. Uncovering intrinsic connectional architecture of functional networks in awake rat brain. J Neurosci. 2011;31:3776&#x2013;3783. doi: 10.1523/JNEUROSCI.4557-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4557-10.2011</ArticleId><ArticleId IdType="pmc">PMC3073070</ArticleId><ArticleId IdType="pubmed">21389232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengler L, Khmelinskii A, Diedenhofen M, Po C, Staring M, Lelieveldt BP, Hoehn M. Brain maturation of the adolescent rat cortex and striatum: changes in volume and myelination. Neuroimage. 2014;84:35&#x2013;44. doi: 10.1016/j.neuroimage.2013.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.08.034</ArticleId><ArticleId IdType="pubmed">23994458</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM. Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcA&#x3b2; mice. Acta Neuropathol. 2011;122:293&#x2013;311. doi: 10.1007/s00401-011-0834-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0834-y</ArticleId><ArticleId IdType="pmc">PMC3168476</ArticleId><ArticleId IdType="pubmed">21688176</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:3587&#x2013;3592. doi: 10.1073/pnas.0709788105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709788105</ArticleId><ArticleId IdType="pmc">PMC2265182</ArticleId><ArticleId IdType="pubmed">18305170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338. doi: 10.1101/cshperspect.a006338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006338</ArticleId><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, Valla J. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res. 2010;1347:179&#x2013;185. doi: 10.1016/j.brainres.2010.05.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.05.084</ArticleId><ArticleId IdType="pmc">PMC2974951</ArticleId><ArticleId IdType="pubmed">20677372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolakakis N, Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab. 2011;31:1354&#x2013;1370. doi: 10.1038/jcbfm.2011.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2011.43</ArticleId><ArticleId IdType="pmc">PMC3130325</ArticleId><ArticleId IdType="pubmed">21468088</ArticleId></ArticleIdList></Reference><Reference><Citation>Princz-Kranz FL, Mueggler T, Knobloch M, Nitsch RM, Rudin M. Vascular response to acetazolamide decreases as a function of age in the arcA&#x3b2; mouse model of cerebral amyloidosis. Neurobiol Dis. 2010;40:284&#x2013;292. doi: 10.1016/j.nbd.2010.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.002</ArticleId><ArticleId IdType="pubmed">20600914</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682. doi: 10.1073/pnas.98.2.676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.676</ArticleId><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239. doi: 10.1002/hbm.20160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20160</ArticleId><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, Liu C, Dixit S, Benzinger T, Fagan A, Goate A, Mintun MA. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF A&#x3b2;42. J Neurosci. 2010a;30:17035&#x2013;17040. doi: 10.1523/JNEUROSCI.3987-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3987-10.2010</ArticleId><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010b;67:584&#x2013;587. doi: 10.1016/j.biopsych.2009.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2009.08.024</ArticleId><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu X, Qin YY, Zhang S, Jiang JJ, Zhang Y, Zhao LY, Shan D, Zhu WZ. Voxel-based diffusion tensor imaging of an APP/PS1 mouse model of Alzheimer's disease. Mol Neurobiol. 2013;48:78&#x2013;83. doi: 10.1007/s12035-013-8418-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8418-6</ArticleId><ArticleId IdType="pubmed">23877934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, M&#xfc;hlau M, Calhoun VD, Eichele T, L&#xe4;er L, Drzezga A, F&#xf6;rstl H, Kurz A, Zimmer C, Wohlschl&#xe4;ger AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765. doi: 10.1073/pnas.0708803104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708803104</ArticleId><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188. doi: 10.1016/j.neuron.2009.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.07.003</ArticleId><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav Neurol. 2009;21:39&#x2013;49. doi: 10.1155/2009/915041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2009/915041</ArticleId><ArticleId IdType="pmc">PMC3010401</ArticleId><ArticleId IdType="pubmed">19847044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol. 1998;153:725&#x2013;733. doi: 10.1016/S0002-9440(10)65616-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65616-7</ArticleId><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25297091</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>41</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease-like pathology induced by amyloid-&#x3b2; oligomers in nonhuman primates.</ArticleTitle><Pagination><StartPage>13629</StartPage><EndPage>13643</EndPage><MedlinePgn>13629-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1353-14.2014</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a major medical problem. Here, we have investigated the impact of amyloid-&#x3b2; (A&#x3b2;) oligomers, AD-related neurotoxins, in the brains of rats and adult nonhuman primates (cynomolgus macaques). Soluble A&#x3b2; oligomers are known to accumulate in the brains of AD patients and correlate with disease-associated cognitive dysfunction. When injected into the lateral ventricle of rats and macaques, A&#x3b2; oligomers diffused into the brain and accumulated in several regions associated with memory and cognitive functions. Cardinal features of AD pathology, including synapse loss, tau hyperphosphorylation, astrocyte and microglial activation, were observed in regions of the macaque brain where A&#x3b2; oligomers were abundantly detected. Most importantly, oligomer injections induced AD-type neurofibrillary tangle formation in the macaque brain. These outcomes were specifically associated with A&#x3b2; oligomers, as fibrillar amyloid deposits were not detected in oligomer-injected brains. Human and macaque brains share significant similarities in terms of overall architecture and functional networks. Thus, generation of a macaque model of AD that links A&#x3b2; oligomers to tau and synaptic pathology has the potential to greatly advance our understanding of mechanisms centrally implicated in AD pathogenesis. Furthermore, development of disease-modifying therapeutics for AD has been hampered by the difficulty in translating therapies that work in rodents to humans. This new approach may be a highly relevant nonhuman primate model for testing therapeutic interventions for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3413629-15$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forny-Germano</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyra e Silva</LastName><ForeName>Natalia M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batista</LastName><ForeName>Andr&#xe9; F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito-Moreira</LastName><ForeName>Jordano</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gralle</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0472-4263</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehnke</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coe</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lablans</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Suelen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Departament of Neurobiology, Institute of Biology, Fluminense Federal University, Niter&#xf3;i, RJ, 24020-140 Brazil, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana Maria B</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houzel</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-5128-438X</Identifier><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21944-590, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Douglas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, Ontario K7L 3N6, Canada, felice@bioqmed.ufrj.br doug.munoz@queensu.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis and felice@bioqmed.ufrj.br doug.munoz@queensu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-38854</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2020 Oct 14;40(42):8204. doi: 10.1523/JNEUROSCI.1827-20.2020.</RefSource><PMID Version="1">33028640</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008845" MajorTopicYN="N">Microinjections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid-&#x3b2; oligomers</Keyword><Keyword MajorTopicYN="N">nonhuman primate</Keyword><Keyword MajorTopicYN="N">synapse loss</Keyword><Keyword MajorTopicYN="N">tau pathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25297091</ArticleId><ArticleId IdType="pmc">PMC6608380</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1353-14.2014</ArticleId><ArticleId IdType="pii">34/41/13629</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest. 2012;122:1339&#x2013;1353. doi: 10.1172/JCI57256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57256</ArticleId><ArticleId IdType="pmc">PMC3314445</ArticleId><ArticleId IdType="pubmed">22476196</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089&#x2013;1099. doi: 10.1016/0896-6273(93)90057-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90057-X</ArticleId><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM. Soluble abeta promotes wild-type tau pathology in vivo. J Neurosci. 2012;32:17345&#x2013;17350. doi: 10.1523/JNEUROSCI.0172-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0172-12.2012</ArticleId><ArticleId IdType="pmc">PMC3586232</ArticleId><ArticleId IdType="pubmed">23197725</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421&#x2013;433. doi: 10.1016/j.cell.2004.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.12.020</ArticleId><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1&#x2013;42) into globular neurotoxins. Biochemistry. 2003;42:12749&#x2013;12760. doi: 10.1021/bi030029q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi030029q</ArticleId><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci. 2013;33:6245&#x2013;6256. doi: 10.1523/JNEUROSCI.3672-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3672-12.2013</ArticleId><ArticleId IdType="pmc">PMC3720142</ArticleId><ArticleId IdType="pubmed">23575824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483:213&#x2013;217. doi: 10.1038/nature10841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10841</ArticleId><ArticleId IdType="pubmed">22388811</ArticleId></ArticleIdList></Reference><Reference><Citation>Crist CF, Yamasaki DS, Komatsu H, Wurtz RH. A grid system and a microsyringe for single cell recording. J Neurosci Methods. 1988;26:117&#x2013;122. doi: 10.1016/0165-0270(88)90160-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(88)90160-4</ArticleId><ArticleId IdType="pubmed">3146006</ArticleId></ArticleIdList></Reference><Reference><Citation>DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, Seren&#xf3; L, Rodr&#xed;guez M, S&#xe1;nchez B, Hyman BT, G&#xf3;mez-Isla T. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol. 2011;70:360&#x2013;376. doi: 10.1097/NEN.0b013e318217a118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318217a118</ArticleId><ArticleId IdType="pmc">PMC3725771</ArticleId><ArticleId IdType="pubmed">21487307</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. A&#x3b2; oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601. doi: 10.1074/jbc.M607483200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M607483200</ArticleId><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A&#x3b2; oligomers. Neurobiol Aging. 2008;29:1334&#x2013;1347. doi: 10.1016/j.neurobiolaging.2007.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.029</ArticleId><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. To serve and neuroprotect. Nat Med. 2012;18:1003&#x2013;1006. doi: 10.1038/nm0712-1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0712-1003</ArticleId><ArticleId IdType="pubmed">22772545</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza M, de Silva R, Dickson DW, Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis. 2008;14:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882247</ArticleId><ArticleId IdType="pubmed">18525123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011;96:529&#x2013;543. doi: 10.1016/j.nlm.2011.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2011.08.003</ArticleId><ArticleId IdType="pmc">PMC4390395</ArticleId><ArticleId IdType="pubmed">21914486</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST. Memantine rescues transient cognitive impairment caused by high-molecular-weight a&#x3b2; oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci. 2013;33:9626&#x2013;9634. doi: 10.1523/JNEUROSCI.0482-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0482-13.2013</ArticleId><ArticleId IdType="pmc">PMC6619709</ArticleId><ArticleId IdType="pubmed">23739959</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M. First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging. 2012;33:1448&#x2013;1456. doi: 10.1016/j.neurobiolaging.2010.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.10.015</ArticleId><ArticleId IdType="pubmed">21196063</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Austad SN. Primate aging in the mammalian scheme: the puzzle of extreme variation in brain aging. Age (Dordr) 2012;34:1075&#x2013;1091. doi: 10.1007/s11357-011-9355-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-011-9355-9</ArticleId><ArticleId IdType="pmc">PMC3448989</ArticleId><ArticleId IdType="pubmed">22218781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher M. Stroke/international stroke conference collaboration. Stroke. 2009;40:1947. doi: 10.1161/STROKEAHA.109.548131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.109.548131</ArticleId><ArticleId IdType="pubmed">19372439</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med. 1998;4:827&#x2013;831. doi: 10.1038/nm0798-827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-827</ArticleId><ArticleId IdType="pubmed">9662375</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781. doi: 10.1126/science.1132814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132814</ArticleId><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422. doi: 10.1073/pnas.1834302100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532&#x2013;544. doi: 10.1038/nrn2420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2420</ArticleId><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20. doi: 10.1016/S0002-9440(10)64700-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64700-1</ArticleId><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1990;87:5827&#x2013;5831. doi: 10.1073/pnas.87.15.5827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.15.5827</ArticleId><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, R&#xfc;b U, Ferretti RE, Nitrini R, Farfel JM, Polichiso L, Gierga K, Jacob-Filho W, Heinsen H. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease: a precocious onset? Neuropathol Appl Neurobiol. 2009;35:406&#x2013;416. doi: 10.1111/j.1365-2990.2008.00997.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2008.00997.x</ArticleId><ArticleId IdType="pubmed">19508444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuer E, Rosen RF, Cintron A, Walker LC. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des. 2012;18:1159&#x2013;1169. doi: 10.2174/138161212799315885.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799315885</ArticleId><ArticleId IdType="pmc">PMC3381739</ArticleId><ArticleId IdType="pubmed">22288403</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132. doi: 10.1002/(SICI)1097-4547(19970415)48:2&lt;128::AID-JNR5&gt;3.0.CO;2-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19970415)48:2&lt;128::AID-JNR5&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108:5819&#x2013;5824. doi: 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaas JH, Gharbawie OA, Stepniewska I. Cortical networks for ethologically relevant behaviors in primates. Am J Primatol. 2013;75:407&#x2013;414. doi: 10.1002/ajp.22065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajp.22065</ArticleId><ArticleId IdType="pmc">PMC3710666</ArticleId><ArticleId IdType="pubmed">22865408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807. doi: 10.1523/JNEUROSCI.3501-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3501-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006320. doi: 10.1101/cshperspect.a006320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006320</ArticleId><ArticleId IdType="pmc">PMC3543097</ArticleId><ArticleId IdType="pubmed">23002015</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Oddo S. Alzheimer's disease: A&#x3b2;, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170&#x2013;176. doi: 10.1016/j.molmed.2005.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2005.02.009</ArticleId><ArticleId IdType="pubmed">15823755</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509. doi: 10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of A&#x3b2;. J Neurochem. 2007;100:23&#x2013;35. doi: 10.1111/j.1471-4159.2006.04157.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04157.x</ArticleId><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012;26:1946&#x2013;1959. doi: 10.1096/fj.11-199851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-199851</ArticleId><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, De Felice FG, Ferreira ST. Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry. 2013;18:1053&#x2013;1054. doi: 10.1038/mp.2012.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.168</ArticleId><ArticleId IdType="pmc">PMC3781315</ArticleId><ArticleId IdType="pubmed">23183490</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung E, Guo L, Bu J, Maloof M, El Khoury J, Geula C. Microglia activation mediates fibrillar amyloid-beta toxicity in the aged primate cortex. Neurobiol Aging. 2011;32:387&#x2013;397. doi: 10.1016/j.neurobiolaging.2009.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.02.025</ArticleId><ArticleId IdType="pmc">PMC2888944</ArticleId><ArticleId IdType="pubmed">19349094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Esp&#xed;rito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, et al. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's &#x3b2;-amyloid oligomers in mice and monkeys. Cell Metab. 2013;18:831&#x2013;843. doi: 10.1016/j.cmet.2013.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.11.002</ArticleId><ArticleId IdType="pubmed">24315369</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin RF, Bowden DM. A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. Neuroimage. 1996;4:119&#x2013;150. doi: 10.1006/nimg.1996.0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.1996.0036</ArticleId><ArticleId IdType="pubmed">9345504</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010;176:870&#x2013;880. doi: 10.2353/ajpath.2010.090452.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090452</ArticleId><ArticleId IdType="pmc">PMC2808092</ArticleId><ArticleId IdType="pubmed">20042680</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56:127&#x2013;129. doi: 10.1212/WNL.56.1.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.127</ArticleId><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639. doi: 10.1038/nature02621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02621</ArticleId><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006;22:281&#x2013;289. doi: 10.1016/j.tig.2006.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2006.03.007</ArticleId><ArticleId IdType="pubmed">16567017</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrick SE, Demoise DC, Lee VM. Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J Biol Chem. 1996;271:5589&#x2013;5594. doi: 10.1074/jbc.271.10.5589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.10.5589</ArticleId><ArticleId IdType="pubmed">8621419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338. doi: 10.1101/cshperspect.a006338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006338</ArticleId><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785&#x2013;796. doi: 10.1016/S1474-4422(11)70156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Negash S, Bennett DA, Wilson RS, Schneider JA, Arnold SE. Cognition and neuropathology in aging: multidimensional perspectives from the rush religious orders study and rush memory and aging project. Curr Alzheimer Res. 2011;8:336&#x2013;340. doi: 10.2174/156720511795745302.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795745302</ArticleId><ArticleId IdType="pmc">PMC3157574</ArticleId><ArticleId IdType="pubmed">21222592</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using Western blotting. J Pathol. 2009;217:497&#x2013;506. doi: 10.1002/path.2504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2504</ArticleId><ArticleId IdType="pubmed">19156775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nov&#xe1;k M. Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol. 1994;38:173&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">7817900</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 1993;12:365&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413214</ArticleId><ArticleId IdType="pubmed">7679073</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003a;24:1063&#x2013;1070. doi: 10.1016/j.neurobiolaging.2003.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.08.012</ArticleId><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003b;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of A&#x3b2; pathology in transgenic mice. J Neurochem. 2007;102:1053&#x2013;1063. doi: 10.1111/j.1471-4159.2007.04607.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04607.x</ArticleId><ArticleId IdType="pubmed">17472708</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa N, Kimura N, Yanagisawa K. Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res. 2010;1315:137&#x2013;149. doi: 10.1016/j.brainres.2009.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.12.005</ArticleId><ArticleId IdType="pubmed">20004650</ArticleId></ArticleIdList></Reference><Reference><Citation>Orban GA, Van Essen D, Vanduffel W. Comparative mapping of higher visual areas in monkeys and humans. Trends Cogn Sci. 2004;8:315&#x2013;324. doi: 10.1016/j.tics.2004.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2004.05.009</ArticleId><ArticleId IdType="pubmed">15242691</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem. 2011;286:23063&#x2013;23076. doi: 10.1074/jbc.M111.237974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.237974</ArticleId><ArticleId IdType="pmc">PMC3123074</ArticleId><ArticleId IdType="pubmed">21550980</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Ed 3. San Diego: Academic; 1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">6110810</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, L&#xf3;pez OL, Klunk W, Hyman BT, G&#xf3;mez-Isla T. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain. 2013;136:2510&#x2013;2526. doi: 10.1093/brain/awt171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt171</ArticleId><ArticleId IdType="pmc">PMC3722351</ArticleId><ArticleId IdType="pubmed">23824488</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577&#x2013;581. doi: 10.1161/STROKEAHA.108.524330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.108.524330</ArticleId><ArticleId IdType="pubmed">19074479</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Tolan DR, Selkoe DJ. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am J Pathol. 1991;138:1423&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886384</ArticleId><ArticleId IdType="pubmed">1905108</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344. doi: 10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647. doi: 10.1523/JNEUROSCI.3279-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3279-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121&#x2013;130. doi: 10.1172/JCI20640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI20640</ArticleId><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508. doi: 10.1212/01.wnl.0000260698.46517.8f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260698.46517.8f</ArticleId><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz C, Hubbard GB, R&#xfc;b U, Braak E, Braak H. Age-related progression of tau pathology in brains of baboons. Neurobiol Aging. 2000;21:905&#x2013;912. doi: 10.1016/S0197-4580(00)00176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00176-7</ArticleId><ArticleId IdType="pubmed">11124441</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebollela A, Freitas-Correa L, Oliveira FF, Paula-Lima AC, Saraiva LM, Martins SM, Mota LD, Torres C, Alves-Leon S, de Souza JM, Carraro DM, Brentani H, De Felice FG, Ferreira ST. Amyloid-&#x3b2; oligomers induce differential gene expression in adult human brain slices. J Biol Chem. 2012;287:7436&#x2013;7445. doi: 10.1074/jbc.M111.298471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.298471</ArticleId><ArticleId IdType="pmc">PMC3293600</ArticleId><ArticleId IdType="pubmed">22235132</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17:1060&#x2013;1065. doi: 10.1038/nm.2460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2460</ArticleId><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sereno MI, Tootell RB. From monkeys to humans: what do we now know about brain homologies? Curr Opin Neurobiol. 2005;15:135&#x2013;144. doi: 10.1016/j.conb.2005.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2005.03.014</ArticleId><ArticleId IdType="pubmed">15831394</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Mielke ML, G&#xf3;mez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011;179:1373&#x2013;1384. doi: 10.1016/j.ajpath.2011.05.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875. doi: 10.1523/JNEUROSCI.4970-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4970-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737&#x2013;7741. doi: 10.1073/pnas.95.13.7737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.13.7737</ArticleId><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426&#x2013;1435. doi: 10.1016/j.ajpath.2012.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.06.033</ArticleId><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Griffin WS, Braak H. Parenchymal and vascular A&#x3b2;-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med. 2008;12:1848&#x2013;1862. doi: 10.1111/j.1582-4934.2008.00411.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00411.x</ArticleId><ArticleId IdType="pmc">PMC4506155</ArticleId><ArticleId IdType="pubmed">18624777</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorpe JR, Morley SJ, Rulten SL. Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as a probe of its phosphorylated target proteins: examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. J Histochem Cytochem. 2001;49:97&#x2013;108. doi: 10.1177/002215540104900110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215540104900110</ArticleId><ArticleId IdType="pubmed">11118482</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledano A, &#xc1;lvarez MI, L&#xf3;pez-Rodriguez AB, Toledano-D&#xed;az A, Fern&#xe1;ndez-Verdecia CI. Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II) Neurologia. 2014;29:42&#x2013;55. doi: 10.1016/j.nrl.2011.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2011.05.004</ArticleId><ArticleId IdType="pubmed">21871692</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC. Cartography and connectomes. Neuron. 2013;80:775&#x2013;790. doi: 10.1016/j.neuron.2013.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.027</ArticleId><ArticleId IdType="pmc">PMC3855872</ArticleId><ArticleId IdType="pubmed">24183027</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer's disease. Cereb Cortex. 2000;10:243&#x2013;251. doi: 10.1093/cercor/10.3.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/10.3.243</ArticleId><ArticleId IdType="pubmed">10731219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Novak M, Th&#xf8;gersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85:4506&#x2013;4510. doi: 10.1073/pnas.85.12.4506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.12.4506</ArticleId><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 1986;232:648&#x2013;650. doi: 10.1126/science.3083509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3083509</ArticleId><ArticleId IdType="pubmed">3083509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006;580:3582&#x2013;3588. doi: 10.1016/j.febslet.2006.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.05.029</ArticleId><ArticleId IdType="pubmed">16753151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25307057</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>515</Volume><Issue>7526</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A three-dimensional human neural cell culture model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>278</EndPage><MedlinePgn>274-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13800</ELocationID><Abstract><AbstractText>Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-&#x3b2; plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-&#x3b2; peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-&#x3b2;-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-&#x3b2; species and phosphorylated tau but did not demonstrate amyloid-&#x3b2; plaques or neurofibrillary tangles. Here we report that FAD mutations in &#x3b2;-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-&#x3b2;, including amyloid-&#x3b2; plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloid-&#x3b2; generation with &#x3b2;- or &#x3b3;-secretase inhibitors not only decreased amyloid-&#x3b2; pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-&#x3b2;-mediated tau phosphorylation. We have successfully recapitulated amyloid-&#x3b2; and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>1] Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young Hye</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>1] Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA [2] Division of Mass Spectrometry Research, Korea Basic Science Institute, Cheongju-si, Chungbuk 363-883, South Korea [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hebisch</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA [2] Institute of Reconstructive Neurobiology, Life and Brain Center, University of Bonn and Hertie Foundation, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sliwinski</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seungkyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>FM Kirby Neurobiology Center, Boston Children's Hospital and Harvard Stem Cell Institute, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Avanzo</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hechao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooli</LastName><ForeName>Basavaraj</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asselin</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muffat</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klee</LastName><ForeName>Justin B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainger</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>FM Kirby Neurobiology Center, Boston Children's Hospital and Harvard Stem Cell Institute, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peitz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Reconstructive Neurobiology, Life and Brain Center, University of Bonn and Hertie Foundation, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Dora M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolf</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>FM Kirby Neurobiology Center, Boston Children's Hospital and Harvard Stem Cell Institute, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doo Yeon</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045860</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK043351</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS045776</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R37MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG031483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01AG15379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD018655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK057521</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489788">MAP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 Dec;15(12):765. doi: 10.1038/nrn3860.</RefSource><PMID Version="1">25354484</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2014 Dec;13(12):887. doi: 10.1038/nrd4494.</RefSource><PMID Version="1">25435212</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25307057</ArticleId><ArticleId IdType="mid">NIHMS656312</ArticleId><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="doi">10.1038/nature13800</ArticleId><ArticleId IdType="pii">nature13800</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K. Transgenic mouse models of Alzheimer&#x2019;s disease: phenotype and mechanisms of pathogenesis. Biochem Soc Symp. 2001;67:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447835</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J. Selecting a mouse model of Alzheimer&#x2019;s disease. Methods Mol Biol. 2011;670:169&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">20967591</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Tanzi RE. iPSCs to the rescue in Alzheimer&#x2019;s research. Cell stem cell. 2012;10:235&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">22385650</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, et al. Modeling familial Alzheimer&#x2019;s disease with induced pluripotent stem cells. Human molecular genetics. 2011;20:4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, et al. Modeling Alzheimer&#x2019;s disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell stem cell. 2013;12:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, et al. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23:3523&#x2013;3536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproul AA, et al. Characterization and Molecular Profiling of PSEN1 Familial Alzheimer&#x2019;s Disease iPSC-Derived Neural Progenitors. PLoS ONE. 2014;9:e84547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>Donato R, et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007;8:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888696</ArticleId><ArticleId IdType="pubmed">17531091</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan PJ, et al. Protection of neurons derived from human neural progenitor cells by veratridine. Neuroreport. 2009;20:1225&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pubmed">19617853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazemondet O, et al. Quantitative and kinetic profile of Wnt/&#x3b2;-catenin signaling components during human neural progenitor cell differentiation. Cell Mol Biol Lett. 2011;16:515&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6275579</ArticleId><ArticleId IdType="pubmed">21805133</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wijekoon A, Leipzig ND. 3D differentiation of neural stem cells in macroporous photopolymerizable hydrogel scaffolds. PLoS One. 2012;7:e48824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492243</ArticleId><ArticleId IdType="pubmed">23144988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster MA, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang-Schomer MD, et al. Bioengineered functional brain-like cortical tissue. Proc Natl Acad Sci U S A. 2014 doi: 10.1073/pnas.1324214111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1324214111</ArticleId><ArticleId IdType="pmc">PMC4183301</ArticleId><ArticleId IdType="pubmed">25114234</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Trojanowski JQ, Lee VM-Y. Tau protein and tauopathy. In: Davis Kenneth L, Charney Dennis, Coyle Joseph T, Nemeroff Charles., editors. Neuropsychopharmacology: The Fifth Generation of Progress. 2002. pp. 1339&#x2013;1354.</Citation></Reference><Reference><Citation>Wagner SL, et al. Soluble gamma-Secretase Modulators Selectively Inhibit the Production of the 42-Amino Acid Amyloid beta Peptide Variant and Augment the Production of Multiple Carboxy-Truncated Amyloid beta Species. Biochemistry. 2014;53:702&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929337</ArticleId><ArticleId IdType="pubmed">24401146</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VMY. The role of tau in Alzheimer&#x2019;s disease. Med Clin North Am. 2002;86:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12168561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cras P, et al. Neuronal and microglial involvement in &#x3b2;-amyloid protein deposition in Alzheimer&#x2019;s disease. Am J Pathol. 1990;137:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877622</ArticleId><ArticleId IdType="pubmed">2117395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler JV, Evenson DA. Use of excitatory amino acids to make axon-sparing lesions of hypothalamus. Autophagy in disease and clinical applications, Part C. 1983;103:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">6199648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004;14:413&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">14698171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby LA, et al. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS ONE. 2012;7:e39329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383737</ArticleId><ArticleId IdType="pubmed">22745733</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Wilson CA, Lee VMY, Klein PS. GSK-3alpha regulates production of Alzheimer&#x2019;s disease amyloid-beta peptides. Nature. 2003;423:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, et al. GSK-3&#x3b1;/&#x3b2; kinases and amyloid production in vivo. Nature. 2003;423:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen RM, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric A&#x3b2;, and Frank neuronal loss. The Journal of neuroscience. 2013;33:6245&#x2013;6256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720142</ArticleId><ArticleId IdType="pubmed">23575824</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, et al. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009;23:2595&#x2013;2604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717763</ArticleId><ArticleId IdType="pubmed">19279139</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien C, Bretteville A, Planel E. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies. Methods Mol Biol. 2012;849:473&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">22528110</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino M, Patani R, Watts C, Chandran S, Spillantini MG. Human stem cell-derived neurons: a system to study human tau function and dysfunction. PLoS ONE. 2010;5:e13947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978712</ArticleId><ArticleId IdType="pubmed">21085657</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25322206</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1498</StartPage><EndPage>1505</EndPage><MedlinePgn>1498-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.2510</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Nocturnal sleep disruption develops in Alzheimer disease (AD) owing to the derangement of the sleep-wake cycle regulation pathways. Orexin contributes to the regulation of the sleep-wake cycle by increasing arousal levels and maintaining wakefulness.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To study cerebrospinal fluid levels of orexin in patients with AD, to evaluate the relationship of orexin cerebrospinal fluid levels with the degree of dementia and the cerebrospinal fluid AD biomarkers (tau proteins and &#x3b2;-amyloid 1-42), and to analyze potentially related sleep architecture changes measured by polysomnography.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We conducted a case-control study from August 1, 2012, through May 31, 2013. We included 48 drug-naive AD patients referred to the Neurological Clinic of the University Hospital of Rome Tor Vergata. Based on the Mini-Mental State Examination score, 21 patients were included in mild AD group (score, &#x2265;21), whereas 27 were included in the moderate to severe AD group (score, &lt;21). The control group consisted of 29 nondemented participants of similar age and sex.</AbstractText><AbstractText Label="EXPOSURE" NlmCategory="METHODS">Laboratory assessment of cerebrospinal fluid levels of orexin, tau proteins, and &#x3b2;-amyloid 1-42 and polysomnographic assessment of sleep variables.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Levels of orexin, tau proteins, and &#x3b2;-amyloid 1-42; macrostructural variables of nocturnal sleep (total sleep time, sleep efficiency, sleep onset and rapid eye movement [REM] sleep latencies, non-REM and REM sleep stages, and wakefulness after sleep onset); and Mini-Mental State Examination scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with moderate to severe AD presented with higher mean (SD) orexin levels compared with controls (154.36 [28.16] vs 131.03 [26.55]; P &lt; .01) and with more impaired nocturnal sleep with respect to controls and patients with mild AD. On the other hand, in the global AD group, orexin levels were positively correlated with total tau protein levels (r = 0.32; P = .03) and strictly related to sleep impairment. Finally, cognitive impairment, as measured by the Mini-Mental State Examination, was correlated with sleep structure deterioration.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Our results demonstrate that, in AD, increased cerebrospinal fluid orexin levels are related to a parallel sleep deterioration, which appears to be associated with cognitive decline. Therefore, the orexinergic system seems to be dysregulated in AD, and its output and function appear to be overexpressed along the progression of the neurodegenerative process. This overexpression may result from an imbalance of the neurotransmitter networks regulating the wake-sleep cycle toward the orexinergic system promoting wakefulness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liguori</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romigi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuccetelli</LastName><ForeName>Marzia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Molecular Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannino</LastName><ForeName>Silvana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sancesario</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy4Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martorana</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy4Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercuri</LastName><ForeName>Nicola Biagio</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy4Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izzi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardini</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Molecular Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitti</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sancesario</LastName><ForeName>Giulia M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Neuroscience Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sica</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marciani</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Placidi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Unit, Sleep Medicine Centre, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068797">Orexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Dec;71(12):1478-80. doi: 10.1001/jamaneurol.2014.2819.</RefSource><PMID Version="1">25317720</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Dec;10(12):672. doi: 10.1038/nrneurol.2014.209.</RefSource><PMID Version="1">25348006</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068797" MajorTopicYN="N">Orexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25322206</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.2510</ArticleId><ArticleId IdType="pii">1915582</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25326800</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1254</StartPage><EndPage>1262</EndPage><MedlinePgn>1254-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3700</ELocationID><Abstract><AbstractText>Neurofibrillary tangles (NFTs), composed of truncated and hyperphosphorylated tau, are a common feature of numerous aging-related neurodegenerative diseases, including Alzheimer's disease (AD). However, the molecular mechanisms mediating tau truncation and aggregation during aging remain elusive. Here we show that asparagine endopeptidase (AEP), a lysosomal cysteine proteinase, is activated during aging and proteolytically degrades tau, abolishes its microtubule assembly function, induces tau aggregation and triggers neurodegeneration. AEP is upregulated and active during aging and is activated in human AD brain and tau P301S-transgenic mice with synaptic pathology and behavioral impairments, leading to tau truncation in NFTs. Tau P301S-transgenic mice with deletion of the gene encoding AEP show substantially reduced tau hyperphosphorylation, less synapse loss and rescue of impaired hippocampal synaptic function and cognitive deficits. Mice infected with adeno-associated virus encoding an uncleavable tau mutant showed attenuated pathological and behavioral defects compared to mice injected with adeno-associated virus encoding tau P301S. Together, these observations indicate that AEP acts as a crucial mediator of tau-related clinical and neuropathological changes. Inhibition of AEP may be therapeutically useful for treating tau-mediated neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhentao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1] Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. [2] Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Mingke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Seong Su</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Il-Sun</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA. [2] Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA. [2] Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>William T</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhixue</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Graduate School of the Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian-Zhi</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, Key Laboratory of Ministry of Education of Neurological Diseases, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Translational Center for Stem Cell Research, Tongji Hospital, Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yi E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Translational Center for Stem Cell Research, Tongji Hospital, Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shan Ping</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>1] Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia, USA. [2] Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Keqiang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG042856</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045627</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060680</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>7006-34-0</RegistryNumber><NameOfSubstance UI="D001216">Asparagine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.34</RegistryNumber><NameOfSubstance UI="C069586">asparaginylendopeptidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2014 Nov;20(11):1236-8. doi: 10.1038/nm.3749.</RefSource><PMID Version="1">25375922</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001216" MajorTopicYN="N">Asparagine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTRS</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25326800</ArticleId><ArticleId IdType="mid">NIHMS623922</ArticleId><ArticleId IdType="pmc">PMC4224595</ArticleId><ArticleId IdType="doi">10.1038/nm.3700</ArticleId><ArticleId IdType="pii">nm.3700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 2565;101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada A, et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994;369:488&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">8202139</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeli-Azad B, McCarty JH, Feinstein SC. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci. 1994;107 (Pt 4):869&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056843</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres A, Kosik KS. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature. 1990;343:461&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">2105469</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem. 2564;259:5301&#x2013;5305.</Citation><ArticleIdList><ArticleId IdType="pubmed">6425287</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Zaidi T, Bancher C, Grundke-Iqbal I. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett. 1994;349:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8045285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopke E, et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993;268:24374&#x2013;24384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8226987</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer&#x2019;s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2:783&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673924</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:5562&#x2013;5566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44036</ArticleId><ArticleId IdType="pubmed">8202528</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA. 2001;98:6923&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34454</ArticleId><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Basurto-Islas G, et al. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:470&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699801</ArticleId><ArticleId IdType="pubmed">18431250</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA. 1993;90:2628&#x2013;2632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46148</ArticleId><ArticleId IdType="pubmed">8464868</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci. 2005;25:5365&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Guo JP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem. 2005;369:5145&#x2013;5153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15542598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1&#x2013;42 pathogenesis. J Neurosci Res. 1998;52:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem. 1997;69:2026&#x2013;2038.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349548</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV, et al. The tau protein in human cerebrospinal fluid in Alzheimer&#x2019;s disease consists of proteolytically derived fragments. J Neurochem. 1997;68:430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978756</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res. 2008;7:2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JM, Dando PM, Stevens RA, Fortunato M, Barrett AJ. Cloning and expression of mouse legumain, a lysosomal endopeptidase. Biochem J. 1998;335 (Pt 1):111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1219758</ArticleId><ArticleId IdType="pubmed">9742219</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JM, Rawlings ND, Stevens RA, Barrett AJ. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 1998;441:361&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">9891971</ArticleId></ArticleIdList></Reference><Reference><Citation>Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem. 2003;278:38980&#x2013;38990.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860980</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, et al. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol Cell. 2008;29:665&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819101</ArticleId><ArticleId IdType="pubmed">18374643</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, et al. Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics. 2012;12:2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787696</ArticleId><ArticleId IdType="pubmed">22718532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Garg S, Mandelkow EM, Mandelkow E. Proteolytic processing of tau. Biochem Soc Trans. 2010;38:955&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">20658984</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem. 1990;55:1624&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">2213015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirchl M, Humpel C. Does acidosis in brain play a role in Alzheimer&#x2019;s disease? Neuropsychiatr. 2009;23:187&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703385</ArticleId></ArticleIdList></Reference><Reference><Citation>Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K. Activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer disease. J Biol Chem. 2013;288:17495&#x2013;17507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682549</ArticleId><ArticleId IdType="pubmed">23640887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet-Bongaarts AL, et al. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem. 2006;97:1005&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, et al. Truncated tau from sporadic Alzheimer&#x2019;s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006;580:3582&#x2013;3588.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753151</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer&#x2019;s disease. Neurology. 1992;42:1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;278. discussion 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirahama-Noda K, et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem. 2003;278:33194&#x2013;33199.</Citation><ArticleIdList><ArticleId IdType="pubmed">12775715</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Duong DM, Peng J. Systematical Optimization of Reverse-Phase Chromatography for Shotgun Proteomics. J Proteome Res. 2009;8:3944&#x2013;3950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749476</ArticleId><ArticleId IdType="pubmed">19566079</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz JH, et al. Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J Proteome Res. 2010;9:6368&#x2013;6379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997170</ArticleId><ArticleId IdType="pubmed">20886841</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Biernat J, Mandelkow E. Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol Biol. 2005;299:35&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y, et al. SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer&#x2019;s disease. J Neurosci. 2012;32:17262&#x2013;17272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518045</ArticleId><ArticleId IdType="pubmed">23197718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One. 2009;4:e7280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748684</ArticleId><ArticleId IdType="pubmed">19794916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25333748</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson's disease.</ArticleTitle><Pagination><StartPage>5181</StartPage><MedlinePgn>5181</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms6181</ELocationID><Abstract><AbstractText>Mitochondrial dysfunction is a common feature of many neurodegenerative disorders, notably Parkinson's disease. Consequently, agents that protect mitochondria have strong therapeutic potential. Here, we sought to divert the natural strategy used by Borna disease virus (BDV) to replicate in neurons without causing cell death. We show that the BDV X protein has strong axoprotective properties, thereby protecting neurons from degeneration both in tissue culture and in an animal model of Parkinson's disease, even when expressed alone outside of the viral context. We also show that intranasal administration of a cell-permeable peptide derived from the X protein is neuroprotective. We establish that both the X protein and the X-derived peptide act by buffering mitochondrial damage and inducing enhanced mitochondrial filamentation. Our results open the way to novel therapies for neurodegenerative diseases by targeting mitochondrial dynamics and thus preventing the earliest steps of neurodegenerative processes in axons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szelechowski</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;tourn&#xe9;</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monnet</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1] ICM, Paris, F-75013, France [2] Sorbonne Universit&#xe9;s, UPMC Universit&#xe9; Paris 06, UM 75, ICM, Paris, F-75005, France [3] CNRS, UMR 7225, ICM, Paris, F-75013, France [4] Inserm, U 1127, ICM, Paris, F-75013, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferr&#xe9;</LastName><ForeName>C&#xe9;cile A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thouard</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foret</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyrin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>1] CNRS UMR 8256, Biological Adaptation and Ageing, Paris, F-75005, France [2] Sorbonne Universit&#xe9;s, UPMC Universit&#xe9; Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Institut de Biologie Paris Seine, Paris, F-75005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunot</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] ICM, Paris, F-75013, France [2] Sorbonne Universit&#xe9;s, UPMC Universit&#xe9; Paris 06, UM 75, ICM, Paris, F-75005, France [3] CNRS, UMR 7225, ICM, Paris, F-75013, France [4] Inserm, U 1127, ICM, Paris, F-75013, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Dunia</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] INSERM UMR 1043, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France [2] CNRS UMR 5282, Toulouse, F-31300, France [3] Universit&#xe9; Toulouse III Paul Sabatier, Toulouse, F-31300, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>03L9OT429T</RegistryNumber><NameOfSubstance UI="D012402">Rotenone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044085" MajorTopicYN="N">Microfluidics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25333748</ArticleId><ArticleId IdType="doi">10.1038/ncomms6181</ArticleId><ArticleId IdType="pii">ncomms6181</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25339735</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>43</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Regulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal &#x3b2;-amyloid fragment.</ArticleTitle><Pagination><StartPage>14210</StartPage><EndPage>14218</EndPage><MedlinePgn>14210-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0326-14.2014</ELocationID><Abstract><AbstractText>Soluble &#x3b2;-amyloid has been shown to regulate presynaptic Ca(2+) and synaptic plasticity. In particular, picomolar &#x3b2;-amyloid was found to have an agonist-like action on presynaptic nicotinic receptors and to augment long-term potentiation (LTP) in a manner dependent upon nicotinic receptors. Here, we report that a functional N-terminal domain exists within &#x3b2;-amyloid for its agonist-like activity. This sequence corresponds to a N-terminal fragment generated by the combined action of &#x3b1;- and &#x3b2;-secretases, and resident carboxypeptidase. The N-terminal &#x3b2;-amyloid fragment is present in the brains and CSF of healthy adults as well as in Alzheimer's patients. Unlike full-length &#x3b2;-amyloid, the N-terminal &#x3b2;-amyloid fragment is monomeric and nontoxic. In Ca(2+) imaging studies using a model reconstituted rodent neuroblastoma cell line and isolated mouse nerve terminals, the N-terminal &#x3b2;-amyloid fragment proved to be highly potent and more effective than full-length &#x3b2;-amyloid in its agonist-like action on nicotinic receptors. In addition, the N-terminal &#x3b2;-amyloid fragment augmented theta burst-induced post-tetanic potentiation and LTP in mouse hippocampal slices. The N-terminal fragment also rescued LTP inhibited by elevated levels of full-length &#x3b2;-amyloid. Contextual fear conditioning was also strongly augmented following bilateral injection of N-terminal &#x3b2;-amyloid fragment into the dorsal hippocampi of intact mice. The fragment-induced augmentation of fear conditioning was attenuated by coadministration of nicotinic antagonist. The activity of the N-terminal &#x3b2;-amyloid fragment appears to reside largely in a sequence surrounding a putative metal binding site, YEVHHQ. These findings suggest that the N-terminal &#x3b2;-amyloid fragment may serve as a potent and effective endogenous neuromodulator.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3414210-09$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>James L M</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and Departments of Pharmacology and Physiology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfulaij</LastName><ForeName>Naghum</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherrin</LastName><ForeName>Tessi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contarino</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellinger</LastName><ForeName>Frederick P</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todorovic</LastName><ForeName>Cedomir</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, University of Hawai'i at Manoa, Honolulu, Hawaii 96813, and robert.nichols@hawaii.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G12 MD007601</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20RR016453</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG21586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20-RR016467</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MD008149</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G12MD007601</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM103466</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 RR016453</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 RR016467</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ca regulation</Keyword><Keyword MajorTopicYN="N">fear memory</Keyword><Keyword MajorTopicYN="N">neuromodulation</Keyword><Keyword MajorTopicYN="N">synaptic plasticity</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25339735</ArticleId><ArticleId IdType="pmc">PMC4205547</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0326-14.2014</ArticleId><ArticleId IdType="pii">34/43/14210</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-&#x3b2; as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci. 2009;12:1567&#x2013;1576. doi: 10.1038/nn.2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2433</ArticleId><ArticleId IdType="pubmed">19935655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT. MAPK recruitment by &#x3b2;-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J Neurochem. 2004;91:349&#x2013;361. doi: 10.1111/j.1471-4159.2004.02722.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02722.x</ArticleId><ArticleId IdType="pubmed">15447668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellinger FP, Wilce PA, Bedi KS, Wilson P. Long-lasting synaptic modification in the rat hippocampus resulting from NMDA receptor blockade during development. Synapse. 2002;43:95&#x2013;101. doi: 10.1002/syn.10020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.10020</ArticleId><ArticleId IdType="pubmed">11754487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Ding W, Delacourte A, Fillit H. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Brain Res. 1993;601:154&#x2013;163. doi: 10.1016/0006-8993(93)91706-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(93)91706-X</ArticleId><ArticleId IdType="pubmed">8431762</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin JH, Ma L, MacTavish D, Jhamandas JH. Amyloid &#x3b2; protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J Neurosci. 2007;27:9262&#x2013;9269. doi: 10.1523/JNEUROSCI.1843-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1843-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673123</ArticleId><ArticleId IdType="pubmed">17728440</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-&#x3b2; in vivo. Neuron. 2008;58:42&#x2013;51. doi: 10.1016/j.neuron.2008.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.02.003</ArticleId><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellisanti CD, Yao Y, Stroud JC, Wang ZZ, Chen L. Crystal structure of the extracellular domain of nAChR &#x3b1;1 bound to &#x3b1;-bungarotoxin at 1.94 &#x212b; resolution. Nat Neurosci. 2007;10:953&#x2013;962. doi: 10.1038/nn1942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1942</ArticleId><ArticleId IdType="pubmed">17643119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JJ, Wu J, Nichols RA. &#x3b2;-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003;23:6740&#x2013;6747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkley PR, Jarvie PE, Health JW, Kidd GJ, Rostas JAP. A rapid method for isolation of synaptosomes on Percoll gradients. Brain Res. 1986;327:115&#x2013;129. doi: 10.1016/0006-8993(86)91464-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(86)91464-2</ArticleId><ArticleId IdType="pubmed">3011205</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ. Cleavage of amyloid &#x3b2;-peptide during constitutive processing of its precursor. Science. 1990;248:1122&#x2013;1124. doi: 10.1126/science.2111583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2111583</ArticleId><ArticleId IdType="pubmed">2111583</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Eckman CB, Younkin SG. Biochemical detection of A&#x3b2; isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000;1502:172&#x2013;187. doi: 10.1016/S0925-4439(00)00043-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4439(00)00043-0</ArticleId><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmeier A, Wozny C, Rost BR, Munter LM, Hua H, Georgiev O, Beyermann M, Hildebrand PW, Weise C, Schaffner W, Schmitz D, Multhaup G. Role of amyloid-&#x3b2; glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci. 2009;29:7582&#x2013;7590. doi: 10.1523/JNEUROSCI.1336-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1336-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665404</ArticleId><ArticleId IdType="pubmed">19515926</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan GM, Tong M, Jhun M, Arora K, Nichols RA. &#x3b2;-amyloid activates presynaptic &#x3b1;7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: involvement of lipid rafts. Eur J Neurosci. 2010;31:788&#x2013;796. doi: 10.1111/j.1460-9568.2010.07116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2010.07116.x</ArticleId><ArticleId IdType="pubmed">20374280</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A. 1990;87:1561&#x2013;1565. doi: 10.1073/pnas.87.4.1561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.4.1561</ArticleId><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu QS, Kawai H, Berg DK. &#x3b2;-amyloid peptide blocks the response of &#x3b1;7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A. 2001;98:4734&#x2013;4739. doi: 10.1073/pnas.081553598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.081553598</ArticleId><ArticleId IdType="pmc">PMC31903</ArticleId><ArticleId IdType="pubmed">11274373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini, Klann E, Blitzer RD, Gouras GK. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 2010;5:e12845. doi: 10.1371/journal.pone.0012845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012845</ArticleId><ArticleId IdType="pmc">PMC2942840</ArticleId><ArticleId IdType="pubmed">20862226</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcinkiewicz M, Seidah NG. Coordinated expression of &#x3b2;-amyloid precursor protein and the putative &#x3b2;-secretase BACE and &#x3b1;-secretase ADAM10 in mouse and human brain. J Neurochem. 2000;75:2133&#x2013;2143. doi: 10.1046/j.1471-4159.2000.0752133.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0752133.x</ArticleId><ArticleId IdType="pubmed">11032903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta TK, Dougherty JJ, Wu J, Choi CH, Khan GM, Nichols RA. Defining pre-synaptic nicotinic receptors regulated by beta amyloid in mouse cortex and hippocampus with receptor null mutants. J Neurochem. 2009;109:1452&#x2013;1458. doi: 10.1111/j.1471-4159.2009.06070.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06070.x</ArticleId><ArticleId IdType="pmc">PMC3979963</ArticleId><ArticleId IdType="pubmed">19457164</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, Nagao M, Fukuda H, Shimizu T, Shirasawa T. Analysis of the secondary structure of &#x3b2;-amyloid (A&#x3b2;42) fibrils by systematic proline replacement. J Biol Chem. 2004;279:52781&#x2013;52788. doi: 10.1074/jbc.M406262200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M406262200</ArticleId><ArticleId IdType="pubmed">15459202</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P, Christian C, Nirenberg M. Synapse formation between clonal neuroblastoma X glioma hybrid cells and striated muscle cells. Proc Natl Acad Sci U S A. 1976;73:123&#x2013;127. doi: 10.1073/pnas.73.1.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.73.1.123</ArticleId><ArticleId IdType="pmc">PMC335852</ArticleId><ArticleId IdType="pubmed">1061105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33. doi: 10.1016/S0896-6273(03)00810-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00810-9</ArticleId><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AN, Jhamandas JH. Neuronal receptors as targets for the action of amyloid-beta protein (A&#x3b2;) in the brain. Expert Rev Mol Med. 2012;14:e2. doi: 10.1017/S1462399411002134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1462399411002134</ArticleId><ArticleId IdType="pubmed">22261393</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. Ed 2. San Diego: Academic; 2001.</Citation></Reference><Reference><Citation>Pettit DL, Shao Z, Yakel JL. &#x3b2;-amyloid1&#x2013;42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci. 2001;21:RC120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762461</ArticleId><ArticleId IdType="pubmed">11150356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirttimaki TM, Codadu NK, Awni A, Pratik P, Nagel DA, Hill EJ, Dineley KT, Parri HR. &#x3b1;7 nicotinic receptor-mediated astrocytic gliotransmitter release: A&#x3b2; effects in a preclinical Alzheimer's mouse model. PLoS One. 2013;8:e81828. doi: 10.1371/journal.pone.0081828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0081828</ArticleId><ArticleId IdType="pmc">PMC3842962</ArticleId><ArticleId IdType="pubmed">24312364</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A. Characterization of amyloid &#x3b2; peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;4439. doi: 10.1021/pr0703627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr0703627</ArticleId><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid &#x3b2; peptide signatures I sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegen. 2010a;5:2. doi: 10.1186/1750-1326-5-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-2</ArticleId><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K. A novel A&#x3b2; isoform pattern in CSF reflects &#x3b3;-secretase inhibition in Alzheimer's disease. Alzheimers Res Ther. 2010b;2:7. doi: 10.1186/alzrt30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt30</ArticleId><ArticleId IdType="pmc">PMC2876785</ArticleId><ArticleId IdType="pubmed">20350302</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;1098. doi: 10.1016/j.neurobiolaging.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.06.002</ArticleId><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-&#x3b2; positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545. doi: 10.1523/JNEUROSCI.2692-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2692-08.2008</ArticleId><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Fa' M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O. Endogenous amyloid-&#x3b2; is necessary for hippocampal synaptic plasticity and memory. Ann Neurol. 2011;69:819&#x2013;830. doi: 10.1002/ana.22313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22313</ArticleId><ArticleId IdType="pmc">PMC4071456</ArticleId><ArticleId IdType="pubmed">21472769</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid &#x3b2;-peptide-induced dysfunction. Biochem Soc Trans. 2007;35:1219&#x2013;1223. doi: 10.1042/BST0351219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0351219</ArticleId><ArticleId IdType="pubmed">17956317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert W, Prior R, Weidemann A, Dircksen H, Multhaup G, Masters CL, Beyreuther K. Localization of Alzheimer &#x3b2;A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res. 1991;563:184&#x2013;194. doi: 10.1016/0006-8993(91)91532-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91532-6</ArticleId><ArticleId IdType="pubmed">1786532</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:742&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts molecular-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584. doi: 10.1146/annurev.pharmtox.43.100901.140248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.43.100901.140248</ArticleId><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrin T, Blank T, Hippel C, Rayner M, Davis RJ, Todorovic C. Hippocampal c-Jun-N-terminal kinases serve as negative regulators of associative learning. J Neurosci. 2010;30:13348&#x2013;13361. doi: 10.1523/JNEUROSCI.3492-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3492-10.2010</ArticleId><ArticleId IdType="pmc">PMC3842488</ArticleId><ArticleId IdType="pubmed">20926661</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin BK, Saxena S. Substantial contribution of the two imidazole rings of His13-His14 dyad to Cu(II) binding in amyloid-&#x3b2;(1&#x2013;16) at physiological pH and its significance. J Phys Chem A. 2011;115:9590&#x2013;9602. doi: 10.1021/jp200379m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jp200379m</ArticleId><ArticleId IdType="pmc">PMC3155642</ArticleId><ArticleId IdType="pubmed">21491887</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent &#x3b1;-secretase competes with &#x3b2;-secretase for cleavage of amyloid-&#x3b2; precursor protein in the trans-Golgi network. J Biol Chem. 2000;275:2568&#x2013;2575. doi: 10.1074/jbc.275.4.2568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.4.2568</ArticleId><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing and function. J Biol Chem. 2008;283:29615&#x2013;29619. doi: 10.1074/jbc.R800019200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R800019200</ArticleId><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the &#x3b1;-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 2009;23:1643&#x2013;1654. doi: 10.1096/fj.08-121392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-121392</ArticleId><ArticleId IdType="pubmed">19144697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M, Arora K, White MM, Nichols RA. Role of key aromatic residues in the ligand-binding domain of &#x3b1;7 nicotinic receptors in the agonist action of &#x3b2;-amyloid. J Biol Chem. 2011;286:34373&#x2013;34381. doi: 10.1074/jbc.M111.241299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.241299</ArticleId><ArticleId IdType="pmc">PMC3190827</ArticleId><ArticleId IdType="pubmed">21828053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. &#x3b2;-amyloid1&#x2013;42 binds to &#x3b1;7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease. J Biol Chem. 2000;275:5626&#x2013;5632. doi: 10.1074/jbc.275.8.5626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.8.5626</ArticleId><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Klyubin I, Wright S, Griswold-Prenner I, Rowan MJ, Anwyl R. &#x3b1;v integrins mediate beta-amyloid induced inhibition of long-term potentiation. Neurobiol Aging. 2008;29:1485&#x2013;1493. doi: 10.1016/j.neurobiolaging.2007.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.018</ArticleId><ArticleId IdType="pubmed">17442458</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson JS, Selkoe DJ, Cotman CW. Amyloid &#x3b2; protein enhances the survival of hippocampal neurons in vitro. Science. 1989;243:1488&#x2013;1490. doi: 10.1126/science.2928783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2928783</ArticleId><ArticleId IdType="pubmed">2928783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25344629</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults.</ArticleTitle><Pagination><StartPage>1798</StartPage><EndPage>1803</EndPage><MedlinePgn>1798-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3850</ELocationID><Abstract><AbstractText>The dentate gyrus (DG) is a region in the hippocampal formation whose function declines in association with human aging and is therefore considered to be a possible source of age-related memory decline. Causal evidence is needed, however, to show that DG-associated memory decline in otherwise healthy elders can be improved by interventions that enhance DG function. We addressed this issue by first using a high-resolution variant of functional magnetic resonance imaging (fMRI) to map the precise site of age-related DG dysfunction and to develop a cognitive task whose function localized to this anatomical site. Then, in a controlled randomized trial, we applied these tools to study healthy 50-69-year-old subjects who consumed either a high or low cocoa flavanol-containing diet for 3 months. A high-flavanol intervention was found to enhance DG function, as measured by fMRI and by cognitive testing. Our findings establish that DG dysfunction is a driver of age-related cognitive decline and suggest non-pharmacological means for its amelioration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>1] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Usman A</ForeName><Initials>UA</Initials><AffiliationInfo><Affiliation>1] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provenzano</LastName><ForeName>Frank A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>1] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Lok-Kin</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>1] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Neural Science, New York University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Hagen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>MARS Inc., McLean, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry, Columbia University, New York, New York, USA. [2] New York State Psychiatric Institute, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry, Columbia University, New York, New York, USA. [2] New York State Psychiatric Institute, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>1] Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Department of Neurology, Columbia University, New York, New York, USA. [3] Department of Psychiatry, Columbia University, New York, New York, USA. [4] Department of Radiology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG035015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044950">Flavanones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2014 Dec;17(12):1624-5. doi: 10.1038/nn.3876.</RefSource><PMID Version="1">25413084</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002099" MajorTopicYN="Y">Cacao</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044950" MajorTopicYN="N">Flavanones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25344629</ArticleId><ArticleId IdType="mid">NIHMS695554</ArticleId><ArticleId IdType="pmc">PMC4940121</ArticleId><ArticleId IdType="doi">10.1038/nn.3850</ArticleId><ArticleId IdType="pii">nn.3850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gazzaley A, Cooney JW, Rissman J, D&#x2019;Esposito M. Top-down suppression deficit underlies working memory impairment in normal aging. Nat. Neurosci. 2005;8:1298&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">16158065</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurology. 1999;52:1392&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227623</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat. Rev. Neurosci. 2012;13:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592200</ArticleId><ArticleId IdType="pubmed">22395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat. Rev. Neurosci. 2011;12:585&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312472</ArticleId><ArticleId IdType="pubmed">21897434</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function across the human life span: is memory decline normal or not? Ann. Neurol. 2002;51:290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa MA, Mattfeld AT, Stark SM, Stark CE. Age-related memory deficits linked to circuit-specific disruptions in the hippocampus. Proc. Natl. Acad. Sci. USA. 2011;108:8873&#x2013;8878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102362</ArticleId><ArticleId IdType="pubmed">21555581</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Chawla MK, Buonocore M, Rapp PR, Barnes CA. Imaging correlates of brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proc. Natl. Acad. Sci. USA. 2004;101:7181&#x2013;7186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406486</ArticleId><ArticleId IdType="pubmed">15118105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara Y, et al. Synaptic distributions of GluA2 and PKMzeta in the monkey dentate gyrus and their relationships with aging and memory. J. Neurosci. 2012;32:7336&#x2013;7344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391702</ArticleId><ArticleId IdType="pubmed">22623679</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno H, et al. Imaging the abeta-related neurotoxicity of Alzheimer disease. Arch. Neurol. 2007;64:1467&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923630</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlopoulos E, et al. Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48. Sci. Transl. Med. 2013;5:200ra115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940031</ArticleId><ArticleId IdType="pubmed">23986399</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 2014;20:659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, et al. Plant-derived flavanol (&#x2212;)epicatechin enhances angiogenesis and retention of spatial memory in mice. J. Neurosci. 2007;27:5869&#x2013;5878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672256</ArticleId><ArticleId IdType="pubmed">17537957</ArticleId></ArticleIdList></Reference><Reference><Citation>Borowsky IW, Collins RC. Metabolic anatomy of brain: a comparison of regional capillary density, glucose metabolism and enzyme activities. J. Comp. Neurol. 1989;288:401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">2551935</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonta C, Imbert M. Vascularization in the primate visual cortex during development. Cereb. Cortex. 2002;12:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W, Celik A, Paczynski RP. Regional cerebral blood volume: a comparison of the dynamic imaging and the steady state methods. J. Magn. Reson. Imaging. 1999;9:44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10030649</ArticleId></ArticleIdList></Reference><Reference><Citation>Belliveau JW, et al. Functional mapping of the human visual cortex by magnetic resonance imaging. Science. 1991;254:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">1948051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira AC, et al. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc. Natl. Acad. Sci. USA. 2007;104:5638&#x2013;5643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838482</ArticleId><ArticleId IdType="pubmed">17374720</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. USA. 2011;108:3017&#x2013;3022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpe JJ, Herscovitch P, Perlman JM, Raichle ME. Positron emission tomography in the newborn: extensive impairment of regional cerebral blood flow with intraventricular hemorrhage and hemorrhagic intracerebral involvement. Pediatrics. 1983;72:589&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">6605514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, et al. The brain in the age of old: the hippocampal formation is differentially affected by diseases of late life. Ann. Neurol. 2008;64:698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867102</ArticleId><ArticleId IdType="pubmed">19107993</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer&#x2019;s disease. Nat. Neurosci. 2014;17:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Stern Y, Small SA. Hippocampal subregions differentially associate with standardized memory tests. Hippocampus. 2011;21:923&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008756</ArticleId><ArticleId IdType="pubmed">20824727</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford University Press; 2006.</Citation></Reference><Reference><Citation>Yassa MA, Stark CE. Pattern separation in the hippocampus. Trends Neurosci. 2011;34:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183227</ArticleId><ArticleId IdType="pubmed">21788086</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent NJ, Squire LR, Clark RE. Spatial memory, recognition memory and the hippocampus. Proc. Natl. Acad. Sci. USA. 2004;101:14515&#x2013;14520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521976</ArticleId><ArticleId IdType="pubmed">15452348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter DL, Cooper LA, Valdiserri M. Implicit and explicit memory for novel visual objects in older and younger adults. Psychol. Aging. 1992;7:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1610519</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, et al. Age-related reductions in human recognition memory due to impaired encoding. Science. 1995;269:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">7618082</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss MB, Rosene DL, Peters A. Effects of aging on visual recognition memory in the rhesus monkey. Neurobiol. Aging. 1988;9:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">3062461</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson CA, Barnes CA. The neurobiology of memory changes in normal aging. Exp. Gerontol. 2003;38:61&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessberger S, et al. Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn. Mem. 2009;16:147&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661246</ArticleId><ArticleId IdType="pubmed">19181621</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer&#x2019;s disease. Nat. Neurosci. 2014;17:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Leemput K, et al. Automated segmentation of hippocampal subfields from ultra-high resolution in vivo MRI. Hippocampus. 2009;19:549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739884</ArticleId><ArticleId IdType="pubmed">19405131</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med. Image Anal. 2008;12:26&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276735</ArticleId><ArticleId IdType="pubmed">17659998</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasi A, Urbina S. Psychological Testing. Upper Saddle River, New Jersey: Prentice Hall; 1997.</Citation></Reference><Reference><Citation>New York State Psychiatric Institute &amp; Mars, Inc. Mars flavanol exercise and cognitive function study.  ClinicalTrials.Gov. 2014  http://clinicaltrials.gov/show/NCT01180127.</Citation></Reference><Reference><Citation>Schroeter H, et al. (&#x2212;)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA. 2006;103:1024&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1327732</ArticleId><ArticleId IdType="pubmed">16418281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorond FA, Hollenberg NK, Panych LP, Fisher ND. Brain blood flow and velocity: correlations between magnetic resonance imaging and transcranial Doppler sonography. J. Ultrasound Med. 2010;29:1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906813</ArticleId><ArticleId IdType="pubmed">20587424</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage. 2010;53:1181&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946852</ArticleId><ArticleId IdType="pubmed">20637289</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangi A, Niessen W, Vincken K, Viergever M. Multiscale vessel enhancement filtering. Med. Image Comput. Comput. Assist. Interv. 1998;1496:130&#x2013;137.</Citation></Reference><Reference><Citation>Buchfuhrer MJ, et al. Optimizing the exercise protocol for cardiopulmonary assessment. J. Appl. Physiol. 1983;55:1558&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">6643191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan YC. Multiple imputation for missing data: concepts and development (Version 9.0) SAS Support. 2012  http://support.sas.com/rnd/app/stat/papers/multipleimputation.pdf.</Citation></Reference><Reference><Citation>Little RJA, Rubin DB. Statistical Analysis with Missing Data. Hoboken, N.J: Wiley; 2002.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25348064</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Primary age-related tauopathy (PART): a common pathology associated with human aging.</ArticleTitle><Pagination><StartPage>755</StartPage><EndPage>766</EndPage><MedlinePgn>755-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-014-1349-0</ELocationID><Abstract><AbstractText>We recommend a new term, "primary age-related tauopathy" (PART), to describe a pathology that is commonly observed in the brains of aged individuals. Many autopsy studies have reported brains with neurofibrillary tangles (NFTs) that are indistinguishable from those of Alzheimer's disease (AD), in the absence of amyloid (A&#x3b2;) plaques. For these "NFT+/A&#x3b2;-" brains, for which formal criteria for AD neuropathologic changes are not met, the NFTs are mostly restricted to structures in the medial temporal lobe, basal forebrain, brainstem, and olfactory areas (bulb and cortex). Symptoms in persons with PART usually range from normal to amnestic cognitive changes, with only a minority exhibiting profound impairment. Because cognitive impairment is often mild, existing clinicopathologic designations, such as "tangle-only dementia" and "tangle-predominant senile dementia", are imprecise and not appropriate for most subjects. PART is almost universally detectable at autopsy among elderly individuals, yet this pathological process cannot be specifically identified pre-mortem at the present time. Improved biomarkers and tau imaging may enable diagnosis of PART in clinical settings in the future. Indeed, recent studies have identified a common biomarker profile consisting of temporal lobe atrophy and tauopathy without evidence of A&#x3b2; accumulation. For both researchers and clinicians, a revised nomenclature will raise awareness of this extremely common pathologic change while providing a conceptual foundation for future studies. Prior reports that have elucidated features of the pathologic entity we refer to as PART are discussed, and working neuropathological diagnostic criteria are proposed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, 10032, USA, john.crary@mountsinai.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Abisambra</LastName><ForeName>Jose F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Hof</LastName><ForeName>Patrick R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Jellinger</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Kofler</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Neltner</LastName><ForeName>Janna H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Santa-Maria</LastName><ForeName>Ismael</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Serrano-Pozo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shelanski</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thor</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Takao</LastName><ForeName>Masaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Masahito</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R173/1110</GrantID><Acronym>DMT_</Acronym><Agency>The Dunhill Medical Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG184440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG036453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Neuropathol. 2014 Dec;128(6):767-72. doi: 10.1007/s00401-014-1356-1.</RefSource><PMID Version="1">25359108</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Acta Neuropathol. 2014 Dec;128(6):773-6. doi: 10.1007/s00401-014-1362-3.</RefSource><PMID Version="1">25380757</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25348064</ArticleId><ArticleId IdType="mid">NIHMS638266</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Bigio EH, Budka H, et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. 2013;126:537&#x2013;544. doi: 10.1007/s00401-013-1171-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1171-0</ArticleId><ArticleId IdType="pmc">PMC3914659</ArticleId><ArticleId IdType="pubmed">23995422</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I. Alzheimer's disease-related lesions. J Alzheimers Dis. 2013;33(Suppl 1):S173&#x2013;179. doi: 10.3233/JAD-2012-129024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-129024</ArticleId><ArticleId IdType="pubmed">22695621</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, et al. Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. Brain. 2013;136:3738&#x2013;3752. doi: 10.1093/brain/awt273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt273</ArticleId><ArticleId IdType="pmc">PMC3859218</ArticleId><ArticleId IdType="pubmed">24136825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2001;101:167&#x2013;173. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">11271372</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex. 1991;1:103&#x2013;116. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42:1681&#x2013;1688. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol. 2006;25:265&#x2013;271. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">17140156</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Lintner F, Jellinger KA. Olfactory involvement in aging and Alzheimer's disease: an autopsy study. J Alzheimers Dis. 2005;7:149&#x2013;157. discussion 173-180.doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851853</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Thal DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer's disease. Biochemical Society Trans. 2012;40:711&#x2013;715. doi: 10.1042/BST20120034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120034</ArticleId><ArticleId IdType="pubmed">22817721</ArticleId></ArticleIdList></Reference><Reference><Citation>Baborie A, Griffiths TD, Jaros E, et al. Frontotemporal dementia in elderly individuals. Arch Neurol. 2012;69:1052&#x2013;1060. doi: 10.1001/archneurol.2011.3323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.3323</ArticleId><ArticleId IdType="pubmed">22529248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ. Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitative study. Acta Neuropathol. 1978;42:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ, Nuttall K. Topography of neurofibrillary tangles and granulovacuoles in hippocampi of patients with Down's syndrome: quantitative comparison with normal ageing and Alzheimer's disease. Neuropathol Appl Neurobiol. 1981;7:13&#x2013;20. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">6453301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Egensperger R, Kosel S, Jellinger K, Graeber MB. Low prevalence of apolipoprotein E epsilon 4 allele in the neurofibrillary tangle predominant form of senile dementia. Acta Neuropathol. 1997;94:403&#x2013;409. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9386771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Jellinger KA. Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathol. 1994;88:565&#x2013;570. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">7879604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Paulus W, Paukner K, Jellinger K. Neuropathologic diagnosis of Alzheimer disease: consensus between practicing neuropathologists? Alzheimer disease and Associated Disorders. 1997;11:207&#x2013;219. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9437438</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer disease and associated disorders. 2007;21:249&#x2013;258. doi: 10.1097/WAD.0b013e318142774e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318142774e</ArticleId><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Roth M, et al. Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Archives of general psychiatry. 1987;44:412&#x2013;417. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">2883954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Roth M, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer disease and associated disorders. 1987;1:256&#x2013;262. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">3453748</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Wischik CM, et al. Evidence of subtypes of Alzheimer's disease and implications for etiology. Archives of general psychiatry. 1993;50:350&#x2013;356. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cerebral cortex. 1994;4:138&#x2013;150. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett. 1993;153:131&#x2013;135. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8327187</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Wisniewski T. Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review. Gerontology. 2014 doi: 10.1159/000358875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000358875</ArticleId><ArticleId IdType="pmc">PMC4149810</ArticleId><ArticleId IdType="pubmed">24732638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowler JV, Hachinski V. Vascular cognitive impairment: a new approach to vascular dementia. Bailliere's Clinical Neurology. 1995;4:357&#x2013;376. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">7496625</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404. doi: 10.1007/s00401-006-0127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;278. discussion 278-284.doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. European Neurology. 1993;33:403&#x2013;408. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging. 2004;25:713&#x2013;718. discussion 743-716. doi:10.1016/j.neurobiolaging.2003.12.015 S0197458004000831 [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">15165692</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121:171&#x2013;181. doi: 10.1007/s00401-010-0789-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0789-4</ArticleId><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin? Current opinion in neurology. 2012;25:708&#x2013;714. doi: 10.1097/WCO.0b013e32835a3432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32835a3432</ArticleId><ArticleId IdType="pubmed">23160422</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. Journal of neuropathology and experimental neurology. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007;114:5&#x2013;22. doi.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110:9535&#x2013;9540. doi: 10.1073/pnas.1301175110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nature cell biology. 2009;11:909&#x2013;913. doi:ncb1901 [pii] 10.1038/ncb1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe RJ, Bennett DA, Schneider JA, Arfanakis K. Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PloS one. 2011;6:e26286. doi:10.1371/journal.pone.0026286 PONE-D-11-13485 [pii]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197137</ArticleId><ArticleId IdType="pubmed">22043314</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of Frontotemporal Lobar Degeneration-tau (FTLD-tau) Journal of Molecular Neurosci. 2011;45(3):384&#x2013;9. doi: 10.1007/s12031-011-9589-0. MN.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9589-0</ArticleId><ArticleId IdType="pmc">PMC3208128</ArticleId><ArticleId IdType="pubmed">21720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN, Hidalgo JA, Chiarolanza G, et al. The distribution of phosphorylated tau in spinal cords of Alzheimer's disease and non-demented individuals. J Alzheimers Dis. 2013;34:529&#x2013;536. doi: 10.3233/JAD-121864.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-121864</ArticleId><ArticleId IdType="pmc">PMC3670745</ArticleId><ArticleId IdType="pubmed">23246918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN, Tu M, Murray ME, Dickson DW. Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Neurosci Lett. 2011 doi:S0304-3940(11)00024-3 [pii] 10.1016/j.neulet.2011.01.020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044604</ArticleId><ArticleId IdType="pubmed">21236314</ArticleId></ArticleIdList></Reference><Reference><Citation>Elobeid A, Soininen H, Alafuzoff I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 2012;123:97&#x2013;104. doi: 10.1007/s00401-011-0906-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0906-z</ArticleId><ArticleId IdType="pmc">PMC3249177</ArticleId><ArticleId IdType="pubmed">22160320</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol. 1996;40:139&#x2013;148. doi: 10.1002/ana.410400204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400204</ArticleId><ArticleId IdType="pubmed">8773594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Lopez-Gonzalez I, Carmona M, et al. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol. 2014;73:81&#x2013;97. doi: 10.1097/NEN.0000000000000030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000030</ArticleId><ArticleId IdType="pubmed">24335532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Santpere G, van Leeuwen FW. Argyrophilic grain disease. Brain. 2008;131:1416&#x2013;1432. doi: 10.1093/brain/awm305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm305</ArticleId><ArticleId IdType="pubmed">18234698</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nature reviews Neuroscience. 2010;11:155&#x2013;159. doi:nrn2786 [pii] 10.1038/nrn2786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852. doi:M808759200 [pii] 10.1074/jbc.M808759200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukutani Y, Kobayashi K, Nakamura I, et al. Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Neurosci Lett. 1995;200:57&#x2013;60. doi:0304-3940(95)12083-G [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">8584267</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Sierra F, Hauw JJ, Duyckaerts C, et al. The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old. Acta Neuropathol. 2000;100:29&#x2013;35. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">10912917</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Winton MJ, Kwong LK, et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol. 2008;115:133&#x2013;145. doi: 10.1007/s00401-007-0257-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0257-y</ArticleId><ArticleId IdType="pubmed">17713769</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol. 1994;87:456&#x2013;468. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059598</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman L. Alzheimer's disease: A clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 1953;117:97&#x2013;130. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">13109530</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Rub U, Ferretti RE, et al. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathol Appl Neurobiol. 2009;35:406&#x2013;416. doi: 10.1111/j.1365-2990.2009.00997.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2009.00997.x</ArticleId><ArticleId IdType="pubmed">19508444</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Wang X, Wang C, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013;125:581&#x2013;593. doi: 10.1007/s00401-013-1080-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1080-2</ArticleId><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien A, Shaw P, Weintraub S, et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007;28:327&#x2013;335. doi:S0197-4580(06)00045-5 [pii] 10.1016/j.neurobiolaging.2006.02.007.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729&#x2013;736. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011 doi:M110.209296 [pii] 10.1074/jbc.M110.209296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Vignolo P, Duyckaerts C, et al. Neuropathological study of 12 centenarians: the incidence of Alzheimer type senile dementia is not particularly increased in this group of very old patients. Revue neurologique. 1986;142:107&#x2013;115. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">3726387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Archin N, Osmand AP, et al. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathol. 1993;86:215&#x2013;223. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8213079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Bouras C, Bu&#xe9;e L, et al. Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol. 1992;85:23&#x2013;30. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">1285493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Perl DP, Loerzel AJ, Morrison JH. Neurofibrillary tangle distribution in the cerebral cortex of parkinsonism-dementia cases from Guam: differences with Alzheimer's disease. Brain Res. 1991;564:306&#x2013;313. doi:0006-8993(91)91467-F [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">1810629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Vogt BA, Bouras C, Morrison JH. Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 1997;37:3609&#x2013;3625. doi:S0042-6989(96)00240-4 [pii] 10.1016/S0042-6989(96)00240-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9425534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, Nishimura T. Glial tau pathology in neurodegenerative diseases: their nature and comparison with neuronal tangles. Neurobiol Aging. 1998;19:S85&#x2013;91. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, et al. Clinical aspects of &#x2018;senile dementia of the tangle type&#x2019;-- a subset of dementia in the senium separable from late-onset Alzheimer's disease. Dement Geriatr Cogn Disord. 1999;10:6&#x2013;11. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, et al. A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele. Ann Neurol. 1997;41:693&#x2013;695. doi: 10.1002/ana.410410522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410522</ArticleId><ArticleId IdType="pubmed">9153535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Kondo H, et al. Thorn-shaped astrocytes: possibly secondarily induced tau-positive glial fibrillary tangles. Acta Neuropathol. 1995;90:620&#x2013;625. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Kondo H, Fujishima T, Kase K, Mizutani Y. A case of atypical senile dementia of Alzheimer type. No To Shinkei = Brain and nerve. 1993;45:455&#x2013;460. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8343297</ArticleId></ArticleIdList></Reference><Reference><Citation>Iseki E, Tsunoda S, Suzuki K, et al. Regional quantitative analysis of NFT in brains of non-demented elderly persons: comparisons with findings in brains of late-onset Alzheimer's disease and limbic NFT dementia. Neuropathology. 2002;22:34&#x2013;39. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">12030413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizawa T, Ko LW, Cookson N, et al. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. J Neuropathol Exp Neurol. 2002;61:1040&#x2013;1047. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484566</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh, Yamada M, Yoshida R, et al. Dementia characterized by abundant neurofibrillary tangles and scarce senile plaques: a quantitative pathological study. European neurology. 1996;36:94&#x2013;97. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">8654493</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y, Yamada M, Suematsu N, Matsushita M, Otomo E. An immunohistochemical study of centenarian brains: a comparison. J Neurol Sci. 1998;157:73&#x2013;81. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">9600680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257&#x2013;262. doi:S1552-5260(11)00100-2 [pii] 10.1016/j.jalz.2011.03.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;775. doi: 10.1002/ana.22628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22628</ArticleId><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Janocko NJ, Brodersen KA, Soto-Ortolaza AI, et al. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol. 2012;124:681&#x2013;692. doi: 10.1007/s00401-012-1044-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1044-y</ArticleId><ArticleId IdType="pmc">PMC3483034</ArticleId><ArticleId IdType="pubmed">22968369</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Challenges in the Neuropathological Diagnosis of Dementias. International Journal of Neuropathology. 2013;1:44.</Citation></Reference><Reference><Citation>Jellinger KA. Neuropathological subtypes of Alzheimer's disease. Acta Neuropathol. 2012;123:153&#x2013;154. doi: 10.1007/s00401-011-0889-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0889-9</ArticleId><ArticleId IdType="pubmed">22009303</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol. 2007;113:107&#x2013;117. doi: 10.1007/s00401-006-0156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0156-7</ArticleId><ArticleId IdType="pubmed">17089134</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis. 2010;21:1283&#x2013;1293. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">21504129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia) Brain Pathol. 1998;8:367&#x2013;376. doi.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098213</ArticleId><ArticleId IdType="pubmed">9546293</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Abner EL, Schmitt FA, et al. Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging. 2012;33:622 e621&#x2013;622 e616. doi: 10.1016/j.neurobiolaging.2011.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.02.018</ArticleId><ArticleId IdType="pmc">PMC3245887</ArticleId><ArticleId IdType="pubmed">21507528</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63:674&#x2013;681. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Parisi JE, et al. Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging. 2008;29:566&#x2013;573. doi: 10.1016/j.neurobiolaging.2006.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.10.032</ArticleId><ArticleId IdType="pmc">PMC2727715</ArticleId><ArticleId IdType="pubmed">17188783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature. 1963;197:192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Caselli RJ. Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegenerative Dis Manag. 2012;2:183&#x2013;195. doi: 10.2217/NMT.12.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/NMT.12.5</ArticleId><ArticleId IdType="pmc">PMC3395065</ArticleId><ArticleId IdType="pubmed">22798965</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol. 2013;73:472&#x2013;480. doi: 10.1002/ana.23816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23816</ArticleId><ArticleId IdType="pmc">PMC3660408</ArticleId><ArticleId IdType="pubmed">23424032</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, Wohrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365&#x2013;384. doi: 10.1007/s00401-013-1157-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1157-y</ArticleId><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Molnar K, Laszlo L, et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol. 2011;122:205&#x2013;222. doi: 10.1007/s00401-011-0819-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0819-x</ArticleId><ArticleId IdType="pubmed">21437732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PloS one. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkani RG, Dickson DW, Simuni T. Hippocampal-sparing Alzheimer's disease presenting as corticobasal syndrome. Parkinsonism Relat Disord. 2012;18:683&#x2013;685. doi: 10.1016/j.parkreldis.2011.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2011.11.022</ArticleId><ArticleId IdType="pubmed">22172552</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui Y, Tanizaki Y, Arima H, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80:366&#x2013;370. doi: 10.1136/jnnp.2008.155481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.155481</ArticleId><ArticleId IdType="pubmed">18977814</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68:709&#x2013;735. doi: 10.1097/NEN.0b013e3181a9d503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a9d503</ArticleId><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging. 1997;18:S91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002;51:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Kasahara M, Yamada S, Mukai M, Amano N. Study on the neuropathological diagnosis of senile dementia of the Alzheimer type. No To Shinkei = Brain and nerve. 1993;45:333&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">8334018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Shimada H. Neuropathological background of twenty-seven centenarian brains. J Neurol Sci. 1992;108:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">1517748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Shimada H. Quantitative study of neurofibrillary tangles in subdivisions of the hippocampus. CA2 as a special area in normal aging and senile dementia of the Alzheimer type. Acta Pathologica Japonica. 1991;41:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">1750357</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11. doi: 10.1007/s00401-011-0910-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging. 2014;35:301&#x2013;308. doi: 10.1016/j.neurobiolaging.2013.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.007</ArticleId><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol. 2014 doi: 10.1007/s00401-014-1302-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1302-2</ArticleId><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet neurology. 2011;10:785&#x2013;796. doi:S1474-4422(11)70156-9 [pii] 10.1016/S1474-4422(11)70156-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya H, Miki T, Seino S, et al. Molecular and functional diversity of ATP-sensitive K+ channels: the pathophysiological roles and potential drug targets. Nihon yakurigaku zasshi Folia pharmacologica Japonica. 2003;122:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, et al. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:774&#x2013;784. doi: 10.1097/NEN.0b013e3181aacbe9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181aacbe9</ArticleId><ArticleId IdType="pmc">PMC2725359</ArticleId><ArticleId IdType="pubmed">19535994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;381. doi: 10.1097/NEN.0b013e31825018f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda K, Sasaki K, Fujimi K, et al. Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only dementia): the Hisayama Study. Neuropathology. 2006;26:508&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203586</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl DP, Hof PR, Purohit DP, Loerzel AJ, Kakulas BA. Hippocampal and entorhinal cortex neurofibrillary tangle formation in Guamanian Chamorros free of overt neurologic dysfunction. J Neuropathol Exp Neurol. 2003;62:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722830</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, et al. Criteria for mild cognitive impairment due to alzheimer's disease in the community. Ann Neurol. 2013 doi: 10.1002/ana.23931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23931</ArticleId><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665&#x2013;672. doi:63/5/665 [pii] 10.1001/archneur.63.5.665.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80:1048&#x2013;1056. doi: 10.1212/WNL.0b013e3182872830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182872830</ArticleId><ArticleId IdType="pubmed">23390179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranginwala NA, Hynan LS, Weiner MF, White CL., 3rd Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008;16:384&#x2013;388. doi: 10.1097/JGP.0b013e3181629971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e3181629971</ArticleId><ArticleId IdType="pubmed">18448850</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A, Kosterin I, Kumar S, et al. Biochemical stages of amyloid-beta peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Brain. 2014;137:887&#x2013;903. doi: 10.1093/brain/awt362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt362</ArticleId><ArticleId IdType="pubmed">24519982</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Corrada MM, et al. Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain. 2011;134:3708&#x2013;3715. doi: 10.1093/brain/awr308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr308</ArticleId><ArticleId IdType="pmc">PMC3235569</ArticleId><ArticleId IdType="pubmed">22120149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Schott JM. Primary progressive aphasia - defining genetic and pathological subtypes. Curr Alzheimer Res. 2011;8:266&#x2013;272. doi:BSP/CAR/0119 [pii]</Citation><ArticleIdList><ArticleId IdType="pubmed">21222598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruben GC, Wang JZ, Iqbal K, Grundke-Iqbal I. Paired helical filaments (PHFs) are a family of single filament structures with a common helical turn period: negatively stained PHF imaged by TEM and measured before and after sonication, deglycosylation, and dephosphorylation. Microscopy research and technique. 2005;67:175&#x2013;195. doi: 10.1002/jemt.20197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jemt.20197</ArticleId><ArticleId IdType="pubmed">16104003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbagh MN, Sandhu SS, Farlow MR, et al. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Disease Assoc Disord. 2009;23:229&#x2013;233. doi:10.1097/WAD.0b013e318199d83300002093-200907000-00009 [pii]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760041</ArticleId><ArticleId IdType="pubmed">19812464</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M, et al. Staging of argyrophilic grains: an age-associated tauopathy. Journal of neuropathology and experimental neurology. 2004;63:911&#x2013;918. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Haggiagi A, Liu X, et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 2012;124:693&#x2013;704. doi: 10.1007/s00401-012-1017-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1017-1</ArticleId><ArticleId IdType="pmc">PMC3608475</ArticleId><ArticleId IdType="pubmed">22802095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Garruto R, Chen J, Lee VM, Trojanowski JQ. Tau epitopes in spinal cord neurofibrillary lesions in Chamorros of Guam. Neuroreport. 2000;11:3427&#x2013;3430.</Citation><ArticleIdList><ArticleId IdType="pubmed">11095492</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Zhukareva V, Perl DP, et al. Spinal cord neurofibrillary pathology in Alzheimer disease and Guam Parkinsonism-dementia complex. J Neuropathol Exp Neurol. 2001;60:1075&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18:691&#x2013;701. doi:D646027568658127 [pii] 10.3233/JAD-2009-1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnitzler JG. Zur Abgrenzung der sogenannten Alzheimerschen Erkrankung. Z ges Neurol Psychiat. 1911;7:34&#x2013;57. doi.</Citation></Reference><Reference><Citation>Schultz C, Ghebremedhin E, Del Tredici K, R&#xfc;b U, Braak H. High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe. Neurobiol Aging. 2004;25:397&#x2013;405. doi: 10.1016/S0197-4580(03)00113-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00113-1</ArticleId><ArticleId IdType="pubmed">15123344</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014;75:597&#x2013;601. doi: 10.1002/ana.24125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24125</ArticleId><ArticleId IdType="pmc">PMC4016558</ArticleId><ArticleId IdType="pubmed">24585367</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013;72:1182&#x2013;1192. doi: 10.1097/NEN.0000000000000016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000016</ArticleId><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiarli AM, Jennings R, Shi J, et al. Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathol Appl Neurobiol. 2006;32:374&#x2013;387. doi:NAN736 [pii] 10.1111/j.1365-2990.2006.00736.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866983</ArticleId></ArticleIdList></Reference><Reference><Citation>Simic G, Stanic G, Mladinov M, et al. Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol. 2009;35:532&#x2013;554. doi:NAN1038 [pii] 10.1111/j.1365-2990.2009.01038.x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787819</ArticleId><ArticleId IdType="pubmed">19682326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. Arch Neurol. 2011;68:1049&#x2013;1056. doi:68/8/1049 [pii] 10.1001/archneurol.2011.157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed A, Chatfield M, Matthews F, et al. Depression in the elderly: pathological study of raphe and locus ceruleus. Neuropathol Appl Neurobiol. 2005;31:405&#x2013;413. doi:NAN662 [pii] 10.1111/j.1365-2990.2005.00662.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008824</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi J, Shibata T, Sasaki M, et al. Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: High-resolution fast spin-echo T1-weighted imaging. Geriatrics &amp; gerontology international. 2014 doi: 10.1111/ggi.12280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ggi.12280</ArticleId><ArticleId IdType="pmc">PMC4405055</ArticleId><ArticleId IdType="pubmed">24661561</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006;2006:re1. doi:2006/6/re1 [pii] 10.1126/sageke.2006.6.re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Schultz C, Botez G, et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol. 2005;31:270&#x2013;279. doi:NAN635 [pii] 10.1111/j.1365-2990.2005.00635.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">15885064</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, von Arnim C, Griffin WS, et al. Pathology of clinical and preclinical Alzheimer's disease. European archives of psychiatry and clinical neuroscience. 2013;263(Suppl 2):S137&#x2013;145. doi: 10.1007/s00406-013-0449-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-013-0449-5</ArticleId><ArticleId IdType="pubmed">24077890</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T, Sahara N, Yen SH, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. Journal of neuropathology and experimental neurology. 2002;61:547&#x2013;556. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071638</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg DI, Trojanowski JQ. Dementia: a word to be forgotten. Arch Neurol. 2008;65:593&#x2013;595. doi: 10.1001/archneur.65.5.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.5.593</ArticleId><ArticleId IdType="pubmed">18474733</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Ishihara T, Higuchi M, et al. Amyotrophic lateral sclerosis/parkinsonism dementia complex: transgenic mice provide insights into mechanisms underlying a common tauopathy in an ethnic minority on Guam. Exp Neurol. 2002;176:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12093078</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol. 2003;29:503&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J, Spillantini MG, Goedert M, Dukas L, Staehelin HB. Abundant neurofibrillary tangles without senile plaques in a subset of patients with senile dementia. Neurodegeneration. 1992:257&#x2013;284.</Citation></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet neurology. 2013;12:957&#x2013;965. doi: 10.1016/S1474-4422(13)70194-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet. 1994;344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA neurology. 2013;70:1512&#x2013;1519. doi: 10.1001/jamaneurol.2013.4013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4013</ArticleId><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Narang HK, Terry RD. Neurofibrillary tangles of paired helical filaments. J Neurol Sci. 1976;27:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">129541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M. Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology. 2003;23:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">14719548</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Itoh Y, Sodeyama N, et al. Aging of the human limbic system: Observations of centenarian brains and analyses of genetic risk factors for senile changes. Neuropathology. 1998;18:228&#x2013;234.</Citation></Reference><Reference><Citation>Yamada M, Itoh Y, Sodeyama N, et al. Senile dementia of the neurofibrillary tangle type: a comparison with Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:117&#x2013;126. doi:51245.</Citation><ArticleIdList><ArticleId IdType="pubmed">11173884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Itoh Y, Suematsu N, Otomo E, Matsushita M. Apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain. Ann Neurol. 1996;40:243&#x2013;245. doi: 10.1002/ana.410400217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400217</ArticleId><ArticleId IdType="pubmed">8773607</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Itoh Y, Yohinori I, et al. Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type. Neuropathology. 1996;16:89&#x2013;98.</Citation></Reference><Reference><Citation>Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology. 2006;26:457&#x2013;470. doi.</Citation><ArticleIdList><ArticleId IdType="pubmed">17080726</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging. 2014;35:819&#x2013;826. doi: 10.1016/j.neurobiolaging.2013.10.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.10.074</ArticleId><ArticleId IdType="pmc">PMC3882071</ArticleId><ArticleId IdType="pubmed">24199961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24898928</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>24</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Joint effect of mid- and late-life blood pressure on the brain: the AGES-Reykjavik study.</ArticleTitle><Pagination><StartPage>2187</StartPage><EndPage>2195</EndPage><MedlinePgn>2187-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000517</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We hypothesized that in participants with a history of hypertension, lower late-life blood pressure (BP) will be associated with more brain pathology.</AbstractText><AbstractText Label="METHODS">Participants are 4,057 older men and women without dementia with midlife (mean age 50 &#xb1; 6 years) and late-life (mean age 76 &#xb1; 5 years) vascular screening, cognitive function, and brain structures on MRI ascertained as part of the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study.</AbstractText><AbstractText Label="RESULTS">The association of late-life BP to brain measures depended on midlife hypertension history. Higher late-life systolic and diastolic BP (DBP) was associated with an increased risk of white matter lesions and cerebral microbleeds, and this was most pronounced in participants without a history of midlife hypertension. In contrast, in participants with a history of midlife hypertension, lower late-life DBP was associated with smaller total brain and gray matter volumes. This finding was reflected back in cognitive performance; in participants with midlife hypertension, lower DBP was associated with lower memory scores.</AbstractText><AbstractText Label="CONCLUSION">In this large population-based cohort, late-life BP differentially affects brain pathology and cognitive performance, depending on the history of midlife hypertension. Our study suggests history of hypertension is critical to understand how late-life BP affects brain structure and function.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Majon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigurdsson</LastName><ForeName>Sigurdur</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjartansson</LastName><ForeName>Olafur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Tamara B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>From the Laboratory of Epidemiology and Population Sciences (M.M., T.B.H., L.J.L.), Intramural Research Program, National Institute on Aging, Bethesda, MD; the Departments of Gerontology and Geriatrics (M.M.) and Radiology (M.v.B.), Leiden University Medical Center; Icelandic Heart Association (S.S., O.K., T.A., V.G.), Kopovagur; the Departments of Neurology &amp; Radiology (O.K.) and Geriatrics (P.V.J.), Landspitali National University Hospital, Reykjavik, Iceland; the Department of Neurology (O.L.L.), University of Pittsburgh, PA; and the Faculty of Medicine (P.V.J.), University of Iceland, Reykjavik. LaunerL@nia.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Age, Gene/Environment Susceptibility-Reykjavik Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-AG-1-2100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Jan 20;84(3):329. doi: 10.1212/01.wnl.0000460552.36620.a9.</RefSource><PMID Version="1">25601884</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Jan 20;84(3):329-30.</RefSource><PMID Version="1">25759868</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007055" MajorTopicYN="N" Type="Geographic">Iceland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24898928</ArticleId><ArticleId IdType="pmc">PMC4113458</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000517</ArticleId><ArticleId IdType="pii">WNL.0000000000000517</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887&#x2013;1898</Citation><ArticleIdList><ArticleId IdType="pubmed">18378519</ArticleId></ArticleIdList></Reference><Reference><Citation>Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684577</ArticleId><ArticleId IdType="pubmed">19454737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005;112:1644&#x2013;1650</Citation><ArticleIdList><ArticleId IdType="pubmed">16145004</ArticleId></ArticleIdList></Reference><Reference><Citation>Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)&#x2013;Dijon Magnetic Resonance Imaging Study. Circulation 2011;123:266&#x2013;273</Citation><ArticleIdList><ArticleId IdType="pubmed">21220733</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial Cognitive Function Assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683&#x2013;689</Citation><ArticleIdList><ArticleId IdType="pubmed">18614402</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487&#x2013;499</Citation><ArticleIdList><ArticleId IdType="pubmed">16033691</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of hypertension in the oldest old: a critical role for frailty? Hypertension 2014;63:433&#x2013;441</Citation><ArticleIdList><ArticleId IdType="pubmed">24324042</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: The Honolulu-Asia Aging Study. JAMA 1995;274:1846&#x2013;1851</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004;44:29&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">15159381</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011;77:461&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146307</ArticleId><ArticleId IdType="pubmed">21810696</ArticleId></ArticleIdList></Reference><Reference><Citation>Euser SM, van BT, Schram MT, et al. The effect of age on the association between blood pressure and cognitive function later in life. J Am Geriatr Soc 2009;57:1232&#x2013;1237</Citation><ArticleIdList><ArticleId IdType="pubmed">19453303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabayan B, Oleksik AM, Maier AB, et al. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus Study. J Am Geriatr Soc 2012;60:2014&#x2013;2019</Citation><ArticleIdList><ArticleId IdType="pubmed">23126669</ArticleId></ArticleIdList></Reference><Reference><Citation>Strandgaard S, Paulson OB. Cerebrovascular consequences of hypertension. Lancet 1994;344:519&#x2013;521</Citation><ArticleIdList><ArticleId IdType="pubmed">7914618</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 2012;71:825&#x2013;833</Citation><ArticleIdList><ArticleId IdType="pubmed">22447734</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 2008;7:476&#x2013;484</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475602</ArticleId><ArticleId IdType="pubmed">18522829</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, van der Graaf Y, Visseren FL, Vlek AL, Mali WP, Geerlings MI. Blood pressure, cerebral blood flow, and brain volumes: The SMART-MR study. J Hypertens 2010;28:1498&#x2013;1505</Citation><ArticleIdList><ArticleId IdType="pubmed">20453669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell GF, van Buchem MA, Sigurdsson S, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility&#x2013;Reykjavik study. Brain 2011;134:3398&#x2013;3407</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212721</ArticleId><ArticleId IdType="pubmed">22075523</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006;166:1003&#x2013;1008</Citation><ArticleIdList><ArticleId IdType="pubmed">16682574</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, van der Graaf Y, Algra A, Hendrikse J, Mali WP, Geerlings MI. Carotid atherosclerosis and progression of brain atrophy: the SMART-MR study. Ann Neurol 2011;70:237&#x2013;244</Citation><ArticleIdList><ArticleId IdType="pubmed">21674583</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment Susceptibility&#x2013;Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 2007;165:1076&#x2013;1087</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723948</ArticleId><ArticleId IdType="pubmed">17351290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson S, Aspelund T, Forsberg L, et al. Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik Study. Neuroimage 2012;59:3862&#x2013;3870</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712156</ArticleId><ArticleId IdType="pubmed">22119006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijdenbos AP, Forghani R, Evans AC. Automatic &#x201c;pipeline&#x201d; analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 2002;21:1280&#x2013;1291</Citation><ArticleIdList><ArticleId IdType="pubmed">12585710</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal JS, Sigurdsson S, Jonsdottir MK, et al. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke 2010;41:891&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298743</ArticleId><ArticleId IdType="pubmed">20360538</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Xue QL, Masaki K, et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009;54:233&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136040</ArticleId><ArticleId IdType="pubmed">19564551</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998;51:319&#x2013;320</Citation><ArticleIdList><ArticleId IdType="pubmed">9674838</ArticleId></ArticleIdList></Reference><Reference><Citation>Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke 2010;41:S103&#x2013;S106</Citation><ArticleIdList><ArticleId IdType="pubmed">20876479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">11779883</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 1999;46:827&#x2013;833</Citation><ArticleIdList><ArticleId IdType="pubmed">10589534</ArticleId></ArticleIdList></Reference><Reference><Citation>Den Heijer T, Skoog I, Oudkerk M, et al. Association between blood pressure levels over time and brain atrophy in the elderly. Neurobiol Aging 2003;24:307&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pubmed">12498964</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141&#x2013;1145</Citation><ArticleIdList><ArticleId IdType="pubmed">8609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochemsen HM, Muller M, Visseren FL, et al. Blood pressure and progression of brain atrophy: the SMART-MR Study. JAMA Neurol 2013;70:1046&#x2013;1053</Citation><ArticleIdList><ArticleId IdType="pubmed">23753860</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter OC, Sunthorn T, Kraftsik R, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002;33:1986&#x2013;1992</Citation><ArticleIdList><ArticleId IdType="pubmed">12154250</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bemmel T, Holman ER, Gussekloo J, Blauw GJ, Bax JJ, Westendorp RG. Low blood pressure in the very old, a consequence of imminent heart failure: the Leiden 85-plus study. J Hum Hypertens 2009;23:27&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">18650839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25378646</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>261</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.</ArticleTitle><Pagination><StartPage>261ra154</StartPage><MedlinePgn>261ra154</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3009835</ELocationID><Abstract><AbstractText>Using therapeutic antibodies that need to cross the blood-brain barrier (BBB) to treat neurological disease is a difficult challenge. We have shown that bispecific antibodies with optimized binding to the transferrin receptor (TfR) that target &#x3b2;-secretase (BACE1) can cross the BBB and reduce brain amyloid-&#x3b2; (A&#x3b2;) in mice. Can TfR enhance antibody uptake in the primate brain? We describe two humanized TfR/BACE1 bispecific antibody variants. Using a human TfR knock-in mouse, we observed that anti-TfR/BACE1 antibodies could cross the BBB and reduce brain A&#x3b2; in a TfR affinity-dependent fashion. Intravenous dosing of monkeys with anti-TfR/BACE1 antibodies also reduced A&#x3b2; both in cerebral spinal fluid and in brain tissue, and the degree of reduction correlated with the brain concentration of anti-TfR/BACE1 antibody. These results demonstrate that the TfR bispecific antibody platform can robustly and safely deliver therapeutic antibody across the BBB in the primate brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Y Joy</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Antibody Engineering, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Raymond K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Protein Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildsmith</LastName><ForeName>Kristin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Development Sciences, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Antibody Engineering, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersom</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Janice A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bumbaca</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Development Sciences, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadkar</LastName><ForeName>Kapil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Development Sciences, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyte</LastName><ForeName>Kwame</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Wilman</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Protein Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Development Sciences, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Antibody Engineering, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. rwatts@gene.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018033">Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C068126">CD71 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2015 Jan;14(1):14-5. doi: 10.1038/nrd4522.</RefSource><PMID Version="1">25503335</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018033" MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25378646</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3009835</ArticleId><ArticleId IdType="pii">6/261/261ra154</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25443857</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>15.e154</EndPage><MedlinePgn>1-15.e1-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2014.07.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(14)02500-X</ELocationID><Abstract><AbstractText>Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission tomography), and now with F-18-labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there has been considerable variability in the exact numbers reported as quantitative outcome measures of tracer retention. In some cases this is as trivial as the choice of units, in some cases it is scanner dependent, and of course, different tracers yield different numbers. Our working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (&#x2264; 45 years) and typical Alzheimer's disease patients. The units of this scale have been named "Centiloids." Basically, we describe a "standard" method of analyzing PiB PET data and then a method for scaling any "nonstandard" method of PiB PET analysis (or any other tracer) to the Centiloid scale.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, University of Pittsburgh, Pittsburgh. PA, USA. Electronic address: klunkwe@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Washington University, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Suffix>Sr</Suffix><AffiliationInfo><Affiliation>Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA; Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Departments of Radiology, Pharmacology and Biological Chemistry, and Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Davneet</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid imaging</Keyword><Keyword MajorTopicYN="N">Centiloid scale</Keyword><Keyword MajorTopicYN="N">Pittsburgh compound B</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword><Keyword MajorTopicYN="N">Standardize</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25443857</ArticleId><ArticleId IdType="mid">NIHMS642914</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pii">S1552-5260(14)02500-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 2011;7:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:474&#x2013;485. e4741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396131</ArticleId><ArticleId IdType="pubmed">21784356</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccardi M, Bocchetta M, Ganzola R, Robitaille N, Redolfi A, Duchesne S, Jack CR, Jr, Frisoni GB. Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. Alzheimers Dement. 2013 (in press): DOI 10.1016/j.jalz.2013.03.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">23706515</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Bocchetta M, Chetelat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR, Jr., Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C. Imaging markers for Alzheimer disease: Which vs how. Neurology. 2013;81:487&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776529</ArticleId><ArticleId IdType="pubmed">23897875</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer&#x2019;s disease diagnosis: a consensus paper from the Alzheimer&#x2019;s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22047631</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, Shaw LM, Stephenson D, Bain L, Zetterberg H. Global standardization measurement of cerebral spinal fluid for Alzheimer&#x2019;s disease: an update from the Alzheimer&#x2019;s Association Global Biomarkers Consortium. Alzheimers Dement. 2013;9:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23274154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2:975&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Madison C, Haight TJ, Markley C, Jagust WJ. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol Aging. 2012;33:2746&#x2013;2755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381075</ArticleId><ArticleId IdType="pubmed">22429886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O&#x2019;Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O&#x2019;Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O&#x2019;Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwertman NC, de Silva R. Identifying outliers with sequential fences. Computational Statistics &amp; Data Analysis. 2007;51:3800&#x2013;3810.</Citation></Reference><Reference><Citation>Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Nebes RD, Saxton JA, Snitz B, Dekosky S, Williamson J, Lopez OL, Price JC, Mathis CA, Klunk WE. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605888</ArticleId><ArticleId IdType="pubmed">23353602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE. Basal Cerebral Metabolism May Modulate the Cognitive Effects of A&#x3b2; in Mild Cognitive Impairment: An Example of Brain Reserve. J Neurosci. 2009;29:14770&#x2013;14778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7:254&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873340</ArticleId><ArticleId IdType="pubmed">10408769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, MacDonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, Narr K, Kabani N, Le Goualher G, Boomsma D, Cannon T, Kawashima R, Mazoyer B. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356:1293&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN. Test-retest variability of quantitative [11C]PIB studies in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2009;36:1629&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758198</ArticleId><ArticleId IdType="pubmed">19384547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaqub M, Tolboom N, Boellaard R, van Berckel BNM, van Tilburg EW, Luurtsema G, Scheltens P, Lammertsma AA. Simplified parametric methods for [11C]PIB studies. NeuroImage. 2008;42:76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541442</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807. J Alzheimers Dis. 2012 (in press): DOI 10.3233/JAD-122059.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">23857514</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamane T, Ikari Y, Nishio T, Ishii K, Kato T, Ito K, Silverman DH, Senda M, Asada T, Arai H, Sugishita M, Iwatsubo T. Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation. AJNR Am J Neuroradiol. 2013 (in press): DOI 10.3174/ajnr.A3665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965770</ArticleId><ArticleId IdType="pubmed">23907243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA. The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O&#x2019;Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Bi W, Weissfeld LA, Aizenstein HA, McDade E, Mountz JM, Nebes RD, Saxton JA, Snitz BE, Lopez OL, Price JC, Mathis CA, Klunk WE. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. Neuroimage. 2012;71:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605888</ArticleId><ArticleId IdType="pubmed">23353602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, Jagust WJ. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230690</ArticleId><ArticleId IdType="pubmed">21884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W, Cohen A, Bi W, Weissfeld L, Aizenstein H, McDade E, Mountz J, Nebes R, Saxton J, Snitz B, Lopez O, Price J, Mathis C. Why we need two cutoffs for amyloid imaging: Early versus Alzheimer&#x2019;s-like amyloid-positivity. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2012;8:P453&#x2013;P454.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25365775</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>24</EndPage><MedlinePgn>15-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.3049</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Recent large-scale genome-wide association studies have discovered several genetic variants associated with Alzheimer disease (AD); however, the extent to which DNA methylation in these AD loci contributes to the disease susceptibility remains unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association of brain DNA methylation in 28 reported AD loci with AD pathologies.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Ongoing community-based clinical pathological cohort studies of aging and dementia (the Religious Orders Study and the Rush Memory and Aging Project) among 740 autopsied participants 66.0 to 108.3 years old.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">DNA methylation levels at individual CpG sites generated from dorsolateral prefrontal cortex tissue using a bead assay.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Pathological diagnosis of AD by National Institute on Aging-Reagan criteria following a standard postmortem examination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 447 participants (60.4%) met the criteria for pathological diagnosis of AD. Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 was associated with pathological AD. The association was robustly retained after replacing the binary trait of pathological AD with 2 quantitative and molecular specific hallmarks of AD, namely, A&#x3b2; load and paired helical filament tau tangle density. Furthermore, RNA expression of transcripts of SORL1 and ABCA7 was associated with paired helical filament tau tangle density, and the expression of BIN1 was associated with A&#x3b2; load.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Brain DNA methylation in multiple AD loci is associated with AD pathologies. The results provide further evidence that disruption of DNA methylation is involved in the pathological process of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois2Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Gyan P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pochet</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois2Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jishu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozubek</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obholzer</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois2Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois7Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois2Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois8Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epigenomics Program, Broad Institute, Cambridge Center, Cambridge, Massachusetts10Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts4Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departme.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois2Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG36836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG041906</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG36042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG46152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411895">ABCA7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017920">Antiporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059847">HLA-DRB5 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C470570">SLC24A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Jan;72(1):8-9. doi: 10.1001/jamaneurol.2014.3057.</RefSource><PMID Version="1">25365705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017920" MajorTopicYN="N">Antiporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018899" MajorTopicYN="N">CpG Islands</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059847" MajorTopicYN="N">HLA-DRB5 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25365775</ArticleId><ArticleId IdType="mid">NIHMS655164</ArticleId><ArticleId IdType="pmc">PMC4344367</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3049</ArticleId><ArticleId IdType="pii">1919424</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatz M, Pedersen NL, Berg S, et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci. 1997;52(2):M117&#x2013;M125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barral S, Lee JH, et al. Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. J Alzheimers Dis. 2011;23(2):249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130303</ArticleId><ArticleId IdType="pubmed">20930268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EADI1 Consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M, Benitez BA, Cairns N, et al. NIA-LOAD/NCRAD Family Study Consortium. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol. 2013;70(6):736&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681841</ArticleId><ArticleId IdType="pubmed">23588422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli MA, John-Williams K, Rajbhandary R, et al. Repeat expansions in the C9ORF72 gene contribute to Alzheimer disease in Caucasians. Neurobiol Aging. 2013;34(5):1519.e5&#x2013;1519.e12. doi:10.1016/j.neurobiolaging.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586789</ArticleId><ArticleId IdType="pubmed">23107433</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakulski KM, Dolinoy DC, Sartor MA, et al. Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis. 2012;29(3):571&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652332</ArticleId><ArticleId IdType="pubmed">22451312</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet. 2011;12(8):529&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508712</ArticleId><ArticleId IdType="pubmed">21747404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Liu X, Deng Y, Qing H. DNA methylation, a hand behind neurodegenerative diseases. Front Aging Neurosci. 2013;5:85. doi:10.3389/fnagi.2013.00085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3851782</ArticleId><ArticleId IdType="pubmed">24367332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Cheng L, Badner JA, et al. Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet. 2010;86(3):411&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833385</ArticleId><ArticleId IdType="pubmed">20215007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res. 2012;9(6):628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(4 suppl 1):S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher RA. Questions and answers #14. Am Stat. 1948;2(5):30&#x2013;31.</Citation></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">3806354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging. 2010;31(12):2025&#x2013;2037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962691</ArticleId><ArticleId IdType="pubmed">19117641</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouliaras L, Mastroeni D, Delvaux E, et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging. 2013;34(9):2091&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955118</ArticleId><ArticleId IdType="pubmed">23582657</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao JS, Keleshian VL, Klein S, Rapoport SI. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry. 2012;2:e132. doi:10.1038/tp.2012 .55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410632</ArticleId><ArticleId IdType="pubmed">22760556</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Srivastava G, Lunnon K, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17(9):1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="pubmed">25129075</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya TK, da Silva PN, Pay&#xe3;o SL, et al. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer's Disease. Neurochem Int. 2012;61(7):973&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">22836009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Kim WS, Kwok JB, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem. 2008;106(2):793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">18429932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Li H, Ruberu K, et al. Deletion of Abca7 increases cerebral amyloid-&#x3b2; accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci. 2013;33(10):4387&#x2013;4394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704948</ArticleId><ArticleId IdType="pubmed">23467355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu CJ. The epigenetic effects of amyloid-&#x3b2;1-40 on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun. 2009;378(1):57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007750</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh T, De Camilli P. BAR, F-BAR (EFC) and ENTH/ANTH domains in the regulation of membrane-cytosol interfaces and membrane curvature. Biochim Biophys Acta. 2006;1761(8):897&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">16938488</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid &#x3b2;-protein involves the endocytic pathway. J Biol Chem. 1994;269(26):17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Hansmannel F, Gistelinck M, et al. GERAD Consortium. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry. 2013;18(11):1225&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807661</ArticleId><ArticleId IdType="pubmed">23399914</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson M, Duffy DL, Zhu G, et al. GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development. Am J Hum Genet. 2011;89(2):334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155193</ArticleId><ArticleId IdType="pubmed">21835309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiho H, Saito K, Tsujita K, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116(pt 20):4159&#x2013;4168.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972505</ArticleId></ArticleIdList></Reference><Reference><Citation>Glennon EB, Whitehouse IJ, Miners JS, et al. BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. PLoS One. 2013;8(10):e78806. doi:10.1371/journal.pone.0078806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804620</ArticleId><ArticleId IdType="pubmed">24205320</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Hove DL, Kompotis K, Lardenoije R, et al. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging. 2014;35(4):731&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">24238656</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk KR, de Jong S, Boks MP, et al. Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. BMC Genomics. 2012;13:636. doi:10.1186/1471-2164-13-636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583143</ArticleId><ArticleId IdType="pubmed">23157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, van der Brug MP, Hernandez DG, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6(5):e1000952. doi:10.1371 /journal.pgen.1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25359108</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Are cases with tau pathology occurring in the absence of A&#x3b2; deposits part of the AD-related pathological process?</ArticleTitle><Pagination><StartPage>767</StartPage><EndPage>772</EndPage><MedlinePgn>767-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-014-1356-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy Section, Department of Neurology, Center for Biomedical Research, University of Ulm, Helmholtzstrasse 8/1, 89081, Ulm, Germany, heiko.braak@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Tredici</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Acta Neuropathol. 2014 Dec;128(6):755-66. doi: 10.1007/s00401-014-1349-0.</RefSource><PMID Version="1">25348064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25359108</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1356-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25390692</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.</ArticleTitle><Pagination><StartPage>e111899</StartPage><MedlinePgn>e111899</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e111899</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0111899</ELocationID><Abstract><AbstractText>Amyloid beta (Abeta) 1-42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD). We have identified a receptor not previously associated with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo. Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated reduction in binding of exogenous Abeta oligomers to neurons of more than 90%. Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals. Specific, high affinity small molecule receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner. These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models. These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small molecules can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models. We propose that sigma-2/PGRMC1 is a key mediator of the pathological effects of Abeta oligomers in AD and is a tractable target for small molecule disease-modifying therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Izzo</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinbin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Chenbo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirk</LastName><ForeName>Molly J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; Department of Neurology, Northeastern University, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozzoni</LastName><ForeName>Kelsie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silky</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehak</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurko</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Look</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rishton</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safferstein</LastName><ForeName>Hank</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Charles Sturt University, Wagga Wagga New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craven</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular and Biological Pharmacology, University of Kentucky, Lexington, Kentucky, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular and Biological Pharmacology, University of Kentucky, Lexington, Kentucky, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeVine</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; The University of Edinburgh, Center for Cognitive and Neural Systems and Euan MacDonald Centre for Motorneurone Disease, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS-083175</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 NS083175</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-49442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG033670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 NS090214</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG033670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AG037337</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-037337</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508868">PGRMC1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001345" MajorTopicYN="N">Autoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>NI, KM, CS, CR, RY, CL, GR, HS, and SC are employees or paid concultants of Cognition Therapeutics, Inc. HL and RC also own stock or stock options of Cognition Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25390692</ArticleId><ArticleId IdType="pmc">PMC4229119</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0111899</ArticleId><ArticleId IdType="pii">PONE-D-14-20886</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klein WL, Krafft G, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum. Trends Neurosci 24: 219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ (2012) Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction. Cold Spring Harb Perspect Med 2: a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, et al. (2012) Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33: 813 &#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683475</ArticleId></ArticleIdList></Reference><Reference><Citation>Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127: 2264&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, et al. (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, et al. (2013) New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 9: 99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8: e67898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699502</ArticleId><ArticleId IdType="pubmed">23844122</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, et al. (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79: 887&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nabavi S, Malinow R (2013) Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A 110: 4033&#x2013;4038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593880</ArticleId><ArticleId IdType="pubmed">23431156</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, et al. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66: 739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al. (2013) Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136: 1383&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam TI, Song S, Gwon Y, Park H, Yan JJ, et al. (2013) FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest 123: 2791&#x2013;2802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696552</ArticleId><ArticleId IdType="pubmed">23921129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, et al. (2012) Amyloid beta peptide 1&#x2013;42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51: 95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22177709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, et al. (2013) Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32: 2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831312</ArticleId><ArticleId IdType="pubmed">24065130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10: 64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22156588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52: 831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, et al. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33: 274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16962789</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, et al. (2011) Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 32: 614&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446369</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, et al. (2006) The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 6: 597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712494</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello E, Epis R, Di Luca M (2008) Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur J Pharmacol 585: 109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18377893</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola KL, Velasco PT, Klein WL (2008) Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 12: 51S&#x2013;57S.</Citation><ArticleIdList><ArticleId IdType="pubmed">18165846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, et al. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36: 293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782414</ArticleId><ArticleId IdType="pubmed">19660551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, et al. (2013) Human LilrB2 Is a b-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science 341: 1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469: 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, et al. (2014) Alzheimer's therapeutics targeting Amyloid beta 1&#x2013;42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS ONE 10: e0111898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229098</ArticleId><ArticleId IdType="pubmed">25390368</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard BE (2004) Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 37 Suppl 3 S166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15547782</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, et al. (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2: 380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624020</ArticleId><ArticleId IdType="pubmed">21730960</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe HJ, Ahmed IS, Twist KE, Craven RJ (2009) PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 121: 14&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659782</ArticleId><ArticleId IdType="pubmed">18992768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill MA (2007) Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 105: 16&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17583495</ArticleId></ArticleIdList></Reference><Reference><Citation>Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, Weinandy F, Waidelich M, et al. (2007) Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 6: 283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir SU, Ahmed IS, Arnold S, Craven RJ (2012) Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 131: E1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21918976</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41: 345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79: 595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathy ME, Prasad PD, Huang W, Seth P, Leibach FH, et al. (1999) Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J Pharmacol Exp Ther 289: 251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">10087012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J (2013) Regulation of dopamine D receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience 248C: 112&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796121</ArticleId><ArticleId IdType="pubmed">23732230</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM (2012) The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain. Brain Res 1450: 138&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319647</ArticleId><ArticleId IdType="pubmed">22440675</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, et al. (2008) Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 22: 151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">18498028</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135: 2155&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381721</ArticleId><ArticleId IdType="pubmed">22637583</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, et al. (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106: 4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, et al. (2011) Abeta(1&#x2013;42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14: 545&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, et al. (2012) Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer 106: 693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322954</ArticleId><ArticleId IdType="pubmed">22251921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Rothfuss JM, Zhang J, Vangveravong S, Chu W, et al. (2013) Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal Biochem 448C: 68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923374</ArticleId><ArticleId IdType="pubmed">24333652</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, et al. (2014) A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci 34: 2884&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608513</ArticleId><ArticleId IdType="pubmed">24553930</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczesna-Skorupa E, Kemper B (2011) Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 79: 340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061357</ArticleId><ArticleId IdType="pubmed">21081644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte I, Jeckel D, Wieland FT, Sohn K (2000) Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim Biophys Acta 1543: 123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087948</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilner BJ, John CS, Bowen WD (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">7812973</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, et al. (2000) Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20: 1386&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772358</ArticleId><ArticleId IdType="pubmed">10662829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT (2011) Caspase activation without apoptosis: insight into Abeta initiation of neurodegeneration. Nat Neurosci 14: 5&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21187847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir SU, Schwarze S, Jin L, Zhang J, Friend W, et al... (2013) Sigma-2 receptor associates with MAP1-LC3B and promotes autophagy.</Citation></Reference><Reference><Citation>Ahmed IS, Rohe HJ, Twist KE, Craven RJ (2010) Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 285: 24775&#x2013;24782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915713</ArticleId><ArticleId IdType="pubmed">20538600</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P, Pang Y, Dong J (2014) Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology: en20131991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929737</ArticleId><ArticleId IdType="pubmed">24424068</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33 Suppl 1 S49&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22785404</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2013) SnapShot: Pathobiology of Alzheimer's Disease. Cell 154: 468&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pubmed">23870132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25390368</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.</ArticleTitle><Pagination><StartPage>e111898</StartPage><MedlinePgn>e111898</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e111898</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0111898</ELocationID><Abstract><AbstractText>Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1-42 oligomers is proposed to underlie cognitive decline in Alzheimer's disease (AD). Alterations in membrane trafficking induced by Abeta oligomers mediates reduction in neuronal surface receptor expression that is the basis for inhibition of electrophysiological measures of synaptic plasticity and thus learning and memory. We have utilized phenotypic screens in mature, in vitro cultures of rat brain cells to identify small molecules which block or prevent the binding and effects of Abeta oligomers. Synthetic Abeta oligomers bind saturably to a single site on neuronal synapses and induce deficits in membrane trafficking in neuronal cultures with an EC50 that corresponds to its binding affinity. The therapeutic lead compounds we have found are pharmacological antagonists of Abeta oligomers, reducing the binding of Abeta oligomers to neurons in vitro, preventing spine loss in neurons and preventing and treating oligomer-induced deficits in membrane trafficking. These molecules are highly brain penetrant and prevent and restore cognitive deficits in mouse models of Alzheimer's disease. Counter-screening these compounds against a broad panel of potential CNS targets revealed they are highly potent and specific ligands of the sigma-2/PGRMC1 receptor. Brain concentrations of the compounds corresponding to greater than 80% receptor occupancy at the sigma-2/PGRMC1 receptor restore cognitive function in transgenic hAPP Swe/Ldn mice. These studies demonstrate that synthetic and human-derived Abeta oligomers act as pharmacologically-behaved ligands at neuronal receptors--i.e. they exhibit saturable binding to a target, they exert a functional effect related to their binding and their displacement by small molecule antagonists blocks their functional effect. The first-in-class small molecule receptor antagonists described here restore memory to normal in multiple AD models and sustain improvement long-term, representing a novel mechanism of action for disease-modifying Alzheimer's therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Izzo</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staniszewski</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>To</LastName><ForeName>Lillian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fa</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teich</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wostein</LastName><ForeName>Harrison</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walko</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaswani</LastName><ForeName>Anisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wardius</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Zanobia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravenscroft</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozzoni</LastName><ForeName>Kelsie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silky</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehak</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurko</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Look</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rishton</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safferstein</LastName><ForeName>Hank</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Miles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johanson</LastName><ForeName>Conrad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stopa</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windisch</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroScios, GmbH, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutter-Paier</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>QPS Austria GmbH, Grambach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamloo</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeVine</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS-083175</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-37337</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 NS083175</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-49442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AG037337</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>NI, HW, TW, AV, MW, ZS, JR, KM, CS, CR, RY, PF, GL, GR, MS, HS, SC, are employees or paid consultants of Cognition Therapeutics. HL owns stock or stock options of Cognition Therapeutics. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25390368</ArticleId><ArticleId IdType="pmc">PMC4229098</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0111898</ArticleId><ArticleId IdType="pii">PONE-D-14-20885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127: 2264&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, et al.. (2012) Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33: : 825 e821&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683475</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, et al. (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, et al. (2013) New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 9: 99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8: e67898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699502</ArticleId><ArticleId IdType="pubmed">23844122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, et al. (2013) Human LilrB2 Is a &#x3b2;-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science 341: 1399&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469: 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, et al. (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136: 1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, et al. (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79: 887&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nabavi S, Malinow R (2013) Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A 110: 4033&#x2013;4038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593880</ArticleId><ArticleId IdType="pubmed">23431156</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, et al. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66: 739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al. (2013) Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136: 1383&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam TI, Song S, Gwon Y, Park H, Yan JJ, et al. (2013) FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest 123: 2791&#x2013;2802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696552</ArticleId><ArticleId IdType="pubmed">23921129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, et al. (2012) Amyloid beta peptide 1&#x2013;42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51: 95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22177709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, et al. (2013) Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32: 2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831312</ArticleId><ArticleId IdType="pubmed">24065130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10: 64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22156588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52: 831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, et al. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33: 274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16962789</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese B, Shaked GM, Tabarean IV, Braga J, Koo EH, et al. (2007) Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci 35: 183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268524</ArticleId><ArticleId IdType="pubmed">17368908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, et al. (2010) Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13: 190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, et al. (2011) Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 32: 614&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446369</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, et al. (2006) The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 6: 597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712494</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello E, Epis R, Di Luca M (2008) Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur J Pharmacol 585: 109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18377893</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola KL, Velasco PT, Klein WL (2008) Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 12: 51S&#x2013;57S.</Citation><ArticleIdList><ArticleId IdType="pubmed">18165846</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, et al. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36: 293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782414</ArticleId><ArticleId IdType="pubmed">19660551</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, De Strooper B (2013) Promiscuous Alzheimer's Amyloid: Yet Another Partner. Science 341: 1354&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">24052299</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41: 345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79: 595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701763</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, et al. (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, et al. (2011) A longitudinal study of behavioral deficits in an AbetaPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 25: 231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944527</ArticleId><ArticleId IdType="pubmed">21403389</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, et al. (2012) Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav 2: 142&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345358</ArticleId><ArticleId IdType="pubmed">22574282</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H III (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335: 81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathy ME, Prasad PD, Huang W, Seth P, Leibach FH, et al. (1999) Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J Pharmacol Exp Ther 289: 251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">10087012</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre V, Nicholls J (1998) Neural circuits and networks. Berlin; New York: Springer. viii, 247 p. p.</Citation></Reference><Reference><Citation>Kaech S, Banker G (2006) Culturing hippocampal neurons. Nat Protoc 1: 2406&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Fong DK, Craig AM (2006) Postsynaptic protein mobility in dendritic spines: long-term regulation by synaptic NMDA receptor activation. Mol Cell Neurosci 31: 702&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gortz P, Fleischer W, Rosenbaum C, Otto F, Siebler M (2004) Neuronal network properties of human teratocarcinoma cell line-derived neurons. Brain Res 1018: 18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, et al. (2008) Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321: 1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Teplow DB (2012) Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 107: 101&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482449</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, et al. (1999) Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry 38: 10424&#x2013;10431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441137</ArticleId></ArticleIdList></Reference><Reference><Citation>Price PJ, Brewer GJ (2001) Serum-Free Media for Neural Cell Cultures. In: Fedoroff S, Richardson A, editors. Protocols for Neural Cell Culture. 3rd ed. Totowa, N.J.: Humana Press. pp. 255.</Citation></Reference><Reference><Citation>Liu Y, Schubert D (1997) Cytotoxic Amyloid Peptides Inhibit Cellular 3- (4,5-Dimethylthiazol-2-yl) -2,5-Diphenyltetrazolium Bromide (MTT) Reduction by Enhancing MTT Formazan Exocytosis. J Neurochem 69.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, et al. (2007) Combining the Rapid MTT Formazan Exocytosis Assay and the MC65 Protection Assay Led to the Discovery of Carbazole Analogs as Small-Molecule Inhibitors of A&#x3b2; Oligomer-Induced Cytotoxicity. Brain Res 1130: 223&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880896</ArticleId><ArticleId IdType="pubmed">17157826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutzmann P, Wolf G, Kupsch K (2010) Minocycline recovers MTT-formazan exocytosis impaired by amyloid beta peptide. Cell Mol Neurobiol 30: 979&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11498743</ArticleId><ArticleId IdType="pubmed">20455019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenili D, Brown M, Rappaport R, McLaurin J (2007) Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl) 85: 603&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7478269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner AM, Housley M, Murphy MP, LeVine H III (2011) Purified high molecular weight synthetic Abeta (1&#x2013;42) and biological Abeta oligomers are equipotent in rapidly inducing MTT formazan exocytosis. Neurosci Lett 497: 1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110692</ArticleId><ArticleId IdType="pubmed">21504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100: 23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, et al. (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282: 2646&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135262</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, et al. (2011) Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging 32: 1784&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895944</ArticleId><ArticleId IdType="pubmed">20031278</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27: 1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, et al. (2005) Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25: 6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Hashimoto T, Roe AD, Hori Y, Spires-Jones TL, et al. (2013) Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J 27: 3239&#x2013;3248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714573</ArticleId><ArticleId IdType="pubmed">23640054</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E (2001) Early for-mation of mature amyloid-beta protein deposits in a mutant APP transgenicmodel depends on levels of Abeta(1&#x2013;42). Journal of Neuroscience Research 66: 573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo NJ, Xu J, Zeng C, Kirk M, Mozzoni K, et al. (2014) Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE 10: e0111899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229119</ArticleId><ArticleId IdType="pubmed">25390692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. (2003) APP processing and synaptic function. Neuron 37: 925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, et al. (2006) A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 98: 57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805796</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dargusch R, Banh C, Miller CA, Schubert D (2004) Detecting bioactive amyloid beta peptide species in Alzheimer's disease. J Neurochem 91: 648&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana S, Hong HS, Barrigan L, Jin LW, Hua DH (2009) Syntheses of tricyclic pyrones and pyridinones and protection of Abeta-peptide induced MC65 neuronal cell death. Bioorg Med Chem Lett 19: 670&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">19121940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, et al. (2009) Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo . J Neurochem 108: 1097&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748761</ArticleId><ArticleId IdType="pubmed">19141069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronicke R, Klemm A, Meinhardt J, Schroder UH, Fandrich M, et al. (2008) Abeta mediated diminution of MTT reduction&#x2013;an artefact of single cell culture? PLoS One 3: e3236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2529401</ArticleId><ArticleId IdType="pubmed">18800168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Balazs R, Thornton PL, Cotman CW (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 24: 6799&#x2013;6809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729714</ArticleId><ArticleId IdType="pubmed">15282285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne SE (2013) Breaking the Code of Amyloid- Oligomers. Int J Cell Biol 2013: 950783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773433</ArticleId><ArticleId IdType="pubmed">24072999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, et al. (2014) Genetic Modulation of Soluble Abeta Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease. J Neurosci 34: 7871&#x2013;7885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25391305</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>23</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT.</ArticleTitle><Pagination><StartPage>2158</StartPage><EndPage>2166</EndPage><MedlinePgn>2158-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001050</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cognitive performance in elderly people with elevated homocysteine (Hcy) levels.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, double-blind, randomized, placebo-controlled trial included 2,919 elderly participants (65 years and older) with Hcy levels between 12 and 50 &#xb5;mol/L. Participants received daily either a tablet with 400 &#xb5;g folic acid and 500 &#xb5;g vitamin B12 (B-vitamin group) or a placebo tablet. Both tablets contained 15 &#xb5;g vitamin D3. Data were available for global cognitive functioning assessed by Mini-Mental State Examination (n = 2,556), episodic memory (n = 2,467), attention and working memory (n = 759), information processing speed (n = 731), and executive function (n = 721).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age was 74.1 (SD 6.5) years. Hcy concentrations decreased 5.0 (95% confidence interval -5.3 to -4.7) &#xb5;mol/L in the B-vitamin group and 1.3 (-1.6 to -0.9) &#xb5;mol/L in the placebo group. Cognitive domain scores did not differ over time between the 2 groups, as determined by analysis of covariance. Mini-Mental State Examination score decreased with 0.1 (-0.2 to 0.0) in the B-vitamin group and 0.3 (-0.4 to -0.2) in the placebo group (p = 0.05), as determined by an independent t test.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Two-year folic acid and vitamin B12 supplementation did not beneficially affect performance on 4 cognitive domains in elderly people with elevated Hcy levels. It may slightly slow the rate of decline of global cognition, but the reported small difference may be attributable to chance.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class I evidence that 2-year supplementation with folic acid and vitamin B12 in hyperhomocysteinemic elderly people does not affect cognitive performance.</AbstractText><CopyrightInformation>&#xa9; 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Zwaluw</LastName><ForeName>Nikita L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhonukshe-Rutten</LastName><ForeName>Rosalie A M</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands. Rosalie.Dhonukshe-Rutten@wur.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wijngaarden</LastName><ForeName>Janneke P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwer-Brolsma</LastName><ForeName>Elske M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Rest</LastName><ForeName>Ondine</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>In 't Veld</LastName><ForeName>Paulette H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enneman</LastName><ForeName>Anke W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Suzanne C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ham</LastName><ForeName>Annelies C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swart</LastName><ForeName>Karin M A</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Velde</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Schoor</LastName><ForeName>Natasja M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Cammen</LastName><ForeName>Tischa J M</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lips</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessels</LastName><ForeName>Roy P C</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Groot</LastName><ForeName>Lisette C P G M</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (N.L.v.d.Z., R.A.M.D.-R., J.P.v.W., E.M.B.-B., O.v.d.R., P.H.I.t.V., L.C.P.G.M.d.G.), Wageningen University; Department of Internal Medicine (A.W.E., S.C.v.D., A.C.H., N.v.d.V., T.J.M.v.d.C., A.G.U.), Erasmus University Medical Center, Rotterdam; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research (K.M.A.S., N.M.v.S., P.L.), and Department of Internal Medicine, Endocrine Section (P.L.), VU University Medical Center, Amsterdam; Radboud Alzheimer Center (R.P.C.K.) and Department of Medical Psychology (R.P.C.K.), Radboud University Medical Center, Nijmegen; and Donders Institute for Brain, Cognition and Behavior (R.P.C.K.), Radboud University Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>935E97BOY8</RegistryNumber><NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6YC3EG204</RegistryNumber><NameOfSubstance UI="D014805">Vitamin B 12</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014805" MajorTopicYN="N">Vitamin B 12</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25391305</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001050</ArticleId><ArticleId IdType="pii">WNL.0000000000001050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25392495</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>46</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>ATP13A2/PARK9 regulates secretion of exosomes and &#x3b1;-synuclein.</ArticleTitle><Pagination><StartPage>15281</StartPage><EndPage>15287</EndPage><MedlinePgn>15281-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1629-14.2014</ELocationID><Abstract><AbstractText>Kufor-Rakeb syndrome (KRS) is caused by loss-of-function mutations in ATP13A2 (PARK9) and characterized by juvenile-onset parkinsonism, pyramidal signs, and cognitive decline. Previous studies suggested that PARK9 deficiency causes lysosomal dysfunction and &#x3b1;-synuclein (&#x3b1;-syn) accumulation, whereas PARK9 overexpression suppresses toxicity of &#x3b1;-syn. However, the precise mechanism of PARK9 effect on lysosomes and &#x3b1;-syn has been unknown. Here, we found that overexpressed PARK9 localized to multivesicular bodies (MVBs) in the human H4 cell line. The results from patient fibroblasts showed that loss of PARK9 function leads to decreased number of the intraluminal vesicles in MVBs and diminished release of exosomes into culture media. By contrast, overexpression of PARK9 results in increased release of exosomes in H4 cells and mouse primary cortical neurons. Moreover, loss of PARK9 function resulted in decreased secretion of &#x3b1;-syn into extracellular space, whereas overexpressed PARK9 promotes secretion of &#x3b1;-syn, at least in part via exosomes. Finally, we found that PARK9 regulates exosome biogenesis through functional interaction with the endosomal sorting complex required for transport machinery. Together, these data suggest the involvement of PARK9 in the biogenesis of exosomes and &#x3b1;-syn secretion and raise a possibility that disruption of these pathways in patients with KRS contributes to the disease pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3415281-07$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsunemi</LastName><ForeName>Taiji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Kana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 krainc@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS076054</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS076054</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514983">ATP13A2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.14</RegistryNumber><NameOfSubstance UI="D006180">Proton-Translocating ATPases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C537177">Kufor-Rakeb syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056827" MajorTopicYN="N">Endosomal Sorting Complexes Required for Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006180" MajorTopicYN="N">Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATP13A2</Keyword><Keyword MajorTopicYN="N">PARK9</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">exosome</Keyword><Keyword MajorTopicYN="N">multivesicular body</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25392495</ArticleId><ArticleId IdType="pmc">PMC4228131</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1629-14.2014</ArticleId><ArticleId IdType="pii">34/46/15281</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42:360&#x2013;367. doi: 10.1016/j.nbd.2011.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.029</ArticleId><ArticleId IdType="pmc">PMC3107939</ArticleId><ArticleId IdType="pubmed">21303699</ArticleId></ArticleIdList></Reference><Reference><Citation>Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010;9:1128&#x2013;1138. doi: 10.1016/S1474-4422(10)70213-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70213-1</ArticleId><ArticleId IdType="pubmed">20846907</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsen KB, Palmgren MG. Evolution of substrate specificities in the P-type ATPase superfamily. J Mol Evol. 1998;46:84&#x2013;101. doi: 10.1007/PL00006286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00006286</ArticleId><ArticleId IdType="pubmed">9419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bache KG, Brech A, Mehlum A, Stenmark H. Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes. J Cell Biol. 2003;162:435&#x2013;442. doi: 10.1083/jcb.200302131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200302131</ArticleId><ArticleId IdType="pmc">PMC2172703</ArticleId><ArticleId IdType="pubmed">12900395</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Th&#xe9;ry C, Raposo G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126:5553&#x2013;5565. doi: 10.1242/jcs.128868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.128868</ArticleId><ArticleId IdType="pubmed">24105262</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42. doi: 10.1186/1750-1326-7-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-42</ArticleId><ArticleId IdType="pmc">PMC3483256</ArticleId><ArticleId IdType="pubmed">22920859</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A. 2012;109:9611&#x2013;9616. doi: 10.1073/pnas.1112368109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112368109</ArticleId><ArticleId IdType="pmc">PMC3386132</ArticleId><ArticleId IdType="pubmed">22647602</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010&#x2013;13015. doi: 10.1073/pnas.0903691106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903691106</ArticleId><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D. &#x3b1;-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17:1945&#x2013;1947. doi: 10.1096/fj.03-0098fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-0098fje</ArticleId><ArticleId IdType="pubmed">14519670</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced &#x3b1;-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838&#x2013;6851. doi: 10.1523/JNEUROSCI.5699-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5699-09.2010</ArticleId><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgui&#xe8;res T, Luyet PP, Bissig C, Scott CC, Velluz MC, Gruenberg J. In vitro budding of intralumenal vesicles into late endosomes is regulated by Alix and Tsg101. Mol Biol Cell. 2008;19:4942&#x2013;4955. doi: 10.1091/mbc.E08-03-0239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E08-03-0239</ArticleId><ArticleId IdType="pmc">PMC2575168</ArticleId><ArticleId IdType="pubmed">18768755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009;41:308&#x2013;315. doi: 10.1038/ng.300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.300</ArticleId><ArticleId IdType="pmc">PMC2683786</ArticleId><ArticleId IdType="pubmed">19182805</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald A, Arns B, Seibler P, Rakovic A, M&#xfc;nchau A, Ramirez A, Sue CM, Klein C. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor&#x2013;Rakeb syndrome. Neurobiol Aging. 2012;33:1843e1&#x2013;1843e7. doi: 10.1016/j.neurobiolaging.2011.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.035</ArticleId><ArticleId IdType="pubmed">22296644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusdon AM, Zhu J, Van Houten B, Chu CT. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol Dis. 2012;45:962&#x2013;972. doi: 10.1016/j.nbd.2011.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.015</ArticleId><ArticleId IdType="pmc">PMC3291101</ArticleId><ArticleId IdType="pubmed">22198378</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345:27&#x2013;32. doi: 10.1016/0014-5793(94)00395-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(94)00395-5</ArticleId><ArticleId IdType="pubmed">8194594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouvenet N. Dynamics of ESCRT proteins. Cell Mol Life Sci. 2012;69:4121&#x2013;4133. doi: 10.1007/s00018-012-1035-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-1035-0</ArticleId><ArticleId IdType="pmc">PMC11114710</ArticleId><ArticleId IdType="pubmed">22669260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BY, Olzmann JA, Barsh GS, Chin LS, Li L. Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol Biol Cell. 2007;18:1129&#x2013;1142. doi: 10.1091/mbc.E06-09-0787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E06-09-0787</ArticleId><ArticleId IdType="pmc">PMC1838976</ArticleId><ArticleId IdType="pubmed">17229889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Stang E, Fang KS, de Moerloose P, Parton RG, Gruenberg J. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature. 1998;392:193&#x2013;197. doi: 10.1038/32440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/32440</ArticleId><ArticleId IdType="pubmed">9515966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Vischer UM, Rosnoblet C, Lebrand C, Lindsay M, Parton RG, Kruithof EK, Gruenberg J. The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell. 2000;11:1829&#x2013;1843. doi: 10.1091/mbc.11.5.1829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.11.5.1829</ArticleId><ArticleId IdType="pmc">PMC14887</ArticleId><ArticleId IdType="pubmed">10793155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong SM, Chan BK, Park JS, Hill KJ, Aitken JB, Cottle L, Farghaian H, Cole AR, Lay PA, Sue CM, Cooper AA. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes &#x3b1;-Synuclein externalization via exosomes. Hum Mol Genet. 2014;23:2816&#x2013;2833. doi: 10.1093/hmg/ddu099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu099</ArticleId><ArticleId IdType="pubmed">24603074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CP, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol. 2012;3:228. doi: 10.3389/fphys.2012.00228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00228</ArticleId><ArticleId IdType="pmc">PMC3384085</ArticleId><ArticleId IdType="pubmed">22754538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016&#x2013;6024. doi: 10.1523/JNEUROSCI.0692-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0692-05.2005</ArticleId><ArticleId IdType="pmc">PMC6724798</ArticleId><ArticleId IdType="pubmed">15976091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol. 2012;44:11&#x2013;15. doi: 10.1016/j.biocel.2011.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2011.10.005</ArticleId><ArticleId IdType="pubmed">22024155</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953. doi: 10.1126/science.1227157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mane SM, Marzella L, Bainton DF, Holt VK, Cha Y, Hildreth JE, August JT. Purification and characterization of human lysosomal membrane glycoproteins. Arch Biochem Biophys. 1989;268:360&#x2013;378. doi: 10.1016/0003-9861(89)90597-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9861(89)90597-3</ArticleId><ArticleId IdType="pubmed">2912382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37&#x2013;52. doi: 10.1016/j.cell.2011.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.06.001</ArticleId><ArticleId IdType="pmc">PMC3132082</ArticleId><ArticleId IdType="pubmed">21700325</ArticleId></ArticleIdList></Reference><Reference><Citation>Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor&#x2013;Rakeb syndrome. Acta Neurol Scand. 1994;89:347&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">8085432</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord. 2013;28:31&#x2013;40. doi: 10.1002/mds.25373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25373</ArticleId><ArticleId IdType="pubmed">23390095</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Mehta P, Cooper AA, Veivers D, Heimbach A, Stiller B, Kubisch C, Fung VS, Krainc D, Mackay-Sim A, Sue CM. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor&#x2013;Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat. 2011;32:956&#x2013;964. doi: 10.1002/humu.21527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21527</ArticleId><ArticleId IdType="pubmed">21542062</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum Mol Genet. 2014;23:2802&#x2013;2815. doi: 10.1093/hmg/ddt623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt623</ArticleId><ArticleId IdType="pmc">PMC4014187</ArticleId><ArticleId IdType="pubmed">24399444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172&#x2013;11177. doi: 10.1073/pnas.0603838103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0603838103</ArticleId><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, Heimbach A, Gr&#xfc;ndemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184&#x2013;1191. doi: 10.1038/ng1884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1884</ArticleId><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramonet D, Podhajska A, Stafa K, Sonnay S, Trancikova A, Tsika E, Pletnikova O, Troncoso JC, Glauser L, Moore DJ. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet. 2012;21:1725&#x2013;1743. doi: 10.1093/hmg/ddr606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr606</ArticleId><ArticleId IdType="pmc">PMC3465694</ArticleId><ArticleId IdType="pubmed">22186024</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161&#x2013;1172. doi: 10.1084/jem.183.3.1161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.183.3.1161</ArticleId><ArticleId IdType="pmc">PMC2192324</ArticleId><ArticleId IdType="pubmed">8642258</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287:3842&#x2013;3849. doi: 10.1074/jbc.M111.277061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.277061</ArticleId><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Short JR, Knox C, Dorrington RA. Subcellular localization and live-cell imaging of the Helicoverpa armigera stunt virus replicase in mammalian and Spodoptera frugiperda cells. J Gen Virol. 2010;91:1514&#x2013;1523. doi: 10.1099/vir.0.020156-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.020156-0</ArticleId><ArticleId IdType="pubmed">20107015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheis PJ, Fleming SM, Clippinger AK, Lewis J, Tsunemi T, Giasson B, Dickson DW, Mazzulli JR, Bardgett ME, Haik KL, Ekhator O, Chava AK, Howard J, Gannon M, Hoffman E, Chen Y, Prasad V, Linn SC, Tamargo RJ, Westbroek W, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet. 2013;22:2067&#x2013;2082. doi: 10.1093/hmg/ddt057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt057</ArticleId><ArticleId IdType="pmc">PMC3633373</ArticleId><ArticleId IdType="pubmed">23393156</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Raposo G. Exosomes: vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575&#x2013;581. doi: 10.1016/j.ceb.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2009.03.007</ArticleId><ArticleId IdType="pubmed">19442504</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics. 2008;8:4083&#x2013;4099. doi: 10.1002/pmic.200800109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200800109</ArticleId><ArticleId IdType="pubmed">18780348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai K, Toyoshima M, Tanaka N, Yamamoto N, Owada Y, Kiyonari H, Murata K, Ueno Y, Ono M, Shimosegawa T, Yaegashi N, Watanabe M, Sugamura K. Loss of hrs in the central nervous system causes accumulation of ubiquitinated proteins and neurodegeneration. Am J Pathol. 2008;173:1806&#x2013;1817. doi: 10.2353/ajpath.2008.080684.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080684</ArticleId><ArticleId IdType="pmc">PMC2626391</ArticleId><ArticleId IdType="pubmed">19008375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, Shiina M, Fukushima K, Hoshino T, Sano K, Ueno Y, Shimosegawa T, Sugamura K. Exosome secretion of dendritic cells is regulated by hrs, an ESCRT-0 protein. Biochem Biophys Res Commun. 2010;399:384&#x2013;390. doi: 10.1016/j.bbrc.2010.07.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.07.083</ArticleId><ArticleId IdType="pubmed">20673754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Zhang T, Jiang L, Chi J, Hu D, Pan Q, Wang D, Zhang Z. Regulation of intracellular manganese homeostasis by Kufor&#x2013;Rakeb syndrome-associated ATP13A2 protein. J Biol Chem. 2011;286:29654&#x2013;29662. doi: 10.1074/jbc.M111.233874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.233874</ArticleId><ArticleId IdType="pmc">PMC3191006</ArticleId><ArticleId IdType="pubmed">21724849</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuma F, Z&#xf6;ller M. Outsmart tumor exosomes to steal the cancer initiating cell its niche. Semin Cancer Biol. 2014;28C:39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24631836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006;349:162&#x2013;166. doi: 10.1016/j.bbrc.2006.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.08.024</ArticleId><ArticleId IdType="pubmed">16930553</ArticleId></ArticleIdList></Reference><Reference><Citation>Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Br&#xfc;gger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244&#x2013;1247. doi: 10.1126/science.1153124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153124</ArticleId><ArticleId IdType="pubmed">18309083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T, Krainc D. Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet. 2014;23:2791&#x2013;2801. doi: 10.1093/hmg/ddt572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt572</ArticleId><ArticleId IdType="pmc">PMC4014186</ArticleId><ArticleId IdType="pubmed">24334770</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski ER, Damian VA, Masliah E, La Spada AR. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med. 2012;4:142ra97. doi: 10.1126/scitranslmed.3003799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003799</ArticleId><ArticleId IdType="pmc">PMC4096245</ArticleId><ArticleId IdType="pubmed">22786682</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci. 2012a;32:4240&#x2013;4246. doi: 10.1523/JNEUROSCI.5575-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5575-11.2012</ArticleId><ArticleId IdType="pmc">PMC3462811</ArticleId><ArticleId IdType="pubmed">22442086</ArticleId></ArticleIdList></Reference><Reference><Citation>Usenovic M, Knight AL, Ray A, Wong V, Brown KR, Caldwell GA, Caldwell KA, Stagljar I, Krainc D. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum Mol Genet. 2012b;21:3785&#x2013;3794. doi: 10.1093/hmg/dds206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds206</ArticleId><ArticleId IdType="pmc">PMC3412378</ArticleId><ArticleId IdType="pubmed">22645275</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25392515</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>46</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Emerging roles of extracellular vesicles in the nervous system.</ArticleTitle><Pagination><StartPage>15482</StartPage><EndPage>15489</EndPage><MedlinePgn>15482-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3258-14.2014</ELocationID><Abstract><AbstractText>Information exchange executed by extracellular vesicles, including exosomes, is a newly described form of intercellular communication important in the development and physiology of neural systems. These vesicles can be released from cells, are packed with information including signaling proteins and both coding and regulatory RNAs, and can be taken up by target cells, thereby facilitating the transfer of multilevel information. Recent studies demonstrate their critical role in physiological processes, including nerve regeneration, synaptic function, and behavior. These vesicles also have a sinister role in the propagation of toxic amyloid proteins in neurodegenerative conditions, including prion diseases and Alzheimer's and Parkinson's diseases, in inducing neuroinflammation by exchange of information between the neurons and glia, as well as in aiding tumor progression in the brain by subversion of normal cells. This article provides a summary of topics covered in a symposium and is not meant to be a comprehensive review of the subject.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/3415482-08$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research and Graduate Schools of Zurich Neuroscience Center and Integrative Physiology, University of Zurich, 8006 Zurich, Switzerland, breakefield@hms.harvard.edu Rajendran@bli.uzh.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bali</LastName><ForeName>Jitin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research and Graduate Schools of Zurich Neuroscience Center and Integrative Physiology, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>Maureen M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0003-4483-2952</Identifier><AffiliationInfo><Affiliation>Human Genetics Institute, Department of Genetics, Rutgers University, Piscataway, New Jersey 08854.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Court</LastName><ForeName>Felipe A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Millenium Nucleus for Regenerative Biology, Faculty of Biology, Pontificia Universidad Catolica de Chile, Santiago, Chile, Neurounion Biomedical Foundation, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xe4;mer-Albers</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Molecular Cell Biology, and Focus Programme of Translational Neuroscience, University of Mainz, 55122 Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picou</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Millenium Nucleus for Regenerative Biology, Faculty of Biology, Pontificia Universidad Catolica de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raposo</LastName><ForeName>Gra&#xe7;a</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Curie, Centre de Recherche, F-75248 Paris, France, Structure and Membrane Compartments, Centre National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche 144, Paris F-75248, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Vos</LastName><ForeName>Kristan E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Niel</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Curie, Centre de Recherche, F-75248 Paris, France, Structure and Membrane Compartments, Centre National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche 144, Paris F-75248, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Human Genetics Institute, Department of Genetics, Rutgers University, Piscataway, New Jersey 08854.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breakefield</LastName><ForeName>Xandra O</ForeName><Initials>XO</Initials><Identifier Source="ORCID">0000-0001-6036-0399</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Radiology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02114 breakefield@hms.harvard.edu Rajendran@bli.uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01DK074746</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA069246</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK074746</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK059418</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA141150</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA141150</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK059418</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 CA179563</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002923" MajorTopicYN="N">Cilia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25392515</ArticleId><ArticleId IdType="pmc">PMC4228143</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3258-14.2014</ArticleId><ArticleId IdType="pii">34/46/15482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron. 2009;64:783&#x2013;790. doi: 10.1016/j.neuron.2009.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.12.016</ArticleId><ArticleId IdType="pubmed">20064386</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8:2014&#x2013;2018. doi: 10.4161/cc.8.13.8988.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.8.13.8988</ArticleId><ArticleId IdType="pubmed">19535896</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakeberg JL, Tammachote R, Woollard JR, Hogan MC, Tuan HF, Li M, van Deursen JM, Wu Y, Huang BQ, Torres VE, Harris PC, Ward CJ. Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin. J Am Soc Nephrol. 2011;22:2266&#x2013;2277. doi: 10.1681/ASN.2010111173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2010111173</ArticleId><ArticleId IdType="pmc">PMC3250208</ArticleId><ArticleId IdType="pubmed">22021705</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180. doi: 10.1038/ncomms1180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1180</ArticleId><ArticleId IdType="pmc">PMC3040683</ArticleId><ArticleId IdType="pubmed">21285958</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, Hetz C, Twiss JL, Alvarez J, Court FA. Axonal degeneration is mediated by the mitochondrial permeability transition pore. J Neurosci. 2011;31:966&#x2013;978. doi: 10.1523/JNEUROSCI.4065-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4065-10.2011</ArticleId><ArticleId IdType="pmc">PMC3245862</ArticleId><ArticleId IdType="pubmed">21248121</ArticleId></ArticleIdList></Reference><Reference><Citation>Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3&#x2032;-untranslated regions. Biol Direct. 2013;8:12. doi: 10.1186/1745-6150-8-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6150-8-12</ArticleId><ArticleId IdType="pmc">PMC3732077</ArticleId><ArticleId IdType="pubmed">23758897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 2012a;40:10937&#x2013;10949. doi: 10.1093/nar/gks832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks832</ArticleId><ArticleId IdType="pmc">PMC3505968</ArticleId><ArticleId IdType="pubmed">22965126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol. 2012b;3:124. doi: 10.3389/fphys.2012.00124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00124</ArticleId><ArticleId IdType="pmc">PMC3342525</ArticleId><ArticleId IdType="pubmed">22563321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrie A, Colombo M, Raposo G, Th&#xe9;ry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12:1659&#x2013;1668. doi: 10.1111/j.1600-0854.2011.01225.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2011.01225.x</ArticleId><ArticleId IdType="pubmed">21645191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari KI, Ogawa D, Balaj L, De Rienzo G, Mineo M, Nakano I, Ostrowski MC, Hochberg F, Weissleder R, Lawler SE, Chiocca EA, Godlewski J. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res. 2014;74:738&#x2013;750. doi: 10.1158/0008-5472.CAN-13-2650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-13-2650</ArticleId><ArticleId IdType="pmc">PMC3928601</ArticleId><ArticleId IdType="pubmed">24310399</ArticleId></ArticleIdList></Reference><Reference><Citation>Court FA, Alvarez J. Local regulation of the axonal phenotype, a case of merotrophism. Biol Res. 2005;38:365&#x2013;374. doi: 10.4067/S0716-97602005000400009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/S0716-97602005000400009</ArticleId><ArticleId IdType="pubmed">16579519</ArticleId></ArticleIdList></Reference><Reference><Citation>Court FA, Hendriks WT, MacGillavry HD, Alvarez J, van Minnen J. Schwann cell to axon transfer of ribosomes: toward a novel understanding of the role of glia in the nervous system. J Neurosci. 2008;28:11024&#x2013;11029. doi: 10.1523/JNEUROSCI.2429-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2429-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671360</ArticleId><ArticleId IdType="pubmed">18945910</ArticleId></ArticleIdList></Reference><Reference><Citation>Court FA, Midha R, Cisterna BA, Grochmal J, Shakhbazau A, Hendriks WT, Van Minnen J. Morphological evidence for a transport of ribosomes from Schwann cells to regenerating axons. Glia. 2011;59:1529&#x2013;1539. doi: 10.1002/glia.21196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21196</ArticleId><ArticleId IdType="pubmed">21656857</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Asti E, Garnier D, Lee TH, Montermini L, Meehan B, Rak J. Oncogenic extracellular vesicles in brain tumor progression. Front Physiol. 2012;3:294. doi: 10.3389/fphys.2012.00294.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00294</ArticleId><ArticleId IdType="pmc">PMC3429065</ArticleId><ArticleId IdType="pubmed">22934045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113&#x2013;123. doi: 10.1083/jcb.200207113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200207113</ArticleId><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>El Andaloussi S, M&#xe4;ger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347&#x2013;357. doi: 10.1038/nrd3978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3978</ArticleId><ArticleId IdType="pubmed">23584393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. PLoS Biol. 2006;4:e6. doi: 10.1371/journal.pbio.0040006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0040006</ArticleId><ArticleId IdType="pmc">PMC1288039</ArticleId><ArticleId IdType="pubmed">16300414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich D, Kuo WP, Fr&#xfc;hbeis C, Sun JJ, Zehendner CM, Luhmann HJ, Pinto S, Toedling J, Trotter J, Kr&#xe4;mer-Albers EM. Multifaceted effects of oligodendroglial exosomes on neurons: impact on neuronal firing rate, signal transduction, and gene regulation. Philos Trans R Soc Lond B Biol Sci. 2014;369 doi: 10.1098/rstb.2013.0510. pii20130510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2013.0510</ArticleId><ArticleId IdType="pmc">PMC4142031</ArticleId><ArticleId IdType="pubmed">25135971</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;hbeis C, Fr&#xf6;hlich D, Kuo WP, Kr&#xe4;mer-Albers EM. Extracellular vesicles as mediators of neuron&#x2013;glia communication. Front Cell Neurosci. 2013a;7:182. doi: 10.3389/fncel.2013.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00182</ArticleId><ArticleId IdType="pmc">PMC3812991</ArticleId><ArticleId IdType="pubmed">24194697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;hbeis C, Fr&#xf6;hlich D, Kuo WP, Amphornrat J, Thilemann S, Saab AS, Kirchhoff F, M&#xf6;bius W, Goebbels S, Nave KA, Schneider A, Simons M, Klugmann M, Trotter J, Kr&#xe4;mer-Albers EM. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol. 2013b;11:e1001604. doi: 10.1371/journal.pbio.1001604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001604</ArticleId><ArticleId IdType="pmc">PMC3706306</ArticleId><ArticleId IdType="pubmed">23874151</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier D, Jabado N, Rak J. Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. Proteomics. 2013;13:1595&#x2013;1607. doi: 10.1002/pmic.201200360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201200360</ArticleId><ArticleId IdType="pubmed">23505048</ArticleId></ArticleIdList></Reference><Reference><Citation>Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, Ceresa BP, Nixon RA, Cataldo AM. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem. 2003;278:31261&#x2013;31268. doi: 10.1074/jbc.M304122200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M304122200</ArticleId><ArticleId IdType="pubmed">12761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald J, Riek R. Biology of amyloid: structure, function, and regulation. Structure. 2010;18:1244&#x2013;1260. doi: 10.1016/j.str.2010.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2010.08.009</ArticleId><ArticleId IdType="pubmed">20947013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;rgy B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles&#x2013;clinical promise and open questions. Ann Rev Pharmacol Toxicol. 2014 doi: 10.1146/annurev-pharmtox-010814-124630. doi: 10.1146/annurev-pharmtox-010814-124630. Advance online publication.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124630</ArticleId><ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124630</ArticleId><ArticleId IdType="pmc">PMC4445965</ArticleId><ArticleId IdType="pubmed">25292428</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer ND, Wang X, McGuffie BA, Chapman MR. Amyloids: friend or foe? J Alzheimers Dis. 2008;13:407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674399</ArticleId><ArticleId IdType="pubmed">18487849</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124:2315&#x2013;2324. doi: 10.1172/JCI72272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI72272</ArticleId><ArticleId IdType="pmc">PMC4089452</ArticleId><ArticleId IdType="pubmed">24892705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg FH, Atai NA, Gonda D, Hughes MS, Mawejje B, Balaj L, Carter RS. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev Mol Diagn. 2014;14:439&#x2013;452. doi: 10.1586/14737159.2014.905202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.2014.905202</ArticleId><ArticleId IdType="pmc">PMC5451266</ArticleId><ArticleId IdType="pubmed">24746164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan MC, Manganelli L, Woollard JR, Masyuk AI, Masyuk TV, Tammachote R, Huang BQ, Leontovich AA, Beito TG, Madden BJ, Charlesworth MC, Torres VE, LaRusso NF, Harris PC, Ward CJ. Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol. 2009;20:278&#x2013;288. doi: 10.1681/ASN.2008060564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008060564</ArticleId><ArticleId IdType="pmc">PMC2637052</ArticleId><ArticleId IdType="pubmed">19158352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurbain I, Geerts WJ, Boudier T, Marco S, Verkleij AJ, Marks MS, Raposo G. Electron tomography of early melanosomes: implications for melanogenesis and the generation of fibrillar amyloid sheets. Proc Natl Acad Sci U S A. 2008;105:19726&#x2013;19731. doi: 10.1073/pnas.0803488105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0803488105</ArticleId><ArticleId IdType="pmc">PMC2604932</ArticleId><ArticleId IdType="pubmed">19033461</ArticleId></ArticleIdList></Reference><Reference><Citation>Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Diff. 2008;15:80&#x2013;88. doi: 10.1038/sj.cdd.4402237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402237</ArticleId><ArticleId IdType="pubmed">17932500</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH. Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. J Biol Chem. 2009;284:2296&#x2013;2306. doi: 10.1074/jbc.M808904200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808904200</ArticleId><ArticleId IdType="pmc">PMC2629115</ArticleId><ArticleId IdType="pubmed">19047044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CP, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front Physiol. 2012;3:228. doi: 10.3389/fphys.2012.00228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00228</ArticleId><ArticleId IdType="pmc">PMC3384085</ArticleId><ArticleId IdType="pubmed">22754538</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CC, Eaton SA, Young PE, Lee M, Shuttleworth R, Humphreys DT, Grau GE, Combes V, Bebawy M, Gong J, Brammah S, Buckland ME, Suter CM. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol. 2013;10:1333&#x2013;1344. doi: 10.4161/rna.25281.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.25281</ArticleId><ArticleId IdType="pmc">PMC3817155</ArticleId><ArticleId IdType="pubmed">23807490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Verrilli MA, Court FA. Transfer of vesicles from Schwann cells to axons: a novel mechanism of communication in the peripheral nervous system. Front Physiol. 2012;3:205. doi: 10.3389/fphys.2012.00205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00205</ArticleId><ArticleId IdType="pmc">PMC3374349</ArticleId><ArticleId IdType="pubmed">22707941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Verrilli MA, Court FA. Exosomes: mediators of communication in eukaryotes. Biol Res. 2013a;46:5&#x2013;11. doi: 10.4067/S0716-97602013000100001.</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/S0716-97602013000100001</ArticleId><ArticleId IdType="pubmed">23760408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Verrilli MA, Picou F, Court FA. Schwann cell-derived exosomes enhance axonal regeneration in the peripheral nervous system. Glia. 2013b;61:1795&#x2013;1806. doi: 10.1002/glia.22558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22558</ArticleId><ArticleId IdType="pubmed">24038411</ArticleId></ArticleIdList></Reference><Reference><Citation>Masyuk AI, Huang BQ, Ward CJ, Gradilone SA, Banales JM, Masyuk TV, Radtke B, Splinter PL, LaRusso NF. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol. 2010;299:G990&#x2013;G999. doi: 10.1152/ajpgi.00093.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00093.2010</ArticleId><ArticleId IdType="pmc">PMC2957333</ArticleId><ArticleId IdType="pubmed">20634433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468:244&#x2013;252. doi: 10.1038/nature09614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09614</ArticleId><ArticleId IdType="pubmed">21068833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte-'t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH, 't Hoen PA. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 2012;40:9272&#x2013;9285. doi: 10.1093/nar/gks658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks658</ArticleId><ArticleId IdType="pmc">PMC3467056</ArticleId><ArticleId IdType="pubmed">22821563</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hagan R, Wang J, Barr MM. Mating behavior, male sensory cilia, and polycystins in C. elegans. Semin Cell Dev Biol. 2014;33:25&#x2013;33. doi: 10.1016/j.semcdb.2014.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2014.06.001</ArticleId><ArticleId IdType="pmc">PMC4680976</ArticleId><ArticleId IdType="pubmed">24977333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampliega O, Orhon I, Patel B, Sridhar S, D&#xed;az-Carretero A, Beau I, Codogno P, Satir BH, Satir P, Cuervo AM. Functional interaction between autophagy and ciliogenesis. Nature. 2013;502:194&#x2013;200. doi: 10.1038/nature12639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12639</ArticleId><ArticleId IdType="pmc">PMC3896125</ArticleId><ArticleId IdType="pubmed">24089209</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Annaert W. Membrane trafficking pathways in Alzheimer's disease. Traffic. 2012;13:759&#x2013;770. doi: 10.1111/j.1600-0854.2012.01332.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2012.01332.x</ArticleId><ArticleId IdType="pubmed">22269004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172&#x2013;11177. doi: 10.1073/pnas.0603838103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0603838103</ArticleId><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Kn&#xf6;lker HJ, Simons K. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science. 2008;320:520&#x2013;523. doi: 10.1126/science.1156609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1156609</ArticleId><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Rak J. Extracellular vesicles: biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013;4:21. doi: 10.3389/fphar.2013.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2013.00021</ArticleId><ArticleId IdType="pmc">PMC3589665</ArticleId><ArticleId IdType="pubmed">23508692</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, Marks MS. Melanosomes: dark organelles enlighten endosomal membrane transport. Nat Rev Mol Cell Biol. 2007;8:786&#x2013;797. doi: 10.1038/nrm2258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2258</ArticleId><ArticleId IdType="pmc">PMC2786984</ArticleId><ArticleId IdType="pubmed">17878918</ArticleId></ArticleIdList></Reference><Reference><Citation>Redzic J, Balaj L, van der Vos K, Breakefield XO. Extracellular RNA mediates and marks cancer progression. Issue: Exosomes in immunity and cancer-friends or foes? Semin Cancer Biol. 2014a;28:14&#x2013;23. 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162815</ArticleId><ArticleId IdType="pubmed">24783980</ArticleId></ArticleIdList></Reference><Reference><Citation>Redzic JS, Ung TH, Graner MW. Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmgenomics Pes Med. 2014b;7:65&#x2013;77. doi: 10.2147/PGPM.S39768.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PGPM.S39768</ArticleId><ArticleId IdType="pmc">PMC3952682</ArticleId><ArticleId IdType="pubmed">24634586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, Marks MS, De Strooper B, Raposo G, van Niel G. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A. 2013;110:10658&#x2013;10663. doi: 10.1073/pnas.1220748110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1220748110</ArticleId><ArticleId IdType="pmc">PMC3696817</ArticleId><ArticleId IdType="pubmed">23754390</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Rajendran L, Honsho M, Gralle M, Donnert G, Wouters F, Hell SW, Simons M. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci. 2008;28:2874&#x2013;2882. doi: 10.1523/JNEUROSCI.5345-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5345-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670660</ArticleId><ArticleId IdType="pubmed">18337418</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmo M, K&#xf6;ttgen M, Hofherr A. The TRPP subfamily and polycystin-1 proteins. Handb Exp Pharmacol. 2014;222:675&#x2013;711. doi: 10.1007/978-3-642-54215-2_27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-54215-2_27</ArticleId><ArticleId IdType="pubmed">24756726</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Raposo G. Exosomes: vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21:575&#x2013;581. doi: 10.1016/j.ceb.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2009.03.007</ArticleId><ArticleId IdType="pubmed">19442504</ArticleId></ArticleIdList></Reference><Reference><Citation>Skog J, W&#xfc;rdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT, Jr, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470&#x2013;1476. doi: 10.1038/ncb1800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1800</ArticleId><ArticleId IdType="pmc">PMC3423894</ArticleId><ArticleId IdType="pubmed">19011622</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic. 2002;3:321&#x2013;330. doi: 10.1034/j.1600-0854.2002.30502.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0854.2002.30502.x</ArticleId><ArticleId IdType="pubmed">11967126</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879. doi: 10.1016/S0002-9440(10)64463-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64463-X</ArticleId><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Okada Y, Hirokawa N. FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination. Nature. 2005;435:172&#x2013;177. doi: 10.1038/nature03494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03494</ArticleId><ArticleId IdType="pubmed">15889083</ArticleId></ArticleIdList></Reference><Reference><Citation>Theos AC, Truschel ST, Raposo G, Marks MS. The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 2005;18:322&#x2013;336. doi: 10.1111/j.1600-0749.2005.00269.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0749.2005.00269.x</ArticleId><ArticleId IdType="pmc">PMC2788625</ArticleId><ArticleId IdType="pubmed">16162173</ArticleId></ArticleIdList></Reference><Reference><Citation>Theos AC, Truschel ST, Tenza D, Hurbain I, Harper DC, Berson JF, Thomas PC, Raposo G, Marks MS. A lumenal domain-dependent pathway for sorting to intralumenal vesicles of multivesicular endosomes involved in organelle morphogenesis. Dev Cell. 2006;10:343&#x2013;354. doi: 10.1016/j.devcel.2006.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2006.01.012</ArticleId><ArticleId IdType="pmc">PMC1773005</ArticleId><ArticleId IdType="pubmed">16516837</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581&#x2013;593. doi: 10.1038/nri2567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2567</ArticleId><ArticleId IdType="pubmed">19498381</ArticleId></ArticleIdList></Reference><Reference><Citation>Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med. 2014;20:385&#x2013;393. doi: 10.1016/j.molmed.2014.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2014.03.002</ArticleId><ArticleId IdType="pmc">PMC4082760</ArticleId><ArticleId IdType="pubmed">24703619</ArticleId></ArticleIdList></Reference><Reference><Citation>van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Saftig P, Marks MS, Rubinstein E, Raposo G. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev Cell. 2011;21:708&#x2013;721. doi: 10.1016/j.devcel.2011.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.08.019</ArticleId><ArticleId IdType="pmc">PMC3199340</ArticleId><ArticleId IdType="pubmed">21962903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella LJ, Sharples RA, Nisbet RM, Cappai R, Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J. 2008;37:323&#x2013;332. doi: 10.1007/s00249-007-0246-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00249-007-0246-z</ArticleId><ArticleId IdType="pubmed">18064447</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas R, Martinez NW, Lillo J, Pihan P, Hernandez D, Twiss JL, Court FA. Calcium release from intra-axonal endoplasmic reticulum leads to axon degeneration through mitochondrial dysfunction. J Neurosci. 2014;34:7179&#x2013;7189. doi: 10.1523/JNEUROSCI.4784-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4784-13.2014</ArticleId><ArticleId IdType="pmc">PMC4028495</ArticleId><ArticleId IdType="pubmed">24849352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Silva M, Haas LA, Morsci NS, Nguyen KC, Hall DH, Barr MM. C. elegans ciliated sensory neurons release extracellular vesicles that function in animal communication. Curr Biol. 2014;24:519&#x2013;525. doi: 10.1016/j.cub.2014.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC4659354</ArticleId><ArticleId IdType="pubmed">24530063</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt B, van Niel G, Raposo G, Marks MS. PMEL: a pigment cell-specific model for functional amyloid formation. Pigment Cell Melanoma Res. 2013;26:300&#x2013;315. doi: 10.1111/pcmr.12067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pcmr.12067</ArticleId><ArticleId IdType="pmc">PMC3633693</ArticleId><ArticleId IdType="pubmed">23350640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood CR, Huang K, Diener DR, Rosenbaum JL. The cilium secretes bioactive ectosomes. Curr Biol. 2013;23:906&#x2013;911. doi: 10.1016/j.cub.2013.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2013.04.019</ArticleId><ArticleId IdType="pmc">PMC3850760</ArticleId><ArticleId IdType="pubmed">23623554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Sun Z. Expanding horizons: ciliary proteins reach beyond cilia. Annu Rev Genet. 2013;47:353&#x2013;376. doi: 10.1146/annurev-genet-111212-133243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genet-111212-133243</ArticleId><ArticleId IdType="pmc">PMC5703194</ArticleId><ArticleId IdType="pubmed">24016188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25401692</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia.</ArticleTitle><Pagination><StartPage>1444</StartPage><EndPage>1451</EndPage><MedlinePgn>1444-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3717</ELocationID><Abstract><AbstractText>Neurodegenerative diseases, such as frontotemporal dementia (FTD), are often associated with behavioral deficits, but the underlying anatomical and molecular causes remain poorly understood. Here we show that forebrain-specific expression of FTD-associated mutant CHMP2B in mice causes several age-dependent neurodegenerative phenotypes, including social behavioral impairments. The social deficits were accompanied by a change in AMPA receptor (AMPAR) composition, leading to an imbalance between Ca(2+)-permeable and Ca(2+)-impermeable AMPARs. Expression of most AMPAR subunits was regulated by the brain-enriched microRNA miR-124, whose abundance was markedly decreased in the superficial layers of the cerebral cortex of mice expressing the mutant CHMP2B. We found similar changes in miR-124 and AMPAR levels in the frontal cortex and induced pluripotent stem cell-derived neurons from subjects with behavioral variant FTD. Moreover, ectopic miR-124 expression in the medial prefrontal cortex of mutant mice decreased AMPAR levels and partially rescued behavioral deficits. Knockdown of the AMPAR subunit Gria2 also alleviated social impairments. Our results identify a previously undescribed mechanism involving miR-124 and AMPARs in regulating social behavior in FTD and suggest a potential therapeutic avenue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gascon</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kelleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Hongyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurosciences, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verheyden</LastName><ForeName>Jamie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Danqiong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hongru</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakovcevski</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbarian</LastName><ForeName>Schahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Wei-Dong</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Division of Neurosciences, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GDS3459</AccessionNumber><AccessionNumber>GPL10999</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA032283</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH086509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS079725</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS066586</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073947</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525139">CHMP2B protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540079">Mirn124 microRNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Jan;16(1):2-3. doi: 10.1038/nrn3884.</RefSource><PMID Version="1">25469755</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2014 Dec;20(12):1381-3. doi: 10.1038/nm.3768.</RefSource><PMID Version="1">25473917</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056827" MajorTopicYN="N">Endosomal Sorting Complexes Required for Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25401692</ArticleId><ArticleId IdType="mid">NIHMS628092</ArticleId><ArticleId IdType="pmc">PMC4257887</ArticleId><ArticleId IdType="doi">10.1038/nm.3717</ArticleId><ArticleId IdType="pii">nm.3717</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dickson DW. Parkinson&#x2019;s disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med. 2012;2:a009258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405828</ArticleId><ArticleId IdType="pubmed">22908195</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239184</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. Lancet. 2014;383:828&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">23927914</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 2014;127:359&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002260</ArticleId><ArticleId IdType="pubmed">24394885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox LE, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS) PLoS One. 2010;5:e9872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844426</ArticleId><ArticleId IdType="pubmed">20352044</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 2005;37:806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli BV, et al. Rare autosomal copy number variations in early-onset familial Alzheimer&#x2019;s disease. Mol. Psychiatry. 2013;19:676&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">23752245</ArticleId></ArticleIdList></Reference><Reference><Citation>Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Dev. Cell. 2011;21:77&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley JH, Hanson PI. Membrane budding and scission by the ESCRT machinery: it&#x2019;s all in the neck. Nat. Rev. Mol. Cell. Biol. 2010;11:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922035</ArticleId><ArticleId IdType="pubmed">20588296</ArticleId></ArticleIdList></Reference><Reference><Citation>Belly A, et al. CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. J. Cell Sci. 2010;123:2943&#x2013;2954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013364</ArticleId><ArticleId IdType="pubmed">20699355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazi-Noori S, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain. 2012;135:819&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">22366797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr. Biol. 2007;17:1561&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Gao FB. Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. J. Neurosci. 2009;29:8506&#x2013;8511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726650</ArticleId><ArticleId IdType="pubmed">19571141</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe M, Bonini NM. MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol. 2013;23:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540990</ArticleId><ArticleId IdType="pubmed">23026030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E, Gao FB. Cause or effect: Misregulation of microRNA pathways in neurodegeneration. Front. Neurosci. 2012;6:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321503</ArticleId><ArticleId IdType="pubmed">22509148</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB. Context-dependent functions of specific microRNAs in neuronal development. Neural Dev. 2010;5:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958854</ArticleId><ArticleId IdType="pubmed">20920300</ArticleId></ArticleIdList></Reference><Reference><Citation>Yizhar O, et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature. 2011;477:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155501</ArticleId><ArticleId IdType="pubmed">21796121</ArticleId></ArticleIdList></Reference><Reference><Citation>Peca J, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011;472:437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090611</ArticleId><ArticleId IdType="pubmed">21423165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 2012;8:423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J. Neurol. Neurosurg. Psychiatry. 2011;82:476&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr. Opin. Neurobiol. 2007;17:381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17498943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. 2003;26:360&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, Noguchi J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci. 2010;33:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">20138375</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba T, Morimoto K, Sato K, Yamada N, Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 1994;638:36&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8199874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron. 2009;62:254&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632349</ArticleId><ArticleId IdType="pubmed">19409270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozov A, Sprengel R, Seeburg PH. GluA2-lacking AMPA receptors in hippocampal CA1 cell synapses: evidence from gene-targeted mice. Front. Mol. Neurosci. 2012;5:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285882</ArticleId><ArticleId IdType="pubmed">22375105</ArticleId></ArticleIdList></Reference><Reference><Citation>Cull-Candy S, Kelly L, Farrant M. Regulation of Ca2+-permeable AMPA receptors: synaptic plasticity and beyond. Curr. Opin. Neurobiol. 2006;16:288&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007;30:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275103</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh KM, et al. Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc. Natl. Acad. Sci. U. S. A. 2005;102:12230&#x2013;12235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189338</ArticleId><ArticleId IdType="pubmed">16093311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambros V. The functions of animal microRNAs. Nature. 2004;431:350&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372042</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel G, Saba R, Schratt G. microRNAs in neurons: manifold regulatory roles at the synapse. Curr. Opin. Genet. Dev. 2011;21:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">21561760</ArticleId></ArticleIdList></Reference><Reference><Citation>Deo M, Yu JY, Chung KH, Tippens M, Turner DL. Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev. Dyn. 2006;235:2538&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16736490</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2:789&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532907</ArticleId><ArticleId IdType="pubmed">23063362</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 47:115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J. Neurosci. 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer&#x2019;s disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J. Alzheimers. Dis. 2013;35:335&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753694</ArticleId><ArticleId IdType="pubmed">23403535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, et al. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum. Mol. Genet. 2008;17:1349&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900863</ArticleId><ArticleId IdType="pubmed">18223198</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 2008;7:965&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">18771956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, et al. Bidirectional control of social hierarchy by synaptic efficacy in medial prefrontal cortex. Science. 2011;334:693&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">21960531</ArticleId></ArticleIdList></Reference><Reference><Citation>Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147039</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 2013;33:5352&#x2013;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, et al. Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. Cereb. Cortex. 2012;22:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256403</ArticleId><ArticleId IdType="pubmed">21653702</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk A, et al. GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum. Behav. Brain Res. 2012;229:265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096766</ArticleId><ArticleId IdType="pubmed">22285418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Hiesinger PR. The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol. Neurodegener. 2013;8:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708831</ArticleId><ArticleId IdType="pubmed">23829673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 2009;11:1143&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YS, et al. Silencing by small RNAs is linked to endosomal trafficking. Nat. Cell Biol. 2009;11:1150&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737091</ArticleId><ArticleId IdType="pubmed">19684574</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta R, et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann. Neurol. 2013;73:637&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679350</ArticleId><ArticleId IdType="pubmed">23595422</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc. Natl. Acad. Sci. U. S. A. 2012;109:2151&#x2013;21515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535614</ArticleId><ArticleId IdType="pubmed">23236149</ArticleId></ArticleIdList></Reference><Reference><Citation>Winslow JT. Mouse social recognition and preference. Curr. Protoc. Neurosci. 2003;22:8.16.1&#x2013;8.16.16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428583</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt RM, Galligan MM, Despinoy JR, Segal R. Olfactory behavioral testing in the adult mouse. J. Vis. Exp. 2009;23:949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782999</ArticleId><ArticleId IdType="pubmed">19229182</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M, et al. Object recognition test in mice. Nat. Protoc. 2013;8:2531&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PLoS One. 2008;3:e1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292261</ArticleId><ArticleId IdType="pubmed">18431482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Ratner D, Zhong L, Esteves-Sena M, Gao G. Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol. 2012;26:14D.1.1&#x2013;14D.1.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358842</ArticleId><ArticleId IdType="pubmed">22875565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K, Elledge SJ, Hannon GJ. Lessons from Nature: microRNA-based shRNA libraries. Nat. Methods. 2006;3:707&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">16929316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao GP, Sena-Esteves M. Introducing Genes into Mammalian Cells: Viral Vectors. In: Green MR, Sambrook J, editors. Molecular Cloning, Vol 2: A Laboratory Manual. Cold Spring Harbor Laboratory Press; New York: 2012. pp. 1209&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">32457039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 2009;4:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">19300443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E, et al. Hepatocyte growth factor-Met signaling is required for Runx1 extinction and peptidergic differentiation in primary nociceptive neurons. J. Neurosci. 2010;30:12414&#x2013;12423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633456</ArticleId><ArticleId IdType="pubmed">20844136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E, Vutskits L, Jenny B, Durbec P, Kiss JZ. PSA-NCAM in postnatally generated immature neurons of the olfactory bulb: a crucial role in regulating p75 expression and cell survival. Development. 2007;134:1181&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">17301083</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25406732</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>5422</StartPage><MedlinePgn>5422</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms6422</ELocationID><Abstract><AbstractText>Astrocytic network alterations have been reported in Alzheimer's disease (AD), but the underlying pathways have remained undefined. Here we measure astrocytic calcium, cerebral blood flow and amyloid-&#x3b2; plaques in vivo in a mouse model of AD using multiphoton microscopy. We find that astrocytic hyperactivity, consisting of single-cell transients and calcium waves, is most pronounced in reactive astrogliosis around plaques and is sometimes associated with local blood flow changes. We show that astroglial hyperactivity is reduced after P2 purinoreceptor blockade or nucleotide release through connexin hemichannels, but is augmented by increasing cortical ADP concentration. P2X receptor blockade has no effect, but inhibition of P2Y1 receptors, which are strongly expressed by reactive astrocytes surrounding plaques, completely normalizes astrocytic hyperactivity. Our data suggest that astroglial network dysfunction is mediated by purinergic signalling in reactive astrocytes, and that intervention aimed at P2Y1 receptors or hemichannel-mediated nucleotide release may help ameliorate network dysfunction in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delekate</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xfc;chtemeier</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Department of Experimental Neurology, Charit&#xe9;-University Medicine Berlin, Charit&#xe9;platz 1, 10117 Berlin, Germany [2] German Center for Neurodegenerative Diseases (DZNE), Charit&#xe9;platz 1, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Toni</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulbrich</LastName><ForeName>Cordula</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foddis</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental Neurology, Charit&#xe9;-University Medicine Berlin, Charit&#xe9;platz 1, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petzold</LastName><ForeName>Gabor C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany [2] Department of Neurology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546383">P2ry1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058472">Receptors, Purinergic P2Y1</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058472" MajorTopicYN="N">Receptors, Purinergic P2Y1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25406732</ArticleId><ArticleId IdType="doi">10.1038/ncomms6422</ArticleId><ArticleId IdType="pii">ncomms6422</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25412207</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7358</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>PLoS computational biology</Title><ISOAbbreviation>PLoS Comput Biol</ISOAbbreviation></Journal><ArticleTitle>Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>e1003956</StartPage><MedlinePgn>e1003956</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1003956</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pcbi.1003956</ELocationID><Abstract><AbstractText>Misfolded proteins (MP) are a key component in aging and associated neurodegenerative disorders. For example, misfolded Amyloid-&#xdf; (A&#xdf;) and tau proteins are two neuropathogenic hallmarks of Alzheimer's disease. Mechanisms underlying intra-brain MP propagation/deposition remain essentially uncharacterized. Here, is introduced an epidemic spreading model (ESM) for MP dynamics that considers propagation-like interactions between MP agents and the brain's clearance response across the structural connectome. The ESM reproduces advanced A&#xdf; deposition patterns in the human brain (explaining 46&#x223c;56% of the variance in regional A&#xdf; loads, in 733 subjects from the ADNI database). Furthermore, this model strongly supports a) the leading role of A&#xdf; clearance deficiency and early A&#xdf; onset age during Alzheimer's disease progression, b) that effective anatomical distance from A&#xdf; outbreak region explains regional A&#xdf; arrival time and A&#xdf; deposition likelihood, c) the multi-factorial impact of APOE e4 genotype, gender and educational level on lifetime intra-brain A&#xdf; propagation, and d) the modulatory impact of A&#xdf; propagation history on tau proteins concentrations, supporting the hypothesis of an interrelated pathway between A&#xdf; pathophysiology and tauopathy. To our knowledge, the ESM is the first computational model highlighting the direct link between structural brain networks, production/clearance of pathogenic proteins and associated intercellular transfer mechanisms, individual genetic/demographic properties and clinical states in health and disease. In sum, the proposed ESM constitutes a promising framework to clarify intra-brain region to region transference mechanisms associated with aging and neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iturria-Medina</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotero</LastName><ForeName>Roberto C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toussaint</LastName><ForeName>Paule J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Alan C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Comput Biol</MedlineTA><NlmUniqueID>101238922</NlmUniqueID><ISSNLinking>1553-734X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lew</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillit</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>Davie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCArli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Lean</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marylyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pogorelec</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grafman</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finley</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedl</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleischman</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kimberly S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massoglia</LastName><ForeName>Dino</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brawman-Mintzer</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behan</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fruehling</LastName><ForeName>J Jay</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harding</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furst</LastName><ForeName>Ansgar J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravdin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25412207</ArticleId><ArticleId IdType="pmc">PMC4238950</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1003956</ArticleId><ArticleId IdType="pii">PCOMPBIOL-D-14-01211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dobson CM (2002) Protein misfolding diseases: Getting out of shape. Nature 418: 729&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM (2003) Protein folding and misfolding. Nature 426: 884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynaud E (2010) Protein Misfolding and Degenerative Diseases. Nat Educ 3(9): 28.</Citation></Reference><Reference><Citation>Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev 11: 301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks, R. &amp; Diamond M (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT (1993) The Carboxy Terminus of the Amyloid Protein Is Critical for the Seeding of Amyloid Formation : Implications for the Pathogenesis of Alzheimer's Disease ? Am Chem Soc 32: 4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-gonzalez I, Soto C (2011) Seminars in Cell &amp; Developmental Biology Misfolded protein aggregates : Mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol 22: 482&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175247</ArticleId><ArticleId IdType="pubmed">21571086</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SR, Douglass A, Vale RD WJ (2004) Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition. PLoS Biol 2: e321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517824</ArticleId><ArticleId IdType="pubmed">15383837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallbeck M, Nath S, Marcusson J (2013) Neuron-to-neuron transmission of neurodegenerative pathology. Neuroscientist 19: 560&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath S, Agholme L, Kurudenkandy FR, Marcusson J (2012) Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of beta-Amyloid and Martin Hallbeck. J Neurosci 32: 8767&#x2013;8777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622335</ArticleId><ArticleId IdType="pubmed">22745479</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, J&#xfc;rgen G (2011) Amyloid-&#x3b2; and tau &#x2014; a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12: 67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloret A, Badia M-C, Giraldo E, Ermak G, Alonso M-D, et al. (2011) Amyloid-&#x3b2; toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis 27: 701&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690537</ArticleId><ArticleId IdType="pubmed">21876249</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldo E, Lloret A, Fuchsberger T, Vi&#xf1;a J (2014) A&#x3b2; and tau toxicities in Alzheimer's are linked via oxidative stress. Redox Biol 2: 873&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4099506</ArticleId><ArticleId IdType="pubmed">25061569</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TM, Al E (2008) Amyloid-&#x3b2; protein dimers drom AD impair synaptic plasticity and memory. Nat Med 14, 8: 837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Desrumaux C, Pisoni A, Meunier J, Deckert V, Athias A, et al. (2013) Increased amyloid-&#x3b2; peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice. Neuropsychopharmacology 38: 817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671992</ArticleId><ArticleId IdType="pubmed">23303044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloret A, Bad&#xed;a M-C, Mora NJ, Ortega A, Pallard&#xf3; F V, et al. (2008) Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. Free Radic Biol Med 44: 2019&#x2013;2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387371</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H-L, Shim S, Kim D-H, Won S-H, Joo S, et al. (2014) &#x3b2;-Amyloid is transmitted via neuronal connections along axonal membranes. Ann Neurol 75: 88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24114864</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters J (2010) The concentration of soluble extracellular amyloid-&#x3b2; protein in acute brain slices from CRND8 mice. PLoS One 5: e15709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012091</ArticleId><ArticleId IdType="pubmed">21209950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501: 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, LeVine H (2012) Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 287: 33109&#x2013;33115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460416</ArticleId><ArticleId IdType="pubmed">22879600</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H BE (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ghebremedhin E, Rub U, Bratzke H DTK (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP AN (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443: 768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative Diseases Target Large-scale Human Brain Networks. Neuron 62: 42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL M V (2004) Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101: 4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R, Snyder A, Shannon B, LaRossa G, Sachs R, et al. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW (2012) Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome. Neuron 73: 1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, et al. (2009) Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29: 1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>De Haan W, Mott K, van Straaten ECW, Scheltens P, Stam CJ (2012) Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol 8: e1002582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420961</ArticleId><ArticleId IdType="pubmed">22915996</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Haan W De, Daffertshofer A, Jones BF, Manshanden I, et al. (2009) Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 132(1): 213&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18952674</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M (2012) A Network Diffusion Model of Disease Progression in Dementia. Neuron 73: 1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Mahanian M, M R, Mizwicki M, Tse E, et al. (2011) MGAT3 mRNA: a biomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids. J Alzheimers Dis 25: 135&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21368380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman J, Ghirmai S, Abel K, Fiala M (2008) Immune defects in Alzheimer's disease: new medications development. BMC Neurosci 9(2): S13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604897</ArticleId><ArticleId IdType="pubmed">19090986</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012): 1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Domert J, Rao SB, Agholme L, Brorsson A-C, Marcusson J, et al. (2014) Spreading of amyloid-&#x3b2; peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis 65: 82&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412310</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant J, Ghosn E, Axtell R, Herges K, Kuipers H, et al. (2012) Reversal of paralysis and reduced inflammation from peripheral administration of &#x3b2;-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 4(145): 145ra105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677069</ArticleId><ArticleId IdType="pubmed">22855462</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Tourville J (2012) 101 Labeled Brain Images and a Consistent Human Cortical Labeling Protocol. Front Neurosci 6: 171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514540</ArticleId><ArticleId IdType="pubmed">23227001</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R, Andrews-Hanna J, Schacter D (2008) The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124: 1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna J, Reidler J, Huang C, Buckner R (2010) Evidence for the default network's role in spontaneous cognition. J Neurophysiol 104(1): 322&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904225</ArticleId><ArticleId IdType="pubmed">20463201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevel K, Ch&#xe9;telat G, Eustache F, Desgranges B (2011) The Default Mode Network in Healthy Aging and Alzheimer's Disease. Int J Alzheimers Dis, Article ID 535816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132539</ArticleId><ArticleId IdType="pubmed">21760988</ArticleId></ArticleIdList></Reference><Reference><Citation>Leech R, Sharp D (2013) The role of the posterior cingulate cortex in cognition and disease. Brain 137(1): 12&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891440</ArticleId><ArticleId IdType="pubmed">23869106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, Sporns O (2011) Weight-conserving characterization of complex functional brain networks. Neuroimage 56: 2068&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">21459148</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow J (1855) On the mode of communication of cholera. London J Churchill, 2.</Citation></Reference><Reference><Citation>Brockmann D, Helbing D (2013) The hidden geometry of complex, network-driven contagion phenomena. Science 342: 1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">24337289</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Heuvel MP, Sporns O (2013) Network hubs in the human brain. Trends Cogn Sci 17: 683&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24231140</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossley N a, Mechelli a, Scott J, Carletti F, Fox PT, et al. (2014) The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain 137(8): 2382&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107735</ArticleId><ArticleId IdType="pubmed">25057133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Higgins G (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan V, Risacher S, Nho K, Kim S, Swaminathan S, et al. (2013) APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry 19: 351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661739</ArticleId><ArticleId IdType="pubmed">23419831</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D, Morris J, Goate A (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano J, Kim J, Stewart F, Jiang H, DeMattos R, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3: 89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie R, Hashimoto T, Tai H, Kay K, Serrano-Pozo A, et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135: 2155&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381721</ArticleId><ArticleId IdType="pubmed">22637583</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (80) 261: 921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro M, et al. (2005) Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 76(1): 15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739315</ArticleId><ArticleId IdType="pubmed">15607989</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, Sleegers K, Al E (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9): 903&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux J, Seeley W, Zhou J, Shirer W, Coppola G, et al. (2012) Gender Modulates the APOE E4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels. J Neurosci 32(24): 8254&#x2013;8262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer L, Cupples L, Haines J, Hyman B, Kukull W, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E, Ghebremedhin E, Taylor M, Thal D, Ohm T, et al. (2004) The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 1019: 24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246987</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue K, Kennedy K, Park D (2009) Beta-Amyloid Deposition and the Aging Brain. Neuropsychol Rev 19(4): 436&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844114</ArticleId><ArticleId IdType="pubmed">19908146</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen N, Aalto S, Karrasch M, N&#xe5;gren K, Savisto N, et al. (2008) Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 63: 112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolstad S, Nordlund A, Eckerstr&#xf6;m C, Gustavsson M, Zetterberg H, et al. (2009) Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment&#x2014;proof of concept. Dement Geriatr Cogn Disord 27: 194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S, Duff K (2008) Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60: 534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf DJ, Garc&#xed;a-Arencibia M, Hochfeld WE, Rubinsztein DC (2012) Autophagy and misfolded proteins in neurodegeneration. Exp Neurol 238: 22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463804</ArticleId><ArticleId IdType="pubmed">21095248</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J, Mucke L (2010) Amyloid-&#x3b2; Induced Neuronal Dysfunction in Alzheimer's Disease: From Synapses toward Neural Networks. Nat Neurosci 13(7): 812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrada E, Kalala-mutombo F, Valverde-colmeiro A (2011) Epidemic spreading in networks with nonrandom long-range interactions. Phys Rev E 036110: 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22060459</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-medina Y (2013) Anatomical Brain Networks on the Prediction of Abnormal Brain States. Brain Connectivity 3(1): 1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23249224</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans A (2013) Networks of anatomical covariance. Neuroimage 80: 489&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">23711536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-&#x3b2; load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4): 363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, et al. (2013) Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5: 189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildsmith K, Holley M, Savage J, Skerrett R, Landreth G (2013) Evidence for impaired amyloid &#x3b2; clearance in Alzheimer's disease. Alzheimers Res Ther 5(4): 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978761</ArticleId><ArticleId IdType="pubmed">23849219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Go&#xf1;i F (2014) Immunotherapy for Alzheimer's disease. Biochem Pharmacol 88: 499&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972315</ArticleId><ArticleId IdType="pubmed">24412277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer P, Cirrito J, Wesson D, Lee C, Karlo J, et al. (2012) ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science 335(6075): 1503&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DK, Cercignani M (2010) Twenty-five pitfalls in the analysis of diffusion MRI data. NMR Biomed 23: 803&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">20886566</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Canales-Rodr&#xed;guez EJ, Melie-Garc&#xed;a L, Vald&#xe9;s-Hern&#xe1;ndez PA, Mart&#xed;nez-Montes E, et al. (2007) Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. Neuroimage 36: 645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">17466539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A, Harding IH, Cocchi L, Y&#xfc;cel M, et al. (2010) Whole-brain anatomical networks: Does the choice of nodes matter? Neuroimage 50: 970&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035887</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspers S, Eickhoff SB, Zilles K, Amunts K (2013) Microstructural grey matter parcellation and its relevance for connectome analyses. Neuroimage 80: 18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010271</ArticleId><ArticleId IdType="pubmed">23571419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotka A (1925) Elements of physical biology. Williams Wilkins, Balt.</Citation></Reference><Reference><Citation>Volterra V (1926) Variazioni e fluttuazioni del numero d&#x2032;individui in specie animali conviventi. Lincei, Mem R Accad Naz dei 2: 31&#x2013;113.</Citation></Reference><Reference><Citation>
http://adni.loni.usc.edu.</Citation></Reference><Reference><Citation>
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Data_Use_Agreement.pdf.</Citation></Reference><Reference><Citation>
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Manuscript_Citations.pdf.</Citation></Reference><Reference><Citation>Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, M F (2005) The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci 14: 1753&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253354</ArticleId><ArticleId IdType="pubmed">15937275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, Toga A, Evans A, Fox P, Lancaster J (1995) A Probablistic Atlas of the Human Brain: Theory and Rationale for Its Development. Neuroimage 2: 89&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343592</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini C (1912) Variability and Mutability. C Cuppini, Bol: 156 pages.</Citation></Reference><Reference><Citation>Lundmark K, Westermark G, Nystrom S, Murphy C, Solomon A, et al. (2002) Transmissibility of systemic a myloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99(10): 6979&#x2013;6984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124514</ArticleId><ArticleId IdType="pubmed">12011456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui D, Kawano H, Takahashi M, Hoshii Y, Setoguchi M, et al. (2002) Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol Int 52(4): 264.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Bandy D, Chen K, Foster N, Landau S, et al. (2010) The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 6: 221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans A, Kamber M, Collins D, Macdonald D (1994) An MRI-based probabilistic atlas of neuroanatomy. S Shorvon, D Fish, F Andermann, G Bydder H Stefan, Ed Magn Reson Scanning Epilepsy, Plenum, New York: 263&#x2013;274.</Citation></Reference><Reference><Citation>Yeh F, Tseng W (2011) NTU-90: a high angular resolution brain atlas constructed by q-space diffeomorphic reconstruction. Neuroimage 58(1): 91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21704171</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, DeMeyer G, Wallin A, et al. (2005) Simultaneous measurement of &#xdf;-amyloid1-42 in CSF by xMAP technology. Clin Chem 51: 336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw L, Vanderstichele H, Knapik-Czajka, Figurski M, Coart E, et al. (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropath 121: 597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeman R, Merenda P, Gold R (1980) Introduction to Bivariate and Multivariate Analysis. Scott, Foresman, Glenview IL: 119.</Citation></Reference><Reference><Citation>Gr&#xf6;mping U (2006) Relative Importance for Linear Regression in R : The Package relaimpo. J Stat Sofw 17 (1).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25419706</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death.</ArticleTitle><Pagination><StartPage>1452</StartPage><EndPage>1457</EndPage><MedlinePgn>1452-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3736</ELocationID><Abstract><AbstractText>We have identified a rare coding mutation, T835M (rs137875858), in the UNC5C netrin receptor gene that segregated with disease in an autosomal dominant pattern in two families enriched for late-onset Alzheimer's disease and that was associated with disease across four large case-control cohorts (odds ratio = 2.15, Pmeta = 0.0095). T835M alters a conserved residue in the hinge region of UNC5C, and in vitro studies demonstrate that this mutation leads to increased cell death in human HEK293T cells and in rodent neurons. Furthermore, neurons expressing T835M UNC5C are more susceptible to cell death from multiple neurotoxic stimuli, including &#x3b2;-amyloid (A&#x3b2;), glutamate and staurosporine. On the basis of these data and the enriched hippocampal expression of UNC5C in the adult nervous system, we propose that one possible mechanism in which T835M UNC5C contributes to the risk of Alzheimer's disease is by increasing susceptibility to neuronal cell death, particularly in vulnerable regions of the Alzheimer's disease brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wetzel-Smith</LastName><ForeName>Monica K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunkapiller</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhangale</LastName><ForeName>Tushar R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Karpagam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Janice A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sa</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaylaoglu</LastName><ForeName>Murat B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Oded</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortmann</LastName><ForeName>Ward</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathore</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, Rockefeller University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. [2] Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA. [2] Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>1] Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA. [2] Department of Neurology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA. [3] Department of Ophthalmology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA. [4] Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA. [5] Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. [3] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>Timothy W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075386">Netrin Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017475">Receptors, Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C115727">UNC5C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000595076">UNC5C protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105653">Unc5c protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>H88EPA0A3N</RegistryNumber><NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056654" MajorTopicYN="N">CA3 Region, Hippocampal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075386" MajorTopicYN="N">Netrin Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017475" MajorTopicYN="N">Receptors, Nerve Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25419706</ArticleId><ArticleId IdType="mid">NIHMS654180</ArticleId><ArticleId IdType="pmc">PMC4301587</ArticleId><ArticleId IdType="doi">10.1038/nm.3736</ArticleId><ArticleId IdType="pii">nm.3736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coppola G, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x2019;s diseases. Human molecular genetics. 2012;21:3500&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PloS one. 2012;7:e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular psychiatry. 2011;16:903&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. The New England journal of medicine. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nature genetics. 2013;45:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nature genetics. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. The New England journal of medicine. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature genetics. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nature genetics. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M, et al. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA neurology. 2013;70:736&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681841</ArticleId><ArticleId IdType="pubmed">23588422</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardo E, et al. Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors. Nature. 1997;386:833&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman S, et al. The mouse rostral cerebellar malformation gene encodes an UNC-5-like protein. Nature. 1997;386:838&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126743</ArticleId></ArticleIdList></Reference><Reference><Citation>Przyborski S, Knowles B, Ackerman S. Embryonic phenotype of Unc5h3 mutant mice suggests chemorepulsion during the formation of the rostral cerebellar boundary. Development (Cambridge, England) 1998;125:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9389662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, et al. Genome-wide association of familial late-onset Alzheimer&#x2019;s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011;7:e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R. Analyses of the National Institute on Aging Late-Onset Alzheimer&#x2019;s Disease Family Study: implication of additional loci. Archives of neurology. 2008;65:1518&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeau JH. Modifier genes and protective alleles in humans and mice. Current opinion in genetics &amp; development. 2003;13:290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787792</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and biophysical research communications. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer&#x2019;s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4:2757&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554575</ArticleId><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Llambi F, Causeret F, Bloch-Gallego E, Mehlen P. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J. 2001;20:2715&#x2013;2722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125255</ArticleId><ArticleId IdType="pubmed">11387206</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiebault K, et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:4173&#x2013;4178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153067</ArticleId><ArticleId IdType="pubmed">12655055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, et al. Autoinhibition of UNC5b revealed by the cytoplasmic domain structure of the receptor. Mol Cell. 2009;33:692&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">19328064</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. European neurology. 1993;33:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta neuropathologica. 1977;37:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">848276</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychological review. 1992;99:195&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao B, et al. Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer&#x2019;s disease from mainland China. Neurobiology of aging. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24866402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, et al. Genome-wide association of familial late-onset Alzheimer&#x2019;s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS genetics. 2011;7:e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nature genetics. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PLoS One. 2012;7:e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Kirichenko A, Axenovich TI, van Duijn CM, Aulchenko YS. An approach for cutting large and complex pedigrees for linkage analysis. European journal of human genetics EJHG. 2008;16:854&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">18301450</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. Nature genetics. 2002;30:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">11731797</ArticleId></ArticleIdList></Reference><Reference><Citation>Drmanac R, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science. 2010;327:78&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19892942</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics. 2011;43:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research. 2010;38:e164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, et al. TREM2 is associated with the risk of Alzheimer&#x2019;s disease in Spanish population. Neurobiology of aging. 2013;34:1711, e1715&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596468</ArticleId><ArticleId IdType="pubmed">23391427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78:256&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer&#x2019;s disease Ibero-American cohort. Alzheimer&#x2019;s research &amp; therapy. 2012;4:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506948</ArticleId><ArticleId IdType="pubmed">22906081</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, et al. Assessment of the pathological stages of Alzheimer&#x2019;s disease in thin paraffin sections: a comparative study. Dementia and geriatric cognitive disorders. 1998;9:140&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. Journal of neuropathology and experimental neurology. 1997;56:1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nature genetics. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer G. meta: Meta-Analysis with R. R package version 2.1&#x2013;0. 2012</Citation></Reference><Reference><Citation>Team, R.D.C. A language and environment for statistical computing. 2012</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25418885</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2014</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>53</StartPage><MedlinePgn>53</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">53</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/1750-1326-9-53</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Synaptic degeneration is an early pathogenic event in Alzheimer's disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of cerebrospinal fluid, however these assays were not sensitive enough for individual samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker for synaptic integrity in Alzheimer's disease was assessed for the first time. We found significantly higher levels of cerebrospinal fluid SNAP-25 fragments in Alzheimer's disease, even in the very early stages, in three separate cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer's disease from controls with area under the curve of 0.901 (P&#x2009;&lt;&#x2009;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, S-431 80 M&#xf6;lndal, Sweden. ann.brinkmalm@neuro.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Honer</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>&#xd6;hrfelt</LastName><ForeName>Annika</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CBG-101827</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP-14037</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494208">SNAP25 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050825">Synaptosomal-Associated Protein 25</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050825" MajorTopicYN="N">Synaptosomal-Associated Protein 25</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25418885</ArticleId><ArticleId IdType="pmc">PMC4253625</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-9-53</ArticleId><ArticleId IdType="pii">1750-1326-9-53</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science. 2008;321:1686&#x2013;1689. doi: 10.1126/science.1162844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer&#x2019;s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103:603&#x2013;618. doi: 10.1007/BF01273157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01273157</ArticleId><ArticleId IdType="pubmed">8811505</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464. doi: 10.1002/ana.410270502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410270502</ArticleId><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer WG. Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals. Neurobiol Aging. 2003;24:1047&#x2013;1062. doi: 10.1016/j.neurobiolaging.2003.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.04.005</ArticleId><ArticleId IdType="pubmed">14643376</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer WG, Barr AM, Sawada K, Thornton AE, Morris MC, Leurgans SE, Schneider JA, Bennett DA. Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl Psychiatry. 2012;2:e114. doi: 10.1038/tp.2012.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2012.38</ArticleId><ArticleId IdType="pmc">PMC3365257</ArticleId><ArticleId IdType="pubmed">22832958</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology. 2001;56:127&#x2013;129. doi: 10.1212/WNL.56.1.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.127</ArticleId><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Minger SL, Honer WG, Esiri MM, McDonald B, Keene J, Nicoll JA, Carter J, Hope T, Francis PT. Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:929&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">11589423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer&#x2019;s disease. Am J Pathol. 2000;157:623&#x2013;636. doi: 10.1016/S0002-9440(10)64573-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64573-7</ArticleId><ArticleId IdType="pmc">PMC1850134</ArticleId><ArticleId IdType="pubmed">10934165</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508. doi: 10.1212/01.wnl.0000260698.46517.8f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260698.46517.8f</ArticleId><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372&#x2013;1384. doi: 10.1016/j.neurobiolaging.2005.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.012</ArticleId><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580. doi: 10.1002/ana.410300410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am. 2013;97:369&#x2013;376. doi: 10.1016/j.mcna.2012.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2012.12.012</ArticleId><ArticleId IdType="pubmed">23642576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn R, Sudhof TC. Membrane fusion and exocytosis. Annu Rev Biochem. 1999;68:863&#x2013;911. doi: 10.1146/annurev.biochem.68.1.863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.68.1.863</ArticleId><ArticleId IdType="pubmed">10872468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science. 2009;323:474&#x2013;477. doi: 10.1126/science.1161748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1161748</ArticleId><ArticleId IdType="pmc">PMC3736821</ArticleId><ArticleId IdType="pubmed">19164740</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol. 1996;27:195&#x2013;210. doi: 10.1007/BF02815094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02815094</ArticleId><ArticleId IdType="pubmed">8962603</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999;20:431&#x2013;437. doi: 10.1002/(SICI)1522-2683(19990301)20:3&lt;431::AID-ELPS431&gt;3.0.CO;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1522-2683(19990301)20:3&lt;431::AID-ELPS431&gt;3.0.CO;2-2</ArticleId><ArticleId IdType="pubmed">10217148</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Kelley M, Yao J, Tsai G, van Kammen DP. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry. 2003;53:1132&#x2013;1137. doi: 10.1016/S0006-3223(02)01599-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3223(02)01599-8</ArticleId><ArticleId IdType="pubmed">12814864</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Rosenberger C, Holt S, Perrone-Bizzozero NI. Measuring synaptosomal associated protein-25&#xa0;kDa in human cerebral spinal fluid. J Psychiatr Res. 1998;32:297&#x2013;300. doi: 10.1016/S0022-3956(98)00018-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3956(98)00018-1</ArticleId><ArticleId IdType="pubmed">9789208</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer&#x2019;s disease. Brain Res. 2010;1362:13&#x2013;22. doi: 10.1016/j.brainres.2010.09.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.09.073</ArticleId><ArticleId IdType="pubmed">20875798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C, Mann M. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res. 2008;7:386&#x2013;399. doi: 10.1021/pr070501k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr070501k</ArticleId><ArticleId IdType="pubmed">18052119</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallien S, Duriez E, Crone C, Kellmann M, Moehring T, Domon B. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics. 2012;11:1709&#x2013;1723. doi: 10.1074/mcp.O112.019802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.O112.019802</ArticleId><ArticleId IdType="pmc">PMC3518128</ArticleId><ArticleId IdType="pubmed">22962056</ArticleId></ArticleIdList></Reference><Reference><Citation>Greber S, Lubec G, Cairns N, Fountoulakis M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer&#x2019;s disease. Electrophoresis. 1999;20:928&#x2013;934. doi: 10.1002/(SICI)1522-2683(19990101)20:4/5&lt;928::AID-ELPS928&gt;3.0.CO;2-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1522-2683(19990101)20:4/5&lt;928::AID-ELPS928&gt;3.0.CO;2-Z</ArticleId><ArticleId IdType="pubmed">10344268</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer&#x2019;s disease. Biochem Biophys Res Commun. 1997;236:239&#x2013;242. doi: 10.1006/bbrc.1997.6940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.6940</ArticleId><ArticleId IdType="pubmed">9240416</ArticleId></ArticleIdList></Reference><Reference><Citation>Connell E, Darios F, Peak-Chew S, Soloviev M, Davletov B. N-terminal acetylation of the neuronal protein SNAP-25 is revealed by the SMI81 monoclonal antibody. Biochemistry. 2009;48:9582&#x2013;9589. doi: 10.1021/bi9012403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9012403</ArticleId><ArticleId IdType="pubmed">19747004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasshauer D, Sutton RB, Brunger AT, Jahn R. Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs. Proc Natl Acad Sci U S A. 1998;95:15781&#x2013;15786. doi: 10.1073/pnas.95.26.15781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15781</ArticleId><ArticleId IdType="pmc">PMC28121</ArticleId><ArticleId IdType="pubmed">9861047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 1998;395:347&#x2013;353. doi: 10.1038/26412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/26412</ArticleId><ArticleId IdType="pubmed">9759724</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosso MF, de Geus EJ, Polderman TJ, Boomsma DI, Heutink P, Posthuma D. Common variants underlying cognitive ability: further evidence for association between the SNAP-25 gene and cognition using a family-based study in two independent Dutch cohorts. Genes Brain Behav. 2008;7:355&#x2013;364. doi: 10.1111/j.1601-183X.2007.00359.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-183X.2007.00359.x</ArticleId><ArticleId IdType="pubmed">17908175</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerini FR, Agliardi C, Sironi M, Arosio B, Calabrese E, Zanzottera M, Bolognesi E, Ricci C, Costa AS, Galimberti D, Griffanti L, Bianchi A, Savazzi F, Mari D, Scarpini E, Baglio F, Nemni R, Clerici M. Possible Association between SNAP-25 Single Nucleotide Polymorphisms and Alterations of Categorical Fluency and Functional MRI Parameters in Alzheimer&#x2019;s Disease. J Alzheimers Dis. 2014;42:1015&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">25024311</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144. doi: 10.1038/nrneurol.2010.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer&#x2019;s disease. Neurosci Lett. 2007;419:18&#x2013;22. doi: 10.1016/j.neulet.2007.03.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.03.064</ArticleId><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer&#x2019;s disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012;73:504&#x2013;517. doi: 10.1111/j.1365-2125.2011.04134.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2011.04134.x</ArticleId><ArticleId IdType="pmc">PMC3376428</ArticleId><ArticleId IdType="pubmed">22035455</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS. Changes in cognition. Neurobiol Aging. 2011;32 Suppl 1:S58&#x2013;S63. doi: 10.1016/j.neurobiolaging.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3929949</ArticleId><ArticleId IdType="pubmed">22078174</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4. Washington DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry. 2005;76:1485&#x2013;1490. doi: 10.1136/jnnp.2004.050385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2004.050385</ArticleId><ArticleId IdType="pmc">PMC1739388</ArticleId><ArticleId IdType="pubmed">16227535</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . The ICD-10 Classification of Mental and Behavioural Disorders. 1992.</Citation></Reference><Reference><Citation>&#xd6;hrfelt A, Zetterberg H, Andersson K, Persson R, Secic D, Brinkmalm G, Wallin A, Mulugeta E, Francis PT, Vanmechelen E, Aarsland D, Ballard C, Blennow K, Westman-Brinkmalm A. Identification of Novel alpha-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochem Res. 2011;36:2029&#x2013;2042. doi: 10.1007/s11064-011-0527-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0527-x</ArticleId><ArticleId IdType="pmc">PMC3183298</ArticleId><ArticleId IdType="pubmed">21674238</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer WG, Falkai P, Young C, Wang T, Xie J, Bonner J, Hu L, Boulianne GL, Luo Z, Trimble WS. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience. 1997;78:99&#x2013;110. doi: 10.1016/S0306-4522(96)00489-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(96)00489-7</ArticleId><ArticleId IdType="pubmed">9135092</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyler GA, Higgins GA, Hart RA, Battenberg E, Billingsley M, Bloom FE, Wilson MC. The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations. J Cell Biol. 1989;109:3039&#x2013;3052. doi: 10.1083/jcb.109.6.3039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.109.6.3039</ArticleId><ArticleId IdType="pmc">PMC2115928</ArticleId><ArticleId IdType="pubmed">2592413</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Portelius E, Ohrfelt A, Mattsson N, Persson R, Gustavsson MK, Vite CH, Gobom J, Mansson J-E, Nilsson J, Halim A, Larson G, Ruetschi U, Zetterberg H, Blennow K, Brinkmalm A. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom. 2012;47:591&#x2013;603. doi: 10.1002/jms.2987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jms.2987</ArticleId><ArticleId IdType="pubmed">22576872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25417150</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Lessons from a failed &#x3b3;-secretase Alzheimer trial.</ArticleTitle><Pagination><StartPage>721</StartPage><EndPage>726</EndPage><MedlinePgn>721-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.10.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)01304-X</ELocationID><Abstract><AbstractText>&#x3b3;-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum &#x3b3;-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing &#x3b3;-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven 3000, Belgium; KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative disorders (LIND), University of Leuven 3000, Belgium; UCL Institute of Neurology, University College London, Queen Square, London WC1N 1PJ, UK. Electronic address: bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.10.016</ArticleId><ArticleId IdType="pii">S0092-8674(14)01304-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25456500</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1033</EndPage><MedlinePgn>1023-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.10.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00922-2</ELocationID><Abstract><AbstractText>Dendritic structure critically determines the electrical properties of neurons and, thereby, defines the fundamental process of input-to-output conversion. The diversity of dendritic architectures enables neurons to fulfill their specialized circuit functions during cognitive processes. It is known that this dendritic integrity is impaired in patients with Alzheimer's disease and in relevant mouse models. It is unknown, however, whether this structural degeneration translates into aberrant neuronal function. Here we use in vivo whole-cell patch-clamp recordings, high-resolution STED imaging, and computational modeling of CA1 pyramidal neurons in a mouse model of Alzheimer's disease to show that structural degeneration and neuronal hyperexcitability are crucially linked. Our results demonstrate that a structure-dependent amplification of synaptic input to action potential output conversion might constitute a novel cellular pathomechanism underlying network dysfunction with potential relevance for other neurodegenerative diseases with abnormal changes of dendritic morphology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#x160;i&#x161;kov&#xe1;</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrichs</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henneberg</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beutel</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitsch</LastName><ForeName>Julika</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Translational Epilepsy Research, Department of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Stra&#xdf;e 25, 53125 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoch</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Translational Epilepsy Research, Department of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Stra&#xdf;e 25, 53125 Bonn, Germany; Department of Epileptology, University of Bonn Medical Center, Sigmund-Freud-Stra&#xdf;e 25, 53125 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Translational Epilepsy Research, Department of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Stra&#xdf;e 25, 53125 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von der Kammer</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurobiology, Evotec AG, Essener Bogen 7, 22419 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remy</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuronal Networks Group, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany; Department of Epileptology, University of Bonn Medical Center, Sigmund-Freud-Stra&#xdf;e 25, 53125 Bonn, Germany. Electronic address: stefan.remy@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>G6D6147J22</RegistryNumber><NameOfSubstance UI="C013411">biocytin</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>CNS Neurosci Ther. 2015 Nov;21(11):867-9. doi: 10.1111/cns.12439.</RefSource><PMID Version="1">26494127</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25456500</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.10.024</ArticleId><ArticleId IdType="pii">S0896-6273(14)00922-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25599931</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.</ArticleTitle><Pagination><StartPage>729</StartPage><EndPage>739</EndPage><MedlinePgn>729-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2014.10.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(14)00793-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">BACE1 (beta site amyloid precursor protein cleaving enzyme 1) is the rate limiting protease in amyloid &#x3b2; production, hence a promising drug target for the treatment of Alzheimer's disease. Inhibition of BACE1, as the major &#x3b2;-secretase in vivo with multiple substrates, however is likely to have mechanism-based adverse effects. We explored the impact of long-term pharmacological inhibition of BACE1 on dendritic spine dynamics, synaptic functions, and cognitive performance of adult mice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sandwich enzyme-linked immunosorbent assay was used to assess A&#x3b2;40 levels in brain and plasma after oral administration of BACE1 inhibitors SCH1682496 or LY2811376. In vivo two-photon microscopy of the somatosensory cortex was performed to monitor structural dynamics of dendritic spines while synaptic functions and plasticity were measured via electrophysiological recordings of excitatory postsynaptic currents and hippocampal long-term potentiation in brain slices. Finally, behavioral tests were performed to analyze the impact of pharmacological inhibition of BACE1 on cognitive performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dose-dependent decrease of A&#x3b2;40 levels in vivo confirmed suppression of BACE1 activity by both inhibitors. Prolonged treatment caused a reduction in spine formation of layer V pyramidal neurons, which recovered after withdrawal of inhibitors. Congruently, the rate of spontaneous and miniature excitatory postsynaptic currents in pyramidal neurons and hippocampal long-term potentiation were reduced in animals treated with BACE1 inhibitors. These effects were not detected in Bace1(-/-) mice treated with SCH1682496, confirming BACE1 as the pharmacological target. Described structural and functional changes were associated with cognitive deficits as revealed in behavioral tests.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings indicate important functions to BACE1 in structural and functional synaptic plasticity in the mature brain, with implications for cognition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Filser</LastName><ForeName>Severin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Ludwig Maximilian University Munich, Munich, Germany; Center for Neuropathology, Ludwig Maximilian University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovsepian</LastName><ForeName>Saak V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Ludwig Maximilian University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masana</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazquez-Llorca</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Ludwig Maximilian University Munich, Munich, Germany; Center for Neuropathology, Ludwig Maximilian University Munich, Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Ludwig Maximilian University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandt Elvang</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration DK, H. Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volbracht</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration DK, H. Lundbeck A/S, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Marianne B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian K E</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Center for Neuropathology, Ludwig Maximilian University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Ludwig Maximilian University Munich, Munich, Germany; Center for Neuropathology, Ludwig Maximilian University Munich, Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Ludwig Maximilian University Munich, Munich, Germany. Electronic address: Jochen.Herms@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569204">LY2811376</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603951">SCH1682496</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013843">Thiazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biol Psychiatry. 2015 Apr 15;77(8):683-4. doi: 10.1016/j.biopsych.2015.03.001.</RefSource><PMID Version="1">25835287</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055366" MajorTopicYN="N">Synaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013843" MajorTopicYN="N">Thiazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">BACE1</Keyword><Keyword MajorTopicYN="N">Dendritic spines</Keyword><Keyword MajorTopicYN="N">In vivo two-photon imaging</Keyword><Keyword MajorTopicYN="N">Learning and memory</Keyword><Keyword MajorTopicYN="N">Long-term potentiation</Keyword><Keyword MajorTopicYN="N">Synaptic transmission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2014.10.013</ArticleId><ArticleId IdType="pii">S0006-3223(14)00793-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25437566</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.</ArticleTitle><Pagination><StartPage>1135</StartPage><EndPage>1150</EndPage><MedlinePgn>1135-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.09.042</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)00825-0</ELocationID><Abstract><AbstractText>Chaperones are central to the proteostasis network (PN) and safeguard the proteome from misfolding, aggregation, and proteotoxicity. We categorized the human chaperome of 332 genes into network communities using function, localization, interactome, and expression data sets. During human brain aging, expression of 32% of the chaperome, corresponding to ATP-dependent chaperone machines, is repressed, whereas 19.5%, corresponding to ATP-independent chaperones and co-chaperones, are induced. These repression and induction clusters are enhanced in the brains of those with Alzheimer's, Huntington's, or Parkinson's disease. Functional properties of the chaperome were assessed by perturbation in C. elegans and human cell models expressing A&#x3b2;, polyglutamine, and Huntingtin. Of 219 C. elegans orthologs, knockdown of 16 enhanced both A&#x3b2; and polyQ-associated toxicity. These correspond to 28 human orthologs, of which 52% and 41% are repressed, respectively, in brain aging and disease and 37.5% affected Huntingtin aggregation in human cells. These results identify a critical chaperome subnetwork that functions in aging and disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brehme</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA; Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voisine</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolland</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wachi</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soper</LastName><ForeName>James H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yitan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orton</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villella</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garza</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: marc_vidal@dfci.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Proteostasis Therapeutics, Inc., Cambridge, MA 02139, USA. Electronic address: hui.ge@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Richard I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL 60208, USA. Electronic address: r-morimoto@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50HG004233</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM038109</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG026647</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM038109</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA060553</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG004233</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026647</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25437566</ArticleId><ArticleId IdType="mid">NIHMS632524</ArticleId><ArticleId IdType="pmc">PMC4255334</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.09.042</ArticleId><ArticleId IdType="pii">S2211-1247(14)00825-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn YY, Bagrow JP, et al. Link communities reveal multiscale complexity in networks. Nature. 2010;466(7307):761&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562860</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese V, Yam AY, et al. Systems analyses reveal two chaperone networks with distinct functions in eukaryotic cells. Cell. 2006;124(1):75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413483</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida A, Bolanos JP, et al. Cdh1/Hct1-APC is essential for the survival of postmitotic neurons. J Neurosci. 2005;25(36):8115&#x2013;8121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725543</ArticleId><ArticleId IdType="pubmed">16148219</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch WE, Morimoto RI, et al. Adapting proteostasis for disease intervention. Science. 2008;319(5865):916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrends C, Langer CA, et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Molecular cell. 2006;23(6):887&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973440</ArticleId></ArticleIdList></Reference><Reference><Citation>Belin AC, Westerlund M. Parkinson's disease: a genetic perspective. The FEBS journal. 2008;275(7):1377&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">18279377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A, Miller EA, et al. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(35):14914&#x2013;14919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736453</ArticleId><ArticleId IdType="pubmed">19706382</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Cribbs DH, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(40):15605&#x2013;15610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563070</ArticleId><ArticleId IdType="pubmed">18832152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocharova NA, Sokolov SS, et al. Unexpected link between anaphase promoting complex and the toxicity of expanded polyglutamines expressed in yeast. Cell Cycle. 2008;7(24):3943&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066445</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77(1):71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, et al. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313(5793):1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings CJ, Mancini MA, et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature genetics. 1998;19(2):148&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620770</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. The Journal of Cell Biology. 2010;190(5):719&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935559</ArticleId><ArticleId IdType="pubmed">20819932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnhoefer DE, Wong BKY, et al. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discov. 2011;10(11):853&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206090</ArticleId><ArticleId IdType="pubmed">22015920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavin AC, Aloy P, et al. Proteome survey reveals modularity of the yeast cell machinery. Nature. 2006;440(7084):631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">16429126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311(5766):1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gieffers C, Peters BH, et al. Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons. Proc Natl Acad Sci U S A. 1999;96(20):11317&#x2013;11322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18031</ArticleId><ArticleId IdType="pubmed">10500174</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature reviews. Molecular cell biology. 2007;8(2):101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Frank R, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592748</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TW, Antoshechkin I, et al. WormBase: a comprehensive resource for nematode research. Nucleic acids research. 2010;38(Database issue):D463&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808986</ArticleId><ArticleId IdType="pubmed">19910365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl FU, Bracher A, et al. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475(7356):324&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">21776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002;295(5561):1852&#x2013;1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11884745</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslbeck V, Eckl JM, et al. Chaperone-interacting TPR proteins in Caenorhabditis elegans. Journal of molecular biology. 2013;425(16):2922&#x2013;2939.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges A, Strand AD, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Human molecular genetics. 2006;15(6):965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter S, Jones P, et al. InterPro in 2011: new developments in the family and domain prediction database. Nucleic acids research. 2012;40(Database issue):D306&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245097</ArticleId><ArticleId IdType="pubmed">22096229</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana NR, Tanaka M, et al. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Human molecular genetics. 2000;9(13):2009&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">10942430</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 2003;30(4):313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">12828945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AH, Puram SV, et al. A centrosomal Cdc20-APC pathway controls dendrite morphogenesis in postmitotic neurons. Cell. 2009;136(2):322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707082</ArticleId><ArticleId IdType="pubmed">19167333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura A, Kubota H, et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nature cell biology. 2006;8(10):1163&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleizen B, Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol. 2004;16(4):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczera T, Stilling RM, et al. The anaphase promoting complex is required for memory function in mice. Learn Mem. 2011;18(1):49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">21191042</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbehn DR, Brinkman RR, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical genetics. 2004;65(4):267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15025718</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Shin YH, et al. The adaptor protein of the anaphase promoting complex Cdh1 is essential in maintaining replicative lifespan and in learning and memory. Nat Cell Biol. 2008;10(9):1083&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914158</ArticleId><ArticleId IdType="pubmed">19160489</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, Reiman EM, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(11):4441&#x2013;4446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393743</ArticleId><ArticleId IdType="pubmed">18332434</ArticleId></ArticleIdList></Reference><Reference><Citation>Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(20):9368&#x2013;9372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40986</ArticleId><ArticleId IdType="pubmed">7568134</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, Lu T, et al. Evolution of the aging brain transcriptome and synaptic regulation. PloS one. 2008;3(10):e3329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Otin C, Blasco MA, et al. The hallmarks of aging. Cell. 2013;153(6):1194&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre C, Delgado-Esteban M, et al. Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity. EMBO J. 2008;27(20):2736&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572178</ArticleId><ArticleId IdType="pubmed">18818692</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrocco K, Thomann A, et al. The APC/C E3 ligase remains active in most post-mitotic Arabidopsis cells and is required for proper vasculature development and organization. Development. 2009;136(9):1475&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">19336465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer MP. Hsp70 chaperone dynamics and molecular mechanism. Trends in biochemical sciences. 2013;38(10):507&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">24012426</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran LB, Duke DC, et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics. 2006;7(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344956</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JF, Brignull HR, et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(16):10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124929</ArticleId><ArticleId IdType="pubmed">12122205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj N, Wisniewski JR, et al. Deep proteome and transcriptome mapping of a human cancer cell line. Molecular systems biology. 2011;7:548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261714</ArticleId><ArticleId IdType="pubmed">22068331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nollen EA, Garcia SM, et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(17):6403&#x2013;6408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404057</ArticleId><ArticleId IdType="pubmed">15084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SH, Kukushkin Y, et al. PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell. 2013;154(1):134&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annual review of biochemistry. 2006;75:271&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756493</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers ET, Balch WE. Diversity in the origins of proteostasis networks -a driver for protein function in evolution. Nature reviews. Molecular cell biology. 2013;14(4):237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718298</ArticleId><ArticleId IdType="pubmed">23463216</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers ET, Morimoto RI, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009;78:959&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">19298183</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodromou C, Siligardi G, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. The EMBO journal. 1999;18(3):754&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171168</ArticleId><ArticleId IdType="pubmed">9927435</ArticleId></ArticleIdList></Reference><Reference><Citation>Queitsch C, Sangster TA, et al. Hsp90 as a capacitor of phenotypic variation. Nature. 2002;417(6889):618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050657</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 1998;396(6709):336&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845070</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyal SH, Schmidt E, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(11):5750&#x2013;5755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18505</ArticleId><ArticleId IdType="pubmed">10811890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayers EW, Barrett T, et al. Database resources of the National Center for Biotechnology Information. Nucleic acids research. 2012;40(Database issue):D13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245031</ArticleId><ArticleId IdType="pubmed">22140104</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochimica et biophysica acta. 2014;1843(1):13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858528</ArticleId><ArticleId IdType="pubmed">23994620</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Fox S, et al. A genetic screening strategy identifies novel regulators of the proteostasis network. PLoS genetics. 2011;7(12):e1002438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248563</ArticleId><ArticleId IdType="pubmed">22242008</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoot ME, Ono K, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031041</ArticleId><ArticleId IdType="pubmed">21149340</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Masison DC. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1). The Journal of biological chemistry. 2005;280(40):34178&#x2013;34185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1343460</ArticleId><ArticleId IdType="pubmed">16100115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam S, Geller R, et al. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nature cell biology. 2006;8(10):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829982</ArticleId><ArticleId IdType="pubmed">16980959</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsuta T, Model K, et al. Formation of membrane-bound ring complexes by prohibitins in mitochondria. Molecular biology of the cell. 2005;16(1):248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539169</ArticleId><ArticleId IdType="pubmed">15525670</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Reumers J, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nature chemical biology. 2011;7(5):285&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">21445056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu A, Shibata Y, et al. Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(15):E1481&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992642</ArticleId><ArticleId IdType="pubmed">24706768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25503365</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>52</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA.</ArticleTitle><Pagination><StartPage>18619</StartPage><EndPage>18624</EndPage><MedlinePgn>18619-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1413994112</ELocationID><Abstract><AbstractText>Transactivation response element (TAR) DNA-binding protein 43 (TDP-43) is the principal component of ubiquitinated inclusions characteristic of most forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia-frontotemporal lobar degeneration with TDP-43-positive inclusions (FTLD-TDP), as well as an increasing spectrum of other neurodegenerative diseases. Previous structural and functional studies on TDP-43 have been mostly focused on its recognized domains. Very recently, however, its extreme N terminus was identified to be a double-edged sword indispensable for both physiology and proteinopathy, but thus far its structure remains unknown due to the severe aggregation. Here as facilitated by our previous discovery that protein aggregation can be significantly minimized by reducing salt concentrations, by circular dichroism and NMR spectroscopy we revealed that the TDP-43 N terminus encodes a well-folded structure in concentration-dependent equilibrium with its unfolded form. Despite previous failure in detecting any sequence homology to ubiquitin, the folded state was determined to adopt a novel ubiquitin-like fold by the CS-Rosetta program with NMR chemical shifts and 78 unambiguous long-range nuclear Overhauser effect (NOE) constraints. Remarkably, this ubiquitin-like fold could bind ssDNA, and the binding shifted the conformational equilibrium toward reducing the unfolded population. To the best of our knowledge, the TDP-43 N terminus represents the first ubiquitin-like fold capable of directly binding nucleic acid. Our results provide a molecular mechanism rationalizing the functional dichotomy of TDP-43 and might also shed light on the formation and dynamics of cellular ribonucleoprotein granules, which have been recently linked to ALS pathogenesis. As a consequence, one therapeutic strategy for TDP-43-causing diseases might be to stabilize its ubiquitin-like fold by ssDNA or designed molecules.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Haina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Faculty of Science, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Liang-Zhong</ForeName><Initials>LZ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Faculty of Science, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National University of Singapore Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 119260.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jianxing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Faculty of Science, and National University of Singapore Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 119260 dbssjx@nus.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004277">DNA, Single-Stranded</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004277" MajorTopicYN="N">DNA, Single-Stranded</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058767" MajorTopicYN="Y">Protein Unfolding</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTLD-TDP</Keyword><Keyword MajorTopicYN="N">NMR spectroscopy</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ubiquitin-like fold</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25503365</ArticleId><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="doi">10.1073/pnas.1413994112</ArticleId><ArticleId IdType="pii">1413994112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2012;13(1):38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Human, Drosophila, and C.elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348(3):575&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276(39):36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat Struct Mol Biol. 2013;20(12):1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280(45):37572&#x2013;37584.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentealba RA, et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem. 2010;285(34):26304&#x2013;26314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924052</ArticleId><ArticleId IdType="pubmed">20554523</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem. 2012;287(10):7512&#x2013;7525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293573</ArticleId><ArticleId IdType="pubmed">22235134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2009;106(18):7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Molecular dissection of TDP-43 proteinopathies. J Mol Neurosci. 2011;45(3):480&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">21678031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet. 2013;22(15):3112&#x2013;3122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425(2):219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J. Insight into &#x201c;insoluble proteins&#x201d; with pure water. FEBS Lett. 2009;583(6):953&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">19233178</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J. Why do proteins aggregate? &#x201c;Intrinsically insoluble proteins&#x201d; and &#x201c;dark mediators&#x201d; revealed by studies on &#x201c;insoluble proteins&#x201d; solubilized in pure water. F1000 Res. 2013;2:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869494</ArticleId><ArticleId IdType="pubmed">24555050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang O, Kay LE, Olivier JP, Forman-Kay JD. Backbone 1H and 15N resonance assignments of the N-terminal SH3 domain of drk in folded and unfolded states using enhanced-sensitivity pulsed field gradient NMR techniques. J Biomol NMR. 1994;4(6):845&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">7812156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyson HJ, Wright PE. Unfolded proteins and protein folding studied by NMR. Chem Rev. 2004;104(8):3607&#x2013;3622.</Citation><ArticleIdList><ArticleId IdType="pubmed">15303830</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilloni C, De Simone A, Vranken WF, Vendruscolo M. Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. Biochemistry. 2012;51(11):2224&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pubmed">22360139</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: Implications for fibrillation. Protein Sci. 2006;15(12):2795&#x2013;2804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242444</ArticleId><ArticleId IdType="pubmed">17088319</ArticleId></ArticleIdList></Reference><Reference><Citation>Altieri AS, Hinton DP, Byrd RA. Association of biomolecular systems via pulsed field gradient NMR self-diffusion measurements. J Am Chem Soc. 1995;117(28):7566&#x2013;7567.</Citation></Reference><Reference><Citation>Palmer AG, III, Kroenke CD, Loria JP. Nuclear magnetic resonance methods for quantifying microsecond-to-millisecond motions in biological macromolecules. Methods Enzymol. 2001;339:204&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462813</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, et al. Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci USA. 2008;105(12):4685&#x2013;4690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290745</ArticleId><ArticleId IdType="pubmed">18326625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange OF, et al. Determination of solution structures of proteins up to 40 kDa using CS-Rosetta with sparse NMR data from deuterated samples. Proc Natl Acad Sci USA. 2012;109(27):10873&#x2013;10878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390869</ArticleId><ArticleId IdType="pubmed">22733734</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman S, et al. NMR structure determination for larger proteins using backbone-only data. Science. 2010;327(5968):1014&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909653</ArticleId><ArticleId IdType="pubmed">20133520</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner LR, et al. Structure of the BamC two-domain protein obtained by Rosetta with a limited NMR data set. J Mol Biol. 2011;411(1):83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182476</ArticleId><ArticleId IdType="pubmed">21624375</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm L, Rosenstr&#xf6;m P. Dali server: Conservation mapping in 3D. Nucleic Acids Res. 2010;38(Web Server issue):W545&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896194</ArticleId><ArticleId IdType="pubmed">20457744</ArticleId></ArticleIdList></Reference><Reference><Citation>Falini G, Fermani S, Tosi G, Arnesano F, Natile G. Structural probing of Zn(II), Cd(II) and Hg(II) binding to human ubiquitin. Chem Commun (Camb) 2008;7(45):5960&#x2013;5962.</Citation><ArticleIdList><ArticleId IdType="pubmed">19030552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sickmeier M, et al. DisProt: The database of disordered proteins. Nucleic Acids Res. 2007;35(Database issue):D786&#x2013;D793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1751543</ArticleId><ArticleId IdType="pubmed">17145717</ArticleId></ArticleIdList></Reference><Reference><Citation>Doszt&#xe1;nyi Z, Csizmok V, Tompa P, Simon I. IUPred: Web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics. 2005;21(16):3433&#x2013;3434.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackness BC, Tran MT, McClain SP, Matthews CR, Zitzewitz JA. Folding of the RNA recognition motif (RRM) domains of the amyotrophic lateral sclerosis (ALS)-linked protein TDP-43 reveals an intermediate state. J Biol Chem. 2014;289(12):8264&#x2013;8276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961654</ArticleId><ArticleId IdType="pubmed">24497641</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201(3):361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich HD. Two-way communications between ubiquitin-like modifiers and DNA. Nat Struct Mol Biol. 2014;21(4):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">24699080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int. 2012;60(4):415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306778</ArticleId></ArticleIdList></Reference><Reference><Citation>King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25521377</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.</ArticleTitle><Pagination><StartPage>1213</StartPage><EndPage>1225</EndPage><MedlinePgn>1213-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.12.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)01091-5</ELocationID><Abstract><AbstractText>Expanded GGGGCC (G4C2) nucleotide repeats within the C9ORF72 gene are the most common genetic mutation associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Sense and antisense transcripts of these expansions are translated to form five dipeptide repeat proteins (DRPs). We employed primary cortical and motor neuron cultures, live-cell imaging, and transgenic fly models and found that the arginine-rich dipeptides, in particular Proline-Arginine (PR), are potently neurotoxic. Factors that anticipated their neurotoxicity included aggregation in nucleoli, decreased number of processing bodies, and stress granule formation, implying global translational dysregulation as path accountable for toxicity. Nuclear PR aggregates were also found in human induced motor neurons and postmortem spinal cord tissues from C9ORF72 ALS and ALS/FTD patients. Intronic G4C2 transcripts, but not loss of C9ORF72 protein, are also toxic to motor and cortical neurons. Interestingly, G4C2 transcript-mediated neurotoxicity synergizes with that of PR aggregates, suggesting convergence of mechanisms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Xinmei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Wenzhi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westergard</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamurthy</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markandaiah</LastName><ForeName>Shashirekha S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yingxiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shaoyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shneider</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Center for Motor Neuron Biology and Disease, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monaghan</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Child Neurology and Neurobiology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, One&#xa0;Children's Hospital Drive, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Udai B</ForeName><Initials>UB</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Child Neurology and Neurobiology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, One&#xa0;Children's Hospital Drive, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasinelli</LastName><ForeName>Piera</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trotti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Frances and Joseph Weinberg Unit for ALS Research, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA. Electronic address: davide.trotti@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-NS051488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS044292</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00-NS07743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS090912</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS081303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-NS090912</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS44292</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS077435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016375">Antisense Elements (Genetics)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016375" MajorTopicYN="N">Antisense Elements (Genetics)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25521377</ArticleId><ArticleId IdType="mid">NIHMS647745</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pii">S0896-6273(14)01091-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of Amyotrophic Lateral Sclerosis. Ann Neurol 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle JG, Lanson NA, Jr, Smith RB, Casci I, Maltare A, Monaghan J, Nichols CD, Kryndushkin D, Shewmaker F, Pandey UB. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet. 2013;22:1193&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578413</ArticleId><ArticleId IdType="pubmed">23257289</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, O&#x2019;Brien C, Phukan J, Lynch C, Pender N, Hardiman O. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013a;126:829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Cosio DM, Petrucelli L. c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. Expert Opin Ther Targets. 2013b;17:991&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pubmed">23844663</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayser MS, McClelland AC, Hughes EG, Dalva MB. Intracellular and trans-synaptic regulation of glutamatergic synaptogenesis by EphB receptors. J Neurosci. 2006;26:12152&#x2013;12164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675446</ArticleId><ArticleId IdType="pubmed">17122040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Tisdale S, Hickman T, Anderson P. Real-time and quantitative imaging of mammalian stress granules and processing bodies. Methods in enzymology. 2008;448:521&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">19111193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanson NA, Jr, Maltare A, King H, Smith R, Kim JH, Taylor JP, Lloyd TE, Pandey UB. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet. 2011;20:2510&#x2013;2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288133</ArticleId><ArticleId IdType="pubmed">21487023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, et al. Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic. Cell reports. 2013;5:1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesuisse C, Martin LJ. Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J Neurobiol. 2002;51:9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11920724</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Sahawneh MA, Przedborski S, Estevez AG, Manfredi G. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci. 2012;32:229&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566782</ArticleId><ArticleId IdType="pubmed">22219285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahr A, Aberle H. The expression pattern of the Drosophila vesicular glutamate transporter: a marker protein for motoneurons and glutamatergic centers in the brain. Gene expression patterns: GEP. 2006;6:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">16378756</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Rollinson S, Robinson A, Bennion Callister J, Thompson JC, Snowden JS, Gendron T, Petrucelli L, Masuda-Suzukake M, Hasegawa M, et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta neuropathologica communications. 2013;1:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893586</ArticleId><ArticleId IdType="pubmed">24252525</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Isaacs AM. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr Opin Neurol. 2014;27:515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalabothula N, Indig FE, Carrier F. The Nucleolus Takes Control of Protein Trafficking Under Cellular Stress. Molecular and cellular pharmacology. 2010;2:203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076688</ArticleId><ArticleId IdType="pubmed">21499571</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, Lehrach H, Krobitsch S. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Molecular biology of the cell. 2007;18:1385&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochs RL, Lischwe MA, Spohn WH, Busch H. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biology of the cell/under the auspices of the European Cell Biology Organization. 1985;54:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">2933102</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, Lynch C, Pender N, Hardiman O. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SY, Macgregor RB, Pearson CE. The disease-associated r(GGGGCC)n repeat from the C9ORF72 gene forms tract length-dependent uni- and multi-molecular RNA G-quadruplex structures. J Biol Chem 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, Stewart H, Finger E, Volkening K, Seeley WW, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of aging. 2012;33:2950 e2955&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617405</ArticleId><ArticleId IdType="pubmed">22840558</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhattar R, Markey SP, Tanese N. Huntington&#x2019;s disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci U S A. 2008;105:10820&#x2013;10825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504805</ArticleId><ArticleId IdType="pubmed">18669659</ArticleId></ArticleIdList></Reference><Reference><Citation>Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, Woolf CJ, Eggan K. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell. 2011;9:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188987</ArticleId><ArticleId IdType="pubmed">21852222</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas MG, Loschi M, Desbats MA, Boccaccio GL. RNA granules: the good, the bad and the ugly. Cellular signalling. 2011;23:324&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001194</ArticleId><ArticleId IdType="pubmed">20813183</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735339</ArticleId><ArticleId IdType="pubmed">23920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IO, Mead S. The C9ORF72 expansion mutation: gene structure, phenotypic and diagnostic issues. Acta Neuropathol. 2014;127:319&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">24515836</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, Zheng Y, Ghani M, Dib S, Keith J, et al. Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72 Expansion. Am J Hum Genet. 2013;92:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL, Li H, Hales CM, Gearing M, Wingo TS, Jin P. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci U S A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, Daughrity L, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25533482</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>NF&#x3ba;B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>115</EndPage><MedlinePgn>101-115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.11.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)01046-0</ELocationID><Abstract><AbstractText>Abnormal NF&#x3ba;B activation has been implicated in Alzheimer's disease (AD). However, the signaling pathways governing NF&#x3ba;B regulation and function in the brain are poorly understood. We identify complement protein C3 as an astroglial target of NF&#x3ba;B and show that C3 release acts through neuronal C3aR to disrupt dendritic morphology and network function. Exposure to A&#x3b2; activates astroglial NF&#x3ba;B and C3 release, consistent with the high levels of C3 expression in brain tissue from AD patients and APP transgenic mice, where C3aR antagonist treatment rescues cognitive impairment. Therefore, dysregulation of neuron-glia interaction through NF&#x3ba;B/C3/C3aR signaling may contribute to synaptic dysfunction in AD, and C3aR antagonists may be therapeutically beneficial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Allysa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Angie C-A</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Stephanie W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Rivera</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taglialatela</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankowsky</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hui-Chen</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine and the Cain Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Houston, TX 77030, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: huiz@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE63012</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U54 HD083092</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033467</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS086794</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS076117</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076117</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033467</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C085567">complement C3a receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Feb;16(2):67. doi: 10.1038/nrn3908.</RefSource><PMID Version="1">25601774</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25533482</ArticleId><ArticleId IdType="mid">NIHMS645931</ArticleId><ArticleId IdType="pmc">PMC4289109</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.11.018</ArticleId><ArticleId IdType="pii">S0896-6273(14)01046-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahamed J, Venkatesha RT, Thangam EB, Ali H. C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J. Immunol. 2004;172:6961&#x2013;6968.</Citation><ArticleIdList><ArticleId IdType="pubmed">15153516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn HJ, Hernandez CM, Levenson JM, Lubin FD, Liou HC, Sweatt JD. c-Rel, an NF-&#x3ba;B family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. Learn. Mem. 2008;15:539&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2505322</ArticleId><ArticleId IdType="pubmed">18626097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002;22:5100&#x2013;5113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139771</ArticleId><ArticleId IdType="pubmed">12077339</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltimore D. NF-&#x3ba;B is 25. Nat. Immunol. 2011;12:683&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">21772275</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC. Control of synaptic strength by glial TNF&#x3b1;. Science. 2002;295:2282&#x2013;2285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910117</ArticleId></ArticleIdList></Reference><Reference><Citation>Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-&#x3ba;B activation, enhanced granulopoiesis, and neonatal lethality in I&#x3ba;B&#x3b1;-deficient mice. Genes. Dev. 1995;9:2736&#x2013;2746.</Citation><ArticleIdList><ArticleId IdType="pubmed">7590249</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;nard M, Raoult E, Vaudry D, Leprince J, Falluel-Morel A, Gonzalez BJ, Galas L, Vaudry H, Fontaine M. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Mol. Immunol. 2008;45:3767&#x2013;3774.</Citation><ArticleIdList><ArticleId IdType="pubmed">18635264</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J. Neurosci. 2011;31:3459&#x2013;3469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3080046</ArticleId><ArticleId IdType="pubmed">21368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-&#x3ba;B is a key event in brain tolerance. J. Neurosci. 2001;21:4668&#x2013;4677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762345</ArticleId><ArticleId IdType="pubmed">11425894</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma MCH, Dresselhaus EC, De Biase LM, Mihalas AB, Bergles DE, Meffert MK. A requirement for nuclear factor-&#x3ba;B in developmental and plasticity-associated synaptogenesis. J. Neurosci. 2011;31:5414&#x2013;5425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3113725</ArticleId><ArticleId IdType="pubmed">21471377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, Schreiter ER, Kerr RA, Orger MB, Jayaraman V, et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013;499:295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777791</ArticleId><ArticleId IdType="pubmed">23868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I&#x3ba;B&#x3b1; activity. Proc. Natl. Acad. Sci. U. S. A. 1994;91:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42879</ArticleId><ArticleId IdType="pubmed">8278379</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulter DA, Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. Glia. 2012;60:1215&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375386</ArticleId><ArticleId IdType="pubmed">22592998</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat. Rev. Neurosci. 2007;8:101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17237803</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragatsis I, Zeitlin S. CaMKII&#x3b1;-Cre transgene expression and recombination patterns in the mouse brain. Genesis. 2000;26:133&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686608</ArticleId></ArticleIdList></Reference><Reference><Citation>Dr&#xf6;gem&#xfc;ller K, Helmuth U, Brunn A, Sakowicz-Burkiewicz M, Gutmann DH, Mueller W, Deckert M, Schl&#xfc;ter D. Astrocyte gp130 expression is critical for the control of toxoplasma encephalitis. J. Immunol. 2008;181:2683&#x2013;2693.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684959</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber K, Cheung G, Mitchell D, Wallis R, Weihe E, Schwaeble W, Kettenmann H. C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. J. Neurosci. Res. 2009;87:644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635544</ArticleId><ArticleId IdType="pubmed">18831010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 2009;183:1375&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067320</ArticleId><ArticleId IdType="pubmed">19561098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesne SE, Jankowsky JL. Genetic modulation of soluble A&#x3b2; rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 2014;34:7871&#x2013;7885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000;49:171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">10904116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W, Banerjee A. Unravelling the complexities of the NF-&#x3ba;B signalling pathway using mouse knockout and transgenic models. Oncogene. 2006;25:6781&#x2013;6799.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogolla N, Galimberti I, DePaola V, Caroni P. Preparation of organotypic hippocampal slice cultures for long-term live imaging. Nat. Protoc. 2006;1:1165&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406399</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrini L, Molteni A, Wirth T, Kistler B, Blasi F. Glutamate-dependent activation of NF-&#x3ba;B during mouse cerebellum development. J. Neurosci. 1997;17:6057&#x2013;6063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568342</ArticleId><ArticleId IdType="pubmed">9236217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanafusa N, Sogabe H, Yamada K, Wada T, Fujita T, Nangaku M. Contribution of genetically engineered animals to the analyses of complement in the pathogenesis of nephritis. Nephrol. Dial. Transplant 17 Suppl. 2002;9:34&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12386282</ArticleId></ArticleIdList></Reference><Reference><Citation>Herkenham M, Rathore P, Brown P, Listwak S. Cautionary notes on the use of NF-&#x3ba;B p65 and p50 antibodies for CNS studies. J. Neuroinflammation. 2011;8:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210105</ArticleId><ArticleId IdType="pubmed">21999414</ArticleId></ArticleIdList></Reference><Reference><Citation>Holers VM. Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 2014;32:433&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">24499275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y. A critical role of astrocyte-mediated nuclear factor-&#x3ba;B-dependent inflammation in Huntington's disease. Hum. Mol. Genet. 2013;22:1826&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">23372043</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 2000;406:998&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC. Nuclear translocation of NF-&#x3ba;B is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1997;94:7531&#x2013;7536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23856</ArticleId><ArticleId IdType="pubmed">9207126</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of A&#x3b2; production in a transgenic model of Alzheimer disease. PLoS. Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt B, Deller T, Frotscher M, Kaltschmidt C. Ultrastructural localization of activated NF-&#x3ba;B in granule cells of the rat fascia dentata. Neuroreport. 2000;11:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">10757530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt B, Ndiaye D, Korte M, Pothion S, Arbibe L, Prullage M, Pfeiffer J, Lindecke A, Staiger V, Israel A, et al. NF-&#x3ba;B regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol. Cell. Biol. 2006;26:2936&#x2013;2946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1446931</ArticleId><ArticleId IdType="pubmed">16581769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-&#x3ba;B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997;94:2642&#x2013;2647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20142</ArticleId><ArticleId IdType="pubmed">9122249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Brain synapses contain inducible forms of the transcription factor NF-&#x3ba;B. Mech. Dev. 1993;43:135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">8297787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Stimulation of ionotropic glutamate receptors activates transcription factor NF-&#x3ba;B in primary neurons. Proc. Natl. Acad. Sci. U. S. A. 1995;92:9618&#x2013;9622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40853</ArticleId><ArticleId IdType="pubmed">7568184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-&#x3ba;B activity in neurons. Mol. Cell. Biol. 1994;14:3981&#x2013;3992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358764</ArticleId><ArticleId IdType="pubmed">8196637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassed CA, Willing AE, Garbuzova-Davis S, Sanberg PR, Pennypacker KR. Lack of NF-&#x3ba;B p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp. Neurol. 2002;176:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12359170</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement J, Rice N, Car B, Abbondanzo S, Powers G, Bhatt P, Chen C, Rosen C, Stewart C. I&#x3ba;B&#x3b1; deficiency results in a sustained NF-&#x3ba;B response and severe widespread dermatitis in mice. Mol. Cell. Biol. 1996;16:2341&#x2013;2349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231222</ArticleId><ArticleId IdType="pubmed">8628301</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo J, Russo S, Ferguson D, Nestler E, Duman R. Nuclear factor-&#x3ba;B is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad. Sci. U. S. A. 2010;107:2669&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823860</ArticleId><ArticleId IdType="pubmed">20133768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyritsis N, Kizil C, Brand M. Neuroinflammation and central nervous system regeneration in vertebrates. Trends. Cell. Biol. 2014;24:128&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">24029244</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalo U, Palygin O, Rasooli-Nejad S, Andrew J, Haydon PG, Pankratov Y. Exocytosis of ATP from astrocytes modulates phasic and tonic inhibition in the neocortex. PLoS. Biol. 2014;12:e1001747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883644</ArticleId><ArticleId IdType="pubmed">24409095</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. 2006;199:454&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545803</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, Pizzi M, Liou HC, Sweatt JD. A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel. J. Neurosci. 2004;24:3933&#x2013;3943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729420</ArticleId><ArticleId IdType="pubmed">15102909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Shim DJ, Gaddam SS, Rodriguez-Rivera J, Bitner BR, Pautler RG, Robertson CS, Zheng H. I&#x3ba;B&#x3b1; deficiency in brain leads to elevated basal neuroinflammation and attenuated response following traumatic brain injury: implications for functional recovery. Mol. Neurodegener. 2012;7:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473257</ArticleId><ArticleId IdType="pubmed">22992283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Moerman-Herzog A, Chen Y, Barger S. Unique aspects of transcriptional regulation in neurons - nuances in NF&#x3ba;B and Sp1-related factors. J. Neuroinflammation. 2009;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693111</ArticleId><ArticleId IdType="pubmed">19450264</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranto J, Rappaport J, Datta PK. Regulation of complement component C3 in astrocytes by IL-1&#x3b2; and morphine. J. Neuroimmune. Pharmacol. 2008;3:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18247123</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranto J, Rappaport J, Datta PK. Role of C/EBP-&#x3b2;, p38 MAPK, and MKK6 in IL-1&#x3b2;-mediated C3 gene regulation in astrocytes. J. Cell. Biochem. 2011;112:1168&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072290</ArticleId><ArticleId IdType="pubmed">21308746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Calcium and neurodegeneration. Aging. Cell. 2007;6:337&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">17328689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Culmsee C, Yu Z, Camandola S. Roles of nuclear factor &#x3ba;B in neuronal survival and plasticity. J. Neurochem. 2000;74:443&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">10646495</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Meffert MK. Roles for NF-&#x3ba;B in nerve cell survival, plasticity, and disease. Cell. Death. Differ. 2006;13:852&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">16397579</ArticleId></ArticleIdList></Reference><Reference><Citation>Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D. NF-&#x3ba;B functions in synaptic signaling and behavior. Nat. Neurosci. 2003;6:1072&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">12947408</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijering E, Jacob M, Sarria J-CF, Steiner P, Hirling H, Unser M. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry. A. 2004;58:167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057970</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon MR, Parikh AA, Pritts TA, Fischer JE, Cottongim S, Szabo C, Salzman AL, Hasselgren PO. Complement component C3 production in IL-1&#x3b2;-stimulated human intestinal epithelial cells is blocked by NF-&#x3ba;B inhibitors and by transfection with ser 32/36 mutant I&#x3ba;B&#x3b1;. J. Surg. Res. 1999;82:48&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10068525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia. 2010;58:300&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795105</ArticleId><ArticleId IdType="pubmed">19705461</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami Y, Imamichi T, Nagasawa S. Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages. Immunology. 1993;79:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421936</ArticleId><ArticleId IdType="pubmed">8406589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends. Neurosci. 1999;22:397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441300</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckinghaus A, Ghosh S. The NF-&#x3ba;B family of transcription factors and its regulation. Cold. Spring. Harb. Perspect. Biol. 2009;1:a000034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773619</ArticleId><ArticleId IdType="pubmed">20066092</ArticleId></ArticleIdList></Reference><Reference><Citation>Peethumnongsin E, Yang L, Kallhoff-Munoz V, Hu L, Takashima A, Pautler RG, Zheng H. Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function. J. Neurosci. 2010;30:13409&#x2013;13418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962595</ArticleId><ArticleId IdType="pubmed">20926667</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng B, Ling J, Lee AJ, Wang Z, Chang Z, Jin W, Kang Y, Zhang R, Shim D, Wang H, et al. Defective feedback regulation of NF-&#x3ba;B underlies Sjogren's syndrome in mice with mutated &#x3ba;B enhancers of the I&#x3ba;B&#x3b1; promoter. Proc. Natl. Acad. Sci. U. S. A. 2010;107:15193&#x2013;15198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930541</ArticleId><ArticleId IdType="pubmed">20696914</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzi M, Spano P. Distinct roles of diverse nuclear factor-&#x3ba;B complexes in neuropathological mechanisms. Eur. J. Pharmacology. 2006;545:22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854410</ArticleId></ArticleIdList></Reference><Reference><Citation>Polito VA, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y, Swartzlander DB, Palmieri M, di Ronza A, Lee VM, et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO. Mol. Med. 2014;6:1142&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197862</ArticleId><ArticleId IdType="pubmed">25069841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK, Zwirner J, Wetsel RA, Gerard C, Pekny M, Pekna M. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO. J. 2006;25:1364&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422160</ArticleId><ArticleId IdType="pubmed">16498410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013;190:3831&#x2013;3838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623009</ArticleId><ArticleId IdType="pubmed">23564577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayah S, Jauneau AC, Patte C, Tonon MC, Vaudry H, Fontaine M. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Mol. Brain. Res. 2003;112:53&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670702</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert G, Steinhauser C. Neuron-astrocyte signaling and epilepsy. Exp. Neurol. 2013;244:4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21925173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard PW, Sun X, Emery JF, Giffard RG, Khammash M. Quantitative characterization and analysis of the dynamic NF-&#x3ba;B response in microglia. BMC. Bioinformatics. 2011;12:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158563</ArticleId><ArticleId IdType="pubmed">21729324</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim DJ, Yang L, Reed JG, Noebels JL, Chiao PJ, Zheng H. Disruption of the NF-&#x3ba;B/I&#x3ba;B&#x3b1; autoinhibitory loop improves cognitive performance and promotes hyperexcitability of hippocampal neurons. Mol. Neurodegener. 2011;6:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141554</ArticleId><ArticleId IdType="pubmed">21663635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinjyo N, St&#xe5;hlberg A, Dragunow M, Pekny M, Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem. Cells. 2009;27:2824&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">19785034</ArticleId></ArticleIdList></Reference><Reference><Citation>Simakajornboon N, Gozal E, Gozal D. Developmental patterns of NF-&#x3ba;B activation during acute hypoxia in the caudal brainstem of the rat. Brain. Res. Dev. Brain. Res. 2001;127:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">11335004</ArticleId></ArticleIdList></Reference><Reference><Citation>Song I, Huganir RL. Regulation of AMPA receptors during synaptic plasticity. Trends. Neurosci. 2002;25:578&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392933</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF&#x3b1;. Nature. 2006;440:1054&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">16547515</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-&#x3b2; peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Vik DP, Amiguet P, Moffat GJ, Fey M, Amiguet-Barras F, Wetsel RA, Tack BF. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry. 1991;30:1080&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">1703437</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 2008;181:8727&#x2013;8734.</Citation><ArticleIdList><ArticleId IdType="pubmed">19050293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2:a006346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada KA. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol. Dis. 1998;5:67&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9746904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Wang Z, Wang B, Justice NJ, Zheng H. Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. J. Neurosci. 2009;29:15660&#x2013;15668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833283</ArticleId><ArticleId IdType="pubmed">20016080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Malik A, Choi HB, Ko RW, Dissing-Olesen L, Macvicar BA. Microglial CR3 Activation Triggers Long-Term Synaptic Depression in the Hippocampus via NADPH Oxidase. Neuron. 2014;82:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">24631344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009;9:729&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25531812</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Rarity of the Alzheimer disease-protective APP A673T variant in the United States.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>216</EndPage><MedlinePgn>209-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.2157</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the frequency of the APP A673T variant in a large group of elderly cognitively normal controls and AD cases from the United States and in 2 case-control cohorts from Sweden.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Case-control association analysis of variant APP A673T in US and Swedish white individuals comparing AD cases with cognitively intact elderly controls. Participants were ascertained at multiple university-associated medical centers and clinics across the United States and Sweden by study-specific sampling methods. They were from case-control studies, community-based prospective cohort studies, and studies that ascertained multiplex families from multiple sources.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Genotypes for the APP A673T variant were determined using the Infinium HumanExome V1 Beadchip (Illumina, Inc) and by TaqMan genotyping (Life Technologies).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The A673T variant genotypes were evaluated in 8943 US AD cases, 10&#x2009;480 US cognitively normal controls, 862 Swedish AD cases, and 707 Swedish cognitively normal controls. We identified 3 US individuals heterozygous for A673T, including 1 AD case (age at onset, 89 years) and 2 controls (age at last examination, 82 and 77 years). The remaining US samples were homozygous for the alanine (A673) allele. In the Swedish samples, 3 controls were heterozygous for A673T and all AD cases were homozygous for the A673 allele. We also genotyped a US family previously reported to harbor the A673T variant and found a mother-daughter pair, both cognitively normal at ages 72 and 84 years, respectively, who were both heterozygous for A673T; however, all individuals with AD in the family were homozygous for A673.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The A673T variant is extremely rare in US cohorts and does not play a substantial role in risk for AD in this population. This variant may be primarily restricted to Icelandic and Scandinavian populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri7Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murcia</LastName><ForeName>Josue D Gonzalez</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannon-Albright</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City10George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Biomedical Genetics, Department of Medicine, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London, England13Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Uni.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York17Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York18Gertrude H. Sergievsky Center, Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Family, Consumer, and Human Development, Utah State University, Logan20Department of Psychology, Utah State University, Logan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tschanz</LastName><ForeName>JoAnn T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Psychology, Utah State University, Logan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munger</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Dietetics, and Food Sciences, Utah State University, Logan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, Utah State University, Logan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chiao-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partch</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada25Cambridge Institute for Medical Research, Department of Clinical Neurosciences, University of Cambridge, Cambridge, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Genetics, Department of Medicine and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri7Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle28Group Health Research Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>Timothy W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech Inc, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Human Genetics and Research, Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, Utah30Department of Biostatistics, Boston University, Boston, Massachusetts31Department of Ophthalmology, Boston University, Boston, Massachusetts32Department of Neurology, Boston University, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida34Dr John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York18Gertrude H. Sergievsky Center, Columbia University, New York, New York35Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Institute on Aging-Late-Onset Alzheimer&#x2019;s Disease (NIA-LOAD) Family Study</CollectiveName></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Crocco</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Demirci</LastName><ForeName>F Yesim</ForeName><Initials>FY</Initials></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gei</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>W Marsel</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Murrell</LastName><ForeName>Jill R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Thornton-Wells</LastName><ForeName>Tricia A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wishnek</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG007584</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR02777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA137788</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL108623</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1 RR00096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG3272</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA132378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000135</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129769</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02NS 059729</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG30146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001417</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS059729</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031272</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL 108623</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG21136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25531812</ArticleId><ArticleId IdType="mid">NIHMS655158</ArticleId><ArticleId IdType="pmc">PMC4324097</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.2157</ArticleId><ArticleId IdType="pii">2048745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer&#x2019;s disease. Acta Neuropathol. 2012;124(3):305&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708460</ArticleId><ArticleId IdType="pubmed">22618995</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, Brindisi M, Tang J. Developing &#x3b2;-secretase inhibitors for treatment of Alzheimer&#x2019;s disease. J Neurochem. 2012;120(suppl 1):71&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276244</ArticleId><ArticleId IdType="pubmed">22122681</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Delrieu J, Ousset PJ, Caillaud C, Vellas B. &#x201c;Clinical trials in Alzheimer&#x2019;s disease&#x201d;: immunotherapy approaches. J Neurochem. 2012;120(suppl 1):186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">21883222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock ML, Warren JT, Jr, Roses AD, Fink JK. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer&#x2019;s disease. Neurology. 1993;43(6):1254&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8170579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kero M, Paetau A, Polvikoski T, et al. Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol Aging. 2013;34(5):e1&#x2013;e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">23102935</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science. 2009;323(5920):1473&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728497</ArticleId><ArticleId IdType="pubmed">19286555</ArticleId></ArticleIdList></Reference><Reference><Citation>Giliberto L, Borghi R, Piccini A, et al. Mutant presenilin 1 increases the expression and activity of BACE1. J Biol Chem. 2009;284(14):9027&#x2013;9038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666551</ArticleId><ArticleId IdType="pubmed">19196715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, et al. Alzheimer&#x2019;s Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Schellenberg GD, Bowen JD, et al. Apolipoprotein E in Alzheimer&#x2019;s disease risk and case detection: a case-control study. J Clin Epidemiol. 1996;49(10):1143&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8826994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer&#x2019;s disease: the NIMH genetics initiative. Neurology. 1997;48(1):139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Beecham GW, Martin ER, et al. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet. 2010;6(9):e1001130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944795</ArticleId><ArticleId IdType="pubmed">20885792</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JCS, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999;53(2):321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg M, Landgren S, Andersson ME, et al. Association of complement factor H Y402H gene polymorphism with Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):720&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">18163432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, et al. NIA-LOAD/NCRAD Family Study Consortium. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PLoS One. 2012;7(2):e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7 (2):180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Martinez A, Behrens IM, et al. E280A PS-1 mutation causes Alzheimer&#x2019;s disease but age of onset is not modified by ApoE alleles. Hum Mutat. 1997;10(3):186&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Daw EW, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer&#x2019;s disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005;132B(1):14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer&#x2019;s disease locus on chromosome 1. Science. 1995;269(5226):970&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science. 1995;269 (5226):973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting SK, Chong MS, Kandiah N, et al. Absence of A673T amyloid-&#x3b2; precursor protein variant in Alzheimer&#x2019;s disease and other neurological diseases. Neurobiol Aging. 2013;34(10):e7&#x2013;e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25531084</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1748-3395</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature nanotechnology</Title><ISOAbbreviation>Nat Nanotechnol</ISOAbbreviation></Journal><ArticleTitle>Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>98</EndPage><MedlinePgn>91-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nnano.2014.254</ELocationID><Abstract><AbstractText>One way to image the molecular pathology in Alzheimer's disease is by positron emission tomography using probes that target amyloid fibrils. However, these fibrils are not closely linked to the development of the disease. It is now thought that early-stage biomarkers that instigate memory loss are composed of A&#x3b2; oligomers. Here, we report a sensitive molecular magnetic resonance imaging contrast probe that is specific for A&#x3b2; oligomers. We attach oligomer-specific antibodies onto magnetic nanostructures and show that the complex is stable and binds to A&#x3b2; oligomers on cells and brain tissues to give a magnetic resonance imaging signal. When intranasally administered to an Alzheimer's disease mouse model, the probe readily reached hippocampal A&#x3b2; oligomers. In isolated samples of human brain tissue, we observed a magnetic resonance imaging signal that distinguished Alzheimer's disease from controls. Such nanostructures that target neurotoxic A&#x3b2; oligomers are potentially useful for evaluating the efficacy of new drugs and ultimately for early-stage Alzheimer's disease diagnosis and disease management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Kirsten L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbarboro</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureka</LastName><ForeName>Ruchi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De</LastName><ForeName>Mrinmoy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bicca</LastName><ForeName>Ma&#xed;ra A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1] Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA [2] Department of Pharmacology, Universidade Federal de Santa Catarina, Santa Catarina 88049900 Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasavada</LastName><ForeName>Shaleen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satpathy</LastName><ForeName>Sreyesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Illinois Math &amp;Science Academy, Aurora, llinois 60506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Summer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Illinois Math &amp;Science Academy, Aurora, llinois 60506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Hrushikesh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Pauline T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacRenaris</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Advanced Molecular Imaging, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>E Alex</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Center for Advanced Molecular Imaging, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacor</LastName><ForeName>Pascale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Pottumarthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, NorthShore University HealthSystems, Evanston, Illinois 60201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dravid</LastName><ForeName>Vinayak P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>1] Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60208, USA [2] International Institute for Nanotechnology (IIN), Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>1] Department of Neurobiology, Northwestern University, Evanston, Illinois 60208, USA [2] International Institute for Nanotechnology (IIN), Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG045637</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG045637</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029460</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54CA119341</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA119341</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029460</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Nanotechnol</MedlineTA><NlmUniqueID>101283273</NlmUniqueID><ISSNLinking>1748-3387</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25531084</ArticleId><ArticleId IdType="mid">NIHMS634115</ArticleId><ArticleId IdType="pmc">PMC4300856</ArticleId><ArticleId IdType="doi">10.1038/nnano.2014.254</ArticleId><ArticleId IdType="pii">nnano.2014.254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>2014 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2014;10:e47&#x2013;e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:2273&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta neuropathologica. 2013;126:659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Slemmon JR, et al. Measurement of Abeta1&#x2013;42 in cerebrospinal fluid is influenced by matrix effects. Journal of neurochemistry. 2012;120:325&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">22023354</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Annals of neurology. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer&#x2019;s Association. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2013;9:e-1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733252</ArticleId><ArticleId IdType="pubmed">23360977</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Annals of neurology. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyborg AC, et al. In vivo and ex vivo imaging of amyloid-beta cascade aggregates with a Pronucleon peptide. Journal of Alzheimer&#x2019;s disease : JAD. 2013;34:957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">23321523</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer&#x2019;s disease conundrum? Trends in neurosciences. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer&#x2019;s Disease. The Mount Sinai journal of medicine, New York. 2010;77:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306842</ArticleId><ArticleId IdType="pubmed">20101723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer&#x2019;s disease. Neurobiology of learning and memory. 2011;96:529&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390395</ArticleId><ArticleId IdType="pubmed">21914486</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnabel J. Amyloid: little proteins, big clues. Nature. 2011;475:S12&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harbor perspectives in medicine. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Synaptic targeting by Alzheimer&#x2019;s-related amyloid beta oligomers. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>De M, Chou SS, Joshi HM, Dravid VP. Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev. 2011;63:1282&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381436</ArticleId><ArticleId IdType="pubmed">21851844</ArticleId></ArticleIdList></Reference><Reference><Citation>Corot C, et al. In: Molecular and Cellular MR Imaging. Modo Michel MJ, Bulte Jeff WM., editors. Ch 4. CRC Press; 2007. pp. 59&#x2013;84.</Citation></Reference><Reference><Citation>Liu S, et al. A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation, characterization and in vivo application. Molecular pharmaceutics. 2009;6:1074&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">19527074</ArticleId></ArticleIdList></Reference><Reference><Citation>Serres S, et al. Molecular MRI enables early and sensitive detection of brain metastases. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:6674&#x2013;6679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340084</ArticleId><ArticleId IdType="pubmed">22451897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Monoclonal antibodies that target pathological assemblies of Abeta. Journal of neurochemistry. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Viola KL, Klein WL. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS &amp; neurological disorders drug targets. 2009;8:65&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19275637</ArticleId></ArticleIdList></Reference><Reference><Citation>Acton P, et al. Anti-ADDL antibodies and uses thereof. 7,811,563. Illinois/USA; New Jersey/USA patent. 2010</Citation></Reference><Reference><Citation>Xiao C, et al. Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-beta Oligomer Antibody in 5XFAD Mice. Journal of Alzheimer&#x2019;s disease : JAD. 2013;35:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722071</ArticleId><ArticleId IdType="pubmed">23542865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, et al. Alzheimer&#x2019;s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, et al. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer&#x2019;s disease drug candidate screening. Journal of molecular neuroscience : MN. 2003;20:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, et al. Temporal memory deficits in Alzheimer&#x2019;s mouse models: rescue by genetic deletion of BACE1. The European journal of neuroscience. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AbetaPP23 transgenic mice. Journal of Alzheimer&#x2019;s disease : JAD. 2010;21:1367&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">21504138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, et al. Transgenic mice as a model of pre-clinical Alzheimer&#x2019;s disease. Current Alzheimer research. 2011;8:4&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">21143159</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamura A, et al. Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer&#x2019;s disease model mouse. Molecular neurodegeneration. 2011;6:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061944</ArticleId><ArticleId IdType="pubmed">21375782</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco PT, et al. Synapse-binding subpopulations of Abeta oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci. 2012;3:972&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503444</ArticleId><ArticleId IdType="pubmed">23173076</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Barick KC, et al. Nanoscale assembly of amine-functionalized colloidal iron oxide. J Magn Magn Mater. 2009;321:1529&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673011</ArticleId><ArticleId IdType="pubmed">20160860</ArticleId></ArticleIdList></Reference><Reference><Citation>Na HB, Song IC, Hyeon T. Inorganic Nanoparticles for MRI Contrast Agents. Advanced materials. 2009;21:2133&#x2013;2148.</Citation></Reference><Reference><Citation>Pinho SLC, et al. Fine Tuning of the Relaxometry of gamma-Fe2O3@SiO2 Nanoparticles by Tweaking the Silica Coating Thickness. ACS nano. 2010;4:5339&#x2013;5349.</Citation><ArticleIdList><ArticleId IdType="pubmed">20795638</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash A, et al. Bilayers as Phase Transfer Agents for Nanocrystals Prepared in Nonpolar Solvents. ACS nano. 2009;3:2139&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19594166</ArticleId></ArticleIdList></Reference><Reference><Citation>Amstad E, Textor M, Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale. 2011;3:2819&#x2013;2843.</Citation><ArticleIdList><ArticleId IdType="pubmed">21629911</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong S, et al. Coating Optimization of Superparamagnetic Iron Oxide Nanoparticles for High T-2 Relaxivity. Nano letters. 2010;10:4607&#x2013;4613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170660</ArticleId><ArticleId IdType="pubmed">20939602</ArticleId></ArticleIdList></Reference><Reference><Citation>Amstad E, et al. Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. Nano letters. 2009;9:4042&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pubmed">19835370</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo A, Napolitano A, Barone P, d&#x2019;Ischia M. Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide induced neurotoxicity in neuronal degeneration. Chemical research in toxicology. 1999;12:1213&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604871</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R. MRI probe for amyloid-beta oligomers offers potential advantages for detecting Alzheimer&#x2019;s disease. Neurology Today. 2012;12:20&#x2013;22.</Citation></Reference><Reference><Citation>Park J, et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater. 2004;3:891&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">15568032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt AP, et al. Targeting activated microglia in Alzheimer&#x2019;s pathology by intraventricular delivery of a phagocytosable MRI contrast agent in APP23 transgenic mice. NeuroImage. 2009;46:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19385010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25533203</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1180</StartPage><EndPage>1190</EndPage><MedlinePgn>1180-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2014.10.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(14)02863-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. Consequently, synaptic biomarkers may be valuable tools for both early diagnosis and disease stage. Neurogranin (Ng) is a postsynaptic protein involved in memory consolidation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed three monoclonal anti-Ng antibodies. Mass spectrometry and a novel enzyme-linked immunosorbent assay were used to analyze cerebrospinal fluid (CSF) Ng in three independent clinical cohorts including patients with AD dementia (n = 100 in total), mild cognitive impairment patients (MCI), (n = 40) and controls (n = 80 in total).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We show in three independent clinical cohorts a marked increase in CSF Ng levels in AD dementia (P &lt; .001 in all studies). In addition, high CSF Ng levels at the MCI stage predicted progression to dementia due to AD with a hazard ratio of 12.8 (95% confidence interval 1.6-103.0, P = .02). In amyloid-positive MCI patients, high CSF Ng correlated with a more rapid change in cognition during clinical follow-up (P = .03).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">These results suggest that CSF Ng is a novel AD biomarker that may be used to monitor synaptic degeneration, and correlates with the rate of cognitive decline in prodromal AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kvartsberg</LastName><ForeName>Hlin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duits</LastName><ForeName>Flora H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Alzheimer Center &amp; Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasen</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of NVS, Karolinska Institute, Center for Alzheimer Research, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;hrfelt</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Geriatrics, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Malm&#xf6;, Memory Clinic, Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Malm&#xf6;, Memory Clinic, Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Neurochemistry Laboratory and Biobank, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center &amp; Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center &amp; Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. Electronic address: kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">Mass spectrometry</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Neurogranin</Keyword><Keyword MajorTopicYN="N">Prognostic marker</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25533203</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.10.009</ArticleId><ArticleId IdType="pii">S1552-5260(14)02863-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>